<SEC-DOCUMENT>0001055726-23-000030.txt : 20230510
<SEC-HEADER>0001055726-23-000030.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510160224
ACCESSION NUMBER:		0001055726-23-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		23906219

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:160750a0-0a71-42f6-8d80-818c69f4d1ac,g:e1c02d6a-4ccd-42cb-9c8b-7f68796035cd,d:1ff6d590f0b0417ea0f0772b34ecc5f0--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ino="http://www.inovio.com/20230331" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV80LTEtMS0xLTYxNDMw_4950e8a9-7643-40a1-995e-17757c75e602">false</ix:nonNumeric><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV82LTEtMS0xLTYxNDMw_e1f2ddbb-f46a-48c0-ab20-34f2c3d92675">2023</ix:nonNumeric><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV83LTEtMS0xLTYxNDMw_02ea1ec4-981a-4e29-913c-7a8c0f8b11dc">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV85LTEtMS0xLTYxNDMw_fe7c4ede-0771-42de-bf1f-5830cfc407bd">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV8xMC0xLTEtMS02MTQzMA_e856c876-0b03-4a18-993a-a18be735b4cc">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i16d63252834144b0aacf7c65dae0426e_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC0wLTEtMS02MTQzMA_ae730f83-897e-47b9-971a-9ff3d67479fe">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82NC9mcmFnOjU4NGY0M2QzZTRmNjQxNTU5M2ZhYWMzNjNkNTM4ZDYwL3RhYmxlOmI4YmE4YjI3YWIwNjQ1MWNiNWU1NzQ1ZGQxODQ5MzAyL3RhYmxlcmFuZ2U6YjhiYThiMjdhYjA2NDUxY2I1ZTU3NDVkZDE4NDkzMDJfMi0xLTEtMS02MTQzMA_aaeeab4e-3e6a-46cf-8192-eda924c14641">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i38c5f671c746440783fba1944fd2c330_D20230101-20230331" decimals="INF" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83Ni9mcmFnOjQ1NDg0OTIxOGQxNDQ3NDViMTlmOGUwMzkxNjFhOTM3L3RleHRyZWdpb246NDU0ODQ5MjE4ZDE0NDc0NWIxOWY4ZTAzOTE2MWE5MzdfNA_0ca35bbd-94eb-49ac-826e-c54d9e05e9f3">50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i38c5f671c746440783fba1944fd2c330_D20230101-20230331" decimals="INF" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83Ni9mcmFnOjQ1NDg0OTIxOGQxNDQ3NDViMTlmOGUwMzkxNjFhOTM3L3RleHRyZWdpb246NDU0ODQ5MjE4ZDE0NDc0NWIxOWY4ZTAzOTE2MWE5MzdfNw_66b03007-0c4a-4c4c-b1e3-84ecba01a3ae">50</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9457abe7151f48629c83cef3a4bc1b10_I20230508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7e013b80260c4d9089f646bfa59fe02d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i4a51b3e565934094b048701d97384fb1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i061af91598d043dbb23f9bec95fcd0cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37852329bf79418fa1da42c06d21d21b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if771a6bc25d34d21bdedcf8ef619d315_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e372dd07124d13b07e1eba2d4ebb48_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e32cf9a419844fc997d07e4f740dc36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i758b5f9af27d4ef997eae8d3e89608ca_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a56e5fa34464fac9afd99a63dad6ef2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572101f4b4394cbab05b6a7efd242b43_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f73c345dc54c3fb85944a872f29625_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcefd5afd949414c8e5a0edaaaf68460_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff70ed56a0f4a22bd78e19f1cc27821_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic67c34d5644f4e6bb650febc8364d7ba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a9a0ba408648df83848a10938d69f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie00cf796b6ae43e6abe0a3ec4dc6c4c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c79ff17a8ad41eebe7c8cacae2d2448_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac43eafb695b45e386c9c3400e86b00f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if130560dfba64db0886b6c2aad0e1266_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i037465b4f55945f6aec5c70683960daf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d63252834144b0aacf7c65dae0426e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d056507ce342c8b4ceade8fbc2431c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18f3cd8f5654cabbdd4c9ca4e61b6e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806e78a728a14bbf808d71382f080b36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad54f853b18472facb941b6fa20e521_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01b0d4a71e24d5180845b2744da7b80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida57e8acbeb64025a8f23f21a9dd2033_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5328efdb974908ae8cfd3253ce76d8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b8747dfa6a496aa4f8ff6db15082f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b90c0f76ed48918a32bab8f7514148_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i384f44b2bbbc4040b18237efb0444e8c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158c20e44ccc4e16864d4c2cb9a584f3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15b0217ea8c48b0ad7e9858e136caa6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i568f04797f3a472aa282f7114d801497_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c48d2543c3428ca9348a16927aa3ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424005e9738e406cbe32ab9e0559a2cc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie808b6354eac4d61890c011e8296a807_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2794060b62c64f55ba10c6d991467be9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1f816c2b0646358f12de50f5ec8fc4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea88717d3bae4c3282823b096cbc0010_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f21b141b3745859c0259a876d2e137_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9148075bf7401a924169db861cdb10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb82e20dd9d4b969625c52a130ea384_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9209877902d45a0a7da1b89265d7c5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id19a9893ad2e465a8c17eb61b026acc4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeba06444a8843ee89be2729dfcafdd2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154f710696af44368c1b60a00236e33c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1662f455f64b0b86af2199c3c89353_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id737e22fc8c34147b1878efbc06b6fa0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:context id="i49aeb1a300754d82b80cb3075a7d276d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9775574f1494394811d44684704ab67_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i507494694b6d4d009b81bc247609f9e0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa977781312f47e69160962e49c81570_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07230fde15e54b399d452926ed0f53a3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b64b5b5c9b64e5fa4434c4e168d2559_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b7e2166f3914844b66ea56e45631aad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ef64995166349eab1facc6cf436dfb4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d7cb8097694cbda0e2e5976080fed6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if837752dbae541949d9b5d2f3fc1d21a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d6af48af3740ed9e7512132b332b10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i249d5e2b1d764f8f9849378142cdf683_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4538d285010f4df39235b50e6df231bb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808771e2c7b748768ba48825de30ab59_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035ac45eddcd4ad0b877179ce402b012_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i100ee50b23804321a39f1344ec331844_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc54f897c91449868d75304b60ed52b5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7764fa9747144127856f5f47e535b68b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeac876368b343568a773a83ca4cfa00_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9438d2a2b449a28a0426195cc69b58_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i651421a71e44472594de779a6c90aa58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fe53fa638d94b9684c5bb12d5d28448_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d8611e12df41f6b46df72274195e75_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f7ea859ca14010a0f5dc0c523bb83a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8621666cb44531a664219b42fb568f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b95b05eddd474fa6a45fb6fbd8ae32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc7276b422b4eb7b9f1e2ecd0d3c68f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8759eb4716482494a75a4509d57041_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76596fa49ec24abb8271d264e6f19bab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ea510fa47e424d943494f963231339_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79060d2c3e3147b3b3d21d5d5bb394ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7398b2d88e70463d906bd72f9a1b2cf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e9b36e3881479fb2114bf17a00489a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ec3a3107ab43409a0d2eeff38d951a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3d830b50b94da7b62468b24771824e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee4653ccc0974003b1771f075fa5970c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a72e62f7c41430690c464a69f2537db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63d19f47994c4a2087e95232f349c61e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5590b7d3f8242afba7128120cfea182_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6835ef9291475398187809336a6e27_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i092045a4d4c24e66871ac745807bd523_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97422d241744aecbec5cdc038a635ef_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ab95fd57f0f426ebe487aa41e25c7d4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fad80428c8a4c91a84c10d223b587df_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768b12453cb44701902fe18cf70b486b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb0a36935424e9b8c96652f09088bcd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc0c0bab6884b4380426817d471b00c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eedc0cc685c44ee9cb4b8772b34620b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282e3fa937b948e186e4be58f112112e_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iae2deb332889417aa796180e6cd43280_D20190219-20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="i7351252adfb6481e91a3344a5a0f071d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5cef3158a4649a18541e2a3562c8711_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0de4d1310e9b417ca7f60cde3199cf93_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie617d1d3144a464890df59e30f71dfd0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic53065c277c54ed285075c2628977167_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd58cfd5707b40a8ba848f715d75243e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib11d128f5b7d46c4afc00ddccd41927b_D20211109-20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8c9b4d47374eb8ac0b52b8d7f5d1ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea599a7a25b45f7b1f330755ed5da57_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dcce6012ae249d88a84eed499079c98_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564a8962d6e44317a92f8b2819e51177_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe75a7506d1456ba7caadb9076e0ed8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f17f0e740b43c29e5c8bb3c1255760_I20220624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27142f229fa048279b6b126bc5f26f7d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51eaae0fbbe940fca869c9447afe074b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d514f11ff234b3093019d9807fa2ffd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921b1a2eed0045048faa0c08a241ab45_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60bda6ceb3ee454d9ac8642950c68c58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ff7bbfafae4ca3999c42f1172d7aa0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c08ae29ea3f4f058c8448338f3ed45b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58a4b297f7b456087c6738a5502b9dd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc5a1af5a8d4d3e8d3c1e7c321d49f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2779b2689b1147a59ccf83b443c35881_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2227a6874dff4a5eb1a92a35dc47787b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf177595aa91424a9dda4724bee8580b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42874be0b5e343d3925a6e3e6d86611e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1ffcee62674f349f88218d19394398_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icffc34c375714623ba96b595bd73a117_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379a776732214db1b029bd03e5346c7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if16f4b4774ea4c47a1523d104d021a00_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5482985971d94cc99e0f3719ecaa6f37_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie151e6230187439faf1df447c5fab34d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie341f3ddd4aa4162b175afe26aeb3606_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a3ce5bb9c3471eb596c306b6ffd0d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41f4dedbddf9489aa3e6277504570a15_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06f13d07dc0c4ec3bd48386ff51e587a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e035331581449cda370e4641f850074_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706026db14224393a7d5617daa1749ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c5f671c746440783fba1944fd2c330_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:JJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc7ccae9f1db4ec7b179375d9ecbf470_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0476acad69a0411cb71f91657c47d0de_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicenseWithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic075c2d8dc3444418dcdc98130ee2157_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicenseWithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf97ac8cf3a4bf6af4f7d01a5e00911_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9a009f4c76409c87d174eac6f87a7f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc24100fe12944b1b8aeebb2b2812137_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib159f7b94137458ebffea9382e581603_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32cb639fd4a343e690f4f52b559444f5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab8e1cd29e04f13a5bc87f121c2aac5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf7bb08585e4f10aed4274ac4f1ec00_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0acd1375e3c24e7fa409126bcc9c1d51_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbba60f01bb241bbabbb479069af98f1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c90d97b8be2421a91f73fa2e1553a92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333fb2acbe2d4abebe17d055f53089d5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic3eae36ce89f42ad9e65603a05d7c7aa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8608f45e71364d6db7f445deb5e26df9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c3ac8cf648e4aa49f2a73b8fabfe262_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a98975b0fc340d4b103c427cf0f43ea_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ino:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i9f906f0a3f6e4602a9e8cab308738534_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58c9cdabcabe4021909afd5c5a3081f2_I20210309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417613e580e94ab98741e8202729ade5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12fc1c502f8942b7ad4bc3b5d8beb886_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a06a61d23a43f185271e37b7571874_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id64c57b813344cb7a27bb83b05c69e89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92384310f07943f08357ffcdc9a44938_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4a785614804e208d698da42727636c_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69f542558464145a2894966df1810dc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i125c5d9c06e64a2796725f967491bb88_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7941aaf07d1455db283f53a3ce532ff_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88027f914c346d898a03e87ce8843cc_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6685e6d0a07641c9a04cb5a2a1f626a0_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6284362eaa524cb1ae66051b9a8416be_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99cbe6e413f48c58eac5aa5bc792556_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc7dbe20d0344d694da0dff99be1e46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226d2be71e7340ca94c685446a1e4897_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ced90de62e425292ba059648c69c3e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d44bceb01724751ae9ac3ef1c97f30c_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31a2498c1414335a0ba4fe5e14b7127_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1e77e31a004c85bce55c93571e12c7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica479a19e2b24b13b5c1515aad9cca2c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8c967179d64c8da0b633e32986c5b4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb01fd6e8e940fbbc1a27ee535e080e_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4156146913df4fe29176b27642589675_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad6c67aa76d4e239862ac53565b8b14_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c3e1e467bd4c8cbd2f2d5dd0b6b83e_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1fd3bca48746d4a3e0157958b1362d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18a5a935641f47e3a61691a74380178e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d4cb06945a44c5b005997ca2058e88_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1066c49f9fa944c18d0649a5a997b41d_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168d6a6b6ac247679a22b560bd6e3455_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f4328f613794f8f851da2eea650c719_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8095048f54b4e7690bb30f2a7181f33_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7d9f2ec0c742c5a03a7fa46f42aa3d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a9b6e99d364eebaef954d914503da2_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7c9f8aacf543c2ba69c1d46e1444ca_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i787f2661dbc54b07898d0c0364957c10_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0284cde70d5b460295a267e2aa3f9418_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec22519de8e349f68787d4e3117cc5d1_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6c4cef707f468e961ad855e0854c2d_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c22ea43f794bf99527a5a0e7aedae4_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0142d3c784c84195a77084a90fd44686_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeccae722fc04ed3b3e297f3f9746ac5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc519a3505b3405fb2c0d3cdd6a35310_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7818a8a0894cb2bb8176800bac1b8f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fc6c62eb8cb4a31ad404dd9dea91a63_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0957b99b9e3448f9b409da3e4e79095_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86f4cd190cda49f78e14fc4d981780f7_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idac4be03517e4f47adf6174fbe4aa9e1_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i407a77b361714c38aa6bd43347213d19_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7582f4c63824263ac27d9d7d9dd30c2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8116a07c8d41bf95c7976eca960b36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8a4fe327134fba97d18909d711eee6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE0_705b0f39-0fc9-424e-85fc-c877f721d971">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTk2OGRhMDg0NWE3NDc1NGI0NzczNTk5NzY4OGFmYzMvdGFibGVyYW5nZTo1OTY4ZGEwODQ1YTc0NzU0YjQ3NzM1OTk3Njg4YWZjM18wLTAtMS0xLTYxNDMw_c1bea774-847d-461b-8097-746640ba4fec">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTI0_9bdf6e56-760f-4320-a7a0-1534e9b99438">MARCH 31, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6ZDFiODU4OGM3NWQ2NGFiZWI0MDYzMTJlMTlmZjI0YzMvdGFibGVyYW5nZTpkMWI4NTg4Yzc1ZDY0YWJlYjQwNjMxMmUxOWZmMjRjM18wLTAtMS0xLTYxNDMw_2017c8f4-2241-4e21-a417-be1f25a29253">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTI2_837e0461-6695-4379-8855-095b1f0f6be0">001-14888</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20230331_g1.jpg" alt="inoviologosw.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE5_dac9c9f4-808f-4784-b673-3d08c5739d65">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8wLTAtMS0xLTYxNDMw_8012ab29-4798-4ea2-9e71-e2980b1ed2b6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8wLTItMS0xLTYxNDMw_252d78dd-5c10-4d14-9974-c0634da9d872">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTc1NA_322f96cc-6fc0-40e3-b988-ba9445cb04ba">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTc2Ng_80207dab-8ff3-4aaf-a345-e295e5a3918c">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTc4NQ_8c3c2de8-f0cc-470d-968a-cb238d691160">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTgwMA_075b956f-875d-487a-9595-81a2d68094df">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTItMS0xLTY4NzQ0_d4164336-e720-4ab8-a416-6cb03a6eef45">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE2_340754cf-d40d-4e50-8794-51a9a817aa5e">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTI3_0754a2bf-a1eb-4139-8d18-b6bb4953d3fa">440-4200</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.069%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTJhZTk1M2Y4MDMxNGZhZmE0ZDU2ODJjYjQ2MzRkOWMvdGFibGVyYW5nZTo1MmFlOTUzZjgwMzE0ZmFmYTRkNTY4MmNiNDYzNGQ5Y18yLTAtMS0xLTYxNDMw_c0d5a8b3-846d-4d62-8041-2dba0eb6f498">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTJhZTk1M2Y4MDMxNGZhZmE0ZDU2ODJjYjQ2MzRkOWMvdGFibGVyYW5nZTo1MmFlOTUzZjgwMzE0ZmFmYTRkNTY4MmNiNDYzNGQ5Y18yLTEtMS0xLTYxNDMw_4c3d840c-590f-4efc-93ec-eefc646a3b72">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTJhZTk1M2Y4MDMxNGZhZmE0ZDU2ODJjYjQ2MzRkOWMvdGFibGVyYW5nZTo1MmFlOTUzZjgwMzE0ZmFmYTRkNTY4MmNiNDYzNGQ5Y18yLTItMS0xLTYxNDMw_67630767-7166-41ad-b944-04ecaf10208c">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTIz_1150cd4e-6445-49a0-9f99-a4130b6368c6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE3_bc424ff2-50fb-4589-82e7-82131b152b38">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6MTFhY2IwNDNkMzRhNGQ2N2E4YzRhZDY1NDM0NzY5ZmEvdGFibGVyYW5nZToxMWFjYjA0M2QzNGE0ZDY3YThjNGFkNjU0MzQ3NjlmYV8yLTAtMS0xLTY4MjI0_c3f05081-060c-4db5-a822-271c9404262d">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6MTFhY2IwNDNkMzRhNGQ2N2E4YzRhZDY1NDM0NzY5ZmEvdGFibGVyYW5nZToxMWFjYjA0M2QzNGE0ZDY3YThjNGFkNjU0MzQ3NjlmYV8yLTQtMS0xLTYxNDMw_9b84e42e-ca56-4138-8612-254003ab8529">&#9746;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6MTFhY2IwNDNkMzRhNGQ2N2E4YzRhZDY1NDM0NzY5ZmEvdGFibGVyYW5nZToxMWFjYjA0M2QzNGE0ZDY3YThjNGFkNjU0MzQ3NjlmYV80LTQtMS0xLTYxNDMw_f8d2ebe9-544b-4b1e-a35c-8c5aa41d9980">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE4_f3dff713-62bd-4e90-ba6d-6b2f01aec1ee">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i9457abe7151f48629c83cef3a4bc1b10_I20230508" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTAw_8d63d2db-5870-4184-a67e-83ad80401e90">262,740,113</ix:nonFraction> as of May&#160;8, 2023.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended March&#160;31, 2023</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_13">Part I.  Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_16">a) Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_19">b) Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_22">c) Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_25">d) Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_28">e) Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_31">f) Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_103">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_103">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_121">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_121">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_124">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_124">30</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_127">Part II.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_127">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_130">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_130">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_133">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_133">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_1167">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_1167">56</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_1211">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_1211">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_136">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_136">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_139">58</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risk factors include, but are not limited to, the following: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary smart device technology.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA medicines and proprietary smart device technology, which may prove difficult and costly to obtain.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are now only pursuing development in collaboration with third parties, as both a primary and heterologous booster vaccine, but there can be no assurance that our candidate will ever receive regulatory approval as a primary vaccine or booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DNA medicines are a novel approach to treating and preventing disease, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our proprietary smart devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary smart devices and DNA medicine candidates.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with government agencies, which are subject to termination and uncertain future funding, which could have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may be harmed if our restructuring plans do not achieve the anticipated results or cause undesirable consequences.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to successfully commercialize our DNA medicines, if approved.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_13"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.  Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_16"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:74.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNC0xLTEtMS02MTQzMA_f8c92235-dff4-4234-959d-ce7e66e746a8">28,238,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNC0zLTEtMS02MTQzMA_730faf00-78ff-4124-ad44-faf6f5a63a05">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNS0xLTEtMS02MTQzMA_9607001a-5c4a-48b6-81ae-5beffe746c05">195,513,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNS0zLTEtMS02MTQzMA_fab582d2-c9c5-4cc9-a054-9b6d36ce88ca">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNi0xLTEtMS02MTQzMA_54c3c50e-131e-4edb-830a-a209bd91efd8">73,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNi0zLTEtMS02MTQzMA_439234c3-202d-46d8-b3bb-88a0709a4a2c">1,701,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNy0xLTEtMS02MTQzMA_53849750-0407-4d34-aa28-d7c0d390d097">4,961,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNy0zLTEtMS02MTQzMA_0d2c4f1d-a20e-4a25-99e0-7f6327cf4405">10,036,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOC0xLTEtMS02MTQzMA_b0c3ddac-ee7b-4c3c-93c7-16b1e497262f">4,914,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOC0zLTEtMS02MTQzMA_b1733727-db0c-4ae9-b208-86227464707d">50,130,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOS0xLTEtMS02MTQzMA_01d5cbfa-1583-49c1-a941-0bc97a04c88e">195,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOS0zLTEtMS02MTQzMA_11ef5032-d6fe-4cb2-b172-d7bd8509d9da">375,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTEtMS0xLTEtNjE0MzA_115d29d3-0af8-412e-9c1a-a096742f27f5">233,896,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTEtMy0xLTEtNjE0MzA_8357877d-f904-4a55-95a2-da744a356840">315,242,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTItMS0xLTEtNjE0MzA_ba50f735-9375-42a5-9ebb-2a347a6e29c4">6,983,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTItMy0xLTEtNjE0MzA_f456e19b-eccd-4101-a2ff-053854a1a67e">7,727,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTMtMS0xLTEtNjE0MzA_e5365d66-01c8-4506-bbe1-638183740bf8">2,623,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTMtMy0xLTEtNjE0MzA_af850985-1b60-408a-ab43-91bd356a9395">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTUtMS0xLTEtNjE0MzA_ad17e521-1c88-41ff-afdf-4e4079976ac1">2,047,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTUtMy0xLTEtNjE0MzA_0defceb8-576d-42e7-af7d-d7ddcf2c1058">2,129,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTYtMS0xLTEtNjE0MzA_03af5d9b-3950-4c31-9aca-44f16020af4b">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTYtMy0xLTEtNjE0MzA_09cfbe87-ed19-4f0a-91af-38e28ff7c4e1">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTctMS0xLTEtNjE0MzA_8cc1e4e6-b36b-401b-ae0c-b7705e97f899">9,865,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTctMy0xLTEtNjE0MzA_a58ab9ab-1b9d-4c39-9167-be7da01cb255">10,228,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTgtMS0xLTEtNjE0MzA_afc727cb-9b32-428c-b23e-d40896922a28">652,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTgtMy0xLTEtNjE0MzA_e14c9e78-86d6-40ea-ab24-a50cc988f043">684,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTktMS0xLTEtNjE0MzA_e79937bc-7ca3-419c-82db-b3de6d399971">266,582,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTktMy0xLTEtNjE0MzA_7c952539-7783-4c7f-9858-bb647e5f7a00">348,533,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjItMS0xLTEtNjE0MzA_3160824e-b446-471d-ac7a-fe9b7980ef55">24,752,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjItMy0xLTEtNjE0MzA_15f009c3-26a9-473d-82b2-a21a3050d2f3">79,686,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjMtMS0xLTEtNjE0MzA_bb629bf5-6e07-414b-9b99-190bd03d6c2d">1,417,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjMtMy0xLTEtNjE0MzA_10f89b6f-e069-4624-a49d-cb2668d0de53">1,220,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjQtMS0xLTEtNjE0MzA_244712d0-5993-4a08-b7dd-265c6ebe872e">5,795,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjQtMy0xLTEtNjE0MzA_309997b1-de9f-40db-94b5-34eb8608ba50">10,594,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjctMS0xLTEtNjE0MzA_c21b8a37-b33d-48d6-ae8a-7fe84176667d">2,579,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjctMy0xLTEtNjE0MzA_8a609c85-9852-4094-b6e6-b6ea8296df4e">2,803,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjgtMS0xLTEtNjE0MzA_18bee8c5-e071-4eba-aa7e-af35a25cc542">4,121,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjgtMy0xLTEtNjE0MzA_0705e849-fed3-40b0-9c9c-989d850b774c">2,475,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjktMS0xLTEtNjE0MzA_31b806cd-2714-4f1e-adbb-f37defb1f8fb">89,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjktMy0xLTEtNjE0MzA_3f58a386-ea86-471e-903a-99b4bee08615">87,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzAtMS0xLTEtNzA4MzQ_8f2c0281-1b70-412c-b950-dd48feabeb2b">16,394,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzAtMy0xLTEtNzA4MzQ_807fb984-4544-405e-b8dd-a6140ce13212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzEtMS0xLTEtNjE0MzA_4d1e6d3f-1900-4ddc-b714-442e20aa6d1e">55,151,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzEtMy0xLTEtNjE0MzA_9066d017-b3f9-4386-9fbe-3099b1810368">96,868,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzQtMS0xLTEtNjE0MzA_c4a68a09-5e78-4305-90eb-4cd529759185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:ConvertibleDebtNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzQtMy0xLTEtNjE0MzA_686dbd38-06ff-4c47-980e-21f08900c98f">16,614,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzYtMS0xLTEtNjE0MzA_a2373b51-7925-4a44-9594-14a3acba9137">12,185,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzYtMy0xLTEtNjE0MzA_828d9d2b-8ccc-43fe-9575-ba2a14d16c49">12,655,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzctMS0xLTEtNjE0MzA_8e4fbd1e-ac32-4f85-84e9-6edabc609aeb">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzctMy0xLTEtNjE0MzA_a12ebc49-331f-444c-8c8c-cde74bbf0f3b">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDAtMS0xLTEtNjE0MzA_fb0893a8-5442-4fb3-97bb-01c31272b3e9">67,369,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDAtMy0xLTEtNjE0MzA_df8f6733-57b3-4457-bc78-968c8ae214b5">126,170,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDItMS0xLTEtNjE0MzA_69faa1b2-6138-4049-a5ff-b9a4aff9330d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDItMy0xLTEtNjE0MzA_88ed493b-333e-4145-b26b-9e1cd38a2937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDMtMS0xLTEtNjE0MzA_d4ae7dbf-b020-4720-880c-b82d5a81400c">262,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDMtMy0xLTEtNjE0MzA_e0f6e1ae-286c-4bcc-a7cb-69cddd163c76">253,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDQtMS0xLTEtNjE0MzA_a0c215b5-a0f7-4a9d-abcf-d8946caa5464">1,728,030,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDQtMy0xLTEtNjE0MzA_2399306a-b4a3-4938-8116-b9af3301d701">1,710,656,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDUtMS0xLTEtNjE0MzA_155773d1-8a3f-4f1d-a53b-66b50b7ad5f9">1,528,497,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDUtMy0xLTEtNjE0MzA_ec90ec2a-ebba-4fb2-ac17-3ed629b94e58">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDYtMS0xLTEtNjE0MzA_bb38ac0a-d4c5-4c8b-945b-cea82562b2fb">582,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDYtMy0xLTEtNjE0MzA_d44e08b6-7921-421e-b7be-f0df15e93cd1">698,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDctMS0xLTEtNjE0MzA_f37e84b6-2393-40b7-87e6-5005719fff5c">199,213,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDctMy0xLTEtNjE0MzA_1c642df4-e4ee-44e5-872e-2c3daf2d9e4f">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNTAtMS0xLTEtNjE0MzA_b5141683-e467-4f31-b228-6bd4be12735e">266,582,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNTAtMy0xLTEtNjE0MzA_a7352e59-06c2-4aa5-9fad-ec7ab0e33c24">348,533,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:73.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfOS0xLTEtMS02MTQzMA_5ad3d125-4a65-4b86-8b06-225f1f4b4710">114,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfOS0zLTEtMS02MTQzMA_bc7f52e4-be33-47ae-9831-fe1748599539">199,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTEtMS0xLTEtNjE0MzA_4c801e63-f0b4-424e-a4fb-4f28f1515ff3">30,176,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTEtMy0xLTEtNjE0MzA_f43360a2-e0d7-4270-ad56-fe6003a9f344">55,978,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTItMS0xLTEtNjE0MzA_3522bc49-a559-4adf-a03e-bb5f24efaff6">13,890,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTItMy0xLTEtNjE0MzA_9aca4e66-e9d0-41aa-afd6-63a7f71ff8fc">15,953,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTQtMS0xLTEtNjE0MzA_b33823f5-9778-4ee7-afd2-70cca16b2ccd">44,067,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTQtMy0xLTEtNjE0MzA_c58cf13b-13a1-4368-a5cc-3f6d306f7807">71,932,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTUtMS0xLTEtNjE0MzA_73fe8816-0226-43da-8de0-fd131df9b9e2">43,952,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTUtMy0xLTEtNjE0MzA_80b86485-1dba-4b0e-ae3a-949ae092ed5c">71,732,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTctMS0xLTEtNjE0MzA_4e07f813-d5d6-4d71-9895-f3d109edba3f">2,207,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTctMy0xLTEtNjE0MzA_ba8c4da9-4161-459e-b4a5-a88ac1c5fbf6">669,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTgtMS0xLTEtNjE0MzA_ed3f0fa3-7569-4053-8124-a3f3b34b9f99">313,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTgtMy0xLTEtNjE0MzA_1bf12b3b-ec06-4a09-94cd-61e1ff15b7a0">313,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjEtMS0xLTEtNjE0MzA_665370c5-0d3f-4816-9922-efa354d41938">616,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjEtMy0xLTEtNjE0MzA_d3033ae9-17ad-442d-9199-386130dc115d">537,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjItMS0xLTEtNjE0MzA_cadef122-51b3-4d1b-aa61-2a519d054936">3,218,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjItMy0xLTEtNjE0MzA_5aa5afc9-4e97-41ca-8927-7eb47e57b8c5">4,840,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjMtMS0xLTEtNjE0MzA_e01d2829-4381-4e58-b924-a8a859d55ed6">2,425,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjMtMy0xLTEtNjE0MzA_aada621e-bccc-4aa0-8e79-e65ce2cd8d05">153,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjgtMS0xLTEtNjE0MzA_13b4cc6e-d039-4763-bedd-89bc6a671358">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjgtMy0xLTEtNjE0MzA_7784827c-46cd-4b66-a229-3554f9d45dbb">76,908,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzAtMS0xLTEtNjE0MzA_15930334-d1ec-46ab-886e-f68c9fed1f3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzAtMy0xLTEtNjE0MzA_2ab1bd51-d829-4a8e-9c95-ae5d084fec7e">2,165,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzEtMS0xLTEtNjE0MzA_916e76b9-7ac4-46ca-888b-4af9f42024dc">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzEtMy0xLTEtNjE0MzA_b73ceb7f-4af6-401d-abd1-c4cc803c6a80">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMS0xLTEtNjE0MzA_7a04c6d4-3433-402c-bbd9-7b245b6b951e"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMS0xLTEtNjE0MzA_cad65ac9-072d-4486-a15f-4094e532fb9a">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMy0xLTEtNjE0MzA_37f711f4-e549-496f-aed8-41fe6e5967e2"><ix:nonFraction unitRef="usdPerShare" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMy0xLTEtNjE0MzA_37fd9d5b-ee89-4af4-aefd-b017e54405bc">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMS0xLTEtNjE0MzA_14374bc8-db81-4b32-9fdd-ff2f83ef1533"><ix:nonFraction unitRef="shares" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMS0xLTEtNjE0MzA_34ccac25-bccd-4bf2-ac3c-22acb1f3a533">258,437,714</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMy0xLTEtNjE0MzA_fe442a46-1677-45c6-be5e-ae038fa9c6f7"><ix:nonFraction unitRef="shares" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMy0xLTEtNjE0MzA_ffb6d700-ae90-4cbb-ba9a-5fd1170b9ea7">218,940,693</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:75.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.910%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.214%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfMi0xLTEtMS02MTQzMA_061f0600-cf4c-4287-aff9-5aa8dd39f97e">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfMi0zLTEtMS02MTQzMA_27cc247f-b1d2-4f36-a810-ab03f7934baf">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNS0xLTEtMS02MTQzMA_3e27a802-6341-4917-9694-ebef05a7cf48">1,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNS0zLTEtMS02MTQzMA_f4aac639-e5b8-406c-b88c-d7e5aa2e1935">6,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNi0xLTEtMS02MTQzMA_6603ff85-ba80-4a63-82d3-dce2adc924dd">117,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNi0zLTEtMS02MTQzMA_1001db79-a43b-4a09-bec0-1bbc042543c1">169,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfOS0xLTEtMS02MTQzMA_3fe4e265-dde4-4846-89c7-20fafbdad587">40,533,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfOS0zLTEtMS02MTQzMA_1e9f1e12-50a5-4419-83b1-171d9ef6bebb">79,249,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i061af91598d043dbb23f9bec95fcd0cd_I20221231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xLTEtMS02MzI4Mg_4f572cae-6d40-47ac-bcd2-cf86f84e2768">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061af91598d043dbb23f9bec95fcd0cd_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0zLTEtMS02MzI4Mg_1b64965b-9261-4a72-a06b-564fc9a53189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37852329bf79418fa1da42c06d21d21b_I20221231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy01LTEtMS02MzI4Mg_1e153498-2385-46d0-926c-57d7692501fd">253,091,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37852329bf79418fa1da42c06d21d21b_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy03LTEtMS02MzI4Mg_e866dc6b-f4fe-4dfb-9b3c-dd115dcf9512">253,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if771a6bc25d34d21bdedcf8ef619d315_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy05LTEtMS02MzI4Mg_0d400929-35f6-4503-b711-9200f2fd52ea">1,710,656,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e372dd07124d13b07e1eba2d4ebb48_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xMS0xLTEtNjMyODI_ea4b114c-446e-447f-8383-7319cdbd1906">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e32cf9a419844fc997d07e4f740dc36_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xMy0xLTEtNjMyODI_cfe2352e-c982-4417-80d1-4298f928e200">698,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xNy0xLTEtNjc2OTk_a8bac6f0-4d61-49bd-aead-702730f4c158">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for legal settlement</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC01LTEtMS02MzI5Ng_2c3a2a7f-17f0-4d98-9e2b-1df251454864">9,121,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC03LTEtMS02MzI5Ng_d6df03e6-3141-4094-b8b0-3e73fe70736b">9,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC05LTEtMS02MzI5Ng_019eeba0-76c7-4535-83f2-7e6234ba2342">13,990,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC0xNy0xLTEtNjc3MzE_d59068f0-d62b-44f6-bf02-8f1d82f581f0">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS01LTEtMS02MzI5Ng_a9ee4b1a-0d5b-49ce-b9cf-fa6e35f438cd">526,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS03LTEtMS02MzI5Ng_d5f79020-b4ab-4c48-ab55-bddc56d24e9e">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS05LTEtMS02MzI5Ng_64a45921-4074-478f-b4a3-74556ae5460e">425,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS0xNy0xLTEtNjc3MzE_b6362100-0feb-4a55-b2f5-ff9030774fbf">424,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNi05LTEtMS02MzI5Ng_d8cd430b-e1d8-4b72-bef5-4b9afade24dc">3,809,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNi0xNy0xLTEtNjc3MzE_71a8beae-1f83-49db-a6a9-29172c735414">3,809,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i758b5f9af27d4ef997eae8d3e89608ca_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNy0xMS0xLTEtNjMyOTY_82cd4713-ec0f-430f-bebc-23d4b1410058">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNy0xNy0xLTEtNjc3MzE_bce5d983-b237-427d-a426-48eeceef62e7">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a56e5fa34464fac9afd99a63dad6ef2_D20230101-20230331" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOC0xMy0xLTEtNjMyOTY_ce9ccabe-ac7b-4e0c-a830-06d9ba1b1a0e">117,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOC0xNy0xLTEtNjc3MzE_ead0c8cd-f83a-451a-8c40-e368186291a1">117,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a56e5fa34464fac9afd99a63dad6ef2_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOS0xMy0xLTEtNjMyOTY_0c71235b-79ea-4981-8959-ba600157f87f">1,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOS0xNy0xLTEtNjc3MzE_75f2a973-6b6d-44e2-ac23-6533822fd138">1,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i572101f4b4394cbab05b6a7efd242b43_I20230331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMS0xLTEtNjc3Mjk_acbdb031-a64e-435c-a260-19280b1450b6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i572101f4b4394cbab05b6a7efd242b43_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMy0xLTEtNjc3Mjk_53fe4c9a-f84a-4c61-97f0-7202c303c32f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43f73c345dc54c3fb85944a872f29625_I20230331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtNS0xLTEtNjc3Mjk_dc32bb63-19d1-46ed-83f2-f1be2ce2d3d1">262,739,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f73c345dc54c3fb85944a872f29625_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtNy0xLTEtNjc3Mjk_0e7d812b-0082-40ed-ab56-98b6e34de30c">262,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcefd5afd949414c8e5a0edaaaf68460_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtOS0xLTEtNjc3Mjk_ad7daf71-e7eb-452a-ba28-ab5649e3426b">1,728,030,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ff70ed56a0f4a22bd78e19f1cc27821_I20230331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMTEtMS0xLTY3NzI5_b35aa8a9-ae19-400c-a197-e2263f9b5870">1,528,497,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic67c34d5644f4e6bb650febc8364d7ba_I20230331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMTMtMS0xLTY3NzI5_dcaceb52-c796-4e7b-ad33-d0bebf524854">582,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMTctMS0xLTY3NzI5_fe6c88ce-a4c2-4125-9fa2-3e72f985d17c">199,213,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06a9a0ba408648df83848a10938d69f5_I20211231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xLTEtMS02MTQzMA_ae345110-dc91-4e80-987e-fc6a50491f02">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a9a0ba408648df83848a10938d69f5_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0zLTEtMS02MTQzMA_3a383181-2111-4663-9fea-4cc489d28ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie00cf796b6ae43e6abe0a3ec4dc6c4c9_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy01LTEtMS02MTQzMA_bbb8b055-cf59-4656-b967-ef8f8d05d1b9">217,382,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00cf796b6ae43e6abe0a3ec4dc6c4c9_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy03LTEtMS02MTQzMA_01d508cd-a0a4-4a5d-963b-70facaa50da0">217,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c79ff17a8ad41eebe7c8cacae2d2448_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy05LTEtMS02MTQzMA_51ca400c-9344-4b67-abe5-e51e1415fb05">1,609,589,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac43eafb695b45e386c9c3400e86b00f_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xMS0xLTEtNjE0MzA_38d12ba0-0bc3-41e4-8e38-dfd7171e4c69">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if130560dfba64db0886b6c2aad0e1266_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xMy0xLTEtNjE0MzA_82d9438c-ae03-4def-95f7-a189daead52c">282,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037465b4f55945f6aec5c70683960daf_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xNy0xLTEtNjE0MzA_cd5936e0-b817-457d-bea1-b1895e91642c">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC0wLTEtMS02MTQzMA_ae730f83-897e-47b9-971a-9ff3d67479fe">Cumulative adjustment from adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6d056507ce342c8b4ceade8fbc2431c_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC05LTEtMS02MTQzMA_417c13f4-2fc6-4b2e-9640-4f972f94bd3d">3,294,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18f3cd8f5654cabbdd4c9ca4e61b6e6_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC0xMS0xLTEtNjE0MzA_aa2027ea-32e7-42f2-aa96-712fa595b7d3">1,825,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i806e78a728a14bbf808d71382f080b36_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC0xNy0xLTEtNjE0MzA_0064cc29-2f4b-4e31-a10f-2671bd5218d9">1,468,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS01LTEtMS02MTQzMA_6ecbd0f8-1379-4fff-a0b8-c6cc0b2b71a9">8,480,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS03LTEtMS02MTQzMA_73f45184-a463-495d-83e5-8247b735ffd0">8,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS05LTEtMS02MTQzMA_fa0e5fc3-8156-4de9-98e8-6020f2d19561">29,356,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS0xNy0xLTEtNjE0MzA_e9fe7ce6-6012-4a7b-b81f-0e1d50199e11">29,364,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi01LTEtMS02MTQzMA_2d332aa9-8ed0-49aa-bf36-292669439a43">647,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi03LTEtMS02MTQzMA_e1f32634-0090-4d17-b7ed-26f50a757ea1">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi05LTEtMS02MTQzMA_0be37665-40e2-43f6-a9c1-4d8ba829708e">943,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi0xNy0xLTEtNjE0MzA_c8973c33-8154-417a-b8b7-74c4b7363f0a">942,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNy05LTEtMS02MTQzMA_da98bf76-668d-4536-a289-003b5b914a5d">7,711,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNy0xNy0xLTEtNjE0MzA_6b2da6a1-436e-4bf0-b207-6cb3f8b1f414">7,711,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ad54f853b18472facb941b6fa20e521_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOC0xMS0xLTEtNjE0MzA_d156d39f-9b07-4bb3-9579-3c182ec42e83">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOC0xNy0xLTEtNjE0MzA_9eed1596-2575-4587-a4f3-f8be2536aad0">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01b0d4a71e24d5180845b2744da7b80_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOS0xMy0xLTEtNjE0MzA_522e1c16-dbf3-4af9-9d79-7076efe79b3c">169,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOS0xNy0xLTEtNjE0MzA_ab3d96df-b45f-42ea-acbf-c2d1b81c25d7">169,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01b0d4a71e24d5180845b2744da7b80_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTAtMTMtMS0xLTYxNDMw_d37f3c52-cec0-4523-b7bd-5d1ad548f925">6,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTAtMTctMS0xLTYxNDMw_13661b0d-2576-49fe-849c-5b81d7e5f3bc">6,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida57e8acbeb64025a8f23f21a9dd2033_I20220331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMS0xLTEtNjE0MzA_d8b4c4ad-edf1-4418-b648-1fddab35b2af">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida57e8acbeb64025a8f23f21a9dd2033_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMy0xLTEtNjE0MzA_2a8f473b-4a42-472d-b111-e113463bbac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c5328efdb974908ae8cfd3253ce76d8_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtNS0xLTEtNjE0MzA_0b7b9b2a-71e5-4b46-8f72-3e2236df6d8b">226,510,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5328efdb974908ae8cfd3253ce76d8_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtNy0xLTEtNjE0MzA_fa8e207b-776f-4f91-85ae-70af9db9a19d">226,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b8747dfa6a496aa4f8ff6db15082f4_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtOS0xLTEtNjE0MzA_b9f99f39-8c4d-4db4-b634-906493d242d1">1,642,419,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0b90c0f76ed48918a32bab8f7514148_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMTEtMS0xLTYxNDMw_8ec67fe6-8bf0-4b90-b869-f59912844760">1,287,103,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i384f44b2bbbc4040b18237efb0444e8c_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMTMtMS0xLTYxNDMw_d855cb06-edce-4302-80b2-9db82c19e786">457,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158c20e44ccc4e16864d4c2cb9a584f3_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMTctMS0xLTYxNDMw_1bfc01d9-12b4-46ad-b8fb-39cc0caf0ae8">355,085,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_28"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMy0xLTEtMS02MTQzMA_1d94bb1c-6219-4dd5-994a-211b410f4749">40,649,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMy0zLTEtMS02MTQzMA_c8c6e0c3-e78b-4aff-b851-f149a311ffa4">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNS0xLTEtMS02MTQzMA_c00ab0cf-3841-404b-a076-6a3e515579f3">707,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNS0zLTEtMS02MTQzMA_6df776ff-0fc4-4d0b-ac2a-2d881729b97c">929,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNi0xLTEtMS02MTQzMA_345d34af-4709-4edf-a233-92acbcfe7814">82,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNi0zLTEtMS02MTQzMA_7cd8673f-77b7-4465-8c02-b8c756efdf74">126,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNy0xLTEtMS02MTQzMA_92f2ce37-911e-466f-9605-0168d290d4d3">362,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNy0zLTEtMS02MTQzMA_92b79048-16d4-46a4-b01e-544a2863247b">319,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfOS0xLTEtMS02MTQzMA_3889ef6b-71c7-4c8e-b719-5c87855bd74e">3,809,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfOS0zLTEtMS02MTQzMA_35d8d2ac-5ca6-4329-858f-3a88760e2289">7,711,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest on senior convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTItMS0xLTEtNjE0MzA_ede78b1b-5c0b-49cb-ac3c-306c1ce38b17">219,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTItMy0xLTEtNjE0MzA_ff7ee72a-5139-452a-aa28-cf835716aac2">219,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of (discounts) premiums on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTMtMS0xLTEtNjE0MzA_adf687ef-e366-4c9b-b194-80f5144f9efa">1,159,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTMtMy0xLTEtNjE0MzA_e846579a-91cd-4d07-89db-98a290402798">125,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized loss on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTQtMS0xLTEtNjE0MzA_ab1429cc-c115-4c0a-ba5c-65051837a086">2,425,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTQtMy0xLTEtNjE0MzA_bddb60be-3a77-4e1a-83ce-1283866fb191">318,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTUtMS0xLTEtNjE0MzA_1d25681c-642f-4a7f-82ef-35b449fd556d">334,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTUtMy0xLTEtNjE0MzA_f7d8e2d8-a939-49cc-a901-2f8d74ee2a40">157,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on remeasurement of investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTYtMS0xLTEtNjE0MzA_12fd392c-2b37-4084-bd94-a9eb53f0f151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTYtMy0xLTEtNjE0MzA_5d69dc35-b06d-457f-9dbf-a1166091a667">165,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on equity investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTgtMS0xLTEtNjE0MzA_47e97fc1-68b3-4da2-ba21-66ebea92d2ad">616,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTgtMy0xLTEtNjE0MzA_52c6240b-e579-44d4-b287-193a90191240">537,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTktMS0xLTEtNjE0MzA_b3cbf27e-50a5-435e-8fbc-8ad466e81160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTktMy0xLTEtNjE0MzA_b1e3469e-ceed-4c19-a2be-1f87542590e0">2,165,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gain) loss on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjItMS0xLTEtNjE0MzA_d650704f-7bea-4625-9443-0ea03382421c">3,218,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjItMy0xLTEtNjE0MzA_7aaf6a18-aacd-4a0d-af79-72416c724d04">4,840,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjktMS0xLTEtNjE0MzA_c66f2125-32e8-4dc1-8433-d881018e8324">6,703,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjktMy0xLTEtNjE0MzA_8fcf762e-6e40-4cec-8850-b606291e3141">541,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzEtMS0xLTEtNjE0MzA_5d320343-8ddc-4b0d-84a6-afb10149d5d2">39,324,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzEtMy0xLTEtNjE0MzA_5969f2e4-30cb-4caa-9cd1-7c99c82a97de">7,075,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzQtMS0xLTEtNjE0MzA_48f9cf41-b5b9-4be4-950a-3ca8f7c732f0">31,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzQtMy0xLTEtNjE0MzA_fa15013f-5e75-4c85-9ffa-9538570c4e93">151,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses, including due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzUtMS0xLTEtNjE0MzA_14065c51-94be-4bff-b4a8-9760efa2310a">40,737,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzUtMy0xLTEtNjE0MzA_0ff07894-1111-49c3-8332-bd6f3dc18b28">9,000,559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzYtMS0xLTEtNjE0MzA_474cbd2e-c901-4202-8f60-d6c6ff043045">4,798,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzYtMy0xLTEtNjE0MzA_5c70d4d3-559b-4daf-a627-608074546f0e">1,501,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzgtMS0xLTEtNjE0MzA_c25819ba-6638-44f3-a3a0-a6ec512f0ebb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzgtMy0xLTEtNjE0MzA_76e6b600-6682-40af-b703-f9c8ed0fe158">9,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDEtMS0xLTEtNjE0MzA_7b7854e3-6dde-4e25-86d8-cd63b61edd1e">693,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDEtMy0xLTEtNjE0MzA_b30fd2ac-9c9a-4767-833e-d8ee2297983f">624,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDItMS0xLTEtNjE0MzA_942da90c-0fed-42dd-9cdc-ab2acf03a2dd">1,648,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDItMy0xLTEtNjE0MzA_6cee1f32-7394-45e5-a6e4-921566d97466">723,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDUtMS0xLTEtNjE0MzA_87aed83c-4366-4647-acdb-a0e711dcc1a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDUtMy0xLTEtNjE0MzA_472a40a4-6f19-435b-b688-4e7ae1d5d0a3">14,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDYtMS0xLTEtNjE0MzA_e370ae86-ba6a-4beb-a0cb-d297f9edf280">36,664,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDYtMy0xLTEtNjE0MzA_670a2490-e493-4027-acdf-ca79be7ab3aa">61,882,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDgtMS0xLTEtNjE0MzA_d3f8f257-52c1-4a73-8680-3478d4110c1a">80,431,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDgtMy0xLTEtNjE0MzA_7d7db468-b2db-4738-bd9c-b2524c7a4be3">99,722,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDktMS0xLTEtNjE0MzA_b43d6674-d5de-408b-a385-ab8d7af784c0">93,657,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDktMy0xLTEtNjE0MzA_673e3807-95a0-43e8-9933-a7eef88bd17f">123,055,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTAtMS0xLTEtNjE0MzA_e1f1f25b-cc99-48a3-9d6d-5cd3b4b39fb8">296,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTAtMy0xLTEtNjE0MzA_b6c97274-fa90-480f-a6fa-d22054405153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Proceeds from sale of capital assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTEtMS0xLTEtNjE0MzA_eb321163-2e64-4f77-9baa-de08a8c76c43">6,071,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTEtMy0xLTEtNjE0MzA_21912b38-f888-4cbe-bb23-10553cd4f3b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTItMS0xLTEtNjE0MzA_0fcc4e23-7ee1-439e-aa5b-0a54b47181d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTItMy0xLTEtNjE0MzA_db5cbac7-8d6b-4d86-9c2a-a17d24695c9c">1,999,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTYtMS0xLTEtNjE0MzA_d586c875-a594-4df6-8eb0-f48f5de979a2">18,999,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTYtMy0xLTEtNjE0MzA_cbf9180e-a9d7-4ce0-b78d-5b3749434fbf">21,332,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjAtMS0xLTEtNjE0MzA_c17eafa6-d0f5-4bec-8050-1b5fee6765ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjAtMy0xLTEtNjE0MzA_ffa1a80b-8d85-4994-aa57-df528b20aa07">29,364,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjEtMS0xLTEtNjE0MzA_a313ab63-c580-43d3-8205-540b4cfd75d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjEtMy0xLTEtNjE0MzA_3c1fe54d-76e1-4e4d-b7f5-8de1d1432334">83,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjItMS0xLTEtNjE0MzA_d51cffef-9877-43fd-ac46-0cbed8672a4c">424,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjItMy0xLTEtNjE0MzA_60808846-cff2-46a2-b59e-e31836d82228">1,026,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjUtMS0xLTEtNjE0MzA_b46999f0-2fe3-4996-a440-1bc2ba5155dc">424,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjUtMy0xLTEtNjE0MzA_8732d0c4-b1d5-4f9c-8009-2e2878c08cf0">28,422,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjYtMS0xLTEtNjE0MzA_7510c60b-66b6-4fc0-9be4-b534079ac8a3">1,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjYtMy0xLTEtNjE0MzA_b62cf9a6-7fa0-4279-a688-a2b9042719db">6,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjctMS0xLTEtNjE0MzA_0dd08681-6cb4-4b3b-ba21-f1da839bbd13">18,091,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjctMy0xLTEtNjE0MzA_84ce376a-d26b-4b75-86f4-a08b5aec0645">12,134,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjgtMS0xLTEtNjE0MzA_acf876fc-7da5-4794-9c34-134691e5ada3">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037465b4f55945f6aec5c70683960daf_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjgtMy0xLTEtNjE0MzA_e159084d-b4c4-4412-8102-7d2aecd116a2">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjktMS0xLTEtNjE0MzA_e656c047-cea2-4828-a07e-e062e393e1ee">28,238,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158c20e44ccc4e16864d4c2cb9a584f3_I20220331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjktMy0xLTEtNjE0MzA_2cd68407-531f-465f-a10f-61dd7dae5920">59,009,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of fixed assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzItMS0xLTEtNjE0MzA_d0cb1353-3eee-4fd3-8971-f76214155235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzItMy0xLTEtNjE0MzA_a28f62a4-e5aa-407f-8ab7-8355cb99c3ac">330,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzMtMS0xLTEtNjE0MzA_d1b55ae4-18cf-41f6-8537-158249210b86">533,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzMtMy0xLTEtNjE0MzA_fb31ccf4-7516-446f-ae7d-502984f15287">533,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for the legal settlement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="ino:ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzUtMS0xLTEtNjE0MzA_d3acecc1-8fa4-4eab-aea4-b6ade4fd0319">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="ino:ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzUtMy0xLTEtNjE0MzA_263ffd50-a722-4ee4-87f1-d732ff4fdeb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_34"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">1. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNC9mcmFnOjE5NGYyZGQzYTJiYzQ4Mjk4MzE3YWQ2ZGMxNDM0OWJjL3RleHRyZWdpb246MTk0ZjJkZDNhMmJjNDgyOTgzMTdhZDZkYzE0MzQ5YmNfMzQwOA_b09a65b4-83a0-451b-87f1-be2fcffa741c" continuedAt="ia61d8a2a34e742d08b6f42503888d32b" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="ia61d8a2a34e742d08b6f42503888d32b"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company&#8217;s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO's lead candidates are focused on diseases associated with HPV. In October 2022 and February 2023, INOVIO announced data from the first and second cohorts, respectively, of its Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated Recurrent Respiratory Papillomatosis (RRP). In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, Indiana University, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for the Ebola virus; HPV-related precancers, including cervical, vulvar and anal dysplasia; HPV-related cancers, including head &amp; neck; other HPV-related disorders, such as RRP; and glioblastoma (GBM).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_37"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfNTc2Nw_46e9089e-5e71-4b53-8ecd-9c7e71618e45" continuedAt="ic80794b0c6f244acbd7c0188c7501ccf" escape="true">Basis of Presentation, Liquidity and Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="ic80794b0c6f244acbd7c0188c7501ccf" continuedAt="iba8643e0d4ad4f65a9f62c6553a051e2"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfNTc2MQ_0f48d2ab-b845-447e-b5cd-14ac1c33200d" continuedAt="ifad91ffd4585409ca7a13399566a261b" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2023 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2023. The balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2023 and December 31, 2022, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="iba8643e0d4ad4f65a9f62c6553a051e2" continuedAt="i6b69bc2016214d7e92944dae8a1223c5"><ix:continuation id="ifad91ffd4585409ca7a13399566a261b" continuedAt="i411fc915ea5f4cda936a85962690a510"><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjMwOA_1411b0be-bd24-45b6-963c-e743849c4cf5">40.6</ix:nonFraction> million for the three months ended March 31, 2023. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-5" name="ino:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjM3OQ_7ffedd1b-daf0-48f1-9b4e-628766b8c5aa">178.7</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjQxMw_33ac9561-3c1b-48df-ab28-8796ba366d48">1.5</ix:nonFraction> billion as of March&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjc2MA_a2c022b7-14a5-4da2-9a7d-344ba26fe7ac">223.8</ix:nonFraction> million as of March&#160;31, 2023 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id15b0217ea8c48b0ad7e9858e136caa6_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMzM4Nw_358f7bcf-2c43-43a2-9794-ddd0df9626eb">83.0</ix:nonFraction>&#160;million under a Sales Agreement for the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2023, <ix:nonFraction unitRef="usd" contextRef="i568f04797f3a472aa282f7114d801497_D20230101-20230331" decimals="INF" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfNDk0NzgwMjMzMTg3Nw_fddbcf85-0618-41d8-8b2d-5b5a830e89f2">no</ix:nonFraction> shares were sold under a Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b69bc2016214d7e92944dae8a1223c5"><ix:continuation id="i411fc915ea5f4cda936a85962690a510">The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation></ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_40"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80MC9mcmFnOmE3NmNlMjAxYzU5NTQ3NGJhMmNhNTViYjAwN2M1Y2RlL3RleHRyZWdpb246YTc2Y2UyMDFjNTk1NDc0YmEyY2E1NWJiMDA3YzVjZGVfNTgxNg_b67367a5-85c7-4fec-bcbe-1dc484e8674e" continuedAt="i5db6deae228d4b80b50c80fe905d3e55" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i5db6deae228d4b80b50c80fe905d3e55" continuedAt="i5ae7b9d99a614c1f9e912cd43f05f7c7"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80MC9mcmFnOmE3NmNlMjAxYzU5NTQ3NGJhMmNhNTViYjAwN2M1Y2RlL3RleHRyZWdpb246YTc2Y2UyMDFjNTk1NDc0YmEyY2E1NWJiMDA3YzVjZGVfNTgxOA_553695a5-6dc2-433a-a6a7-9b5eca1b792c" continuedAt="i69c60344c1ec4886b1ea600d8fd1d178" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i5ae7b9d99a614c1f9e912cd43f05f7c7"><ix:continuation id="i69c60344c1ec4886b1ea600d8fd1d178"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#8217;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#8217;s or the collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80MC9mcmFnOmE3NmNlMjAxYzU5NTQ3NGJhMmNhNTViYjAwN2M1Y2RlL3RleHRyZWdpb246YTc2Y2UyMDFjNTk1NDc0YmEyY2E1NWJiMDA3YzVjZGVfNTgxOQ_306b72a5-8166-4883-805f-001a8e195d3a" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary smart device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_46"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfNDUw_55eea66f-cd86-432a-8aac-70b22b747cb0" continuedAt="ifee4514e12874171862544c84f398f42" escape="true">Revenue Recognition  </ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifee4514e12874171862544c84f398f42">During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i27c48d2543c3428ca9348a16927aa3ef_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfNzk_24703d69-a700-40c0-89e1-c71c5ce6b7e5">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i424005e9738e406cbe32ab9e0559a2cc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfODY_5a970dd4-5045-43b6-9816-c1722dffdb59">9,000</ix:nonFraction>, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $<ix:nonFraction unitRef="usd" contextRef="ie808b6354eac4d61890c011e8296a807_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfMjE5OTAyMzI1NjMzNA_f580d70d-5acf-4f89-9e14-cbf18ddac52f">115,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2794060b62c64f55ba10c6d991467be9_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfMjE5OTAyMzI1NjMyNA_b635b3ed-997b-4ba0-9d45-1166cc8339e9">190,000</ix:nonFraction>, respectively, from various other contracts as a result of performance obligations being satisfied.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYzMg_7b71e932-053b-4a93-b3a9-1b8ac62d53be" continuedAt="i40b52610699542369a211b6fb1f09b03" escape="true"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYzMg_fc12dfb6-2eb2-448c-b042-5f73580e289a" continuedAt="i8541b93d8b0744e0ac22057336f8ad2f" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i40b52610699542369a211b6fb1f09b03" continuedAt="iaf0959b9db24427b9d648f8336fe9f6c"><ix:continuation id="i8541b93d8b0744e0ac22057336f8ad2f" continuedAt="ibe91427f4d4f40afb2df4d0f94474bae"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYyNw_0b2b0a67-9459-4679-9487-5af633ee3b5f" continuedAt="i2c955d4ccd794d8c8cd77b742ce094bd" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi0zLTEtMS02MTQzMA_8d5f0e33-c76c-41ea-aa0c-c4b7d8b47763">85,986,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi01LTEtMS02MTQzMA_a8023257-3efa-4764-a60b-13c7d26e0926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi03LTEtMS02MTQzMA_1f3cc85e-2d0b-4cd7-9e0d-85a5605cc17f">6,155,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi05LTEtMS02MTQzMA_acdb1d5c-83ca-43e9-b27b-f6570c1dbe46">79,831,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="iea88717d3bae4c3282823b096cbc0010_D20230101-20230331" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOmE4ZDY4NDg0NDI4NzQ2YThiOWVlMjkyNTNhZjBhZDAzXzE0_304db787-1ed4-43f5-a194-c481fd9d423f">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy0zLTEtMS02MTQzMA_24f0f9c1-0c90-4ee4-b2e0-d8174d4589fd">111,591,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy01LTEtMS02MTQzMA_a2bf81dc-bad3-41bc-bac8-6de7b9941fa3">57,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy03LTEtMS02MTQzMA_66296d73-5b85-42d4-afc1-c53a48e3fea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy05LTEtMS02MTQzMA_65fc74b6-b5b0-4b90-b839-2d191dd483d9">111,649,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="if7f21b141b3745859c0259a876d2e137_D20230101-20230331" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOmU1NDAzYmY0MWVkMDQwZjg5YjczMjZkMjU3NDQwNDdlXzE0_6525f5c8-0921-42ff-b481-b4188a03199b">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9148075bf7401a924169db861cdb10_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS0zLTEtMS02MTQzMA_4978988c-0cc8-4bfa-974a-d100040b1fca">2,977,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9148075bf7401a924169db861cdb10_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS01LTEtMS02MTQzMA_6d95a20b-7165-4b33-9b91-fb6d64833e13">13,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f9148075bf7401a924169db861cdb10_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS03LTEtMS02MTQzMA_35dbef5d-b765-4e62-9a3e-5986fa7cf27d">314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9148075bf7401a924169db861cdb10_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS05LTEtMS02MTQzMA_7344f6c0-0823-4866-ab88-1361ede9a83c">2,990,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi0zLTEtMS02MTQzMA_90947b0c-b374-4413-bbd6-66f531bbc057">1,402,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi01LTEtMS02MTQzMA_d31f864d-d248-49be-95f0-74a5abf60d36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi03LTEtMS02MTQzMA_3b66ad6a-411e-4b04-821f-1b8d53d1cd47">360,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi05LTEtMS02MTQzMA_e7c441f5-e0ec-48ef-95cc-a58399eccb72">1,041,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy0zLTEtMS02MTQzMA_6a0a5965-9029-4615-af3e-ea95f3133579">201,958,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy01LTEtMS02MTQzMA_abb80c0a-c0d9-44d9-94df-6356ed2a0c79">71,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy03LTEtMS02MTQzMA_238e601c-88c8-45fa-9171-3a872dc1106b">6,516,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy05LTEtMS02MTQzMA_6e03b933-2bbd-40be-851c-5f5cb1f7b570">195,513,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="iaf0959b9db24427b9d648f8336fe9f6c" continuedAt="i3eb1cc94057a47878caf2500f34cc1a7"><ix:continuation id="ibe91427f4d4f40afb2df4d0f94474bae" continuedAt="i8388ee53bb72416bbbcd2819b28e2956"><ix:continuation id="i2c955d4ccd794d8c8cd77b742ce094bd"><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi0zLTEtMS02MTQzMA_28f6b457-cd0b-4b81-b43c-dfc5d757c0a7">117,036,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi01LTEtMS02MTQzMA_fd688fd2-385f-4d6c-bac5-3845dffa4671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi03LTEtMS02MTQzMA_cfa69dce-88c2-47fd-92fd-d3be41b4cb8b">9,373,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi05LTEtMS02MTQzMA_196fe28d-4edc-4bb1-8c61-e91cd2a26fb1">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;<ix:nonNumeric contextRef="id19a9893ad2e465a8c17eb61b026acc4_D20220101-20220630" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOmY5OTEzZDZkYTJkNzRmNGJhNzI4ZjY0MTc0ZWFkMDlkXzE0_1eb4bd84-1e3a-4542-b60d-9c6f7049e4f7">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy0zLTEtMS02MTQzMA_8d203c7b-cfd7-4c84-9508-921162e29968">95,001,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy01LTEtMS02MTQzMA_6f91b7cb-2e12-4a8f-82c9-d712f60568ce">7,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy03LTEtMS02MTQzMA_0521d1ab-1882-49aa-bd14-deeab9d1bc6b">44,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy05LTEtMS02MTQzMA_76a49dbf-d291-4bd3-88fe-478d8244826f">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i154f710696af44368c1b60a00236e33c_D20220101-20220630" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOjUzYzRmNzRkYWEyNjRiMzNiYzI3OGJmMGNkZWQyMDAxXzE0_2cb7239e-cf28-414c-bba6-9c26b367d3b9">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS0zLTEtMS02MTQzMA_859f1b80-47da-462f-b0b1-446633f68339">2,977,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS01LTEtMS02MTQzMA_73ca5645-d5bf-4f4b-a105-586840356363">13,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS03LTEtMS02MTQzMA_e790144d-bd1d-4612-ac77-44bb4560921c">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS05LTEtMS02MTQzMA_b92b7e15-d534-4252-8174-67e3a3b7c3b1">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi0zLTEtMS02MTQzMA_7e36e35a-137c-498e-b242-f3f8415ed0dd">1,435,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi01LTEtMS02MTQzMA_ca63571f-5514-4bf4-aea7-0e983502c6df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi03LTEtMS02MTQzMA_ce577b53-e1d0-4db8-a1ae-577edde488a9">384,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi05LTEtMS02MTQzMA_7ebe5d6d-04f9-421c-8644-e6a1576047d7">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy0zLTEtMS02MTQzMA_b295131a-d6d6-4be7-8f45-fd6220b5f274">216,450,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy01LTEtMS02MTQzMA_5c362d94-3ca6-4ad7-9d51-5bdcdf069b75">21,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy03LTEtMS02MTQzMA_a1a82ff7-0318-47b7-8128-5997c61643d1">9,802,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy05LTEtMS02MTQzMA_e2a5ba81-b4bf-4f32-be80-df2f1404503a">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2023 and 2022, the Company recorded gross realized gain on investments of $<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMjQw_349628a0-182a-4848-ac91-7cd86b49bc09">300</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMjQ3_03fdff45-a01f-4a36-b6d6-0665e9da3f61">20,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMzA3_a4d8a9b9-28a1-49ec-ac53-6a9051019e76">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMzE0_d79c1c28-17b8-4dda-82eb-acbffe1b04ff">339,000</ix:nonFraction>, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNTk3_811d6abf-f1fa-4553-b727-d5ed4225a759">3.2</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNjA0_503533a4-5c30-4f18-8bb5-e34082d69cdf">4.8</ix:nonFraction>) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2023 and 2022. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2023, the Company had <ix:nonFraction unitRef="position" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMTAzMw_5e4905d4-b031-4f63-b358-f739eab2841a">24</ix:nonFraction> available-for-sale securities in an unrealized loss position with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMTE1Mw_4b5da662-2670-4565-a4c9-3145af5465c7">6.5</ix:nonFraction> million, all of which were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2023&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2023, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYyOQ_f46cfa5d-704f-4c34-904f-7fc2273a081d" continuedAt="i1e404e36517245b6a84f598cf27dfb14" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aeb1a300754d82b80cb3075a7d276d_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC0xLTEtMS02MTQzMA_b0d44745-bc27-4c2c-83d1-84841fcf63d0">79,831,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9775574f1494394811d44684704ab67_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC0zLTEtMS02MTQzMA_9a2696eb-c2be-45df-ba0e-c5818f41417a">79,831,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507494694b6d4d009b81bc247609f9e0_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC01LTEtMS02MTQzMA_0f087fef-c3e8-4c7f-b0e8-3c9e6101053c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa977781312f47e69160962e49c81570_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC03LTEtMS02MTQzMA_73f4f462-ce97-4d20-b9fb-203f842bb5fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07230fde15e54b399d452926ed0f53a3_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS0xLTEtMS02MTQzMA_1bed00a4-da95-4fbb-8591-c4f4f44bf2f6">111,649,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b64b5b5c9b64e5fa4434c4e168d2559_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS0zLTEtMS02MTQzMA_ff172641-73dd-4c8e-8155-4516d917a937">111,649,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b7e2166f3914844b66ea56e45631aad_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS01LTEtMS02MTQzMA_327108fa-38de-4514-b792-308b474db7e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef64995166349eab1facc6cf436dfb4_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS03LTEtMS02MTQzMA_3a9749f6-4bc5-4324-b4f8-7c374b0a6ac5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d7cb8097694cbda0e2e5976080fed6_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy0xLTEtMS02MTQzMA_a2372a8f-0eb2-441d-a704-0432035c0788">2,990,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if837752dbae541949d9b5d2f3fc1d21a_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy0zLTEtMS02MTQzMA_177b434c-c45f-48f1-8457-e401b2a90957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d6af48af3740ed9e7512132b332b10_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy01LTEtMS02MTQzMA_20900158-e08c-4c6f-88d5-2ec18bb02b57">2,990,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i249d5e2b1d764f8f9849378142cdf683_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy03LTEtMS02MTQzMA_f0c582d5-1828-49fa-981c-54714f2c4875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4538d285010f4df39235b50e6df231bb_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC0xLTEtMS02MTQzMA_e369dbf6-48db-44e6-95f9-247864a0d5b1">1,041,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808771e2c7b748768ba48825de30ab59_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC0zLTEtMS02MTQzMA_939399eb-2a3a-4508-a65d-c9c4bc8c2ab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035ac45eddcd4ad0b877179ce402b012_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC01LTEtMS02MTQzMA_04db7cf8-3a19-42f6-a183-1f598c9000de">1,041,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100ee50b23804321a39f1344ec331844_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC03LTEtMS02MTQzMA_78f929df-258b-4915-bb23-f25a194cf62c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc54f897c91449868d75304b60ed52b5_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS0xLTEtMS02MTQzMA_fc210337-8b88-4636-882a-2571ab9beb73">195,513,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7764fa9747144127856f5f47e535b68b_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS0zLTEtMS02MTQzMA_d3eec53f-bb98-4a48-84dc-23586b881345">191,480,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeac876368b343568a773a83ca4cfa00_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS01LTEtMS02MTQzMA_90da2648-ad4f-40e5-80df-3b1658597cb1">4,032,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9438d2a2b449a28a0426195cc69b58_I20230331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS03LTEtMS02MTQzMA_80bfe309-4c4e-4933-ab6c-e92f4a1f9d55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc54f897c91449868d75304b60ed52b5_I20230331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtMS0xLTEtNjE0MzA_af227dc0-b9c4-469a-88a7-d38d4f284982">2,623,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7764fa9747144127856f5f47e535b68b_I20230331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtMy0xLTEtNjE0MzA_1d046af1-ecc1-45bb-acf6-b41e2fabb2a5">2,623,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeac876368b343568a773a83ca4cfa00_I20230331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtNS0xLTEtNjE0MzA_2976bd22-bc45-470d-b580-95ca37748d64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9438d2a2b449a28a0426195cc69b58_I20230331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtNy0xLTEtNjE0MzA_e4dc48b5-3430-4589-a831-73b8fa7929bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc54f897c91449868d75304b60ed52b5_I20230331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItMS0xLTEtNjE0MzA_20b0bbe1-4e9c-4073-90ab-57411984fc72">198,136,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7764fa9747144127856f5f47e535b68b_I20230331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItMy0xLTEtNjE0MzA_d021dba8-ea04-4f29-93be-c375f0f48408">194,104,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeac876368b343568a773a83ca4cfa00_I20230331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItNS0xLTEtNjE0MzA_14a35094-71fa-4078-8d52-be1727305aba">4,032,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9438d2a2b449a28a0426195cc69b58_I20230331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItNy0xLTEtNjE0MzA_c472e83f-a6de-4d67-8ec4-3c0dc76d6fd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i3eb1cc94057a47878caf2500f34cc1a7"><ix:continuation id="i8388ee53bb72416bbbcd2819b28e2956"><div><ix:continuation id="i1e404e36517245b6a84f598cf27dfb14"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i651421a71e44472594de779a6c90aa58_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC0xLTEtMS02MTQzMA_6b588531-6551-404b-b84d-e78bf17ed5cb">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe53fa638d94b9684c5bb12d5d28448_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC0zLTEtMS02MTQzMA_6db59d4d-4308-4829-ab0c-ffbbafb158a1">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d8611e12df41f6b46df72274195e75_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC01LTEtMS02MTQzMA_775e4482-41ef-47b0-baec-5184fca6f7e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f7ea859ca14010a0f5dc0c523bb83a_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC03LTEtMS02MTQzMA_9ebe70ec-91b4-4bc6-ae37-94ff8482bbe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8621666cb44531a664219b42fb568f_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS0xLTEtMS02MTQzMA_c55ee8cd-4c82-42a1-90df-6864ed6e107d">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b95b05eddd474fa6a45fb6fbd8ae32_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS0zLTEtMS02MTQzMA_b0f8ec0e-ac4d-4eb5-bdf9-917833e61890">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc7276b422b4eb7b9f1e2ecd0d3c68f_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS01LTEtMS02MTQzMA_25dc83d5-10bb-4339-8bcf-dc8e16897411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8759eb4716482494a75a4509d57041_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS03LTEtMS02MTQzMA_cfcb9a1b-f98f-4ab7-9751-8238695ed830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76596fa49ec24abb8271d264e6f19bab_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy0xLTEtMS02MTQzMA_71dd3647-1ea9-4176-8bf9-a827d3fc6c7f">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ea510fa47e424d943494f963231339_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy0zLTEtMS02MTQzMA_1153f4fe-ee1d-45ee-807b-0293e606469e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79060d2c3e3147b3b3d21d5d5bb394ab_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy01LTEtMS02MTQzMA_1a8d44fc-7a87-4182-a4f6-bf9971dfbddd">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7398b2d88e70463d906bd72f9a1b2cf7_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy03LTEtMS02MTQzMA_1828b431-c9e3-40cb-974e-c9986529ad7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e9b36e3881479fb2114bf17a00489a_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC0xLTEtMS02MTQzMA_df393e52-1b25-4d08-8598-abc3e63a1984">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ec3a3107ab43409a0d2eeff38d951a_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC0zLTEtMS02MTQzMA_b10cd081-3f73-49c1-9c55-ca9e2941df35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3d830b50b94da7b62468b24771824e_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC01LTEtMS02MTQzMA_2a541832-3eea-42a0-9154-a17e42bca69b">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4653ccc0974003b1771f075fa5970c_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC03LTEtMS02MTQzMA_fb52c065-c405-453c-a128-7e8d8e1a86a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a72e62f7c41430690c464a69f2537db_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS0xLTEtMS02MTQzMA_6b2aca1c-922b-4370-a33e-7637d9f53302">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS0zLTEtMS02MTQzMA_fe6908ac-ad84-4316-b8f1-1e1f349e298d">202,627,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS01LTEtMS02MTQzMA_d6322eb4-2634-48c9-a7e4-7e0083b77be5">4,042,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d19f47994c4a2087e95232f349c61e_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS03LTEtMS02MTQzMA_7d67e1cb-ff17-4750-b575-e9eee6dcfb4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a72e62f7c41430690c464a69f2537db_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtMS0xLTEtNjE0MzA_d30587ec-80d5-422f-b1cf-106741a198aa">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtMy0xLTEtNjE0MzA_327c8188-cc2c-441c-bbf6-8368da504ae3">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtNS0xLTEtNjE0MzA_f6cda8ac-2d29-4aef-9c7e-b0bbb1fd7edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d19f47994c4a2087e95232f349c61e_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtNy0xLTEtNjE0MzA_d201d136-2f2a-4cdf-8c26-adc5a1bdce99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a72e62f7c41430690c464a69f2537db_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItMS0xLTEtNjE0MzA_c850dd97-cfb7-45e2-b7a1-48d97e759dc2">208,676,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItMy0xLTEtNjE0MzA_a28c6aea-40e2-4209-89f1-8a5e10230dcf">204,634,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItNS0xLTEtNjE0MzA_09d5919d-d34f-4756-bafa-49f59451f34e">4,042,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d19f47994c4a2087e95232f349c61e_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItNy0xLTEtNjE0MzA_529e7493-b491-4392-a654-50b76e4f655a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="ib5590b7d3f8242afba7128120cfea182_I20230331" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMjkxNw_60dc93e7-c0d6-4e0e-bb62-811ce8e3f218">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2023 or December 31, 2022.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_55"></div><div style="margin-top:5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfODMw_becff48a-de3e-4d75-a3b3-cd855ea65c6b" continuedAt="ie12d382d99074431ad611aaff271e763" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="ie12d382d99074431ad611aaff271e763" continuedAt="i6b745f30e8a0436a833400732dc46b45"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfODMx_b98c733d-25a3-487f-a7f3-c1decee1daf0" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMS0xLTEtMS02MTQzMA_d68d4863-27f4-4583-9710-55b0990ae9ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMS0zLTEtMS02MTQzMA_09c4f8a4-9db5-4c56-b1d5-a9d591524687">30,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMi0xLTEtMS02MTQzMA_304a32c5-526c-41db-97b6-773c673f0dd7">565,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMi0zLTEtMS02MTQzMA_2c56f160-a495-4eb7-b615-2a67a4a61fb0">1,401,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMy0xLTEtMS02MTQzMA_e875ec11-650a-4007-978e-27550e95b863">4,349,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMy0zLTEtMS02MTQzMA_92ab50e2-3ba0-472d-bcb8-d3e7e5359791">18,729,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfNC0xLTEtMS02MTQzMA_71869f19-780f-4804-a7a8-92b623b0a4e0">4,914,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfNC0zLTEtMS02MTQzMA_2b08a06c-5221-48d5-9b75-a9a454ea7591">50,130,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfODMy_a32eb9b4-ed96-4204-8c43-14317e173c51" continuedAt="i1566da8768724879b5f460bcb5c7cb4d" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMS0xLTEtMS02MTQzMA_4a515882-93ce-40ef-bf81-9527bee47489">11,194,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMS0zLTEtMS02MTQzMA_63a39825-bd49-42c3-8cbc-581e464b6b9c">19,862,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMi0xLTEtMS02MTQzMA_9b49e938-cb6e-45c0-bdbb-d65bf123b3cb">7,607,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMi0zLTEtMS02MTQzMA_9719073c-7c38-4c99-bfc5-536bd85d60b5">12,574,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMy0xLTEtMS02MTQzMA_a503314e-fbfa-438c-bcfc-35961430e66c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMy0zLTEtMS02MTQzMA_1241f662-a49d-4218-94d2-24c345a8622e">44,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNS0xLTEtMS02MTQzMA_d1544a6f-9a07-491d-acbe-cec66400e481">5,950,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNS0zLTEtMS02MTQzMA_dbc7e693-d7c7-409f-80ed-0a68d4639f56">3,249,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNi0xLTEtMS02MTQzMA_8a11ee10-ec2f-44ee-b433-8f037488931c">24,752,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNi0zLTEtMS02MTQzMA_34660b34-f7a0-4afb-9663-58366e5bcbf1">79,686,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:-4.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b745f30e8a0436a833400732dc46b45"><ix:continuation id="i1566da8768724879b5f460bcb5c7cb4d">(a)&#160;&#160;&#160;&#160;In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221; The final judicial order for the settlement was issued in January 2023. The settlement consisted of $<ix:nonFraction unitRef="usd" contextRef="ifd6835ef9291475398187809336a6e27_I20220731" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfMzk4_7c71a5f2-e885-4708-8f07-3dc16fcd9a0c">30.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="ifd6835ef9291475398187809336a6e27_I20220731" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfNDEz_375595a3-39cd-4628-b955-67cc2c41701b">14.0</ix:nonFraction>&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $<ix:nonFraction unitRef="usd" contextRef="i092045a4d4c24e66871ac745807bd523_D20230101-20230331" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfNjg5_54f473a6-7f05-459f-bc51-523167f65284">252,000</ix:nonFraction> of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued <ix:nonFraction unitRef="shares" contextRef="ib97422d241744aecbec5cdc038a635ef_I20230228" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfNTQ5NzU1ODE2MjE4_a15dbcd0-5549-48e5-aa2c-f69885ae1c37">9,121,000</ix:nonFraction> shares of common stock pursuant to the securities class action settlement.</ix:continuation></ix:continuation></span></div><div style="text-indent:-4.5pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_58"></div><div style="margin-bottom:3pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODU2_b060af59-adc6-4e5d-91e7-7f22352aa187" continuedAt="i1842d8ef0b6e4cbcab39e1b9f162031d" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i1842d8ef0b6e4cbcab39e1b9f162031d"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODQ4_bb3d8f25-c1af-45cc-b5fd-cf57e90a4552" continuedAt="i0ab20d12924b41a89a72fc8288c5c377" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.918%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy0zLTEtMS02MTQzMA_e13bdcea-f076-413a-81db-3dcd6283b82b">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy03LTEtMS02MTQzMA_ca37a7e0-d97a-420c-ade2-95948f12f0c9">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy05LTEtMS02MTQzMA_3b87eafe-54fd-4dc5-b7ed-5a22ddc69203">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy0xMy0xLTEtNjE0MzA_b2eee07f-3ee5-4581-9899-3e9e88c3c527">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ab95fd57f0f426ebe487aa41e25c7d4_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0xLTEtMS02MTQzMA_e45560b7-21fd-4fda-b31e-d50228f9d2d4">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0zLTEtMS02MTQzMA_4da0ef77-8cc9-465c-8f14-112560d51421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi01LTEtMS02MTQzMA_4eb81d03-b662-4df9-b027-b9c5f639b6ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi03LTEtMS02MTQzMA_7bc1f10e-835d-4e53-ba99-a17b1b4052fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi05LTEtMS02MTQzMA_897d10dc-c997-46ab-88ab-03a69bfd6134">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0xMS0xLTEtNjE0MzA_757794fd-1dd7-44b8-88a8-38b845463773">1,323,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0xMy0xLTEtNjE0MzA_c5578105-d3a6-4904-8d67-b41155cfaae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2fad80428c8a4c91a84c10d223b587df_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0xLTEtMS02MTQzMA_8bdd8eb3-8ece-4c2b-94b4-cb8654a8423e">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768b12453cb44701902fe18cf70b486b_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0zLTEtMS02MTQzMA_baab67b3-d09c-4910-9d13-4a9499d709ed">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i768b12453cb44701902fe18cf70b486b_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS01LTEtMS02MTQzMA_10e58d6d-0a0c-43cf-b25f-df3b5c4823a7">3,052,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768b12453cb44701902fe18cf70b486b_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS03LTEtMS02MTQzMA_c8c35b23-61d7-4841-ad15-f047039a335b">2,047,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS05LTEtMS02MTQzMA_325ce742-85ad-41de-b661-05133c80f2af">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0xMS0xLTEtNjE0MzA_6d51a1a6-ca1c-4d99-b42e-f2d9a29b89c1">2,988,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0xMy0xLTEtNjE0MzA_7258bb9e-17ad-4c52-a5ae-86be0afdea87">2,111,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6fb0a36935424e9b8c96652f09088bcd_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMS0xLTEtNjE0MzA_04279b1a-7c7b-4ce8-b3c3-8ca2503e6365">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMy0xLTEtNjE0MzA_ed277668-a84b-4dc8-ba90-5a50bb513c4a">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtNS0xLTEtNjE0MzA_5c68d359-f06f-4705-9010-1d27710b6b6f">4,050,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtNy0xLTEtNjE0MzA_9f08f9fb-8b78-465b-ab09-d74a4cafc6ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc0c0bab6884b4380426817d471b00c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtOS0xLTEtNjE0MzA_ae345fb4-7b62-44bb-b2a4-5fd7e336e116">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cc0c0bab6884b4380426817d471b00c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMTEtMS0xLTYxNDMw_85aef25a-ce2b-4218-8457-79da9e4784f5">4,031,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc0c0bab6884b4380426817d471b00c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMTMtMS0xLTYxNDMw_d3dac945-ead7-4bda-ae12-6f34b4b633d6">18,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9eedc0cc685c44ee9cb4b8772b34620b_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMS0xLTEtNjE0MzA_302ef114-2c01-455b-bcc4-6c6363272d9d">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMy0xLTEtNjE0MzA_9ca6c4ac-9701-460f-bdaf-b6beaafc4e93">9,150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtNS0xLTEtNjE0MzA_95363714-8fe4-4380-81a8-28b14b2d8d3d">7,102,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtNy0xLTEtNjE0MzA_e71d34e1-039e-4975-bb33-99ed65b2eb3e">2,047,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtOS0xLTEtNjE0MzA_963a8a9f-447f-42ef-8a6a-70a7ff1381c8">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMTEtMS0xLTYxNDMw_b10b6b8e-f3ee-48bf-9fc5-b7add15d3f32">8,343,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMTMtMS0xLTYxNDMw_0536ea74-e2e6-43d0-a7d7-9c640ee61166">2,129,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItMy0xLTEtNjE0MzA_94c6b166-e074-4a25-9e3c-ffe330207845">19,663,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItNS0xLTEtNjE0MzA_f8358a70-25af-4d09-b571-90a859505ce3">7,102,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItNy0xLTEtNjE0MzA_d299b084-561e-4d25-832c-442a2bb64501">12,561,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItOS0xLTEtNjE0MzA_cdb8416c-c5df-4498-b488-5164cc855658">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItMTEtMS0xLTYxNDMw_5bb04c29-ffa2-446a-a61d-739de1961825">8,343,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItMTMtMS0xLTYxNDMw_ba25f666-717c-49ec-b0fe-e7f557a622f9">12,643,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0ab20d12924b41a89a72fc8288c5c377" continuedAt="i25d59a89c0584e5cbd91ac0719d67917">(b)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"><ix:continuation id="i25d59a89c0584e5cbd91ac0719d67917">Other intangible assets represent the estimated fair value of acquired intellectual property.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets for the three months ended March 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNDQ3_77996159-7075-4d6d-b47d-15e0635fef5c">82,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNTM5_488d52fc-3015-4cde-919c-c1a17dd483db">127,000</ix:nonFraction>, respectively. Estimated aggregate amortization expense is $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjA5_397e6c36-004f-4f19-83cd-d337f8debf68">190,000</ix:nonFraction> for the remainder of fiscal year 2023, $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjQ5_0a8f3bf1-c73c-42c5-9ab5-3ae2844819e9">253,000</ix:nonFraction> for 2024, $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjYx_4a218ee2-f0d2-4411-be4e-6d9470a33985">253,000</ix:nonFraction> for 2025, $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjcz_740bf366-318c-4c94-bf2a-6cf55b4d5170">253,000</ix:nonFraction> for 2026, $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjg1_4f431a79-171a-4f95-8b71-6b702eee73cf">253,000</ix:nonFraction> for 2027 and $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNzAw_fe52e923-ba97-4724-a90f-734b9cc77ba1">845,000</ix:nonFraction> for 2028 and subsequent years combined. There were <ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNzUy_e9f8fa0f-2868-4108-a2b8-64e076d7cc0c"><ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNzUy_ed69688a-516b-4ca1-ac60-7fbcb3591706">no</ix:nonFraction></ix:nonFraction> impairment or impairment indicators present and <ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODAz_a3973b94-e34e-46c8-ad96-9f3e538c26b0"><ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODAz_dffcb68d-bd0e-4cae-883e-4dfecb1bf34a">no</ix:nonFraction></ix:nonFraction> losses were recorded during the three months ended March 31, 2023 or 2022.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_61"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTg1MA_ece3a0a1-8bec-4830-9f16-cfb753b80388" continuedAt="id0816b90271f4680b81ee2fc6024b61a" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="id0816b90271f4680b81ee2fc6024b61a" continuedAt="i7a0d70d051a348468a1e523fede17588"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="i282e3fa937b948e186e4be58f112112e_I20190301" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTM2_a94e8501-f6a1-4112-a28d-8f27d201541e">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i282e3fa937b948e186e4be58f112112e_I20190301" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTcz_87433d53-ad80-4076-ace1-e930e966bcad">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDA1_55a0397b-0092-4e9d-ae12-6ec1f6dd5941">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of <ix:nonFraction unitRef="number" contextRef="i282e3fa937b948e186e4be58f112112e_I20190301" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTgy_10b5df17-9965-417c-990f-fed57368a7d0">6.50</ix:nonFraction>% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i282e3fa937b948e186e4be58f112112e_I20190301" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTM4MA_06bc82b2-45b8-4245-b014-959dc7920082">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i7a0d70d051a348468a1e523fede17588"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTYwNg_a51a8bca-6cfc-4352-bcb8-ebc039d8b6d3">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTY1Nw_a1e40747-4d96-4ee1-bcc0-8c0c068f46ea">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="day" contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTcxMw_7047755a-dbe1-4252-a39a-60d0a7918939">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTk4NA_c35cd689-4623-4c3c-a5a1-55000fb7e2c0">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $<ix:nonFraction unitRef="usd" contextRef="i282e3fa937b948e186e4be58f112112e_I20190301" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjUwOA_125f8e0b-3704-4251-94dc-5a89c29458b8">16.3</ix:nonFraction>&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjYyNw_06aa3f0f-a96e-406a-82b3-05c191f42528">13.1</ix:nonFraction>%. In addition, the Company allocated $<ix:nonFraction unitRef="usd" contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjY2Ng_0045015b-167d-4a88-adab-307a8003c561">592,000</ix:nonFraction> of debt issuance costs to the equity component and the remaining debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ib5cef3158a4649a18541e2a3562c8711_I20230331" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjc1Nw_bc97abe5-4bc5-4b33-95df-75ab5a55b3cc">2.2</ix:nonFraction>&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMzc3Mw_a6b4f760-2729-486c-9321-4425972f0f08">1.8</ix:nonFraction>&#160;million, a decrease to additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMzgyMQ_f6ef2c8a-5fa9-4685-aab9-0252f91c5d8c">3.3</ix:nonFraction>&#160;million, and an increase to convertible senior notes of $<ix:nonFraction unitRef="usd" contextRef="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101" decimals="-5" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMzg3Mg_fdd16c04-e26a-4a9b-93ac-6e74c48ca495">1.5</ix:nonFraction>&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.</span></div><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTg1NQ_100abfb4-174f-43ef-ba4e-a2f01ba789e2" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2023 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331" decimals="0" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfMC0xLTEtMS02MTQzMA_ff3748d2-d83f-4012-923e-26a71b3973a6">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331" decimals="0" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfMS0xLTEtMS02MTQzMA_02eb8e7a-1782-4327-8dd3-f62003d4900b">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331" decimals="0" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfMy0xLTEtMS02MTQzMA_a8d6168b-9e79-46d9-ad4a-04d275603474">109,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331" decimals="0" name="ino:DebtInstrumentAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfNC0xLTEtMS02MTQzMA_c73ffcd6-3f4a-4d22-8ba0-a3e0d117b3ca">88,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfNS0xLTEtMS02MTQzMA_2aea0ea4-efd1-474e-8625-8393bb301097">16,394,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the three months ended March 31, 2023 and 2022,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i0de4d1310e9b417ca7f60cde3199cf93_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDE3Mg_8455f797-d775-48db-9a55-ebbfbbe7e80f"><ix:nonFraction unitRef="usd" contextRef="ie617d1d3144a464890df59e30f71dfd0_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDE3Mg_f2dac2c7-7af6-42cf-bd51-4a7536ac1f80">313,000</ix:nonFraction></ix:nonFraction> of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="ie617d1d3144a464890df59e30f71dfd0_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDI0OA_2d85c0be-da6d-4076-bc05-edefc50114ad"><ix:nonFraction unitRef="usd" contextRef="i0de4d1310e9b417ca7f60cde3199cf93_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDI0OA_e0890f03-6a0e-44d8-91e4-941c3c2d0c8a">267,000</ix:nonFraction></ix:nonFraction> related to the contractual interest coupon. </span></div><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTg1Mg_f6a676e9-47d2-4e69-8a55-ec1aa9280d34" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDYzNg_d842cba9-2197-46f9-bb5c-90290297f695">6.5</ix:nonFraction>% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmQ3MjAzZmE0Yjc2MzRkZmRiMGMxN2E0MzY0MWEyNmZhL3RhYmxlcmFuZ2U6ZDcyMDNmYTRiNzYzNGRmZGIwYzE3YTQzNjQxYTI2ZmFfMy0yLTEtMS02MTQzMA_bb24298c-4003-4cd0-83d4-90736abd83d3">533,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmQ3MjAzZmE0Yjc2MzRkZmRiMGMxN2E0MzY0MWEyNmZhL3RhYmxlcmFuZ2U6ZDcyMDNmYTRiNzYzNGRmZGIwYzE3YTQzNjQxYTI2ZmFfNC0yLTEtMS02MTQzMA_04adbeeb-55ba-4c1d-9ddb-b60aaaf39816">16,948,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmQ3MjAzZmE0Yjc2MzRkZmRiMGMxN2E0MzY0MWEyNmZhL3RhYmxlcmFuZ2U6ZDcyMDNmYTRiNzYzNGRmZGIwYzE3YTQzNjQxYTI2ZmFfNi0yLTEtMS02MTQzMA_730c4594-303e-47e6-9200-703b515dbac7">17,481,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_67"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDA5MQ_9b57014e-6af6-4fe9-9cc2-ae957d0f129b" continuedAt="i042e3b459c2049758f1df15cfe1396d9" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i042e3b459c2049758f1df15cfe1396d9" continuedAt="i72e6eae7fb6f449b89e31b0ff3789197"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDA4Nw_378d2ef2-b5eb-4b84-afd9-600d4bf06ff1" escape="true"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2023 and December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjZjZDAxZDQyYThmMjRjOWM4ZDMxYTEwNTk4NWYyMjEzXzI4_4063d3ac-7e8a-48ce-afee-2b068a7c1b84"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjZjZDAxZDQyYThmMjRjOWM4ZDMxYTEwNTk4NWYyMjEzXzI4_9f68f3cc-56cf-4d05-9fcd-d5a2b6a9d3d8">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0xLTEtMS02MTQzMA_ea5111e4-1e8e-47b0-b2bb-fe5914badeab">600,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0zLTEtMS02MTQzMA_a66438e1-601c-4f02-ada9-2f1df19c6c1c">262,739,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi01LTEtMS02MTQzMA_4554b33f-b78c-41d0-9c30-8584323aeff5">262,739,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a51b3e565934094b048701d97384fb1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi03LTEtMS02MTQzMA_628501d4-74e4-4b73-8207-e924ee4e9853">253,091,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ic53065c277c54ed285075c2628977167_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjg1ZmI3MzY4NmZkMDRiNDY4YTNmYzUzNTEyMmE4YTg3XzQw_55ce9553-0a65-4b72-907e-101848a12e0a"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd58cfd5707b40a8ba848f715d75243e_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjg1ZmI3MzY4NmZkMDRiNDY4YTNmYzUzNTEyMmE4YTg3XzQw_f4884089-c263-44db-ba56-c1b5da5f04f2">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53065c277c54ed285075c2628977167_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0xLTEtMS02MTQzMA_f52de025-3346-4067-8192-84d89a5787b9">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53065c277c54ed285075c2628977167_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0zLTEtMS02MTQzMA_ffa08e65-3689-4296-b3c1-a87d56f79c51">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53065c277c54ed285075c2628977167_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS01LTEtMS02MTQzMA_91bc69da-e534-4472-95a7-49d01418aed1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd58cfd5707b40a8ba848f715d75243e_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS03LTEtMS02MTQzMA_2f338b49-0225-4488-8b6d-eb5537ad2b3d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i72e6eae7fb6f449b89e31b0ff3789197" continuedAt="i96bc66cb05af47ab9004a00bb895009c"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ib11d128f5b7d46c4afc00ddccd41927b_D20211109-20211109" decimals="-5" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDMx_7576e8eb-7a53-42f8-b74a-be1af62ec539">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="ib11d128f5b7d46c4afc00ddccd41927b_D20211109-20211109" decimals="INF" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNTUy_3fa58da9-86c9-47f6-acf3-a8a4255db82b">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. <ix:nonFraction unitRef="shares" contextRef="i3a8c9b4d47374eb8ac0b52b8d7f5d1ec_D20230101-20230331" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNTQ5NzU1ODE5NTIz_4e5e2e57-752f-4b9e-a0e9-ce6e9d7830dc">No</ix:nonFraction> shares were sold under the 2021 Sales Agreement during the three months ended March 31, 2023. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company sold <ix:nonFraction unitRef="shares" contextRef="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjE5OTAyMzI2MTg1NQ_a709d56e-c3a7-43b2-9dbd-40e0eb522e18">8,480,483</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331" decimals="INF" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjE5OTAyMzI2MTg2Ng_28c2a5e2-e860-4273-93bc-49eee02896f8">3.52</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjE5OTAyMzI2MTg3Mw_abe47116-f8b5-43f9-ba61-c32a37f32ab9">29.4</ix:nonFraction>&#160;million. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> there was $<ix:nonFraction unitRef="usd" contextRef="i1ea599a7a25b45f7b1f330755ed5da57_I20230331" decimals="-5" name="ino:StockSalesAgreementRemainingAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfODYy_ae5555b4-d7f4-4ce0-9aa4-6192374deb33">167.4</ix:nonFraction> million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib97422d241744aecbec5cdc038a635ef_I20230228" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNTQ5NzU1ODE4ODEy_a15dbcd0-5549-48e5-aa2c-f69885ae1c37">9,121,000</ix:nonFraction> shares of common stock pursuant to the securities class action settlement, as described in Note 13.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i5dcce6012ae249d88a84eed499079c98_I20160513" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMTk0OQ_9ac480be-66c6-4aa7-93d1-390306b61e99">24,000,000</ix:nonFraction> shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i5dcce6012ae249d88a84eed499079c98_I20160513" decimals="INF" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjA2MQ_7c62ccf6-adf9-411e-a88b-4e4806f1bf3b">2,000,000</ix:nonFraction> shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by <ix:nonFraction unitRef="shares" contextRef="i564a8962d6e44317a92f8b2819e51177_I20220101" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjM2OA_e6a004ed-842f-4e1c-8e59-b8b400e3fe29">2,000,000</ix:nonFraction>. At March&#160;31, 2023, the Company had <ix:nonFraction unitRef="shares" contextRef="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjM5NQ_ac671580-41d2-4678-8278-c7f648611df5">2,761,477</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjQ3OQ_23a912ca-cab0-4ce7-bdd3-26b915fc2660">1,994,799</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjU2Ng_71990a41-f1c5-45c2-be5a-b61171082d8c">13,239,324</ix:nonFraction> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over <ix:nonNumeric contextRef="ifbe75a7506d1456ba7caadb9076e0ed8_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjcyMw_ec03712c-8de5-40b8-81f8-da1f75f42d53">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="ifbe75a7506d1456ba7caadb9076e0ed8_D20230101-20230331" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjc2NQ_354b4fcd-1ca3-4c6d-b766-505f97467264">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company's board of directors approved a new 2023 Omnibus Incentive Plan, subject to stockholder approval.  If approved, no further grants will be made under the 2016 Incentive Plan. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed <ix:nonFraction unitRef="shares" contextRef="i40f17f0e740b43c29e5c8bb3c1255760_I20220624" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzM0MQ_e7daf2d2-bbb3-4885-b7ba-3a4189d017c1">2,000,000</ix:nonFraction> shares. At March&#160;31, 2023, the Company had <ix:nonFraction unitRef="shares" contextRef="i27142f229fa048279b6b126bc5f26f7d_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzM3NA_6da5a0c1-b2da-4b93-a700-dad7e1d39305">1,573,125</ix:nonFraction> shares of common stock available for future grant under the 2022 Inducement Plan, <ix:nonFraction unitRef="shares" contextRef="i27142f229fa048279b6b126bc5f26f7d_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzQ1OQ_92df0589-ec8d-4a8d-9fcb-3edf2338ed4e">155,000</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i27142f229fa048279b6b126bc5f26f7d_I20230331" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzU0Ng_fd6ff9d8-6a7a-4704-af7f-86f2da408e27">271,875</ix:nonFraction> shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i96bc66cb05af47ab9004a00bb895009c" continuedAt="i5ca7769b3c0f42ac9a160be4d483c0d7">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on M</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ca7769b3c0f42ac9a160be4d483c0d7">arch&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2023, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i51eaae0fbbe940fca869c9447afe074b_I20230331" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzkwOQ_74ea4278-7911-4b19-a40e-bc964d5d5f14">1,748,245</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="i1d514f11ff234b3093019d9807fa2ffd_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDAzNQ_178455ae-f31c-4595-aa46-b75ea583633f">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i1d514f11ff234b3093019d9807fa2ffd_D20230101-20230331" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDA3Nw_ff0ac801-9815-429b-b5cb-9bd2b81bde2d">ten years</ix:nonNumeric>.</ix:continuation> </span></div><div><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_70"></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RleHRyZWdpb246OGExOWZlNTllMmVmNDgzZmE0YWI2ZTBkMTY2ODVjZmNfMTYxMA_b87c5c70-d47d-4951-a3a9-ea7ecccde1d1" continuedAt="icdb92c772c204a2e8917672c35e3766d" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><ix:continuation id="icdb92c772c204a2e8917672c35e3766d" continuedAt="i08be0d889fb1478d910b11963b751d94"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 8) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.</span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i08be0d889fb1478d910b11963b751d94"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RleHRyZWdpb246OGExOWZlNTllMmVmNDgzZmE0YWI2ZTBkMTY2ODVjZmNfMTYxOA_4a87496b-c0e9-4e47-8e8e-632c4891b44c" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i921b1a2eed0045048faa0c08a241ab45_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMi0xLTEtMS02MTQzMA_c3d641e4-0b9c-4ede-81a4-477a52f36b76">15,259,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60bda6ceb3ee454d9ac8642950c68c58_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMi0zLTEtMS02MTQzMA_e8df7a78-209f-42e3-90d7-1c58e882408b">14,097,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03ff7bbfafae4ca3999c42f1172d7aa0_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMy0xLTEtMS02MTQzMA_7f8a0e68-dcaf-46c1-ae8d-76aa32f9a857">2,149,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c08ae29ea3f4f058c8448338f3ed45b_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMy0zLTEtMS02MTQzMA_f29e53fb-c8dd-41a4-b10c-ea5af93c360a">3,491,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib58a4b297f7b456087c6738a5502b9dd_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNC0xLTEtMS02MTQzMA_d8272ed6-f09f-44fd-a11b-497001118ab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdc5a1af5a8d4d3e8d3c1e7c321d49f3_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNC0zLTEtMS02MTQzMA_fd59b684-4424-42b9-9e1a-065216a5158f">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2779b2689b1147a59ccf83b443c35881_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNS0xLTEtMS02MTQzMA_4af28eb6-c2e1-4e4c-a36e-44cbcd2398ad">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2227a6874dff4a5eb1a92a35dc47787b_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNS0zLTEtMS02MTQzMA_77fc7650-26dd-48db-9a2a-3684247da8f5">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf177595aa91424a9dda4724bee8580b_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNi0xLTEtMS02MTQzMA_24c9ecd4-dcdf-4b90-a3ef-ea6a14830303">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42874be0b5e343d3925a6e3e6d86611e_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNi0zLTEtMS02MTQzMA_dc884862-a2a6-440e-b024-45f9dff4e7bd">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfOS0xLTEtMS02MTQzMA_b4a06d63-17d5-464a-9e8c-402e1370e9dc">20,462,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfOS0zLTEtMS02MTQzMA_c5f9a5d6-d49b-4e56-855e-968a4002da59">21,305,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_73"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfNDIzMA_a59f5e60-3e50-4510-94cc-dba7bfa4651c" continuedAt="i824bd9a7ad5c4329847349dece6fd446" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i824bd9a7ad5c4329847349dece6fd446" continuedAt="ic0335d741b8b48ea9adc97b4053c50c4"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfNDI0MA_c2c1f2e2-26e1-43a5-b662-eb22b8effeef" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMi0xLTEtMS02MTQzMA_fb7b3cc5-8035-457a-b7ab-36b999e54491">4.09</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMi0zLTEtMS02MTQzMA_a9ddcaaa-9213-4afc-ae77-fea45cdafc2f">1.88</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMy0xLTEtMS02MTQzMA_c6697570-4149-480b-97e3-e78ad0adba27">99</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMy0zLTEtMS02MTQzMA_7ea59fa5-ef8b-4178-a552-3ef6c8e51b5f">93</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNC0xLTEtMS02MTQzMA_93bda79e-8f57-4402-bfb7-df127748be85">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNC0zLTEtMS02MTQzMA_f18ff0b0-c7c4-40a1-8c17-74c238b31f53">5.7</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNS0xLTEtMS02MTQzMA_f07eecb3-2d4d-4eb5-b954-76b1dacefd6c">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNS0zLTEtMS02MTQzMA_ce4ec6fc-6df7-4852-bc04-32e03f9a0dfa">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="icffc34c375714623ba96b595bd73a117_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMTU1OA_ef60992e-bb54-4533-9b00-aebb82fbf02c">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i379a776732214db1b029bd03e5346c7a_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI1OTgwNw_8b52be36-bdfc-40de-a4ff-7c70043a3950">7.2</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="if16f4b4774ea4c47a1523d104d021a00_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMTU5NA_fb57ac79-1dec-4f73-8f2e-6ff41331d61c">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5482985971d94cc99e0f3719ecaa6f37_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI1OTgxNA_563dfe82-f0de-4208-b1a4-18f168c63f5c">3.7</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="ie151e6230187439faf1df447c5fab34d_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMTY3Ng_84c29113-fb8e-4c3a-8f4e-53cefabf7aab">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie341f3ddd4aa4162b175afe26aeb3606_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI1OTgyMQ_81887b1c-2571-448e-b3fa-b2947cd284b1">3.5</ix:nonFraction> million, respectively, was included in general and administrative expenses. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjc5NQ_8eb3de79-9c5f-487e-85a5-ef0389c19223">10.5</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjk0NQ_3c0e5660-114b-48e6-8546-371868bbe5ad">1.7</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzA2NA_7659ace3-fb67-4863-be18-85b39a663861">0.97</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI2MDg0Mg_d38392bc-18b8-4af9-955e-b4e839cd344a">2.48</ix:nonFraction> for employee and director stock options granted during the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i28a3ce5bb9c3471eb596c306b6ffd0d6_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzIwOQ_053e04f2-3402-4604-a7b9-0d399f6f064e">6.1</ix:nonFraction> million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i41f4dedbddf9489aa3e6277504570a15_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzM2NA_bb283730-faf9-49b8-a293-d48f6f7c7702">1.7</ix:nonNumeric> years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i41f4dedbddf9489aa3e6277504570a15_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzQzMw_0a6ad0df-3f58-4d69-ac31-93453a96ea24">1.20</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i06f13d07dc0c4ec3bd48386ff51e587a_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI2MDg5NA_31fbf74c-e028-417d-9a51-0f5e09cfdc0d">3.33</ix:nonFraction> for service-based RSUs granted during the three months ended March 31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0335d741b8b48ea9adc97b4053c50c4">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9e035331581449cda370e4641f850074_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzc1OQ_d3c236e2-058a-4b50-bb51-e27f9b3b11ab">220,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i706026db14224393a7d5617daa1749ee_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI2MDk0NQ_1201ed25-116f-4aaf-a539-8d83a3dd8e7c">550,000</ix:nonFraction>, respectively.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_79"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzczMw_4c97bb39-9332-4dad-970c-708604484098" continuedAt="ifce5a22bd7a4477aab9eaf16cabc8c7c" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ifce5a22bd7a4477aab9eaf16cabc8c7c"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned <ix:nonFraction unitRef="shares" contextRef="ibc7ccae9f1db4ec7b179375d9ecbf470_I20230331" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfODU_0a743407-5c2f-4120-8eec-6aeec40518f7">597,808</ix:nonFraction> shares of common stock in PLS as of March&#160;31, 2023, representing an <ix:nonFraction unitRef="number" contextRef="ibc7ccae9f1db4ec7b179375d9ecbf470_I20230331" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMTQz_4143926b-e260-4566-b0f1-3f289e981f05">18.7</ix:nonFraction>% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2023 and 2022, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="i0476acad69a0411cb71f91657c47d0de_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzgz_da5248c4-107d-4484-a14f-ec520dddd30b">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic075c2d8dc3444418dcdc98130ee2157_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfNDEy_115dc1b1-1ff2-43dd-9106-51b45700d657">9,000</ix:nonFraction>, respectively. At each of March&#160;31, 2023 and December&#160;31, 2022, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i2cf97ac8cf3a4bf6af4f7d01a5e00911_I20221231" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfNTE5_03e733e1-8b63-4daf-80ed-71e9ce1f5d66"><ix:nonFraction unitRef="usd" contextRef="i8b9a009f4c76409c87d174eac6f87a7f_I20230331" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfNTE5_e308313a-245a-4790-9a92-581f0545f9d6">59,000</ix:nonFraction></ix:nonFraction> due from PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="icc24100fe12944b1b8aeebb2b2812137_D20160301-20160331" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMTE3MQ_cd2da2ec-973b-4ac0-908f-3d66dfcde58a">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="icc24100fe12944b1b8aeebb2b2812137_D20160301-20160331" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzcyNw_09d8bea9-04c8-481e-880d-16830339a709">five-year</ix:nonNumeric> term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="ib159f7b94137458ebffea9382e581603_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjMxMw_319e358c-82ba-4bc3-98db-3ec38d2b9b1a">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to $<ix:nonFraction unitRef="usd" contextRef="i16d63252834144b0aacf7c65dae0426e_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjM3MQ_0ef96d04-ed63-4916-bd3c-369e0e246119">13.6</ix:nonFraction>&#160;million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2022. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="i32cb639fd4a343e690f4f52b559444f5_D20230101-20230331" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjU2Nw_077d88ef-5143-4688-8359-a9483dfe0e78">6.0</ix:nonFraction>&#160;million in funding through June 2024, of which $<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-5" name="ino:CollaborativeAgreementAwardedExercisedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjYxMA_888ec9a2-a351-4562-a841-2c3f8032ea94">3.3</ix:nonFraction>&#160;million had been exercised as of March&#160;31, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i5ab8e1cd29e04f13a5bc87f121c2aac5_D20230101-20230331" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjg2Mg_85d8a6ce-782f-465a-96c0-9212d552a13d">211,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0bf7bb08585e4f10aed4274ac4f1ec00_D20220101-20220331" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjkyMw_a72b298d-7c8b-40db-bca4-b94e06a04989">1.5</ix:nonFraction> million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 14). Research and development expenses recorded from Wistar for the three months ended March 31, 2023 and 2022 were $<ix:nonFraction unitRef="usd" contextRef="i32cb639fd4a343e690f4f52b559444f5_D20230101-20230331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzI1OA_46367bab-2318-475d-b2b9-7786aa280df3">422,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0acd1375e3c24e7fa409126bcc9c1d51_D20220101-20220331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzM2Mg_88e711a6-ef03-46ed-b387-9560bb3439d8">181,000</ix:nonFraction>, respectively. At March&#160;31, 2023 and December&#160;31, 2022, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzQ1MQ_09334e58-8579-43df-8b03-37e67d2ad3a9">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c90d97b8be2421a91f73fa2e1553a92_I20221231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzQ1OA_c7bb0ea1-81b8-49ab-94f4-ec99ff7121e0">9.9</ix:nonFraction> million, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzUzMw_f6b15116-62e8-4b02-9929-00fe53f06055">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7c90d97b8be2421a91f73fa2e1553a92_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzU0MA_180f25f6-155b-40da-b6e4-0036e1299c5e">1.2</ix:nonFraction> million, respectively, related to Wistar. As of March&#160;31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzYwOA_66e7a702-daae-4123-88cf-731409e19ea9">89,000</ix:nonFraction> as deferred grant funding and $<ix:nonFraction unitRef="usd" contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzY0MQ_7c477856-6e7a-4991-bc5f-0e3a0fc6f584">196,000</ix:nonFraction> as prepaid expenses on the condensed consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_82"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMTIxMjM_eebd81e6-8705-4216-8227-b8ef933c5bd7" continuedAt="ief0990f4e0064caebb4d43325e3f9e03" escape="true">Commitments and Contingencies                                                  </ix:nonNumeric></span></div><ix:continuation id="ief0990f4e0064caebb4d43325e3f9e03" continuedAt="i3b525ad568204ade9dd54c1bdca59b9c"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i333fb2acbe2d4abebe17d055f53089d5_D20230101-20230331" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMTMw_4090a353-c80f-47b8-827d-e433ca31d99e">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="ic3eae36ce89f42ad9e65603a05d7c7aa_D20230101-20230331" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjIx_fc60dccb-d7d7-41ad-863b-a33539ef0674">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of <ix:nonNumeric contextRef="i8608f45e71364d6db7f445deb5e26df9_I20230331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMzgy_1a941b0b-c7e4-4380-b21e-a0b396ddbef2">0.7</ix:nonNumeric> to <ix:nonNumeric contextRef="i4c3ac8cf648e4aa49f2a73b8fabfe262_I20230331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMzg4_a4672f8b-c2d2-4b78-b195-3077c5d9cd4c">6.8</ix:nonNumeric> ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMTIxMjU_7b7f29d2-e1db-457c-85b5-2bb7b6779d4c" continuedAt="ia5525f6599064dcda4eaaaf1753d5889" escape="true">As of March&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i3b525ad568204ade9dd54c1bdca59b9c" continuedAt="ib29c999f75ae4fbfb005d19c8bc3e177"><div><ix:continuation id="ia5525f6599064dcda4eaaaf1753d5889"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMC0xLTEtMS02MTQzMA_0df65584-6128-4011-8a10-ab75791bce14">3,136,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMS0xLTEtMS02MTQzMA_a0c43587-dcf2-4852-828d-906fa4cc1a55">3,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMi0xLTEtMS02MTQzMA_90832ea0-35cd-435e-b473-b0e3ca34fa41">3,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMy0xLTEtMS02MTQzMA_385ab8bf-b0f3-423d-8552-0955fd66b592">3,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNC0xLTEtMS02MTQzMA_b22d7aa8-cb09-461e-a384-851395d6f4f7">2,526,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNS0xLTEtMS02MTQzMA_b09cc1b3-cc75-428f-9d4b-40a46e77b130">4,223,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNi0xLTEtMS02MTQzMA_7d0422d8-c7de-4a63-96e5-b6c406ca17ac">19,137,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNy0xLTEtMS02MTQzMA_b0862323-c6f7-44de-a655-24b6ffccc722">4,371,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfOC0xLTEtMS02MTQzMA_298db68e-19e3-4d60-9b17-32df0d7da917">14,766,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfOS0xLTEtMS02MTQzMA_6d137f4c-a9dd-4b2f-b8ec-7c5edbbfcfcb">2,580,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMTAtMS0xLTEtNjE0MzA_4f7bf0d1-5539-41ea-9328-228a2e1bad0b">12,186,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMTItMS0xLTEtNjE0MzA_d3407d02-090b-4cc3-bb0e-250c999d7b8c">5.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMTMtMS0xLTEtNjE0MzA_e1ae89d8-cab7-4a84-ac3c-c2829ff011c6">8.6</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 were $<ix:nonFraction unitRef="usd" contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjA1Ng_7dd8d3f1-63ab-4d9c-a96b-7ccd4b11b359">840,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjE5NQ_63d61c75-113c-459e-96f9-566e23868ec0">830,000</ix:nonFraction>, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="agreement" contextRef="i3a98975b0fc340d4b103c427cf0f43ea_D20191001-20191231" decimals="INF" name="ino:LesseeOperatingLeaseNumberOfAgreementsToSublease" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjQ4NA_63019596-c405-44a0-a69e-12be6e8746eb">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="i9f906f0a3f6e4602a9e8cab308738534_D20191001-20191231" decimals="-2" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjUzNQ_5b739ff9-6f82-47be-ac27-76c894d0b8fa">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i58c9cdabcabe4021909afd5c5a3081f2_I20210309" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfNTA3MQ_ac1ece7e-9834-4f66-8444-adfdaf9102d0">30.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="i58c9cdabcabe4021909afd5c5a3081f2_I20210309" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfNTA4Ng_84c6410a-b0db-4ca6-a804-b8842a4f12d9">14.0</ix:nonFraction>&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $<ix:nonFraction unitRef="usd" contextRef="i58c9cdabcabe4021909afd5c5a3081f2_I20210309" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfNTIwMA_0452a3c6-7695-4d2a-802e-4faf0256b169">30.0</ix:nonFraction>&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="ib97422d241744aecbec5cdc038a635ef_I20230228" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjE5OTAyMzI3Mjg0MA_a15dbcd0-5549-48e5-aa2c-f69885ae1c37">9,121,000</ix:nonFraction> shares of common stock pursuant to the securities class action settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="ib29c999f75ae4fbfb005d19c8bc3e177" continuedAt="ie33d12554dcf48bd96559272674a90d8"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania.  The proposed settlement provides for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie33d12554dcf48bd96559272674a90d8">carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTUyNzk_4f14e26e-d9d2-4968-8da9-e7d05d20142c" continuedAt="i8573d4859b2a4c3ca479275f53306b33" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="i8573d4859b2a4c3ca479275f53306b33" continuedAt="i4750266ca97a41da9dfb63de80ad296b"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTc4OA_71253738-fa95-4830-ac97-b5a615678bd3">3.0</ix:nonFraction>&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTkwMQ_c16acd84-f80e-4a5c-ae85-87e618812b22">200.0</ix:nonFraction>&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for <ix:nonNumeric contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjYwNg_329f33c3-e25f-43ad-92b8-b70cb0c58493">ten years</ix:nonNumeric> after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331" decimals="-5" name="us-gaap:CostMaintenance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjk5OQ_b67e69c5-b87e-42ac-bb62-772e2c8697ba">1.5</ix:nonFraction>&#160;million for a period of <ix:nonNumeric contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331" name="ino:AnnualMaintenancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMzAxOA_83d26c02-2404-414a-bcdb-3cd58c5123a8">five years</ix:nonNumeric>, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or <ix:nonNumeric contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNDY2MA_38779e7b-b432-418a-8a95-4b01167081b7">18</ix:nonNumeric> months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i4750266ca97a41da9dfb63de80ad296b" continuedAt="i5a3d53d0e1e74bf1a2debf2ec8b1dc20"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQxMQ_1a3d54f8-bd3e-47bb-932b-dd77290cc241">3.0</ix:nonFraction>&#160;million upfront payment received in January 2021 plus a $<ix:nonFraction unitRef="usd" contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131" decimals="-5" name="ino:CollaborationAgreementPaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ2Mg_120aec79-54f7-4ddb-95bd-9f3bfdd1996e">2.0</ix:nonFraction>&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i12fc1c502f8942b7ad4bc3b5d8beb886_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNjMzNA_4d94e151-4f05-41b1-a61c-d1b1a6cb1ce0">5.0</ix:nonFraction>&#160;million was allocated to the license performance obligation. For each of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, <ix:nonFraction unitRef="usd" contextRef="ic5a06a61d23a43f185271e37b7571874_D20230101-20230331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNjQyNw_15ec477c-1db2-4dd2-aa11-eb7cad892045"><ix:nonFraction unitRef="usd" contextRef="ic5a06a61d23a43f185271e37b7571874_D20230101-20230331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNjQyNw_f0226d65-cf55-4910-b683-a097931ab70b">no</ix:nonFraction></ix:nonFraction> revenue was recognized from Advaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. During the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="id64c57b813344cb7a27bb83b05c69e89_D20220101-20220331" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MzY0Mw_c6b8c953-c9ef-4253-8b0d-75686a10b1bb">1.2</ix:nonFraction>&#160;million from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNzQ4MA_65c9caf2-2f35-4410-9f00-16ec6509c0e8">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfODAyNg_d94aaada-2257-40e7-9f02-7a326bcee2f4">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfODY0OA_c194aa44-dc2d-4b99-ab84-8184cdba34cd">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfODY5Ng_5f55bfd8-d64b-4daa-80d0-69807e054e3c">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2023 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i7a4a785614804e208d698da42727636c_D20180401-20180430" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfOTQ4Mw_c31d7a96-b5d5-4f0d-a485-5e4f0f0d0f39">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="i7a4a785614804e208d698da42727636c_D20180401-20180430" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTUyNzQ_58c573c7-625a-4d7f-b0c1-fde7fa340b38">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2023 and 2022, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="ia69f542558464145a2894966df1810dc_D20230101-20230331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfOTc2OQ_b7bcc2ab-2605-4b7a-a989-d07e4f18ce85">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i125c5d9c06e64a2796725f967491bb88_D20220101-20220331" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MDg2OQ_441e1417-40eb-4df9-a6a3-e6386d21aa29">2.0</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="if7941aaf07d1455db283f53a3ce532ff_I20230331" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjc0ODc3OTA4NjI1NQ_dad61296-2bed-4f71-ad51-bb6864b2b08e">1.7</ix:nonFraction>&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="ia88027f914c346d898a03e87ce8843cc_D20200101-20200131" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTAyNTU_bdea094c-6ee3-4114-89d6-4d2928cfe4a8">9.0</ix:nonFraction> million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i6685e6d0a07641c9a04cb5a2a1f626a0_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA0MjE_c3d11786-0734-4d17-8680-b7637527cdd7">6.9</ix:nonFraction> million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i5a3d53d0e1e74bf1a2debf2ec8b1dc20" continuedAt="i39c945ad7d5d4cb0929e0367c48753fb"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials of INO-4800 in South Korea, a grant of $<ix:nonFraction unitRef="usd" contextRef="i6284362eaa524cb1ae66051b9a8416be_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA1OTk_e5de5e50-792c-4d1d-bee7-ea2904d72304">5.0</ix:nonFraction> million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="ib99cbe6e413f48c58eac5aa5bc792556_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA3ODE_9e8a80c4-d683-49c1-8d7d-b4970232e337">1.3</ix:nonFraction> million to support large-scale manufacturing of INO-4800. During the three months ended March 31, 2023 and 2022, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="iabc7dbe20d0344d694da0dff99be1e46_D20230101-20230331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA4ODE_f3c7f890-fa60-43a2-a0b6-f75e7192fad8">53,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i226d2be71e7340ca94c685446a1e4897_D20220101-20220331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MTMwNQ_04995738-5790-44aa-b549-de1934aa1ff7">510,000</ix:nonFraction>, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib3ced90de62e425292ba059648c69c3e_I20230331" decimals="-5" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTEyMzg_337cfb36-5a2b-44f7-a22d-0f8f9f26742c">2.3</ix:nonFraction> million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i3d44bceb01724751ae9ac3ef1c97f30c_D20181001-20181031" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTE0NTk_ddf43136-e951-4096-a757-1f06bbf6a222">2.2</ix:nonFraction> million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="ie31a2498c1414335a0ba4fe5e14b7127_D20190801-20190830" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTE4MjI_7abb97d5-5539-46bc-a293-68702500bfce">1.1</ix:nonFraction> million for the project. During the three months ended March 31, 2023 and 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i7f1e77e31a004c85bce55c93571e12c7_D20230101-20230331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTE4Nzg_8029a706-31f3-496b-a594-4d44f90fd559">59,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ica479a19e2b24b13b5c1515aad9cca2c_D20220101-20220331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MTUxNg_3591b75c-7c54-40dd-9268-f9024bf3fd41">80,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="icc8c967179d64c8da0b633e32986c5b4_I20230331" decimals="-3" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTIxNjk_93f88ae2-2f40-4282-83d0-14525e7de634">96,000</ix:nonFraction> recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="iffb01fd6e8e940fbbc1a27ee535e080e_D20200301-20200331" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTIzMzY_1bf25633-ba02-4704-ba1a-30608906964e">5.0</ix:nonFraction> million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2023 and 2022, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i4156146913df4fe29176b27642589675_D20230101-20230331" decimals="INF" name="ino:CollaborativeAgreementFundingReceived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTI0Nzc_4d13870a-ff71-4645-91dc-3102c7158b25"><ix:nonFraction unitRef="usd" contextRef="i3ad6c67aa76d4e239862ac53565b8b14_D20220101-20220331" decimals="INF" name="ino:CollaborativeAgreementFundingReceived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTI0Nzc_a15533d8-5bfa-4ae0-a882-66e09f6f3c6e">no</ix:nonFraction></ix:nonFraction> contra-research and development expense related to this Gates grant.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $<ix:nonFraction unitRef="usd" contextRef="i34c3e1e467bd4c8cbd2f2d5dd0b6b83e_D20200601-20200630" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTMwNTk_83e529c8-1792-4f4e-86f1-16c27f2a9564">54.5</ix:nonFraction> million. The Company determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. The Company recorded contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses were incurred. During the three months ended March 31, 2022, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i4e1fd3bca48746d4a3e0157958b1362d_D20220101-20220331" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ5NzU1ODMxMDUy_f7ade52e-8605-4e55-86f2-6c4b8decf48a">3.2</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as contra-research and development expense related to the OTA Agreement. <ix:nonFraction unitRef="usd" contextRef="i18a5a935641f47e3a61691a74380178e_D20230101-20230331" decimals="INF" name="ino:GrantProceedsReceived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTY0OTI2NzQ2MDAxNw_ebf1635a-bead-46f3-b1c8-7f9bf96e6e98">No</ix:nonFraction> amounts were recorded during the three months ended March 31, 2023.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i39c945ad7d5d4cb0929e0367c48753fb" continuedAt="id173d95474c7478aac68cd5a685862b7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total purchase price under the Procurement Contract was $<ix:nonFraction unitRef="usd" contextRef="i63d4cb06945a44c5b005997ca2058e88_D20200601-20200630" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTM3ODk_2b2bdb19-623f-48ec-818d-68fc8a6210c9">16.8</ix:nonFraction>&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id173d95474c7478aac68cd5a685862b7">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD discontinued funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $<ix:nonFraction unitRef="usd" contextRef="i1066c49f9fa944c18d0649a5a997b41d_D20220101-20220131" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTQ1MzM_838fce7c-08ea-445d-9fc2-5d1fbc16d797">10.7</ix:nonFraction>&#160;million. All performance obligations under the Procurement Contract have been satisfied. During the three months ended March 31, 2023 and 2022, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i168d6a6b6ac247679a22b560bd6e3455_D20220101-20220331" decimals="INF" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ5NzU1ODMxNjYz_1aabbeee-21aa-4d49-9452-8b2274d9bacf"><ix:nonFraction unitRef="usd" contextRef="i1f4328f613794f8f851da2eea650c719_D20230101-20230331" decimals="INF" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ5NzU1ODMxNjYz_cd3ba51f-c0b3-4f67-ad1e-e411980527a3">no</ix:nonFraction></ix:nonFraction> revenue from the Procurement Contract.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_88"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84OC9mcmFnOmNjODVlYTMzNmVhYjRhYjA4MjEyMTZlNTcxMDJhZDk0L3RleHRyZWdpb246Y2M4NWVhMzM2ZWFiNGFiMDgyMTIxNmU1NzEwMmFkOTRfOTU3_a804e905-f417-4f3f-a5fd-b3cc0ed0fec5" continuedAt="if33d3f9c36814b8ba1577414c4195fc4" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if33d3f9c36814b8ba1577414c4195fc4" continuedAt="i2b203556ad57481c8be36b719cf2bf8c">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</ix:continuation></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2b203556ad57481c8be36b719cf2bf8c">&#160;For the three months ended March 31, 2023 and 2022, the Company did not record any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_91"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfOTExMA_277d302b-6a44-405d-a1d5-c4759e6efcd3" continuedAt="i30c75eb6ff4c4c16b733c883b3841078" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i30c75eb6ff4c4c16b733c883b3841078" continuedAt="i71e79c512b114d47923f66a3b3978729">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i71e79c512b114d47923f66a3b3978729" continuedAt="i9d7a5601799f44bbb5b92414d2d5d888"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$<ix:nonFraction unitRef="usd" contextRef="ic8095048f54b4e7690bb30f2a7181f33_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMzYy_c52106a0-b297-41ae-b4a6-4a97dcdbe925">1.2</ix:nonFraction> million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i7b7d9f2ec0c742c5a03a7fa46f42aa3d_I20191231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNDkx_19d9b6bb-ed39-42b4-a947-76c4ff8c6911">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i78a9b6e99d364eebaef954d914503da2_I20200131" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNzg0_59721137-c45c-4d9e-a191-9c93fa08a5f0">800,000</ix:nonFraction>. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="ide7c9f8aacf543c2ba69c1d46e1444ca_I20200131" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODMz_8f1cadb7-5551-4545-a68b-0370f2f8396f">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i787f2661dbc54b07898d0c0364957c10_I20200630" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTA4NA_b7a95716-b190-4830-9ff9-e788335f64e3">800,000</ix:nonFraction>.  Following this transaction, the Company owned <ix:nonFraction unitRef="number" contextRef="i0284cde70d5b460295a267e2aa3f9418_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTEzNQ_789e5037-c074-46f0-ba53-475cd8ed1ff4">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="iec22519de8e349f68787d4e3117cc5d1_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTgwNA_457e6132-447e-4a8a-aafe-a0f2a37beccd">4.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="iec22519de8e349f68787d4e3117cc5d1_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTgxNw_df57cca4-c922-492c-98c6-3286cba7ff6f">2.4</ix:nonFraction> million related to the remeasurement of the retained noncontrolling interest investment to fair value.  </span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i0f6c4cef707f468e961ad855e0854c2d_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNDgyNQ_be278d0e-2b82-4da4-88a5-983ff8d5c773">1.4</ix:nonFraction>&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="ia4c22ea43f794bf99527a5a0e7aedae4_I20201130" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTQ1OA_f08b61a4-5666-4788-ae81-471c83a6ffcf">36</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0142d3c784c84195a77084a90fd44686_D20210101-20210331" decimals="-5" sign="-" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTgyNQ_1d7cae29-eecd-4785-8463-56e4cf3a1004">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="i0142d3c784c84195a77084a90fd44686_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTg0Mw_dac26e57-9e39-4e39-b46f-a60b5e9d137c">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="ieeccae722fc04ed3b3e297f3f9746ac5_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTkxMw_11acc0a4-676f-4767-925c-f4b104204a39">0</ix:nonFraction>. Of the total amount, $<ix:nonFraction unitRef="usd" contextRef="ifc519a3505b3405fb2c0d3cdd6a35310_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTkzOA_216340d4-2cb2-4366-9989-d707c9c76903">819,000</ix:nonFraction> has been allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i8e7818a8a0894cb2bb8176800bac1b8f_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjAyNQ_e1125cb2-42b2-4841-a369-4eb97cf4b125">0</ix:nonFraction> as of March 31, 2021. The remaining $<ix:nonFraction unitRef="usd" contextRef="i8fc6c62eb8cb4a31ad404dd9dea91a63_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjA2NA_2bccd27f-85c3-48e2-ab3e-a4ef17e5caab">4.2</ix:nonFraction> million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="id0957b99b9e3448f9b409da3e4e79095_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjIzMA_a102a4bd-6f21-4d4d-865e-3c5d524eff54">0</ix:nonFraction> as of March 31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><ix:continuation id="i9d7a5601799f44bbb5b92414d2d5d888" continuedAt="ie26bff334f1f471ba4c0f7f028111562"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i86f4cd190cda49f78e14fc4d981780f7_I20210228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjYxNg_51f88dc8-5bcd-4d4e-9a45-7d911534f764">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="idac4be03517e4f47adf6174fbe4aa9e1_D20220301-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjc5Ng_d3392517-c671-4b50-81ca-493e87f6998a">2.0</ix:nonFraction>&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i407a77b361714c38aa6bd43347213d19_I20220331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNzQzMQ_b082e989-8ff1-46f9-b19c-2141c6d9d3e7">28</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company has concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $<ix:nonFraction unitRef="usd" contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331" decimals="-3" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODE4Nw_bee329fb-e928-4235-9f04-44c7a616bfbe">165,000</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfOTEwOQ_5a0ebda1-f593-4074-aab3-cef5476b0c02" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $<ix:nonFraction unitRef="usd" contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODI3Mw_dc633547-496c-4ead-94e0-60d6db45fde7">2.2</ix:nonFraction>&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="if7582f4c63824263ac27d9d7d9dd30c2_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODQwMA_609f6526-2f9a-42ad-86b0-524ac1dca157">0</ix:nonFraction> as of March 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8116a07c8d41bf95c7976eca960b36_I20221231" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfMS0yLTEtMS02MTQzMA_9af11ed8-0844-4054-b92a-2055bd2acd61">1,999,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331" decimals="0" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfMi0yLTEtMS02MTQzMA_18119724-b97d-4e29-994a-03d3a8878841">165,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfMy0yLTEtMS02MTQzMA_9ebbb511-9a20-457a-908a-fb521c5bafb2">2,165,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7582f4c63824263ac27d9d7d9dd30c2_I20220331" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfNC0yLTEtMS02MTQzMA_63722e69-244f-41ab-ba1a-0e958806302f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="if7582f4c63824263ac27d9d7d9dd30c2_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMjE5OTAyMzI2NTAxNQ_936a7858-a41c-40f8-a20f-250026ac76ad">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Geneos completed the closing of a Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i2b8a4fe327134fba97d18909d711eee6_I20230331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTQ5NzU1ODIzOTQz_eede03ac-6280-4cd4-993b-e48df896162c">26</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. </span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="ie26bff334f1f471ba4c0f7f028111562" continuedAt="id9971f253bcc4ca49145cc608e2a0ccc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9971f253bcc4ca49145cc608e2a0ccc">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2022 included in our Annual Report on Form 10-K, or 2022 Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on March 1, 2023. Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2022 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our proprietary smart device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our DNA medicine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare laws and proposals; and the impact of COVID-19 on us and our third-party contractors and suppliers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_106"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. Our goal is to advance our diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, our DNA medicine candidates have shown the ability to generate immune responses, especially CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and memory T-cell responses against targeted pathogens and cancers, via our precisely designed plasmids. These plasmids are delivered into cells using our investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our lead candidates are focused on diseases associated with HPV. In October 2022 and February 2023, we announced data from the first and second cohorts, respectively, of our Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated Recurrent Respiratory Papillomatosis, or RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces our belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, Indiana University, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, our DNA medicines for the Ebola virus; HPV-related precancers, including cervical, vulvar and anal dysplasia; HPV-related cancers, including head &amp; neck; other HPV-related disorders, such as RRP; and glioblastoma (GBM).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had an accumulated deficit of $1.5 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reduction in Force</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, we committed to and communicated a corporate reorganization plan, including a reduction in force, or the Reduction. The purpose of the Reduction was to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, we reduced overall headcount by approximately 24 employees, which represented 11% of our full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. We incurred a one-time pre-tax charge of $1.1 million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action Settlement</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the United States District Court for the Eastern District of Pennsylvania, or the Court, entered an order, or the Order, granting final approval for the settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement includes $30.0 million in cash and $14.0 million in shares of our common stock to settle all outstanding claims. Our insurance carriers paid the cash component of the settlement and we will therefore not incur any material cash expenses associated with the litigation, other than legal fees and related expenses, which were approximately $11.0 million through March 31, 2023. During the three months ended March 31, 2023, we issued 9,121,000 shares of common stock pursuant to the securities class action settlement.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_109"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting estimates since December 31, 2022. For a description of our critical accounting estimates and significant judgments used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2022 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2022 Annual Report. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_115"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue, all of which was derived under collaborative arrangements and other contracts, was $115,000 and $199,000 for the three months ended March 31, 2023 and 2022, respectively.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants, and outside expenses. We utilize a labor reporting system to record employee compensation on a project-by-project basis. Unallocated research and development expenses include </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engineering and device-related expenses that are not allocable to a specific project, as well as stock-based compensation, other employee-related expenses that are not related to a specific project, and facilities and depreciation expenses.    </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our research and development expense by product candidate for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:37.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-4800 and other COVID-19</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,952)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VGX-3100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3107</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-5401 and other Immuno-oncology </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engineering and device-related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,802)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:30.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.414%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $25.8 million overall decrease for the three-month period year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$14.3 million in lower drug manufacturing, clinical study expenses and outside services related to INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.7 million in lower expensed inventory and outside services related to our CELLECTRA 3PSP device and array automation project; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.0 million in lower employee and consultant compensation, including stock-based compensation; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$2.9 million in lower immunology, clinical study expenses, outside services and expensed inventory related to VGX-3100.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by $4.4 million of lower contra-research and development expense recorded from grant agreements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $3.1 million and $7.5 million for the three months ended March 31, 2023 and 2022, respectively. The decrease for the three-month period year over year was primarily due to a decrease of $3.2 million earned under the DoD 3PSP device development grant, and a decrease of $946,000 earned under the sub-grant through Wistar for DARPA COVID-19 dMAb. These decreases were offset by an increase of $1.2 million in reimbursements from Advaccine. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $13.9 million and $16.0 million for the three months ended March 31, 2023 and 2022, respectively. The $2.1 million overall decrease for the three-month period year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.5 million in lower employee and consultant stock-based compensation;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$576,000 in lower insurance expenses;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$528,000 in lower other outside services; and </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$486,000 in lower employee compensation.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were offset by $1.5 million in higher legal expenses, primarily related to litigation matters.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the three months ended March 31, 2023 and 2022 was $3.6 million and $7.2 million, respectively. Of these amounts, $1.5 million and $3.7 million, respectively, was included in research and development expenses, and $2.1 million and $3.5 million, respectively, was included in general and administrative expenses. The year over year decrease was primarily related to a lower weighted average grant date fair value for the awards granted in the first quarter of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended March 31, 2023 and 2022 was $2.2 million and $670,000, respectively. The increase for the three-month period year over year was due to higher interest rates.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for both the three months ended March 31, 2023 and 2022 was $313,000.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (loss) on investment in affiliated entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) resulted from the change in the fair market value of our investment in PLS of $617,000 and $(538,000) for the three months ended March 31, 2023 and 2022, respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net unrealized gain (loss) on available-for-sale equity securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain (loss) on available-for-sale equity securities for the three months ended March 31, 2023 and 2022 of $3.2 million and $(4.8) million, respectively, resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense for the three months ended March 31, 2023 and 2022 of $2.4 million and $153,000, respectively, related primarily to the realized loss on short-term investments sold during the period.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in net loss of Geneos.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation. As described in Note 16 to our condensed consolidated financial statements included in this report, we reduced the value of our investment in Geneos to zero as of March 31, 2022. We will not reduce our investment below $0 and will not record our share of further net losses of Geneos subsequent to that date, as we have no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_118"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities for the advancement of DNA medicine candidates. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of $223.8 million and working capital of $178.7 million, as compared to $253.0 million and $218.4 million, respectively, as of December&#160;31, 2022. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $36.7 million and $61.9 million for the three months ended March 31, 2023 and 2022, respectively. The variance was primarily due to the timing and changes in working capital balances, offset by decreased operating expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $19.0 million and $21.3 million for the three months ended March 31, 2023 and 2022, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by financing activities was $(425,000) and $28.4 million for the three months ended March 31, 2023 and 2022, respectively. The variance was primarily due to no proceeds from the sale of common stock under the Sales Agreement (defined below) in 2023 compared to net proceeds of $29.4 million received during the three months ended March 31, 2022.  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Issuances of Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement, or the Sales Agreement, with outside sales agents, or collectively, the Sales Agents, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock with aggregate gross proceeds of up to $300.0 million, through the Sales Agents.</span></div><div style="text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221;. The Sales Agents will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from us, including any price, time or size limits or other customary parameters or conditions we may impose. We will pay the Sales Agents a commission of up to three percent (3.0%) of the gross sales proceeds of any common stock sold through the Sales Agents under the Sales Agreement, and we have provided the Sales Agents with certain indemnification rights. During the three months ended March 31, 2023, no shares were sold under the Sales Agreement. During the year ended December 31, 2022, we sold 34,445,743 shares of common stock under the Sales Agreement for aggregate net proceeds of $83.0 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, no stock options were exercised and tax payments of $425,000 were made related to the net sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are settlement of RSU awards. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, stock options to purchase 26,069 shares of common stock were exercised for aggregate net proceeds to us of $84,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $1.0 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we issued 9,121,000 shares of common stock pursuant to the securities class action settlement, as described in Note 13 to our condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Funding Requirements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had an accumulated deficit of $1.5 billion, and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. Our current cash resources, including amounts that we may be able to obtain through sales of common stock under the Sales Agreement, will not be sufficient to complete the clinical development of any of our product candidates, and we anticipate that additional financing will be required in order to commercialize and generate revenues from the sale of any product candidates that receive regulatory approval. If these activities are successful and if we receive approval from the FDA to market our DNA medicine candidates, then we will need to raise additional funding to market and sell the approved products and equipment. In addition to the potential issuance of equity or debt securities in order to raise capital, we are also evaluating potential collaborations as an additional way to fund our operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In January 2023 and July 2022, we undertook actions to decrease our expenses, extend our cash runway, and maintain a streamlined organization to support key clinical programs that we expect to drive our long-term growth. Also, in the fourth quarter of 2022, we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. We expect these actions collectively to reduce our operating expenses and extend our cash runway into the first quarter of 2025, without giving effect to any further capital raising activities, whether under the Sales Agreement or otherwise.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have existing supply agreements with contract manufacturers to manufacture drug substance. At March&#160;31, 2023, we had an approximately $6.1&#160;million minimum purchase obligation in connection with these agreements. We expect to satisfy these obligations from existing cash over the next twelve months.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here have been no other significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our 2022 Annual Report.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_121"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. During much of 2022 and into the three months ended March 31, 2023, there was a pronounced overall increase in prevailing interest rates in the United States compared to the first quarter of 2022, which contributed to the unrealized loss of $6.5 million in the market value of our investment portfolio as of March 31, 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness is fixed and not subject to fluctuations in interest rates.</span></div><div style="margin-top:5pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the three months ended March 31, 2023 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor. Although inflation increased generally in the United States in 2022 and continuing into 2023, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the three months ended March 31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_124"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of March&#160;31, 2023 at the reasonable assurance level. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our former President and Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff. On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants. On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants&#8217; motion to dismiss. The court granted Defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements. The court denied Defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, Defendants filed their answer to the complaint. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was ultimately approved by the court on January 18, 2023. Under the settlement, we agreed to pay $30.0 million in cash and $14.0 million in shares of our common stock to settle all outstanding claims. Our insurance carriers paid the $30.0 million cash component of the settlement. During the three months ended March 31, 2023, we issued 9,121,000 shares of common stock pursuant to the securities class action settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v. Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name our current directors as defendants. The Devarakonda complaint also names one of our former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania.  The proposed settlement provides for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1ff6d590f0b0417ea0f0772b34ecc5f0_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. On January 29, 2021, we filed preliminary objections to the complaint. On August 23, 2021, the Court overruled our preliminary objections to the complaint. On September 13, 2021, we filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement, and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. On October 18, 2021, GeneOne filed its answer to our counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_133"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, the risk factors discussed in our 2022 Annual Report, which we filed with the SEC on March 1, 2023, in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock could decline. You should also consider the more detailed description of our business contained in our 2022 Annual Report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of March&#160;31, 2023, our accumulated deficit was $1.5 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA medicine candidates or proprietary smart device technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary smart device technology.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our DNA medicine candidates, including securing regulatory approval for conducting clinical trials with DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">developing our proprietary smart device technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary smart device and DNA medicine candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generate any revenues from product sales. We are not permitted to market or promote our proprietary smart device and DNA medicine candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of proprietary smart device and DNA medicine products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have derived a significant portion of our revenue from a limited number of licensing partners and government grants and contracts and we expect that a significant portion of our revenue will continue to be derived from a limited number of licensing partners and/or government grants and contracts unless and until we are able to commercialize our product candidates. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA medicines and proprietary smart device technology, which may prove difficult and costly to obtain.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our DNA medicine candidates and proprietary smart device technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of geopolitical turmoil, inflation and rising interest rates, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Rising interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our product candidates, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our proprietary smart device and DNA medicine candidates in the United States. If we fail to obtain FDA approval to market our proprietary smart device and DNA medicine candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our proprietary smart device and DNA medicine candidates are both safe and effective for each indication for which approval is sought. To the extent that our DNA medicine candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our proprietary smart device and any of our DNA medicine candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our proprietary smart device and DNA medicine candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our product candidates or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any proprietary smart device and DNA medicine candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our DNA medicine candidates may not be approved for all indications requested, which could limit the uses of our DNA medicine candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and DNA medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our proprietary smart device or product candidate is safe and effective for any indication; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary smart device or DNA medicine candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary smart device or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our DNA medicine candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or that of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our proprietary smart device and DNA medicine candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining Internal Review Board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to clinical trials of product candidates for rare diseases, such as our clinical trial of INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease. Because RRP is caused by specific HPV types, 6 and 11, and there is currently no standard protocol for diagnostic/screening of RRP patients unless there are symptoms of respiratory distress, it may be difficult to identify and diagnose patients for whom INO-3107 may be a potential treatment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proprietary smart device and our DNA medicine candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. For example, in November 2022 we announced the discontinuation of the development programs for our product candidates INO-4700 for MERS and INO-4500 for Lassa Fever. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DNA medicines programs are in various stages of research and development, and currently include DNA medicine candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of DNA medicine candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our DNA medicine candidates. The success of our efforts to develop and commercialize our DNA medicine candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our DNA medicine candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are now only pursuing development in collaboration with third parties, as both a primary and heterologous booster vaccine, but there can be no assurance that our candidate will ever receive regulatory approval as a primary vaccine or a booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we expended significant resources on the clinical development of a COVID-19 vaccine candidate, INO-4800. We were previously conducting a Phase 2/3 clinical trial of INO-4800 called INNOVATE. Based on regulatory feedback and the competitive landscape for COVID-19 vaccines, in 2022 we discontinued the INNOVATE trial and pursued a strategy to develop our COVID-19 vaccine as a potential heterologous booster following administration of other primary vaccines. Following an assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines, in the fourth quarter of 2022 we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are no longer conducting any active clinical trials of INO-4800 and do not expect that it will ever receive regulatory approval in the United States. Our collaborator, Advaccine, is continuing the clinical development of INO-4800 in a Phase 2 clinical trial in China and may seek an Emergency Use Authorization, or EUA, from regulatory authorities in China and other countries in Asia for the use of INO-4800 as a heterologous booster. However, any such decision would be made by Advaccine, and there is no guarantee that Advaccine will apply for an EUA or other similar authorization or, if it does apply, that Advaccine will be able to obtain such authorization. An EUA may not be available if countries are no longer in a state of public health emergency, in which case full approval would need to be sought.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our COVID-19 vaccine candidate continues to be evaluated as part of the World Health Organization&#8217;s Solidarity Trial Vaccines. Depending on the results of that trial, we could also pursue a strategy of seeking EUA for the vaccine candidate in other countries outside of the United States. Even if an EUA or other authorization is ultimately granted, we will rely on the applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our vaccine candidate. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we or Advaccine fail to comply with the conditions of authorization. If we or Advaccine apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our and Advaccine&#8217;s ability to market and sell our COVID-19 vaccine.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA medicines are a novel approach to treating and preventing disease, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to other nucleic acid based vaccines such as mRNA vaccines, gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our pipeline of DNA medicine candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our proprietary smart devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary smart device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our proprietary smart devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our DNA medicine candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our DNA medicine candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and DNA medicine candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our proprietary smart device to our partners and to supply DNA medicine candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates, including INO-4800. In 2020, VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we had to engage several additional third-party contract manufacturers. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity for any of our DNA medicine candidates on commercially reasonable terms. Our inability to secure sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for our DNA medicine candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the quality system regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our product candidates and investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our product candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that may not be interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, regulators may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our DNA medicine candidates, or the manufacturing facilities for our DNA medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing some of our investigational DNA medicines and sometimes using new endpoints or methodologies for the treatment of diseases in which there is little clinical experience. As a result, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. For example, our product candidate INO-3107 is being developed for RRP, a rare condition for which there are no approved non-surgical treatments. In particular, there are challenges associated with agreeing to a primary endpoint with the FDA for the treatment of RRP where no precedent exists.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our DNA medicine candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional DNA medicine candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of RRP. We have sought and may continue to seek Orphan Drug Designation for one or more of our other DNA medicine candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of RRP, and even if we obtain Orphan Drug Designation for our other DNA medicine candidates in specific indications, we may not be the first to obtain marketing approval of these DNA medicine candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our DNA medicine candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our DNA medicine candidates, we may never receive such designations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek a breakthrough therapy designation for one or more of our investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our DNA medicine candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding, which could have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases, DARPA, Medical CBRN Defense Consortium and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and we intend to continue entering into these types of agreements with government agencies in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in 2021 the DoD discontinued funding for the Phase 3 segment of our INNOVATE trial, which resulted in increased expenditures by us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our proprietary smart device and DNA medicine candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our DNA medicine candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our DNA medicine candidates. As a result, our financial results and the commercial prospects for our DNA medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our DNA Medicine Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only a small commercial organization to support pre-commercial activities for our proprietary smart device and DNA medicine candidates, if approved, and we do not currently have a sales organization. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our DNA medicine candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our proprietary smart device and DNA medicine candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our DNA medicine candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our proprietary smart device by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our proprietary smart device and DNA medicine candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our DNA medicine candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our proprietary smart device and DNA medicine candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our DNA medicine candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our DNA medicine candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our DNA medicine candidates or procedures using our DNA medicine candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be harmed if our restructuring plans do not achieve the anticipated results or cause undesirable consequences.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between July 2022 and January 2023, we undertook restructuring plans that resulted in a total reduction in headcount of more than 25% of our employees and a significant majority of our contractors. Restructuring plans may yield unintended consequences, such as attrition beyond our intended reduction in workforce and reduced employee morale, which may cause our employees who were not affected by the reduction in workforce to seek alternate employment. During the second half of 2022, we experienced increased attrition after conducting the first reduction in force. Additional attrition could impede our ability to meet our operational goals, which could have a material adverse effect on our financial performance. In addition, as a result of the reductions in our workforce, we may face an increased risk of employment litigation. </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, employees whose positions have been or will be eliminated in connection with these restructuring plans may seek future employment with our competitors. Although all our employees are required to sign a confidentiality agreement with us at the time of hire, we cannot be certain that the confidential nature of our proprietary information will be maintained in the course of such future employment. We cannot be certain that any of our restructuring efforts will be successful, or that we will be able to realize the cost savings and other anticipated benefits from our current or any future restructuring plans. In addition, if we continue to reduce our workforce, it may adversely impact our ability to respond rapidly to any new growth or revenue opportunities. Any restructuring activities we undertake may take longer than expected and may require changes to our business that we are unable to implement. If we are unsuccessful in implementing our cost saving initiatives and restructuring plans or if we do not achieve our expected results, our results of operations and cash flows could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of INO-4800 in violation of certain federal securities laws. Although we have settled the current class action securities litigation and expect to settle the related stockholder derivative action in the near term, there can be no guarantee that we will not become subject to similar claims in the future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. There can be no assurance that we will ultimately prevail in the ongoing litigation matters described in this report or in future litigation matters. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced changes to our senior leadership team, which creates uncertainty and could harm our business. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced changes to our senior leadership team over the past year. Our former President and Chief Executive Officer, Dr. J. Joseph Kim, who served in those roles since 2009, resigned in May 2022, and Dr. Jacqueline Shea, previously our Chief Operating Officer, was appointed to those roles. Although Dr. Shea has served with our Company since 2019, the management transition had the potential to create uncertainty and disrupt our operations and relationships with employees, suppliers and partners and result in operational inefficiencies, decreased employee morale and productivity and increased turnover. Any departure at a senior level could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. In addition, our competitors may seek to use this management transition and the related potential disruptions to gain a competitive advantage over us. If we are unable to successfully navigate the transition of our chief executive officer, our business could suffer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and DNA medicine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, such as the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. These or similar events could result in future business and manufacturing disruption, or in reduced operations, any of which would materially affect our business, financial condition and results of operations. The COVID-19 pandemic also caused supply chain disruptions and supply shortages globally. As a result, we experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and had to secure new vendors for certain supplies and components at higher prices. There can be no assurance that we will not encounter similar difficulties in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future health epidemics could adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. Further, future epidemics could also result in delays in our clinical trials due to prioritization of hospital resources toward the disease, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting disease or other health conditions. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology, may impede our ability to successfully commercialize our DNA medicines, if approved. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates and introduce new, disruptive technology, we may not be able to commercialize our products, if approved, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or product candidates obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors include large pharmaceutical companies broadly engaged in vaccine/immunotherapy research and development, such as Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline plc, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, as well as various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, such as CureVac, Dynavax, Genexine, Hookipa, Iovance, Nektar, Nykode, Precigen, Translate Bio, Zydus, and Vir Biotechnology. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is working to develop a treatment based on a gorilla adenovirus vector. Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small biotechnology companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our proprietary smart device and DNA medicine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial, and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage was eliminated, along with the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect until 2031, unless Congressional action is taken. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In addition, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our DNA medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a license and collaboration agreement with a China-based company, ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, China's "zero COVID" policy has caused delays in Advaccine&#8217;s conduct of clinical trials for INO-4800 in China under our collaboration with them, which has in turn resulted in delays in obtaining clinical data to evaluate the safety and potential efficacy of INO-4800. Further, the threat of a trade war between the United States and China could lead to supply chain disruptions or increased costs for clinical materials manufactured in China that are necessary for our development efforts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interruptions or failures could then impede commercialization of our DNA medicine candidates and impair our competitive position. We may also be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary smart device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our DNA medicine candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot be certain that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, and economic and other external factors; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics, including COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general can experience relatively large price and volume fluctuations from time to time. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. For example, our operating expenses increased significantly from 2020 to 2022 due to development and manufacturing activities for our COVID-19 vaccine program, for which we discontinued internal funding in the fourth quarter of 2022. We may not deploy our current capital resources effectively. The failure by our management to apply our funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our investigational medicines. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes in laws and regulations, such as alternative minimum taxes or suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply or regain compliance with Nasdaq&#8217;s continued listing standards, our common stock may be delisted and the price of our common stock, our ability to access the capital markets and our financial condition could be negatively impacted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on the Nasdaq Global Select Market. To maintain the listing of our common stock on the Nasdaq Global Select Market, we are required to meet certain listing requirements, including, among others, maintaining a minimum closing bid price of $1.00 per share. In May 2023, we received a written notice, or the Notice, from the Listing Qualifications Department of The Nasdaq Stock Market, or Nasdaq, that we are not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. Pursuant to Nasdaq listing rules, we have been provided an initial compliance period of 180 calendar days from receipt of the Notice, or until October 31, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for our common stock would need to close at $1.00 per share or more for a minimum of 10 consecutive business days during this 180-day grace period, among other requirements. While we may be able to qualify for additional time to attempt to regain compliance, there can be no assurance that we will qualify for additional time to regain compliance, or that we will regain compliance with or without such additional time.  If necessary to regain compliance with Nasdaq listing standards, we may, subject to approval of our board of directors and stockholders, implement a reverse stock split. However, there can be no assurance that a reverse stock split, or any other alternatives we may consider to regain compliance with the minimum bid price requirement, would be approved or would result in a sustained higher stock price that would allow us to meet the Nasdaq stock price listing requirements. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to regain compliance within the compliance period allotted by Nasdaq, our common stock could be delisted, which would have a further material adverse effect on the market price of our common stock and on stockholder liquidity. We intend to actively monitor the bid price of our common stock and will consider available options to regain compliance with the listing requirement; however, there can be no assurance that we will be able to regain compliance with the listing requirement or will otherwise be in compliance with other Nasdaq listing criteria. If Nasdaq delists our common stock for failure to meet its listing standards, and our common stock is not eligible for quotation or listing on another market or exchange, we and our stockholders could face significant negative consequences, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading of our common stock being conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities, such as the Pink Sheets or the OTC Bulletin Board, which could result in limited availability of market quotations for our common stock and increased difficulty of disposing of shares of common stock;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that the common stock is a &#8220;penny stock,&#8221; which would require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of our common stock;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of analyst coverage; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our proprietary smart device, DNA medicine candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our proprietary smart device and DNA medicine candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our DNA medicine candidates receive regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, rising interest rates, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Similarly, in March 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Further, uncertainty remains over liquidity concerns in the broader financial services industry including, for example, in the case of First Republic Bank and Credit Suisse during March 2023. In March 2023, CS agreed to be acquired by UBS following the intervention of the Swiss Federal Department of Finance, the Swiss National Bank and the Swiss Financial Market Supervisory Authority.  In May 2023, First Republic Bank was acquired by JP Morgan Chase after being seized by the FDIC. </span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not have any deposits at any of the banks mentioned in the preceding paragraph, we maintain deposits at financial institutions as a part of doing business that could be at risk if another similar event were to occur. Our ongoing cash management strategy is to maintain the majority of our deposit accounts in large financial institutions, but there can be no assurance this strategy will be successful. Increasing concerns regarding the U.S. or international financial systems, including bank failures and bailouts, and their potential broader effects and potential systemic risk on the banking sector generally, may adversely affect our access to capital. Any decline in available funding or access to our cash and liquidity resources could, among other risks, limit our ability to meet our capital needs and fund future growth or fulfill our other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In 2017, tax legislation commonly known as the Tax Cuts and Jobs Act, or Tax Act, was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, resulted in significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). It is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or legislative changes proposed or implemented, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_1167"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.                UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the settlement of class action securities litigation described in Part II, Item 1. above, we issued a total of 9,121,000 shares during the three months ended March 31, 2023. These securities were issued in reliance on the exemption under Section 3(a)(10) of the Securities Act of 1933, as amended.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_1211"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, we received a notice from The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) that we are not in compliance with Nasdaq&#8217;s Listing Rule 5450(a)(1), as the minimum bid price of our common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of our common stock on The Nasdaq Global Select Market.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 180 calendar days, or until October 31, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of our common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period. In the event we do not regain compliance with the minimum bid price requirement by October 31, 2023, we may be eligible for an additional 180-calendar day compliance period if we elect to transfer to The Nasdaq Capital Market to take advantage of the additional compliance period offered on that market. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">need to provide written notice of our intention to cure the bid price deficiency during the second compliance period. Our failure to regain compliance during this period could result in delisting.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to actively monitor the bid price of our common stock and will consider available options to regain compliance with the listing requirements. There can be no assurance that we will be able to regain compliance with Nasdaq&#8217;s Listing Rule 5450(a)(1) or will otherwise be in compliance with other Nasdaq listing criteria.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span><br/></span></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_136"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit 3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August 10, 2011 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Form 8-K current report filed on August 12, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33123x10qex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33123x10qex311.htm">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-3312310qex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-3312310qex312.htm">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33123x10qex321.htm">32.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33123x10qex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="margin-top:7.5pt;padding-left:11.25pt;text-indent:-11.25pt"><span><br/></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i1ff6d590f0b0417ea0f0772b34ecc5f0_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JACQUELINE E. SHEA&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ino-33123x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0942b58fe97b4ca597d94084a48d57a9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqueline E. Shea, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:5pt;margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;JACQUELINE E. SHEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ino-3312310qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1c43a2116c364fc5b2c73b155841cf36_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:9pt;padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ino-33123x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibe20e7e40f164bb987cc80b5530426e4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;JACQUELINE E. SHEA</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ino-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:160750a0-0a71-42f6-8d80-818c69f4d1ac,g:e1c02d6a-4ccd-42cb-9c8b-7f68796035cd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.inovio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.inovio.com/role/OrganizationandOperations">
        <link:definition>0000008 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertainties" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties">
        <link:definition>0000009 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>0000010 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>0000011 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>0000012 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.inovio.com/role/CertainBalanceSheetItems">
        <link:definition>0000013 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000014 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>0000015 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.inovio.com/role/NetLossPerShare">
        <link:definition>0000017 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>0000018 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>0000019 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>0000021 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>0000023 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies">
        <link:definition>0000024 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>0000025 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables">
        <link:definition>0000026 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000027 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>0000028 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>0000029 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>0000030 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000032 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>0000033 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesDetails" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
        <link:definition>0000034 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionDetails">
        <link:definition>0000035 - Disclosure - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>0000036 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>0000037 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000038 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails">
        <link:definition>0000039 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails">
        <link:definition>0000040 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
        <link:definition>0000041 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>0000042 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>0000043 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
        <link:definition>0000044 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>0000045 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
        <link:definition>0000046 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000047 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
        <link:definition>0000048 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationDetails">
        <link:definition>0000049 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000051 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000052 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails">
        <link:definition>0000053 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>0000054 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>0000055 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredstockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails">
        <link:definition>0000056 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_PrepaidManufacturingExpensesCurrent" abstract="false" name="PrepaidManufacturingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedExercisedAmount" abstract="false" name="CollaborativeAgreementAwardedExercisedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" abstract="true" name="McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementRevenueFromTheProcurementContract" abstract="false" name="CollaborativeArrangementRevenueFromTheProcurementContract" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesTable" abstract="true" name="AccountsPayableAndAccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_LossContingencyEstimateOfPossibleLossValueOfShares" abstract="false" name="LossContingencyEstimateOfPossibleLossValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_JJosephKimMember" abstract="true" name="JJosephKimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AllOtherCustomersMember" abstract="true" name="AllOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A2022InducementPlanMember" abstract="true" name="A2022InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" abstract="false" name="ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GainLossOnRemeasurementOfEquityMethodInvestment" abstract="false" name="GainLossOnRemeasurementOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CertainBalanceSheetItemsAbstract" abstract="true" name="CertainBalanceSheetItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesLineItems" abstract="true" name="AccountsPayableAndAccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LicenseWithAffiliatedEntitiesMember" abstract="true" name="LicenseWithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SeriesA2OnePreferredStockMember" abstract="true" name="SeriesA2OnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AnnualMaintenancePeriod" abstract="false" name="AnnualMaintenancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SalesAgreementsMember" abstract="true" name="SalesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementPaymentEarned" abstract="false" name="CollaborationAgreementPaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" abstract="false" name="LesseeOperatingLeaseNumberOfAgreementsToSublease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_DebtInstrumentAccruedInterest" abstract="false" name="DebtInstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesIncMember" abstract="true" name="PlumblineLifeSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CELLECTRA2000DeviceMember" abstract="true" name="CELLECTRA2000DeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ino-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:160750a0-0a71-42f6-8d80-818c69f4d1ac,g:e1c02d6a-4ccd-42cb-9c8b-7f68796035cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_089b8d5d-bb59-4c06-bb98-385f16e4052c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d820444b-e470-46de-9e39-5f192ea626eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_089b8d5d-bb59-4c06-bb98-385f16e4052c" xlink:to="loc_us-gaap_Liabilities_d820444b-e470-46de-9e39-5f192ea626eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0ca13930-8049-469f-b7fc-605574a06b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_089b8d5d-bb59-4c06-bb98-385f16e4052c" xlink:to="loc_us-gaap_StockholdersEquity_0ca13930-8049-469f-b7fc-605574a06b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d8539b1b-c169-400b-9cab-67a2e1964687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0bf2080-33dd-4638-8cfb-063e35ad8b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8539b1b-c169-400b-9cab-67a2e1964687" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0bf2080-33dd-4638-8cfb-063e35ad8b51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_5e347b8b-4ceb-4d50-8c03-d6a93155f012" xlink:href="ino-20230331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8539b1b-c169-400b-9cab-67a2e1964687" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_5e347b8b-4ceb-4d50-8c03-d6a93155f012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bc45d0fd-435e-48d6-b1f2-397f32496160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8539b1b-c169-400b-9cab-67a2e1964687" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bc45d0fd-435e-48d6-b1f2-397f32496160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c66b4274-56c0-4c71-9b2a-a0f8cc84e516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8539b1b-c169-400b-9cab-67a2e1964687" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c66b4274-56c0-4c71-9b2a-a0f8cc84e516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_73be00f5-9aa0-4929-b711-0ce7786a0cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8539b1b-c169-400b-9cab-67a2e1964687" xlink:to="loc_us-gaap_ShortTermInvestments_73be00f5-9aa0-4929-b711-0ce7786a0cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_019631c9-8586-479d-9501-3e6da14424c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d8539b1b-c169-400b-9cab-67a2e1964687" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_019631c9-8586-479d-9501-3e6da14424c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_5c6e98b1-7f7c-4338-854a-5e531ad447e8" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_5c6e98b1-7f7c-4338-854a-5e531ad447e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8a19f1a7-82b3-4ce6-8d67-a9f4503d8f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8a19f1a7-82b3-4ce6-8d67-a9f4503d8f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_458a024c-a899-4743-94e9-c282a8e0fc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_458a024c-a899-4743-94e9-c282a8e0fc34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_9f12ff54-8372-4503-a99c-e258fa7653ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_9f12ff54-8372-4503-a99c-e258fa7653ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_37e7c0e5-7886-46fc-af85-11c6589ad2c9" xlink:href="ino-20230331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_37e7c0e5-7886-46fc-af85-11c6589ad2c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_16d2b521-8ae0-4a3e-bb68-d48746ca362f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_16d2b521-8ae0-4a3e-bb68-d48746ca362f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_e9091e18-94a8-42a4-b195-4ed530729cf8" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb2997c4-9e47-4722-b5de-35f7275a7084" xlink:to="loc_ino_DeferredGrantFundingCurrent_e9091e18-94a8-42a4-b195-4ed530729cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_94131afe-24ec-481d-a96d-ec1e434bbb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5fdb73c5-6b91-46d6-ae78-63cf0d460e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94131afe-24ec-481d-a96d-ec1e434bbb74" xlink:to="loc_us-gaap_LiabilitiesCurrent_5fdb73c5-6b91-46d6-ae78-63cf0d460e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9254e074-f8c2-482f-841a-bfe84b7c5e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94131afe-24ec-481d-a96d-ec1e434bbb74" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9254e074-f8c2-482f-841a-bfe84b7c5e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_beff21f6-fb8f-494f-aca2-60e55c2180dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94131afe-24ec-481d-a96d-ec1e434bbb74" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_beff21f6-fb8f-494f-aca2-60e55c2180dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_f8eb54d3-08ee-4383-a928-47b5698eb748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94131afe-24ec-481d-a96d-ec1e434bbb74" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_f8eb54d3-08ee-4383-a928-47b5698eb748" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_690e44ae-53c7-4d2c-8f7f-10ede72618c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b2622c07-6d70-4291-8e2a-d62883ca1b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_690e44ae-53c7-4d2c-8f7f-10ede72618c5" xlink:to="loc_us-gaap_PreferredStockValue_b2622c07-6d70-4291-8e2a-d62883ca1b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dd6bfa0c-1110-4ca1-9381-6a3626c40cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_690e44ae-53c7-4d2c-8f7f-10ede72618c5" xlink:to="loc_us-gaap_CommonStockValue_dd6bfa0c-1110-4ca1-9381-6a3626c40cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8fa76555-14ab-46ef-b567-e3afb1b487e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_690e44ae-53c7-4d2c-8f7f-10ede72618c5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8fa76555-14ab-46ef-b567-e3afb1b487e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4e937c5-dbfd-478a-8826-e21c47558553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_690e44ae-53c7-4d2c-8f7f-10ede72618c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4e937c5-dbfd-478a-8826-e21c47558553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2a1996a9-d333-4e19-9d72-75bf104c60a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_690e44ae-53c7-4d2c-8f7f-10ede72618c5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2a1996a9-d333-4e19-9d72-75bf104c60a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c8821ff-ff99-440c-83d2-39895f3d2d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c8821ff-ff99-440c-83d2-39895f3d2d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6d02460c-40c4-44a0-9424-ab7c539b9a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6d02460c-40c4-44a0-9424-ab7c539b9a82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_4956e284-922d-4e22-9451-a975a107057e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_4956e284-922d-4e22-9451-a975a107057e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3666b01a-e377-4e10-b8dd-05fb7e4c3b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3666b01a-e377-4e10-b8dd-05fb7e4c3b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a3173399-201a-4193-8c38-507a22af7dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a3173399-201a-4193-8c38-507a22af7dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c8434d95-5409-4e20-b37e-553fd86d632b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:to="loc_us-gaap_AssetsCurrent_c8434d95-5409-4e20-b37e-553fd86d632b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5452b9da-bd29-4bbd-bf32-230835d3341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ed75f19e-37e0-499d-9e99-d25f6e4228f8" xlink:to="loc_us-gaap_Goodwill_5452b9da-bd29-4bbd-bf32-230835d3341f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e8eb0f52-38bd-4aa8-a7b0-ace16c351002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3cd94dc9-d268-4434-9cfb-ede7b5128a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e8eb0f52-38bd-4aa8-a7b0-ace16c351002" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3cd94dc9-d268-4434-9cfb-ede7b5128a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_d1313d89-b95c-484b-b619-48f9b1386d4f" xlink:href="ino-20230331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e8eb0f52-38bd-4aa8-a7b0-ace16c351002" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_d1313d89-b95c-484b-b619-48f9b1386d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ac7886a5-cff3-437c-aa5a-2042958a21d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e8eb0f52-38bd-4aa8-a7b0-ace16c351002" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ac7886a5-cff3-437c-aa5a-2042958a21d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4e11af30-e1d0-4c39-a511-aa6c3e68263b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e8eb0f52-38bd-4aa8-a7b0-ace16c351002" xlink:to="loc_us-gaap_InterestExpense_4e11af30-e1d0-4c39-a511-aa6c3e68263b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9da076fb-7c3e-403c-bca8-2aeb95fd8963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e8eb0f52-38bd-4aa8-a7b0-ace16c351002" xlink:to="loc_us-gaap_OperatingIncomeLoss_9da076fb-7c3e-403c-bca8-2aeb95fd8963" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_a58fa30f-5fd2-4741-85fa-e4aca2cfe749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e8eb0f52-38bd-4aa8-a7b0-ace16c351002" xlink:to="loc_us-gaap_InterestIncomeOperating_a58fa30f-5fd2-4741-85fa-e4aca2cfe749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c39fb2f2-69d6-433f-ac9b-9219744bd889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8201dcbe-e6ba-4e3d-8b45-bd2694281c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c39fb2f2-69d6-433f-ac9b-9219744bd889" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8201dcbe-e6ba-4e3d-8b45-bd2694281c7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1cebe0c3-a08c-45a8-8abb-dc77d592e714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c39fb2f2-69d6-433f-ac9b-9219744bd889" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1cebe0c3-a08c-45a8-8abb-dc77d592e714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_37cc5b7d-f34c-4eea-ac34-ef7592fd9e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f18d2584-11d8-4324-a2b7-ef5373f2d411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_37cc5b7d-f34c-4eea-ac34-ef7592fd9e3d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f18d2584-11d8-4324-a2b7-ef5373f2d411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_19927ceb-da52-4959-a741-2f12a6afa9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_37cc5b7d-f34c-4eea-ac34-ef7592fd9e3d" xlink:to="loc_us-gaap_OperatingExpenses_19927ceb-da52-4959-a741-2f12a6afa9e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41215cab-958d-422c-ad41-5618ea41ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dddd3ec0-9bb6-4a69-b1f0-d4426d1f18e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41215cab-958d-422c-ad41-5618ea41ad11" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dddd3ec0-9bb6-4a69-b1f0-d4426d1f18e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_985a3675-2819-4938-b186-b96a92639cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41215cab-958d-422c-ad41-5618ea41ad11" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_985a3675-2819-4938-b186-b96a92639cb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3c81cea4-a7c1-467c-bcab-d66dcac29433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_123b1e58-c86a-4d05-b0e0-d90b555eabc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3c81cea4-a7c1-467c-bcab-d66dcac29433" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_123b1e58-c86a-4d05-b0e0-d90b555eabc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e9b0ccf6-2ef4-49ea-839e-2704276b3acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3c81cea4-a7c1-467c-bcab-d66dcac29433" xlink:to="loc_us-gaap_NetIncomeLoss_e9b0ccf6-2ef4-49ea-839e-2704276b3acf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_45cfea04-b9b9-4295-b68b-2b5815364756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3c81cea4-a7c1-467c-bcab-d66dcac29433" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_45cfea04-b9b9-4295-b68b-2b5815364756" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_80efc283-75bb-4e24-b334-b74d8e55931e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_80efc283-75bb-4e24-b334-b74d8e55931e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e79f9b1b-33ba-4c85-8d5f-6f4e2d9d659a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e79f9b1b-33ba-4c85-8d5f-6f4e2d9d659a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_babb30da-ef23-440f-a34d-976c4919b7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_babb30da-ef23-440f-a34d-976c4919b7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9c66b1b2-ca70-4e52-98d1-2af515bf65f8" xlink:href="ino-20230331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9c66b1b2-ca70-4e52-98d1-2af515bf65f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4cbf23fa-ac2b-41b3-bc2e-1ae1ff158f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4cbf23fa-ac2b-41b3-bc2e-1ae1ff158f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_46c2f839-6794-4149-803b-bb225bbaaa83" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_46c2f839-6794-4149-803b-bb225bbaaa83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_ad351ee8-be32-4139-b4f3-82d784a48fa9" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_ad351ee8-be32-4139-b4f3-82d784a48fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6715e002-3ed5-435a-b19e-f541a7690836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6715e002-3ed5-435a-b19e-f541a7690836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8e24e809-1d5d-4013-b21b-ab5ac6164235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_8e24e809-1d5d-4013-b21b-ab5ac6164235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_162c149d-e79f-4bfa-8aa4-072fb1b14cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_162c149d-e79f-4bfa-8aa4-072fb1b14cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_10078524-3739-4517-b6b9-f0a3d176216d" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_10078524-3739-4517-b6b9-f0a3d176216d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_00eff6d4-181d-40c9-b6ab-8d8940f717d6" xlink:href="ino-20230331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_ino_NonCashInterestIncomeExpense_00eff6d4-181d-40c9-b6ab-8d8940f717d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e71420de-817a-4bd0-a7a5-8e878ab72349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_ShareBasedCompensation_e71420de-817a-4bd0-a7a5-8e878ab72349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9486a45c-1621-4366-8d5c-5d6c5da1b68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9486a45c-1621-4366-8d5c-5d6c5da1b68d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d67a6e30-b5fc-404d-af9f-5c905d08bb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d67a6e30-b5fc-404d-af9f-5c905d08bb68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d7d91dd0-8ba8-4cf2-bd64-5b85a07778ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d7d91dd0-8ba8-4cf2-bd64-5b85a07778ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c0e21741-91db-4f87-ab08-777c957f29ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c0e21741-91db-4f87-ab08-777c957f29ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a8221c9a-fdf0-4045-aeb9-198621990538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a8221c9a-fdf0-4045-aeb9-198621990538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cdb925df-a8aa-4e32-b088-39f1bdb12bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_Depreciation_cdb925df-a8aa-4e32-b088-39f1bdb12bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_000b7f4a-5ae0-4fd2-9b22-4d6dd702d72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_000b7f4a-5ae0-4fd2-9b22-4d6dd702d72e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23db1b41-e0fe-4715-a469-e11bc6e04bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_us-gaap_NetIncomeLoss_23db1b41-e0fe-4715-a469-e11bc6e04bff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_7009016e-019c-418b-9cb2-02daf6b38c9a" xlink:href="ino-20230331.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a4159ac4-ae80-441e-a97a-d2ce0b4108d5" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_7009016e-019c-418b-9cb2-02daf6b38c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437e8aa2-c583-486e-8d63-70afd814e5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ccd5a86-fb64-4878-8f64-b33d97b41235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437e8aa2-c583-486e-8d63-70afd814e5ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ccd5a86-fb64-4878-8f64-b33d97b41235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65a2b326-94da-4cd7-b321-9b660ad86578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437e8aa2-c583-486e-8d63-70afd814e5ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65a2b326-94da-4cd7-b321-9b660ad86578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_851fcf04-4149-4020-a38b-5db384286821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437e8aa2-c583-486e-8d63-70afd814e5ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_851fcf04-4149-4020-a38b-5db384286821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce3549c6-f829-413a-855b-313d3cdd5430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_437e8aa2-c583-486e-8d63-70afd814e5ef" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce3549c6-f829-413a-855b-313d3cdd5430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bc24dfc-5fe3-4b4a-9b22-907fe79843e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4330e7b9-ed15-463c-a9c2-02b79e1d2c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bc24dfc-5fe3-4b4a-9b22-907fe79843e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4330e7b9-ed15-463c-a9c2-02b79e1d2c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1444f73f-a7c1-496a-98b9-0e129a409d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bc24dfc-5fe3-4b4a-9b22-907fe79843e6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1444f73f-a7c1-496a-98b9-0e129a409d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4fd213bd-c37e-43f9-bf49-7ab69b2d39da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bc24dfc-5fe3-4b4a-9b22-907fe79843e6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4fd213bd-c37e-43f9-bf49-7ab69b2d39da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ea1917-ec97-4a7f-aad3-a0830c8db488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1c5a0708-81d5-402a-b977-cb957ecbc7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ea1917-ec97-4a7f-aad3-a0830c8db488" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1c5a0708-81d5-402a-b977-cb957ecbc7eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9a3ec3ca-8221-4947-ad8c-307bb53c5ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ea1917-ec97-4a7f-aad3-a0830c8db488" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9a3ec3ca-8221-4947-ad8c-307bb53c5ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_8e2fdfdb-848e-4c63-8a9e-7ece8fb6ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ea1917-ec97-4a7f-aad3-a0830c8db488" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_8e2fdfdb-848e-4c63-8a9e-7ece8fb6ea1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_dac7dabf-69a3-4bce-aa36-e43f54cdf7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ea1917-ec97-4a7f-aad3-a0830c8db488" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_dac7dabf-69a3-4bce-aa36-e43f54cdf7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5884ded9-d875-481f-9d3d-008428d41525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32ea1917-ec97-4a7f-aad3-a0830c8db488" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5884ded9-d875-481f-9d3d-008428d41525" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d020f672-3059-4243-8605-5b21f1f7ae83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a9030255-0421-4ef7-a384-71056199c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d020f672-3059-4243-8605-5b21f1f7ae83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a9030255-0421-4ef7-a384-71056199c9ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b27546cb-684e-4e2b-b085-58a7f1ecbd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d020f672-3059-4243-8605-5b21f1f7ae83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b27546cb-684e-4e2b-b085-58a7f1ecbd1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c016f53-c566-4f50-b69a-50edfb979c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d020f672-3059-4243-8605-5b21f1f7ae83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c016f53-c566-4f50-b69a-50edfb979c6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8c35b6d5-710b-4eab-81af-dea6b07195f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7da2c7be-7ff8-44f9-9a04-432b51d2315e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8c35b6d5-710b-4eab-81af-dea6b07195f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7da2c7be-7ff8-44f9-9a04-432b51d2315e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_45d8cf2c-6e2f-40f0-870a-d3e6c50ba570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8c35b6d5-710b-4eab-81af-dea6b07195f7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_45d8cf2c-6e2f-40f0-870a-d3e6c50ba570" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be54fb21-2f96-4154-836e-67b5a8d88462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_54d4c994-aed8-4508-84dd-0f1150d58511" xlink:href="ino-20230331.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be54fb21-2f96-4154-836e-67b5a8d88462" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_54d4c994-aed8-4508-84dd-0f1150d58511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a3c0ed36-4aba-4b05-b2a1-628d65ef9f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be54fb21-2f96-4154-836e-67b5a8d88462" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a3c0ed36-4aba-4b05-b2a1-628d65ef9f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_b6f253f7-dff5-47e3-ac2d-64d75e80747a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be54fb21-2f96-4154-836e-67b5a8d88462" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_b6f253f7-dff5-47e3-ac2d-64d75e80747a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5e83bea4-7ec2-43cd-9462-7d6fe7a9f474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_a0edfdb6-a7f4-4b0f-b1b9-8f0ac052021c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5e83bea4-7ec2-43cd-9462-7d6fe7a9f474" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_a0edfdb6-a7f4-4b0f-b1b9-8f0ac052021c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_a2b9c6bd-6620-451b-ab7d-01792bdc8235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5e83bea4-7ec2-43cd-9462-7d6fe7a9f474" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_a2b9c6bd-6620-451b-ab7d-01792bdc8235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_3a901fa1-8fea-48ef-9846-038bc2aeadeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5e83bea4-7ec2-43cd-9462-7d6fe7a9f474" xlink:to="loc_us-gaap_AccruedSalariesCurrent_3a901fa1-8fea-48ef-9846-038bc2aeadeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_2e1c8b74-6f58-4bb0-8b4f-6e0761a1a45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5e83bea4-7ec2-43cd-9462-7d6fe7a9f474" xlink:to="loc_us-gaap_LitigationReserveCurrent_2e1c8b74-6f58-4bb0-8b4f-6e0761a1a45d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37b900a3-d2cb-4f01-96b2-bd54d5b3e8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_92e1c999-c23b-49c0-8b62-aad39dc78957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37b900a3-d2cb-4f01-96b2-bd54d5b3e8a8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_92e1c999-c23b-49c0-8b62-aad39dc78957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9372e585-8ff1-4047-90dc-bb89c1666abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_37b900a3-d2cb-4f01-96b2-bd54d5b3e8a8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9372e585-8ff1-4047-90dc-bb89c1666abf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ef0e70c4-26a6-4c10-a265-84ec9ddba065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_212e6030-b499-48f9-837e-798348d374d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_ef0e70c4-26a6-4c10-a265-84ec9ddba065" xlink:to="loc_us-gaap_GoodwillGross_212e6030-b499-48f9-837e-798348d374d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_ec511ddb-0d2c-49b6-acbd-43fdfb44fa8e" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_b63d699a-18b9-456a-abe0-1b10018d24a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_ec511ddb-0d2c-49b6-acbd-43fdfb44fa8e" xlink:to="loc_us-gaap_GoodwillGross_b63d699a-18b9-456a-abe0-1b10018d24a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e40eeb07-6d7f-4bd8-942c-a56c2b841491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_ec511ddb-0d2c-49b6-acbd-43fdfb44fa8e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e40eeb07-6d7f-4bd8-942c-a56c2b841491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_e2d6a619-82e6-4b07-9816-c0fb7d7de93b" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_94886d2f-e781-4ae9-b0af-53abe96b1bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_e2d6a619-82e6-4b07-9816-c0fb7d7de93b" xlink:to="loc_us-gaap_Goodwill_94886d2f-e781-4ae9-b0af-53abe96b1bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_de273166-a64a-4192-a1aa-22069b0c1f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_e2d6a619-82e6-4b07-9816-c0fb7d7de93b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_de273166-a64a-4192-a1aa-22069b0c1f0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8ac4138a-e5a5-4548-86b0-de083008febe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7635418d-9ebb-4ca1-aa80-0994c4e1232a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8ac4138a-e5a5-4548-86b0-de083008febe" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7635418d-9ebb-4ca1-aa80-0994c4e1232a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_75c84f0e-6968-4f71-91f3-8df4d1fc1d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8ac4138a-e5a5-4548-86b0-de083008febe" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_75c84f0e-6968-4f71-91f3-8df4d1fc1d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_5092a368-e752-4435-9f44-c5820fdc97a5" xlink:href="ino-20230331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8ac4138a-e5a5-4548-86b0-de083008febe" xlink:to="loc_ino_DebtInstrumentAccruedInterest_5092a368-e752-4435-9f44-c5820fdc97a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_fcf82732-7eca-4f5e-a404-81ddb26c4ed0" xlink:href="ino-20230331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8ac4138a-e5a5-4548-86b0-de083008febe" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_fcf82732-7eca-4f5e-a404-81ddb26c4ed0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b997ab9-fb1a-4d3b-ac73-4ada96a306cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_10d1be5d-e0f3-418d-9427-9ef4f2b046ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0b997ab9-fb1a-4d3b-ac73-4ada96a306cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_10d1be5d-e0f3-418d-9427-9ef4f2b046ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_60ebd01a-e58c-441b-bb8c-47dc5e3c3fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0b997ab9-fb1a-4d3b-ac73-4ada96a306cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_60ebd01a-e58c-441b-bb8c-47dc5e3c3fcb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_79b677f5-9c7c-44cd-b28d-528cc33c676c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_91e17cc3-c6e0-4265-be58-d3f7bbaa29ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_79b677f5-9c7c-44cd-b28d-528cc33c676c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_91e17cc3-c6e0-4265-be58-d3f7bbaa29ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6a6d1ef-2ff9-4904-b6b0-b41b07b57b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_79b677f5-9c7c-44cd-b28d-528cc33c676c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6a6d1ef-2ff9-4904-b6b0-b41b07b57b23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_248e838b-e69d-4eff-8af5-0fa1e76e1073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_319f536b-bb49-43cd-9564-20b11f47c858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_248e838b-e69d-4eff-8af5-0fa1e76e1073" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_319f536b-bb49-43cd-9564-20b11f47c858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5a0b07b-af67-41d7-b3b3-785af623e292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_248e838b-e69d-4eff-8af5-0fa1e76e1073" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5a0b07b-af67-41d7-b3b3-785af623e292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ad45273b-7687-46d7-99ea-2ba97f9d2358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_248e838b-e69d-4eff-8af5-0fa1e76e1073" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ad45273b-7687-46d7-99ea-2ba97f9d2358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5219ed0c-f06c-456a-b461-459ee88b63f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_248e838b-e69d-4eff-8af5-0fa1e76e1073" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5219ed0c-f06c-456a-b461-459ee88b63f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71e0c082-6b44-48a1-8a01-4bc6be6525f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_248e838b-e69d-4eff-8af5-0fa1e76e1073" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_71e0c082-6b44-48a1-8a01-4bc6be6525f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e18abfb0-a955-45d4-b5a2-0e53219939b4" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_248e838b-e69d-4eff-8af5-0fa1e76e1073" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e18abfb0-a955-45d4-b5a2-0e53219939b4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ino-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:160750a0-0a71-42f6-8d80-818c69f4d1ac,g:e1c02d6a-4ccd-42cb-9c8b-7f68796035cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="if657a0f67db44f51a4f3d63b8f66a9fa_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_279d6966-769c-4d2e-bae2-83f96f12c1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_279d6966-769c-4d2e-bae2-83f96f12c1d1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_03ddacac-b50e-4731-aee5-1db239f1e938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_SharesIssued_03ddacac-b50e-4731-aee5-1db239f1e938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c313a283-633c-4b01-bf3e-4ae670947489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockholdersEquity_c313a283-633c-4b01-bf3e-4ae670947489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76e8a294-460b-483d-ab12-fff210cecbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76e8a294-460b-483d-ab12-fff210cecbfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5a2beab0-9969-4532-ae35-7ea36acdd768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5a2beab0-9969-4532-ae35-7ea36acdd768" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8488ca5e-be2b-4b43-a4dd-4b1c70d9e7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8488ca5e-be2b-4b43-a4dd-4b1c70d9e7d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3deb5ddf-776a-46d4-b151-1fe75cd78042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3deb5ddf-776a-46d4-b151-1fe75cd78042" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dcd3a3de-bc4c-4757-90de-615863442a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dcd3a3de-bc4c-4757-90de-615863442a62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1eaa5116-eaa3-4baf-ba0b-6d09c03cc192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_NetIncomeLoss_1eaa5116-eaa3-4baf-ba0b-6d09c03cc192" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1045912c-095b-4b9e-bcce-5fdf28c600fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1045912c-095b-4b9e-bcce-5fdf28c600fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_575cba9a-bc18-4b40-9e6b-16b7f02e2d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_575cba9a-bc18-4b40-9e6b-16b7f02e2d68" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c67b0769-86f2-47e6-a007-daa62313e5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_618f966c-e615-4dcc-bc90-4c10beff44e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_279d6966-769c-4d2e-bae2-83f96f12c1d1" xlink:to="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_646dfb69-ca7e-4e55-999b-44d0966c19ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_646dfb69-ca7e-4e55-999b-44d0966c19ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_646dfb69-ca7e-4e55-999b-44d0966c19ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_646dfb69-ca7e-4e55-999b-44d0966c19ba" xlink:to="loc_us-gaap_EquityComponentDomain_646dfb69-ca7e-4e55-999b-44d0966c19ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_646dfb69-ca7e-4e55-999b-44d0966c19ba" xlink:to="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_03748c01-2780-4b12-8e1a-ab461e7c33a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_PreferredStockMember_03748c01-2780-4b12-8e1a-ab461e7c33a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4dcf3b42-82ff-4a0d-bde8-b328eb303d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_CommonStockMember_4dcf3b42-82ff-4a0d-bde8-b328eb303d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6719e3bc-5368-4ba3-b695-9b7ebc1348d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6719e3bc-5368-4ba3-b695-9b7ebc1348d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_054d33b1-7cc5-4cff-947b-eace3f386d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_RetainedEarningsMember_054d33b1-7cc5-4cff-947b-eace3f386d59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e754567-b31b-49f2-8162-0ff2fd6cfa08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e754567-b31b-49f2-8162-0ff2fd6cfa08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_385098a1-3300-47d0-aa56-ba721b23d8f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_385098a1-3300-47d0-aa56-ba721b23d8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e87a2cef-9217-49ed-a8b0-0a8908d4d0d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_385098a1-3300-47d0-aa56-ba721b23d8f5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e87a2cef-9217-49ed-a8b0-0a8908d4d0d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended" id="i58efb9b5093840128dd6ee3f90fb1ff7_BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a37aa348-017e-486b-8c84-79224ac44b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_NetIncomeLoss_a37aa348-017e-486b-8c84-79224ac44b5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_d5608abb-158b-4969-9af0-d74bc431531e" xlink:href="ino-20230331.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_ino_WorkingCapital_d5608abb-158b-4969-9af0-d74bc431531e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eba236c6-777c-4a18-9146-5faef82679e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eba236c6-777c-4a18-9146-5faef82679e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1df461ee-85e4-4561-899a-182f794edfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1df461ee-85e4-4561-899a-182f794edfaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a4db10d-bc43-43e3-ac59-ea44891815d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a4db10d-bc43-43e3-ac59-ea44891815d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e1ab803a-0d2d-4f66-86dd-ecf5507a3858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e1ab803a-0d2d-4f66-86dd-ecf5507a3858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1ab803a-0d2d-4f66-86dd-ecf5507a3858_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e1ab803a-0d2d-4f66-86dd-ecf5507a3858" xlink:to="loc_us-gaap_ClassOfStockDomain_e1ab803a-0d2d-4f66-86dd-ecf5507a3858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fdfe38d1-88c1-4325-bd15-7105877e5c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e1ab803a-0d2d-4f66-86dd-ecf5507a3858" xlink:to="loc_us-gaap_ClassOfStockDomain_fdfe38d1-88c1-4325-bd15-7105877e5c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f0a2f38c-6cdd-4c96-8086-ba5ef67ed875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fdfe38d1-88c1-4325-bd15-7105877e5c38" xlink:to="loc_us-gaap_CommonStockMember_f0a2f38c-6cdd-4c96-8086-ba5ef67ed875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d699300-968b-48bf-816e-9a18cf3a3603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d699300-968b-48bf-816e-9a18cf3a3603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d699300-968b-48bf-816e-9a18cf3a3603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d699300-968b-48bf-816e-9a18cf3a3603" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d699300-968b-48bf-816e-9a18cf3a3603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7212bc4-c790-4495-8ec4-1c35a5cb2746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d699300-968b-48bf-816e-9a18cf3a3603" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7212bc4-c790-4495-8ec4-1c35a5cb2746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_1323ff95-286d-4aeb-9658-4b5fb4cb792f" xlink:href="ino-20230331.xsd#ino_SalesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7212bc4-c790-4495-8ec4-1c35a5cb2746" xlink:to="loc_ino_SalesAgreementsMember_1323ff95-286d-4aeb-9658-4b5fb4cb792f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#RevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended" id="i6ca3e5cd0c2b4c71afc6a6aa69d15e7d_RevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac2e5a-aaef-4b71-8b93-f80af9d7758d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c5e5534-88bc-485f-b33d-f5ef0bb87524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac2e5a-aaef-4b71-8b93-f80af9d7758d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c5e5534-88bc-485f-b33d-f5ef0bb87524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_aa5b44f7-314f-4ca8-94f7-1d33e73a3b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac2e5a-aaef-4b71-8b93-f80af9d7758d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_aa5b44f7-314f-4ca8-94f7-1d33e73a3b4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e34dcd25-b414-4576-a9aa-c8b565ba6e1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aa5b44f7-314f-4ca8-94f7-1d33e73a3b4d" xlink:to="loc_srt_MajorCustomersAxis_e34dcd25-b414-4576-a9aa-c8b565ba6e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e34dcd25-b414-4576-a9aa-c8b565ba6e1b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e34dcd25-b414-4576-a9aa-c8b565ba6e1b" xlink:to="loc_srt_NameOfMajorCustomerDomain_e34dcd25-b414-4576-a9aa-c8b565ba6e1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e34dcd25-b414-4576-a9aa-c8b565ba6e1b" xlink:to="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_82bae3df-0724-4f15-851a-ec5c08c8e13b" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_82bae3df-0724-4f15-851a-ec5c08c8e13b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_0f0cc8ef-1f7c-4b4c-b931-391e07afcae7" xlink:href="ino-20230331.xsd#ino_AllOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:to="loc_ino_AllOtherCustomersMember_0f0cc8ef-1f7c-4b4c-b931-391e07afcae7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="id212f978e3054621bf4502e21134b921_ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_3562ff90-0afa-4ba8-8d65-46e1df36ecce" xlink:href="ino-20230331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_3562ff90-0afa-4ba8-8d65-46e1df36ecce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_346b1454-b336-4f76-8f08-e910d563083c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_346b1454-b336-4f76-8f08-e910d563083c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7366cf0d-9bb6-4b03-bcfe-4bee9995d034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7366cf0d-9bb6-4b03-bcfe-4bee9995d034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45a1dbc9-839f-4d5e-b99b-3fa4cf70a2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45a1dbc9-839f-4d5e-b99b-3fa4cf70a2e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c0aaf46-187b-49d4-a853-20fb4415c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c0aaf46-187b-49d4-a853-20fb4415c69e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_49dfbdc8-63af-49fb-9dea-f3be98e0c222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_49dfbdc8-63af-49fb-9dea-f3be98e0c222" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9a3c157b-1cb0-4e32-8184-312ad9fa8443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_49dfbdc8-63af-49fb-9dea-f3be98e0c222" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9a3c157b-1cb0-4e32-8184-312ad9fa8443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a3c157b-1cb0-4e32-8184-312ad9fa8443_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9a3c157b-1cb0-4e32-8184-312ad9fa8443" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a3c157b-1cb0-4e32-8184-312ad9fa8443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9a3c157b-1cb0-4e32-8184-312ad9fa8443" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_558ecda2-fbfa-497f-a553-28fab1601f49" xlink:href="ino-20230331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_ino_MutualFundsMember_558ecda2-fbfa-497f-a553-28fab1601f49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_ac6b1231-873a-44c8-adcd-ff03d73415c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_ac6b1231-873a-44c8-adcd-ff03d73415c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4b51a218-fbf8-4a63-855d-bb787e5c2ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4b51a218-fbf8-4a63-855d-bb787e5c2ea8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aff976d3-73f5-42c7-9af2-9d5a6f45345a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aff976d3-73f5-42c7-9af2-9d5a6f45345a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i4931c5a0e06b43668fa4f31b9d4fa90f_ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_047fd920-dd46-49d7-b436-386467a5ebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_047fd920-dd46-49d7-b436-386467a5ebf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_483e17b6-099e-4ed8-8c60-e01f3bf70b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_483e17b6-099e-4ed8-8c60-e01f3bf70b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_47e53577-6b9c-42c7-8b39-b8c1c0720762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_47e53577-6b9c-42c7-8b39-b8c1c0720762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6dd2332c-0628-4d06-b2ec-e61193894264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6dd2332c-0628-4d06-b2ec-e61193894264" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_135cc35c-6ee4-4d38-b458-5ad55944bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_135cc35c-6ee4-4d38-b458-5ad55944bbe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_13aee705-f033-42d0-ab0d-313767022305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_13aee705-f033-42d0-ab0d-313767022305" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec17863a-0076-4599-afe7-8fb18cbdb7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec17863a-0076-4599-afe7-8fb18cbdb7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ec17863a-0076-4599-afe7-8fb18cbdb7a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec17863a-0076-4599-afe7-8fb18cbdb7a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ec17863a-0076-4599-afe7-8fb18cbdb7a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7419a506-b6c9-47dc-9170-8a2007c93c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec17863a-0076-4599-afe7-8fb18cbdb7a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7419a506-b6c9-47dc-9170-8a2007c93c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d65353d8-095c-42a2-8db8-cf9f089ca56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7419a506-b6c9-47dc-9170-8a2007c93c9b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d65353d8-095c-42a2-8db8-cf9f089ca56e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d171872d-96b9-4bf3-91d4-95469fe12c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:to="loc_us-gaap_InvestmentTypeAxis_d171872d-96b9-4bf3-91d4-95469fe12c47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d171872d-96b9-4bf3-91d4-95469fe12c47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_d171872d-96b9-4bf3-91d4-95469fe12c47" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d171872d-96b9-4bf3-91d4-95469fe12c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1b72fe0a-f4f6-4356-a6a5-49a3e385dbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_d171872d-96b9-4bf3-91d4-95469fe12c47" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1b72fe0a-f4f6-4356-a6a5-49a3e385dbf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_212425e0-b7a6-4809-b72a-54a47db86489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1b72fe0a-f4f6-4356-a6a5-49a3e385dbf1" xlink:to="loc_us-gaap_CommonStockMember_212425e0-b7a6-4809-b72a-54a47db86489" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="iff6d23cb14054f10a8d9817223d5e188_ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1cb340c-5be2-4117-bf9f-532fe7676073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1cb340c-5be2-4117-bf9f-532fe7676073" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68fd2054-a341-4421-a6d5-ccfd11798ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68fd2054-a341-4421-a6d5-ccfd11798ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_850ed910-2a7c-482f-8300-cffd14746be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_850ed910-2a7c-482f-8300-cffd14746be6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0c7b69e2-a375-437f-b2c1-93be7970c53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0c7b69e2-a375-437f-b2c1-93be7970c53b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1cb340c-5be2-4117-bf9f-532fe7676073" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34cbad67-99fe-4f19-a88b-2224969a33d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34cbad67-99fe-4f19-a88b-2224969a33d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_34cbad67-99fe-4f19-a88b-2224969a33d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34cbad67-99fe-4f19-a88b-2224969a33d3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_34cbad67-99fe-4f19-a88b-2224969a33d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_321263fb-bbae-416a-b979-91123bd2b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34cbad67-99fe-4f19-a88b-2224969a33d3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_321263fb-bbae-416a-b979-91123bd2b3c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5b02f43f-ea9a-4490-a38e-e2519946e7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_321263fb-bbae-416a-b979-91123bd2b3c1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5b02f43f-ea9a-4490-a38e-e2519946e7d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bc528626-af87-43bb-9800-26303a1ac31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bc528626-af87-43bb-9800-26303a1ac31c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc528626-af87-43bb-9800-26303a1ac31c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc528626-af87-43bb-9800-26303a1ac31c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc528626-af87-43bb-9800-26303a1ac31c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc528626-af87-43bb-9800-26303a1ac31c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_cd003f1c-0991-4e9a-a742-2faae9fbd628" xlink:href="ino-20230331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_ino_MutualFundsMember_cd003f1c-0991-4e9a-a742-2faae9fbd628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_082d7f6f-f860-4f54-bc9a-f8b7a5d902b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_082d7f6f-f860-4f54-bc9a-f8b7a5d902b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_23810147-76b1-4547-a3bf-d8798f671ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_us-gaap_CertificatesOfDepositMember_23810147-76b1-4547-a3bf-d8798f671ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e2773cfe-e430-45f7-855f-12075be50714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e2773cfe-e430-45f7-855f-12075be50714" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a9c8172-6744-495d-84d2-b25489aafd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a9c8172-6744-495d-84d2-b25489aafd6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a9c8172-6744-495d-84d2-b25489aafd6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a9c8172-6744-495d-84d2-b25489aafd6e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a9c8172-6744-495d-84d2-b25489aafd6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a9c8172-6744-495d-84d2-b25489aafd6e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1e0f28d5-c948-4114-a3c8-164803f476a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1e0f28d5-c948-4114-a3c8-164803f476a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3f275c6c-7391-43f5-ad6b-7b0a82287b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3f275c6c-7391-43f5-ad6b-7b0a82287b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7856e91d-c389-433e-ae5b-a39dd9eb90c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7856e91d-c389-433e-ae5b-a39dd9eb90c3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended" id="i0444db64099046259d1a0fc4da571663_CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:href="ino-20230331.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_aba87219-dba2-4344-aad8-32889cdca689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_aba87219-dba2-4344-aad8-32889cdca689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_8937d52a-9054-4847-8642-a69eef707c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_AccruedSalariesCurrent_8937d52a-9054-4847-8642-a69eef707c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_c604b771-9066-4ef9-b314-f8563772623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_LitigationReserveCurrent_c604b771-9066-4ef9-b314-f8563772623e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bdda4792-88fb-4ca9-96ab-468e03466c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bdda4792-88fb-4ca9-96ab-468e03466c5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db4ac57a-0712-4ba5-b5bd-493498a945bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db4ac57a-0712-4ba5-b5bd-493498a945bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4236055f-cea0-44f0-8687-9109a6cdb51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4236055f-cea0-44f0-8687-9109a6cdb51d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_5f8a7016-3d95-4bd4-aa40-f92db3bc24dd" xlink:href="ino-20230331.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_5f8a7016-3d95-4bd4-aa40-f92db3bc24dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_cb5c61d9-1b0e-418e-9f8f-530f4f1e7cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_cb5c61d9-1b0e-418e-9f8f-530f4f1e7cdd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5f39e96f-48cd-48db-9aeb-b71c74c14a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_CommonStockSharesIssued_5f39e96f-48cd-48db-9aeb-b71c74c14a08" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_32055e12-918c-471c-8195-cf7b25d83afc" xlink:href="ino-20230331.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_32055e12-918c-471c-8195-cf7b25d83afc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8ac2e4bf-9b79-47f7-9165-3819055fea99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_32055e12-918c-471c-8195-cf7b25d83afc" xlink:to="loc_srt_LitigationCaseAxis_8ac2e4bf-9b79-47f7-9165-3819055fea99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8ac2e4bf-9b79-47f7-9165-3819055fea99_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_8ac2e4bf-9b79-47f7-9165-3819055fea99" xlink:to="loc_srt_LitigationCaseTypeDomain_8ac2e4bf-9b79-47f7-9165-3819055fea99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9c1c61ec-2823-4720-9e07-1ba44f95902b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_8ac2e4bf-9b79-47f7-9165-3819055fea99" xlink:to="loc_srt_LitigationCaseTypeDomain_9c1c61ec-2823-4720-9e07-1ba44f95902b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_705ca8c8-9f1f-4788-8297-7aec0ebdf7bb" xlink:href="ino-20230331.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9c1c61ec-2823-4720-9e07-1ba44f95902b" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_705ca8c8-9f1f-4788-8297-7aec0ebdf7bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="ib30f522b1cb84e76a7de280b19cada9d_GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c19b506c-802e-47ba-b7e3-28cde318377b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c19b506c-802e-47ba-b7e3-28cde318377b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_22b08e13-41d4-414e-9a1f-fca057c075f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:to="loc_us-gaap_GoodwillGross_22b08e13-41d4-414e-9a1f-fca057c075f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_db524fbc-e96d-4b8c-9521-10a3f91c4e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:to="loc_us-gaap_Goodwill_db524fbc-e96d-4b8c-9521-10a3f91c4e09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0eadff2-f057-4b6b-9dc3-27d963702b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0eadff2-f057-4b6b-9dc3-27d963702b51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3671afb-b114-42b5-b54f-e8bbc3377e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3671afb-b114-42b5-b54f-e8bbc3377e2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0d9957e2-1fa7-4028-ae2e-1e362c8aa9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0d9957e2-1fa7-4028-ae2e-1e362c8aa9d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9a6a71e4-a304-4fb9-a6a6-45ae001bb1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9a6a71e4-a304-4fb9-a6a6-45ae001bb1e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_84aaa186-bc11-4a81-9ceb-033b44d19949" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_84aaa186-bc11-4a81-9ceb-033b44d19949" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_67541660-4304-4dbf-99dc-78c0b156648d" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_67541660-4304-4dbf-99dc-78c0b156648d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c19b506c-802e-47ba-b7e3-28cde318377b" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_243c12e9-8525-479e-9712-77e717ba076f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:to="loc_srt_RangeAxis_243c12e9-8525-479e-9712-77e717ba076f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_243c12e9-8525-479e-9712-77e717ba076f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_243c12e9-8525-479e-9712-77e717ba076f" xlink:to="loc_srt_RangeMember_243c12e9-8525-479e-9712-77e717ba076f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77959037-9e28-49d9-b66a-49bd3697c03b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_243c12e9-8525-479e-9712-77e717ba076f" xlink:to="loc_srt_RangeMember_77959037-9e28-49d9-b66a-49bd3697c03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_79e0f20e-6cc5-4fa4-b5b1-49c8e6141ee5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_77959037-9e28-49d9-b66a-49bd3697c03b" xlink:to="loc_srt_WeightedAverageMember_79e0f20e-6cc5-4fa4-b5b1-49c8e6141ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70623736-fd73-495a-9ea9-6b70a156e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70623736-fd73-495a-9ea9-6b70a156e9fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70623736-fd73-495a-9ea9-6b70a156e9fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70623736-fd73-495a-9ea9-6b70a156e9fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70623736-fd73-495a-9ea9-6b70a156e9fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70623736-fd73-495a-9ea9-6b70a156e9fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_cd830d06-9949-4ae1-958a-f2e226939db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:to="loc_us-gaap_LicensingAgreementsMember_cd830d06-9949-4ae1-958a-f2e226939db2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_c20bfbd1-5a77-4c3a-a343-5af6716e5aaf" xlink:href="ino-20230331.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:to="loc_ino_BiojectMember_c20bfbd1-5a77-4c3a-a343-5af6716e5aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1d2181f1-b983-48c2-bdaa-e321ac482c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1d2181f1-b983-48c2-bdaa-e321ac482c23" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="ie998d01f87d842b0a7e6fa3fe7310ead_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_de056d4b-75d3-4e7a-b75f-26073850c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_de056d4b-75d3-4e7a-b75f-26073850c7ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9d1ea22-e36c-47ae-8088-92fbe2a77173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9d1ea22-e36c-47ae-8088-92fbe2a77173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_5ebe841c-cc21-46b4-b0af-8c4991fc3d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_5ebe841c-cc21-46b4-b0af-8c4991fc3d64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4075f621-e9f4-4800-835e-5f6de52144f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4075f621-e9f4-4800-835e-5f6de52144f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4fb9a7f7-b155-40c1-bbe7-8c803378ee64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4fb9a7f7-b155-40c1-bbe7-8c803378ee64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b8d1122e-3ee2-42f6-8b32-f457bcbba2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b8d1122e-3ee2-42f6-8b32-f457bcbba2fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_c4041a5c-6825-4f2e-bcdd-4b245126345d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_c4041a5c-6825-4f2e-bcdd-4b245126345d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_eed49af0-a711-44af-a906-09b5f3afd18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_eed49af0-a711-44af-a906-09b5f3afd18f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b55b9b66-0a09-4f01-a68d-6416a41c420c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b55b9b66-0a09-4f01-a68d-6416a41c420c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ffd51164-52c6-4f8b-be4f-8057b53faa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ffd51164-52c6-4f8b-be4f-8057b53faa0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_247ecf87-7944-4589-b4ea-6d633e3a63d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_247ecf87-7944-4589-b4ea-6d633e3a63d7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_dbe3d94b-19ce-435e-94c2-c455f11d9cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_dbe3d94b-19ce-435e-94c2-c455f11d9cf7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1388812b-f593-4d17-911e-c8471f2496f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1388812b-f593-4d17-911e-c8471f2496f1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_00fca087-1dfd-4e7a-ba8a-01bc47889222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_00fca087-1dfd-4e7a-ba8a-01bc47889222" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_567632b2-3378-4d5e-9281-d26c7b12abf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_ConvertibleDebt_567632b2-3378-4d5e-9281-d26c7b12abf9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c53a21d0-03dd-4bc0-a5c4-2933764cfcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_InterestExpense_c53a21d0-03dd-4bc0-a5c4-2933764cfcf9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_03390e0d-d295-4c48-8880-a00dacce3e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_InterestExpenseDebt_03390e0d-d295-4c48-8880-a00dacce3e9e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e187a2cf-8d7a-4624-8d04-cc05fc568a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e187a2cf-8d7a-4624-8d04-cc05fc568a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e187a2cf-8d7a-4624-8d04-cc05fc568a9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e187a2cf-8d7a-4624-8d04-cc05fc568a9b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e187a2cf-8d7a-4624-8d04-cc05fc568a9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_036ec8f2-d412-446b-9c10-a2d3e9c232b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e187a2cf-8d7a-4624-8d04-cc05fc568a9b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_036ec8f2-d412-446b-9c10-a2d3e9c232b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_efed0176-0a1a-4f49-956c-965e5dc02f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_036ec8f2-d412-446b-9c10-a2d3e9c232b0" xlink:to="loc_us-gaap_ConvertibleDebtMember_efed0176-0a1a-4f49-956c-965e5dc02f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c841bb90-6d8f-468a-9da7-1a6c92d49a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c841bb90-6d8f-468a-9da7-1a6c92d49a84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_c841bb90-6d8f-468a-9da7-1a6c92d49a84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c841bb90-6d8f-468a-9da7-1a6c92d49a84" xlink:to="loc_us-gaap_TypeOfAdoptionMember_c841bb90-6d8f-468a-9da7-1a6c92d49a84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d28e2279-e406-49f6-ace1-0795aee16183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c841bb90-6d8f-468a-9da7-1a6c92d49a84" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d28e2279-e406-49f6-ace1-0795aee16183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_18543be0-9f6c-4f1f-86f7-1466d85101ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d28e2279-e406-49f6-ace1-0795aee16183" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_18543be0-9f6c-4f1f-86f7-1466d85101ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_be0617c1-7f5d-4533-b752-bf45f8db8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:to="loc_us-gaap_DebtInstrumentAxis_be0617c1-7f5d-4533-b752-bf45f8db8ea4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be0617c1-7f5d-4533-b752-bf45f8db8ea4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_be0617c1-7f5d-4533-b752-bf45f8db8ea4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be0617c1-7f5d-4533-b752-bf45f8db8ea4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6a40e0b-5510-4570-be1a-269518cb1632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_be0617c1-7f5d-4533-b752-bf45f8db8ea4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6a40e0b-5510-4570-be1a-269518cb1632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_cfeb5cef-348b-4671-8063-3911fc3b3408" xlink:href="ino-20230331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6a40e0b-5510-4570-be1a-269518cb1632" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_cfeb5cef-348b-4671-8063-3911fc3b3408" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended" id="i573fa813a3bd46b19ea053b054b4ad02_ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4de67ba8-b65c-4dfb-8cac-dd9919a5263c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4de67ba8-b65c-4dfb-8cac-dd9919a5263c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_6079eb6c-5b27-4792-8e52-84cea6d8375a" xlink:href="ino-20230331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_6079eb6c-5b27-4792-8e52-84cea6d8375a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_378dee7f-5ae9-4962-8857-2e10ca595be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_378dee7f-5ae9-4962-8857-2e10ca595be1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_193ed01f-f48c-4fdf-a800-c53227586c28" xlink:href="ino-20230331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_ino_DebtInstrumentAccruedInterest_193ed01f-f48c-4fdf-a800-c53227586c28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5eaeb8fe-4319-4293-a40b-d70cb50a4096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_us-gaap_LongTermDebt_5eaeb8fe-4319-4293-a40b-d70cb50a4096" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_90849603-2765-4554-8303-184d0091958d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_us-gaap_DebtInstrumentTable_90849603-2765-4554-8303-184d0091958d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_90849603-2765-4554-8303-184d0091958d" xlink:to="loc_us-gaap_DebtInstrumentAxis_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9b20af9-a26d-47aa-9d57-8bb7942a1528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9b20af9-a26d-47aa-9d57-8bb7942a1528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eec47daf-0d5d-4ec1-86e8-22151bdb365f" xlink:href="ino-20230331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9b20af9-a26d-47aa-9d57-8bb7942a1528" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eec47daf-0d5d-4ec1-86e8-22151bdb365f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="i5acd9d0411704087acabc92ccabfda00_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_532935f0-f869-409e-9096-d452c4d86663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_532935f0-f869-409e-9096-d452c4d86663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_65020958-dd78-4dfb-870c-3c06b03f8db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_65020958-dd78-4dfb-870c-3c06b03f8db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ad3197e5-d44c-46c6-92c5-54097a51369d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ad3197e5-d44c-46c6-92c5-54097a51369d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d9141a10-7c91-4201-ae3c-6e448fc572d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_LongTermDebt_d9141a10-7c91-4201-ae3c-6e448fc572d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb45e571-2a37-4e7f-a181-01b44a5c01f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb45e571-2a37-4e7f-a181-01b44a5c01f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fb45e571-2a37-4e7f-a181-01b44a5c01f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb45e571-2a37-4e7f-a181-01b44a5c01f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fb45e571-2a37-4e7f-a181-01b44a5c01f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a32ee0a9-1e2a-4c2a-8f24-66f4c2cc58a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb45e571-2a37-4e7f-a181-01b44a5c01f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a32ee0a9-1e2a-4c2a-8f24-66f4c2cc58a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_fdcbb8fb-7a99-4ce2-a834-ba2645b4e10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a32ee0a9-1e2a-4c2a-8f24-66f4c2cc58a5" xlink:to="loc_us-gaap_ConvertibleDebtMember_fdcbb8fb-7a99-4ce2-a834-ba2645b4e10d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1006736f-ccca-4892-ba11-fab502463414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:to="loc_us-gaap_DebtInstrumentAxis_1006736f-ccca-4892-ba11-fab502463414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1006736f-ccca-4892-ba11-fab502463414_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1006736f-ccca-4892-ba11-fab502463414" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1006736f-ccca-4892-ba11-fab502463414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_21e49fd6-7274-47fd-8da5-4a2008ee9059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1006736f-ccca-4892-ba11-fab502463414" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_21e49fd6-7274-47fd-8da5-4a2008ee9059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_96bc0fa0-617e-4aa4-a856-3d5adf780ce8" xlink:href="ino-20230331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21e49fd6-7274-47fd-8da5-4a2008ee9059" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_96bc0fa0-617e-4aa4-a856-3d5adf780ce8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended" id="ice0e8ff6aceb4475b34e02852d23f4db_StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_758bcb92-e8aa-4a1f-a1ed-2872cad0e3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_758bcb92-e8aa-4a1f-a1ed-2872cad0e3b2" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ce6191c-3a34-4ea4-bee7-2168d0d9b4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ce6191c-3a34-4ea4-bee7-2168d0d9b4c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_58bf7d7b-557f-4d3b-9fdf-7f7ad05e3eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_58bf7d7b-557f-4d3b-9fdf-7f7ad05e3eda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_118ad1ce-75c0-4520-9e0e-9020e3426a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockSharesIssued_118ad1ce-75c0-4520-9e0e-9020e3426a92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f556f914-9fb6-4b66-abbf-ffd85fa924a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f556f914-9fb6-4b66-abbf-ffd85fa924a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d1531726-fdaa-4070-aa5a-16c1a772e5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d1531726-fdaa-4070-aa5a-16c1a772e5ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ee7ddff9-0f1c-48c8-98f4-d93c68a09808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ee7ddff9-0f1c-48c8-98f4-d93c68a09808" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b0efe88a-7fd6-458a-ad89-59a122c81113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b0efe88a-7fd6-458a-ad89-59a122c81113" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_94eb475a-fb73-4322-9485-66d1784befdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_94eb475a-fb73-4322-9485-66d1784befdb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_720c2753-230a-40f8-aa3c-c3a481d5b164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_758bcb92-e8aa-4a1f-a1ed-2872cad0e3b2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_720c2753-230a-40f8-aa3c-c3a481d5b164" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc0dfe90-de92-44c5-83e5-e57db7edb64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_720c2753-230a-40f8-aa3c-c3a481d5b164" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc0dfe90-de92-44c5-83e5-e57db7edb64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fc0dfe90-de92-44c5-83e5-e57db7edb64c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc0dfe90-de92-44c5-83e5-e57db7edb64c" xlink:to="loc_us-gaap_ClassOfStockDomain_fc0dfe90-de92-44c5-83e5-e57db7edb64c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61de8ec7-4d4a-46d2-9179-16f3ded83fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc0dfe90-de92-44c5-83e5-e57db7edb64c" xlink:to="loc_us-gaap_ClassOfStockDomain_61de8ec7-4d4a-46d2-9179-16f3ded83fba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_2fb6eaa1-1038-4b82-87b2-40ab6f2fbebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_61de8ec7-4d4a-46d2-9179-16f3ded83fba" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_2fb6eaa1-1038-4b82-87b2-40ab6f2fbebb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="if2694937b7cf45bda23dec71112c707e_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20c910f7-c52e-4576-8a01-adf28e7905bc" xlink:href="ino-20230331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20c910f7-c52e-4576-8a01-adf28e7905bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_74e8e796-83c1-4711-9a92-ff0c39026978" xlink:href="ino-20230331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_74e8e796-83c1-4711-9a92-ff0c39026978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_e7ae1cb7-088e-4c76-9e81-acdbbb6bc7d9" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_e7ae1cb7-088e-4c76-9e81-acdbbb6bc7d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_3fbd66d7-d509-453f-9d26-6c3799942fad" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_3fbd66d7-d509-453f-9d26-6c3799942fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_50e94ad8-718d-4765-8b06-a1f87bc09e1d" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_50e94ad8-718d-4765-8b06-a1f87bc09e1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_304426ae-d94c-4e86-8bef-6d609e4fc106" xlink:href="ino-20230331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_304426ae-d94c-4e86-8bef-6d609e4fc106" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e17b3654-edb2-4fb9-914f-dee266b9d660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_CommonStockSharesIssued_e17b3654-edb2-4fb9-914f-dee266b9d660" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ae062ce4-bc0e-4334-aec9-5ca9ed630bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ae062ce4-bc0e-4334-aec9-5ca9ed630bdd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_26b690eb-3361-454e-a811-3524f51922c9" xlink:href="ino-20230331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_26b690eb-3361-454e-a811-3524f51922c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5bc3002e-7129-4670-8d2f-956e2e3c3326" xlink:href="ino-20230331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5bc3002e-7129-4670-8d2f-956e2e3c3326" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15607819-3560-4850-8016-e731d6285f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15607819-3560-4850-8016-e731d6285f91" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa3f0804-9fac-4e24-a0e0-b1085f10c3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa3f0804-9fac-4e24-a0e0-b1085f10c3cc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_666e56b0-1fe4-4293-b405-7ff9e90cec99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_666e56b0-1fe4-4293-b405-7ff9e90cec99" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23b171f2-9e9e-40c2-9790-e857f240f6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23b171f2-9e9e-40c2-9790-e857f240f6fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ec2578a1-7df8-4754-ac58-60af98477bc5" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ec2578a1-7df8-4754-ac58-60af98477bc5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e4d68453-5acf-4c92-a61f-62888f2e435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e4d68453-5acf-4c92-a61f-62888f2e435e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e4d68453-5acf-4c92-a61f-62888f2e435e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e4d68453-5acf-4c92-a61f-62888f2e435e" xlink:to="loc_us-gaap_ClassOfStockDomain_e4d68453-5acf-4c92-a61f-62888f2e435e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_382404be-e0c9-48c2-84d3-53cd92c511d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e4d68453-5acf-4c92-a61f-62888f2e435e" xlink:to="loc_us-gaap_ClassOfStockDomain_382404be-e0c9-48c2-84d3-53cd92c511d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b88a77c3-a945-431a-a358-ac32ca84c615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_382404be-e0c9-48c2-84d3-53cd92c511d5" xlink:to="loc_us-gaap_CommonStockMember_b88a77c3-a945-431a-a358-ac32ca84c615" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_537b86b7-41ea-4dc6-a563-5571d1d91fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_537b86b7-41ea-4dc6-a563-5571d1d91fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_537b86b7-41ea-4dc6-a563-5571d1d91fa7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_537b86b7-41ea-4dc6-a563-5571d1d91fa7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_537b86b7-41ea-4dc6-a563-5571d1d91fa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9362d0ae-1bd1-4436-808c-8a35a9223209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_537b86b7-41ea-4dc6-a563-5571d1d91fa7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9362d0ae-1bd1-4436-808c-8a35a9223209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_326869cd-a2e0-4a64-857a-29662a92b63d" xlink:href="ino-20230331.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9362d0ae-1bd1-4436-808c-8a35a9223209" xlink:to="loc_ino_SalesAgreementMember_326869cd-a2e0-4a64-857a-29662a92b63d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c1f7b2d8-ea71-4979-893b-4759dfd64595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_PlanNameAxis_c1f7b2d8-ea71-4979-893b-4759dfd64595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c1f7b2d8-ea71-4979-893b-4759dfd64595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c1f7b2d8-ea71-4979-893b-4759dfd64595" xlink:to="loc_us-gaap_PlanNameDomain_c1f7b2d8-ea71-4979-893b-4759dfd64595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c1f7b2d8-ea71-4979-893b-4759dfd64595" xlink:to="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_cf23dda7-e76e-4152-b46a-01759541106b" xlink:href="ino-20230331.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:to="loc_ino_A2016IncentivePlanMember_cf23dda7-e76e-4152-b46a-01759541106b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_c6bb86e5-3fb3-465b-a06f-bc07d16613b5" xlink:href="ino-20230331.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:to="loc_ino_A2007IncentivePlanMember_c6bb86e5-3fb3-465b-a06f-bc07d16613b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_b5aa9aa6-e694-4f22-80f4-3a62866454f4" xlink:href="ino-20230331.xsd#ino_A2022InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:to="loc_ino_A2022InducementPlanMember_b5aa9aa6-e694-4f22-80f4-3a62866454f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fdd85379-56be-4b55-957e-79ad4f6ea823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fdd85379-56be-4b55-957e-79ad4f6ea823" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fdd85379-56be-4b55-957e-79ad4f6ea823_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fdd85379-56be-4b55-957e-79ad4f6ea823" xlink:to="loc_us-gaap_EquityComponentDomain_fdd85379-56be-4b55-957e-79ad4f6ea823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2c92ebf7-9df6-448f-aa13-9e9c608391a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fdd85379-56be-4b55-957e-79ad4f6ea823" xlink:to="loc_us-gaap_EquityComponentDomain_2c92ebf7-9df6-448f-aa13-9e9c608391a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a32b7c62-67b0-4b35-bf7f-dc5047d86ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2c92ebf7-9df6-448f-aa13-9e9c608391a9" xlink:to="loc_us-gaap_CommonStockMember_a32b7c62-67b0-4b35-bf7f-dc5047d86ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9b555078-2e67-4571-83c9-878f8f1bb279" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_srt_LitigationCaseAxis_9b555078-2e67-4571-83c9-878f8f1bb279" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9b555078-2e67-4571-83c9-878f8f1bb279_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9b555078-2e67-4571-83c9-878f8f1bb279" xlink:to="loc_srt_LitigationCaseTypeDomain_9b555078-2e67-4571-83c9-878f8f1bb279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_04864f43-b9c3-4e4c-b146-1fa1428c3410" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9b555078-2e67-4571-83c9-878f8f1bb279" xlink:to="loc_srt_LitigationCaseTypeDomain_04864f43-b9c3-4e4c-b146-1fa1428c3410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_3bb8d0f5-e3f0-40a7-9196-dd3e2acd0417" xlink:href="ino-20230331.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_04864f43-b9c3-4e4c-b146-1fa1428c3410" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_3bb8d0f5-e3f0-40a7-9196-dd3e2acd0417" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended" id="i67def94da4f442b1b2e96a3b7d40b2a9_NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aea9d67b-98fc-4510-a3d4-dfd9dd19f245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c661859-899e-4f35-a057-5f0b1fec3b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aea9d67b-98fc-4510-a3d4-dfd9dd19f245" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c661859-899e-4f35-a057-5f0b1fec3b9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17a2873c-b91b-45aa-ae40-c83e756f34f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aea9d67b-98fc-4510-a3d4-dfd9dd19f245" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17a2873c-b91b-45aa-ae40-c83e756f34f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17a2873c-b91b-45aa-ae40-c83e756f34f3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b8fb3ff8-1528-4c5a-93c9-b401889f845d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b8fb3ff8-1528-4c5a-93c9-b401889f845d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_59e378df-0130-4008-b894-1c88a9bd494f" xlink:href="ino-20230331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_59e378df-0130-4008-b894-1c88a9bd494f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cc45ce3f-be3e-41e0-87f7-e0cf7cea5cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cc45ce3f-be3e-41e0-87f7-e0cf7cea5cf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5884dc18-b38c-43be-8fa8-22b694e62d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5884dc18-b38c-43be-8fa8-22b694e62d89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_d1f3683c-1ed9-4af1-a2db-feb85d18bde0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_d1f3683c-1ed9-4af1-a2db-feb85d18bde0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i2f1cbe93b73846e182426c2e89113f43_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d618ac8c-a531-42a2-b4ba-eff9147b11b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d618ac8c-a531-42a2-b4ba-eff9147b11b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01698977-a327-4e9a-bb20-73109933936a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01698977-a327-4e9a-bb20-73109933936a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aabeecab-4cf1-4504-8311-5f7b2ee0c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aabeecab-4cf1-4504-8311-5f7b2ee0c8e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b92c52bd-bf07-45ed-b99d-018445f59d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b92c52bd-bf07-45ed-b99d-018445f59d79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:to="loc_us-gaap_AwardTypeAxis_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0592fb7-5ae3-4b86-9f92-56a4b9f775fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0592fb7-5ae3-4b86-9f92-56a4b9f775fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bc9d4ce3-7dbf-4b86-a050-b9d58d1e5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0592fb7-5ae3-4b86-9f92-56a4b9f775fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bc9d4ce3-7dbf-4b86-a050-b9d58d1e5ecf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_afe85a9e-4510-496d-bab2-d6bc32eda283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:to="loc_srt_TitleOfIndividualAxis_afe85a9e-4510-496d-bab2-d6bc32eda283" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afe85a9e-4510-496d-bab2-d6bc32eda283_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_afe85a9e-4510-496d-bab2-d6bc32eda283" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_afe85a9e-4510-496d-bab2-d6bc32eda283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_95267ed6-a956-477d-977b-f5419c073c50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_afe85a9e-4510-496d-bab2-d6bc32eda283" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_95267ed6-a956-477d-977b-f5419c073c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_f4b93b79-bb67-4b10-b051-ae3d0d83b2cd" xlink:href="ino-20230331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_95267ed6-a956-477d-977b-f5419c073c50" xlink:to="loc_ino_EmployeesAndDirectorsMember_f4b93b79-bb67-4b10-b051-ae3d0d83b2cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i8f427fc148a845f5a1d0973f5d8b6885_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5ffc1960-a4e6-4de3-af99-4957418bdfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_ShareBasedCompensation_5ffc1960-a4e6-4de3-af99-4957418bdfaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ba659a6f-227f-4ce3-ac51-6b8631b903d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ba659a6f-227f-4ce3-ac51-6b8631b903d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0e4cd73-fbcd-4f30-a362-a080983262fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0e4cd73-fbcd-4f30-a362-a080983262fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a71d83e0-28c4-4fa1-8815-d77f849a7206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a71d83e0-28c4-4fa1-8815-d77f849a7206" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d08b000-f6f6-49b5-b86b-5f703e68d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d08b000-f6f6-49b5-b86b-5f703e68d3ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f40537ab-65f8-446f-9d74-9a48cbb996ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f40537ab-65f8-446f-9d74-9a48cbb996ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares_3c5d8585-49fe-45c7-9c06-075e03873509" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares_3c5d8585-49fe-45c7-9c06-075e03873509" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash_e434207d-f534-450f-9719-7f963678066d" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash_e434207d-f534-450f-9719-7f963678066d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f749cb1-3566-461a-bf49-5aa30fa99acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_us-gaap_AwardTypeAxis_9f749cb1-3566-461a-bf49-5aa30fa99acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f749cb1-3566-461a-bf49-5aa30fa99acc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9f749cb1-3566-461a-bf49-5aa30fa99acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f749cb1-3566-461a-bf49-5aa30fa99acc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9f749cb1-3566-461a-bf49-5aa30fa99acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6017f209-38b3-4b93-87b7-8750622937d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6017f209-38b3-4b93-87b7-8750622937d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b17d6d0c-6fe3-4380-8c6a-11a54e055404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b17d6d0c-6fe3-4380-8c6a-11a54e055404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9b54193d-9928-4172-8028-f0a69312e85d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_srt_TitleOfIndividualAxis_9b54193d-9928-4172-8028-f0a69312e85d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b54193d-9928-4172-8028-f0a69312e85d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_9b54193d-9928-4172-8028-f0a69312e85d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9b54193d-9928-4172-8028-f0a69312e85d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_9b54193d-9928-4172-8028-f0a69312e85d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_94516dff-6fda-4f08-898a-30d280d764c2" xlink:href="ino-20230331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:to="loc_ino_EmployeesAndDirectorsMember_94516dff-6fda-4f08-898a-30d280d764c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_cb51e6e9-9cb0-4a72-8698-0f9c14563cb2" xlink:href="ino-20230331.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:to="loc_ino_NonEmployeeMember_cb51e6e9-9cb0-4a72-8698-0f9c14563cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cabc4f60-10d1-4c22-a575-4fac5898f882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cabc4f60-10d1-4c22-a575-4fac5898f882" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cabc4f60-10d1-4c22-a575-4fac5898f882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cabc4f60-10d1-4c22-a575-4fac5898f882" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cabc4f60-10d1-4c22-a575-4fac5898f882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cabc4f60-10d1-4c22-a575-4fac5898f882" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b4ba2e21-e004-4a0c-9a94-6eb1737659da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b4ba2e21-e004-4a0c-9a94-6eb1737659da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_18497a7c-ff5d-4982-8bb4-507fe1ab643f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_18497a7c-ff5d-4982-8bb4-507fe1ab643f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4e8e454f-a820-49b9-b009-9e1a840ad1fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_srt_CounterpartyNameAxis_4e8e454f-a820-49b9-b009-9e1a840ad1fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e8e454f-a820-49b9-b009-9e1a840ad1fe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4e8e454f-a820-49b9-b009-9e1a840ad1fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e8e454f-a820-49b9-b009-9e1a840ad1fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efbe1e1a-fc4a-41d9-a15a-d798aeef64b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4e8e454f-a820-49b9-b009-9e1a840ad1fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efbe1e1a-fc4a-41d9-a15a-d798aeef64b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_JJosephKimMember_1567ca11-ae72-403a-a77d-10adcbff019a" xlink:href="ino-20230331.xsd#ino_JJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efbe1e1a-fc4a-41d9-a15a-d798aeef64b9" xlink:to="loc_ino_JJosephKimMember_1567ca11-ae72-403a-a77d-10adcbff019a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="ic3074a97ea974f7998370ea6f64a64fb_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_c5127c80-673b-43e0-8462-1497752d4c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_c5127c80-673b-43e0-8462-1497752d4c34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ea2bbdab-e930-41ae-ba0c-434a6b69eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ea2bbdab-e930-41ae-ba0c-434a6b69eabb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f86dfef-6195-4568-bc6a-3bd738a1ec0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f86dfef-6195-4568-bc6a-3bd738a1ec0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_8205f916-d571-403c-82ea-132a464d1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_8205f916-d571-403c-82ea-132a464d1ca8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_b9feba49-e994-4269-8922-bd6399427fc5" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_b9feba49-e994-4269-8922-bd6399427fc5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_d4c0b95a-8056-4c4c-a538-d1ac81428ca8" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeArrangementTerm_d4c0b95a-8056-4c4c-a538-d1ac81428ca8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_b36c837b-431c-44b3-b13a-ba37c44c9967" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_b36c837b-431c-44b3-b13a-ba37c44c9967" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_d852a211-8bd0-4bfb-b6fe-e089bfb1e28c" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_d852a211-8bd0-4bfb-b6fe-e089bfb1e28c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_59d413f6-28a2-40b8-929d-31d426878a76" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_59d413f6-28a2-40b8-929d-31d426878a76" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_5b6dc879-4770-4bb9-bfe9-4fdde0594879" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_5b6dc879-4770-4bb9-bfe9-4fdde0594879" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_515dac6c-3a79-4529-a039-6217fc997478" xlink:href="ino-20230331.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_GrantProceedsReceived_515dac6c-3a79-4529-a039-6217fc997478" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_563473b3-fcae-4a69-a2d4-694848811973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_563473b3-fcae-4a69-a2d4-694848811973" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e0aea99b-1c06-4499-9b66-8083a3aec084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e0aea99b-1c06-4499-9b66-8083a3aec084" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_e20cc824-03f1-4f52-b844-df9685cd74f0" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_e20cc824-03f1-4f52-b844-df9685cd74f0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_2bdbe012-0d74-4e57-a8c4-3ca1c359e3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_2bdbe012-0d74-4e57-a8c4-3ca1c359e3e2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_981f5c06-7299-4196-9399-a4bb7e757751" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_srt_CounterpartyNameAxis_981f5c06-7299-4196-9399-a4bb7e757751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981f5c06-7299-4196-9399-a4bb7e757751_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_981f5c06-7299-4196-9399-a4bb7e757751" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_981f5c06-7299-4196-9399-a4bb7e757751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94f3c28b-a016-4ee3-bd17-9046b3284921" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_981f5c06-7299-4196-9399-a4bb7e757751" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94f3c28b-a016-4ee3-bd17-9046b3284921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_fa4c59bf-385d-4645-b52c-55903f1f87d1" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94f3c28b-a016-4ee3-bd17-9046b3284921" xlink:to="loc_ino_PlumblineLifeSciencesMember_fa4c59bf-385d-4645-b52c-55903f1f87d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f514138-b32a-4e24-a75a-b25e5567a300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f514138-b32a-4e24-a75a-b25e5567a300" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6f514138-b32a-4e24-a75a-b25e5567a300_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f514138-b32a-4e24-a75a-b25e5567a300" xlink:to="loc_us-gaap_RelatedPartyDomain_6f514138-b32a-4e24-a75a-b25e5567a300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f514138-b32a-4e24-a75a-b25e5567a300" xlink:to="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3dce4884-2404-459c-9261-d26629b43940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:to="loc_srt_DirectorMember_3dce4884-2404-459c-9261-d26629b43940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_35fa95ea-358f-497a-8159-864fa46e4a7a" xlink:href="ino-20230331.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:to="loc_ino_TheWistarInstituteMember_35fa95ea-358f-497a-8159-864fa46e4a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d38c52f5-8940-40ee-b284-f8bc6182ede4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_srt_ProductOrServiceAxis_d38c52f5-8940-40ee-b284-f8bc6182ede4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d38c52f5-8940-40ee-b284-f8bc6182ede4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d38c52f5-8940-40ee-b284-f8bc6182ede4" xlink:to="loc_srt_ProductsAndServicesDomain_d38c52f5-8940-40ee-b284-f8bc6182ede4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_51367e8b-66a6-4619-bfe8-6d4d19737fe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d38c52f5-8940-40ee-b284-f8bc6182ede4" xlink:to="loc_srt_ProductsAndServicesDomain_51367e8b-66a6-4619-bfe8-6d4d19737fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicenseWithAffiliatedEntitiesMember_4b69b481-bfb6-4e25-ad2f-75e0694dd06c" xlink:href="ino-20230331.xsd#ino_LicenseWithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51367e8b-66a6-4619-bfe8-6d4d19737fe3" xlink:to="loc_ino_LicenseWithAffiliatedEntitiesMember_4b69b481-bfb6-4e25-ad2f-75e0694dd06c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_fc8c28ae-80ed-4b09-8d70-69b827668679" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_srt_OwnershipAxis_fc8c28ae-80ed-4b09-8d70-69b827668679" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fc8c28ae-80ed-4b09-8d70-69b827668679_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_fc8c28ae-80ed-4b09-8d70-69b827668679" xlink:to="loc_srt_OwnershipDomain_fc8c28ae-80ed-4b09-8d70-69b827668679_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_95848ce1-9dff-4b35-84d0-a38f7248b703" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_fc8c28ae-80ed-4b09-8d70-69b827668679" xlink:to="loc_srt_OwnershipDomain_95848ce1-9dff-4b35-84d0-a38f7248b703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_dbdc9300-66ba-4aec-b487-0ac7fbaf0c99" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_95848ce1-9dff-4b35-84d0-a38f7248b703" xlink:to="loc_ino_PlumblineLifeSciencesMember_dbdc9300-66ba-4aec-b487-0ac7fbaf0c99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i063385b01f564177b39ccf32b6266927_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_a2c23918-18e3-402f-812a-a5f2e267c20b" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_a2c23918-18e3-402f-812a-a5f2e267c20b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a8d05ca0-a6f1-4587-aff0-6e564a987d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a8d05ca0-a6f1-4587-aff0-6e564a987d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_96c03b20-73bd-40be-b76b-f49a4374153f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_LeaseCost_96c03b20-73bd-40be-b76b-f49a4374153f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_976ba3ff-6886-4c5d-9b65-d84990b3df29" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_976ba3ff-6886-4c5d-9b65-d84990b3df29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4a51d441-5298-406b-9f09-9868a79e2440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4a51d441-5298-406b-9f09-9868a79e2440" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_4bb39773-8743-47ec-93b9-e7e0263f1bfa" xlink:href="ino-20230331.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_4bb39773-8743-47ec-93b9-e7e0263f1bfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0cd21a21-6b6f-4e6a-b439-b49ea1fc47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_CommonStockSharesIssued_0cd21a21-6b6f-4e6a-b439-b49ea1fc47e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_513fe2d7-268b-46ac-aef0-5a313880f290" xlink:href="ino-20230331.xsd#ino_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:to="loc_ino_SanDiegoOfficeMember_513fe2d7-268b-46ac-aef0-5a313880f290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_23f2cbf0-7f39-43ae-ac04-ef1ff5219fb1" xlink:href="ino-20230331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_23f2cbf0-7f39-43ae-ac04-ef1ff5219fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_563c51b4-dad8-4879-9a0d-c49b2004f834" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:to="loc_srt_RangeAxis_563c51b4-dad8-4879-9a0d-c49b2004f834" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_563c51b4-dad8-4879-9a0d-c49b2004f834_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_563c51b4-dad8-4879-9a0d-c49b2004f834" xlink:to="loc_srt_RangeMember_563c51b4-dad8-4879-9a0d-c49b2004f834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_563c51b4-dad8-4879-9a0d-c49b2004f834" xlink:to="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7500503c-3f7b-4e60-ac3f-96a008a06d55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:to="loc_srt_MinimumMember_7500503c-3f7b-4e60-ac3f-96a008a06d55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18927523-015a-4e42-862d-8e1b0c84a98e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:to="loc_srt_MaximumMember_18927523-015a-4e42-862d-8e1b0c84a98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a70c74ae-f3ee-4ad2-95be-d447af62595d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:to="loc_srt_LitigationCaseAxis_a70c74ae-f3ee-4ad2-95be-d447af62595d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a70c74ae-f3ee-4ad2-95be-d447af62595d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a70c74ae-f3ee-4ad2-95be-d447af62595d" xlink:to="loc_srt_LitigationCaseTypeDomain_a70c74ae-f3ee-4ad2-95be-d447af62595d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e22955ae-f59d-40bc-b7a9-c8be5d11aeaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a70c74ae-f3ee-4ad2-95be-d447af62595d" xlink:to="loc_srt_LitigationCaseTypeDomain_e22955ae-f59d-40bc-b7a9-c8be5d11aeaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_b16e82b3-6555-43a6-a361-f399d5449a34" xlink:href="ino-20230331.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e22955ae-f59d-40bc-b7a9-c8be5d11aeaf" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_b16e82b3-6555-43a6-a361-f399d5449a34" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="iedbdafcdca4843d2bbcb8d08d26436f9_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87821733-6ce7-4b31-bd59-fa24c8b91750" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87821733-6ce7-4b31-bd59-fa24c8b91750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_eaffd8ba-89ce-4841-afa4-a765b7ba4e98" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_eaffd8ba-89ce-4841-afa4-a765b7ba4e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_2cc5aa3e-013c-4346-834f-200a10e38748" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_2cc5aa3e-013c-4346-834f-200a10e38748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_ae6ba9fd-0df2-486a-99b7-5033bab3aa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_us-gaap_CostMaintenance_ae6ba9fd-0df2-486a-99b7-5033bab3aa40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_6c89ad4e-157e-4a93-bde3-7f720aa834a6" xlink:href="ino-20230331.xsd#ino_AnnualMaintenancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_AnnualMaintenancePeriod_6c89ad4e-157e-4a93-bde3-7f720aa834a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_83a3f24a-c327-40eb-9fea-45a18c2393fb" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_83a3f24a-c327-40eb-9fea-45a18c2393fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_6374a2a2-4614-4197-a006-3a202ceedaee" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_6374a2a2-4614-4197-a006-3a202ceedaee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8aeadb82-938e-4978-9bbf-4e8b64bec7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8aeadb82-938e-4978-9bbf-4e8b64bec7af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_439b0de7-9d8a-41ba-8c65-5fa35d691c05" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_439b0de7-9d8a-41ba-8c65-5fa35d691c05" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_3d5c9d10-1051-40cc-ad4a-69d97bb5db7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_us-gaap_GrantsReceivable_3d5c9d10-1051-40cc-ad4a-69d97bb5db7e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_94cc76f5-be03-44ae-900a-6ab49d1092c4" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_94cc76f5-be03-44ae-900a-6ab49d1092c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_920052ce-1733-40ef-8568-c67be899611b" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_920052ce-1733-40ef-8568-c67be899611b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_633513d5-18e6-4c2f-9249-93a501029328" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_633513d5-18e6-4c2f-9249-93a501029328" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_09d9b5c8-0a70-4151-bfcf-5aab7f51d554" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_DeferredGrantFundingCurrent_09d9b5c8-0a70-4151-bfcf-5aab7f51d554" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_7d9039b0-c1d2-40ea-b286-73af59e79377" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_7d9039b0-c1d2-40ea-b286-73af59e79377" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_9e8b671c-3447-4f2a-b64a-1b973b55a5af" xlink:href="ino-20230331.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_GrantProceedsReceived_9e8b671c-3447-4f2a-b64a-1b973b55a5af" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_b9c998af-ea0f-4d16-bf43-2d94b754a322" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_b9c998af-ea0f-4d16-bf43-2d94b754a322" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_srt_CounterpartyNameAxis_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_0d9c1d2a-39e6-4244-a97d-82ce38e07678" xlink:href="ino-20230331.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_AdvaccineMember_0d9c1d2a-39e6-4244-a97d-82ce38e07678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_64f06c01-b957-4c39-affd-9f7022857f69" xlink:href="ino-20230331.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_ApolloBioMember_64f06c01-b957-4c39-affd-9f7022857f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c8b22df9-d791-4dfa-81ca-7da2ae4a4dfb" xlink:href="ino-20230331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c8b22df9-d791-4dfa-81ca-7da2ae4a4dfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_a182a5a6-e442-410e-bb3a-8b6ff91387b2" xlink:href="ino-20230331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_a182a5a6-e442-410e-bb3a-8b6ff91387b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_47e75681-37fd-4971-b6be-8eed530fecc1" xlink:href="ino-20230331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_DepartmentOfDefenceMember_47e75681-37fd-4971-b6be-8eed530fecc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_805c7899-3a9f-4c94-b1a6-659388fc1a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_805c7899-3a9f-4c94-b1a6-659388fc1a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_daad6f2c-9640-48ec-a548-0f7104d6bb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_805c7899-3a9f-4c94-b1a6-659388fc1a43" xlink:to="loc_us-gaap_CollaborativeArrangementMember_daad6f2c-9640-48ec-a548-0f7104d6bb91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_15757b94-ad6e-47df-a61c-bb06e2b5fc19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_srt_MajorCustomersAxis_15757b94-ad6e-47df-a61c-bb06e2b5fc19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_15757b94-ad6e-47df-a61c-bb06e2b5fc19_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_15757b94-ad6e-47df-a61c-bb06e2b5fc19" xlink:to="loc_srt_NameOfMajorCustomerDomain_15757b94-ad6e-47df-a61c-bb06e2b5fc19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_67f397bc-f7a9-43f8-b4ff-fbef9b5ba9ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_15757b94-ad6e-47df-a61c-bb06e2b5fc19" xlink:to="loc_srt_NameOfMajorCustomerDomain_67f397bc-f7a9-43f8-b4ff-fbef9b5ba9ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_2488e02a-7465-484a-a5a7-b4a70a2caf78" xlink:href="ino-20230331.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_67f397bc-f7a9-43f8-b4ff-fbef9b5ba9ac" xlink:to="loc_ino_AdvaccineMember_2488e02a-7465-484a-a5a7-b4a70a2caf78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b16166dc-534e-4c47-918e-57f5a37ef0a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_srt_ProductOrServiceAxis_b16166dc-534e-4c47-918e-57f5a37ef0a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b16166dc-534e-4c47-918e-57f5a37ef0a7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b16166dc-534e-4c47-918e-57f5a37ef0a7" xlink:to="loc_srt_ProductsAndServicesDomain_b16166dc-534e-4c47-918e-57f5a37ef0a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b16166dc-534e-4c47-918e-57f5a37ef0a7" xlink:to="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_631b498a-eef5-43dc-80c9-1aa26dd3939d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_us-gaap_LicenseMember_631b498a-eef5-43dc-80c9-1aa26dd3939d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_aeb36b9c-68f7-4e92-b103-088bdf401240" xlink:href="ino-20230331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_aeb36b9c-68f7-4e92-b103-088bdf401240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_bef34df7-bfd8-4cf3-88fa-4c66a7a9eb83" xlink:href="ino-20230331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_bef34df7-bfd8-4cf3-88fa-4c66a7a9eb83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_4bc548ba-c5b8-4587-a0f2-5cfa478e7600" xlink:href="ino-20230331.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_INO4800Member_4bc548ba-c5b8-4587-a0f2-5cfa478e7600" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_7814ee52-36d2-4aa6-90b0-00f1b238acab" xlink:href="ino-20230331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_7814ee52-36d2-4aa6-90b0-00f1b238acab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_91d2e851-1d8c-4a55-a069-7f1926cc5219" xlink:href="ino-20230331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_CELLECTRA2000DeviceMember_91d2e851-1d8c-4a55-a069-7f1926cc5219" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="i9f1a38703e684fe9a34459464e635602_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_18eb4002-6f0c-42d4-abfd-ba26fd390278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_18eb4002-6f0c-42d4-abfd-ba26fd390278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d311bf17-d6b5-4665-bfc1-55128a77d7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d311bf17-d6b5-4665-bfc1-55128a77d7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_6c94e6d7-185e-4a2b-bd79-f3ffdbc5baaf" xlink:href="ino-20230331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_6c94e6d7-185e-4a2b-bd79-f3ffdbc5baaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b1e45571-327f-4485-9291-95a8085ba24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b1e45571-327f-4485-9291-95a8085ba24b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_463393f1-cd4d-4a3b-a446-34648d2849bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_463393f1-cd4d-4a3b-a446-34648d2849bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_086a9ee0-c5f6-432a-94c1-52a580640dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_086a9ee0-c5f6-432a-94c1-52a580640dc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_9bb229d5-f97c-48e5-8caa-5c2960f0439e" xlink:href="ino-20230331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_9bb229d5-f97c-48e5-8caa-5c2960f0439e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa5563a5-4b36-440a-8fd3-eb7fecdb45e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa5563a5-4b36-440a-8fd3-eb7fecdb45e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_865f5fcd-cd36-4dd9-938b-d97431dd7459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_EquityMethodInvestments_865f5fcd-cd36-4dd9-938b-d97431dd7459" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e67bcbfb-b026-474c-8815-62205905a19c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_srt_CounterpartyNameAxis_e67bcbfb-b026-474c-8815-62205905a19c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e67bcbfb-b026-474c-8815-62205905a19c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e67bcbfb-b026-474c-8815-62205905a19c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e67bcbfb-b026-474c-8815-62205905a19c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c320b79-4ad3-4a7a-b63f-0516573c35bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e67bcbfb-b026-474c-8815-62205905a19c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c320b79-4ad3-4a7a-b63f-0516573c35bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_e2e853d0-98f3-4c28-8f1a-33ea9ed7565b" xlink:href="ino-20230331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c320b79-4ad3-4a7a-b63f-0516573c35bb" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_e2e853d0-98f3-4c28-8f1a-33ea9ed7565b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_820abbd6-28ae-45f4-a792-eefc08848ec9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_srt_OwnershipAxis_820abbd6-28ae-45f4-a792-eefc08848ec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_820abbd6-28ae-45f4-a792-eefc08848ec9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_820abbd6-28ae-45f4-a792-eefc08848ec9" xlink:to="loc_srt_OwnershipDomain_820abbd6-28ae-45f4-a792-eefc08848ec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fed0ecc8-bb0b-412b-9d39-04129cc2f83c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_820abbd6-28ae-45f4-a792-eefc08848ec9" xlink:to="loc_srt_OwnershipDomain_fed0ecc8-bb0b-412b-9d39-04129cc2f83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_fc44286e-b67f-4afe-9e02-72f0254ff799" xlink:href="ino-20230331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_fed0ecc8-bb0b-412b-9d39-04129cc2f83c" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_fc44286e-b67f-4afe-9e02-72f0254ff799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6292e8c5-afc4-4e35-a9f1-81aa185e09ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6292e8c5-afc4-4e35-a9f1-81aa185e09ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6292e8c5-afc4-4e35-a9f1-81aa185e09ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6292e8c5-afc4-4e35-a9f1-81aa185e09ad" xlink:to="loc_us-gaap_ClassOfStockDomain_6292e8c5-afc4-4e35-a9f1-81aa185e09ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6292e8c5-afc4-4e35-a9f1-81aa185e09ad" xlink:to="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_29e6dc08-8ad0-47e3-942b-f85fd3548519" xlink:href="ino-20230331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_ino_SeriesAOnePreferredStockMember_29e6dc08-8ad0-47e3-942b-f85fd3548519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2a8f953b-8ed6-47d9-abc7-13dbb7cec7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_us-gaap_CommonStockMember_2a8f953b-8ed6-47d9-abc7-13dbb7cec7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c4eb3a57-7818-4a69-bc32-bf25cef1d1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_us-gaap_PreferredStockMember_c4eb3a57-7818-4a69-bc32-bf25cef1d1c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_7abb058a-b6da-4873-8e6e-b3a10161f881" xlink:href="ino-20230331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_7abb058a-b6da-4873-8e6e-b3a10161f881" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fbea4fa2-7cb9-424e-9a33-06f8a1628d4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fbea4fa2-7cb9-424e-9a33-06f8a1628d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_825ea443-9b14-4017-b65f-bcbf2322b1a8" xlink:href="ino-20230331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fbea4fa2-7cb9-424e-9a33-06f8a1628d4e" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_825ea443-9b14-4017-b65f-bcbf2322b1a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended" id="i139b658779c3491ab4d537acccb9d3e9_GeneosTherapeuticsIncPreferredstockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_862a0665-b720-460b-bd05-8b823766a3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_EquityMethodInvestments_862a0665-b720-460b-bd05-8b823766a3fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_211aeea4-9fa2-4dd1-8b1d-dce9ede65223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_211aeea4-9fa2-4dd1-8b1d-dce9ede65223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a6851c3-3ee8-4363-aa54-618d21647921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a6851c3-3ee8-4363-aa54-618d21647921" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cdce0a08-717e-4ae0-979b-46342a766359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d6ec4928-5201-4e3f-907d-3f680ab17bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_MinorityInterestTable_d6ec4928-5201-4e3f-907d-3f680ab17bab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_33a69471-fb15-426b-b19f-c1f657a87b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_d6ec4928-5201-4e3f-907d-3f680ab17bab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_33a69471-fb15-426b-b19f-c1f657a87b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_33a69471-fb15-426b-b19f-c1f657a87b96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_33a69471-fb15-426b-b19f-c1f657a87b96" xlink:to="loc_us-gaap_ClassOfStockDomain_33a69471-fb15-426b-b19f-c1f657a87b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a187a29b-ed39-4d20-803e-b8d05c6baa95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_33a69471-fb15-426b-b19f-c1f657a87b96" xlink:to="loc_us-gaap_ClassOfStockDomain_a187a29b-ed39-4d20-803e-b8d05c6baa95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_dc6fb4f8-7421-4753-b561-4c1007de694e" xlink:href="ino-20230331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a187a29b-ed39-4d20-803e-b8d05c6baa95" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_dc6fb4f8-7421-4753-b561-4c1007de694e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ino-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:160750a0-0a71-42f6-8d80-818c69f4d1ac,g:e1c02d6a-4ccd-42cb-9c8b-7f68796035cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_f4c56a68-ccb6-4302-ae26-a7635ac6e03e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_54f2c743-fa90-4ed2-882f-c54d701ebedc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4bf58f3-2f0e-4f3d-9bd2-1b0e5b9be25e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b0883c6b-c3e2-468d-aca1-12d71b98b3e5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_93506b79-ba56-42a2-9d4f-76580008e0f5_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest on senior convertible notes</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20230331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2937b344-24c3-48d5-86d6-0add8cdf4394_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_64abfd93-9dfa-4d86-b988-9bdff587e342_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_67824248-6784-4754-8558-c1e54ac30c5b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ea1c6e38-1d68-4d3d-8d89-68690460cc01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cdbe4dfa-6760-48b5-8950-102e6c028c7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0502b121-3172-41d1-8e30-e8e3c5891513_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5a5e0159-1313-4792-841b-fca66a7f9207_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ee76a015-4e25-4479-92d6-a5456de5a0cf_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_843183ad-ae36-4af9-abb8-29537636c556_negatedLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_d0af63fa-6cfd-41e6-bd24-460fb00ce22b_terseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under share based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20230331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_62349191-c373-4103-88e6-1093288826f2_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20230331.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3c8d85ff-30e9-4b38-8231-3f9cbb8432ca_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e1463b7-5839-4594-9be5-048190e515ef_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_7feca8c5-d371-40c7-9098-1754b767560f_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, payment earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_label_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementPaymentEarned" xlink:to="lab_ino_CollaborationAgreementPaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_85c30112-ce67-4634-9f96-77a192e54260_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d0c3d3cc-35cf-496a-bf0f-b6e99ba2677d_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_df0fec30-7384-4c01-a735-017aa0a41859_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_21f0450a-4225-43a3-a9fe-97b24cbbc743_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_4be3534d-8540-4341-aa08-0c1a3a1c6ec9_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20230331.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4c7015df-7621-483b-becf-ce3423764b46_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5334754-de70-4f5a-9610-4930199a271e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_fd0f2f9d-2b92-4d35-840f-82e308737787_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Net Book Value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_7d378dc7-6ec4-458f-af8a-fe36311bf8a6_terseLabel_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2028</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ino-20230331.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_30e8decc-89d5-4120-b3dc-8df7c749ec03_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2541f19b-e4a6-4dbb-b08b-843826c04ba6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0b086ef8-adb2-4570-a019-7b9acece460e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8fcb71d2-7cde-47e2-91be-2e74c0df7938_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0f29db00-a0f1-4780-9c64-7966755bc30e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4462ddaa-c4fd-4785-bd39-6f21b01907d6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c4ebe2ac-9ed7-4317-8f27-23b0d67afd06_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_e26fb5c3-5c9d-4f80-a8d6-61cc6ee7e870_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_c7b2521e-e79b-44ba-a2a5-4a3a961fd129_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_bcd0a651-aee1-4615-9871-9d44af844c4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares_58d8f641-7d68-4eb4-ad84-99a723d0e4ba_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled in shares percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Shares</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4c6a9956-d148-489b-86c6-35d0899c6581_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_b752fef7-6701-431c-bfc8-95bde2cc8874_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_f6feeb38-980d-4367-ae10-af89cb0b326a_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_db7dcdbf-7dd8-4258-9b49-9f0391abafb0_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ab2f7e84-e19e-4a36-9ed3-318ad715086d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_3b523363-f656-4b35-9dbe-dbb2235b6854_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20230331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_ad38f05a-705b-42d9-9e8a-b6aa2b322be2_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_53f0c656-ccfb-4579-b980-de37a429bdde_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cash settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_56e430a7-f50b-4dbd-863f-c0be82294f35_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_2bab46a2-bbe4-400c-8d58-a7dadb35ea9a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c7c67132-50c3-4d57-a286-fd58aa7268f3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f366fd87-5e70-4916-93b2-07b213bb21f2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92f7397b-06a4-4da0-a029-ca4649d3e670_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_803c2c30-5708-432d-aba4-4009d8e7339f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d5097f17-1c91-4e99-b8e1-85800dc2159b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_3b41ed59-edc2-45f8-baa8-c475ce5dd95d_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20230331.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_bbaa7bdf-3d3d-4b66-a774-318907ad0973_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4455b79c-4107-40a2-94c2-a0b57be00264_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_d50e718d-bd8f-402c-9cfc-42863f949447_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20230331.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f10e33ef-23ae-4b53-97e2-4a0f117955d7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_efc4b656-6efc-4048-a135-bbbb1a1dc87a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b995bff6-2368-4fad-80ce-592e7512b316_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_390d51a1-783c-4c4e-8044-88501c442b10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f55476f7-1e08-48fe-9e09-d44703466e11_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d9a7a41e-cc00-489c-a7f7-7519792d926a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_826d3bfa-2908-4251-bb21-9aad85a07037_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_78931e20-2dce-40b2-86a6-ed137b5072fa_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20230331.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_44a422cf-b30b-40cf-9032-1f394a7e135f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fa98ae3e-7083-4df1-bdf1-ab64db767b02_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a45c4e0-dcfe-43d2-aaa5-3ce11b401fd3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_30f03cd2-7b99-4244-b8b4-b3c2f9a2efad_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2910454c-118d-4474-8d08-e7a299e37077_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9b8c6483-667d-4f74-abb4-f226b40fcf14_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_dfc28417-65c5-4041-a28f-d8f380247415_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_45175cd7-8bce-4ecd-a61d-ef4ce4b4b57d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostMaintenance_02cb6c71-c941-4bb2-a71e-cb42643ac0ac_terseLabel_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_us-gaap_CostMaintenance_label_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMaintenance" xlink:to="lab_us-gaap_CostMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b16b12d-e7b2-4788-904a-d5a6830c60d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_f3c96c34-87cd-4c76-b240-353e536a82fb_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20230331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_5d5086f3-6518-43df-b1e9-efaba7b0c752_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_150bf80f-e11a-4c9e-b7b3-5b51032adf73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_82666c68-5b71-48b1-b483-5f4eb8bd09ce_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_22601fa6-982f-4c82-80e2-52af1ddff0eb_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20230331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2483bead-b3f0-4964-a32a-b891c9b0d249_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed38d393-60c3-4006-8ea1-f94b57507bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_c9d77cba-08b8-463f-bb7c-7b8c799043f7_verboseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20230331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e3cc638b-450b-4390-af8b-5aa43ed41157_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_87225cbd-5436-4ca4-a45f-fdd5b6815b66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (discounts) premiums on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b7c3f9ca-44dd-4866-a43b-e3f98e3d379f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for legal settlement and cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9957c1c7-aa90-4d2d-9770-d53096368370_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b768d012-696e-470a-84e0-13ad0d20e52b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_ed42d022-f979-43eb-a056-e8a41df28e2c_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill and Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20230331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_d2c73e58-9f3e-4eff-b708-b061818254bc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid balance</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_97741671-cd65-4e6e-a28f-88b7929a02a9_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_36443924-19cc-44c2-97e8-3ca809f6e4f0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b119f2cf-2c6e-478f-a344-9fc6a8037bb5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_cffa95dd-efe4-456f-8332-077c31fafbef_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20230331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5d14db35-d4c9-4b13-9493-cf286207d491_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4432f177-ea23-4819-9879-09aba224f8db_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3b982066-5ab4-4786-a816-0392bc9838d2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2f9ee2da-6160-4b16-8649-fc8b77b71234_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_ff72bde4-755e-4e15-8ab4-933519578dbc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_22ee1b6a-4d31-4740-8064-c0ca83e84a97_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_06dc4ae4-e51a-4f38-ae92-0fcb202c0bbc_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8d8b256b-9c5a-4f12-bdec-2be99809b5ed_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_c4dc6fa4-b5e2-4015-bc20-c64a722f9ac6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementMember_587caef0-ebdf-4328-8466-329912987573_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_label_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember" xlink:href="ino-20230331.xsd#ino_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember" xlink:to="lab_ino_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_57b7c495-48d6-4d52-ba05-19cbfbe903d6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_cc130ed5-2000-426c-9b13-a9d826ccba09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_b34c4db1-5a84-4b94-bc9c-a8515c739cd7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_cb04fcef-5b61-4bf1-aadb-9a2a4db1cdbc_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementsMember_8e47f1fd-a0eb-4bf7-9bd1-6f1ef67fb1fa_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_label_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember" xlink:href="ino-20230331.xsd#ino_SalesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementsMember" xlink:to="lab_ino_SalesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ad508332-e350-47f6-a6d4-fe271a0270aa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AllOtherCustomersMember_8bd0a4cf-c9ee-4b04-9f1b-b808ac9af012_terseLabel_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_label_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_documentation_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember" xlink:href="ino-20230331.xsd#ino_AllOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AllOtherCustomersMember" xlink:to="lab_ino_AllOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_22dc7931-1d1c-46f8-8f7a-92740d9a2dda_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1381693b-1c34-4467-a441-0e53335de624_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_febd24f8-f63e-479e-b592-dafe68027dc4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fc3d2258-6651-4756-99f9-fbf74522daf4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_38ee5c3f-a90f-48f9-a7b1-91feb84426f0_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_7b110684-8751-4091-ad76-fe41e6cf7d98_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_fad7ac0e-d884-47e2-a811-31d01c999e99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_9703bb7f-b531-4c3f-8430-dc8546dabd45_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_b9452da9-e74a-4711-91e1-7f6063bb725c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eb77658-35ea-422b-9a58-a62e55a40bd7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b6220a16-9390-49e9-bf31-4b64cb43942d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_b8287aa0-2b0c-4bcd-b8b5-2c8d6f6de935_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_892583b2-d4dc-4ce8-b521-626f72146e5a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_e177b2ea-73b9-488f-99f7-babe7cc4edf2_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20230331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff989f1b-506f-44f2-80c6-e461019c794c_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc4061e7-dc40-4b7b-b56e-e4b3cab70233_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_e25af6bd-bee6-44bf-8cba-484576fb2e3c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4d82a1b3-b3b7-4c64-b446-aacf5b732e49_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ea6a3bd0-1b0b-43da-8885-7cdeb782e3cc_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d69cd3e2-65f1-46f3-b5f1-bec102dc3eae_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_c94d4efa-faf4-4d57-ade6-f86de4a9ddfb_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_15d4b703-fb82-44dd-8b5d-d4e13393a765_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_1fdcff9e-6940-4168-bdff-080a8f6598f6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b93b770-65fa-4087-a15a-0ff2259ff27e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c94a19ac-731f-4c7d-9874-b9b5f031c6bf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_ff8ccbab-94e4-4407-b448-9dfff2d70d23_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0ae1f115-3416-4f2b-ac8f-dbe3ac2d7b20_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32f02bbf-8892-47c3-8225-e6495d718bfe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for legal settlement and cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0ffdee5a-1b4e-4afc-948e-54534e321835_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_2db564e9-adff-4e03-bc72-295d4442392f_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20230331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_5cb5360a-b13b-45b5-9510-5c6fcb498f91_terseLabel_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_label_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_documentation_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:href="ino-20230331.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:to="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ebd23b92-9dda-469c-8296-a36f36895583_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_edc50780-4f01-495d-9869-19ee65437db4_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2782b570-4917-40b2-a63b-c3c855b9fced_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_ffcae096-c786-4792-967d-894a7a17024c_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences Inc</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences Inc [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesIncMember" xlink:to="lab_ino_PlumblineLifeSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ec4f096f-c01a-48d8-8ed1-1b96973ecabd_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_ac6ac296-681c-4c5e-a297-09e6e4a411ed_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20230331.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_c740edcb-e5d4-459f-85c1-eafa8b1e5e50_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, sales proceeds of any common stock, percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20230331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_3f610afd-8b25-4da0-96ef-cc3e80e181bf_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2c247e47-7c55-42b6-8d42-271e68b84772_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_149eecdc-15c6-4d0e-968e-6d20d709ee46_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bc1e79d1-8cb4-41f6-b259-f2c48faebf28_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3c26399b-c4e2-4f6d-ba88-f3913987d795_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_da282232-cb1d-47a6-881c-935d5628d714_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_f3b86150-6475-48fb-9236-fc80551d6606_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_8c7f2fda-d7b3-4f0e-9e43-03130ba1bb0a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_a2983eda-e62e-4c55-b8ab-5ee637a5da4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_11c1cf3f-26ff-4ebc-94fd-f20c66d4fc90_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f4d3d2ed-e21c-40eb-a902-242df55125fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c385c955-51fa-4238-a936-0e8039b84f58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_1ef25e23-1c1a-4e6e-af27-94cb5a0fc0c4_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20230331.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b747b024-606d-4305-89a6-2884828d6b55_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8c8bc374-5e66-476e-8e18-e48196958fb1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_278c4820-92e1-4292-80b1-afc4c407daf3_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_ff0929bf-612f-400d-adce-6084234e04df_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of Geneos Series A-1 preferred stock</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4334a7ea-3d12-4eb5-8013-d80f8dcf6d04_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_bcdddf38-3ad8-46d2-9d8a-14653fedbb84_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20230331.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7f3dd194-006f-4abd-a923-a13d162ef9a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_c562aab2-8de4-4199-867d-f79b0c58e7ec_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_6e69b0a2-8321-4e87-b7cd-006f1582c136_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7d6e66d9-ad51-4212-b946-57fd3b3f2be8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_27662a58-1322-420f-aa2e-800ceeb2db23_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_b67758b4-98cf-4cac-85a7-f5c90824b137_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20230331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ca36dd26-f3e4-44e5-a2a0-cffbecbe6947_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d4bcf96a-93c6-41f1-bbd6-618dffea4121_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4344961d-efa2-4c6b-b216-4683953c0b9e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses, including due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ada4ba53-581f-40c4-8b22-ff896142e350_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_080fe98d-2c2f-4393-8fac-8004f8a0e42b_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable/accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_5ba734ab-f45e-4fbd-a8f5-528bc4ef830c_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20230331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_607d6e01-3440-4578-9b28-4bee26205501_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_391d4e6b-57fe-4c05-916d-a65e78b8e56f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense on intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_143b2f0a-8e64-45d8-bc7f-6bf4e9178c0a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_305e8f51-0103-4c6d-8c1a-d11b1f53aba6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_40ca9dce-0d0e-465d-94f1-76e41b5dae0f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_ab23c08c-7b70-48c2-84cf-a581a2da7bcd_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entity</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38418dae-00a8-40c9-b782-5eae59b7b21d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2179c06-0d04-4e49-8f1c-84c4dd6488ab_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_bc87bec9-8c5b-4612-9c44-d817e89fe3c4_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_701d6e60-7f10-4628-a79b-c172276d070d_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest" xlink:href="ino-20230331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccruedInterest" xlink:to="lab_ino_DebtInstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8ba813cb-07a6-4133-82ef-05809eecab90_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9bc1cede-6a4a-48f3-bff7-a0f37aa9c8e5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f261cd51-37b0-4492-ab59-fd33dc594a39_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_64276b72-8bcc-4805-83ca-82dffcfb6814_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_9ea5a0a9-32e4-40ab-be7f-c946287a4d45_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bdb8562f-3db8-4831-903b-7e761ccdecc8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_9408fe5d-bbdb-4f4c-ad16-e28384a08bd6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_1a7fd41c-72e4-4d31-9aec-5ae23c8cf5f6_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_57d46d4a-c405-4d46-a319-ba35abdeacc3_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20230331.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5bf757e3-1fc5-42df-b450-16475c0328da_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_5aadae2b-7e6b-44ca-89ff-723e4ed03821_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a03884ce-9ea5-4ed4-bbae-8e6e3477df3f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_47e5b2d2-6fc9-4f68-a518-f66e223d77da_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_f937a580-6309-4753-b9a9-5091847f82e3_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturity&#160;(in&#160;years)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20230331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7b645592-adf3-4244-852b-a899bb6f0883_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_1900c259-2d0f-42a3-b57f-1a9b7fbbab4f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_62a30782-8e40-4310-a23a-f140ad445293_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0f265ffa-4ab8-41b5-a70c-248f68a18f8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_38f8b1d1-192b-4e24-87ce-1811a9f42504_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b14416c1-a07d-41d9-ae6d-2b5b4ff5e7ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d7b879d4-c905-4266-b278-47515a084150_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8121a3c1-02f3-4961-9344-8524924d3918_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_92bb35d0-4504-40ab-aa38-e4e748fa240b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fc1d6e5a-9507-4b3d-983d-bc0b18fa623d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9a463ad3-2a39-4772-a3ed-16a208c3dfe6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5039cb51-f0f4-4dc3-b7d9-8f3476572e4f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b9ac71df-d9fa-4b86-a2e8-8b0ce22ce975_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b2432105-b8e0-4a94-ba87-4f5bc5729612_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_00abdd7e-c260-42b5-bc3e-3fd07c2032b7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash_c2ba15e0-81b6-484f-b4a9-c3347d971deb_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled in cash percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Cash</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b9bc524c-5665-4fef-854d-cfc8838d9279_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1649de79-4c8d-4a87-8b3a-bfb1e63fc92b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d0d47b16-a0ac-4172-abb1-05141664c3ef_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e6c05d36-5680-4775-8fec-5fd4d3e6272e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c448b50b-5ba3-4fe3-961b-4f6395a2c14b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d4a25a21-024d-4ebd-87bb-2e75a0a81804_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_787c7117-8e51-4881-aec9-46f3f8bb781b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_52b5af7a-3b10-480d-b638-7400202d5c6c_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_20d921d3-e346-48f2-aabd-b3df3346d278_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24944371-d6d9-4d06-a388-c03282bcdb63_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_13d501a7-3d42-44f0-8504-7376cb2ab63e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_24a37428-d2a3-4724-9e07-100d64396dbe_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16157d15-029c-4b4a-b883-974dc074d9a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_e3ac2537-d7ba-437c-a9a7-9b5880556088_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20230331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_126227e2-7102-41b0-96ca-f77133a2d36a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d0a055e-2987-46cd-b5d8-f452aa1f5559_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8a3e0e52-b042-46a5-b1de-61fff7e70acd_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bf409b0f-fd35-4b6d-989d-42690422e27d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_2316b720-22fa-4955-b549-fda5711031f0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_36ffb5d7-6e49-4274-8a93-8a5ea39169e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_2f528c9b-c478-49c0-aeec-617c9e06f177_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20230331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_4db3ad0b-386a-4209-9e82-28d3424a53b7_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_51767fdc-9557-4d57-9f52-dba265024013_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a749e937-4a6c-419c-be5c-77272f0bfaf1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_204c52e9-da83-4885-9bc2-38a3671bfc6b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f303a8de-a17d-4f1b-9588-74a725dacf5c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_8885eb39-f932-4ff3-b3df-1e1997653016_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6b52b94d-1101-4daa-a097-1a97113b0bb1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_450bcff2-6796-4bdc-98ad-cc13e0ec3204_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_eecc0f51-0d07-4f85-899f-f1b06213bbfd_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, net book value</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_8d66cdeb-5325-4c50-abd6-8289eed8dff3_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20230331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_939e3904-4f62-4022-bdf4-b4bb1679ce7a_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2069409f-5007-4936-9cc0-f6a8d3ab4094_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ee7eafed-ac69-4276-b36c-70a9813ffb2d_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e2d97dc7-e8cf-40ac-bbc5-f5e886e80e65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_7b8cb533-1782-415a-b8fc-6323e40c0504_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5db009f3-043b-4557-baee-6b7a4efd576c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b58f0b88-5070-4b86-a3c4-adeeb7b62a5d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d0178d59-bebe-4472-8d7b-d1bd5d79beb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d86f49c1-9041-4314-a622-68d1c00c6860_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_20c6e122-7294-44a4-9055-30f5afcf1749_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_089b44b3-677c-4754-8033-03e13e161564_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_66293962-0474-450a-af67-ba5089e9c3be_terseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20230331.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2022InducementPlanMember_d35cbb6c-4f87-4b22-9234-0a54f6181478_terseLabel_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_label_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_documentation_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember" xlink:href="ino-20230331.xsd#ino_A2022InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2022InducementPlanMember" xlink:to="lab_ino_A2022InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bea84088-98e4-4e1d-8d42-9ea9bf191f1e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_b7bb0565-4159-406e-9568-ed02cf4b3c6a_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60f72984-6b58-46d9-8576-80026229b18d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_63eb7eca-4926-4c55-81c1-041c28f77f05_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, awarded exercised amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b995ed98-3db4-4ee2-b1a0-8ae8ddaa306d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_f06c3e0c-0e78-4af2-9075-339db6c128ad_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:href="ino-20230331.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_f2f00482-028a-4474-9bc6-a7e3c9160869_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_547021cb-862c-4f0e-b234-ac8713dd97fa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_960db9be-69b1-43a3-8a30-1280be3b5ce5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eb3eb524-3f9d-4445-a4cc-a1e05d968b2e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2cf676de-90b3-4f6f-9217-aad41c41cc33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_33f2a5bf-cf81-4867-833c-b2553f763ec2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_09beee65-2fdb-41e5-a335-051dca88bf70_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_17a54be9-37d0-4a69-82b8-865c13c5a7c1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e6d0e5ea-cdbf-4671-9a2f-42ec3fb5dbd7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoOfficeMember_cd9e7197-0000-43d4-a108-a10008677396_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember" xlink:href="ino-20230331.xsd#ino_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember" xlink:to="lab_ino_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_7f82010f-884d-4f16-afba-2ebf307766ee_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4b4e9762-b581-4b60-b38b-a72eb5bd98b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_13fa1065-f118-4592-97a9-7998d2fc6fb1_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_af99cc15-bd8e-43ce-bd25-5c2e0f7a8fba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e6968f1e-7169-4a98-b56a-9fa4aee1b531_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0498e98f-93f9-4a3c-94bf-ea51da05b125_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_58dc5d6c-f5b8-48a0-9cec-c4b57fdf02b4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d149a0b5-e087-4329-8a5b-e3223c723601_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8468c2cf-72f9-46fe-b1de-b26a33014688_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfef7805-b45a-4661-8e0e-3b237befbf90_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_eb42df0f-3be0-4cb4-a582-05696a8892bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_6618ae21-b2b8-40c0-87f3-f9257754a0ae_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4d2c3e7d-3ece-4593-9745-15619cc63af9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_b8848e8c-ad7a-4570-a2b8-8fd81715cdea_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement , revenue from the procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_label_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:to="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_814b2039-3910-45db-a828-42cbafb7a903_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_a761bd51-706a-4699-b0ce-c8344054922d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d633bd95-d55d-4b94-9bcf-e748f8242ece_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_91f915ff-4942-40c8-a060-8d278447685e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_67cfd572-8f22-4286-84e8-851851311c13_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_570f94c9-9d2a-4164-9014-0e930d0fb3f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_a94112fb-1d57-4566-a171-940f2cd6472a_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_079e2f56-93b1-4b2a-a25a-3bdb2d3d7f77_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e3d3de12-7102-4bec-affe-94c3f7379ddc_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_de7488e2-7195-4676-9c3b-09dd6d453609_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9e5a904e-0f9f-49e4-9558-b88418778913_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_12b09cba-cf5c-417e-b387-4e4f4f6fb0c9_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_57cd5783-8975-440d-9422-83e503ba76b7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_9cadda17-59cf-4cda-80e2-b4634e572034_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c2fc9438-e31d-47b7-8879-25fc0b05515d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e139dc81-4b6c-4b90-b7a4-b41cdcb3e020_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f914815a-a453-4ae3-8e02-9025d6a4f6c3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3bb05248-904d-40c0-89b0-5db78464c4c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_b5104eec-de6a-4cbe-b124-61a18d448de3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicenseWithAffiliatedEntitiesMember_33103592-5524-4e96-90b3-51e0fdf26d10_terseLabel_en-US" xlink:label="lab_ino_LicenseWithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements with affiliated entities</link:label>
    <link:label id="lab_ino_LicenseWithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicenseWithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License With Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicenseWithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicenseWithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicenseWithAffiliatedEntitiesMember" xlink:href="ino-20230331.xsd#ino_LicenseWithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicenseWithAffiliatedEntitiesMember" xlink:to="lab_ino_LicenseWithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_d3a1b672-9aef-43f2-ad53-bc96950ff492_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_84fcae19-6259-45fe-86f4-84be1fdd518d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fd619658-45c9-45d4-8f35-7a4cdf9fe5aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_bf194087-dace-45c0-bcc0-c7ec3d07d4a9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2f09d68e-615c-4759-aec8-e40268c85473_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_499d2ed3-eb7e-45e8-8f98-476c2ae36ba7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_61f66965-cb05-45b8-8926-6d838dea42eb_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_7b43f49f-707e-4d4b-b3f8-95c4dbe9b7d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_c1550760-3e97-49dd-b787-645119d37114_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_dbaa42c4-6f08-437c-b224-a5f372b0b68b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_292921bd-cff3-4cd1-91ed-20ab57f17ddc_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20230331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cdd33760-daca-4e5c-9525-f571020b0acb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_4b3ddba5-3953-4f94-90c1-5d50088e3856_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d4c2ea9d-e076-43bb-9c04-569a6cbb7ff2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b008e87-3157-41a9-8275-801b2c38860f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f34ac3b2-557a-4f12-85af-2d1fdc60f60b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6240757a-3443-4f60-aa42-7c483af440f9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ed4e1477-efa5-4824-b6c5-6a605c007ba3_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement_2ba3c62f-b703-44f1-a8ac-3262461e37c9_terseLabel_en-US" xlink:label="lab_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for the legal settlement</link:label>
    <link:label id="lab_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement_label_en-US" xlink:label="lab_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Accrued Expenses Related To Issuance Of Common Stock For Legal Settlement</link:label>
    <link:label id="lab_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement_documentation_en-US" xlink:label="lab_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Accrued Expenses Related To Issuance Of Common Stock For Legal Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" xlink:href="ino-20230331.xsd#ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" xlink:to="lab_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a710241d-c133-4ea5-86e1-062b57edc71d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d17b183a-6342-4322-920e-84d860940f0b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3f6a1ec-31e1-41f2-8e01-2bb709b76f71_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4fa99bc1-0906-4930-9f32-a29ba2c2cc2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_86349121-de6d-4579-9263-1e2ff1cf35a6_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_203ab329-0684-46cb-8df5-17011327b7a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b7f93f60-208d-4006-80bf-59b2dc5a77ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ef5cbc85-2e32-42b2-bb69-8104648448ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_a23896f6-a860-4c2c-87e1-06080bbb71d8_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20230331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b3c59ce2-baec-495c-b201-bfe2ebb6f7bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8103e07a-b0fc-4c02-b1ec-0465002c8860_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e4dfa381-a89c-4cb1-afe8-0d4f7192ed87_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8848300a-7e1b-4bb5-84b8-36aa2ac4d04f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_01a070be-b812-4ecc-8390-7a53d4977b1b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e8042774-009c-4241-b096-dfd33379213a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, including from affiliated entity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_93874fd7-f3c5-4e46-a5bc-ae1dab541a2c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_6bddc33d-9554-4fdb-bf74-2f6ba4255faa_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ca719236-ce8a-4408-a41d-9bef5d45331e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_fe056495-086c-4fe3-8b92-0e63e8b01923_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_08b3a697-7f3d-40ca-ac73-cc5e219fb94f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9bb5a66e-e38b-4f4b-92ed-4c9da3199fc6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5a290654-d655-4a7a-952e-66dd8cf58baf_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6819ffa4-bc8d-4188-8dbf-37d77c68b5c0_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_58977bd1-44cf-4596-a5af-c51990c2fdf0_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_783423c8-1b6a-460d-ad5d-f914bd5c1db0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9eae6670-1dd7-4625-869a-ab6f10767213_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_4d7ab3ee-6384-4c52-9d39-8829b432c371_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_cd450795-859f-4f5e-9cc4-deb7924b9bf0_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20230331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6ebc3d6a-c3dc-4fd5-b96d-dd2e68b1cb26_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b33cf632-3bcb-4bca-af77-37307a70b713_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cc33639f-6b65-4318-9a5c-61774b5bfe2f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_11914ca0-6613-421a-940a-565e403c397e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_c44ff1a6-ca37-46ff-beb3-c0b534e68dcc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_7a3378e4-9349-453f-8add-468610e334a7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_dd281bdc-0d30-498f-9ba6-b258da619a8a_terseLabel_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:href="ino-20230331.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:to="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_46d74c78-38e9-4b9e-b1d9-5fa8b1ceb311_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6d808f5-337b-45a1-9096-d29e3d4d399f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1b59871c-b176-4b30-8d30-ab0c7e8b609c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_19bd4abd-26b2-4b56-a318-d1e1746121b5_negatedTerseLabel_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on remeasurement of investment in Geneos</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_label_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:href="ino-20230331.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:to="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bbefc1a1-e515-465e-bf40-5a2e87800c5c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_df70b567-1688-4788-8eb9-77d68abe13da_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c07fc9c1-a2c6-4d77-a304-02c30f0864b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4e8721e8-7a03-466f-af44-3453bdc26f05_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9144015b-44d8-417b-b92d-00fbc1fb63a5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b2a9b675-2db8-4b98-8b07-8ab97a7cb3e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Intangible Assets by Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_60259804-9b07-4478-97ed-b22735e3abf4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_ee8cb14d-ee48-4290-b612-5fb4efbff8c2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_58696d03-d3db-4bf6-a70f-f5c4ddcec61c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_681e17a1-834e-4a6b-b1f3-07fcec23e6f0_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_81ad77bd-51f5-40a0-8a1d-8bde378ae1ae_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9238aef-feb4-4cf9-a93b-faf96872cfea_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_eedd7540-9a3f-4b90-adf2-c013d5b52cb0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ce24bc4e-5597-4540-87e5-22f84fd13b69_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2751369f-f212-4790-9396-4f66721f85e2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_b6ac4618-3773-45e4-b29b-7da482f6f908_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_8f94c7d1-fe80-4a71-bec5-267d84c70050_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_18c94935-04ab-482e-9a36-b01ed6583139_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d6b38367-e601-499f-bb7c-ecc8f0907979_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9333227a-642d-484b-9670-93b69039a6da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c423907c-45e2-47d8-917c-d582e16c65cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef7d729d-2e2e-42a6-9f6b-35453eae0aa5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_39ee90e5-6d99-4a8f-92b3-296a02fa5196_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_34261a4b-9ec5-4a3b-b9a6-740c7ef077f9_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20230331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1cb150bf-1bb9-4b07-93e9-6bd8f5628496_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c23dfac6-2d5e-4110-b155-9f06bc1ada37_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_d265478c-5182-4845-85c8-b0b814f239d8_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_34cd48f9-fd32-4966-ad06-8409fee5a7d3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5194066d-d43e-4296-98b9-f3a74f528436_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_1617d9ea-558d-41b5-9a09-ada36d3b1b83_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_cbc42cc1-85ae-484f-bb5a-24973b2f056e_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_cb8d3a7b-6240-4b1b-be3c-c7d3ce26c86b_verboseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d6fb69c6-bdda-40ab-80f9-e0e4024407b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0f6e869a-6783-44b6-b05f-eed5fd01576c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_34e1b3e6-d159-41c8-bb57-3fb7b8eb8c23_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20230331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c549b95c-5be8-43e6-a41b-65657f506312_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a60d11f7-fffd-4dd5-a206-858e55246109_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative arrangements and other contracts</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a5ff6f8-88c8-4e41-b920-a5f8285dd5b0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9e8c8d5-e563-489b-8515-6b8d83a6d749_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_3eb23c70-6c54-4412-8393-2c987f55c340_terseLabel_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember" xlink:href="ino-20230331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesA2OnePreferredStockMember" xlink:to="lab_ino_SeriesA2OnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a9d7790f-4565-44ea-b9f6-eed585c07655_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_582a96f6-8b5c-41e2-b88e-dabc6374409a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7cd156f7-83eb-4459-9583-141028488ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e5437780-7e66-4c72-85e5-e236f50aeee3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_722b898f-2384-4aba-8cb6-371de1ab613e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_c653a10e-84e9-4917-9bb8-8baa847031aa_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc0aea98-3ec9-4dd1-a2cd-7f7b6bc36549_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b15e500f-be22-4496-9d92-e4d9165dcb94_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_8b4cb156-5714-438d-bea0-c027e2ff92df_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_082ab9e9-815f-4b6d-91e0-ae65f3758178_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f97aa8e9-909b-479b-9925-298628a36238_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_157b8971-67af-478e-9c97-b1ed66ecd35f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_a1bc2e6f-90dc-4c23-bc03-2b368c7d5a41_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e282d99d-97fd-4da2-807e-aa714c510ba1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8c853b05-185c-485f-b01c-4ab2cf573d7e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_62493fdc-18cc-4b90-ab2c-c93ae6c0b744_negatedLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20230331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e35caa5e-c4e1-4775-8c79-c913785f3f17_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_JJosephKimMember_4aeb6dcf-b7ef-45f4-98f1-61614e43e5b1_terseLabel_en-US" xlink:label="lab_ino_JJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J. Joseph Kim</link:label>
    <link:label id="lab_ino_JJosephKimMember_label_en-US" xlink:label="lab_ino_JJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J. Joseph Kim [Member]</link:label>
    <link:label id="lab_ino_JJosephKimMember_documentation_en-US" xlink:label="lab_ino_JJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J. Joseph Kim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_JJosephKimMember" xlink:href="ino-20230331.xsd#ino_JJosephKimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_JJosephKimMember" xlink:to="lab_ino_JJosephKimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_7e1690a1-e4bc-4e70-add9-2de5c4898590_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember" xlink:href="ino-20230331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA2000DeviceMember" xlink:to="lab_ino_CELLECTRA2000DeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a03b42da-bcf6-4c9d-b4fa-6dda0533ac71_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_55f53efe-d657-4960-8b69-e920bb3bc95c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_abfea5be-f293-415a-b16f-b064585b7884_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ded2d7cd-9982-45ac-849d-80583a3a877f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_35bbe2cd-7a62-442a-84e1-14e078e252c1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_af0c85b5-84bd-4138-bc59-1e3b0a21466a_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_a4413060-0309-4a0b-a176-463c8daa384b_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8352fe2e-b6d9-4b66-9310-9d049c5b83b3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b010aef5-791d-4aa5-b08c-53894eaf81ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of capital assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3c184995-e87b-4b35-8128-b9b86d202764_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a5a57876-033d-485e-98d1-8285cc316bff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_02a042bd-fc2a-4dd5-866c-9fdeb1e9bcef_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_ec7fe7fb-ea3d-4bbe-9705-69bf755c22a8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_43cf34d1-53f2-415d-9efc-804f44976d7a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_079d5b0e-e37d-4ff7-9fb8-8ad7664eb612_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6613c719-36a2-4d2d-9706-8e6aa1164a3b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2c5c139e-595a-45c0-92e8-7904b640d920_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_21e16674-525c-4597-b411-d4b4350c56cb_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20230331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_3d82ec54-5e93-4af9-a12a-3ff0ceefc9d6_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:href="ino-20230331.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3d345d35-fb61-4d39-bcd8-a41a463e9476_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_c8676b01-dfab-4dfd-9445-060d62757390_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e686c281-f5f8-4b99-8f5a-e1c443ee20e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_73d53c64-5dd1-4e1f-84c1-149f68c70615_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gain) loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4d88e68c-84b2-41e3-b62c-b61484a0b3e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ee7f4c58-c1a8-472f-b6a9-9897744fd7e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c7924ce0-a5c3-4f96-b54e-ec0ad54bec81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AnnualMaintenancePeriod_22d5db5d-7274-4198-8063-ad9a529520fa_terseLabel_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_label_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_documentation_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod" xlink:href="ino-20230331.xsd#ino_AnnualMaintenancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AnnualMaintenancePeriod" xlink:to="lab_ino_AnnualMaintenancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_21747877-5900-407b-94ed-a2d96287afc5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1d0e4ee6-de21-41b3-9630-87c9aeb820a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_b3530cd9-022f-4c35-b1f0-1865c2d44370_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b48d2e12-6ebb-445b-b53c-f58c8eeb21d5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9a0fa1fd-c320-4009-992f-760f9be05f1d_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2488b288-3eb1-4a75-81a7-a42e5833e904_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_bdf99268-85fa-4a6f-b682-fb2dabadfea7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_3b600a68-0f5b-4306-84f5-b6505cf4a237_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_940a0827-e4fc-4ed9-b6a0-bc04c986a057_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_da56b2a2-c842-423d-bac5-0d4550266a0c_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_299cb15c-cb7f-4b2e-adc7-52fb2942bb83_terseLabel_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of shares settlement</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_label_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_documentation_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:href="ino-20230331.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:to="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_ba2f0b35-69cb-4050-b6bd-6c4acff5c071_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement, number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_47742162-455e-42e4-a3d1-2da1b2176fc4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a93a55ab-872c-4c54-b58e-27c0af484f4c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_28102354-e44d-4b37-9c5f-940d41c352eb_terseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance recovery</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_label_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_documentation_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract" xlink:href="ino-20230331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract" xlink:to="lab_ino_CertainBalanceSheetItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_59e66563-2079-4f7b-98ce-70a9cf4d4168_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4909f1d5-d811-4caa-a8ef-5a457308e8f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_e8d1d829-427c-415b-9fed-b558b2e489b4_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20230331.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_d594a9fc-f33b-4619-b3cf-1b81ade795a1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_5a541e05-3d65-4367-a0b1-7d0462524bb6_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7c8865e7-fc61-42f5-9937-8829a1fe6fe8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_5bbb1372-6832-40b7-9ae4-c9904886b996_verboseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of investment</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_01fba928-ecfa-45c3-acf6-2750de33ef80_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3514c48-6178-4f08-af7f-adeb41f7123b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_3322e27d-3b8f-4a35-9f6d-5a74e94803af_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement weighted average price (in dollars per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_c04585d4-4851-45fe-93a4-26ea12d425fa_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20230331.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cdd7721b-bef0-4790-89c7-d29d4848974e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_56593143-86ef-4b1d-b664-8f47236d75e9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_493f7557-fe7c-4d5c-a9e8-3e650d3c3eb8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_a76aaafb-c812-4943-b2eb-60774d81e963_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses - Clinical Trial Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e5b80e5a-b72c-40af-aaa8-e189f14d5457_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d26a138e-7bf7-474a-ab2b-8b57733713f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_668f2a78-7370-4785-93d1-d10bda7d163b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0337cfaf-af62-4991-b235-9ed35fb1749c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_8de788c9-64c4-4c05-be4c-af1fae7998d6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_664a7171-7e21-44af-b740-babd9a35f6e1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e02988fe-b1f8-475e-956f-02108292db57_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a5ff06a9-5379-4070-a875-f57c8917407d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_fbb01e06-41b8-4157-86ec-9caea4094c41_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c0949b29-a307-433b-aab0-a7b6ede1c033_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d2e7d5fd-5f2f-47f4-b551-ab8781540ab6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a8926b9e-9de3-473b-a718-a0da07d6af99_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_28aa23ea-48b3-41d4-b23f-1f9a7955c3e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8ffa9745-2a21-4940-b3e5-0a75390f18dd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_ddc6fd6a-bfb3-40e8-a58d-1189dec68bd6_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8fea7cc3-d13d-4200-8d79-29c7d450ec73_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9fddc37f-d1bc-4810-98a6-20dd68828422_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6277aec6-dce4-40b4-bacb-70436bcd7b2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_bc1549e8-0dc5-4712-a91c-a7e4c8900c49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_99e409c6-eb3f-4c16-b6d4-5310f3d2ca89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_eacacae7-509e-496b-af37-24cf6e6e8b41_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3b835479-e64a-4c48-b67a-880850a64259_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67eb7b1a-672a-434b-af77-df6517d817df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_22ae2b98-ff3c-4926-b460-09a03f207ad3_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:to="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_34c9e342-f319-40f8-bf2a-645f5a6d8ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_35fa5322-c9d6-4800-8867-2c4d205dab51_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_28e56859-29fd-40b3-a29e-5c3a01a5f2b4_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life (Yrs)</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cf4ebbef-4e40-4d3a-8dda-8cf52e2707d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_445091ba-0c74-4435-838d-3228591dbf7b_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever and MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20230331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_dc9deca9-2192-46dd-875d-d7d057aedfea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_a19aa630-4b6c-4ceb-8bea-cf6eea47a4c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_65ecf65c-0403-4fb9-be60-c0e5b3657626_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Liquidity and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_bfbe94a9-72ed-40a2-ab34-6cb4bc2c721a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_7e4a7bf0-ae6f-47d3-a5ac-4573b8a6b9f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ino-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:160750a0-0a71-42f6-8d80-818c69f4d1ac,g:e1c02d6a-4ccd-42cb-9c8b-7f68796035cd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/Cover" xlink:type="simple" xlink:href="ino-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a22d565c-f2c9-4b03-b569-b29a0433afc4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_DocumentType_a22d565c-f2c9-4b03-b569-b29a0433afc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0d303937-c23a-43f1-a22e-7ba8b0a8d0bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_DocumentQuarterlyReport_0d303937-c23a-43f1-a22e-7ba8b0a8d0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_654c1000-9459-4c04-bf4a-e882c81cd002" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_DocumentPeriodEndDate_654c1000-9459-4c04-bf4a-e882c81cd002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ec85eeac-231f-4564-8b6a-47c034590bc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_DocumentTransitionReport_ec85eeac-231f-4564-8b6a-47c034590bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c18f80d-df6e-470d-9add-e246b4058b45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityFileNumber_4c18f80d-df6e-470d-9add-e246b4058b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9d7ebacd-c4d5-45e7-ad51-e4809c15cbfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityRegistrantName_9d7ebacd-c4d5-45e7-ad51-e4809c15cbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_52b03b95-3aba-432e-940f-f96c74aab8b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_52b03b95-3aba-432e-940f-f96c74aab8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d67be53f-a530-4c7f-a77d-1f9bd9e85cc6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityTaxIdentificationNumber_d67be53f-a530-4c7f-a77d-1f9bd9e85cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_dc3c40be-75b4-476c-bca1-7520e64fc73b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityAddressAddressLine1_dc3c40be-75b4-476c-bca1-7520e64fc73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_776616c3-71e3-4920-a630-5b7f1abd48bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityAddressAddressLine2_776616c3-71e3-4920-a630-5b7f1abd48bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4b5d845c-7535-4d7d-8c70-617cf3f23638" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityAddressCityOrTown_4b5d845c-7535-4d7d-8c70-617cf3f23638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6c997113-4e62-44dd-8c13-c19b0e8deb80" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityAddressStateOrProvince_6c997113-4e62-44dd-8c13-c19b0e8deb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fcb653d3-db55-437a-a3c6-c1573c23e2f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityAddressPostalZipCode_fcb653d3-db55-437a-a3c6-c1573c23e2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1fa9b0a6-d63f-4891-91d4-9a87dcaf1f8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_CityAreaCode_1fa9b0a6-d63f-4891-91d4-9a87dcaf1f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a75f2e99-4ed4-4ba1-872e-2349bb10f24c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_LocalPhoneNumber_a75f2e99-4ed4-4ba1-872e-2349bb10f24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8af1d454-3f26-413f-a656-d2c1c96cec67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_Security12bTitle_8af1d454-3f26-413f-a656-d2c1c96cec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6b7f2301-a397-4712-b368-11bf328b301b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_TradingSymbol_6b7f2301-a397-4712-b368-11bf328b301b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_51211abf-691e-4ddf-9949-03c196c309ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_SecurityExchangeName_51211abf-691e-4ddf-9949-03c196c309ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9542c564-b003-4d04-b05e-5f945d22860c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityCurrentReportingStatus_9542c564-b003-4d04-b05e-5f945d22860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a340dd1a-9aa0-4337-9190-58703e78d29e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityInteractiveDataCurrent_a340dd1a-9aa0-4337-9190-58703e78d29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_86cb6ff7-b5a2-4f02-a886-07e5551c286c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityFilerCategory_86cb6ff7-b5a2-4f02-a886-07e5551c286c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c13a23a6-0685-470f-b1ca-fc45e1f18f37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntitySmallBusiness_c13a23a6-0685-470f-b1ca-fc45e1f18f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_550c8242-a404-4566-afcd-a84707907578" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityEmergingGrowthCompany_550c8242-a404-4566-afcd-a84707907578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5d63d018-e309-4771-b559-9d81b700469d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityShellCompany_5d63d018-e309-4771-b559-9d81b700469d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_48c18a26-a326-4c27-b1b3-b2227d032ef9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_48c18a26-a326-4c27-b1b3-b2227d032ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1933344d-149f-4741-addb-86cbfadb0d1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_AmendmentFlag_1933344d-149f-4741-addb-86cbfadb0d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cbf551c5-fa52-40c2-86f3-8bba913465af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_DocumentFiscalYearFocus_cbf551c5-fa52-40c2-86f3-8bba913465af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_49c9ae7b-d275-4508-aac8-9730049f20e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_49c9ae7b-d275-4508-aac8-9730049f20e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ca6642e3-0235-4ff0-a6e9-943e6acd6e24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_EntityCentralIndexKey_ca6642e3-0235-4ff0-a6e9-943e6acd6e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d319f105-bc02-458b-b876-4d4c7397d2de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78dfc8a0-2242-4190-aa04-c87e31cf7e3b" xlink:to="loc_dei_CurrentFiscalYearEndDate_d319f105-bc02-458b-b876-4d4c7397d2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0a04ee5b-4588-4043-a8fa-49072cc65acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a04ee5b-4588-4043-a8fa-49072cc65acc" xlink:to="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c75b0905-b483-4989-b637-20e3965acdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c75b0905-b483-4989-b637-20e3965acdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_e92b87cd-86d4-42bd-9991-b0bc1023a780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:to="loc_us-gaap_ShortTermInvestments_e92b87cd-86d4-42bd-9991-b0bc1023a780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d7f03873-9784-489a-b585-d28806791bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d7f03873-9784-489a-b585-d28806791bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_cd1e280e-cec9-4629-b430-8d5b783e4655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_cd1e280e-cec9-4629-b430-8d5b783e4655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb4e6295-c395-40f0-94b2-38188708ee99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb4e6295-c395-40f0-94b2-38188708ee99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_c1f29c42-c33d-4a67-b2cb-0748db5ef1a8" xlink:href="ino-20230331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_c1f29c42-c33d-4a67-b2cb-0748db5ef1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f0b3e5de-cd66-413c-96e2-34b70eb8efd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cca05264-c15e-4d21-8dd7-8f275e3995b7" xlink:to="loc_us-gaap_AssetsCurrent_f0b3e5de-cd66-413c-96e2-34b70eb8efd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ea74b5b1-0d7d-45d2-9168-b7f0aeea8326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ea74b5b1-0d7d-45d2-9168-b7f0aeea8326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0e4ef3e9-6ddb-4a6d-b9ab-4679fb2fb84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_0e4ef3e9-6ddb-4a6d-b9ab-4679fb2fb84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_be52a0fc-8334-4533-aac5-47969e3f8d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_be52a0fc-8334-4533-aac5-47969e3f8d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b33756b0-e61b-417b-8bea-bb372b3e5e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_Goodwill_b33756b0-e61b-417b-8bea-bb372b3e5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4854a47b-51ca-49da-886b-062604f9e662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4854a47b-51ca-49da-886b-062604f9e662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e975afb7-733d-4698-94bd-a8bf716357c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e975afb7-733d-4698-94bd-a8bf716357c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ced12211-4612-4308-a02c-181e9f521ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66c55d5f-ea52-4ca2-b3f1-f92baf76ed97" xlink:to="loc_us-gaap_Assets_ced12211-4612-4308-a02c-181e9f521ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a04ee5b-4588-4043-a8fa-49072cc65acc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db2da816-7753-45e9-bba1-95ca5cbee7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db2da816-7753-45e9-bba1-95ca5cbee7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_11fbfbd8-0782-4724-b1ec-111a9a04ce8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_11fbfbd8-0782-4724-b1ec-111a9a04ce8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_75f481ee-3d96-4657-a88f-e3b55e20854b" xlink:href="ino-20230331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_75f481ee-3d96-4657-a88f-e3b55e20854b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae70bba6-9486-4237-bffb-8a7a5246003e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae70bba6-9486-4237-bffb-8a7a5246003e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_dbf4e1ed-98c8-4f8f-8576-1e09d2e2c46f" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_ino_DeferredGrantFundingCurrent_dbf4e1ed-98c8-4f8f-8576-1e09d2e2c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b39c753-f58b-4164-a438-453ec8c0e977" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b39c753-f58b-4164-a438-453ec8c0e977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_a7fbe2bc-a4e7-4256-9a3d-ea7714646543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_a7fbe2bc-a4e7-4256-9a3d-ea7714646543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_08fb8b06-7f78-41b4-98d5-32fbb1ee5707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bdab2320-07f2-4946-b3f9-fd2af70708c2" xlink:to="loc_us-gaap_LiabilitiesCurrent_08fb8b06-7f78-41b4-98d5-32fbb1ee5707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_e0622033-66bd-4eb3-9e00-57537722e870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_e0622033-66bd-4eb3-9e00-57537722e870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3f62900-79f1-46bb-9ced-1ac06322ea46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3f62900-79f1-46bb-9ced-1ac06322ea46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_385f2453-0fb0-4cf6-a097-a3becbfda5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_385f2453-0fb0-4cf6-a097-a3becbfda5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ab7ccfb2-ca22-4430-b2df-eb0869e99d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:to="loc_us-gaap_Liabilities_ab7ccfb2-ca22-4430-b2df-eb0869e99d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2ccacbd5-88c4-4d25-ac8c-892fc76648dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:to="loc_us-gaap_PreferredStockValue_2ccacbd5-88c4-4d25-ac8c-892fc76648dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3f50cbbf-67b3-444d-bd84-f1b23d74d33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:to="loc_us-gaap_CommonStockValue_3f50cbbf-67b3-444d-bd84-f1b23d74d33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_749212d1-e7cd-447b-8b00-439474a7dc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:to="loc_us-gaap_AdditionalPaidInCapital_749212d1-e7cd-447b-8b00-439474a7dc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce77e9a8-cb0b-4837-83a7-1fb4e5aebf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce77e9a8-cb0b-4837-83a7-1fb4e5aebf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f23f86e7-ca57-4158-a8d2-afec767b6381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f23f86e7-ca57-4158-a8d2-afec767b6381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_85268dbe-2c9a-439d-bd2c-ba9c4f91dc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0229d8a6-9499-4ef0-b0de-b2f0ece04714" xlink:to="loc_us-gaap_StockholdersEquity_85268dbe-2c9a-439d-bd2c-ba9c4f91dc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_77c0dc69-3cda-471d-99eb-685940c88ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_980d14a8-a834-4901-b651-4f5c80a9cd25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_77c0dc69-3cda-471d-99eb-685940c88ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_366f4f97-62d8-445a-9b07-ae11a31e4a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_RevenuesAbstract_366f4f97-62d8-445a-9b07-ae11a31e4a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_860009b8-dc4f-47b5-a716-a000ed385e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_366f4f97-62d8-445a-9b07-ae11a31e4a23" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_860009b8-dc4f-47b5-a716-a000ed385e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_16d6bc05-59d6-43ab-be87-79addfe89ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_OperatingExpensesAbstract_16d6bc05-59d6-43ab-be87-79addfe89ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2d1e73c5-4dfd-43b7-9a76-658833812d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_16d6bc05-59d6-43ab-be87-79addfe89ea6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2d1e73c5-4dfd-43b7-9a76-658833812d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9c2f053b-70b4-4454-af8a-a9b60b231e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_16d6bc05-59d6-43ab-be87-79addfe89ea6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9c2f053b-70b4-4454-af8a-a9b60b231e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_220fd9c0-7b04-4ea6-a5cc-11abcf18b1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_16d6bc05-59d6-43ab-be87-79addfe89ea6" xlink:to="loc_us-gaap_OperatingExpenses_220fd9c0-7b04-4ea6-a5cc-11abcf18b1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e441889d-3f1e-4082-a9e6-c7391428c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_OperatingIncomeLoss_e441889d-3f1e-4082-a9e6-c7391428c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_52e31612-52f6-4f0d-a591-dbb04991d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_52e31612-52f6-4f0d-a591-dbb04991d48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_4252fdc7-754a-4cce-8b77-bb412cd37137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_52e31612-52f6-4f0d-a591-dbb04991d48a" xlink:to="loc_us-gaap_InterestIncomeOperating_4252fdc7-754a-4cce-8b77-bb412cd37137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5177fb13-83e8-4ff7-9530-d552b9fe3847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_52e31612-52f6-4f0d-a591-dbb04991d48a" xlink:to="loc_us-gaap_InterestExpense_5177fb13-83e8-4ff7-9530-d552b9fe3847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_a89d0ebe-d72f-4f8e-b6cf-91890b1ac678" xlink:href="ino-20230331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_52e31612-52f6-4f0d-a591-dbb04991d48a" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_a89d0ebe-d72f-4f8e-b6cf-91890b1ac678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_42e70076-2476-45ba-91f2-d1843ac56e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_52e31612-52f6-4f0d-a591-dbb04991d48a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_42e70076-2476-45ba-91f2-d1843ac56e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4b10271c-00f8-4a61-8a13-819a4a3d008c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_52e31612-52f6-4f0d-a591-dbb04991d48a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4b10271c-00f8-4a61-8a13-819a4a3d008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0df4fa05-371d-42ef-a395-061c3d39acce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0df4fa05-371d-42ef-a395-061c3d39acce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_12cca755-c6f9-4292-922a-92ec93516c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_12cca755-c6f9-4292-922a-92ec93516c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14911022-4b21-492e-b6f9-30905c9f7d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_NetIncomeLoss_14911022-4b21-492e-b6f9-30905c9f7d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_998975d0-95f5-4940-8566-39ca11fc2bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_EarningsPerShareAbstract_998975d0-95f5-4940-8566-39ca11fc2bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0d3835a7-9514-45ee-8aab-fac2f91e9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_998975d0-95f5-4940-8566-39ca11fc2bee" xlink:to="loc_us-gaap_EarningsPerShareBasic_0d3835a7-9514-45ee-8aab-fac2f91e9f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fa4be4cd-6a75-4d19-bdae-be26b60fdbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_998975d0-95f5-4940-8566-39ca11fc2bee" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fa4be4cd-6a75-4d19-bdae-be26b60fdbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1d1742ca-c4f8-4745-9f95-a8da6ad5ff12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ecf1bcd1-5e45-4c1f-a836-3c812b731804" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1d1742ca-c4f8-4745-9f95-a8da6ad5ff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6fd571e2-523f-42e2-90b5-9d9325cc3a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1d1742ca-c4f8-4745-9f95-a8da6ad5ff12" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6fd571e2-523f-42e2-90b5-9d9325cc3a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2695a923-f1d2-4853-8098-6e974da90885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1d1742ca-c4f8-4745-9f95-a8da6ad5ff12" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2695a923-f1d2-4853-8098-6e974da90885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a66cae7d-afd6-49fb-8632-da9c006baba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d81d050d-8c18-481e-a1c9-7352a3a2baaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a66cae7d-afd6-49fb-8632-da9c006baba5" xlink:to="loc_us-gaap_NetIncomeLoss_d81d050d-8c18-481e-a1c9-7352a3a2baaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cee08d1a-ef7f-4f8e-8bd3-2be4ff18a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a66cae7d-afd6-49fb-8632-da9c006baba5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cee08d1a-ef7f-4f8e-8bd3-2be4ff18a07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5a164edc-c881-4aa9-967c-258041c2c472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cee08d1a-ef7f-4f8e-8bd3-2be4ff18a07a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5a164edc-c881-4aa9-967c-258041c2c472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_edd8af9b-d07b-40ec-92c7-42b4e199fda4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cee08d1a-ef7f-4f8e-8bd3-2be4ff18a07a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_edd8af9b-d07b-40ec-92c7-42b4e199fda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cfc96f47-0ea1-4e8a-9549-d9a98ab56838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a66cae7d-afd6-49fb-8632-da9c006baba5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_cfc96f47-0ea1-4e8a-9549-d9a98ab56838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_004a21c3-8634-4925-b15f-785550dfa33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_004a21c3-8634-4925-b15f-785550dfa33f" xlink:to="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_646dfb69-ca7e-4e55-999b-44d0966c19ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_646dfb69-ca7e-4e55-999b-44d0966c19ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_646dfb69-ca7e-4e55-999b-44d0966c19ba" xlink:to="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_03748c01-2780-4b12-8e1a-ab461e7c33a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_PreferredStockMember_03748c01-2780-4b12-8e1a-ab461e7c33a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4dcf3b42-82ff-4a0d-bde8-b328eb303d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_CommonStockMember_4dcf3b42-82ff-4a0d-bde8-b328eb303d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6719e3bc-5368-4ba3-b695-9b7ebc1348d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6719e3bc-5368-4ba3-b695-9b7ebc1348d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_054d33b1-7cc5-4cff-947b-eace3f386d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_RetainedEarningsMember_054d33b1-7cc5-4cff-947b-eace3f386d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e754567-b31b-49f2-8162-0ff2fd6cfa08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ab2a693d-0c6b-42d8-b909-0a678bc85e1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e754567-b31b-49f2-8162-0ff2fd6cfa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_385098a1-3300-47d0-aa56-ba721b23d8f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_91bdf7ed-0cbb-42b2-aec8-21d2557eaf9b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_385098a1-3300-47d0-aa56-ba721b23d8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e87a2cef-9217-49ed-a8b0-0a8908d4d0d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_385098a1-3300-47d0-aa56-ba721b23d8f5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e87a2cef-9217-49ed-a8b0-0a8908d4d0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_279d6966-769c-4d2e-bae2-83f96f12c1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7da47503-231d-4518-a9c3-5da5ba1f23da" xlink:to="loc_us-gaap_StatementLineItems_279d6966-769c-4d2e-bae2-83f96f12c1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_279d6966-769c-4d2e-bae2-83f96f12c1d1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_03ddacac-b50e-4731-aee5-1db239f1e938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_SharesIssued_03ddacac-b50e-4731-aee5-1db239f1e938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c313a283-633c-4b01-bf3e-4ae670947489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockholdersEquity_c313a283-633c-4b01-bf3e-4ae670947489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76e8a294-460b-483d-ab12-fff210cecbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76e8a294-460b-483d-ab12-fff210cecbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5a2beab0-9969-4532-ae35-7ea36acdd768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5a2beab0-9969-4532-ae35-7ea36acdd768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8488ca5e-be2b-4b43-a4dd-4b1c70d9e7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8488ca5e-be2b-4b43-a4dd-4b1c70d9e7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3deb5ddf-776a-46d4-b151-1fe75cd78042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3deb5ddf-776a-46d4-b151-1fe75cd78042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dcd3a3de-bc4c-4757-90de-615863442a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dcd3a3de-bc4c-4757-90de-615863442a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1eaa5116-eaa3-4baf-ba0b-6d09c03cc192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_NetIncomeLoss_1eaa5116-eaa3-4baf-ba0b-6d09c03cc192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1045912c-095b-4b9e-bcce-5fdf28c600fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1045912c-095b-4b9e-bcce-5fdf28c600fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_575cba9a-bc18-4b40-9e6b-16b7f02e2d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_575cba9a-bc18-4b40-9e6b-16b7f02e2d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c67b0769-86f2-47e6-a007-daa62313e5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_StockholdersEquity_c67b0769-86f2-47e6-a007-daa62313e5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_618f966c-e615-4dcc-bc90-4c10beff44e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_372f63ea-08d0-49c4-b9b2-6be8297288f1" xlink:to="loc_us-gaap_SharesIssued_618f966c-e615-4dcc-bc90-4c10beff44e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_660a823f-690f-4be5-aed1-e204e9e551d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4cd100a6-2178-40b4-88e1-9398cf4aae15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_660a823f-690f-4be5-aed1-e204e9e551d1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_4cd100a6-2178-40b4-88e1-9398cf4aae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62486cff-5d92-4175-a471-d1a63b95bc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62486cff-5d92-4175-a471-d1a63b95bc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_347071e0-4b66-4de0-a611-b306d00480ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62486cff-5d92-4175-a471-d1a63b95bc3d" xlink:to="loc_us-gaap_NetIncomeLoss_347071e0-4b66-4de0-a611-b306d00480ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62486cff-5d92-4175-a471-d1a63b95bc3d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_569fbed5-aa1c-4bf3-8cd9-fa9d25497cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_Depreciation_569fbed5-aa1c-4bf3-8cd9-fa9d25497cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_de299f77-0699-41dd-960b-60e5265f1f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_de299f77-0699-41dd-960b-60e5265f1f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_570171c0-53f9-492d-9310-5134a78b57ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_570171c0-53f9-492d-9310-5134a78b57ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e1907327-d7da-4c60-beb0-1439327023bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_ShareBasedCompensation_e1907327-d7da-4c60-beb0-1439327023bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_4c0bcf0a-e2cb-414a-a2d0-024a0500a4fa" xlink:href="ino-20230331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_ino_NonCashInterestIncomeExpense_4c0bcf0a-e2cb-414a-a2d0-024a0500a4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_7dab81f1-f3a4-46f1-9ac8-8f91c22ccd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_7dab81f1-f3a4-46f1-9ac8-8f91c22ccd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_1379bacd-386e-4a07-bada-5151935247a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_1379bacd-386e-4a07-bada-5151935247a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_71e7cd9c-257f-4f0b-883e-10230932f13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_71e7cd9c-257f-4f0b-883e-10230932f13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_a263a8c4-2cfa-4e91-b3b6-45e304624592" xlink:href="ino-20230331.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_a263a8c4-2cfa-4e91-b3b6-45e304624592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_67dd3863-d187-4eb6-a517-1f33de85215d" xlink:href="ino-20230331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_67dd3863-d187-4eb6-a517-1f33de85215d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_72efee01-38eb-413e-8cc9-b2f9b00edfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_72efee01-38eb-413e-8cc9-b2f9b00edfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_131b0169-74f5-48c0-b46b-02639feac45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_131b0169-74f5-48c0-b46b-02639feac45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_93017cce-f543-4870-a4d9-a4551ba6bc94" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c947bc99-b50b-41dc-a421-73850e94a973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c947bc99-b50b-41dc-a421-73850e94a973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ae32320b-a62b-4795-be99-6b0a1a0ae966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ae32320b-a62b-4795-be99-6b0a1a0ae966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f68f45e2-6b12-4b9c-a9de-68c2675910d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f68f45e2-6b12-4b9c-a9de-68c2675910d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c4ca9fa5-c448-4faf-9a28-f7c93ed0eb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c4ca9fa5-c448-4faf-9a28-f7c93ed0eb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6a7d1b3a-61ae-4053-9e78-469d292afa27" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6a7d1b3a-61ae-4053-9e78-469d292afa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_66de8465-fefa-4314-8fc1-16755cefc0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_66de8465-fefa-4314-8fc1-16755cefc0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_ad4d77b6-348d-4a8a-8bc5-e8bc00aece30" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_ad4d77b6-348d-4a8a-8bc5-e8bc00aece30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_4dcf8ffb-9c87-436c-956e-68821cd1ed39" xlink:href="ino-20230331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_4dcf8ffb-9c87-436c-956e-68821cd1ed39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fe2507fd-15ed-45bc-a9f5-5ab6db19b677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2565a432-5a41-4cf5-871a-42e4f8752556" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fe2507fd-15ed-45bc-a9f5-5ab6db19b677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ac9746d-9697-4899-8f57-2ea04ed50899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62486cff-5d92-4175-a471-d1a63b95bc3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ac9746d-9697-4899-8f57-2ea04ed50899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_203a29a3-27d4-4770-8e80-4140d9a51d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_203a29a3-27d4-4770-8e80-4140d9a51d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7bf9d37d-dd0f-46cb-8a11-239e2f07a539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_7bf9d37d-dd0f-46cb-8a11-239e2f07a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03fce8be-beb3-4608-a29f-dc7264c0b404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03fce8be-beb3-4608-a29f-dc7264c0b404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7ea505b3-7cd8-45a0-96ed-3b1d61c0d09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7ea505b3-7cd8-45a0-96ed-3b1d61c0d09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2dcf042c-1855-4847-8448-07f1a8ab1dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2dcf042c-1855-4847-8448-07f1a8ab1dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d656770-b0a1-469a-8882-eee2467b639c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_53521408-ce07-4f5e-a76e-0a2cd61e97a7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d656770-b0a1-469a-8882-eee2467b639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2b3eab14-eb7e-433f-8c3e-d3bd0f2541c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2b3eab14-eb7e-433f-8c3e-d3bd0f2541c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78592ff1-9bdc-4a6a-bf78-f57cb8baded9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2b3eab14-eb7e-433f-8c3e-d3bd0f2541c0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_78592ff1-9bdc-4a6a-bf78-f57cb8baded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9cf3e392-e168-48cc-9ffd-964e693b1641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2b3eab14-eb7e-433f-8c3e-d3bd0f2541c0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9cf3e392-e168-48cc-9ffd-964e693b1641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_044850f4-28c2-4f20-8bd4-8677b22ec80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2b3eab14-eb7e-433f-8c3e-d3bd0f2541c0" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_044850f4-28c2-4f20-8bd4-8677b22ec80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59c28861-3bff-4d1a-9efa-fd8bfaccd297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2b3eab14-eb7e-433f-8c3e-d3bd0f2541c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59c28861-3bff-4d1a-9efa-fd8bfaccd297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4f9680a-fe27-4f27-b3cc-0f6c18a40c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4f9680a-fe27-4f27-b3cc-0f6c18a40c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_356a7da5-198f-4ee6-98a4-79e3ccb5bc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_356a7da5-198f-4ee6-98a4-79e3ccb5bc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9820bc24-b1e6-4484-8b30-85159f98ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9820bc24-b1e6-4484-8b30-85159f98ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56f10a41-bc23-46ba-843f-9dcf24cbce3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56f10a41-bc23-46ba-843f-9dcf24cbce3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c157a56f-7279-4a43-9b1f-a632bd6d3b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cd59494f-3e4d-45d9-ba18-d38af087c6f7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c157a56f-7279-4a43-9b1f-a632bd6d3b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6d05ebfa-decf-4b36-b57b-fb80af1cc5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c157a56f-7279-4a43-9b1f-a632bd6d3b1f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6d05ebfa-decf-4b36-b57b-fb80af1cc5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d035b9c6-e2ed-4bdb-8e2f-adf71ab810cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c157a56f-7279-4a43-9b1f-a632bd6d3b1f" xlink:to="loc_us-gaap_InterestPaidNet_d035b9c6-e2ed-4bdb-8e2f-adf71ab810cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement_3833f442-ff66-4030-8871-9828280e2388" xlink:href="ino-20230331.xsd#ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c157a56f-7279-4a43-9b1f-a632bd6d3b1f" xlink:to="loc_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement_3833f442-ff66-4030-8871-9828280e2388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20230331.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60660bbc-57c0-4741-8c2a-2c1559dad2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_443688fa-12ca-496c-a650-0d843af25cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60660bbc-57c0-4741-8c2a-2c1559dad2ea" xlink:to="loc_us-gaap_NatureOfOperations_443688fa-12ca-496c-a650-0d843af25cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20230331.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8b3bab15-fab2-440d-9afc-03c424fcb48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_69fa8afb-5f52-4417-95ee-9fc9ef7413f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8b3bab15-fab2-440d-9afc-03c424fcb48d" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_69fa8afb-5f52-4417-95ee-9fc9ef7413f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20230331.xsd#CriticalAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3addfd08-9826-442c-b36d-8c64ef659ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_baa36036-8aba-47aa-b6db-666afe4c16c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3addfd08-9826-442c-b36d-8c64ef659ac2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_baa36036-8aba-47aa-b6db-666afe4c16c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20230331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7b24eb09-1022-4ce0-80d0-509acbb2d914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3a834244-3cca-49cc-b258-60c81af33b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7b24eb09-1022-4ce0-80d0-509acbb2d914" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3a834244-3cca-49cc-b258-60c81af33b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dca3c4de-d518-4367-ad3f-8d87c8aaabdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f8a5a2b2-5198-4971-abbe-461ccea5a3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dca3c4de-d518-4367-ad3f-8d87c8aaabdf" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f8a5a2b2-5198-4971-abbe-461ccea5a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0075c387-ee55-4253-b8b1-87427a9a5591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dca3c4de-d518-4367-ad3f-8d87c8aaabdf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0075c387-ee55-4253-b8b1-87427a9a5591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="ino-20230331.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_899b6bbb-b5c4-4a82-88d8-09f766e84e39" xlink:href="ino-20230331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_3c5532fb-f406-478b-b767-cbe97550bc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_899b6bbb-b5c4-4a82-88d8-09f766e84e39" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_3c5532fb-f406-478b-b767-cbe97550bc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20230331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a884ad98-62f7-475c-950b-5db2edfc60f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_87da8b15-593b-4b8a-89e1-86e2cab82330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a884ad98-62f7-475c-950b-5db2edfc60f9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_87da8b15-593b-4b8a-89e1-86e2cab82330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9175e60d-50cb-4d26-8533-fbc8df82e2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6fa0edc1-23d4-4b9b-a979-dbf13c308c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9175e60d-50cb-4d26-8533-fbc8df82e2b6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6fa0edc1-23d4-4b9b-a979-dbf13c308c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_98f4cc41-83aa-4b9f-a82e-5b51500fe658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a1615773-8e5d-44fc-b930-6242e3887ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_98f4cc41-83aa-4b9f-a82e-5b51500fe658" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a1615773-8e5d-44fc-b930-6242e3887ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e77e0831-bcd8-4141-b5af-238dcf6d0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ea41d988-758c-4b73-a897-e97ce775d279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e77e0831-bcd8-4141-b5af-238dcf6d0ae1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ea41d988-758c-4b73-a897-e97ce775d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714c9f78-654b-4cf6-aef4-5a311c119814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158f0143-c7fe-43b3-846c-3561e1be8982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_714c9f78-654b-4cf6-aef4-5a311c119814" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_158f0143-c7fe-43b3-846c-3561e1be8982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20230331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_c8061c81-d122-4d1d-bd55-1f6772f83ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1173f415-e1e0-49ab-89ce-d7202d423559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_c8061c81-d122-4d1d-bd55-1f6772f83ef8" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1173f415-e1e0-49ab-89ce-d7202d423559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66995d1a-5a50-4903-8d01-99d2e02062d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f3cccc40-35ff-45da-aa12-35d28bb8c95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66995d1a-5a50-4903-8d01-99d2e02062d0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f3cccc40-35ff-45da-aa12-35d28bb8c95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20230331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_163d7524-aa0a-4287-b0ec-fe218e9c8df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_720facbf-71d7-49cc-82d3-74a051918b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_163d7524-aa0a-4287-b0ec-fe218e9c8df1" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_720facbf-71d7-49cc-82d3-74a051918b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_beeedd51-8832-4456-bfaf-76618242ea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cd7c818c-73fd-4e54-b38c-5847c5d98060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_beeedd51-8832-4456-bfaf-76618242ea3f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cd7c818c-73fd-4e54-b38c-5847c5d98060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20230331.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_3bd92b4d-28ec-4b62-b222-1c755cd4fa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_27f0e4b9-0d23-49b1-ad95-750409135fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3bd92b4d-28ec-4b62-b222-1c755cd4fa20" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_27f0e4b9-0d23-49b1-ad95-750409135fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20230331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd420fe8-5a61-4084-97e0-5154f3b88ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3bf62eda-b8e3-4f0e-960a-892bf49e5282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd420fe8-5a61-4084-97e0-5154f3b88ec5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3bf62eda-b8e3-4f0e-960a-892bf49e5282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_91cfb4ad-ee20-4503-a97e-765c8fd2844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd420fe8-5a61-4084-97e0-5154f3b88ec5" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_91cfb4ad-ee20-4503-a97e-765c8fd2844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5791cb62-4b5c-41d0-9b66-0657dd2baa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd420fe8-5a61-4084-97e0-5154f3b88ec5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5791cb62-4b5c-41d0-9b66-0657dd2baa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2dad1df-9a70-4ae4-90a0-fd114e18be40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b96b8d42-ece9-4281-a3dd-bf5ee81f1770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2dad1df-9a70-4ae4-90a0-fd114e18be40" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b96b8d42-ece9-4281-a3dd-bf5ee81f1770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fb05d8c5-0c55-4831-b69b-9cf18c365c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2dad1df-9a70-4ae4-90a0-fd114e18be40" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fb05d8c5-0c55-4831-b69b-9cf18c365c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="ino-20230331.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_62270e3c-418d-43d5-acbf-901d533ec424" xlink:href="ino-20230331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_3d4a3578-6803-4d89-b10e-2768b61275b1" xlink:href="ino-20230331.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_62270e3c-418d-43d5-acbf-901d533ec424" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_3d4a3578-6803-4d89-b10e-2768b61275b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f7bf297d-ab47-4aba-903c-bb4f15b14b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_62270e3c-418d-43d5-acbf-901d533ec424" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f7bf297d-ab47-4aba-903c-bb4f15b14b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20230331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_779bcb0c-4aba-46f0-955f-e113da44e9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e23fbd07-f55f-42e3-9d48-e01f745b9834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_779bcb0c-4aba-46f0-955f-e113da44e9d3" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e23fbd07-f55f-42e3-9d48-e01f745b9834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dd6472c5-e546-49a3-a313-310794ac1ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_f6d5ab69-6ac8-4208-b381-b9931e6b57ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dd6472c5-e546-49a3-a313-310794ac1ee6" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_f6d5ab69-6ac8-4208-b381-b9931e6b57ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0c5976cb-b10c-42e6-944b-c999626a7060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dd6472c5-e546-49a3-a313-310794ac1ee6" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0c5976cb-b10c-42e6-944b-c999626a7060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_eae2c8ea-22ef-4c5f-8aa8-f577d8bf2f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_d5a98bb8-c436-471d-97b1-14a702bbcf20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_eae2c8ea-22ef-4c5f-8aa8-f577d8bf2f64" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_d5a98bb8-c436-471d-97b1-14a702bbcf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c99cea8d-1e28-4243-a0bd-c4a56f6218e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_91c65bb6-2239-41fe-b537-72b7b31da6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c99cea8d-1e28-4243-a0bd-c4a56f6218e1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_91c65bb6-2239-41fe-b537-72b7b31da6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_049fef97-478d-4d42-b7d4-3e6e529f293e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ef750eb9-77f1-43b5-ac0b-17f3784138c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_049fef97-478d-4d42-b7d4-3e6e529f293e" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ef750eb9-77f1-43b5-ac0b-17f3784138c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20230331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57601dda-9572-4d5e-8d7c-307fd3b42ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f18a1a4e-8fee-4cb1-8d01-0359edca2277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_57601dda-9572-4d5e-8d7c-307fd3b42ce1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f18a1a4e-8fee-4cb1-8d01-0359edca2277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20230331.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_f0233ba9-1a22-4e09-a555-36926fbbec86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_8a6a0b96-bf21-45f8-8de3-8b8ac17bdbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_f0233ba9-1a22-4e09-a555-36926fbbec86" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_8a6a0b96-bf21-45f8-8de3-8b8ac17bdbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_77ab073f-833d-4f79-b66a-fb12e388c669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_77ab073f-833d-4f79-b66a-fb12e388c669" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e1ab803a-0d2d-4f66-86dd-ecf5507a3858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e1ab803a-0d2d-4f66-86dd-ecf5507a3858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fdfe38d1-88c1-4325-bd15-7105877e5c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e1ab803a-0d2d-4f66-86dd-ecf5507a3858" xlink:to="loc_us-gaap_ClassOfStockDomain_fdfe38d1-88c1-4325-bd15-7105877e5c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f0a2f38c-6cdd-4c96-8086-ba5ef67ed875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fdfe38d1-88c1-4325-bd15-7105877e5c38" xlink:to="loc_us-gaap_CommonStockMember_f0a2f38c-6cdd-4c96-8086-ba5ef67ed875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d699300-968b-48bf-816e-9a18cf3a3603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d699300-968b-48bf-816e-9a18cf3a3603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7212bc4-c790-4495-8ec4-1c35a5cb2746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d699300-968b-48bf-816e-9a18cf3a3603" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7212bc4-c790-4495-8ec4-1c35a5cb2746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_1323ff95-286d-4aeb-9658-4b5fb4cb792f" xlink:href="ino-20230331.xsd#ino_SalesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c7212bc4-c790-4495-8ec4-1c35a5cb2746" xlink:to="loc_ino_SalesAgreementsMember_1323ff95-286d-4aeb-9658-4b5fb4cb792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5c477db4-0d47-45b9-9474-708ee2b08418" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a37aa348-017e-486b-8c84-79224ac44b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_NetIncomeLoss_a37aa348-017e-486b-8c84-79224ac44b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_d5608abb-158b-4969-9af0-d74bc431531e" xlink:href="ino-20230331.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_ino_WorkingCapital_d5608abb-158b-4969-9af0-d74bc431531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eba236c6-777c-4a18-9146-5faef82679e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_eba236c6-777c-4a18-9146-5faef82679e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1df461ee-85e4-4561-899a-182f794edfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_1df461ee-85e4-4561-899a-182f794edfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a4db10d-bc43-43e3-ac59-ea44891815d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_64c91655-6c30-419d-8ef5-fd24c8b2af1c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a4db10d-bc43-43e3-ac59-ea44891815d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#RevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1f7be9a9-b5c7-4c69-9996-135404d5aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_aa5b44f7-314f-4ca8-94f7-1d33e73a3b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1f7be9a9-b5c7-4c69-9996-135404d5aa28" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_aa5b44f7-314f-4ca8-94f7-1d33e73a3b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e34dcd25-b414-4576-a9aa-c8b565ba6e1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aa5b44f7-314f-4ca8-94f7-1d33e73a3b4d" xlink:to="loc_srt_MajorCustomersAxis_e34dcd25-b414-4576-a9aa-c8b565ba6e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e34dcd25-b414-4576-a9aa-c8b565ba6e1b" xlink:to="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_82bae3df-0724-4f15-851a-ec5c08c8e13b" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_82bae3df-0724-4f15-851a-ec5c08c8e13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_0f0cc8ef-1f7c-4b4c-b931-391e07afcae7" xlink:href="ino-20230331.xsd#ino_AllOtherCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1888aa8b-5e35-4d84-85d4-8a30c16ffd76" xlink:to="loc_ino_AllOtherCustomersMember_0f0cc8ef-1f7c-4b4c-b931-391e07afcae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac2e5a-aaef-4b71-8b93-f80af9d7758d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aa5b44f7-314f-4ca8-94f7-1d33e73a3b4d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac2e5a-aaef-4b71-8b93-f80af9d7758d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c5e5534-88bc-485f-b33d-f5ef0bb87524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4cac2e5a-aaef-4b71-8b93-f80af9d7758d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c5e5534-88bc-485f-b33d-f5ef0bb87524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b06adecb-88b7-4363-b810-5c92f33ffa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_49dfbdc8-63af-49fb-9dea-f3be98e0c222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b06adecb-88b7-4363-b810-5c92f33ffa12" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_49dfbdc8-63af-49fb-9dea-f3be98e0c222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9a3c157b-1cb0-4e32-8184-312ad9fa8443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_49dfbdc8-63af-49fb-9dea-f3be98e0c222" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9a3c157b-1cb0-4e32-8184-312ad9fa8443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9a3c157b-1cb0-4e32-8184-312ad9fa8443" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_558ecda2-fbfa-497f-a553-28fab1601f49" xlink:href="ino-20230331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_ino_MutualFundsMember_558ecda2-fbfa-497f-a553-28fab1601f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_ac6b1231-873a-44c8-adcd-ff03d73415c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_ac6b1231-873a-44c8-adcd-ff03d73415c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4b51a218-fbf8-4a63-855d-bb787e5c2ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4b51a218-fbf8-4a63-855d-bb787e5c2ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aff976d3-73f5-42c7-9af2-9d5a6f45345a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f1ece16-a49f-4aad-9aef-590cf7ebb483" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aff976d3-73f5-42c7-9af2-9d5a6f45345a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_49dfbdc8-63af-49fb-9dea-f3be98e0c222" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_3562ff90-0afa-4ba8-8d65-46e1df36ecce" xlink:href="ino-20230331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_3562ff90-0afa-4ba8-8d65-46e1df36ecce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e3d9da27-2b18-448f-8243-b4112352775f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_346b1454-b336-4f76-8f08-e910d563083c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_346b1454-b336-4f76-8f08-e910d563083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7366cf0d-9bb6-4b03-bcfe-4bee9995d034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7366cf0d-9bb6-4b03-bcfe-4bee9995d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45a1dbc9-839f-4d5e-b99b-3fa4cf70a2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45a1dbc9-839f-4d5e-b99b-3fa4cf70a2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c0aaf46-187b-49d4-a853-20fb4415c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6cd27932-e026-4ede-9391-4f45ecd2579e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c0aaf46-187b-49d4-a853-20fb4415c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d445be7a-077f-457b-a3d3-e1b5619a8b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d445be7a-077f-457b-a3d3-e1b5619a8b4c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec17863a-0076-4599-afe7-8fb18cbdb7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec17863a-0076-4599-afe7-8fb18cbdb7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7419a506-b6c9-47dc-9170-8a2007c93c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec17863a-0076-4599-afe7-8fb18cbdb7a1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7419a506-b6c9-47dc-9170-8a2007c93c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d65353d8-095c-42a2-8db8-cf9f089ca56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7419a506-b6c9-47dc-9170-8a2007c93c9b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d65353d8-095c-42a2-8db8-cf9f089ca56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d171872d-96b9-4bf3-91d4-95469fe12c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:to="loc_us-gaap_InvestmentTypeAxis_d171872d-96b9-4bf3-91d4-95469fe12c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1b72fe0a-f4f6-4356-a6a5-49a3e385dbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_d171872d-96b9-4bf3-91d4-95469fe12c47" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1b72fe0a-f4f6-4356-a6a5-49a3e385dbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_212425e0-b7a6-4809-b72a-54a47db86489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1b72fe0a-f4f6-4356-a6a5-49a3e385dbf1" xlink:to="loc_us-gaap_CommonStockMember_212425e0-b7a6-4809-b72a-54a47db86489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8489d45a-1698-4337-86a7-eb0479f95769" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_047fd920-dd46-49d7-b436-386467a5ebf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_047fd920-dd46-49d7-b436-386467a5ebf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_483e17b6-099e-4ed8-8c60-e01f3bf70b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_483e17b6-099e-4ed8-8c60-e01f3bf70b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_47e53577-6b9c-42c7-8b39-b8c1c0720762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_47e53577-6b9c-42c7-8b39-b8c1c0720762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6dd2332c-0628-4d06-b2ec-e61193894264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6dd2332c-0628-4d06-b2ec-e61193894264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_135cc35c-6ee4-4d38-b458-5ad55944bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_135cc35c-6ee4-4d38-b458-5ad55944bbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_13aee705-f033-42d0-ab0d-313767022305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_510e195d-5f73-4141-bd23-5a5bb8372fb8" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_13aee705-f033-42d0-ab0d-313767022305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_df45b915-a659-4dd1-a64f-4f05fd3ddb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_df45b915-a659-4dd1-a64f-4f05fd3ddb3f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34cbad67-99fe-4f19-a88b-2224969a33d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34cbad67-99fe-4f19-a88b-2224969a33d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_321263fb-bbae-416a-b979-91123bd2b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_34cbad67-99fe-4f19-a88b-2224969a33d3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_321263fb-bbae-416a-b979-91123bd2b3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5b02f43f-ea9a-4490-a38e-e2519946e7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_321263fb-bbae-416a-b979-91123bd2b3c1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5b02f43f-ea9a-4490-a38e-e2519946e7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bc528626-af87-43bb-9800-26303a1ac31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bc528626-af87-43bb-9800-26303a1ac31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bc528626-af87-43bb-9800-26303a1ac31c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_cd003f1c-0991-4e9a-a742-2faae9fbd628" xlink:href="ino-20230331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_ino_MutualFundsMember_cd003f1c-0991-4e9a-a742-2faae9fbd628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_082d7f6f-f860-4f54-bc9a-f8b7a5d902b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_082d7f6f-f860-4f54-bc9a-f8b7a5d902b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_23810147-76b1-4547-a3bf-d8798f671ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_us-gaap_CertificatesOfDepositMember_23810147-76b1-4547-a3bf-d8798f671ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e2773cfe-e430-45f7-855f-12075be50714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c52214-5e19-4b84-996f-c46fba849230" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e2773cfe-e430-45f7-855f-12075be50714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a9c8172-6744-495d-84d2-b25489aafd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a9c8172-6744-495d-84d2-b25489aafd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a9c8172-6744-495d-84d2-b25489aafd6e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1e0f28d5-c948-4114-a3c8-164803f476a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1e0f28d5-c948-4114-a3c8-164803f476a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3f275c6c-7391-43f5-ad6b-7b0a82287b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3f275c6c-7391-43f5-ad6b-7b0a82287b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7856e91d-c389-433e-ae5b-a39dd9eb90c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e38dd05b-6e55-47d1-8564-a90f47878915" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7856e91d-c389-433e-ae5b-a39dd9eb90c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1cb340c-5be2-4117-bf9f-532fe7676073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_848b8738-8399-476d-a8c3-24bd38e96bea" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1cb340c-5be2-4117-bf9f-532fe7676073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d1cb340c-5be2-4117-bf9f-532fe7676073" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68fd2054-a341-4421-a6d5-ccfd11798ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68fd2054-a341-4421-a6d5-ccfd11798ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_850ed910-2a7c-482f-8300-cffd14746be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_850ed910-2a7c-482f-8300-cffd14746be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0c7b69e2-a375-437f-b2c1-93be7970c53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_dab7623f-6a4b-4d93-958c-0ff44e0b86b8" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0c7b69e2-a375-437f-b2c1-93be7970c53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_563697a8-1803-43f4-8c86-4ed602ad2766" xlink:href="ino-20230331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_42a17639-0797-49b4-bae7-19f2773e1977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_563697a8-1803-43f4-8c86-4ed602ad2766" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_42a17639-0797-49b4-bae7-19f2773e1977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_6fc91df4-20da-471c-abe4-073553a2e870" xlink:href="ino-20230331.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_563697a8-1803-43f4-8c86-4ed602ad2766" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_6fc91df4-20da-471c-abe4-073553a2e870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_00f4fe6b-ec29-4a4f-b6ca-d07ae5337649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_563697a8-1803-43f4-8c86-4ed602ad2766" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_00f4fe6b-ec29-4a4f-b6ca-d07ae5337649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d54fae31-e6bb-4418-8fa3-617f24ee50c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_563697a8-1803-43f4-8c86-4ed602ad2766" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d54fae31-e6bb-4418-8fa3-617f24ee50c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_d67925cb-b802-460f-a215-592dcf8b0c33" xlink:href="ino-20230331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_32055e12-918c-471c-8195-cf7b25d83afc" xlink:href="ino-20230331.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_d67925cb-b802-460f-a215-592dcf8b0c33" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_32055e12-918c-471c-8195-cf7b25d83afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8ac2e4bf-9b79-47f7-9165-3819055fea99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_32055e12-918c-471c-8195-cf7b25d83afc" xlink:to="loc_srt_LitigationCaseAxis_8ac2e4bf-9b79-47f7-9165-3819055fea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9c1c61ec-2823-4720-9e07-1ba44f95902b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_8ac2e4bf-9b79-47f7-9165-3819055fea99" xlink:to="loc_srt_LitigationCaseTypeDomain_9c1c61ec-2823-4720-9e07-1ba44f95902b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_705ca8c8-9f1f-4788-8297-7aec0ebdf7bb" xlink:href="ino-20230331.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9c1c61ec-2823-4720-9e07-1ba44f95902b" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_705ca8c8-9f1f-4788-8297-7aec0ebdf7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:href="ino-20230331.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_32055e12-918c-471c-8195-cf7b25d83afc" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_aba87219-dba2-4344-aad8-32889cdca689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_aba87219-dba2-4344-aad8-32889cdca689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_8937d52a-9054-4847-8642-a69eef707c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_AccruedSalariesCurrent_8937d52a-9054-4847-8642-a69eef707c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_c604b771-9066-4ef9-b314-f8563772623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_LitigationReserveCurrent_c604b771-9066-4ef9-b314-f8563772623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bdda4792-88fb-4ca9-96ab-468e03466c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_bdda4792-88fb-4ca9-96ab-468e03466c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db4ac57a-0712-4ba5-b5bd-493498a945bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_db4ac57a-0712-4ba5-b5bd-493498a945bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4236055f-cea0-44f0-8687-9109a6cdb51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4236055f-cea0-44f0-8687-9109a6cdb51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_5f8a7016-3d95-4bd4-aa40-f92db3bc24dd" xlink:href="ino-20230331.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_5f8a7016-3d95-4bd4-aa40-f92db3bc24dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_cb5c61d9-1b0e-418e-9f8f-530f4f1e7cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_cb5c61d9-1b0e-418e-9f8f-530f4f1e7cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5f39e96f-48cd-48db-9aeb-b71c74c14a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_a7bc134f-6461-416d-9e88-766f4ad6d23f" xlink:to="loc_us-gaap_CommonStockSharesIssued_5f39e96f-48cd-48db-9aeb-b71c74c14a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1d7d3173-7e53-471c-b719-73a62e97378d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1d7d3173-7e53-471c-b719-73a62e97378d" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_243c12e9-8525-479e-9712-77e717ba076f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:to="loc_srt_RangeAxis_243c12e9-8525-479e-9712-77e717ba076f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77959037-9e28-49d9-b66a-49bd3697c03b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_243c12e9-8525-479e-9712-77e717ba076f" xlink:to="loc_srt_RangeMember_77959037-9e28-49d9-b66a-49bd3697c03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_79e0f20e-6cc5-4fa4-b5b1-49c8e6141ee5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_77959037-9e28-49d9-b66a-49bd3697c03b" xlink:to="loc_srt_WeightedAverageMember_79e0f20e-6cc5-4fa4-b5b1-49c8e6141ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70623736-fd73-495a-9ea9-6b70a156e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70623736-fd73-495a-9ea9-6b70a156e9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70623736-fd73-495a-9ea9-6b70a156e9fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_cd830d06-9949-4ae1-958a-f2e226939db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:to="loc_us-gaap_LicensingAgreementsMember_cd830d06-9949-4ae1-958a-f2e226939db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_c20bfbd1-5a77-4c3a-a343-5af6716e5aaf" xlink:href="ino-20230331.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:to="loc_ino_BiojectMember_c20bfbd1-5a77-4c3a-a343-5af6716e5aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1d2181f1-b983-48c2-bdaa-e321ac482c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17040085-17d8-4fd3-912d-ae558e69abfa" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1d2181f1-b983-48c2-bdaa-e321ac482c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c19b506c-802e-47ba-b7e3-28cde318377b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_d246e460-da19-4fe0-b5cf-e5d2ed04e71e" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c19b506c-802e-47ba-b7e3-28cde318377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_c19b506c-802e-47ba-b7e3-28cde318377b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_22b08e13-41d4-414e-9a1f-fca057c075f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:to="loc_us-gaap_GoodwillGross_22b08e13-41d4-414e-9a1f-fca057c075f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_db524fbc-e96d-4b8c-9521-10a3f91c4e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ca828a15-5d19-4e96-a502-813d3e52ba08" xlink:to="loc_us-gaap_Goodwill_db524fbc-e96d-4b8c-9521-10a3f91c4e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0eadff2-f057-4b6b-9dc3-27d963702b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e0eadff2-f057-4b6b-9dc3-27d963702b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3671afb-b114-42b5-b54f-e8bbc3377e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3671afb-b114-42b5-b54f-e8bbc3377e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0d9957e2-1fa7-4028-ae2e-1e362c8aa9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0d9957e2-1fa7-4028-ae2e-1e362c8aa9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9a6a71e4-a304-4fb9-a6a6-45ae001bb1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ca5c20fa-4f7c-4fbc-89eb-0ae145d64000" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9a6a71e4-a304-4fb9-a6a6-45ae001bb1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_84aaa186-bc11-4a81-9ceb-033b44d19949" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_84aaa186-bc11-4a81-9ceb-033b44d19949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_67541660-4304-4dbf-99dc-78c0b156648d" xlink:href="ino-20230331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_d97b8dcb-8c48-455d-aff7-51c0d29da7d9" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_67541660-4304-4dbf-99dc-78c0b156648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_687eb8f6-b279-4cc6-89b5-78ceccd0f5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_687eb8f6-b279-4cc6-89b5-78ceccd0f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a02ce016-2dab-41cc-9a5d-a297ba244bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a02ce016-2dab-41cc-9a5d-a297ba244bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_47d97a27-0072-42d4-a8b6-de8c562e2fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_47d97a27-0072-42d4-a8b6-de8c562e2fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cfa249ce-9048-467c-847d-add087dbb44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cfa249ce-9048-467c-847d-add087dbb44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dc54504a-0f8c-4ca4-b7db-051b14e9efa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dc54504a-0f8c-4ca4-b7db-051b14e9efa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5d220e39-1e3e-4a27-ac14-13f85e9e3a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5d220e39-1e3e-4a27-ac14-13f85e9e3a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_78985ad5-8111-4366-aa1a-9c27cccb3ebe" xlink:href="ino-20230331.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_78985ad5-8111-4366-aa1a-9c27cccb3ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_92c5f55c-5026-492e-95a1-f4e039e61a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_92c5f55c-5026-492e-95a1-f4e039e61a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4f348fb6-a983-4dfd-bada-b0f835b7ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_877b055b-73a5-4116-9e82-bca484a882e7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4f348fb6-a983-4dfd-bada-b0f835b7ab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_199b1c78-257e-4dc3-be05-80d7104b58c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_199b1c78-257e-4dc3-be05-80d7104b58c1" xlink:to="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e187a2cf-8d7a-4624-8d04-cc05fc568a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e187a2cf-8d7a-4624-8d04-cc05fc568a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_036ec8f2-d412-446b-9c10-a2d3e9c232b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e187a2cf-8d7a-4624-8d04-cc05fc568a9b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_036ec8f2-d412-446b-9c10-a2d3e9c232b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_efed0176-0a1a-4f49-956c-965e5dc02f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_036ec8f2-d412-446b-9c10-a2d3e9c232b0" xlink:to="loc_us-gaap_ConvertibleDebtMember_efed0176-0a1a-4f49-956c-965e5dc02f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c841bb90-6d8f-468a-9da7-1a6c92d49a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c841bb90-6d8f-468a-9da7-1a6c92d49a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d28e2279-e406-49f6-ace1-0795aee16183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c841bb90-6d8f-468a-9da7-1a6c92d49a84" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d28e2279-e406-49f6-ace1-0795aee16183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_18543be0-9f6c-4f1f-86f7-1466d85101ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d28e2279-e406-49f6-ace1-0795aee16183" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_18543be0-9f6c-4f1f-86f7-1466d85101ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_be0617c1-7f5d-4533-b752-bf45f8db8ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:to="loc_us-gaap_DebtInstrumentAxis_be0617c1-7f5d-4533-b752-bf45f8db8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6a40e0b-5510-4570-be1a-269518cb1632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_be0617c1-7f5d-4533-b752-bf45f8db8ea4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6a40e0b-5510-4570-be1a-269518cb1632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_cfeb5cef-348b-4671-8063-3911fc3b3408" xlink:href="ino-20230331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6a40e0b-5510-4570-be1a-269518cb1632" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_cfeb5cef-348b-4671-8063-3911fc3b3408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e2deed4-dff7-4841-835a-5b162ad250d7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_de056d4b-75d3-4e7a-b75f-26073850c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_de056d4b-75d3-4e7a-b75f-26073850c7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9d1ea22-e36c-47ae-8088-92fbe2a77173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c9d1ea22-e36c-47ae-8088-92fbe2a77173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_5ebe841c-cc21-46b4-b0af-8c4991fc3d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_5ebe841c-cc21-46b4-b0af-8c4991fc3d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4075f621-e9f4-4800-835e-5f6de52144f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4075f621-e9f4-4800-835e-5f6de52144f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4fb9a7f7-b155-40c1-bbe7-8c803378ee64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4fb9a7f7-b155-40c1-bbe7-8c803378ee64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b8d1122e-3ee2-42f6-8b32-f457bcbba2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_b8d1122e-3ee2-42f6-8b32-f457bcbba2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_c4041a5c-6825-4f2e-bcdd-4b245126345d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_c4041a5c-6825-4f2e-bcdd-4b245126345d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_eed49af0-a711-44af-a906-09b5f3afd18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_eed49af0-a711-44af-a906-09b5f3afd18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b55b9b66-0a09-4f01-a68d-6416a41c420c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b55b9b66-0a09-4f01-a68d-6416a41c420c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ffd51164-52c6-4f8b-be4f-8057b53faa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ffd51164-52c6-4f8b-be4f-8057b53faa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_247ecf87-7944-4589-b4ea-6d633e3a63d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_247ecf87-7944-4589-b4ea-6d633e3a63d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_dbe3d94b-19ce-435e-94c2-c455f11d9cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_dbe3d94b-19ce-435e-94c2-c455f11d9cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1388812b-f593-4d17-911e-c8471f2496f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1388812b-f593-4d17-911e-c8471f2496f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_00fca087-1dfd-4e7a-ba8a-01bc47889222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_00fca087-1dfd-4e7a-ba8a-01bc47889222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_567632b2-3378-4d5e-9281-d26c7b12abf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_ConvertibleDebt_567632b2-3378-4d5e-9281-d26c7b12abf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c53a21d0-03dd-4bc0-a5c4-2933764cfcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_InterestExpense_c53a21d0-03dd-4bc0-a5c4-2933764cfcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_03390e0d-d295-4c48-8880-a00dacce3e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fcdc3f92-30a7-4a0a-9ee0-77036bdb01dd" xlink:to="loc_us-gaap_InterestExpenseDebt_03390e0d-d295-4c48-8880-a00dacce3e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_91478f43-79dc-4088-b236-99de0e24d710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_90849603-2765-4554-8303-184d0091958d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_91478f43-79dc-4088-b236-99de0e24d710" xlink:to="loc_us-gaap_DebtInstrumentTable_90849603-2765-4554-8303-184d0091958d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_90849603-2765-4554-8303-184d0091958d" xlink:to="loc_us-gaap_DebtInstrumentAxis_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9b20af9-a26d-47aa-9d57-8bb7942a1528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_da6ed397-f783-4bc1-8a77-5b1bd4d5f4ee" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9b20af9-a26d-47aa-9d57-8bb7942a1528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eec47daf-0d5d-4ec1-86e8-22151bdb365f" xlink:href="ino-20230331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9b20af9-a26d-47aa-9d57-8bb7942a1528" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eec47daf-0d5d-4ec1-86e8-22151bdb365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_90849603-2765-4554-8303-184d0091958d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4de67ba8-b65c-4dfb-8cac-dd9919a5263c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4de67ba8-b65c-4dfb-8cac-dd9919a5263c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_6079eb6c-5b27-4792-8e52-84cea6d8375a" xlink:href="ino-20230331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_6079eb6c-5b27-4792-8e52-84cea6d8375a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_378dee7f-5ae9-4962-8857-2e10ca595be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_378dee7f-5ae9-4962-8857-2e10ca595be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_193ed01f-f48c-4fdf-a800-c53227586c28" xlink:href="ino-20230331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_ino_DebtInstrumentAccruedInterest_193ed01f-f48c-4fdf-a800-c53227586c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5eaeb8fe-4319-4293-a40b-d70cb50a4096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bafdd60e-abb3-4a4d-a7d0-ee99ba6c5cf8" xlink:to="loc_us-gaap_LongTermDebt_5eaeb8fe-4319-4293-a40b-d70cb50a4096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_291376f4-c717-44a3-84c6-b9608304b959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_291376f4-c717-44a3-84c6-b9608304b959" xlink:to="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fb45e571-2a37-4e7f-a181-01b44a5c01f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fb45e571-2a37-4e7f-a181-01b44a5c01f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a32ee0a9-1e2a-4c2a-8f24-66f4c2cc58a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fb45e571-2a37-4e7f-a181-01b44a5c01f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a32ee0a9-1e2a-4c2a-8f24-66f4c2cc58a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_fdcbb8fb-7a99-4ce2-a834-ba2645b4e10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a32ee0a9-1e2a-4c2a-8f24-66f4c2cc58a5" xlink:to="loc_us-gaap_ConvertibleDebtMember_fdcbb8fb-7a99-4ce2-a834-ba2645b4e10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1006736f-ccca-4892-ba11-fab502463414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:to="loc_us-gaap_DebtInstrumentAxis_1006736f-ccca-4892-ba11-fab502463414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_21e49fd6-7274-47fd-8da5-4a2008ee9059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1006736f-ccca-4892-ba11-fab502463414" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_21e49fd6-7274-47fd-8da5-4a2008ee9059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_96bc0fa0-617e-4aa4-a856-3d5adf780ce8" xlink:href="ino-20230331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_21e49fd6-7274-47fd-8da5-4a2008ee9059" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_96bc0fa0-617e-4aa4-a856-3d5adf780ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_33f53f61-2917-4d7f-a1dc-559d69d40b5b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_532935f0-f869-409e-9096-d452c4d86663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_532935f0-f869-409e-9096-d452c4d86663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_65020958-dd78-4dfb-870c-3c06b03f8db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_65020958-dd78-4dfb-870c-3c06b03f8db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ad3197e5-d44c-46c6-92c5-54097a51369d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ad3197e5-d44c-46c6-92c5-54097a51369d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d9141a10-7c91-4201-ae3c-6e448fc572d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c85364c6-3401-4a9b-9853-603330f8154f" xlink:to="loc_us-gaap_LongTermDebt_d9141a10-7c91-4201-ae3c-6e448fc572d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_99fa75a7-8bea-4c37-8885-d32e5ad03f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_720c2753-230a-40f8-aa3c-c3a481d5b164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_99fa75a7-8bea-4c37-8885-d32e5ad03f95" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_720c2753-230a-40f8-aa3c-c3a481d5b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc0dfe90-de92-44c5-83e5-e57db7edb64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_720c2753-230a-40f8-aa3c-c3a481d5b164" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc0dfe90-de92-44c5-83e5-e57db7edb64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_61de8ec7-4d4a-46d2-9179-16f3ded83fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc0dfe90-de92-44c5-83e5-e57db7edb64c" xlink:to="loc_us-gaap_ClassOfStockDomain_61de8ec7-4d4a-46d2-9179-16f3ded83fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_2fb6eaa1-1038-4b82-87b2-40ab6f2fbebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_61de8ec7-4d4a-46d2-9179-16f3ded83fba" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_2fb6eaa1-1038-4b82-87b2-40ab6f2fbebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_758bcb92-e8aa-4a1f-a1ed-2872cad0e3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_720c2753-230a-40f8-aa3c-c3a481d5b164" xlink:to="loc_us-gaap_ClassOfStockLineItems_758bcb92-e8aa-4a1f-a1ed-2872cad0e3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_758bcb92-e8aa-4a1f-a1ed-2872cad0e3b2" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ce6191c-3a34-4ea4-bee7-2168d0d9b4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ce6191c-3a34-4ea4-bee7-2168d0d9b4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_58bf7d7b-557f-4d3b-9fdf-7f7ad05e3eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_58bf7d7b-557f-4d3b-9fdf-7f7ad05e3eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_118ad1ce-75c0-4520-9e0e-9020e3426a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockSharesIssued_118ad1ce-75c0-4520-9e0e-9020e3426a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f556f914-9fb6-4b66-abbf-ffd85fa924a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f556f914-9fb6-4b66-abbf-ffd85fa924a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d1531726-fdaa-4070-aa5a-16c1a772e5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d1531726-fdaa-4070-aa5a-16c1a772e5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ee7ddff9-0f1c-48c8-98f4-d93c68a09808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ee7ddff9-0f1c-48c8-98f4-d93c68a09808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b0efe88a-7fd6-458a-ad89-59a122c81113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b0efe88a-7fd6-458a-ad89-59a122c81113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_94eb475a-fb73-4322-9485-66d1784befdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_519cc318-772f-460b-bd8e-3f83bb86059b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_94eb475a-fb73-4322-9485-66d1784befdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a2e13d8c-36d3-4d46-abec-20d514b9e4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a2e13d8c-36d3-4d46-abec-20d514b9e4cc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e4d68453-5acf-4c92-a61f-62888f2e435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e4d68453-5acf-4c92-a61f-62888f2e435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_382404be-e0c9-48c2-84d3-53cd92c511d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e4d68453-5acf-4c92-a61f-62888f2e435e" xlink:to="loc_us-gaap_ClassOfStockDomain_382404be-e0c9-48c2-84d3-53cd92c511d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b88a77c3-a945-431a-a358-ac32ca84c615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_382404be-e0c9-48c2-84d3-53cd92c511d5" xlink:to="loc_us-gaap_CommonStockMember_b88a77c3-a945-431a-a358-ac32ca84c615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_537b86b7-41ea-4dc6-a563-5571d1d91fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_537b86b7-41ea-4dc6-a563-5571d1d91fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9362d0ae-1bd1-4436-808c-8a35a9223209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_537b86b7-41ea-4dc6-a563-5571d1d91fa7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9362d0ae-1bd1-4436-808c-8a35a9223209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_326869cd-a2e0-4a64-857a-29662a92b63d" xlink:href="ino-20230331.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9362d0ae-1bd1-4436-808c-8a35a9223209" xlink:to="loc_ino_SalesAgreementMember_326869cd-a2e0-4a64-857a-29662a92b63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c1f7b2d8-ea71-4979-893b-4759dfd64595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_PlanNameAxis_c1f7b2d8-ea71-4979-893b-4759dfd64595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c1f7b2d8-ea71-4979-893b-4759dfd64595" xlink:to="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_cf23dda7-e76e-4152-b46a-01759541106b" xlink:href="ino-20230331.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:to="loc_ino_A2016IncentivePlanMember_cf23dda7-e76e-4152-b46a-01759541106b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_c6bb86e5-3fb3-465b-a06f-bc07d16613b5" xlink:href="ino-20230331.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:to="loc_ino_A2007IncentivePlanMember_c6bb86e5-3fb3-465b-a06f-bc07d16613b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_b5aa9aa6-e694-4f22-80f4-3a62866454f4" xlink:href="ino-20230331.xsd#ino_A2022InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_af72a0a8-66e1-48ac-bd6e-ef5d7ca9f1b6" xlink:to="loc_ino_A2022InducementPlanMember_b5aa9aa6-e694-4f22-80f4-3a62866454f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fdd85379-56be-4b55-957e-79ad4f6ea823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fdd85379-56be-4b55-957e-79ad4f6ea823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2c92ebf7-9df6-448f-aa13-9e9c608391a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fdd85379-56be-4b55-957e-79ad4f6ea823" xlink:to="loc_us-gaap_EquityComponentDomain_2c92ebf7-9df6-448f-aa13-9e9c608391a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a32b7c62-67b0-4b35-bf7f-dc5047d86ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2c92ebf7-9df6-448f-aa13-9e9c608391a9" xlink:to="loc_us-gaap_CommonStockMember_a32b7c62-67b0-4b35-bf7f-dc5047d86ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9b555078-2e67-4571-83c9-878f8f1bb279" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_srt_LitigationCaseAxis_9b555078-2e67-4571-83c9-878f8f1bb279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_04864f43-b9c3-4e4c-b146-1fa1428c3410" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9b555078-2e67-4571-83c9-878f8f1bb279" xlink:to="loc_srt_LitigationCaseTypeDomain_04864f43-b9c3-4e4c-b146-1fa1428c3410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_3bb8d0f5-e3f0-40a7-9196-dd3e2acd0417" xlink:href="ino-20230331.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_04864f43-b9c3-4e4c-b146-1fa1428c3410" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_3bb8d0f5-e3f0-40a7-9196-dd3e2acd0417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4d764fff-5735-482b-81bd-5b6c7ba40f27" xlink:to="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20c910f7-c52e-4576-8a01-adf28e7905bc" xlink:href="ino-20230331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_20c910f7-c52e-4576-8a01-adf28e7905bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_74e8e796-83c1-4711-9a92-ff0c39026978" xlink:href="ino-20230331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_74e8e796-83c1-4711-9a92-ff0c39026978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_e7ae1cb7-088e-4c76-9e81-acdbbb6bc7d9" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_e7ae1cb7-088e-4c76-9e81-acdbbb6bc7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_3fbd66d7-d509-453f-9d26-6c3799942fad" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_3fbd66d7-d509-453f-9d26-6c3799942fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_50e94ad8-718d-4765-8b06-a1f87bc09e1d" xlink:href="ino-20230331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_50e94ad8-718d-4765-8b06-a1f87bc09e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_304426ae-d94c-4e86-8bef-6d609e4fc106" xlink:href="ino-20230331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_304426ae-d94c-4e86-8bef-6d609e4fc106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e17b3654-edb2-4fb9-914f-dee266b9d660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_CommonStockSharesIssued_e17b3654-edb2-4fb9-914f-dee266b9d660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ae062ce4-bc0e-4334-aec9-5ca9ed630bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ae062ce4-bc0e-4334-aec9-5ca9ed630bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_26b690eb-3361-454e-a811-3524f51922c9" xlink:href="ino-20230331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_26b690eb-3361-454e-a811-3524f51922c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5bc3002e-7129-4670-8d2f-956e2e3c3326" xlink:href="ino-20230331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5bc3002e-7129-4670-8d2f-956e2e3c3326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15607819-3560-4850-8016-e731d6285f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_15607819-3560-4850-8016-e731d6285f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa3f0804-9fac-4e24-a0e0-b1085f10c3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa3f0804-9fac-4e24-a0e0-b1085f10c3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_666e56b0-1fe4-4293-b405-7ff9e90cec99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_666e56b0-1fe4-4293-b405-7ff9e90cec99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23b171f2-9e9e-40c2-9790-e857f240f6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23b171f2-9e9e-40c2-9790-e857f240f6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ec2578a1-7df8-4754-ac58-60af98477bc5" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cc18c6b0-3f42-4d56-a11d-17edef1d73e6" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ec2578a1-7df8-4754-ac58-60af98477bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_77dd3e15-81ee-41b5-8362-c8316da1a2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17a2873c-b91b-45aa-ae40-c83e756f34f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_77dd3e15-81ee-41b5-8362-c8316da1a2c2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17a2873c-b91b-45aa-ae40-c83e756f34f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17a2873c-b91b-45aa-ae40-c83e756f34f3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c2c446f8-9e98-4aed-b04b-f70b5b2aebe3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b8fb3ff8-1528-4c5a-93c9-b401889f845d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b8fb3ff8-1528-4c5a-93c9-b401889f845d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_59e378df-0130-4008-b894-1c88a9bd494f" xlink:href="ino-20230331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_59e378df-0130-4008-b894-1c88a9bd494f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cc45ce3f-be3e-41e0-87f7-e0cf7cea5cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cc45ce3f-be3e-41e0-87f7-e0cf7cea5cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5884dc18-b38c-43be-8fa8-22b694e62d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5884dc18-b38c-43be-8fa8-22b694e62d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_d1f3683c-1ed9-4af1-a2db-feb85d18bde0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8a956ca-9fd3-4549-abc7-935a4c610887" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_d1f3683c-1ed9-4af1-a2db-feb85d18bde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aea9d67b-98fc-4510-a3d4-dfd9dd19f245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_17a2873c-b91b-45aa-ae40-c83e756f34f3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aea9d67b-98fc-4510-a3d4-dfd9dd19f245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c661859-899e-4f35-a057-5f0b1fec3b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_aea9d67b-98fc-4510-a3d4-dfd9dd19f245" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7c661859-899e-4f35-a057-5f0b1fec3b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0667c8b7-cf74-436a-815f-ea1cf7be1fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0667c8b7-cf74-436a-815f-ea1cf7be1fc2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:to="loc_us-gaap_AwardTypeAxis_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0592fb7-5ae3-4b86-9f92-56a4b9f775fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_529a7ab6-a0d2-4de8-9001-8d0738f9f8d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0592fb7-5ae3-4b86-9f92-56a4b9f775fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bc9d4ce3-7dbf-4b86-a050-b9d58d1e5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d0592fb7-5ae3-4b86-9f92-56a4b9f775fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bc9d4ce3-7dbf-4b86-a050-b9d58d1e5ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_afe85a9e-4510-496d-bab2-d6bc32eda283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:to="loc_srt_TitleOfIndividualAxis_afe85a9e-4510-496d-bab2-d6bc32eda283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_95267ed6-a956-477d-977b-f5419c073c50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_afe85a9e-4510-496d-bab2-d6bc32eda283" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_95267ed6-a956-477d-977b-f5419c073c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_f4b93b79-bb67-4b10-b051-ae3d0d83b2cd" xlink:href="ino-20230331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_95267ed6-a956-477d-977b-f5419c073c50" xlink:to="loc_ino_EmployeesAndDirectorsMember_f4b93b79-bb67-4b10-b051-ae3d0d83b2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aac0a8b7-124b-473e-a87b-7e14178be61c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d618ac8c-a531-42a2-b4ba-eff9147b11b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d618ac8c-a531-42a2-b4ba-eff9147b11b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01698977-a327-4e9a-bb20-73109933936a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01698977-a327-4e9a-bb20-73109933936a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aabeecab-4cf1-4504-8311-5f7b2ee0c8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aabeecab-4cf1-4504-8311-5f7b2ee0c8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b92c52bd-bf07-45ed-b99d-018445f59d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c3850f4-e33b-423d-9a1e-82e25e0eb130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b92c52bd-bf07-45ed-b99d-018445f59d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca862cf4-2caf-44ea-a8c7-68360be36411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca862cf4-2caf-44ea-a8c7-68360be36411" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f749cb1-3566-461a-bf49-5aa30fa99acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_us-gaap_AwardTypeAxis_9f749cb1-3566-461a-bf49-5aa30fa99acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9f749cb1-3566-461a-bf49-5aa30fa99acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6017f209-38b3-4b93-87b7-8750622937d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6017f209-38b3-4b93-87b7-8750622937d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b17d6d0c-6fe3-4380-8c6a-11a54e055404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f82cf683-da1e-4fa4-901d-cc91cd8f9656" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b17d6d0c-6fe3-4380-8c6a-11a54e055404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9b54193d-9928-4172-8028-f0a69312e85d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_srt_TitleOfIndividualAxis_9b54193d-9928-4172-8028-f0a69312e85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_9b54193d-9928-4172-8028-f0a69312e85d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_94516dff-6fda-4f08-898a-30d280d764c2" xlink:href="ino-20230331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:to="loc_ino_EmployeesAndDirectorsMember_94516dff-6fda-4f08-898a-30d280d764c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_cb51e6e9-9cb0-4a72-8698-0f9c14563cb2" xlink:href="ino-20230331.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3d927b8a-8eea-4966-9555-0abe9fbd6180" xlink:to="loc_ino_NonEmployeeMember_cb51e6e9-9cb0-4a72-8698-0f9c14563cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cabc4f60-10d1-4c22-a575-4fac5898f882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cabc4f60-10d1-4c22-a575-4fac5898f882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cabc4f60-10d1-4c22-a575-4fac5898f882" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b4ba2e21-e004-4a0c-9a94-6eb1737659da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b4ba2e21-e004-4a0c-9a94-6eb1737659da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_18497a7c-ff5d-4982-8bb4-507fe1ab643f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28235c2e-a7d4-419b-9333-f59a1ce190ec" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_18497a7c-ff5d-4982-8bb4-507fe1ab643f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4e8e454f-a820-49b9-b009-9e1a840ad1fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_srt_CounterpartyNameAxis_4e8e454f-a820-49b9-b009-9e1a840ad1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efbe1e1a-fc4a-41d9-a15a-d798aeef64b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4e8e454f-a820-49b9-b009-9e1a840ad1fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efbe1e1a-fc4a-41d9-a15a-d798aeef64b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_JJosephKimMember_1567ca11-ae72-403a-a77d-10adcbff019a" xlink:href="ino-20230331.xsd#ino_JJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_efbe1e1a-fc4a-41d9-a15a-d798aeef64b9" xlink:to="loc_ino_JJosephKimMember_1567ca11-ae72-403a-a77d-10adcbff019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91b8ef6d-679d-46f1-822e-3a8fcb494f53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5ffc1960-a4e6-4de3-af99-4957418bdfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_ShareBasedCompensation_5ffc1960-a4e6-4de3-af99-4957418bdfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ba659a6f-227f-4ce3-ac51-6b8631b903d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ba659a6f-227f-4ce3-ac51-6b8631b903d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0e4cd73-fbcd-4f30-a362-a080983262fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b0e4cd73-fbcd-4f30-a362-a080983262fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a71d83e0-28c4-4fa1-8815-d77f849a7206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a71d83e0-28c4-4fa1-8815-d77f849a7206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d08b000-f6f6-49b5-b86b-5f703e68d3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9d08b000-f6f6-49b5-b86b-5f703e68d3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f40537ab-65f8-446f-9d74-9a48cbb996ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f40537ab-65f8-446f-9d74-9a48cbb996ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares_3c5d8585-49fe-45c7-9c06-075e03873509" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares_3c5d8585-49fe-45c7-9c06-075e03873509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash_e434207d-f534-450f-9719-7f963678066d" xlink:href="ino-20230331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f09a5e01-1b98-4296-a99c-ec0e8600d527" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash_e434207d-f534-450f-9719-7f963678066d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_a0d0d299-d358-470d-a4ed-fec2de3aab82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_a0d0d299-d358-470d-a4ed-fec2de3aab82" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_981f5c06-7299-4196-9399-a4bb7e757751" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_srt_CounterpartyNameAxis_981f5c06-7299-4196-9399-a4bb7e757751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94f3c28b-a016-4ee3-bd17-9046b3284921" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_981f5c06-7299-4196-9399-a4bb7e757751" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94f3c28b-a016-4ee3-bd17-9046b3284921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_fa4c59bf-385d-4645-b52c-55903f1f87d1" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94f3c28b-a016-4ee3-bd17-9046b3284921" xlink:to="loc_ino_PlumblineLifeSciencesMember_fa4c59bf-385d-4645-b52c-55903f1f87d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f514138-b32a-4e24-a75a-b25e5567a300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f514138-b32a-4e24-a75a-b25e5567a300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f514138-b32a-4e24-a75a-b25e5567a300" xlink:to="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3dce4884-2404-459c-9261-d26629b43940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:to="loc_srt_DirectorMember_3dce4884-2404-459c-9261-d26629b43940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_35fa95ea-358f-497a-8159-864fa46e4a7a" xlink:href="ino-20230331.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_606db34b-659d-4c7c-8606-90bd4958dfad" xlink:to="loc_ino_TheWistarInstituteMember_35fa95ea-358f-497a-8159-864fa46e4a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d38c52f5-8940-40ee-b284-f8bc6182ede4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_srt_ProductOrServiceAxis_d38c52f5-8940-40ee-b284-f8bc6182ede4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_51367e8b-66a6-4619-bfe8-6d4d19737fe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d38c52f5-8940-40ee-b284-f8bc6182ede4" xlink:to="loc_srt_ProductsAndServicesDomain_51367e8b-66a6-4619-bfe8-6d4d19737fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicenseWithAffiliatedEntitiesMember_4b69b481-bfb6-4e25-ad2f-75e0694dd06c" xlink:href="ino-20230331.xsd#ino_LicenseWithAffiliatedEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51367e8b-66a6-4619-bfe8-6d4d19737fe3" xlink:to="loc_ino_LicenseWithAffiliatedEntitiesMember_4b69b481-bfb6-4e25-ad2f-75e0694dd06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_fc8c28ae-80ed-4b09-8d70-69b827668679" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_srt_OwnershipAxis_fc8c28ae-80ed-4b09-8d70-69b827668679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_95848ce1-9dff-4b35-84d0-a38f7248b703" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_fc8c28ae-80ed-4b09-8d70-69b827668679" xlink:to="loc_srt_OwnershipDomain_95848ce1-9dff-4b35-84d0-a38f7248b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_dbdc9300-66ba-4aec-b487-0ac7fbaf0c99" xlink:href="ino-20230331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_95848ce1-9dff-4b35-84d0-a38f7248b703" xlink:to="loc_ino_PlumblineLifeSciencesMember_dbdc9300-66ba-4aec-b487-0ac7fbaf0c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9d1cc4c0-c9ef-4bcb-8378-7d045e35f2c4" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_c5127c80-673b-43e0-8462-1497752d4c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_c5127c80-673b-43e0-8462-1497752d4c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ea2bbdab-e930-41ae-ba0c-434a6b69eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ea2bbdab-e930-41ae-ba0c-434a6b69eabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f86dfef-6195-4568-bc6a-3bd738a1ec0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f86dfef-6195-4568-bc6a-3bd738a1ec0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_8205f916-d571-403c-82ea-132a464d1ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_8205f916-d571-403c-82ea-132a464d1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_b9feba49-e994-4269-8922-bd6399427fc5" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_b9feba49-e994-4269-8922-bd6399427fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_d4c0b95a-8056-4c4c-a538-d1ac81428ca8" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeArrangementTerm_d4c0b95a-8056-4c4c-a538-d1ac81428ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_b36c837b-431c-44b3-b13a-ba37c44c9967" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_b36c837b-431c-44b3-b13a-ba37c44c9967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_d852a211-8bd0-4bfb-b6fe-e089bfb1e28c" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_d852a211-8bd0-4bfb-b6fe-e089bfb1e28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_59d413f6-28a2-40b8-929d-31d426878a76" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_59d413f6-28a2-40b8-929d-31d426878a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_5b6dc879-4770-4bb9-bfe9-4fdde0594879" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_5b6dc879-4770-4bb9-bfe9-4fdde0594879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_515dac6c-3a79-4529-a039-6217fc997478" xlink:href="ino-20230331.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_GrantProceedsReceived_515dac6c-3a79-4529-a039-6217fc997478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_563473b3-fcae-4a69-a2d4-694848811973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_563473b3-fcae-4a69-a2d4-694848811973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e0aea99b-1c06-4499-9b66-8083a3aec084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e0aea99b-1c06-4499-9b66-8083a3aec084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_e20cc824-03f1-4f52-b844-df9685cd74f0" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_e20cc824-03f1-4f52-b844-df9685cd74f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_2bdbe012-0d74-4e57-a8c4-3ca1c359e3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_73fe517e-360e-486e-a0ea-c1fc70be81f3" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_2bdbe012-0d74-4e57-a8c4-3ca1c359e3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24b6fc67-de5a-4120-9edd-9b4750e65105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_24b6fc67-de5a-4120-9edd-9b4750e65105" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_2d8563ba-dc6c-46a5-a7be-f19ac1bee1ef" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_513fe2d7-268b-46ac-aef0-5a313880f290" xlink:href="ino-20230331.xsd#ino_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:to="loc_ino_SanDiegoOfficeMember_513fe2d7-268b-46ac-aef0-5a313880f290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_23f2cbf0-7f39-43ae-ac04-ef1ff5219fb1" xlink:href="ino-20230331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_67a3b043-6291-4d68-812f-d6ad00f57507" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_23f2cbf0-7f39-43ae-ac04-ef1ff5219fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_563c51b4-dad8-4879-9a0d-c49b2004f834" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:to="loc_srt_RangeAxis_563c51b4-dad8-4879-9a0d-c49b2004f834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_563c51b4-dad8-4879-9a0d-c49b2004f834" xlink:to="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7500503c-3f7b-4e60-ac3f-96a008a06d55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:to="loc_srt_MinimumMember_7500503c-3f7b-4e60-ac3f-96a008a06d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18927523-015a-4e42-862d-8e1b0c84a98e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba57bdd1-fabc-406b-921a-a1063cca2fc4" xlink:to="loc_srt_MaximumMember_18927523-015a-4e42-862d-8e1b0c84a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a70c74ae-f3ee-4ad2-95be-d447af62595d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:to="loc_srt_LitigationCaseAxis_a70c74ae-f3ee-4ad2-95be-d447af62595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e22955ae-f59d-40bc-b7a9-c8be5d11aeaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a70c74ae-f3ee-4ad2-95be-d447af62595d" xlink:to="loc_srt_LitigationCaseTypeDomain_e22955ae-f59d-40bc-b7a9-c8be5d11aeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_b16e82b3-6555-43a6-a361-f399d5449a34" xlink:href="ino-20230331.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e22955ae-f59d-40bc-b7a9-c8be5d11aeaf" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_b16e82b3-6555-43a6-a361-f399d5449a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fade8310-62ca-4a67-aaa0-dad5046cf7aa" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_a2c23918-18e3-402f-812a-a5f2e267c20b" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_a2c23918-18e3-402f-812a-a5f2e267c20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a8d05ca0-a6f1-4587-aff0-6e564a987d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_a8d05ca0-a6f1-4587-aff0-6e564a987d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_96c03b20-73bd-40be-b76b-f49a4374153f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_LeaseCost_96c03b20-73bd-40be-b76b-f49a4374153f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_976ba3ff-6886-4c5d-9b65-d84990b3df29" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_976ba3ff-6886-4c5d-9b65-d84990b3df29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4a51d441-5298-406b-9f09-9868a79e2440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_4a51d441-5298-406b-9f09-9868a79e2440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_4bb39773-8743-47ec-93b9-e7e0263f1bfa" xlink:href="ino-20230331.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_4bb39773-8743-47ec-93b9-e7e0263f1bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0cd21a21-6b6f-4e6a-b439-b49ea1fc47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fba499f5-121d-4c0f-8d25-8decebd71aef" xlink:to="loc_us-gaap_CommonStockSharesIssued_0cd21a21-6b6f-4e6a-b439-b49ea1fc47e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1466bc9e-ef67-4b0f-a285-7e7434e14233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1466bc9e-ef67-4b0f-a285-7e7434e14233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b5da84aa-9c9b-4c46-a381-82b8223872b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b5da84aa-9c9b-4c46-a381-82b8223872b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb024332-4698-46c1-aef0-14423db9fca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fb024332-4698-46c1-aef0-14423db9fca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_86c35525-59a0-4a3e-80de-eb88b70e580f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_86c35525-59a0-4a3e-80de-eb88b70e580f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3afe47e4-93dc-4f08-bb5f-8c5493dd645f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3afe47e4-93dc-4f08-bb5f-8c5493dd645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_cd95e615-19b4-4905-8126-008938693b06" xlink:href="ino-20230331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_cd95e615-19b4-4905-8126-008938693b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_254e4b4c-e627-4aeb-acdf-308cddb27c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_254e4b4c-e627-4aeb-acdf-308cddb27c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a63e9e00-edf9-4151-b1fa-3e9fe1415c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a63e9e00-edf9-4151-b1fa-3e9fe1415c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e7a75794-d784-4e67-b3b2-a7f6a250d414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_OperatingLeaseLiability_e7a75794-d784-4e67-b3b2-a7f6a250d414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f26ce817-1eb4-498f-b530-41ef8168a367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f26ce817-1eb4-498f-b530-41ef8168a367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_de2bbc67-1ed2-48f7-93f8-cb612325f7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_de2bbc67-1ed2-48f7-93f8-cb612325f7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_810f348f-6150-4fdc-b5ad-f716c7fdf28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_810f348f-6150-4fdc-b5ad-f716c7fdf28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5e6eca98-622d-4cb0-9f47-095b9175286f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_112f73d1-62a2-411c-8e71-f84ead71064c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5e6eca98-622d-4cb0-9f47-095b9175286f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9090a901-df84-4068-856d-7c34da5181f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9090a901-df84-4068-856d-7c34da5181f4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_srt_CounterpartyNameAxis_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e415ea26-5be9-4aef-9aa8-7bd4f5cf602a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_0d9c1d2a-39e6-4244-a97d-82ce38e07678" xlink:href="ino-20230331.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_AdvaccineMember_0d9c1d2a-39e6-4244-a97d-82ce38e07678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_64f06c01-b957-4c39-affd-9f7022857f69" xlink:href="ino-20230331.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_ApolloBioMember_64f06c01-b957-4c39-affd-9f7022857f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c8b22df9-d791-4dfa-81ca-7da2ae4a4dfb" xlink:href="ino-20230331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c8b22df9-d791-4dfa-81ca-7da2ae4a4dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_a182a5a6-e442-410e-bb3a-8b6ff91387b2" xlink:href="ino-20230331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_a182a5a6-e442-410e-bb3a-8b6ff91387b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_47e75681-37fd-4971-b6be-8eed530fecc1" xlink:href="ino-20230331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1677824a-5fb0-4739-90e8-50ce4b303104" xlink:to="loc_ino_DepartmentOfDefenceMember_47e75681-37fd-4971-b6be-8eed530fecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_805c7899-3a9f-4c94-b1a6-659388fc1a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fb7aa7bd-faf0-44e1-88f7-a782f995b6fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_805c7899-3a9f-4c94-b1a6-659388fc1a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_daad6f2c-9640-48ec-a548-0f7104d6bb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_805c7899-3a9f-4c94-b1a6-659388fc1a43" xlink:to="loc_us-gaap_CollaborativeArrangementMember_daad6f2c-9640-48ec-a548-0f7104d6bb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_15757b94-ad6e-47df-a61c-bb06e2b5fc19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_srt_MajorCustomersAxis_15757b94-ad6e-47df-a61c-bb06e2b5fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_67f397bc-f7a9-43f8-b4ff-fbef9b5ba9ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_15757b94-ad6e-47df-a61c-bb06e2b5fc19" xlink:to="loc_srt_NameOfMajorCustomerDomain_67f397bc-f7a9-43f8-b4ff-fbef9b5ba9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_2488e02a-7465-484a-a5a7-b4a70a2caf78" xlink:href="ino-20230331.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_67f397bc-f7a9-43f8-b4ff-fbef9b5ba9ac" xlink:to="loc_ino_AdvaccineMember_2488e02a-7465-484a-a5a7-b4a70a2caf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b16166dc-534e-4c47-918e-57f5a37ef0a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_srt_ProductOrServiceAxis_b16166dc-534e-4c47-918e-57f5a37ef0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b16166dc-534e-4c47-918e-57f5a37ef0a7" xlink:to="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_631b498a-eef5-43dc-80c9-1aa26dd3939d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_us-gaap_LicenseMember_631b498a-eef5-43dc-80c9-1aa26dd3939d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_aeb36b9c-68f7-4e92-b103-088bdf401240" xlink:href="ino-20230331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_aeb36b9c-68f7-4e92-b103-088bdf401240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_bef34df7-bfd8-4cf3-88fa-4c66a7a9eb83" xlink:href="ino-20230331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_bef34df7-bfd8-4cf3-88fa-4c66a7a9eb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_4bc548ba-c5b8-4587-a0f2-5cfa478e7600" xlink:href="ino-20230331.xsd#ino_INO4800Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_INO4800Member_4bc548ba-c5b8-4587-a0f2-5cfa478e7600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_7814ee52-36d2-4aa6-90b0-00f1b238acab" xlink:href="ino-20230331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_7814ee52-36d2-4aa6-90b0-00f1b238acab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_91d2e851-1d8c-4a55-a069-7f1926cc5219" xlink:href="ino-20230331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f35ec5ca-42ef-4239-a00f-9c878072c685" xlink:to="loc_ino_CELLECTRA2000DeviceMember_91d2e851-1d8c-4a55-a069-7f1926cc5219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_70ee41d9-ddf4-4a4f-9707-00056ebce5e2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87821733-6ce7-4b31-bd59-fa24c8b91750" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87821733-6ce7-4b31-bd59-fa24c8b91750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_eaffd8ba-89ce-4841-afa4-a765b7ba4e98" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_eaffd8ba-89ce-4841-afa4-a765b7ba4e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_2cc5aa3e-013c-4346-834f-200a10e38748" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_2cc5aa3e-013c-4346-834f-200a10e38748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_ae6ba9fd-0df2-486a-99b7-5033bab3aa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_us-gaap_CostMaintenance_ae6ba9fd-0df2-486a-99b7-5033bab3aa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_6c89ad4e-157e-4a93-bde3-7f720aa834a6" xlink:href="ino-20230331.xsd#ino_AnnualMaintenancePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_AnnualMaintenancePeriod_6c89ad4e-157e-4a93-bde3-7f720aa834a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_83a3f24a-c327-40eb-9fea-45a18c2393fb" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_83a3f24a-c327-40eb-9fea-45a18c2393fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_6374a2a2-4614-4197-a006-3a202ceedaee" xlink:href="ino-20230331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_6374a2a2-4614-4197-a006-3a202ceedaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8aeadb82-938e-4978-9bbf-4e8b64bec7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8aeadb82-938e-4978-9bbf-4e8b64bec7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_439b0de7-9d8a-41ba-8c65-5fa35d691c05" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_439b0de7-9d8a-41ba-8c65-5fa35d691c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_3d5c9d10-1051-40cc-ad4a-69d97bb5db7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_us-gaap_GrantsReceivable_3d5c9d10-1051-40cc-ad4a-69d97bb5db7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_94cc76f5-be03-44ae-900a-6ab49d1092c4" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_94cc76f5-be03-44ae-900a-6ab49d1092c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_920052ce-1733-40ef-8568-c67be899611b" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_920052ce-1733-40ef-8568-c67be899611b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_633513d5-18e6-4c2f-9249-93a501029328" xlink:href="ino-20230331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_633513d5-18e6-4c2f-9249-93a501029328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_09d9b5c8-0a70-4151-bfcf-5aab7f51d554" xlink:href="ino-20230331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_DeferredGrantFundingCurrent_09d9b5c8-0a70-4151-bfcf-5aab7f51d554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_7d9039b0-c1d2-40ea-b286-73af59e79377" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_7d9039b0-c1d2-40ea-b286-73af59e79377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_9e8b671c-3447-4f2a-b64a-1b973b55a5af" xlink:href="ino-20230331.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_GrantProceedsReceived_9e8b671c-3447-4f2a-b64a-1b973b55a5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_b9c998af-ea0f-4d16-bf43-2d94b754a322" xlink:href="ino-20230331.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d7e7092f-5855-4cf6-8729-1cc7d7db7d1b" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_b9c998af-ea0f-4d16-bf43-2d94b754a322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_e101b4e9-ea66-4f07-b67d-24a2651d8f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_e101b4e9-ea66-4f07-b67d-24a2651d8f0a" xlink:to="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e67bcbfb-b026-474c-8815-62205905a19c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_srt_CounterpartyNameAxis_e67bcbfb-b026-474c-8815-62205905a19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c320b79-4ad3-4a7a-b63f-0516573c35bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e67bcbfb-b026-474c-8815-62205905a19c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c320b79-4ad3-4a7a-b63f-0516573c35bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_e2e853d0-98f3-4c28-8f1a-33ea9ed7565b" xlink:href="ino-20230331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9c320b79-4ad3-4a7a-b63f-0516573c35bb" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_e2e853d0-98f3-4c28-8f1a-33ea9ed7565b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_820abbd6-28ae-45f4-a792-eefc08848ec9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_srt_OwnershipAxis_820abbd6-28ae-45f4-a792-eefc08848ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fed0ecc8-bb0b-412b-9d39-04129cc2f83c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_820abbd6-28ae-45f4-a792-eefc08848ec9" xlink:to="loc_srt_OwnershipDomain_fed0ecc8-bb0b-412b-9d39-04129cc2f83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_fc44286e-b67f-4afe-9e02-72f0254ff799" xlink:href="ino-20230331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_fed0ecc8-bb0b-412b-9d39-04129cc2f83c" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_fc44286e-b67f-4afe-9e02-72f0254ff799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6292e8c5-afc4-4e35-a9f1-81aa185e09ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6292e8c5-afc4-4e35-a9f1-81aa185e09ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6292e8c5-afc4-4e35-a9f1-81aa185e09ad" xlink:to="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_29e6dc08-8ad0-47e3-942b-f85fd3548519" xlink:href="ino-20230331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_ino_SeriesAOnePreferredStockMember_29e6dc08-8ad0-47e3-942b-f85fd3548519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2a8f953b-8ed6-47d9-abc7-13dbb7cec7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_us-gaap_CommonStockMember_2a8f953b-8ed6-47d9-abc7-13dbb7cec7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c4eb3a57-7818-4a69-bc32-bf25cef1d1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_us-gaap_PreferredStockMember_c4eb3a57-7818-4a69-bc32-bf25cef1d1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_7abb058a-b6da-4873-8e6e-b3a10161f881" xlink:href="ino-20230331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f8dd5af3-6dfa-4715-acc1-98bf023a6ce0" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_7abb058a-b6da-4873-8e6e-b3a10161f881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fbea4fa2-7cb9-424e-9a33-06f8a1628d4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8e9e31a4-075a-4ae2-9f6c-45aba8c7377f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fbea4fa2-7cb9-424e-9a33-06f8a1628d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_825ea443-9b14-4017-b65f-bcbf2322b1a8" xlink:href="ino-20230331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fbea4fa2-7cb9-424e-9a33-06f8a1628d4e" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_825ea443-9b14-4017-b65f-bcbf2322b1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b2375924-2bad-40e8-aeb0-51df640dcdc8" xlink:to="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_18eb4002-6f0c-42d4-abfd-ba26fd390278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_18eb4002-6f0c-42d4-abfd-ba26fd390278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d311bf17-d6b5-4665-bfc1-55128a77d7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d311bf17-d6b5-4665-bfc1-55128a77d7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_6c94e6d7-185e-4a2b-bd79-f3ffdbc5baaf" xlink:href="ino-20230331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_6c94e6d7-185e-4a2b-bd79-f3ffdbc5baaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b1e45571-327f-4485-9291-95a8085ba24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b1e45571-327f-4485-9291-95a8085ba24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_463393f1-cd4d-4a3b-a446-34648d2849bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_463393f1-cd4d-4a3b-a446-34648d2849bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_086a9ee0-c5f6-432a-94c1-52a580640dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_086a9ee0-c5f6-432a-94c1-52a580640dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_9bb229d5-f97c-48e5-8caa-5c2960f0439e" xlink:href="ino-20230331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_9bb229d5-f97c-48e5-8caa-5c2960f0439e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa5563a5-4b36-440a-8fd3-eb7fecdb45e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa5563a5-4b36-440a-8fd3-eb7fecdb45e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_865f5fcd-cd36-4dd9-938b-d97431dd7459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6629350a-fcec-45ac-a550-f9b89f00e20b" xlink:to="loc_us-gaap_EquityMethodInvestments_865f5fcd-cd36-4dd9-938b-d97431dd7459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20230331.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_c51afc13-cd8e-46dc-ba60-94be4d53b84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_d6ec4928-5201-4e3f-907d-3f680ab17bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_c51afc13-cd8e-46dc-ba60-94be4d53b84f" xlink:to="loc_us-gaap_MinorityInterestTable_d6ec4928-5201-4e3f-907d-3f680ab17bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_33a69471-fb15-426b-b19f-c1f657a87b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d6ec4928-5201-4e3f-907d-3f680ab17bab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_33a69471-fb15-426b-b19f-c1f657a87b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a187a29b-ed39-4d20-803e-b8d05c6baa95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_33a69471-fb15-426b-b19f-c1f657a87b96" xlink:to="loc_us-gaap_ClassOfStockDomain_a187a29b-ed39-4d20-803e-b8d05c6baa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_dc6fb4f8-7421-4753-b561-4c1007de694e" xlink:href="ino-20230331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a187a29b-ed39-4d20-803e-b8d05c6baa95" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_dc6fb4f8-7421-4753-b561-4c1007de694e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_d6ec4928-5201-4e3f-907d-3f680ab17bab" xlink:to="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_862a0665-b720-460b-bd05-8b823766a3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_EquityMethodInvestments_862a0665-b720-460b-bd05-8b823766a3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_211aeea4-9fa2-4dd1-8b1d-dce9ede65223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_211aeea4-9fa2-4dd1-8b1d-dce9ede65223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a6851c3-3ee8-4363-aa54-618d21647921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a6851c3-3ee8-4363-aa54-618d21647921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cdce0a08-717e-4ae0-979b-46342a766359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d71e2903-2702-467c-8103-883338965971" xlink:to="loc_us-gaap_EquityMethodInvestments_cdce0a08-717e-4ae0-979b-46342a766359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ino-20230331_g1.jpg
<TEXT>
begin 644 ino-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
MY20?0Q61'R>>HY._/U9('=SB^3KCX-1F%-]=>:V1FKRQSP2R031&TD4T,A1R
MQF/F)QR [&!L_FQ"[.WNY7%75^&ZLROE?N6I/R[$NJ?PDOO0;[K=;=TUZPKX
MX^SII/&VG>3?MAZICPE^CM5K@I6T2>\O)OC[OGX<Y/WZ7).+;LIE">[E-J(,
MR\]3+A79=J:OU[H[/:GBPLUREI.W5H9C(4V\1R]:@*P-IZ48O*(5XA$K\D8G
M# ,@3EX<3R-%RYB;W\^7U6\_[RAG6]#R]/G"&7193YT';1.4)*O(J4Y5>;1-
MI*VM60G6Y1WY9PE7+EG&45Q,X[\']:X6U.>F:WB3Q[UO.FU)RQLW'4Y5QRL.
M_90OHG*$H\RVG"<9TW0KNA97'^W)<1UMHRAGJ$N/R$77%*W(2"[#-!*+/X<\
M!NS]$D;OY>3B3.X2"<9&!<H(_J+\G?ZJ_'0>(L[2L[$U/3<N_ U# R*LK#S,
M6R561C9%,E.JVFR+4HSC)?@UNI)Q;1Z.&,;*P<G'S<*VW&RL6V%^/D4RE7;3
M;6U*$ZYQ:<91:_L?1M')^P]WC6J>S]E:^A];O<U%ME*?1CY(Q*;(Z>@>0?S5
MA.H^9:$0GQ>P!._@FPR8R2%G>*]:1U[J_!ZZVLU%EM.92IF,+F](YN6AD:4O
M7!8B+&VF\B<>N*0#%XYH9HPF@E$XIHXY0(1J+:UT;1SU$Z-Z)B!_;BE9A\:M
M,S.P3P$[/T&/+L[>8F+N!L0$0OUOV<>UCKWL_9?(XJ(CS&D,[#8ARFG[$TL6
M,R4-F ZIY+%R/XXXO-0B0^)+$!^-X<<%T)X/ D#OS[-WC_I7C%I=N!D2Q=+\
M1\+#F\[!7)CX7%-%=;5FJ:='W:Z<UKWL_%CM&NR3NC'Z+-V8_>WV5_:NCQ'I
MRTC6W&O5J<=UV+;ECE5J'(\K%CV:VV>3B1]ZAMV4)T?5U]JZ%/KQI?+S #_+
M_2L_N_E_YSA]S1D_^1]?TN?.+/8RVP^UY#8QSPOQ^@9G*J_N?GGGEN.'4#NT
M.I*F3H2R4Y6,6!QDC=V\6$G;EHY1;S$N/<_'2;>T+NSLZFC[FG(].:W)HN_O
MIZ9MQCR7M<3YN&8N/H&Z?S.SOY$74WO$?*K?A)IV5I?&UNGYN/=BY54\JB_'
MOKE5;59'%MDXSA-)Q?N)KIM)---IHFWPZFX:MIR:V;636T^G7Z-=+K^<>A/2
MB(KUEI3$_MU_$YN3]J.7_>Q*J?I__FL_^[_X.K6';J^)S<G[4<O^]B54_3W_
M #6?_=_\'5-/:B_Y5IG^B7^_D5^\6/\ "6+_ *C+_>VD_/<]SF^WF=C<G<(]
M6W>@?+@>NCCR+C_O/YJ6=1)]SQ\7^H/MMM?@['J6Q62\-/\  &E?ZG7_ &DI
M\!O_ -3X'^@7_>D%$]WQN2>':W#PLY<7M=86L[,S.SM'BL_>X)W\V'FFSLX^
M?6PM]"[NTL*AJ[Y^^S:-T53]GF;6+V>'=V+BK@\I$[LWN<6]=9B=_-G<./>Z
M^?$F[DT+5)?_ '64?Z<HP_\ $?7C^SET;/?QIY/Z<X0V_/FV(.<A[.*#_P"^
M_P!5E:7[O_'>K;-;?!QQXF"&UQT]'+7;=JZS\?*SM8YZ_P#K&?K?Z)59,^73
MC8V_[!/_ "_O*SCM=O5I3;+93;C(:KRU;&Q#H32[15O$::]D+98*E--!C:8O
MZQ=E>0S+B('"('ZY2BC9R:KGLWYN/B6ZQG9=]6-C48TG=D7V0JIJ@\B#<IV3
M<8Q7N=VTO3N1+X:95&-E9N5DVUT448"\VZZ<:ZZXRMK;<YS:C%>YW;Z^AG5+
M((B1D0B(LY$1.PB(BW)$1/PS,S,[N[NS,WO4&G;S[T[%8^KE=$[=209C*6X;
M.*RVI79Y,5BXYP>M:BQ3^0Y/(B!R -ENJA5E;JYN&)0C@1VR.\AU5N2UG#8C
MUC2VCR?H+'5K+MD\M&+OYYF[ X,\$OD18NN[U&9F">6YQUO&$(,\L8LW#=3-
M]1O\RUGQ/]JZ6?DUZ/POS5X]^15CY&K60<+KH661KE#!JFE*B$E+;Z3;%7--
M^554U&UZ'Q[[0WTRW]': W&B<U5=J,XN-EL92Y91Q*Y)2J@T]O/L2M>[\N%3
M4;)9,:(B:/'F[-PS1,+,W[3-_>X6*N[,W5=C'^EC-_\ YBX__(\OVUEK@!Z,
M4;^[EA;_ #%[EAIN1,QY$^'YZ(P!^'Y\^9"?]O@FY5?^+;O[UU![_P KDT5K
M_9FK=O\ LS3.(7RXM4?BXK;\]_[#J.W\O[7^E<8M_+^NZY/;^7Z_#<+E^WVT
M&9U1E:.)Q6/N9#(Y&<:]'&4H7ENW)2_0B/+-#&PLYRS2N,<43'+*<<8/(WE\
M+?"?7^+]06FZ!I]N9<MIY%W2K#P:-_>R<[,LY:,6B"3;E;-2GLX4PLM<8/&Z
M31.R<8PBYM[)))O=M]%T3ZOLEW;Z(RPV>M-=TWBY?>\<#U2?Y>JJ90<?6\HV
M;ZG''"['>E];C^7\OD636Z78ER&S&"TE4R=V&Y=S]?(7+\56-O4\9?KG3\3'
M03N[G;:.&S"4EJ1A\>SZR4(-"(\=%/$+_)_>4%^+W!=O#'$NKZ#=D4Y=FG9*
M@\G&5JQKXWTU94+*/.C79*IUWQY)RA%S7O<JWV.%7M)<*Y/#G'?$^DWU.F5.
MIVY,*WM[E&HPAJ6-'IT26/EU;)=NW38XJ]'ZW^;S_P!"X)J:R.*R.!RQM[ W
MWQ-@N/9"OF0&"(G_ +IPXUG=_9$',G\F7<;PCS[EU/OAACL:4S;0L[SUJ1WX
M&%GZO&Q[M<CZ>GSZ^J'@6'DN7;I]KA93P'U&F'&'#U65/R\3/U&O1\NU_P")
MP]=A9HN9?W[T8N?=:GZ.">TMMGY_9ZXUEI/&_#&:VX06K8V-=+?;EQ\^3T_(
M;VVZ*C*LW]-M]U+LY;>ZT[/YZFU=<U_DX7+$:5(JN(8Q^=V]16(FZIFZOH@Q
M5*1S\F_/5RL3$/JY@=BAEB#V!<?I^'9W;Z?37MXS)Z;H9@IRZ/'M9#*Q-=RD
M]MP\FM/?FL!+$[\UGC:HPQA7&,,OUVZX%X(_]'M/KTV<5')JE+Z;MU_OO[-L
M4]EO&IQ54'LMXP4FDVS^KS@K0XX&GTU])66I7WS3W4K;8IO9^L81Y:XOUC%2
M[MGAU7@[\SMB/0Q539C 6^,EJ*&OD]9' []=73K3.='$G(W]#DS5FOXMJ-G\
M1\96>*86KY$6EG(WOW@Q6@]*YG568+BGB:9SC#U"$MVT_L4Z%?J\GL7;)1UX
MFX?ASZR;H G:G#GL:.MM2YK6VIX MYC.79<C>E*29P9SX""K$Q2-TUJ=<(JE
M6-F9@@AC%F;AUL=7C/PWP;J.+G<04Y^8JHRR,;#TZG'NMG?"2C3.U9.3BUQA
M&7-.OWVY6UQW7*I;ZKXI\2RQ\5X&-)++S*Y)MMI58_6,I2:3:=KWA'H]XJSL
MTC!KF/&T?D$R#E^>/(6;ZO\ +_.ZM3]RWV.2T9HZ7<;/5"AU5KVK&5..<7:Q
MB](M*,^.KN!,SP2YHXX<Q:!O:*#X+CG8)ZQ110S]BWL8R[J;P08JW ;Z)TV=
M?4>HY.'*&>@TY/CL!UOPW5EKD!U91Y>3X-KWI0]L&)KHM:M'" 11 $448#'%
M%&(A''& L(  "S"( +,(B+,PBS,S,S<*UGB_XPXFK:1IE&CW^9BZMAXNIW6+
MI)8N17&[&QK$FU"V3:LR*V^:MPA%])21'/@3P).N5VKYD4[7.RO'WZISW<;+
M8M]=HK>N#[-N;[Q1^Z(BK"6<"Z?W[WOP.W&D<YK/4MGU?$X.F=F41=GL6YWX
M"ICJ<;NSS7LA9**I4A;Z.:4.IQ!B(>WW?R\_+Z_U/K_M*FQWK?;?/=S6@Z0T
MS<>70&CKDL,<U:;KJZFU!$1P6\PY1\!8Q]%NJEAWZI8I6]9R,9D-NOX,A>&O
M ENOZC#&7-'%JY;<VY?XNG?[$7V\VYIPJ77;WK-G&N1I_''%M.C8%F58X^8T
MXT0;^W9MW:W3<(?:GMZ;1W3DC!;>7>7/;KZWS>O=3'Q:RDWYEIB3E6P^)KNX
M8[$U!=WX@IU^&(OHK-D[%J5RFL2._,.S?V>LUO#KO$Z'P;20UYB]9SF5 .J+
M!X*N0^NY"1R9X_&)G:O0B-G]8OSP1=+Q^(0='VAF'U;%XZO-;O6YH:E6I4B*
M>U;MV#&&O5KP1"4DT\TT@10Q1B1R2D("SD0JYSW:_8CK[-:(CBR 0S:UU$\6
M1U7>%@-X)G#FK@JLHN?-+$1D\;D!D%J\=RXW 311Q7'\3.-,?AC2(4XD:X9-
ME?T;3J(I<M<:X*+N<>OU>/%Q:3W4['7![J4VJF^'7"U_$^KV9^9SRQ:I^;;*
M6^\^:3:@GZ3N:?;;DK4FMGLGFOM3M?A=%:<PVE=.U!HX7!4(,?0KL_4310 S
M/+-(_M3V;!]4]JP?,D]B26:1W,W==@HBY]773LG.RR4IV62E.<Y-RE.<FY2E
M)OJVVVVWU;ZLN_77&$8PA%1C"*C&,4E&,8K91271))))+HD$1>'=?F?<@V[W
MW:@0ETSK:"/@I6/3F1,6?@G!I[^,(W]S$POD 9_HB;I%WZ8Q952NVSI/YYA<
MU&+>V$^-LOPWFX/ZS4=^/^R]L7=_D:-O)F5@3O/N\2IZJU=2VITA)5O:>P>5
M:356=B>.Q%>SD$-FO%B<9*S$+5\1-*[W[<1<SY ?5(W\&M.\\//:@P;7='WS
MZ>3HS5;8OQR[,,X0R<?6Z)GZO^R+_(WERB]K[PXR^#_$_1=4MH^C8_%VG8VH
MPC]GW[K+M*R(V0Z<MDG1CYTUMU^DPG+ZQS2Y[^.\,5ZUGV8DE.,X5VVN'V5D
MUQY;E%KONZDY2[.<Y]UU>$W8J[5N7V1W+T_N!BFEFAH2O2U!C8W9OAG35TXF
MR^-X(A!Y2CBBMT7,A"/(U*<IDP@2V5^A=:XO4F%Q6H,+;BOXC-8^IE,;<A?F
M.S2NP!8KRC\HN<1BY 3,<9=0&S$+LVJ[MU??_+^^KBGHY?:X/.Z-S^T>8NO+
MDM%SEF=---*SS'I3*2"UBC$QOUR1X;,E,X.SDT%7*5*K###7@8K*^SKQNZLF
MS1[I/RLKFNQ=WTAD0CO9!?!6UK?^?6MEO.3-M]FKCWRLNS1KI[TYN]V+N^E>
M57#>R"W]+Z8;_!3IBDN:R3++:(BN07;"(B (B( B(@"(B (B( B(@"(B (B(
M NN]VMLL9K/3&=TIF <\;G\9;QEOIXZXPM1$ SQ<^RTU>1PL0N3.+2Q@Y,[<
ML_8B(#74;F[<Y72&H<UI;-QM%EL!DK6+O,'5X1S59'C\>!R9B>M:#HLUB)A(
MJ\T9$(N[LW!E/YWZ_9I?%ZDP>Y^-@<:.HJ\>!U T<3M'%F\>$LF.O2F/+=>2
MQKO3/J8!8L3"0O))9DZ8 T 1$0!$1 %;*[CKM)-J'0=[;V_8Z\IH:<I<<)E\
M]ETWE;$L]<6Y\Y QV0.U49_-H*LE"!F$!CYJ:K,;L$=H]]J]T=.ZHFF>'$22
MEA=1^VX1O@,J<(7)9N/(HZ$T57*])<MUT )FY9G8"^4B_.*43$3 A,#%B A=
MB$A)N1(2;EB%V=G9V=V=G9V\E^B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
M7)V9?B_@XFI^A&3H=W?R;H;I^J_N?CWO\C*QOW/_ '=LE :>\6O:#ME;<+RZ
M'P=V)V/%5)?(=1W*TH,\>3N1,7P3'(Q%3HS>MD 6YXO5KSZSJNE\':)&-<%&
MNF/E8N.FO-RLB2<O>EMNY3>]E]K34([M+^3@Z9Z9@9_&>L2LL;^CJ?/98T_+
MKKB]DU'MM%>[5#?WI;;O;>2RY[K?N\HMI<&6IM3P16-QM15Q>\9-'*VFL7*,
M4@:?I2B4@%.\@-/E[D1LUFQX=:-RK4XCEEK1%0#B'B#*U3,NS<RSS+[I;OTC
M"*Z0KKCN^6NN.T81WZ);MN3;=W-'TC'P,:K%QH*NFJ/+%>K?K*3^].3ZR?JW
MTV6R14Y.\IR[2ZWW1EZG=SRTU)G+WOX<=2@X^7Z$1C(1]WLBWR\LK<^XNXF%
MTE@\GJ3460KXK"8>I)=R-^T;!#7@BX\W?WG)(;C%!"#%+/,<<,0')( O20[7
M>XD.IK^>S]4)XJVJ=2Y#,U(;(@-F&E?N6<E5AL !& S0UI88IA S!I1)A(A?
MJ?GM[>'/+3.$<?EEY=_$DK>;KRR>#ARE9%=-I.$,I.6SW@IQW6TT5:]L+6(8
M_#T(.24V\FU1WZ],:>/"6W=;V9"BG\=_@R-J[7]_E_+_ -_Y>]<1NU?K?YOY
M?^_^9=GW:O\ +^7_ ++B5ZO[U4?$R/\ C_C_ (_K.5.D:AVZDPOH_63>MOED
MJK.3-?T-EQ=F9G%_5<ABYO:=_-O-V<>GWO[_ "5T]4I^X9AZ=_.>/_V(U'^^
M,2KK"Z2>S-<Y\,QW>ZCGY<8_)?52V_?)O\SKC[)&2[.$5OVAJ6;"/R35,W_U
MIR?YA$16#+.A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$-O?4]FM]7[9AJ['
M5_%S6@;!9$V &*:QIVYT09F%G;VOS([5<K[W9HJ-D1 CE$AJ K8^YK#5<C3M
MX^]!'9I7JT].W6E;F.>M9C*&>&1O+D)8C("9G9^'?AV5 KM7[!V]LMPM3Z+L
M]90XK(REB[!MYV\);?UG$67?@6>0Z,D06.EF!K4<XA[(L[@8[HB( B(@"Y+H
MO6&0T]F,5G\3.5;*83(TLMCYP?AXKF/LQVJY/\A \D0C+&7(2QN49B0$0OQI
M$!L+]@-X\?N!HO3>LL60/4S^+KW?# V/U:T[/%>I&3<NTE&['8J2B3"8R0D)
MB),XMW"JWO<.]I-BCU%M5D+'M1/+JK34<A^7A2'#7SU*!G;RZ)SJ9(81=N2L
M7[ @[^.;60D 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 %UKO%NEC=$Z6S^K,N?1CM/XNWDK#=3"4WJ\3E%6B=V=O&MS>'6@
M9VX>64&?RY792KS=^_VD7IX?3VU^.L.,^8E'46HQC-NIL71,XL32E87<O#N9
M%I+IB3#_ ,UP,W6$ALP%;[<G<+)ZMU!F=3YF7Q<KGLE:REXF=W$9K<I2/#$Y
M/SX-<7&O S^8PQ1C\BX2B( B(@"(B *VOW('9K;36W]S7M^MX>6UW/\ F$I0
M9I8M-XN::"ET<^V$>1N>M7O<+6*[4)O;C:$FK*=G#9:[N)KK2^BZ EXF>RL%
M6Q,+%Q4QL?59RMTW'Z$:>.ALSMYLY& 1 _B2 S[ 32>F*.$Q>.PV,@"KCL51
MJXZA6C%A""I2@"O7B$19F9HXHQ'R9O=[D!R!$1 $1$ 1$0!$1 $1$ 1$0!8%
M=Z!\0>YGV#A_"N/6>JP*[T#X@]S/L'#^%<>@*,B(B (B( B(@+?W<8_$I8^W
M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
M<3CDC)F(#%V(29B%V=F=7+.ZN[> [L:6^ ,_99]>Z4IUXLH4G0!Y_&#TUZVH
M(A%A$IC-@@RX1@ PWB"88XH+M<& E>1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY5_
M >)0&"B(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S
M.DOQDQRIC( B(@"(B *[3W1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;R DG1$0
M!$1 $1$!U5O9LSI_<'3.5TEJ>FUW$9>#P9@]D9J\H$TE:[3E<2]7NTYQCL59
MV9W"4&Y$@<@*C+VO.RIJ#9_65W2V; IJQ/);T_F&!AKYS#/*X07(N'=H[$?L
MP9"KSU5+;$/M0'7FEOWK#GMN=CO![S:-LX#(>#3S509K6F,\\ S3X?*/&S"Y
M<.$LF.N.$<.3IA+'ZQ (&)!8@KRQ 4-47/MTML,YHO4.6TMJ2A+C<UA;15+U
M65G\BZ1DAG@-V89ZEN X[5.R#/'9JS131NXFRX"@"(B (B( LC^RKVG=0[2:
MQQ^K=/FQ^$05LOC)"=JN:P\DH%<QUCA_8(Q'Q*=G@BIW AL,$@!)#+C@B V%
M^PN^>GMQ]*XG6&F+;6L5E87(1+@;-.U$3Q7,?=BY=X+M*P)P3Q/\HM)&YPR1
MR'W"J1'=R]N^]LQJKIR!VKFA<[)'#J/&1D4CTI.1"'4&/@]IGNT@]FS#&PED
M*75 [O-#4*.Z[IW45#+4*>4Q=ROD,;D*T-RC>J3!8JVZMB-I8+$$T9$$L4L9
M"0&+NSL[(#[2(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(")[
MOJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1 %>&[J?Z7[;C['Y
M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
MQ<3!V+Z)G9W;W>7R?7ZATWH+26A:4]R*.EBH(P<K>5OSBTOAMR3M+<L$S@#>
M;^%&X@_N8'X94VXW]H?Z91IVF8\\C6LNB*Q<3 Q(RL@[IRY:][*XS>1;+>-5
M4:8W3Y81K7)SMN ^).,[[XXV(LAY5>+'RL>$-VES/HN:*?F3Y>6N.W,XPC&"
MVZ[XE;/]CV:;PK^K/G,#LQQX:"4AL&W+.WK]B)V\ 7;GF"O(\O#LQRQ/R"G/
M[(/8CSFXDT$>.K1X/2&/E:M<R_@M%7B")F>2CB:["PV[W!,+BW36K.3G8EZV
M&&7#KL4Z-U%VCM<'IS0<5_%;?X,VEUSN?-4$(ZD7SIXL!I:M<%QFU+E1D(JM
MB[5L5<;3@GR%NF;%1AMW7M!Z%Q6F<-C<!A*84,5B:D5*C5C(S:*"$>ENN20C
MEFE-^3FGF,YIY2.6:0Y#(GES@#V+^(]8RL75O$CS-+QMH9.-PI&3JS_*GM.O
M])5QDY:5&V/+OC6R>KV5[_2(X,?(E;O? /@WE:E.&;K7/1B1:E7AK>-U_7M/
MUHJZ;2_Q\EO%>5LI''-H-G,!H;"5<!IVD-2C6%G,W?Q+5VPXLTMV]8=F.Q:G
M+VC-^ !N(H(XH CB#M%$71W3-,Q\+'IQ,2BK&Q<>N%-&/1"-=--5:485UUP2
MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
MW6=N>MV?]!"Q/[V(@X;G[;)=^K_@0Q/5]=XAO4<?S:JD^CAO6H+?OTVC#Y2D
M^9_-G0O:4V@QFGK,%["F88^Y(44E.0_$>K88>OF W?K>O*+$[ ;D41L[,9 8
MB&+\4QQR1RQD4<L1M)%+&11RQ2-[CBD!Q.,V?S8P<29_-G7+-8:[RF=F:;(V
M2E87?PH1;HKP,_R11MY<NWT4A.4A-QU'PS,W#E]2R'#^'DX^'13EWO)OKCM*
MYMN4ENW%2DTG.44U%S:WEMN]WU<U_8O[^S?C:$:N-R&5_FH:6K,P#@=<9"Y/
MDHH6Z6:#':P<+V9IL LX0_"$6:K5V(1CI/%&$*N/=A+OH=E=]GJXK&YGYD=;
M6&=FT3JR:M1R=J4(_$E'!VVE^#\^(#U'T8^9[K1 <LU&$ /IUF2_>O8.*2.:
M,Y(IH9(YH9HC*.6&:(F..6*0'$XY8S83CD!Q,"9B%V)F=1)QGX,:-JZE9"E8
M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 42??94QDV'RDCN_-;4FEYAX]SD>
M3&L[%Y/Y=-@G;W>VP^?R/+8HN^^4C(NSUK)Q9W8,AHTC=FY81?6>!!G+ZC.9
M@+/_ $Q"WRH"EFB(@"(B (B("[SW2^3];[/>W4G49>'6U!4YD][>H:MS]'I;
MS?YV'J_1$WN:(09F9O)I%U&#W.,Y%V>M$B_NBNZQ /+W"6M-03.S_5]N4WY?
MY'9O<S*3Y $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %1:[S;X^]S?LY5_ >
M)5Z546N\V^/O<W[.5?P'B4!@HB(@"(B *17NE?IB]L_[?J[^#W5RCJ4BO=*_
M3%[9_P!OU=_![JY 7>T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$5'?1?$#J3[,Z
M2_&3'*F,KG/?1?$#J3[,Z2_&3'*F,@"(B (B( KM/='?$)HK^['X9O*DLKM/
M='?$)HK^['X9O("2=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 ?A9K1SQR0S1A-#,!Q2Q2@,D<L<@N!QR1FSB8&+N)@3.)"
M[L[.S\*G1WIO=\2[5YY]5:8J2R;?ZBMRD 1MUAI?*S&\KXB;ANJ/&V>HSPTQ
M=0 ,<M"4P.*J]FX\N#[D[<875^!RNFM0T8<EALS3FHWZDS<C)#,/'5&;>W#8
MA+IFK68G&:M8CCGA,)8P)@-=.BS/[<O8VS6S&LI\);\6Y@,@\MS2V<<> R6-
MZA=X)W%NF/)XYY!KWX?)B)H[47->S'QA@@"(B (B( OO:6U/D,)D\?F<1<GQ
M^4Q5ROD,=>K&\<]2Y4E&:O/$;>XHY %^'Y$QY V*,B%_@H@+P?=V]NG';T:3
M$[1UJ>ML)''!J?#Q&S,3N[QU\U1B+@WQN286-V9G:C<>:B9FT<4T\AJUZ_9]
MW[U%MGJO&:OTQ9\#(X\W&6 W+U3)4)2![F+O@+\RT[@@+&WT44@0V(N)H(B&
M]'V7^TKIW=?1^/U?IR7YQ99X,ACY)(SN8;*P@!6\7>:-^&G@\0)(SX$;-66O
M;C%HYP0&0J(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7AN
MZG^E^VX^Q^7_ !DS*H\J\-W4_P!+]MQ]C\O^,F90$A2(B (B( B(@"(B (B(
M B(@"<HL<>U)VEL'M7I2WJ7,EXLO/JN(Q<9L-K,9202>"G79_,09A>6W8=O#
MK5@DE/EV$#]FGX%V5?5C8]<K;[YQKJK@MY3G)[)+^UO916[;239X]0SZ<6BW
M)R+(U440E9;9-[1A"*W;?]B6[;V23;2.LNVYVSL1M'IXIOG&0U5DHI!T_@SD
M=O%)N0+)7FCYDBQE0W9Y29P.U(S5*YB9'+#36WFW'S6KLYDM1:BOS9++Y.=Y
M[5J9W^1NF.""/GHKU:T8C#6K1<100@( S,R[LWGW>SVNLUD=3ZCN%<R61D<W
M][5ZE87?U>A2B]T%*I&[1P1#YO[4LI23R2R'BWG?>_Z[_P#Y2O5P+X;T:!AK
MFY;=0O@GE9"ZI=GY%+>SC3!^O1VR7F3VVA"NA''/B;D<0Y[VYJ=.HFUB8SZ-
M]T\B]+=2OL3Z+K&F#\N&[=D[.K;_ ,GZ_P#YKX)_^7_BOO7_ )/U_P#S7P3_
M /+_ ,5FI?:E^)YL7LCTS^7]M>A,3"Q$3L(@+D9$["(B/FY$3\,+-[W=_)EW
MELCL1J3</4-+36E\;/DLG>)W&&%N&C@!Q:>W8F)O"JTZ[$/CW;!!7A<P%R*6
M2**2T_MKW&NU(;?6M+ZXK2:@U#E8X9;^I:%NWCY\3<B9R -/D)!TUH)'?K>_
M!,V0;@K-:./PZT.L\3<<Z?H_D_3)S<[7'EIIC&=WEM[2N<92@HUQZ[.4ESM.
M,%)QEM)'"/ ^9JF\JXJNB&_-=9NH-]U"'1N4WT]-HI[R?5)T<]7;INSE!C>E
MV;D7MDW/5]>N!?)SSQ(;>?O$?/E=#W;ARF4DAE)(3\F9DY$3_5=W=^?K?492
MO=XUW6&<V,RY/CM4Z?UGINU9**D5?)XZKJ['"1/X5?.Z9*UZTY WSM\EBQL4
MI7'Q)X<:\@UAC6I[5YFSQ\YC@9_EFDX=OE\QC:0OY?44F\/ZAB9F-7DX4U=3
M:MXV)23?Q4HS49PDO6,HQ:^&SW-V6!1IK=5G)3./VG.4>>6WKOOU3Z[<ON^B
M1U?-*ODSR_YUD[C>SQ/([/9MD_\ V8(NG]=F.1R=_K/T"NS,1V;\:+?/*TEA
MW^6:67_5C*,?VN';_,MAA6_@>#(XVTW'3YK^?;T@O_ZG$X;V4>VCK#:O4%3,
M:>SU[#6X7:)KM<R..2OQP]'+4CZJV5QAOQS7M13> ;#/#TRQQ21WB.[Z[X[2
MFZ08[3NLRH:4UM8""&I,,_3IS5%@V81/$697+U"Y8)V>/$W)Y",R\.E;N%[#
M4C-;]D@I:LEC!D\-J,7)J5@S."QT^;QQS&Y20S./E'UN<9$S 3QL;R!C)MQN
MM;TW:>G=&:2@,[A/6?EK%"8)'&22!G=G$XS9_%AZA9R!R#HDY=]!XZ\,]/UR
MI_2*_*RHQVJS*DE=#;[,9=E=6F^M4^FS?ERKF^8SO"W&%=ZLNTF]6JN2>3@S
M>R?-VDH]?+G))\MD'R3:VENXN)MNN453_NT>^5GP\&*TGN;DYLUI2< APNM3
M-[60PL9.PPULV;_/\CBHF<HFND\V2Q[",4HVJX\U+6>.R5>W7@MU)X;-6U#%
M8K6:\H35[%><&DAG@FC<HYHIHR&2.2,B P(2$G%V=45XSX(SM#R?(RX;PGS.
MC(ANZ;X1?5Q;ZQG'=>95+:<&UNG%QE*9M$UZC/K<ZFU./2VF?2RJ7PE'X;I[
M271[-=&FE[J(BT\S01$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 7RLYG:6,IV<ADK=:A0I0R6;EVY-'6JU:\0N4DT\\Q!
M%%%&+.1F9"(MYNZ^%K_<#"Z6P][/ZAR-7$X?&PO/<O7)&CAA!N&%OE(Y9#<8
MX88V.6:4@CB S(1>G/WB?>49[=^Y+@\,]O!;>U9>*^)<_#N9Z6(^0R.>*,N"
M!W8)*>*8B@J?T2=[%KI.#=>"^!\K6;FJTZ\:N25^3);PAZ\D%T\RUKM!/9+:
M4W&.S>D<:<=8NC4IV/S<JU/Z/C1>TY[=.>;_ ,75%]YM;M[Q@I2WVR:[Q'OB
M[^I"OZ,VFMV,7IQVL4\IK"/Q:V5S8OS$<6#?YW-BL88^(SWG8<E= P*%L=&!
M>LU^3][_ %_-W^J[^]W^J[^]W?SY7N2?^?\ I9>F?O5P>&^&\32Z%CXE:A'9
M.<WL[;IKISVSV7-+OLME&*Z0C&.R*I:UQ%EZG>\C+LYY/=0@NE=4?U*H;OEC
MT6[W<I=YRE+J>B?_ )?^*]$_<O>/_P O_%>B7N6TU^G_ !ZGEJ_L/3D^7]O_
M $,O0F]Z[9VKV?U+KG-U-.Z3PUW-YB\1#!4I1/([ +-XL\\GE'7JP#[<]F<H
MX(0\Y#'R9YS<CZ.WJ6_MM</YO*F-W.F ;=/'QP%+I:,&AZGP5[) #Y$;-B1W
M"7-4H9(*AB(Q4+T+%-/B-:XPTW2Y51SLNNB5THJ$6I3GRM[>9*%<92C5%[[V
M22AT:3W6QNG#_#.9GN3QZ92KAOS6OW:UT^RI/I*>W:$=WU6^RZE8'6NY%/%B
M48=-JXWN@ N!C?AN'GD;E@^3V!YD=OD'GE8<ZLU)<R=CQ[DKF3$[1@WLQ0C_
M $L4;.XBWU7\R+ANHBX;CO;M%; :RVQU1D='Z[P5[ 9_'DQ25KD;^%;KR-S#
MD<;<;FOD\=99^8;U.26$C:2"0H[,,\$>-MSWM_WE).G^5.N%M4XVPLBIUVPD
MI0G"23C*$H[IQDGNFFTUZDE:-HM>+O[K=JZ2G-;23[-)/["^*[^C;/GO_P"7
M^A2,]V_WENN.S=JWX9P!29G2N3, U9HBU<D@QF;@9A!KU0N)(\=J"E&WYBR8
M1.TH-ZE>":H0^#',_P#Y?Z%X34]+Q\W'MQ<NF%^/='DMJFFXRCW[IJ491:4H
M3BXSA)*4)*236R56RA)2BW&2>Z:]/^/7]QMK.RKVIM';R:)Q&O=#Y(<CA<K%
MP<9,P7<7?BX&[B<I6Y<JF1H2N\-B$O)^!EB*2"2*4LC%J^.Z^[RK5'9OUU'E
MZ)3Y/1&;GK0:YTGXA>#DJ0/X8Y;' [^'6U#BHB*2E98>+< GC+7,$L<E;9=[
M-[P:=U_I;!ZSTGDX,OIW46/AR6*R%=^0GKR\BXF/T45BO,,E:W6DXFJVH9J\
MPC+$8M0'Q2\-+N'\M.'-=IV1*3Q,A]7%]WCW-))75KJI)*-L%SQ2:G77O.FZ
MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?8.'\*X]9Z
MK KO0/B#W,^P</X5QZ HR(B( B(@"(B M_=QC\2EC[=]0?O3#J9)0V]QC\2E
MC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0!$1 $1$!X=5)>_#[.SZ;W#QVN:5=@
MQ>NJ;C=DC!V"/4>'CBALM*7'2)W\:=*Q"[EUS'5OOTLT/45MM8*]XWV;_P":
M=M/J3"U86ESF-@?4&G&]AC/+XF,YPIB9<,'PG6]8QO4Y"(%:"0W<8W%P*+*+
MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1<6UOK3&:<Q&2SV9MQ4,3B*5C(9"Y.3#%7JUHREED)W][L(\"+<D9
MN("SD3,X$=_>G=L@-JMOIZ6+M#%K+6$5S$Z>$7YFHU_#"/*YUF;Z'X,@LQA3
M,_9^$K--^B6..8%2I=W=W=W(G=W<B)W(B)WY<B)^2(B=W<B=W=W=W=^7=94=
MLOM1Y3=W7N6U9>>6&@YE0T[C3/J'%8&M+)ZC7X\A:Q.Q%<OD+,QW+$W'L#&S
M8K( B(@"(B +MK8C9[)[@:QT]HS#B3WM09&*D,@CU^JUF$Y[]XV]WA4*$-FY
M*Y>ST0.S^]=2JT%W&O9-?&X?([L9FIT7LZTV&THTT?$D6#AD#X1RD;$W4#96
M]$U6 O)RJX]Y@<H+@.X$Z>U^W6+TAIS!Z7PL/J^*P&+I8FC'Y=7J]* (!DE)
MF;Q+$W0\UB4O;FGDDE-W,R=^=HB (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B *BUWFWQ][F_9RK^ \2KTJHM=YM\?>YOV<J_@/$H#!1$1 $1$
M 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@
M"(B (B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y[Z+X@=2?9G27XR8Y4QD 1$
M0!$1 %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_#-Y 23HB( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B +U+]""U!-5LPQ6*UF*2O8KS@,L,\$P/'+#-$;
M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
M %N&$1%F$19F9F9F7[(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( L"N] ^(/<S[!P_A7'K/58%=Z!\0>Y
MGV#A_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=
M3)( B(@"(B (B( B(@"(B (B( B(@"(B (B("F9WN79$;;;<23.XFL\6E=>2
MW<O1:,>*^/S?B#-F\4W2S#"!2V!R-*'R#U>U+#79XZ1A%%$K\?;2[,5#=O;[
M-Z1L^%#D)(2NZ?R$H,7P;GZD<A8ZR[\=30'([U;H@[')2L6 %V)Q=J'FK-*Y
M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
MWFF>)'N_1JOUIPZ?C-?V(Q7UAD&&]-R3,PBSN[NS,WO=W=W]S<>;N_N4SW=Z
M]S;K#=-J>J-;^NZ,T%(\4]?JC&+4FI*Y#UL^*JSQFV.H2-TM\*7X>9!/JHT[
M(\S1R!]T7W5NC,IA,+O3KF,-2Y#,26[6F]-7Z@OA,-%C<E9QT&2NUYNL<OD+
M)T'NTWFC&C4@F@<()[#>LM9C$69F9F9F9N&9O<S-\C?49OD957\4?&9T9&3I
M^E+:ZJVVC(S)Q_D[*Y.$X8T)+9RC).+NFG'=/RHOW;2Q?!'AY"S'QLG-ZPE3
M5.O'B_M1E!2C*Z2Z[---0BT_UVNL#%W!;+Z/VDVWS>*T7A*>"Q.(T]E[A!"Y
M-/:EJ8RQ*5W)9"4I+ERW)X;E-=M32S<N[]3,S"U"+:V'HI1,WN&L+>[ZD3,K
M^7;$RCTMI=S[0NXG!M]K$XR86)QD^9[(-$_2_D[-(XN_/EQ[VX5![0,?13)_
MJ0\-_>9EFO9HG995K.1;.=EMV3B\]DY.<YRA7?)RE*3;<F[=VV]^II'M'*%>
M/@4UQC"$86J$(I1C%2G5%)12V2]WHDOP+#_H^>/=[>\=TA]GG0E2(F+Y1;5T
MTXN'UF.L[$[<>9"+OP2LHJOEZ/QBV;2VYN1Z69[&K\90ZO#X=VH82*RPO-^C
M8?A1R:+_ *IS(_\ KU8-4%^-5W/Q/JC^$\:'_1X6-!_QBR9_"VGDT#38_P":
MLE_2OME_:%"9W]7Q+XW[>L!^]LHILU"9W]7Q+XW[>L!^]LHL5X7?^T.C_P"N
MU?ULRW&_^"-1_P!5M_[I53/_ )H_;?\ T.KO_=K_ !#[6_:G1_UI52 /_FC]
MM_\ 0ZN_]VO\0^UOVIT?]:564]IG_!>G?Z]_\O<5S]G+_ENJ?S'_ +Z!G B(
MJ7%M2H]W\>):OO'I.VS?G_0M9R?VW9RJ9O*Q.WM>PSB) _ ?TS.3<DSO%YH[
M,?!^K]"Y-_\ \WZNTI?\Q(FXI9ZA8?D1<2,7:)V(!(7)O98F=V=IB_2#\5X.
MLMILAQQZ[@=64V+V_/X-R6 G=O/V'Z?A9G]EW)NKDV87#F"G75N2'&A:BZ7E
MKQ/-%U>8O)!S)'RS.S]/6(\LSL_OX==$O"1?2>%=.@WTGC74?E'(OH?[N7;\
MBCOBJ_(XK\S;;:^N?3YTU6?Q[FQO4?/;B[OW3>\&/>X'A876=& AQ>H(X_9L
M"(EX>.S40-U7,>Y.WAR-Q;I$S%6D\)YJ\^?="Z%F"&Q$[O%/%'-&[MP[QR@,
M@.[?(_23>7R+VG5 -(U?)T_(ADXELZ+ZG[LX_P#6C*+]V<)+I*$DXR71HNKG
MX%.53*F^$;*IKK%_PE%KK&2[QDFFGU3-?1V@>S]J/1>=NZ?U)C),5GJ'!2P&
M3'!<K%U-#<I61^=6ZD[ 3UK47LGTE&;!*!QQXNF7#N+MP[.[.S^3L[/P[.WO
M\G\E:K[_ *T\4&F]NM3PPBY4]1Y#!VY7%N2K93&G<BA(^.6;QL8<@<>74SOP
M[<L]9O46 :Y$UNJ/$O3R<?#?/F9N7X_^ZM\G'T;>7OX5ZN#-:GK.DX^I.N-=
MECLKOA6VX*VJ;A)QWWE%32C8HMMI34>:37,ZC<:</U8&HVXL)\SVC97S)*4Z
MYQ4OP<X=8R<4N;EYN6/5'6+R?77\.:_ B=GX=G9V?AV?WL_U/K/\C\_+Y+\2
M-; JS555\OWG[2L)BXDS$+MP[/[N/E9__+_RY;I_5&#DJ\S1\G7=_/Y2B=_D
M/CAW'GR$OD\F+Y.>UWD7XR<$SB3,0DSL0NW+$SMP[.WN=G;RX=>NB3@^G;X;
M]/Q_$R>#?*F6ZZQ?VHOHG\_QV[/]^ZZ&-TM[Z_\ +^7N7YTLX=::.:-_: F?
MC^F;ENH7_P"\WE];WK[VMM)G4Z[55B.M[SC9G<H.?E^J47N\_>'/#^7#OUOB
M:%O*W:6+Q\4EF_E+M3&4*\3.4MB]D+$5.G7B%N7*6>S-'%&#-R1F(MR[\+-U
MRBUSI]$MVV]E';J]_AMZ_(W_  ZX7PYH^]&71Q]5\8M>C^*[? D5T#GVF@B&
M43$+,,4P-(! 10S@,D,C";,[A(!"<9LSB8NQ"[B[.I%^[C[5A;,;G59\A,4>
MCM924L%J=G<O"J1O8,<3GR9F=G'#6;<SV"$2D'&VL@X,YL$<F>_>T]WO7TOH
M'1FNM)5!<M :>P&CM6Q4JS]5S"T8(,=C<^; +R?\G6C\"Z?#]&/N1SSN%;&N
M<4#)C'DZ'2_!&,?'GY\B[>;>[Y/]'NXX6MZ-JVG\6Z)<G'>C)5N+?4VG.FR#
MW33VV4X_59%,O3>MM;II1AQ%IV5PGKU635TAS0L4ETA.$]UU2]'[]-B]=FNV
MS-BQ#*)B)@0F!LQ 8NQ"0DS.)"3<LXDSLXNSNSL[.SK]%"[W,G;'+7.B#T%G
M[WCZOT#!'7"2S,1W,OI4I7BQ60)Y/;FDQ;%%AKLS%(?SNA8LEXU]G.:)<_N)
M^'K]*S\G R%]9CV./-LU&R#]ZNV&_P!RVMQG'U2>SV::5V-#UBG/Q*,NA[UW
MUJ:6^[B_O0E^U"6\7\UNNFQC-VN^S+A]W- YO166XA>]#ZQB<AT,<F(SE5B/
M&9.)G^B\"=^BQ&SB]BG+9K]0M,Y-12R6F,MI7.9?2.IJKT<S@[UC%Y2H[N0A
M9KETN41N(^+7F'HGJS=#>-7EBD818^&V(KJNUWX78M>]0AWITW3(LEA(:V/U
MM7JQN4EW!@7@T<[( ,Y22X4C"K>FX<AQ!A-*35L6SQS1X!>('T#-_163/;$S
MYKR')]*<Q[1BOE')25<N_P!:JFMDYLBGQHX%CJ>"\JJ/]\XD&WLO>G2O>>WK
MS5/><?V7/N^5$6W=R]KF797<F$LA.X:(U?+3Q&J1?J(*7SPPQ>H! >>7Q4UF
M3UOI I#QL]MHQ.6.('NT5[ 2@$D9C)'((R1R1DQQR 8L0&!CR) 0NSB3.XNS
ML[<MPM=4+1Y2BX/P1B'Z_4W'N5HCN6.VH^J]-R;6:DNE+JG1E1Y,)8MS$=C-
M:2"4(H1ZY/:ELZ>DF@QTW)E(="3'2DQ$-B1;O[0WA_YD%KN)7O.M1JU",5UE
M4O=JR6EW=7NTV/OY;K?2-4F:7X#<=-J6BYDMK*W)XSD]NO>=2W])];(?M*:[
MRBB=1%X9UY50BSYT]OYL=@-Q])9K1NIJWK.)S55X)''I:Q4G FEJ9"G(0EX-
MVC9".S6E9GZ98V8F("(7HH;S;*Y_:?6V8T)J<&>WCI>JI< '&MF,1.1_!^7J
M=7GX%R('<X^7>M:CL53(C@(GV![J+;O3>PG'O!HQLE@Z\0Z_TE#8N:=F81&3
M+579I;VFYYN1?HO-&TF/*1SCK9(0)FCCLV2>;?!;Q'>C9OT7)GMIV;.*L<G[
MN->_=AD+T4)=*\CM[BC8V_*47%7BMP%#6<&4JX;YF/"3JV7O6P[NKYR7657[
M>\>G.VJKO9X[06=V>UUBM>:=^?A#S4S.,<^B'-8&S)$5_&2\>0R$T86*<SL[
M5K\%:?I, *,[TFT.[&#USIK#:MTW<&]A<Y2CNTK#-TFPD[C)!/'R[PVJLPR5
MK4!>U#8BDC)W<>7U].%ME*,N/N125[$!R5YH+ %%/6L0F44T$T4C#)%+%()1
MRQ&S%&8N!,Q-PI7^Z7[<![6ZM^8#4UKP]"ZOOMZK:L3.-?36I)Q&*"U\\?HB
MQV8((J=[I>,8;95;I\!ZT;SOXY>'"U3$_2F%#?.Q*VYQ@MY96+'>4H]/M6T]
M;*MNLXN=:4I.M*%?!;CV>GY,M&U";C5.>U,YOI7:_=3Z]H6=(S](R49O9<S=
MO]%X9^69V]S^;+RJ-EOPL)^W=V+L)O9HR; WG"EG<=X][2F=Z.J3$Y9XNEAE
MZ6ZY,9?Z(Z^3K#_1(6"6/BQ7KF&;"+WZ7J=^%D4Y6-9*G(HFK*K(]XR7\'%I
MN,HO>,HMQDG%M'ES<.K(JLHN@K*K8N$X2[.+_J:[IK9Q:33329KO]0Z5S>C\
M_EM'ZKH28W-X6T=')4I'ZF"46$HYH).&:>K9A..S4L@S#8K2Q3"S,7#8K]IW
M0-273]^[( \TH7MUIO<X2=8"PB_U)N6B(?<_4WEU"SJ3;O[>VSIN]V@JVFL+
M1HR1:&P$6#U7J&FT9WKN?N3_  A\&&<3?/ZVF:IPUW:20I0OY+*5NB'U+BQ"
MYK+="]N-8HZ2P<4L.,>8+.2O3"[&44+B[R%&W]"K0?1")$YVK+PCQ&(,Y],.
M$M9NS]+PLW*I^C79&-"^=6^ZCS+=2CW:A9':V$9-SC":C+WDRGV3X=9>F:_&
M[#GM@PN\V_(DU&$:(/FFI;;;W;)U<L5[[?-LH;M>GV0]M7L6YM2V@^<T^NMC
MF?W26S;B>PW+?0UXG>(/_NLI/Y/$S/:V[E'L_/G]>7M>7('+':)JR08\R;YV
M>H<Q5EJB[<^R;TL5-<D<'9_#EMU)V<3"-W@]T/H\:L&-P.&IRS$SP4,?2K1%
M+9M69Y6CBBCBC9SGM7+,C/TBSR2SRO[R)7MNQ%V:8=J=NL)I;B(LH['E=168
MNEVMYZ^$3W3ZQ_H@5HXJ^/KGR_-2E +/PS*(?'+BY86ESQX2VR-14L:N*?O1
MQME])G^#@U4_B[MU]E[2CPGBRU35GESB_H^(XV13[*2;\B'\YR3N>W1.+79H
MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
M>_Z"(!C'WN[^X6][N_UW]Z]Q$7+UO?J_4OND1,]]GE?5>SYJ7@NDK69TI4%O
M$\-R\74%!S86]\CC$!R%&WO ")^!$G:H5CS8,4;L+<\"W/Z%W;SY<7;CGRX?
MGV7]_2K5W?TY9X-D:5;JX^$==Z<K<=+%U>!7RN0X<N/G;,])BZF][BT;^1NJ
MIWT.)?Z__DKS^SE3RZ!9)K^4U#)GO\E5C5_UPD4[]H>WFU/#AOVJQU^?FVR_
MM1<B[GC%O6[/^C'=N/6I<[<Y<NKEILW>X=OZ5N!X8?T+-PI/%@-W76.]5V!V
MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 7YRQ"8D!BQ 8N)B3<B0DSL0
MDS^3L[.[.S^3LOT1 41>\)[.1;7[K:ET_#"\>%N3MG=.$WT!8;+.5B. ?)F9
M\=;];QA#Y._J8RLS1R@L*5;:[[SLUEJ?;ZCKK'0=>6T+:([W0/)SZ9R3C%?;
MR;ERQ]T:5X7=V$*K9#R(S#BI*@"(B (B( B(@"(B ++#L0=G8]TMSM,Z1*,C
MQLUDLEGR;GB/ 8OHL9+K<?,&LL\..C+D?S1>@!C$C%UB>K6/<8]FQ\'HW*[C
MY"N4>0UC.6/P[R"S&.G,58*,IPY;K$,CE8[!_(TT%*I./5&<1N!.Q5JQP11P
M0QA%##&$4448L,<<<8L 1@+<,( +,(BS,S,S,WDOW1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
MM_=QC\2EC[=]0?O3#J9)0V]QC\2EC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!10]L7NDMO]RWMYG!
MQAHK6$[.99/&P<XG)3<.[/E\*!QURD,G^>7Z/JMTV?FP=KHC )7D0%!CM-]B
M_<+:.[ZOK#"E'1EF*&EJ''%)>T]D"9_9:OD/!A>"6078@J9""E==NKBO[!].
M*RV/&H-/4,M2LXW*4JN1Q]V$J]NC=@BM5+4!MP<4]>83BEC+Y1,7;W/QRR@L
M[5W<=Z:SQV<QM?D6TIDY".633V1>2SIJ<W9W8:4H!)D,.Y'Y$+/?ILSBT-6L
MP/X@%5I%W?OAV;M<[;Y!\9K7361P4[DXP3S@$^-NLSDS'0RE0Y\?<$NEW9H;
M!2CPXRQQF) /2" (B( B(@"(B (B( O#MSY.W+?47E$!W#MCV@]=:*,2TGJ[
M4& 8..F''9.S%4\GYX>B1G3,2?Z(3KD)MY&SMY*23:CONMY<%X<6?? :UK"_
MMGDL9%B,D0LW#"-S!#2I,S-Y]4F*FD)_,I'Y=0](@+3VVW?Z:(M>%%JS1>IL
M+(70)VL/+CLY2 G=NN22.:QBKL<(^;\0079G9F9HR=_*0/;KO,]C=3L#4-P<
M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
MUK$Y*AE*K\<6<=<KW8'Y;EN)JTDL;\MYMP7FR^\M<!A<Q<QM@+F-MV\=;C\X
M[>/LSTK4;_5CL5CBF!_/WB;++71'>#;U:>8 QVY.IY(@Z6:+*76S8$PLS"Q%
MEX[LSMPS,_SUG?SY?S= 7RD5.C27?=;X8WI:W)I+/"+=/&5T_)$3MY>;GALC
MB7ZO+WOSR[\DQ+)W2/I FH(V ,]MMA[GT+23X?4%W'\-^B<*=W'9/JY;Z%BO
M#P[>9%SY 6>D4"6G._WT),PME-$:LQY<-U%6GQ-^)GX?Z%WLU97\_+VHA\GY
M^JS=XX3ON]C[3LUBQJG'._/+VM.RR /#$_OHV+9/[F;Z#WF/R,3B!+XBC:Q/
M>Z=GRWPWS?-6-V=^BYIO5E=FX9G?JE+!/79_/AF\9W=V?AG\N>RL;WD.Q-IF
M>/='2<?/1^>[[T']MO+EKT==VX_1\LWA^Z3I= 9MHL7J7;=V;LN0U]U-O9G%
MF<FBUA@3<6=^&=^F\_#<KD='M6[861<Z^XFB9A%^DBBU1A39BXYX=QNNS/QY
M\(#OY%T=_/-[<?I]T=]\N'_]8OPL]J7;2&,I9=P=%QQ@W)&>IL,(BSNS,[D]
MSAO-V;S^5T!WPBQCN=M79^N'B3[H[?PAU,/7)J[ @/4_+LW)7F;EV9W9OEX7
M#LIWB6QE3J\3=314G0XL_J>:K9#GJXXZ/4"L^(S<^TX=3!Y];CP_ &9J*.O+
M=['V?:7+2;B5)B9Y!9J6#U1?8BC][#)3PDT7!/\ T,RD&*3S<#(6)VZKS7?6
M[$57=H,KJ+)<>YZ.FKX,7GQRWPAZA\GM>UT^3?TWD@):$4%>HN_MVVK]38W2
M>L<EY/T.88F@+OQY=7BWY"%N?)W82=FY=A)_)8\:L]('N/UC@ML:X^?L3YC4
MTCN+?)UTZ6'X+G_LW@9N/EY\@++:*H-JSOS]YK[&&/HZ)P8/_0SIX;(7+(-_
MVI,GF+=<R;W=34XQ=OT'/FL4];]YCOGGV,;6X>8IQ2<]4.&"EAQ]K^EDH5H;
M <?H>B<>/>WFW* O,W\C7J0R6+4\-:O"/7+/8D"&&(/=U22R$( //'F1,WN6
M)^X_;XV<TIXC9G</302QM[5:C>'+VW=O>(5L4UR8C;Y08')GY9V9_)45-7ZY
MSFH9_6=09O,9VRSN36,UE+V5G9W]_3+?GL&/+,S<,3-PS-QPS<<586;R9F9O
MK-P@+:FY/?O;68QSBTY@]6:IE'Z"PU2I@L9(WFWE/DK+Y02Y9G;JPS"XOSU\
MMTJ._=3OW=R\H,D.E<!IS2L1,XC:L!/G\B#<^1QO9*KCXY&\FXFHVX^.?8Y=
MG&#Q$!DONIVR]U=;M(.J->ZBR4,KGUTPN#C,<[2<=8MC<1'0QXQFS,SQM6:-
MQ9F<>&X6,PBPMPS,S?49N&Y^7W?YW^5?TB (B( B(@"(B (B( B(@"+FVWNV
MVH=69.'#:8PN2SV5G_H='%U);4_3Y_/)/#%P@A;AW*><XH09G<Y!9G=3X]E#
MN+KMIZN8W<RAX^)B@G^9# 6H9;<@M[9ULQG(VF@@!_**>'#%+*0O)ZOEH28)
M' @OV:V.U9N#F P.C<'=SN2=A.6.H#>!3A(NAK&0N2.%6A7ZO+QK4T0$[.P.
M1,[*RCV/>Y)T[I[U3.;J3UM5YF,@GCTY2DL#IFE(S,X#=D(*UK.21EYG%-'7
MQI$WAG4MQMUG-!M7M!IC1&(@P6D\)C\%BH/,:M" 8FDD=F8I[,GG-:L&S,QV
M+,DLQLS,1NPBS=CH#TL9C*U*O#4IUX*E6O&,->M6B""O!$#=(10PQ",<<8,W
M @ L(MY,R]Y$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!46N\V^/O<W[.5?P'B5>E5%KO-OC[W
M-^SE7\!XE 8*(B( B(@"D5[I7Z8O;/\ M^KOX/=7*.I2*]TK],7MG_;]7?P>
MZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT
M7Q ZD^S.DOQDQRIC( B(@"(B *[3W1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;
MR DG1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$!WJ?=[1[HX,]7:6IQCK_3U.1QBB 0/5.+A9Y7Q,Q>RQ
MY"NS2'AYC?EY#*C(;131E7IZ6*\D,DD,T<D,T1G%-#*!Q2Q2QDX212Q2,,D<
MD9BX21F(F!LX$S.SK9%*MKWPO=V,WKV[VB*#N[D\^N\/5#RZ>CVM44X1\N1Z
M!'-PQ-R3&V4Z>1OR$!6Y1$0!$1 $1$ 1$0!7ANZG^E^VX^Q^7_&3,JCRKPW=
M3_2_;<?8_+_C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"Z?WRV(TKN-
MIR]I;6&(KY?$70X>.46&Q3L,S^#?QUMF\:C?K%P5>U7() ?D2ZHC.,NX$7[8
MV3939"VJ<ZK:Y*==E<G"<)Q>\90E%IQDGU3333/SNIA9&4+(QG":<90DE*,H
MOHTT]TTUW3*./;Z[K_6>RMBSF\<UG56WI3-ZOJ"M6(KN&"7S"MJ:K")M4:,_
MG$>7#_DVV_@O(]*U9"DT9%7-^[VOUO-;+RY4BL12P3Q1SP31G%-#, RQ2Q2"
MX21RQFSA)&8NXF!LXD+N),[.J]7;G[BK!ZE*]J;9^>II7/2==B?2ETY(]+Y*
M;ESD?'S $TV LS.[\1 $^**3I9J]%BEG5M_#OV@*[%7B:ZU5;TC#4(QVJL]%
M])A%?53^-L%Y3WWG&I)R<&<5^%"WE=IZYHO=RQF_>C_H9/?F7[$MIKTE/=)5
M>8,PSMP[\L_D[/YL_P!7R]S\KU)X!^BB?D7XY'Y1^LWU6_SLO<WBV=UGMQF9
M-/ZWT]DM.94'/PX;\/$-L(W%BGQ]V(I*61K^V#M/1L3Q-UAR3=3,N!5<UY>_
M_P %9FJVK(KA;59"RN<5*NVN49PG%]I0G%N,HOXIM,AW]&W8EDMHR@T]IUR3
MCV])1>S4EZ/NO@T]C/CL=]N37&S&7]<TY<>WA;<H%F=+WY)"Q&3$7]J0!]HL
M?D&'D8\C4%I>. L!9A;PE<)[(';]T#O+0 L%>'&ZBC@>7(Z1RDL,>:I]#L,L
MM<&)@RE 7X<;U+K !.)K<=28_ &@Y6R@%QS\OR_^RYKI[.V\?;K9'&7+-&]3
ME">I>HV)*UJM,/T,L%B$@EB-O-NH"%W9W%^1)V>(_$'PEP=94KMOHF=M[N75
M'=6;+91R*]XJU;;)3WC;%))3<8\CD3A?CG(PMH=;:/O8\WUA\75/KR]>NVS@
MWOO%2;:V1JA,[^KXE\;]O6 _>V46!_9,[\/46#"MA]T\?)JC'1N$0:DQ<<$&
MHH(F$1_-]-R@H9=Q<7?QHRQ]HF=_&]:DY-^]>]S[3^@]RMB,9?T7J7'9H&UK
MIV:Q3CD>OE*0G5R?LW\5:&'(4R$GZ3\>N L3MP3L0.5>>&O#S5=&XCTGZ7CN
M5"SZ5'+IWLQI=>F]B2=;?I"Z-<WZ)KJ25KG%.%GZ/J'DVI6?1+6Z+-H6KW>O
MNM^\E^M!RC\65SC_ .:/VW_T.KO_ ':_Q#[6_:G1_P!:54@)/^:/VW_T.KO_
M ':_Q#[6_:G1_P!:52[[3/\ @O3O]>_^7N(5]G+_ );JG\Q_[Z!G B]#)Y6K
M1KRV[MF"I5@'KGLVIHZ]>$.6;KEFE((XQY=FZC)FY=FY477:9[Z?LX[6#-!F
M-PJ.>S,3D#:>T3%)JO+%*//SN4L9UXK&N[,3A+F,GCH#Z>D)2-Q$JA:5HF9G
M6*K#Q<C*L?W,>F=K7S?)%\J7=RELDNK:1;&RZ$%O.48KXR:7]9*HJ)'> 8SU
M#M$;JU^GHZM3C<X<&C=VR6)QF1ZF9O)V-K76Q^^1BZW\R=>SVRO2==P]3A9P
M^SVGZNWV*E::$]1YL8,YJV6(Q>,3H5Q=\'A)?>?BRQ9N<6-FA.K/$TY0:8CM
MB:CDMW,GJ22YJK.7[4MNWF<ID9Y<C?L3GU,]R>0)3D<&XAA8.!BKQPP11A'$
M(M;[P.\,M4T?(OS]055*R,7R(XRFK+XMW56J=CAO5%*-;7+&R4]YKF4-FG#?
MBWASU735BX</-MC<I]90K3CY=D7L[)1]91[[=-]C)SM8RE'IW*.$LD3RA6A?
MPY"C\:.:[6&6N?23>)%+%UM)$_(&#%UBXL[**7G^]_F6:N=P6X6Y<\4MNC%A
ML3&75$,[25*L?#?T5XY.N]>GZ7Z1)HAB9W\FA%R)9$;9=EC3^$*.U>%\UD X
M(9+8B-.$V?GJ@IMR#DSLW!V"F)OT'0_5U6&NRJX;]=WOV7Q^;[+\^J^!HG!\
MHZ)ID,7*LA;D\TK)4X\E8H-QA%5RL7N)KDWD_1M\O.EN\)]I>SEF]3D%F0'Q
M>(=VZKUF,NN<&XY:C7+I>=WYX&8G&NS\NQR.+@\P79G[+5G(9&CI#06"GR&6
MR)@,AQAUSRL/#27\I=<>BM2KL[G++,4=6N#],8]9B!YK]D+L"ZWW<M038ZL^
M'TJ$KA=U3D(B&D(1OTR0XJ#V),K;Y%XA"OQ5@D9VM6H.EA*U[V8>R5H[:;"_
M!6F*+^LV!C?+9JWTRY7+S@S_ #VW.S,P0B3D\%.NT=6N+\!'UN<AP?XC^,&+
MI<9X]+ADY^S4<>$MZJ)>DLJ:[./?R4_,ELD_+4E8;3IFB9^MRC.[FQ=/4N;9
M;IVI;=*TU]8WV\V2\N/5QC*2<3HGL']@#![/XUKUIZ^8UQD*WA9;.M&[Q4X3
M-I#Q6%&5GEKT1<8FLV'Z)\E+"$\X0QC!5KR)(R*E>LZSDZAD6967;*Z^U[RE
M+LEZ0A%=(0BND(12C%=$B;-.TZG$IA1CUJNJ"V45ZOUE)]Y2D^LI/=M]PB(L
M6>X(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@/@ZITQ1S6,R&'R=8+>.RE*SC[]6
M3GHL4[D)U[$)<<.S21&0\B[$W/(NSLSMK^>T;L??VWUOJ/161>227 Y&6M7L
MR X%>QLC-/C+_3PS-ZY0EKSFP<QC(9@!$(]3["15Q._A[-+20Z>W7QT'$E9H
M=*ZF(.&%ZTLTT^ NRBWN..U/;QTD[LY2#:H0&?$$ ("M4B(@"(B (B( B(@.
MUMC-H\CKW6&G-'8H7]<U#EJF/:5A(AJ5I)&*]?E8?/P:%(;%R;CS>.%Q'VB%
MGV!F@=#X[36$Q.GL3 U;&87'U,91A'AF"M3A"&)GX9F<G$&(RX;J-R+CS5<W
MN'^S4\UO4>Z>2K\Q50?3&F",?)[$G3/GKX?7BB]2Q\!-RS^-D!)N1!VLP( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( L"N] ^(/<S[!P_A7'K/58%=Z!\0>YGV#A
M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
M$1$ 1$0!0Q>D-_27=H#[3ZWXQ813.J&+TAOZ2[M ?:?6_&+"(#46+P_N=>5X
M?W.@-SEW3OTK'9I^X!LW_!UIQ9_K #NG?I6.S3]P#9O^#K3BS_0!$1 $1$ 1
M$0!$4&?I#';_ 'V"[.&IKF)M-#K?< WV_P!%B,@A/!=S5>?X8S8"XF3A@,#%
MD+XNP=)7_@ZJ<D/K8R@!K[._E[>@]H+M(ZPU#C+7K6CM'D>WVAS G>O/A=/7
M;0W\O W+_.\]FY<A?BD9_GU#U B8'9HPAN7YPQ#& @//2 L(\OR_ MPW+OYN
M_E[W\W]Z\FY,WL <IOPP11"YRRR$_2$48-YG)(;L$8,W)&3"S<N@+7GHEW8*
M+<+>[);QYJIXFF-FJI#AWD;F&YN#J"E-5H\-[C;3^!GO9$A)N OW\/8C+Q*I
M,VRW43O<H=@>+LZ=GC16A;-88M59&*35^O)GB&.>QK#44<-B_!8X "-L+3CQ
M^G*GBL\HT</5"0CD$C*6) :Q#TJ_L%OMAV@/YIV(KO'I3>VN^9D$1XAQ^N<+
M4IX_4M0'\(6:/,5H\?J,&*6>4K]S-/\ .*H4X1J_+;G]_CV!V[079PU=@,?4
M:QK'2#-K[0I!'U3EG]/5+;S8R-QXD>/.X:SD\.<0]?5);@F"&2Q7K].HJKSC
M+&$@?0R )C^L3=3<_4?A_-OD= 2G=S-V[).SOVA]":\LV)(M+7KH:/UX =9"
M^D-26JM6]>*(!-Y3P-L*6> & C./'35XNB2P,@[B&K:BGCCFAD":&4 EBEB,
M9(Y8Y!8XY(S!W$P,'8@,7<2%V=G=G9:).2,3$@)F(29Q)G]SB[<.S_6=O)UM
M5O1GNWY+O9V<,1A\[>];UQM/:^8+4)RRF=K(8NI"%C2.;E\1R-RMX"6MC[<K
MR'XV4Q60G88(YHH(P+#J(B (B( B(@"(B (B( B(@"(B (B( J_GI0_TDF[/
MV3VO_A8T2K :K^>E#_22;L_9/:_^%C1* U22^;F?SI:_8\W[F2^DOFYG\Z6O
MV/-^YD@-IEWR_=RR=H/L<:<^ *0V=PMM]'::UQHIFZ1FR)8_3=1M0:;&0G8&
M?/83UJ&GU](#EX,8<DD4+3$M6\)<LS\.W/O8A<2%_E$A)F(29_)Q)F(79V)F
M=G9;PGLW_%WH+[2]+?@.BM6CZ1#W=S=G[M#YPL-3>MH+=(LAK[1@QP^'4Q\U
MRZQ:KTY6(.8FCPN;MM9JUQ:,JF)S&+K>#X<4<\X$$9@Q"XDS$),XD+MRSL[<
M.SL_D[.WD[?46SZ]%H[Q0MWMBWVZU%>]8USLQ)4TW(\TO7:RVB)JXEI+,%UO
MXDDE4([>GKI-UCXN(@LD8O?&"+6#J3GN>^WM:[.._P#HC<,[,L6EI[?S,;@5
M =O!NZ-SKM4NSV!?WOI^X=/4U4Q<9 FQ+P]3U[5J&<#<;HOF8;,5,C3J9"A8
MAMT;U:"Y3MUS&6"U4M1#/7L02@[C)#-$82QR"[B8$),[L_*^F@"(B (B( B(
M@"(B (B( B(@([^]2[=V*[..QVM=S[QPEDZ%-L5I''2N/5F=99GJJ:>QT<9,
M_B#ZT[WKOLDT.+I7K4C>%7D=M-MJ+4>1S.1R.9S%R;(Y?,Y&]E\OD;)E)8R&
M5REN:_D;TYDY$4UN[8GL2.[N[G([\JTAZ5OWB8;H;STMG].7QLZ-V9>0,K)7
MD8ZV4W%RM2-\H;$/D8Z9Q<\>$!V?ALC:SD9,[0PR*JP@/#OQYOY,RV3_ *)O
MW=$VV^T>3WHU/0"OJW> X),#'(Q/:QNV^.?_ )%&429F@GU%D7NYZ2(6(O@V
M3"#.0V FKP4;^ZM[!.0[2>^&CMKX!LQX.U8?-ZYR%9GZ\9H;#S5I,],,O(C7
ML9 9J^#H3D7,.0RM:88YGB\$]R3IW3U'$8^CBL95AHXW&4ZV/Q]*L#1UZ=*G
M"%>K5@C'RCA@@CCBC!O(0 6;W(#2 ;_?&!N!]ONM?QGRJZG7;&_WQ@;@?;[K
M7\9\JNIT!LE?0U?I:-QON_ZD_@SVF5MM5)/0U?I:-QON_P"I/X,]IE;;0!$1
M 8O]M[XEMWON7Z__ !4RRTCV'_.E7]CP?N0K=P]M[XEMWON7Z_\ Q4RRTCV'
M_.E7]CP?N0H#Z*VT/HU?TDNQW[#UO_"9K-:EY;:'T:OZ278[]AZW_A,UF@)S
MT1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 :'S"_G.K_:(O]05]-?,POYSJ_VB
M+_4%?30&SC]$+^E*F^ZQKW_5PBM&JKEZ(7]*5-]UC7O^KA%:-0!$1 $1$ 1$
M0!$1 $1$ 7S<QAZF0J6J%^M!=HW:\U2Y3M0QV*UJK8C**>O8@E$HYH9HC*.6
M*02 P(A)G9W9?21 :P'TB;N0&[.FHX]S=M,?+_,5U=D'@FQX&\S;=:FM2=46
M%Y/YXVFLPY&^G9"*5\?8BGP\\@1OBO&K&K>!]I'L^:7W6T'JS;G6F/CRFF-8
MX2[@\M4D;@F@N1. 6JTC.TE:_0G\*]C[D)!/3O5Z]J"2.:$#'33]N'LDY_8G
M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
M0?$\7QH_HNGP_+J?/! =)]I;XN-?_:3JK\!7U"SZ/K_T4W&^V'"?@F13N;EZ
M.^:+3FH-/^L>I_#N$RN'];\'UCU7X3H3TO6? \6'Q_ \?Q?!\:+Q.GH\6/JZ
MFPM[OOL'ML3BM1XSYJGU5\/Y"E?\=\(V$]4]3J%5\+PVR^6\?Q.KQ.OKAZ..
MGH+Z) 2$*J=VL]/7>S)VC\1N-@*ICI+55F;*24H6^=G5N'##K+"1MR =8RS-
ME\=&Y"$4EBG%PT5;J*UBL.>V_P!CK%;UZ.'2]^_\"W:F2K97#YT*(Y&;&6X1
MD@F9JKVJ+V*]RG//6G@];A$NJ*?EY:\3B! Q!9D[6':<@E#Q;>VVC68Q(HY(
MJ[Z:Q,Y2@[Q2"SM9U7G"C$QE$)RQC^V+CCAB&U5'&("("+"(LPB(LS"(BW#"
MS-Y,S,W#,WDS+!'L%=A3%[&8#+8ROE_FCRV;R?KV0SLF,'%2'6A@C@H8V*HU
M[(^'6I\6)N7MF4UBW/(3 /AQQYXH"$/O[OB@TS]TO#_BKK-9Y]WI\2.V/VIX
MW_4)?+[>W8V;?#2&,TH^HWTQ\':EIZB]?;$?#/C>J8K,XSU/U7X3Q7A^)\+^
M-X_K!]'J_A^ 7B^)%WSV>MI/F"T1IC1OPA\*_,YB:V+^$?5?4?7/5V=O']4]
M9M^K]?/]"]9GZ?\ XA(#N1$1 $1$ 1$0!$1 $1$ 6D7[8'QO[N?=5W(_'3.+
M=T+2+]L#XW]W/NJ[D?CIG$!CNMCWZ&O\0&Y'W7;WXI:66N$6Q[]#7^(#<C[K
MM[\4M+("WJB(@"(B (B( B(@"(B (B( M:/Z8G3 .U'HZ83!Y)]B]+#)"+#X
M@-7UUN3X<Q\/U.T[3%&#D+?G8V$BZ7$-ENM7EZ6GN%%FNU]9QT3LY:1VLT'I
MVQP/'3/8N:GU8P$_N(O5]45SY;W 8#\B K.K,#N\?IA-@ONX[0_PB:<6'ZSW
M[JS15C47:;[/V)JB13'N_H3)<!T\^%I[/5-26'?J\NGU?$2]7'M=//3P_#L!
MN>41$!#WW[7;CDV![-.O-78ZUZKJK.10:&T20OQ)\T^J1GK0V8O<[/B,7%E<
M\;BXFT.+D>(O%Z&?4'Q1L B#<NPLP\D[D3\-QR3OYN3^]W?S=_-U=-],K[43
MY37VU>SE.P)UM*X&[K_.0CY]&5U'/8PF" R$N&DBQF-R\Q02 \@17JLPN$=A
MO&I;( KNGH@O=R5<SEM2=I;4^/&>+35V]HG;,+,;]$69DH0_-;JBLQ<-))7H
M9%M,TK LX0G8U!$Q%8%_5J3.*PU[)6Z>,QE<[>3R=RIC<94C$CDM9'(6(Z="
MM& ^T1V+<T,("/FY&S,MU-V!^RGC-D-G-O-J\3& P:/TW2Q]J0&C_-F8FZ[^
M>R)E&$8239+-V\A?GFZ!>::R<IMUF3H#+Q$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$!5=]*K[N.MNCLJ^\&#IL^M]E*N0R]@X0)Y<MM]8\*;5&.G:-G>4L0U:'4.
M/DD$FJM4R<(G!#D;<BUF#/S[EO6=0X"GE:%[%Y&M%<Q^2IV:%^I8C&6"U3N0
M'7M5IXC8@DAG@DDBD A<3 G$F=G=GTM?>"]E*;8[>S<O:B1I?5M':HMT\,<[
MD<DVF[T<.7TS,<AB!S$6!R&/$[! #V)!.;I'KX8##M;([T1#MLGK7974&SV7
MME-FMGLL!8@9CZI)-$:LGO9#$A&[\$\6*R\.9Q@QMUM5JACPZ@BEKPAK<5/A
MZ-#VFVVU[7.AH;%AX,7N/C<SMKD>J7PX"ES+5LMA"FY+I<OAW!4*U?V")YKC
M1#T#-(; ;8!$1 %I^._,[)8[,=J7=72U2L-7!YG,?-]IJ*/^A1X76QSY8JT8
ML #''1S+Y>A!%'UA#6K01>(\@2 &X'5'/TR[LC>MX3:S?3'U2*;!V[6V^J9P
M%N/@G,R2YC2\\Q.3.P4<U'EZ<0@!N1Y\C+HCB(D!0;4W7H[/:I+:?M:;;7)[
M+5\)KHLCMGJ'K( B.GJJ.*3$'))()='J^J\9I^9G#IDD$3K 7YH=GA%7N8W+
M7<?9JY'&69*62QUJMD,;=A+IFI9&C/';HVX2;GIEK6H89XWX?@XQ?S]S@;V1
M%B-V">TU5WEV7VRW/J] OK31F"S5Z&/EAIYB>C$&;H,SF9?F'+QW:C.Y$Y#"
MQ=3L3.^7* (B( B(@"(O5O7H:T$UFQ($->O%)//-(3!'%#$#R2R2$_D(1@)$
M1/Y,+.[H"@)Z9;VLWR&J=J-D<=<=ZVGJ&3W%U54!VZ3RN6XP6D6F9Q8A.EC(
MM43#TD4<@Y8'+B2NS-246=/>:]JJ?>S?_=C<LY2DHY_6.4KZ=$NIF@TE@IGP
M6E8A I)1B*3"8^I=MC"30R9&Y=LQBWCOS@L@,X^[0[*LF]V_NU.U_@/8HZFU
M93+/"P=8!I?"1S:@U-),/DSPOA,7=@(2(!E.>.!C$Y@=;H+'T(:L$%6O&,5>
MM#'!!$'T,<,(#'%&/O?I !$6Y^1E0(]#4[([9#4VZ>^5^N3PZ>JU=M--S$#>
M'\(Y2*GJ+5!PG[7,L&/^9N(_Z&<<=[@2,)Y!'8!(#@^YFWN,U;IS/:6S, V<
M3J+#Y'"9* Q$QEI92I+3LCTFQ"[^%,73RSLQ,S_(RTF/:3V'RNUNXFNMMLW$
M<63T)JS.Z6L=8R#ZQ'B,C/5I7XO%$3.KD\>%3)TI^.FQ3N06 <@D$GW@RUK_
M *7MV0VT;OKI3=7'U'BQ6[FFI:V3G 6:)]7Z(]2HV?%Z!]FQ=T]D<*<1SR==
MD,=:& 'CH3.(%2]6B_1,^V V@NTA8VZR-@XL)O)IZUB*K$7%>+5^EX+>H,*1
M]<@QQ/D,5%G\<T@@<MBZ6*J-Y&*JZ+M38K>/*[=ZWT?K_!.39C16IL+J?'L!
M/&4L^&OPW"JM(+L4;788Y:9R"[$$=@W%V=F= ;QQ%U7L9N[B-P-%:1UW@)VM
M8/6>F<'JG$6&$@\7'9[&5LI3-P+VXS\"T#212<21'U1R,QB3+M1 $1$ 1$0!
M$7QM19^KBL?>REZ48*.-IV;]R<N&&&K3A.Q8E)W=FXCBC,G\_<R UR?IA/:J
M;5&]VB-JJ5IY*&U^E9<ME8 .(HH]3:X*K8$9&!O%"W5T_C,=(\<K\!7RD<D7
ME:D5119,]M'M%6]W=WMS-SKDQ3EK?6V?SE,B\3YWAI;LE?3U6,92*0(*6GZV
M,I5XS=SC@KQ@?M,_.,R D![JKLKS[U=HK:';L(GEH936.-RNHWZ"((M)Z7/Y
MI-1O(XBXQ^M8W&2XNN<O$3WLA3A)R*48SW-->O'#&$40!'%$ QQQQBP!'& L
M(  BS"("+,(BS,S,S,S<,J!GH9O93>]J'=O>R_59Z^$JXS;735HF%W?)7PBU
M'JUHB9^H'KX]]*QFQ-TR->\N7AY:_P H B(@"TK?>/?3&=H3[N^\?\(^I5NI
M%I6^\>^F,[0GW=]X_P"$?4J PS6PF]"U^+#?'[I.#_%*DM>RMA-Z%K\6&^/W
M2<'^*5) 72D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 4[/3.OB-VC^[&'XAZ
MR6NB6Q=],Z^(W:/[L8?B'K):Z) 91]AOX[=F_NJ[>?C;B%NS5I,NPW\=NS?W
M5=O/QMQ"W9J (B( B(@"(B (B( B(@"(B *DSZ:??C;0>PE5^AYI-=:KL-[0
M^(,<.F8XRX#Z/H,IPZB;@6(!9^7=N+LRUX/IF6^-?([H[1;=UK'B2Z8T=F-4
MY:NS<C7GU/E(\=B"<O<TLE;!90CC^C&-X3)A"6-Y *9J^=F/SI:_8\W[F2^B
MNX>SOM)>U_N%H+0F,C\3(:TUKI72M4>'=F/.YRCCCFD^08:T-B6S8D)VCAKP
MRS2D,49DP&Z;[+T11[9[=@;=)AH72($+^\2' 8\2;R^H[.R[T7SL/BH*%2K1
MJ@T5:E7@J5XV]T<%>,880;ZP1@(M^LOHH JR_I:_TH&3^Z-M[^%I59H59?TM
M?Z4#)_=&V]_"TJ U>Z^=F/SI:_8\_P"Y$OHKYV8_.EK]CS_N1(#>]U_Z''_W
M!_U67[+\:_\ 0X_^X/\ JLOV0!$1 :^+TTSXPM@OM-U]^&],*E8KJ?IIGQA;
M!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN @
M/FY?$5;]2U1O5H;E*[7FJ7*EF()JUJK9C*"Q6L0R,4<T$\1G%+%()!)&1 3.
M+\+5E^D'=R]<[,^N"UMHRGXFR.O,L0:?:%I"?0VH;$,MNQHR^Y=3-CYV@M7=
M*V^MF.D$^'D 9\7%->VHRZ7[0_9]TGNKHK4>WNN<3!F]+:JQLV+RV/G9O;AE
MX*.Q7D<2>O=ISC%<HVP;Q:MR"&Q&['&R T>Z\?K.[.SL[$).)"[/R+B3.SB0
MOPXD+L0NS.SL[,ZDP[UKNR-7=E?=.YH3/>L9/3>3CFR^WVL"B 8-4:;\=X6\
M=X>8*^H,1)T4\]CN(CCE*MDH( QN4H$<:" V1OHTG?>%N_@JVQ&Z>6EGW6TK
MC)9=+Z@R!Q]>X.D\>PBT<TS,'B:KTY7*.'(@8>+F,6$.9&2Q:BS+U[<:T7>@
MM>9O2N<P^IM,Y6Y@]1:?R-7+X3,X^3P;N,R=*09:MNO([./5&8\''()PSQ%)
M7L1RP2RQEMC^X^[WG"=JK;4;%^2GC=UM'P4J&XNFX >O$=F6)QJZHP<)R2^)
MI[.G#.40A+)+C+L5C'VQCZ:LEH";5$1 $1$ 1$0!$1 8[=K[XI=T?N=ZV_%K
M)K2#X?\ .E7]CP?N0K=\=K[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"@/HK;!^C$
M_2/[+?LC=/\ AFW#6I\6V#]&)^D?V6_9&Z?\,VX: GM1$0!5AO2LNV^^V/9T
M+;_%W/5]3;W7K6D(HXY&&=M'4(:]O7-KI8AD]5EHVL?I^P8=3-)J*O%(#Q3&
M[6>5JZ/2LNU%\WO:EMZ3JSO+B]H],XS28 W+1AG,R$6I,\[>?09^'<P]>20/
M-BJO7D=CKD  5IEX(F9G=W9F9G=W=^&9F][N_P C-\KKRLU.[C[+_P#-IWXV
MHVM.(Y:>K]7TJV7 &9W^9[%06=0:E)V?] .G\1DGDX\VCZG;A^'8#8J^C!]W
MU7V=[/6,UOE*(PZWWJ@QNM<M8ECZ;=72TE>271&$+J;JBBKXJ]+F)(.?*]F[
M;R<$S1Q61UZ&+QE>E5K4ZL005:D$-6M#&S#'#7KQC%#$ MY"$<8" LWDS,S,
MO?0!$1 $1$ 1$0!$1 $1$ 1$0!$1 12]]CV-(-].S5N7HT*D5K.T,--J[1Y&
M!G+7U7I:&;)XPJOA1RS-/=CCM8EQB%GL09&>I(7@6)F?3Q5IVECCE%G89 "1
MF?WLQBQ,S_)SP_GQY+>[*LEF?1)^R+<N6[C4]QZ36[5BTU/'ZWDJ4*C6)CF:
MK1JAC'"M3K]?@UH!=VA@ (V=^GEP-7ZMA/Z&;VBSR>W.[&U=F8S/1NJL;JS&
M1./ 18O6M.>"=@-WY,BS&G[\L@#[,32QDXB4W5)F3^5%>R-_2;I??_-_NQ2#
M]W7W)6RO9>U+G]5;7'K0,CJ7!AI_*Q:BU,6:HS4H;\&1@D"L5*NX6Z\\!##/
MXC]$-JW&P/XSD($O*(B (B( B(@"(B (B( B(@,;NV3\4&ZOW-]<_BQE%I#\
M/^=*O['@_<A6[P[9/Q0;J_<WUS^+&46D/P_YTJ_L>#]R% ?16V8]&D^DFV3_
M &/KC^$C6"U,ZVS'HTGTDVR?['UQ_"1K! 3L(B( B(@"(B (B( B(@"(B (B
M(#74^F$=BFOIC<W1.^.'IA7I[ET#TMJR2(789M6Z6I1/AK\PB'2UG(:6C]0.
M4Y&>6#3M4 BZHII#IRK;&>DH]FB/<KLC;B]%9K&5T"6.W*P;L#G-%=TO)*.0
M]781(FEMZ<R&=QI./#M#>F\W9W$M3DS\LSMYL_F@.5Z$UWD]+9[ ZIPLIP9G
M2^<P^I<1-$?AR193 9*ME\>82</X9#<IPNQLSN+^TWFRW:79BWSQNYVW6A]Q
M,03%C=:Z5P>IJG2W2PQ9C'P7?#Z7.1P>(I2B<",C!P<3?J9UI UM#O1.]]SU
M7V2\1INS8\:YMMK#5NE1$B.26/%7LI)JG$ 9F1?.X8,_+2J1CTA!3I5X  8X
M@Y LQ(B( M7)Z65].%DON9: _=-0+:-K5R>EE?3A9+[F6@/W34" K5*U9Z'U
M]-#J;[CNH_QGT>JJ:M6>A]?30ZF^X[J/\9]'H#9B+K7>+9_36X&EL[HO6&(I
MY[3&I<;9Q.:Q-Z)I:UVC:!PDC,7\Q,?*2&8'&6"8(YH3"6,";LI$!I]>^)[J
MC4W91W0ETS<.;*Z"U*=[*;:ZJD9W?)X:*87FPF4-AZ0U)IP9Z];)@SN-ZL=/
M,0, 7):U2)E;I3O">P9HKM'[7Y[;'6\!#5R(-;PN:K1PEE-,:AJB;XO/XHY@
MD$;-.4G&:$F\*[2EM4)V>&R:U"/;2['6M]@]R=1[7[@8]Z>=P%ABKW(A?X-U
M#A++D>(U)A9NHQFQF5K,T@AXA3T+0VL7>&*_1LP@!CIIG4V2PF2Q^9PN0N8G
M,8B[6R6*RN.L'5OX[(TI@L5+M.S$['#8KS $D9L_'+<$Q Y"^U4[@SOEL?VH
MMOBPFIIHJ>\V@J&/K:VH]$->'4M0Q>M3USA(86"+U3*R0&.8H0Q1? F9>2NT
M(8ZUB9[6J07?W9;[3VL]F=?:;W+V_P F6*U1I>\%NH9.14LA5)Q&_A,O +MZ
MYALQ58Z61JN[.\1M/ <-N"M8A W>2*/;NRN\6T9VG-K,1N+I,_5;;O\ !FK-
M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
M'$[%:KD)0R-Z(3A8Z%*RQ6*P\SQZ<:]D+-NQ8N7;,]V[<L3V[MVU*4]J[<M2
MG8MW+,QNYS6+5B22>>4W<Y)9#,G<B=W ]53Z^C<]@X=[^TM@+F6HE:T;M/%6
MW%U$\@2/4GR="]&.C,3.0N($5W.Q?"?JI2<6:>"O#+%/6:>$X"#-A%R)V$19
MR(G?AF9FY=W=_)F9O-W^1EM3/1E.P6>S/9NPV>S- Z.L]WI8=?Y^.Q&T=RIB
M;<'AZ.Q<X.WBP'5T\]:[/3D=CJW\G=CEBBL>.* L2LO*(@"U%??Z]A2'8'M+
MZQP&*IA2TAK4!W'T9!!&05*F*U'>O!D\37\F 1Q.H*>4A"M'PU2C/CXV 82@
M<]NHJO'I7'86_FF=GHMR<11*UJK9&W+J9G@&/UB;1.1*I4UQ"1$/457'4(:N
MJ)XQDC?HT^1BTT@!7F UBRGS]&[[>!;(]I;3M')W'KZ,W8"';W4T<AL-:'(W
M;+2Z.S!]3LS34<Z38SJ;EWIYV\/29^%T0&,Z_DQ=V=A(HR_0R1DXR1DWF,D9
M-YC(!,Q 3>8DS$WFS(#>Y(HCNX_[>P=HCLZZ)UE=N0VM7X:L.C-?C'P)QZPT
M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
MB%V=P.6HB( B(@"(B (B( B(@"(B *OYZ4/]))NS]D]K_P"%C1*L!JOYZ4/]
M))NS]D]K_P"%C1* U22^;F?SI:_8\W[F2^DOFYG\Z6OV/-^YD@-XUV;_ (N]
M!?:7I;\!T5W0NE^S?\7>@OM+TM^ Z*[H0!$1 1&]]UW>\7:/[/NK]'4J<-C6
MF$@DU?MW,;QQR1ZOPE6S)3HA9D$O AS]:2W@+9=0!X&2(I#$0ZAU DL$L1R0
MV()JUB&22&Q5LQE#9JV(3**>M9A-FDAL5Y@.&>$V8XI0.,V8A=EO;5JY?2?>
M[BDV9WWL;@X*B$&W^\\EG/TFK5WAK8;6\ 1OJS#'T1C6'X4E(-3TNAVDE?(9
M6,HF]1\>P!6I6PZ]$1[Q:'4VA,YV<]0WF;/[=C8U)H8;$G,N2T-ELB<F4H57
M*1RD+2N=NB)0, -!C,WC!@>2."<*NO%66?86[8>?V"W9T5NSIP9;%O266CL9
M'%QS' V>TY:_,VHL!(8<\-E,5)/%7*098H,@-*U)#,U?PR W7J+KK:+=? :[
MTMI_6>E<C7R^G-48BAG,+DJL@207,=DJ\=JM,)1D8\O'(S2!U.\<C'&7! [-
MV*@"(B (B("%'O\ 3O#P[/'9YU1E<5D IZ_UM7LZ(V]$>@[4&;S%66&WGJ\,
MC/&?S+XP[&98I@DKM;@I130SC.U>74>\N_+D1F1.Y&<A$<DAD[D<DDA.Y22&
M3N1F3N1F[D3N3NZGQ](T[Q>'M =H/(U<!>:[H#:@<CH;24L,Q2TLED8[D?S8
MZBJ-P$3Q93+4:^/K68Q,;N-P5"U'8FK35^B Y ?Q(;"+D3L(BSD1._#"+>;N
M[_(S-R[NMI]Z,UW<;[';!4M59_'%3W WDCQ>LM0#9B\*_C-/O4DDT9IRQ')&
M$]23'XR_/D;M&;Y[5R^9R,,XQRQO#%1@[AGN\9^T5VAM+X>_0]9T#HB>OK;<
M6:6-SJOBL:<LN%P1CQX<TNIL]7J4#KR&(/B(LS9(9O56JV=N?#"$8!'& QQQ
MB(  "P@ "S"( (LS"(BS,(LS,S,S,S,@/U1$0!$1 :.??[XP-P/M]UK^,^57
M4Z[8W^^,#<#[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_
M %)_!GM,K;: (B(#%_MO?$MN]]R_7_XJ99:1[#_G2K^QX/W(5NX>V]\2V[WW
M+]?_ (J99:1[#_G2K^QX/W(4!]%;4#T=3L\;?YSL:;+93-:%T=F,G;IZS>UD
M<IIC"9"_9>+<?6$$3V+ENC-8F>.&*.$'DD)QBC",>  6;5?K;0^C5_22['?L
M/6_\)FLT!*=_.F;5_P!C/;_[S-.?[M3^=,VK_L9[?_>9IS_=JR!1 8_?SIFU
M?]C/;_[S-.?[M3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/
MYTS:O^QGM_\ >9IS_=JR!1 8_?SIFU?]C/;_ .\S3G^[4_G3-J_[&>W_ -YF
MG/\ =JR!1 8_?SIFU?\ 8SV_^\S3G^[4_G3-J_[&>W_WF:<_W:L@40&/W\Z9
MM7_8SV_^\S3G^[4_G3-J_P"QGM_]YFG/]VK(%$!C]_.F;5_V,]O_ +S-.?[M
M3^=,VK_L9[?_ 'F:<_W:L@40'Q-.Z:QV'I5\9B:%+%XVG'X53'XZK!2HU8NI
MR\.M4K1Q001]1$71%&(]1._'+OS]M$0!$1 :'S"_G.K_ &B+_4%?37S,+^<Z
MO]HB_P!05]- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1
M$0!$1 $1$ 1$0!$1 $1$!J?O2;]01Y'MH;GR1]+M2Q.A<4?2Y/Q)1TM18^KJ
M8?;YE\V9G%O+@G\U @I0.^LW%BU5VL]_LO7D\2LVX5_$PDTK2B/S/4J&!L1B
M;,+,T=W'6A(./G4C'&_+B[O%^@)BO1^]/R9'MD;$#&#'ZEJ;)9*5NHAXBIZ8
MSKN?LL_+@YB_2_2+^?+\>3[>9:L/T5+0,F:[8^F;@Q>)#I?0>OM0V?J1@5/'
MZ>@E?S;Z&WJ"L+>_VC;RXYXVGB (B("HIZ9+]+SMY]V'%_BCJY:WI;(7TR7Z
M7G;S[L.+_%'5RUO2 [\[)_QK[5?=/V\_''"K=Z+2%]D_XU]JONG[>?CCA5N]
M$ 1$0%,CTT/2Q3;2;+9MH^1Q^Z61Q12_//8+,:,S5L8^&;PG\1L$1<F_B-X3
M>&SB\O&O&6T ]+9VP+/]D:WE@%R/1&Y&AM4"S"1N,=F7(Z-L&S#[F"MJV8Y#
M=G$(FD,N&'J'5_H#U+\+R031M[Y(I ;]<@<6_P!*W4W=NZU;4G9]V3SXOU#F
M-K-"Y$2Z1#J&UIO'2B_2'LCRQ,_ ^3+2R+;0>C9[M?-=V,=FI)91DN:<HZBT
M7;$7(O!;2>K,WAL6!N3-[<F!KXFR0CR(>L= N["@)T$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!:@7O[_IQ^T!]N53\6, MOTM0+W]_TX_: ^W*I
M^+& 0$1*O!^A3?\ 2/M(?87:7]_;DJCXKP?H4W_2/M(?87:7]_;DH"_:B(@"
MX;N+_P!'L[]ALI^\9US)<-W%_P"CV=^PV4_>,Z T6&'_ #I5_8\'[D*^BOG8
M?\Z5?V/!^Y"OHH#:A>BM?2:Z(^V?7_XUY%6+E71]%:^DUT1]L^O_ ,:\BK%R
M (B( B(@"KS=_P"]R]C^T[H3YI])5*]3>S0U"<])W>J*M%JK%#(5FWHC-3R,
MP^!:)Y;."N2&/P5F2%R,:%W(A+891 :*3/8*]BK]_%92G9QV4Q5ZYB\ICKD3
MP7,?DL=9EIWZ%N$O:AM4[<,U>Q$_F$L9CR_'*^4M@[Z3KW'QZPIY'M);28=B
MU7AZ4EC=32^,I\S:KPM& 7'6./@K,QS:BP56$X\Q$,$]C-X=H9F..SAQ"]KX
M -B9B%V(29B$F=G9Q=N6=G;R=G;S9V\G9 33=R-WNF<[*>Y@6[LMJ_M/K"S3
MI[D:>BCDLRPPQ,<-/5V$KB;=.<P32N]B*,#/,XAI\<0'9CQLE;;,;<[BX/5V
M!P^J-,Y2GF]/9_'5,MALOCYAGI9''7H0GJVJ\H^11RQ&+\/P8/R$@B8D+:,-
M6T?1JN^Z_F.9^IL7NGF8X=I]3WC;2.>R=@Q@V^U1?L,34)K$I/!5TEJ&S-*4
MY2O%7PN9D&WX@4[]QX -D^B\,_/N^7W?77E $1$!KT?32/C-V'^T76OX?P:I
M>JZ%Z:1\9NP_VBZU_#^#5+U 38^CD_3L["_977'\%6O%MOUJ0/1R?IV=A?LK
MKC^"K7BVWZ (B( M6AZ5U]./J#[GFWW[VRBVEZU:'I77TX^H/N>;??O;*("M
M\K1OHD>WV U)VD=7T-18/#Y^C'L_G;,=/-XREE:L=D-6:-C&Q'7OP6(HYQCD
MDC&8 :1HY) 8NDS9ZN2M>>AW_3.:Q^XQG_QOT4@-AG_.F;5_V,]O_O,TY_NU
M/YTS:O\ L9[?_>9IS_=JR!1 8_?SIFU?]C/;_P"\S3G^[4_G3-J_[&>W_P!Y
MFG/]VK(%$!C]_.F;5_V,]O\ [S-.?[M3^=,VK_L9[?\ WF:<_P!VK(%$!C]_
M.F;5_P!C/;_[S-.?[M3^=,VK_L9[?_>9IS_=JR!1 8_?SIFU?]C/;_[S-.?[
MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
MOVHB( N&[B_]'L[]ALI^\9US)<-W%_Z/9W[#93]XSH#188?\Z5?V/!^Y"OHK
MYV'_ #I5_8\'[D*^B@-J%Z*U])KHC[9]?_C7D58N5='T5KZ371'VSZ__ !KR
M*L7( B(@"(B (B(#^#!B9Q)F(29Q(79G9V=N'9V?EG9V\G9V\V6M8])7[DO^
M8OG[V^VVF/$-J-6Y:%M586J!,&@=6Y>R\;68(Q'HBTKJ2])&-?S%L5G;3T>'
MJ9"D%?95+A^X6W^$U9@LOIG4F,IYK 9_'7,1F<3D(1L4LCC;\!UK=2S"?D<4
MT,A@7N)N>H7$F9V T7Z_DP$A<29B$F<29VY9Q=N'9V?RX=G=G;Y?E4TO?;=T
M1G.RCN3ZE1#(93:?5TMJWMWJ:U\_DB&(BEM:/S=L!$'S^$A*,HIY(X/AK&$%
M^ "FKY(*T+B V%_HQ??>2:XQ]#LY[N9UY];XB"2/;#4>3-AFU;IVC4:5]+7[
MAE^:]3Z?KPV)*,TC#8S& A#K>SD<9>LV[H*T56F=39+"Y+'9G#7[6*R^(O5,
MGBLG1E*"[C\C1G"S3NU9A\XYZ\\82@_#B[CTF) Y"^U2[@WOF<9VH= /@M36
M*E'>C0F/H0ZSQ@"]>/45 ^NI2UOAHB9HY*V3DKD.;I5#E^ \L;1S1UJ62P[V
M + :(B UZ/II'QF[#_:+K7\/X-4O5="]-(^,W8?[1=:_A_!JEZ@)L?1R?IV=
MA?LKKC^"K7BVWZU('HY/T[.POV5UQ_!5KQ;;] $1$ 6K0]*Z^G'U!]SS;[][
M91;2]:M#TKKZ<?4'W/-OOWME$!6^5KST._Z9S6/W&,_^-^BE5#5KST._Z9S6
M/W&,_P#C?HI ;+1$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1?C8ZN@^CR+H+I?Z
MA</T_P"=:E7<#OZ.VC@]0ZBP=C?3403X/4.=PLP_ ND&Z9,1EKF.-N/@ ^."
MK.W'6?'NZS^B<#;8(M1'^6#^V7_9VU%_^!M(_P 7E>6]&-[=^X.^^RNK<IN;
MJFUJ_5>FMP\AAY<M=KX^K8;'6<5BLGCZKPXVG2KM'!%:)@/PG,W<W(W+EF L
MC(B( B(@"(B (B( B(@"(B X7N'MU@=78/*::U1A\;J#3V:IS4,MALO3@OX[
M(4YQZ9:UNI8 X9HB;SX,7<283%V(1=M6YW_O<KGV6]9TM2:(AN6]EM;6#AT]
M)9LV<A<T=GHXY)[.D<I=M'-;M5):X/=T]E;<\]BU -O'W9/6J$5C(;5=1U][
M%V/<?OMV>]S]N+@ US):=L933MLFY/&ZKTZXYW3=^-Q$I&"/+4*T5R*-P*YC
MI[N/.0(;<CH#31HO#!(/LS1E#,#N$T)?10S _3+$7DWM1R,0%Y-YBZ\H#:$^
MBE=KBSN-V8H=*96T]C-;0:ENZ&?Q"8II--RU*><TK.7#,_AQ4LC8PL;R.\IG
MA)C)W$@(K,ZH >A9:ZLQZLW\TPS\4[. T-J$A\O:MU<AG\8)/Y<MTPV79O:X
M?J?R\N5?_0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 6D7[8'QO[
MN?=5W(_'3.+=T+2+]L#XW]W/NJ[D?CIG$!CNMCWZ&O\ $!N1]UV]^*6EEKA%
ML>_0U_B W(^Z[>_%+2R MZHB( B(@"(B (B( B(@"(B (B( B(@"(B CH[V+
ML30=H38'</;#HB^%\KB6R6E;,@B[T=78*8,MIVS&3G%T=>0JQT['$L0S4K5J
MM,?J\\PEIJ[%2Q7DEK7*TU.Y6EEK7*=B,HK%.Y7D*"U4L12"$D<]:>.2":,P
M$PDC(3$29V;>UK6/^E,=VC+M)O)_-<TUC&AV_P!X[-B_>.L+-!A]R6>:UJ&K
M-%& A6BU) \>H*4C^5O(_#[&XRQ@4X%6]6W?1/.\MAVWW-R.P^J;;5]);MW"
MR.EK<\[A7Q6XU*A%"%,P/YU%#JS"T!I!.)QDV7Q6)J$$[Y$#J5(E[F.R5JE9
MK7:-JQ1O4;->[1O4Y3KVZ-VI,%BI<J3QNTD%JI8CCL5Y@=CBFC"078A9 ;V1
M% /W!7?#8WM/;:AB-1W(8-X] T<?0US0,8J[Z@@\+P*>M\5 #M&=+,'#(V4@
MKB(XK,-/7*&"I8QSSS\( B(@"(B (B( B(@"(B (B( B+ #O+.\,T;V9]J\W
MN1JR1K,\ M0TOIR&6,<EJK4MIG#'8B@!D+M&QOZUD[G]"QV+@M7).7C".0"N
M)Z7!WEH:7T7B>SCI:Z#Z@W B#-[@R03MXN)T/3G!\?AYXP+J"?5V4C=_GK='
MP1A\@'0Y7:\L6O)7=W:2[1&J]VM>:JW(UOD"R6J-7Y>SELG/R_@5VE=@IXRA
M'P(P8S$T@KXW&UP !BIUHF<>MS)^D4 =^&=W\F^J_P G\O\ ZUM!_16NP\>U
MW9QJZYR]+U74^]-V/64WB1N%F+24(2U-$US(F8O!M8HI-00Q\] MGB+AC,V:
MB-W-W=UY#M,[Z:8T,5>5]&XF:#4^Y&0#AHZFD,;9C*?'-([$PW=2V6CP5(>D
MG$;5JYTE'1E9;@_"X>KCJ=3'T8(ZM*C6@ITZT(],->K6B"&O!$+>0QQ1 $8#
M\@BS(#Z:(B (B( B(@*+GIFG9/*6AM'O=CJW_-UG*[<ZLF "?\RY1H\WI*W*
M0^S''5O4\]CS.7DI9LQ0B P\/HDH9+<@]\+V2'WN[-F[.@*U<+.<MZ5O9C2@
M'Q_TMTV'P[IT!(G88WM9.A!1*8F-H8K1RL)$#+3=QFY").) [LSN!MTF#_*$
M@OYB8/R)B_T),[?(@.Y.SUO=D]M->Z+W$P[RMD]#ZGPNIZH0%T2S_!-Z&S9J
M ?Z%[U,;%)RX?@;!?K+=I;5[CXK6.E]-ZNP=J&]A-58'#ZCP]ZL;2U[F+SF.
MKY/'VH)&\I(;%2U#+$;<,8&)-Y.M&8MIAZ+-VK0W%[*NG].6)RES.TF5O[>W
M@D<RD'&UNC*Z9-R,GZX_@+(U*L11LT,;4RJA[=>01 L):^UOCM,X+,:CS$[5
M<5@<7>S&2L$X,T-''5I;=H^9" .1AA/I8C%G+ANIN>5I+^T[V@LKNQN/KK<W
M-R')DM=ZIS&I96,S/U6MD;9GB\;$Y^TU;$XD:.*J [-T5:<(NW+.[[+CTISM
M<EMKV6LSIO'VO S^[N9H: I]!=,P825I,OJVP/E_0SP>.FPYN+M)'+F8) ^@
M(AU:K( MBWZ'3V2RT_M!KG>'(U&BO;DZJDP6 F(?;ETEHH7HG.!\^<=G5<^H
M:_AN/(_!8RL;M-TAKO-.Z6R>=R..P>$JR7LUG,C0PN&I1,Q2W,OEK<..QE2)
MG\GDL7;,$(,[LW4;=7#<K=C=COLY8W:':S0.V6)8'I:)TKA]/C)&Y$-B>C3C
MCN6V*01E/UNYX]GKE;Q2\7F1W/J= 9)(B( B(@"(B (B("E%Z9-V/I,MHK;/
M?+&0.4VBLM;T-JH@ >?@#5QP6,%>F-W8FCQNHZ#8T #K(CU-UD/APE)'K[%N
MI^\*[*]7>W9+<W:VR\4<VL=(9G&8JU,+F&/S_JDD^G\D3")&XT,S#1M2C'Q)
M)#')$)#XG*TLV4P]W'6[>-R=66CD\;;M8[)TIVZ9J61H6)*=^G,WN:6K;AF@
MDXY;JC?I=VX= >SI[4=_#9''9G$S^K97#9"CE\59\_S-D\7:AO8^QY>_P;=>
M&1V\^6'AV=GX6ZG["7:<H;S[-[:[I8YQ:'6ND</F;$+&,A4LK)6&#-XR4P$0
M*?%9F&_C;/0+ UBK(P^3,M*"MB5Z'1VN6S^UFOMF<A:<\AMSJ"/4F#@D)NLM
M+:U.U/,,'43D84=1TLFTX@+1U@R-'JX*RSD!<CD,1%R)V$19R(B=A81;S<B=
MW9F9F\W=_)F;S6FI[VWM73;U=I#=W7OCE/BK&K\GI_2_)F8!I+2=B33V .)C
M9GB'(U:#YN:!N0AN96T G(S>(>T'[Z_M=-LEV8MU];UYABS1X!]+Z7%_#(I-
M3:PL0Z<Q)C'(<;2QX^3(GE[@"32MC\=<DB8I $7T[D,?0 CR1=(L/43\D7#<
M=1/\I%[R?Y7=W0'ZJ]3Z&;V2QDDW9WROTV=XI:6V&F;4D3.[.$-+4FJSJROP
M0"7K6G*UA@8HYC@8')I*I"U$^U.T44DKL[M'&9NS>]V 7)V;GY?);D/N=.R*
MVQ_9NVKT!/7]7S%;3D&;U,+B0R%J?4I%G<[XPFS&,L-Z])5*-W)H6@&",GBC
MC0$FB(B (B( B(@"TK?>/?3&=H3[N^\?\(^I5NI%I6^\>^F,[0GW=]X_X1]2
MH##-;";T+7XL-\?NDX/\4J2U[*V$WH6OQ8;X_=)P?XI4D!=*1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$!3L],Z^(W:/[L8?B'K):Z);%WTSKXC=H_NQA^(>L
MEKHD!E'V&_CMV;^ZKMY^-N(6[-6DR[#?QV[-_=5V\_&W$+=FH B(@"(B (B(
M B(@"(B (B(#PM0)W]NV4>D>V-O]B(8PBAFU=CM00QQLPQB&K=(Z;U231L(B
M+"TN8D%V%N!D8P=W(2=]OXM65Z5KIF*AVR-26H^GJS>W^WN5G81<7\:*CD,(
MSF[N[&;P8:#VV8?G;1AQR'4X%<17+?0OM=RUMV][=,LY-!F=N=-9TQ8G8"ET
MUJ:UCXW(&9Q(@#5DK";DSBQFPL3&71325I#T1#4S4^U3E*'6(EF-J=4PL#@9
M%(U++Z<N.PF/L1N+@).\GD3>R/M(#9P(B( JR_I:_P!*!D_NC;>_A:56:%67
M]+7^E R?W1MO?PM*@-7NOG9C\Z6OV//^Y$OHKYV8_.EK]CS_ +D2 WO=?^AQ
M_P#<'_59?LOQK_T./_N#_JLOV0!$1 :^+TTSXPM@OM-U]^&],*E8KJ?IIGQA
M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
M@"(B (B( B(@"(B *A_Z3YW'O!9GM.[28EW.0O6]X-*8VL[N8A $;[A8FK#[
M#'$$ !JVI!"TMMY&U"WB6!RI3WP%Z]NI%8BE@GBCG@GC.&:&8!DBFBD%PDBE
MC-B"2.0"<# V<2%W$F=G=D!HEF)G9G;S9V\G][.WR.WR.S_57E67_2(^Y-L=
MG75Y;D[=8E_YAVLKHB%>L92-MYJJW-*1Z=GA(&>#3649PETM9&:<*\S7<'8&
MF%?#?"%:! 76/1A.^Z^9:[B>S1NQF7;3>3LO5VEU/E+7SO Y&P3%'H"_9F\H
ML3D9GD+2TTLK14;TC8 &"O9Q44&P79:(TP8FX?GY/-G<29V?D2$A=B$A=F(2
M%V(29B%V=F=;+KT;;OO'WPT]%LQN?DP+=W1^,!\)E[)QQR;B:5H1-&UU_H?%
MU/@X8PCU (MU9"N4&: 7*3(#7 L8=K[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"M
MWQVOOBEW1^YWK;\6LFM(/A_SI5_8\'[D* ^BML'Z,3](_LM^R-T_X9MPUJ?%
MM@_1B?I']EOV1NG_  S;AH">U$1 %4R]+H[%9:ZV,P.[.+JE+G-F<Q//?*(2
M(Y=$:M/'8_4#2LQ@'1CLE1P&7:>0)BK5Z=^* 8VOV#5LU=?[L;8876VE]1Z.
MU)2BR6G]58/*:=S="<6*&YBLS2GQ]^N;/\DM:Q('+<$+NQ"[$S.P&C/7\F#$
MSB3,0DSB0NS.SL[<.SL_D[.WD[/Y.RR[[>78]SFP6[VN=I=0>-)9TEEGAQN0
MF9O^6].7H8\AIS.1R,$83-D<19JE9., "/(QWJA1PS5IH8\1D!M6O1I>W[#O
M7V;]/X')7WLZXV?@H;?ZHCGL>->L8ZA5*+1^=GZ_G\@9? U8X#MR/*]G)8O*
M,=B6Q#88+"RT_7<M=YA=[+N]F(UC:.>70>H0@TSN5CH6*0I--3V1DBS=:!B%
MILEI>T3Y.H#OU3U"R5$.#NL[;>326K,9GL7CLWA;U;)XC+T:N2QF1IRC/4O4
M+L(6*ENM,#N$D-B"0)8S%^"$F= <A1$0!$1 $1$ 1$0!$1 $1$ 1%ZE^_!5@
MFM6IHJ]:M#)8L6)Y!BA@@A!Y)9II3<0CBBC$CDD,A$ $B)V9G= 1D=\/W@%#
MLV[#:PW .S"&I;-<M-:!HR'&TN2UMF:UH<1'#'(,C3!CHX+><NMX4HACL5;D
MD#PP):=26S/,<D]JQ-;M3R23VK=F0YK-NU.92V+5F:0BDFL69C.:>:0BDEE,
MY#(B)R>?/TA+O77[2^[QXS3%LI-IML[%_#:*<2=HM19.5HH,_K,P=AXBR$\#
MT,$S\E\"UH[I$)Y26O! 2@"^=F/SI:_8\_[D2^BOG9C\Z6OV//\ N1(#? HB
M( B(@"(B (B( B(@"(B QN[9/Q0;J_<WUS^+&46D/P_YTJ_L>#]R%;O#MD_%
M!NK]S?7/XL91:0_#_G2K^QX/W(4!]%;9CT:3Z2;9/]CZX_A(U@M3.MLQZ-)]
M)-LG^Q]<?PD:P0$["(B (B( B(@"(B (B( B(@"(H(>_][U6EV:=G+]?!Y&&
M/=C<*GD<!M[2%XIK6-,X@KY764M8NIFIZ9@MA8K'8!ZUG,R8VF83#++"X%)/
MTFWMYQ[R]I#*:<PEP+6C=GJ\FB,1-7F:6MD=0N4-O664C(/G1A#E6# 02"4O
M4.$EL!*\=MHXZ[*_2>>6622:>::Q//+)/8L6)#FL6+$QE+/8L32.4DUB>4SE
MFFD(I)93*0R(R=W_ #0&97=Y]E.]O?O?MCM;2@.6'5.K<5'G9!C:0:.DL?9C
MR6K<A,),\?16T_5OC"$KC'8O2U*7B =H"6Z4P^(K8^I5H4H8ZU.E6@J5*\3=
M,<%:M$,,$,;>? 11 $8-SY"+,J.WH>O=]V:5/6?:.U)C_"?,1OH7;9YPXE/%
M59WGUCGXF=N6K9'(18["42Y B^!LK(X'7LU)7O-H B(@"U<GI97TX62^YEH#
M]TU MHVM7)Z65].%DON9: _=-0("M4K5GH?7TT.ION.ZC_&?1ZJIJU9Z'U]-
M#J;[CNH_QGT>@-F(B(@"(B (B( B(@"_.2,3%Q(1(29Q(29B$A)G8A<79V=G
M;R=G\G9_/ZC_ *(@-:'Z2/W(?\Q'45G>K:_%..TFKLG))J/"T(":';K5&2M/
M(_@Q!R$&DL_:G?X-"$(X,'?Z\9T1TI\?T52UO--T-L<!K33F<TEJK%4\YIO4
MF+NX;-XC(0C/3R.-R$!UK56>(F=G&2*0F8AZ3C+IDC(9 $FU,7?6=T?J'LI[
MF34((K.2VJU98L7=MM3R2%8-ZP"TMS2F;E<1*+4.!(B$2/Q!R^&>EE(K$EM\
MI5H 0RR1B8N)"Q"3.Q"[<L[/[V=G\G9;%WT97OO'W(P]'L][KYGKW"TWC@BT
M!J/*7.NSKO3N/A)GP]RQ8?Q+.J].TX0=Y9)9K.=Q(/>)SN4<@<FNE7(-(ZLR
MF R^)U!@LA:Q.<P.3HYK"9:C)X5W%Y;&68[>/OU)>'8+%6S%'+&[B0NX])B8
M$0N!O4%#%Z0W])=V@/M/K?C%A%U[W$7?%XSM4;=O6STE+';PZ+KP5M=X.OTP
M0Y.%R\"EK+"U>IR'$9AV%K4 =;8G*O/CR)XO5)9^PO2&_I+NT!]IU;\8L(@-
M18O#^YUY7A_<Z W.7=._2L=FG[@&S?\ !UIQ9_K #NG?I6.S3]P#9O\ @ZTX
ML_T 1$0$)'I O;]?L_\ 9OU9EL3;"#6^MG#0.A@:4 GBRF>CD#)YF,"ZI"'3
MVGX\IEA<(S$KT%"K*< 6O'CU(@#PS-R1<-YD9.1$_P I$1.Y$3OYD1.[D[N[
MN[NK+/I27;T/=KM$3Z$Q%WQM&;+U9-,UHXI'*M>UG>\.UJW*%TN\<I4_S!I^
MJ;.?@_!V0*,A]?F!JU" _B200$C)V81%R)W\F9A;EW?]9F=_VEM9O1JNP.6R
M/9NPN1R]0J^M-V+$6X6I6GA\*U1J7Z-:MIC!%R(GX6,PD,-HP-R_Y3RN4EC=
MHI@ -?!W-/83_GBNT1H7;V[6*QI:K-+K'7@L[B):-TU/3DR%20F9^(\SD+>*
MP,OG&[Q961HY0F\)UN)X( B (H@&..,1".,!8   9A   681$19A$19F%F9F
M9F9 ?JB(@"(B (B( B(@"(B *J'Z6EV$"W"V-QV[6#I#/J;9K(G?R91Q]5FW
MM]F1:KJ.(79N7^![PXG4/!%TM2H9,  [$T+-:\7%M<:*Q>I,-EM/9RG%D<-G
M<;=P^6H3]7@W<=D:TM2[5D<"$V">O-)&Y 0&+%U 0DPNP&BX7YRQB8D!-U"3
M.),_N=B;AV?ZSLZRU[=79%R^PV[NN]I<R\LLNCLW/3QEZ9N#RVF[/%S368+B
M.('ER&%FJ2V_"C&".^UN&%RCB$BQ.0&UL]&T[?DF^/9OP-+.WWN:YVOF^8'5
M$DTKR6K]7'1B>ELW,YG)(1Y+3IT8KDIE\^RM+(R"$41QQ#8$6J5]&L[>O\Q+
MM)X7%Y:]ZKHO=RO#M_J$9'9JM?-6+33Z*S$CN0]$M3,G+AFD]H?5=16V.,C:
M&2#:U( B(@"(B (B( B(@"(B *OYZ4/]))NS]D]K_P"%C1*L!JOYZ4/]))NS
M]D]K_P"%C1* U22^;F?SI:_8\W[F2^DOFYG\Z6OV/-^YD@-XUV;_ (N]!?:7
MI;\!T5W0NE^S?\7>@OM+TM^ Z*[H0!$1 $1$!%WWQ/=_U>TEL+K+;V,*L>J(
MJWS0Z$R%F-W&AK#"B=K% 4H,\T-7*\2X7(21,9#1R$\G@SN PGIX\OA[F.N7
M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
M:@I9#=E+M2ZTV5W TWN7M_E),5J;35V.S [&;4\I1(P^$<!F(0?BYA<S6!Z>
M1JFS_.R&S7>*[6JV(>NMV-IM3:#U-G=%ZTPMO3NJ],Y&;$Y["7O#>QC\A7XZ
MXGDA.2"Q#(!1SU;=:66M<JRPV:\LD,H$_7R W,_=E]XOHOM.;6XG<724L=6X
M[_!NK=,26(Y<GI'4T$8E=Q%\1X)XC8@N8NYT#%DL9/6MQ?1F$<A*TX_=.]YY
MJOLJ[I5=<80+&6TOE8X,1N#I )!:/4NGAF>5I*C3$,%?4.'D([>$O$4?ME8Q
MUB5J&0M,MNMV?]^]*;H:,T[K_0^6@SFE=4XROE</DJ_+-+6G'EXYHBXDK6ZT
MC'6N5)A&>K:BEKS",D9,P%#/TTCXS=A_M%UK^'\&J7JNA>FD?&;L/]HNM?P_
M@U2]0$V/HY/T[.POV5UQ_!5KQ;;]:D#T<GZ=G87[*ZX_@JUXMM^@"(B +5H>
ME=?3CZ@^YYM]^]LHMI>M6AZ5U]./J#[GFWW[VRB K?*UYZ'?],YK'[C&?_&_
M12JAJUYZ'?\ 3.:Q^XQG_P ;]%(#9:(B( B(@"(B (B( B(@"(B (B( B(@"
MTS7>U;4GHCM.[\:;("$:^YFI,E"Y 8>+#J.RVI8Y0:1W?PC^%W\-V=P<6]CI
M%ND=S*M9EZ73V:)])]I3$[@00.V(W5T/B[!SL_LMJ;1IO@,M X,+#&)8,M+6
M(B<G*Q,=XND?!<C JN*Z=Z&-VAXZ&X&\FU-J<Q;4FE\+K["P&?$'K6F,C\S^
MH/#9WX*U8J:AT\;1CP95\;8D%B&&8@I8J0KNI^V@W9^W_P!NMT;)RA@\3EO@
MK5S0B4DA:/SXMC=02!$/G*="M(&5CA%NN>3'C #B4K$P&YF1>GC\A!;@@M59
MHK-:S#'8K6() F@L03 ,D,T,L;E'+%+&0G'(!$!@0D+NSLZ]Q $1$ 1$0!$1
M $1$ 1$0!?G+$)B0&(F!BXF!,Q"0DW!"0NSL0DSNSL[.SL[LZ_1=,=HW=BCH
M/;_6VM<G:"EC])Z4S^HK=N1V$*\&(Q=J\<I.[LS,#0<N[NS-\KL@-)]O15@@
MUMK:"L3'6@UKJZ&N0CTB5>+4>3CA<1X;I%XQ'I%F9A;AF9N%UNO=R>:FR5NY
MD[ N%C*7;F3L [N3A8R-F6[./4[,[],LYMR[-S]1O<WI("YWZ%S$3[H[Z2=/
ML#H'2 $7EPQGJ++$(_5?D0)_=Y<>?O;G8:JCEZ%GM3(&G]^-=2UB&*WJ#26C
MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
MGY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_P"N>R_W[ZF_B GY4,[6?]<]E_OW
MU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B K\/=6=F#4FR_9\VNVOU?+BIM2:-T
MY'B,K+A+4]W%G9CLV9>JG:LTZ$\T3A*#]4M2 F+D>GRY>05$ 1$0$!WI!/=;
M[A]JS;;0VD-N,MHO$973.OAU5>FUMD\YB\?-CVTUGL*\-2;!:;U-9.YZQE8)
M&CFIP0>#'*_K#2, '4Y_*<_:G_3GL!]^.XO_  D6RW1 :[#LW^B5=IC2&XN@
M-6Y35^Q<V,TKK;2NI,C#0U9K^:_-0P>=HY.Y%2AL;65*\MN2O5D"M'/:K0G,
MX#)8A BE'8GHB (B( B(@"(B (B( B(@"(B *-KO:NP-%VE=B=8[5QV:./SF
M0"EE](Y;)/.%'%:LP=D+V&M73K5KEF.A-($N.R1UJMBPV-O7&@A.5Q922H@-
M:1^4Y^U/^G/8#[\=Q?\ A(GY3G[4_P"G/L__ 'X[B_\ "1;+=$!%'W,O9:WC
MV2V.P&U&\N4T3G,EHJS<QFE<QHG-9[+P3:/.5[>*QV4?/Z6TO/7NX,IY\35]
M6AN0S8FMCRDE"R$S'*XB( H>N_*[O[6O:8V'N;7Z!R.E\5J&QJO2V=CMZOO9
M;'89JF#N26;,1V<+@]0W6L2B0C (XXHW=R>26-F;JF%1 :TC\IS]J?\ 3GV?
M_OQW%_X2+U[GH;_:GEAEB^;7L_CXL9Q]7S8;BOT]8N//'\R5N>.>>.6Y]W*V
M7Z(#\X1<0$7]["+/Q[N69F\O=_H9?HB( B(@*LOI"W<D[M]K#5.V.<VVSNW6
M(JZ+P&IL5E8M<9K4V*GGL9K(XBY6/'C@=':HCEACCQTHSO8DJ&QF#1A(/435
MXORG/VI_TY[ ??CN+_PD6RW1 46>Z=]&;[0.Q?:#VYW6UAJ?9R_IO2-W,V,I
M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616403904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,740,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746613262784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,238,152<span></span>
</td>
<td class="nump">$ 46,329,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">195,513,005<span></span>
</td>
<td class="nump">206,669,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">73,304<span></span>
</td>
<td class="nump">1,701,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">4,961,802<span></span>
</td>
<td class="nump">10,036,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,914,313<span></span>
</td>
<td class="nump">50,130,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">195,853<span></span>
</td>
<td class="nump">375,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">233,896,429<span></span>
</td>
<td class="nump">315,242,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">6,983,305<span></span>
</td>
<td class="nump">7,727,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in affiliated entity</a></td>
<td class="nump">2,623,781<span></span>
</td>
<td class="nump">2,007,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,047,778<span></span>
</td>
<td class="nump">2,129,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">9,865,543<span></span>
</td>
<td class="nump">10,228,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">652,517<span></span>
</td>
<td class="nump">684,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">266,582,724<span></span>
</td>
<td class="nump">348,533,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">24,752,171<span></span>
</td>
<td class="nump">79,686,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">1,417,274<span></span>
</td>
<td class="nump">1,220,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">5,795,846<span></span>
</td>
<td class="nump">10,594,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,579,949<span></span>
</td>
<td class="nump">2,803,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">4,121,989<span></span>
</td>
<td class="nump">2,475,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entity</a></td>
<td class="nump">89,007<span></span>
</td>
<td class="nump">87,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">16,394,841<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">55,151,077<span></span>
</td>
<td class="nump">96,868,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,614,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">12,185,919<span></span>
</td>
<td class="nump">12,655,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">67,369,042<span></span>
</td>
<td class="nump">126,170,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">262,738<span></span>
</td>
<td class="nump">253,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,728,030,842<span></span>
</td>
<td class="nump">1,710,656,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,528,497,101)<span></span>
</td>
<td class="num">(1,487,847,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(582,797)<span></span>
</td>
<td class="num">(698,741)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">199,213,682<span></span>
</td>
<td class="nump">222,362,756<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 266,582,724<span></span>
</td>
<td class="nump">$ 348,533,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746613238320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts</a></td>
<td class="nump">$ 114,943<span></span>
</td>
<td class="nump">$ 199,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30,176,511<span></span>
</td>
<td class="nump">55,978,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,890,610<span></span>
</td>
<td class="nump">15,953,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,067,121<span></span>
</td>
<td class="nump">71,932,069<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,952,178)<span></span>
</td>
<td class="num">(71,732,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">2,207,171<span></span>
</td>
<td class="nump">669,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(313,488)<span></span>
</td>
<td class="num">(313,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entity</a></td>
<td class="nump">616,639<span></span>
</td>
<td class="num">(537,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">3,218,215<span></span>
</td>
<td class="num">(4,840,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(2,425,676)<span></span>
</td>
<td class="num">(153,468)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before share in net loss of Geneos</a></td>
<td class="num">(40,649,317)<span></span>
</td>
<td class="num">(76,908,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,165,213)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,649,317)<span></span>
</td>
<td class="num">$ (79,073,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">258,437,714<span></span>
</td>
<td class="nump">218,940,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">258,437,714<span></span>
</td>
<td class="nump">218,940,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616334784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,649,317)<span></span>
</td>
<td class="num">$ (79,073,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(1,918)<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">117,862<span></span>
</td>
<td class="num">(169,097)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (40,533,373)<span></span>
</td>
<td class="num">$ (79,249,371)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746614364672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 399,669,421<span></span>
</td>
<td class="num">$ (1,468,216)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 217,382<span></span>
</td>
<td class="nump">$ 1,609,589,797<span></span>
</td>
<td class="num">$ (3,294,019)<span></span>
</td>
<td class="num">$ (1,209,855,522)<span></span>
</td>
<td class="nump">$ 1,825,803<span></span>
</td>
<td class="num">$ (282,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for legal settlement and cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,480,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for legal settlement and cash, net of financing costs</a></td>
<td class="nump">29,364,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,481<span></span>
</td>
<td class="nump">29,356,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(942,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
<td class="num">(943,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,711,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,711,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(79,073,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,073,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="num">(169,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(6,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">355,085,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 226,509<span></span>
</td>
<td class="nump">1,642,419,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,287,103,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457,888)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">226,510,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">253,091,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">222,362,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 253,090<span></span>
</td>
<td class="nump">1,710,656,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,487,847,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(698,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for legal settlement and cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for legal settlement and cash, net of financing costs</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,121<span></span>
</td>
<td class="nump">13,990,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(424,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
<td class="num">(425,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,809,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,649,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,649,317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="nump">117,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(1,918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 199,213,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 262,738<span></span>
</td>
<td class="nump">$ 1,728,030,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,528,497,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (582,797)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">262,739,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746614540080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746614928848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,649,317)<span></span>
</td>
<td class="num">$ (79,073,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">707,378<span></span>
</td>
<td class="nump">929,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">82,083<span></span>
</td>
<td class="nump">126,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">362,664<span></span>
</td>
<td class="nump">319,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">3,809,003<span></span>
</td>
<td class="nump">7,711,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest on senior convertible notes</a></td>
<td class="num">(219,999)<span></span>
</td>
<td class="num">(219,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of (discounts) premiums on investments</a></td>
<td class="num">(1,159,083)<span></span>
</td>
<td class="nump">125,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Realized loss on short-term investments</a></td>
<td class="nump">2,425,676<span></span>
</td>
<td class="nump">318,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">334,297<span></span>
</td>
<td class="nump">157,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment', window );">Gain on remeasurement of investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(165,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Gain) loss on equity investment in affiliated entity</a></td>
<td class="num">(616,639)<span></span>
</td>
<td class="nump">537,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,165,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gain) loss on available-for-sale equity securities</a></td>
<td class="num">(3,218,215)<span></span>
</td>
<td class="nump">4,840,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, including from affiliated entities</a></td>
<td class="nump">6,703,110<span></span>
</td>
<td class="nump">541,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, including from affiliated entities</a></td>
<td class="nump">39,324,542<span></span>
</td>
<td class="nump">7,075,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">31,527<span></span>
</td>
<td class="nump">151,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses, including due to affiliated entities</a></td>
<td class="num">(40,737,879)<span></span>
</td>
<td class="num">(9,000,559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="num">(4,798,227)<span></span>
</td>
<td class="nump">1,501,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue, including from affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(693,691)<span></span>
</td>
<td class="num">(624,673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="nump">1,648,292<span></span>
</td>
<td class="nump">723,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(36,664,478)<span></span>
</td>
<td class="num">(61,882,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(80,431,174)<span></span>
</td>
<td class="num">(99,722,697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="nump">93,657,050<span></span>
</td>
<td class="nump">123,055,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(296,983)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of capital assets</a></td>
<td class="nump">6,071,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,999,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">18,999,893<span></span>
</td>
<td class="nump">21,332,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,364,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(424,704)<span></span>
</td>
<td class="num">(1,026,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(424,704)<span></span>
</td>
<td class="nump">28,422,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1,918)<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(18,091,207)<span></span>
</td>
<td class="num">(12,134,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">46,329,359<span></span>
</td>
<td class="nump">71,143,778<span></span>
</td>
<td class="nump">$ 71,143,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">28,238,152<span></span>
</td>
<td class="nump">59,009,491<span></span>
</td>
<td class="nump">$ 46,329,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">330,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">533,487<span></span>
</td>
<td class="nump">533,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement', window );">Issuance of common stock for the legal settlement</a></td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Accrued Expenses Related To Issuance Of Common Stock For Legal Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Remeasurement Of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GainLossOnRemeasurementOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746619736992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company&#8217;s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO's lead candidates are focused on diseases associated with HPV. In October 2022 and February 2023, INOVIO announced data from the first and second cohorts, respectively, of its Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated Recurrent Respiratory Papillomatosis (RRP). In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, Indiana University, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for the Ebola virus; HPV-related precancers, including cervical, vulvar and anal dysplasia; HPV-related cancers, including head &amp; neck; other HPV-related disorders, such as RRP; and glioblastoma (GBM).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746620555104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Liquidity and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Liquidity and Risks and Uncertainties<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2023 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2023. The balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2023 and December 31, 2022, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $40.6 million for the three months ended March 31, 2023. The Company had working capital of $178.7 million and an accumulated deficit of $1.5 billion as of March&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $223.8 million as of March&#160;31, 2023 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million under a Sales Agreement for the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2023, no shares were sold under a Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div>The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616805744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting Policies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#8217;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#8217;s or the collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary smart device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616495392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition  During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $0 and $9,000, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $115,000 and $190,000, respectively, from various other contracts as a result of performance obligations being satisfied.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616403104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,986,541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,155,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,591,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,958,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,516,128)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,513,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2023 and 2022, the Company recorded gross realized gain on investments of $300 and $20,000, respectively, and gross realized loss on investments of $2.4 million and $339,000, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $3.2 million and $(4.8) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2023 and 2022. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2023, the Company had 24 available-for-sale securities in an unrealized loss position with an aggregate total unrealized loss of $6.5 million, all of which were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2023&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2023, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,513,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,480,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,032,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,136,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,104,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,032,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2023 or December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,986,541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,155,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,591,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,958,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,516,128)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,513,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2023 and 2022, the Company recorded gross realized gain on investments of $300 and $20,000, respectively, and gross realized loss on investments of $2.4 million and $339,000, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $3.2 million and $(4.8) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2023 and 2022. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2023, the Company had 24 available-for-sale securities in an unrealized loss position with an aggregate total unrealized loss of $6.5 million, all of which were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2023&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2023, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,513,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,480,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,032,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,136,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,104,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,032,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2023 or December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616678960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,194,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,607,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)&#160;&#160;&#160;&#160;In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221; The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746620447552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,052,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,050,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,102,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,663,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,102,222)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,561,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,643,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets for the three months ended March 31, 2023 and 2022 was $82,000 and $127,000, respectively. Estimated aggregate amortization expense is $190,000 for the remainder of fiscal year 2023, $253,000 for 2024, $253,000 for 2025, $253,000 for 2026, $253,000 for 2027 and $845,000 for 2028 and subsequent years combined. There were no impairment or impairment indicators present and no losses were recorded during the three months ended March 31, 2023 or 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616926096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2023 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,394,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the three months ended March 31, 2023 and 2022,&#160;the Company recognized $313,000 of interest expense related to the Notes, of which $267,000 related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,481,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615025680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2023 and December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,739,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,739,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,091,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. No shares were sold under the 2021 Sales Agreement during the three months ended March 31, 2023. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company sold 8,480,483 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $3.52 per share, resulting in aggregate net proceeds of $29.4&#160;million. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> there was $167.4 million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement, as described in Note 13.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was 24,000,000 shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by 2,000,000. At March&#160;31, 2023, the Company had 2,761,477 shares of common stock available for future grant under the 2016 Incentive Plan, 1,994,799 shares underlying outstanding but unvested RSUs and options outstanding to purchase 13,239,324 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company's board of directors approved a new 2023 Omnibus Incentive Plan, subject to stockholder approval.  If approved, no further grants will be made under the 2016 Incentive Plan. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed 2,000,000 shares. At March&#160;31, 2023, the Company had 1,573,125 shares of common stock available for future grant under the 2022 Inducement Plan, 155,000 shares underlying outstanding but unvested RSUs and options outstanding to purchase 271,875 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div>The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2023, the Company had options outstanding to purchase 1,748,245 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616741168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 8) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.</span><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,462,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,305,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616490480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 was $3.6 million and $7.2 million, respectively, of which $1.5 million and $3.7 million, respectively, was included in research and development expenses, and $2.1 million and $3.5 million, respectively, was included in general and administrative expenses. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, there was $10.5 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.7 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $0.97 and $2.48 for employee and director stock options granted during the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, there was $6.1 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 1.7 years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $1.20 and $3.33 for service-based RSUs granted during the three months ended March 31, 2023 and 2022, respectively.</span></div>The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2023 and 2022 was $220,000 and $550,000, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615182656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned 597,808 shares of common stock in PLS as of March&#160;31, 2023, representing an 18.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2023 and 2022, the Company recognized revenue from PLS of $0 and $9,000, respectively. At each of March&#160;31, 2023 and December&#160;31, 2022, the Company had an accounts receivable balance of $59,000 due from PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through June 2024, of which $3.3&#160;million had been exercised as of March&#160;31, 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2023 and 2022, the Company recorded $211,000 and $1.5 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 14). Research and development expenses recorded from Wistar for the three months ended March 31, 2023 and 2022 were $422,000 and $181,000, respectively. At March&#160;31, 2023 and December&#160;31, 2022, the Company had an accounts receivable balance of $4.9 million and $9.9 million, respectively, and an accounts payable and accrued liability balance of $1.4 million and $1.2 million, respectively, related to Wistar. As of March&#160;31, 2023, the Company recorded $89,000 as deferred grant funding and $196,000 as prepaid expenses on the condensed consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616827024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies                                                  <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 0.7 to 6.8 ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,137,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,371,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,766,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,580,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,186,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6%</span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 were $840,000 and $830,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania.  The proposed settlement provides for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance </span></div>carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616797568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $200.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus a $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. For each of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, no revenue was recognized from Advaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. During the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022, the Company received funding of $1.2&#160;million from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2023 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2023 and 2022, the Company received funding of $1.6 million and $2.0 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2023, the Company had $1.7&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three months ended March 31, 2023 and 2022, the Company received funding of $53,000 and $510,000, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2023, the Company had $2.3 million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2023 and 2022, the Company recorded $59,000 and $80,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2023, the Company had $96,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2023 and 2022, the Company recorded no contra-research and development expense related to this Gates grant.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5 million. The Company determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. The Company recorded contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses were incurred. During the three months ended March 31, 2022, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.2&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as contra-research and development expense related to the OTA Agreement. No amounts were recorded during the three months ended March 31, 2023.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total purchase price under the Procurement Contract was $16.8&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD discontinued funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7&#160;million. All performance obligations under the Procurement Contract have been satisfied. During the three months ended March 31, 2023 and 2022, the Company recorded no revenue from the Procurement Contract.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616889440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&#160;For the three months ended March 31, 2023 and 2022, the Company did not record any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616490480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's <div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  </span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company has concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Geneos completed the closing of a Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 26% of the outstanding equity of Geneos on an as-converted to common stock basis. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615622976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2023 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2023. The balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2023 and December 31, 2022, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $40.6 million for the three months ended March 31, 2023. The Company had working capital of $178.7 million and an accumulated deficit of $1.5 billion as of March&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $223.8 million as of March&#160;31, 2023 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million under a Sales Agreement for the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2023, no shares were sold under a Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div>The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements and Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#8217;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#8217;s or the collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses - Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary smart device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746614350544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,986,541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,155,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,591,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,958,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,516,128)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,513,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,831,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,649,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,513,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,480,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,032,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,136,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,104,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,032,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746620381248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,349,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,914,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,194,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,607,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)&#160;&#160;&#160;&#160;In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221; The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616796336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Summary of Intangible Assets by Major Asset Class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,052,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,050,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,102,222)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,663,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,102,222)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,561,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,643,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div>(b)Other intangible assets represent the estimated fair value of acquired intellectual property.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746792036288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2023 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,394,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,481,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616796336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2023 and December&#160;31, 2022: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,739,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,739,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,091,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616915520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,462,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,305,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746620353184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.09%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616823296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text">As of March&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,136,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,137,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,371,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,766,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,580,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,186,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616869136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615478672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 40,649,317<span></span>
</td>
<td class="nump">$ 79,073,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="nump">178,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">1,528,497,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,487,847,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">223,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 29,364,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746614373856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts</a></td>
<td class="nump">$ 114,943<span></span>
</td>
<td class="nump">$ 199,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All Other Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AllOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615139552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 201,958,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,450,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">71,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(6,516,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,802,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">195,513,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,669,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">85,986,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,036,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(6,155,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,373,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 79,831,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 111,591,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,001,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">57,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 111,649,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,964,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 2,977,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,977,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">13,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">2,990,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,402,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(360,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 1,041,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,051,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616472352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">339,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">$ 3,218,215<span></span>
</td>
<td class="num">$ (4,840,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss</a></td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746608855088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 195,513,005<span></span>
</td>
<td class="nump">$ 206,669,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">79,831,242<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,990,765<span></span>
</td>
<td class="nump">2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,041,578<span></span>
</td>
<td class="nump">1,051,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">195,513,005<span></span>
</td>
<td class="nump">206,669,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">2,623,781<span></span>
</td>
<td class="nump">2,007,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">198,136,786<span></span>
</td>
<td class="nump">208,676,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">191,480,662<span></span>
</td>
<td class="nump">202,627,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">2,623,781<span></span>
</td>
<td class="nump">2,007,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">194,104,443<span></span>
</td>
<td class="nump">204,634,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">4,032,343<span></span>
</td>
<td class="nump">4,042,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">4,032,343<span></span>
</td>
<td class="nump">4,042,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">79,831,242<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">79,831,242<span></span>
</td>
<td class="nump">107,662,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">111,649,420<span></span>
</td>
<td class="nump">94,964,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">111,649,420<span></span>
</td>
<td class="nump">94,964,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,990,765<span></span>
</td>
<td class="nump">2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,990,765<span></span>
</td>
<td class="nump">2,990,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,041,578<span></span>
</td>
<td class="nump">1,051,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,041,578<span></span>
</td>
<td class="nump">1,051,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746614389648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Insurance recovery</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidManufacturingExpensesCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">565,072<span></span>
</td>
<td class="nump">1,401,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">4,349,241<span></span>
</td>
<td class="nump">18,729,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other assets, current</a></td>
<td class="nump">$ 4,914,313<span></span>
</td>
<td class="nump">$ 50,130,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746611506720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 11,194,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,862,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">7,607,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,574,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">5,950,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,249,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 24,752,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,686,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">262,739,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Amount paid to other party</a></td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccountsPayableAndAccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccountsPayableAndAccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746611720880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">9,150,000<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(7,102,222)<span></span>
</td>
<td class="num">(8,343,900)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">2,047,778<span></span>
</td>
<td class="nump">2,129,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, Gross</a></td>
<td class="nump">19,663,371<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, Net Book Value</a></td>
<td class="nump">12,561,149<span></span>
</td>
<td class="nump">12,643,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,323,761)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(3,052,222)<span></span>
</td>
<td class="num">(2,988,889)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">2,047,778<span></span>
</td>
<td class="nump">2,111,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(4,050,000)<span></span>
</td>
<td class="num">(4,031,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs) | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs) | Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746619604096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense on intangible assets</a></td>
<td class="nump">$ 82,083<span></span>
</td>
<td class="nump">$ 126,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated aggregate amortization expense for remainder of 2023</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense for 2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense for 2025</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense for 2026</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense for 2027</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Estimated aggregate amortization expense for 2028</a></td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746611779824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,528,497,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,487,847,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,728,030,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,710,656,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,488<span></span>
</td>
<td class="nump">$ 313,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615261136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance of Convertible Bonds and Notes (Details) - Convertible senior notes<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(109,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">88,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 16,394,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615228144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - Convertible senior notes - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 16,394,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">16,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 17,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746605743392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">262,739,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">262,739,126<span></span>
</td>
<td class="nump">253,091,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746608890736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,739,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under share based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,761,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,239,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sale of stock, sales proceeds of any common stock, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,480,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2022InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615569136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">20,462,532<span></span>
</td>
<td class="nump">21,305,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">15,259,444<span></span>
</td>
<td class="nump">14,097,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">2,149,799<span></span>
</td>
<td class="nump">3,491,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">663,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">3,049,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615035424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Stock Options - Employees and Directors<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="nump">1.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746616433184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">$ 3,809,003<span></span>
</td>
<td class="nump">$ 7,711,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_JJosephKimMember', window );">J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares', window );">Settled in shares percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash', window );">Settled in cash percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_JJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_JJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746611752720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,943<span></span>
</td>
<td class="nump">$ 199,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Collaborative agreement, amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedExercisedAmount', window );">Collaborative agreement, awarded exercised amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicenseWithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,000<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedExercisedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Exercised Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedExercisedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicenseWithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicenseWithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746615165984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>agreement</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares) | shares</a></td>
<td class="nump">262,739,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet) | ft&#178;</a></td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet) | ft&#178;</a></td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Agreements To Sublease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseNumberOfAgreementsToSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746605880352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 3,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">3,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">3,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">3,139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">2,526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">4,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">19,137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(4,371,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">14,766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,579,949)<span></span>
</td>
<td class="num">$ (2,803,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 12,185,919<span></span>
</td>
<td class="nump">$ 12,655,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746608237408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,943<span></span>
</td>
<td class="nump">$ 199,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,121,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,475,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AnnualMaintenancePeriod', window );">Annual maintenance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementPaymentEarned', window );">Collaboration agreement, payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements, including from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract', window );">Collaborative arrangement , revenue from the procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AnnualMaintenancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AnnualMaintenancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Payment Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement , Revenue from the Procurement Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementRevenueFromTheProcurementContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746606165264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,165,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember', window );">Series A-2 One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,165,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139746613261248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,165,213)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember', window );">Series A-2 One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="nump">$ 165,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</a></td>
<td class="num">(2,165,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>ino-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ino="http://www.inovio.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20230331.xsd" xlink:type="simple"/>
    <context id="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9457abe7151f48629c83cef3a4bc1b10_I20230508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="i7e013b80260c4d9089f646bfa59fe02d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4a51b3e565934094b048701d97384fb1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i061af91598d043dbb23f9bec95fcd0cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37852329bf79418fa1da42c06d21d21b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if771a6bc25d34d21bdedcf8ef619d315_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0e372dd07124d13b07e1eba2d4ebb48_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e32cf9a419844fc997d07e4f740dc36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i758b5f9af27d4ef997eae8d3e89608ca_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0a56e5fa34464fac9afd99a63dad6ef2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i572101f4b4394cbab05b6a7efd242b43_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i43f73c345dc54c3fb85944a872f29625_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibcefd5afd949414c8e5a0edaaaf68460_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2ff70ed56a0f4a22bd78e19f1cc27821_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic67c34d5644f4e6bb650febc8364d7ba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06a9a0ba408648df83848a10938d69f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie00cf796b6ae43e6abe0a3ec4dc6c4c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c79ff17a8ad41eebe7c8cacae2d2448_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac43eafb695b45e386c9c3400e86b00f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if130560dfba64db0886b6c2aad0e1266_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i037465b4f55945f6aec5c70683960daf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16d63252834144b0aacf7c65dae0426e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6d056507ce342c8b4ceade8fbc2431c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib18f3cd8f5654cabbdd4c9ca4e61b6e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i806e78a728a14bbf808d71382f080b36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9ad54f853b18472facb941b6fa20e521_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib01b0d4a71e24d5180845b2744da7b80_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ida57e8acbeb64025a8f23f21a9dd2033_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c5328efdb974908ae8cfd3253ce76d8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42b8747dfa6a496aa4f8ff6db15082f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic0b90c0f76ed48918a32bab8f7514148_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i384f44b2bbbc4040b18237efb0444e8c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i158c20e44ccc4e16864d4c2cb9a584f3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id15b0217ea8c48b0ad7e9858e136caa6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i568f04797f3a472aa282f7114d801497_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i27c48d2543c3428ca9348a16927aa3ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i424005e9738e406cbe32ab9e0559a2cc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie808b6354eac4d61890c011e8296a807_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2794060b62c64f55ba10c6d991467be9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iec1f816c2b0646358f12de50f5ec8fc4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea88717d3bae4c3282823b096cbc0010_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if7f21b141b3745859c0259a876d2e137_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0f9148075bf7401a924169db861cdb10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieeb82e20dd9d4b969625c52a130ea384_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9209877902d45a0a7da1b89265d7c5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id19a9893ad2e465a8c17eb61b026acc4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieeba06444a8843ee89be2729dfcafdd2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i154f710696af44368c1b60a00236e33c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9b1662f455f64b0b86af2199c3c89353_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id737e22fc8c34147b1878efbc06b6fa0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49aeb1a300754d82b80cb3075a7d276d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9775574f1494394811d44684704ab67_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i507494694b6d4d009b81bc247609f9e0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaa977781312f47e69160962e49c81570_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07230fde15e54b399d452926ed0f53a3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8b64b5b5c9b64e5fa4434c4e168d2559_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b7e2166f3914844b66ea56e45631aad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2ef64995166349eab1facc6cf436dfb4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92d7cb8097694cbda0e2e5976080fed6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if837752dbae541949d9b5d2f3fc1d21a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i47d6af48af3740ed9e7512132b332b10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i249d5e2b1d764f8f9849378142cdf683_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4538d285010f4df39235b50e6df231bb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i808771e2c7b748768ba48825de30ab59_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i035ac45eddcd4ad0b877179ce402b012_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i100ee50b23804321a39f1344ec331844_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc54f897c91449868d75304b60ed52b5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7764fa9747144127856f5f47e535b68b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibeac876368b343568a773a83ca4cfa00_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1c9438d2a2b449a28a0426195cc69b58_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i651421a71e44472594de779a6c90aa58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fe53fa638d94b9684c5bb12d5d28448_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81d8611e12df41f6b46df72274195e75_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55f7ea859ca14010a0f5dc0c523bb83a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife8621666cb44531a664219b42fb568f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76b95b05eddd474fa6a45fb6fbd8ae32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bc7276b422b4eb7b9f1e2ecd0d3c68f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb8759eb4716482494a75a4509d57041_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i76596fa49ec24abb8271d264e6f19bab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34ea510fa47e424d943494f963231339_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79060d2c3e3147b3b3d21d5d5bb394ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7398b2d88e70463d906bd72f9a1b2cf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31e9b36e3881479fb2114bf17a00489a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2ec3a3107ab43409a0d2eeff38d951a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f3d830b50b94da7b62468b24771824e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee4653ccc0974003b1771f075fa5970c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a72e62f7c41430690c464a69f2537db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63d19f47994c4a2087e95232f349c61e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5590b7d3f8242afba7128120cfea182_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd6835ef9291475398187809336a6e27_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i092045a4d4c24e66871ac745807bd523_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib97422d241744aecbec5cdc038a635ef_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i6ab95fd57f0f426ebe487aa41e25c7d4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fad80428c8a4c91a84c10d223b587df_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i768b12453cb44701902fe18cf70b486b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fb0a36935424e9b8c96652f09088bcd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5cc0c0bab6884b4380426817d471b00c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9eedc0cc685c44ee9cb4b8772b34620b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i282e3fa937b948e186e4be58f112112e_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="iae2deb332889417aa796180e6cd43280_D20190219-20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="i7351252adfb6481e91a3344a5a0f071d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib5cef3158a4649a18541e2a3562c8711_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0de4d1310e9b417ca7f60cde3199cf93_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie617d1d3144a464890df59e30f71dfd0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic53065c277c54ed285075c2628977167_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd58cfd5707b40a8ba848f715d75243e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib11d128f5b7d46c4afc00ddccd41927b_D20211109-20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="i3a8c9b4d47374eb8ac0b52b8d7f5d1ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ea599a7a25b45f7b1f330755ed5da57_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5dcce6012ae249d88a84eed499079c98_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="i564a8962d6e44317a92f8b2819e51177_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifbe75a7506d1456ba7caadb9076e0ed8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40f17f0e740b43c29e5c8bb3c1255760_I20220624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="i27142f229fa048279b6b126bc5f26f7d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i51eaae0fbbe940fca869c9447afe074b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d514f11ff234b3093019d9807fa2ffd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i921b1a2eed0045048faa0c08a241ab45_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i60bda6ceb3ee454d9ac8642950c68c58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i03ff7bbfafae4ca3999c42f1172d7aa0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3c08ae29ea3f4f058c8448338f3ed45b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib58a4b297f7b456087c6738a5502b9dd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibdc5a1af5a8d4d3e8d3c1e7c321d49f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2779b2689b1147a59ccf83b443c35881_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2227a6874dff4a5eb1a92a35dc47787b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf177595aa91424a9dda4724bee8580b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i42874be0b5e343d3925a6e3e6d86611e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2d1ffcee62674f349f88218d19394398_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icffc34c375714623ba96b595bd73a117_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i379a776732214db1b029bd03e5346c7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if16f4b4774ea4c47a1523d104d021a00_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5482985971d94cc99e0f3719ecaa6f37_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie151e6230187439faf1df447c5fab34d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie341f3ddd4aa4162b175afe26aeb3606_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i28a3ce5bb9c3471eb596c306b6ffd0d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i41f4dedbddf9489aa3e6277504570a15_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06f13d07dc0c4ec3bd48386ff51e587a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e035331581449cda370e4641f850074_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i706026db14224393a7d5617daa1749ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38c5f671c746440783fba1944fd2c330_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:JJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibc7ccae9f1db4ec7b179375d9ecbf470_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0476acad69a0411cb71f91657c47d0de_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicenseWithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic075c2d8dc3444418dcdc98130ee2157_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicenseWithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2cf97ac8cf3a4bf6af4f7d01a5e00911_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b9a009f4c76409c87d174eac6f87a7f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc24100fe12944b1b8aeebb2b2812137_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="ib159f7b94137458ebffea9382e581603_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32cb639fd4a343e690f4f52b559444f5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ab8e1cd29e04f13a5bc87f121c2aac5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0bf7bb08585e4f10aed4274ac4f1ec00_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0acd1375e3c24e7fa409126bcc9c1d51_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icbba60f01bb241bbabbb479069af98f1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7c90d97b8be2421a91f73fa2e1553a92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i333fb2acbe2d4abebe17d055f53089d5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic3eae36ce89f42ad9e65603a05d7c7aa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8608f45e71364d6db7f445deb5e26df9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4c3ac8cf648e4aa49f2a73b8fabfe262_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a98975b0fc340d4b103c427cf0f43ea_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f906f0a3f6e4602a9e8cab308738534_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i58c9cdabcabe4021909afd5c5a3081f2_I20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i417613e580e94ab98741e8202729ade5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i12fc1c502f8942b7ad4bc3b5d8beb886_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5a06a61d23a43f185271e37b7571874_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id64c57b813344cb7a27bb83b05c69e89_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92384310f07943f08357ffcdc9a44938_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a4a785614804e208d698da42727636c_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ia69f542558464145a2894966df1810dc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i125c5d9c06e64a2796725f967491bb88_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7941aaf07d1455db283f53a3ce532ff_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia88027f914c346d898a03e87ce8843cc_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i6685e6d0a07641c9a04cb5a2a1f626a0_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i6284362eaa524cb1ae66051b9a8416be_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ib99cbe6e413f48c58eac5aa5bc792556_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="iabc7dbe20d0344d694da0dff99be1e46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i226d2be71e7340ca94c685446a1e4897_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib3ced90de62e425292ba059648c69c3e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d44bceb01724751ae9ac3ef1c97f30c_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ie31a2498c1414335a0ba4fe5e14b7127_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i7f1e77e31a004c85bce55c93571e12c7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ica479a19e2b24b13b5c1515aad9cca2c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icc8c967179d64c8da0b633e32986c5b4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iffb01fd6e8e940fbbc1a27ee535e080e_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4156146913df4fe29176b27642589675_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ad6c67aa76d4e239862ac53565b8b14_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i34c3e1e467bd4c8cbd2f2d5dd0b6b83e_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4e1fd3bca48746d4a3e0157958b1362d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i18a5a935641f47e3a61691a74380178e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i63d4cb06945a44c5b005997ca2058e88_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1066c49f9fa944c18d0649a5a997b41d_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i168d6a6b6ac247679a22b560bd6e3455_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1f4328f613794f8f851da2eea650c719_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic8095048f54b4e7690bb30f2a7181f33_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7b7d9f2ec0c742c5a03a7fa46f42aa3d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78a9b6e99d364eebaef954d914503da2_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ide7c9f8aacf543c2ba69c1d46e1444ca_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i787f2661dbc54b07898d0c0364957c10_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0284cde70d5b460295a267e2aa3f9418_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iec22519de8e349f68787d4e3117cc5d1_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i0f6c4cef707f468e961ad855e0854c2d_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ia4c22ea43f794bf99527a5a0e7aedae4_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i0142d3c784c84195a77084a90fd44686_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieeccae722fc04ed3b3e297f3f9746ac5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifc519a3505b3405fb2c0d3cdd6a35310_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8e7818a8a0894cb2bb8176800bac1b8f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8fc6c62eb8cb4a31ad404dd9dea91a63_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id0957b99b9e3448f9b409da3e4e79095_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86f4cd190cda49f78e14fc4d981780f7_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="idac4be03517e4f47adf6174fbe4aa9e1_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i407a77b361714c38aa6bd43347213d19_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if7582f4c63824263ac27d9d7d9dd30c2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9c8116a07c8d41bf95c7976eca960b36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b8a4fe327134fba97d18909d711eee6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="agreement">
        <measure>ino:agreement</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV80LTEtMS0xLTYxNDMw_4950e8a9-7643-40a1-995e-17757c75e602">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV82LTEtMS0xLTYxNDMw_e1f2ddbb-f46a-48c0-ab20-34f2c3d92675">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV83LTEtMS0xLTYxNDMw_02ea1ec4-981a-4e29-913c-7a8c0f8b11dc">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV85LTEtMS0xLTYxNDMw_fe7c4ede-0771-42de-bf1f-5830cfc407bd">0001055726</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80L2ZyYWc6NTQxODY5NmEzNWVkNDdkNmJkNjBkYjAxOTAxZjlhNDAvdGFibGU6ZTE1YTYxYTkzYWI5NDcwYzlhZmE2ZTM5MDMwMjkxN2UvdGFibGVyYW5nZTplMTVhNjFhOTNhYjk0NzBjOWFmYTZlMzkwMzAyOTE3ZV8xMC0xLTEtMS02MTQzMA_e856c876-0b03-4a18-993a-a18be735b4cc">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i16d63252834144b0aacf7c65dae0426e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC0wLTEtMS02MTQzMA_ae730f83-897e-47b9-971a-9ff3d67479fe">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82NC9mcmFnOjU4NGY0M2QzZTRmNjQxNTU5M2ZhYWMzNjNkNTM4ZDYwL3RhYmxlOmI4YmE4YjI3YWIwNjQ1MWNiNWU1NzQ1ZGQxODQ5MzAyL3RhYmxlcmFuZ2U6YjhiYThiMjdhYjA2NDUxY2I1ZTU3NDVkZDE4NDkzMDJfMi0xLTEtMS02MTQzMA_aaeeab4e-3e6a-46cf-8192-eda924c14641"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash
      contextRef="i38c5f671c746440783fba1944fd2c330_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83Ni9mcmFnOjQ1NDg0OTIxOGQxNDQ3NDViMTlmOGUwMzkxNjFhOTM3L3RleHRyZWdpb246NDU0ODQ5MjE4ZDE0NDc0NWIxOWY4ZTAzOTE2MWE5MzdfNA_0ca35bbd-94eb-49ac-826e-c54d9e05e9f3"
      unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares
      contextRef="i38c5f671c746440783fba1944fd2c330_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83Ni9mcmFnOjQ1NDg0OTIxOGQxNDQ3NDViMTlmOGUwMzkxNjFhOTM3L3RleHRyZWdpb246NDU0ODQ5MjE4ZDE0NDc0NWIxOWY4ZTAzOTE2MWE5MzdfNw_66b03007-0c4a-4c4c-b1e3-84ecba01a3ae"
      unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares>
    <dei:DocumentType
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE0_705b0f39-0fc9-424e-85fc-c877f721d971">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTk2OGRhMDg0NWE3NDc1NGI0NzczNTk5NzY4OGFmYzMvdGFibGVyYW5nZTo1OTY4ZGEwODQ1YTc0NzU0YjQ3NzM1OTk3Njg4YWZjM18wLTAtMS0xLTYxNDMw_c1bea774-847d-461b-8097-746640ba4fec">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTI0_9bdf6e56-760f-4320-a7a0-1534e9b99438">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6ZDFiODU4OGM3NWQ2NGFiZWI0MDYzMTJlMTlmZjI0YzMvdGFibGVyYW5nZTpkMWI4NTg4Yzc1ZDY0YWJlYjQwNjMxMmUxOWZmMjRjM18wLTAtMS0xLTYxNDMw_2017c8f4-2241-4e21-a417-be1f25a29253">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTI2_837e0461-6695-4379-8855-095b1f0f6be0">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE5_dac9c9f4-808f-4784-b673-3d08c5739d65">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8wLTAtMS0xLTYxNDMw_8012ab29-4798-4ea2-9e71-e2980b1ed2b6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8wLTItMS0xLTYxNDMw_252d78dd-5c10-4d14-9974-c0634da9d872">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTc1NA_322f96cc-6fc0-40e3-b988-ba9445cb04ba">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTc2Ng_80207dab-8ff3-4aaf-a345-e295e5a3918c">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTc4NQ_8c3c2de8-f0cc-470d-968a-cb238d691160">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTAtMS0xLTYzMzQ4L3RleHRyZWdpb246YjNjMTNiZTM1YzU1NDFkN2EzZGUxYjI0YmNkNDkzMDVfMTY0OTI2NzQ0MTgwMA_075b956f-875d-487a-9595-81a2d68094df">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NmNhODY1M2NkNjE5NGE2MTg5ZTVhMWJlNzRmNTM1YzQvdGFibGVyYW5nZTo2Y2E4NjUzY2Q2MTk0YTYxODllNWExYmU3NGY1MzVjNF8zLTItMS0xLTY4NzQ0_d4164336-e720-4ab8-a416-6cb03a6eef45">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE2_340754cf-d40d-4e50-8794-51a9a817aa5e">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTI3_0754a2bf-a1eb-4139-8d18-b6bb4953d3fa">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTJhZTk1M2Y4MDMxNGZhZmE0ZDU2ODJjYjQ2MzRkOWMvdGFibGVyYW5nZTo1MmFlOTUzZjgwMzE0ZmFmYTRkNTY4MmNiNDYzNGQ5Y18yLTAtMS0xLTYxNDMw_c0d5a8b3-846d-4d62-8041-2dba0eb6f498">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTJhZTk1M2Y4MDMxNGZhZmE0ZDU2ODJjYjQ2MzRkOWMvdGFibGVyYW5nZTo1MmFlOTUzZjgwMzE0ZmFmYTRkNTY4MmNiNDYzNGQ5Y18yLTEtMS0xLTYxNDMw_4c3d840c-590f-4efc-93ec-eefc646a3b72">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6NTJhZTk1M2Y4MDMxNGZhZmE0ZDU2ODJjYjQ2MzRkOWMvdGFibGVyYW5nZTo1MmFlOTUzZjgwMzE0ZmFmYTRkNTY4MmNiNDYzNGQ5Y18yLTItMS0xLTYxNDMw_67630767-7166-41ad-b944-04ecaf10208c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTIz_1150cd4e-6445-49a0-9f99-a4130b6368c6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE3_bc424ff2-50fb-4589-82e7-82131b152b38">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6MTFhY2IwNDNkMzRhNGQ2N2E4YzRhZDY1NDM0NzY5ZmEvdGFibGVyYW5nZToxMWFjYjA0M2QzNGE0ZDY3YThjNGFkNjU0MzQ3NjlmYV8yLTAtMS0xLTY4MjI0_c3f05081-060c-4db5-a822-271c9404262d">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6MTFhY2IwNDNkMzRhNGQ2N2E4YzRhZDY1NDM0NzY5ZmEvdGFibGVyYW5nZToxMWFjYjA0M2QzNGE0ZDY3YThjNGFkNjU0MzQ3NjlmYV8yLTQtMS0xLTYxNDMw_9b84e42e-ca56-4138-8612-254003ab8529">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGFibGU6MTFhY2IwNDNkMzRhNGQ2N2E4YzRhZDY1NDM0NzY5ZmEvdGFibGVyYW5nZToxMWFjYjA0M2QzNGE0ZDY3YThjNGFkNjU0MzQ3NjlmYV80LTQtMS0xLTYxNDMw_f8d2ebe9-544b-4b1e-a35c-8c5aa41d9980">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTE4_f3dff713-62bd-4e90-ba6d-6b2f01aec1ee">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9457abe7151f48629c83cef3a4bc1b10_I20230508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xL2ZyYWc6NDlhYjNkOGRkZTE2NGIyMGI3ZjE5MDRmNjZiYzMyY2QvdGV4dHJlZ2lvbjo0OWFiM2Q4ZGRlMTY0YjIwYjdmMTkwNGY2NmJjMzJjZF8yMTAw_8d63d2db-5870-4184-a67e-83ad80401e90"
      unitRef="shares">262740113</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNC0xLTEtMS02MTQzMA_f8c92235-dff4-4234-959d-ce7e66e746a8"
      unitRef="usd">28238152</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNC0zLTEtMS02MTQzMA_730faf00-78ff-4124-ad44-faf6f5a63a05"
      unitRef="usd">46329359</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNS0xLTEtMS02MTQzMA_9607001a-5c4a-48b6-81ae-5beffe746c05"
      unitRef="usd">195513005</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNS0zLTEtMS02MTQzMA_fab582d2-c9c5-4cc9-a054-9b6d36ce88ca"
      unitRef="usd">206669397</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNi0xLTEtMS02MTQzMA_54c3c50e-131e-4edb-830a-a209bd91efd8"
      unitRef="usd">73304</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNi0zLTEtMS02MTQzMA_439234c3-202d-46d8-b3bb-88a0709a4a2c"
      unitRef="usd">1701726</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNy0xLTEtMS02MTQzMA_53849750-0407-4d34-aa28-d7c0d390d097"
      unitRef="usd">4961802</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNy0zLTEtMS02MTQzMA_0d2c4f1d-a20e-4a25-99e0-7f6327cf4405"
      unitRef="usd">10036490</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOC0xLTEtMS02MTQzMA_b0c3ddac-ee7b-4c3c-93c7-16b1e497262f"
      unitRef="usd">4914313</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOC0zLTEtMS02MTQzMA_b1733727-db0c-4ae9-b208-86227464707d"
      unitRef="usd">50130481</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOS0xLTEtMS02MTQzMA_01d5cbfa-1583-49c1-a941-0bc97a04c88e"
      unitRef="usd">195853</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfOS0zLTEtMS02MTQzMA_11ef5032-d6fe-4cb2-b172-d7bd8509d9da"
      unitRef="usd">375227</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTEtMS0xLTEtNjE0MzA_115d29d3-0af8-412e-9c1a-a096742f27f5"
      unitRef="usd">233896429</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTEtMy0xLTEtNjE0MzA_8357877d-f904-4a55-95a2-da744a356840"
      unitRef="usd">315242680</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTItMS0xLTEtNjE0MzA_ba50f735-9375-42a5-9ebb-2a347a6e29c4"
      unitRef="usd">6983305</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTItMy0xLTEtNjE0MzA_f456e19b-eccd-4101-a2ff-053854a1a67e"
      unitRef="usd">7727997</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTMtMS0xLTEtNjE0MzA_e5365d66-01c8-4506-bbe1-638183740bf8"
      unitRef="usd">2623781</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTMtMy0xLTEtNjE0MzA_af850985-1b60-408a-ab43-91bd356a9395"
      unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTUtMS0xLTEtNjE0MzA_ad17e521-1c88-41ff-afdf-4e4079976ac1"
      unitRef="usd">2047778</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTUtMy0xLTEtNjE0MzA_0defceb8-576d-42e7-af7d-d7ddcf2c1058"
      unitRef="usd">2129861</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTYtMS0xLTEtNjE0MzA_03af5d9b-3950-4c31-9aca-44f16020af4b"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTYtMy0xLTEtNjE0MzA_09cfbe87-ed19-4f0a-91af-38e28ff7c4e1"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTctMS0xLTEtNjE0MzA_8cc1e4e6-b36b-401b-ae0c-b7705e97f899"
      unitRef="usd">9865543</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTctMy0xLTEtNjE0MzA_a58ab9ab-1b9d-4c39-9167-be7da01cb255"
      unitRef="usd">10228207</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTgtMS0xLTEtNjE0MzA_afc727cb-9b32-428c-b23e-d40896922a28"
      unitRef="usd">652517</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTgtMy0xLTEtNjE0MzA_e14c9e78-86d6-40ea-ab24-a50cc988f043"
      unitRef="usd">684044</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTktMS0xLTEtNjE0MzA_e79937bc-7ca3-419c-82db-b3de6d399971"
      unitRef="usd">266582724</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMTktMy0xLTEtNjE0MzA_7c952539-7783-4c7f-9858-bb647e5f7a00"
      unitRef="usd">348533302</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjItMS0xLTEtNjE0MzA_3160824e-b446-471d-ac7a-fe9b7980ef55"
      unitRef="usd">24752171</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjItMy0xLTEtNjE0MzA_15f009c3-26a9-473d-82b2-a21a3050d2f3"
      unitRef="usd">79686885</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjMtMS0xLTEtNjE0MzA_bb629bf5-6e07-414b-9b99-190bd03d6c2d"
      unitRef="usd">1417274</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjMtMy0xLTEtNjE0MzA_10f89b6f-e069-4624-a49d-cb2668d0de53"
      unitRef="usd">1220439</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjQtMS0xLTEtNjE0MzA_244712d0-5993-4a08-b7dd-265c6ebe872e"
      unitRef="usd">5795846</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjQtMy0xLTEtNjE0MzA_309997b1-de9f-40db-94b5-34eb8608ba50"
      unitRef="usd">10594073</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjctMS0xLTEtNjE0MzA_c21b8a37-b33d-48d6-ae8a-7fe84176667d"
      unitRef="usd">2579949</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjctMy0xLTEtNjE0MzA_8a609c85-9852-4094-b6e6-b6ea8296df4e"
      unitRef="usd">2803973</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjgtMS0xLTEtNjE0MzA_18bee8c5-e071-4eba-aa7e-af35a25cc542"
      unitRef="usd">4121989</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjgtMy0xLTEtNjE0MzA_0705e849-fed3-40b0-9c9c-989d850b774c"
      unitRef="usd">2475031</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjktMS0xLTEtNjE0MzA_31b806cd-2714-4f1e-adbb-f37defb1f8fb"
      unitRef="usd">89007</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMjktMy0xLTEtNjE0MzA_3f58a386-ea86-471e-903a-99b4bee08615"
      unitRef="usd">87673</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzAtMS0xLTEtNzA4MzQ_8f2c0281-1b70-412c-b950-dd48feabeb2b"
      unitRef="usd">16394841</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzAtMy0xLTEtNzA4MzQ_807fb984-4544-405e-b8dd-a6140ce13212"
      unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzEtMS0xLTEtNjE0MzA_4d1e6d3f-1900-4ddc-b714-442e20aa6d1e"
      unitRef="usd">55151077</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzEtMy0xLTEtNjE0MzA_9066d017-b3f9-4386-9fbe-3099b1810368"
      unitRef="usd">96868074</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzQtMS0xLTEtNjE0MzA_c4a68a09-5e78-4305-90eb-4cd529759185"
      unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzQtMy0xLTEtNjE0MzA_686dbd38-06ff-4c47-980e-21f08900c98f"
      unitRef="usd">16614840</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzYtMS0xLTEtNjE0MzA_a2373b51-7925-4a44-9594-14a3acba9137"
      unitRef="usd">12185919</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzYtMy0xLTEtNjE0MzA_828d9d2b-8ccc-43fe-9575-ba2a14d16c49"
      unitRef="usd">12655586</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzctMS0xLTEtNjE0MzA_8e4fbd1e-ac32-4f85-84e9-6edabc609aeb"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfMzctMy0xLTEtNjE0MzA_a12ebc49-331f-444c-8c8c-cde74bbf0f3b"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDAtMS0xLTEtNjE0MzA_fb0893a8-5442-4fb3-97bb-01c31272b3e9"
      unitRef="usd">67369042</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDAtMy0xLTEtNjE0MzA_df8f6733-57b3-4457-bc78-968c8ae214b5"
      unitRef="usd">126170546</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDItMS0xLTEtNjE0MzA_69faa1b2-6138-4049-a5ff-b9a4aff9330d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDItMy0xLTEtNjE0MzA_88ed493b-333e-4145-b26b-9e1cd38a2937"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDMtMS0xLTEtNjE0MzA_d4ae7dbf-b020-4720-880c-b82d5a81400c"
      unitRef="usd">262738</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDMtMy0xLTEtNjE0MzA_e0f6e1ae-286c-4bcc-a7cb-69cddd163c76"
      unitRef="usd">253090</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDQtMS0xLTEtNjE0MzA_a0c215b5-a0f7-4a9d-abcf-d8946caa5464"
      unitRef="usd">1728030842</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDQtMy0xLTEtNjE0MzA_2399306a-b4a3-4938-8116-b9af3301d701"
      unitRef="usd">1710656191</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDUtMS0xLTEtNjE0MzA_155773d1-8a3f-4f1d-a53b-66b50b7ad5f9"
      unitRef="usd">-1528497101</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDUtMy0xLTEtNjE0MzA_ec90ec2a-ebba-4fb2-ac17-3ed629b94e58"
      unitRef="usd">-1487847784</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDYtMS0xLTEtNjE0MzA_bb38ac0a-d4c5-4c8b-945b-cea82562b2fb"
      unitRef="usd">-582797</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDYtMy0xLTEtNjE0MzA_d44e08b6-7921-421e-b7be-f0df15e93cd1"
      unitRef="usd">-698741</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDctMS0xLTEtNjE0MzA_f37e84b6-2393-40b7-87e6-5005719fff5c"
      unitRef="usd">199213682</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNDctMy0xLTEtNjE0MzA_1c642df4-e4ee-44e5-872e-2c3daf2d9e4f"
      unitRef="usd">222362756</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNTAtMS0xLTEtNjE0MzA_b5141683-e467-4f31-b228-6bd4be12735e"
      unitRef="usd">266582724</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xNi9mcmFnOmM3MTA3NWM4MWMzZjQwMjg5MTFiYmVhNWZhM2VmMDA1L3RhYmxlOjNkMTFmZjBkNmY3NjRjZWRhMDQxNDljNzhmMDEzMjBiL3RhYmxlcmFuZ2U6M2QxMWZmMGQ2Zjc2NGNlZGEwNDE0OWM3OGYwMTMyMGJfNTAtMy0xLTEtNjE0MzA_a7352e59-06c2-4aa5-9fad-ec7ab0e33c24"
      unitRef="usd">348533302</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfOS0xLTEtMS02MTQzMA_5ad3d125-4a65-4b86-8b06-225f1f4b4710"
      unitRef="usd">114943</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfOS0zLTEtMS02MTQzMA_bc7f52e4-be33-47ae-9831-fe1748599539"
      unitRef="usd">199074</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTEtMS0xLTEtNjE0MzA_4c801e63-f0b4-424e-a4fb-4f28f1515ff3"
      unitRef="usd">30176511</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTEtMy0xLTEtNjE0MzA_f43360a2-e0d7-4270-ad56-fe6003a9f344"
      unitRef="usd">55978611</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTItMS0xLTEtNjE0MzA_3522bc49-a559-4adf-a03e-bb5f24efaff6"
      unitRef="usd">13890610</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTItMy0xLTEtNjE0MzA_9aca4e66-e9d0-41aa-afd6-63a7f71ff8fc"
      unitRef="usd">15953458</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTQtMS0xLTEtNjE0MzA_b33823f5-9778-4ee7-afd2-70cca16b2ccd"
      unitRef="usd">44067121</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTQtMy0xLTEtNjE0MzA_c58cf13b-13a1-4368-a5cc-3f6d306f7807"
      unitRef="usd">71932069</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTUtMS0xLTEtNjE0MzA_73fe8816-0226-43da-8de0-fd131df9b9e2"
      unitRef="usd">-43952178</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTUtMy0xLTEtNjE0MzA_80b86485-1dba-4b0e-ae3a-949ae092ed5c"
      unitRef="usd">-71732995</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTctMS0xLTEtNjE0MzA_4e07f813-d5d6-4d71-9895-f3d109edba3f"
      unitRef="usd">2207171</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTctMy0xLTEtNjE0MzA_ba8c4da9-4161-459e-b4a5-a88ac1c5fbf6"
      unitRef="usd">669814</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTgtMS0xLTEtNjE0MzA_ed3f0fa3-7569-4053-8124-a3f3b34b9f99"
      unitRef="usd">313488</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMTgtMy0xLTEtNjE0MzA_1bf12b3b-ec06-4a09-94cd-61e1ff15b7a0"
      unitRef="usd">313488</us-gaap:InterestExpense>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjEtMS0xLTEtNjE0MzA_665370c5-0d3f-4816-9922-efa354d41938"
      unitRef="usd">616639</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjEtMy0xLTEtNjE0MzA_d3033ae9-17ad-442d-9199-386130dc115d"
      unitRef="usd">-537728</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjItMS0xLTEtNjE0MzA_cadef122-51b3-4d1b-aa61-2a519d054936"
      unitRef="usd">3218215</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjItMy0xLTEtNjE0MzA_5aa5afc9-4e97-41ca-8927-7eb47e57b8c5"
      unitRef="usd">-4840641</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjMtMS0xLTEtNjE0MzA_e01d2829-4381-4e58-b924-a8a859d55ed6"
      unitRef="usd">-2425676</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjMtMy0xLTEtNjE0MzA_aada621e-bccc-4aa0-8e79-e65ce2cd8d05"
      unitRef="usd">-153468</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjgtMS0xLTEtNjE0MzA_13b4cc6e-d039-4763-bedd-89bc6a671358"
      unitRef="usd">-40649317</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMjgtMy0xLTEtNjE0MzA_7784827c-46cd-4b66-a229-3554f9d45dbb"
      unitRef="usd">-76908506</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzAtMS0xLTEtNjE0MzA_15930334-d1ec-46ab-886e-f68c9fed1f3c"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzAtMy0xLTEtNjE0MzA_2ab1bd51-d829-4a8e-9c95-ae5d084fec7e"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzEtMS0xLTEtNjE0MzA_916e76b9-7ac4-46ca-888b-4af9f42024dc"
      unitRef="usd">-40649317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzEtMy0xLTEtNjE0MzA_b73ceb7f-4af6-401d-abd1-c4cc803c6a80"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMS0xLTEtNjE0MzA_7a04c6d4-3433-402c-bbd9-7b245b6b951e"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMS0xLTEtNjE0MzA_cad65ac9-072d-4486-a15f-4094e532fb9a"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMy0xLTEtNjE0MzA_37f711f4-e549-496f-aed8-41fe6e5967e2"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzUtMy0xLTEtNjE0MzA_37fd9d5b-ee89-4af4-aefd-b017e54405bc"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMS0xLTEtNjE0MzA_14374bc8-db81-4b32-9fdd-ff2f83ef1533"
      unitRef="shares">258437714</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMS0xLTEtNjE0MzA_34ccac25-bccd-4bf2-ac3c-22acb1f3a533"
      unitRef="shares">258437714</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMy0xLTEtNjE0MzA_fe442a46-1677-45c6-be5e-ae038fa9c6f7"
      unitRef="shares">218940693</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8xOS9mcmFnOjFiNWRmNjVlNjBhZDRmZjRiM2I1OTQ5MWU5MjBiYTQyL3RhYmxlOmY5NDQxMThiNGVjMjQ3Y2VhMmQ4Y2ZiYjhmNDI1NWZjL3RhYmxlcmFuZ2U6Zjk0NDExOGI0ZWMyNDdjZWEyZDhjZmJiOGY0MjU1ZmNfMzgtMy0xLTEtNjE0MzA_ffb6d700-ae90-4cbb-ba9a-5fd1170b9ea7"
      unitRef="shares">218940693</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfMi0xLTEtMS02MTQzMA_061f0600-cf4c-4287-aff9-5aa8dd39f97e"
      unitRef="usd">-40649317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfMi0zLTEtMS02MTQzMA_27cc247f-b1d2-4f36-a810-ab03f7934baf"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNS0xLTEtMS02MTQzMA_3e27a802-6341-4917-9694-ebef05a7cf48"
      unitRef="usd">-1918</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNS0zLTEtMS02MTQzMA_f4aac639-e5b8-406c-b88c-d7e5aa2e1935"
      unitRef="usd">-6555</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNi0xLTEtMS02MTQzMA_6603ff85-ba80-4a63-82d3-dce2adc924dd"
      unitRef="usd">117862</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfNi0zLTEtMS02MTQzMA_1001db79-a43b-4a09-bec0-1bbc042543c1"
      unitRef="usd">-169097</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfOS0xLTEtMS02MTQzMA_3fe4e265-dde4-4846-89c7-20fafbdad587"
      unitRef="usd">-40533373</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yMi9mcmFnOmNkZTcyNjE2MzE0ZjQ5MDRiNTVkY2FjOTFkOGZkNDAyL3RhYmxlOjlmMTYzMGE1MWEyNDQwNTk4MTE4YzIwNjM0MTgzMWYwL3RhYmxlcmFuZ2U6OWYxNjMwYTUxYTI0NDA1OTgxMThjMjA2MzQxODMxZjBfOS0zLTEtMS02MTQzMA_1e9f1e12-50a5-4419-83b1-171d9ef6bebb"
      unitRef="usd">-79249371</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i061af91598d043dbb23f9bec95fcd0cd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xLTEtMS02MzI4Mg_4f572cae-6d40-47ac-bcd2-cf86f84e2768"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i061af91598d043dbb23f9bec95fcd0cd_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0zLTEtMS02MzI4Mg_1b64965b-9261-4a72-a06b-564fc9a53189"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i37852329bf79418fa1da42c06d21d21b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy01LTEtMS02MzI4Mg_1e153498-2385-46d0-926c-57d7692501fd"
      unitRef="shares">253091319</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i37852329bf79418fa1da42c06d21d21b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy03LTEtMS02MzI4Mg_e866dc6b-f4fe-4dfb-9b3c-dd115dcf9512"
      unitRef="usd">253090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if771a6bc25d34d21bdedcf8ef619d315_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy05LTEtMS02MzI4Mg_0d400929-35f6-4503-b711-9200f2fd52ea"
      unitRef="usd">1710656191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0e372dd07124d13b07e1eba2d4ebb48_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xMS0xLTEtNjMyODI_ea4b114c-446e-447f-8383-7319cdbd1906"
      unitRef="usd">-1487847784</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e32cf9a419844fc997d07e4f740dc36_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xMy0xLTEtNjMyODI_cfe2352e-c982-4417-80d1-4298f928e200"
      unitRef="usd">-698741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMy0xNy0xLTEtNjc2OTk_a8bac6f0-4d61-49bd-aead-702730f4c158"
      unitRef="usd">222362756</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC01LTEtMS02MzI5Ng_2c3a2a7f-17f0-4d98-9e2b-1df251454864"
      unitRef="shares">9121000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC03LTEtMS02MzI5Ng_d6df03e6-3141-4094-b8b0-3e73fe70736b"
      unitRef="usd">9121</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC05LTEtMS02MzI5Ng_019eeba0-76c7-4535-83f2-7e6234ba2342"
      unitRef="usd">13990879</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNC0xNy0xLTEtNjc3MzE_d59068f0-d62b-44f6-bf02-8f1d82f581f0"
      unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS01LTEtMS02MzI5Ng_a9ee4b1a-0d5b-49ce-b9cf-fa6e35f438cd"
      unitRef="shares">526807</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2e318d434b2b408782a34df0a7553c61_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS03LTEtMS02MzI5Ng_d5f79020-b4ab-4c48-ab55-bddc56d24e9e"
      unitRef="usd">527</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS05LTEtMS02MzI5Ng_64a45921-4074-478f-b4a3-74556ae5460e"
      unitRef="usd">-425231</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNS0xNy0xLTEtNjc3MzE_b6362100-0feb-4a55-b2f5-ff9030774fbf"
      unitRef="usd">-424704</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5c4fb406a7d44ee68c47433d5da7075a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNi05LTEtMS02MzI5Ng_d8cd430b-e1d8-4b72-bef5-4b9afade24dc"
      unitRef="usd">3809003</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNi0xNy0xLTEtNjc3MzE_71a8beae-1f83-49db-a6a9-29172c735414"
      unitRef="usd">3809003</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i758b5f9af27d4ef997eae8d3e89608ca_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNy0xMS0xLTEtNjMyOTY_82cd4713-ec0f-430f-bebc-23d4b1410058"
      unitRef="usd">-40649317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfNy0xNy0xLTEtNjc3MzE_bce5d983-b237-427d-a426-48eeceef62e7"
      unitRef="usd">-40649317</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0a56e5fa34464fac9afd99a63dad6ef2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOC0xMy0xLTEtNjMyOTY_ce9ccabe-ac7b-4e0c-a830-06d9ba1b1a0e"
      unitRef="usd">117862</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOC0xNy0xLTEtNjc3MzE_ead0c8cd-f83a-451a-8c40-e368186291a1"
      unitRef="usd">117862</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0a56e5fa34464fac9afd99a63dad6ef2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOS0xMy0xLTEtNjMyOTY_0c71235b-79ea-4981-8959-ba600157f87f"
      unitRef="usd">-1918</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfOS0xNy0xLTEtNjc3MzE_75f2a973-6b6d-44e2-ac23-6533822fd138"
      unitRef="usd">-1918</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i572101f4b4394cbab05b6a7efd242b43_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMS0xLTEtNjc3Mjk_acbdb031-a64e-435c-a260-19280b1450b6"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i572101f4b4394cbab05b6a7efd242b43_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMy0xLTEtNjc3Mjk_53fe4c9a-f84a-4c61-97f0-7202c303c32f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i43f73c345dc54c3fb85944a872f29625_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtNS0xLTEtNjc3Mjk_dc32bb63-19d1-46ed-83f2-f1be2ce2d3d1"
      unitRef="shares">262739126</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i43f73c345dc54c3fb85944a872f29625_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtNy0xLTEtNjc3Mjk_0e7d812b-0082-40ed-ab56-98b6e34de30c"
      unitRef="usd">262738</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibcefd5afd949414c8e5a0edaaaf68460_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtOS0xLTEtNjc3Mjk_ad7daf71-e7eb-452a-ba28-ab5649e3426b"
      unitRef="usd">1728030842</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ff70ed56a0f4a22bd78e19f1cc27821_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMTEtMS0xLTY3NzI5_b35aa8a9-ae19-400c-a197-e2263f9b5870"
      unitRef="usd">-1528497101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic67c34d5644f4e6bb650febc8364d7ba_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMTMtMS0xLTY3NzI5_dcaceb52-c796-4e7b-ad33-d0bebf524854"
      unitRef="usd">-582797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOmYwMjVmODdiMTE3ZTRiZjk4NzMxYzY1OGQzZDcxMDgwL3RhYmxlcmFuZ2U6ZjAyNWY4N2IxMTdlNGJmOTg3MzFjNjU4ZDNkNzEwODBfMTAtMTctMS0xLTY3NzI5_fe6c88ce-a4c2-4125-9fa2-3e72f985d17c"
      unitRef="usd">199213682</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i06a9a0ba408648df83848a10938d69f5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xLTEtMS02MTQzMA_ae345110-dc91-4e80-987e-fc6a50491f02"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i06a9a0ba408648df83848a10938d69f5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0zLTEtMS02MTQzMA_3a383181-2111-4663-9fea-4cc489d28ad1"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ie00cf796b6ae43e6abe0a3ec4dc6c4c9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy01LTEtMS02MTQzMA_bbb8b055-cf59-4656-b967-ef8f8d05d1b9"
      unitRef="shares">217382887</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie00cf796b6ae43e6abe0a3ec4dc6c4c9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy03LTEtMS02MTQzMA_01d508cd-a0a4-4a5d-963b-70facaa50da0"
      unitRef="usd">217382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c79ff17a8ad41eebe7c8cacae2d2448_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy05LTEtMS02MTQzMA_51ca400c-9344-4b67-abe5-e51e1415fb05"
      unitRef="usd">1609589797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac43eafb695b45e386c9c3400e86b00f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xMS0xLTEtNjE0MzA_38d12ba0-0bc3-41e4-8e38-dfd7171e4c69"
      unitRef="usd">-1209855522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if130560dfba64db0886b6c2aad0e1266_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xMy0xLTEtNjE0MzA_82d9438c-ae03-4def-95f7-a189daead52c"
      unitRef="usd">-282236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i037465b4f55945f6aec5c70683960daf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMy0xNy0xLTEtNjE0MzA_cd5936e0-b817-457d-bea1-b1895e91642c"
      unitRef="usd">399669421</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6d056507ce342c8b4ceade8fbc2431c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC05LTEtMS02MTQzMA_417c13f4-2fc6-4b2e-9640-4f972f94bd3d"
      unitRef="usd">-3294019</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib18f3cd8f5654cabbdd4c9ca4e61b6e6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC0xMS0xLTEtNjE0MzA_aa2027ea-32e7-42f2-aa96-712fa595b7d3"
      unitRef="usd">1825803</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i806e78a728a14bbf808d71382f080b36_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNC0xNy0xLTEtNjE0MzA_0064cc29-2f4b-4e31-a10f-2671bd5218d9"
      unitRef="usd">-1468216</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS01LTEtMS02MTQzMA_6ecbd0f8-1379-4fff-a0b8-c6cc0b2b71a9"
      unitRef="shares">8480483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS03LTEtMS02MTQzMA_73f45184-a463-495d-83e5-8247b735ffd0"
      unitRef="usd">8481</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS05LTEtMS02MTQzMA_fa0e5fc3-8156-4de9-98e8-6020f2d19561"
      unitRef="usd">29356057</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNS0xNy0xLTEtNjE0MzA_e9fe7ce6-6012-4a7b-b81f-0e1d50199e11"
      unitRef="usd">29364538</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi01LTEtMS02MTQzMA_2d332aa9-8ed0-49aa-bf36-292669439a43"
      unitRef="shares">647350</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i31a1965e10044d8bb58b365893ad7f60_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi03LTEtMS02MTQzMA_e1f32634-0090-4d17-b7ed-26f50a757ea1"
      unitRef="usd">646</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi05LTEtMS02MTQzMA_0be37665-40e2-43f6-a9c1-4d8ba829708e"
      unitRef="usd">-943167</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNi0xNy0xLTEtNjE0MzA_c8973c33-8154-417a-b8b7-74c4b7363f0a"
      unitRef="usd">-942521</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia6407ef15a4b4adfb10ca73adfba9b8d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNy05LTEtMS02MTQzMA_da98bf76-668d-4536-a289-003b5b914a5d"
      unitRef="usd">7711151</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfNy0xNy0xLTEtNjE0MzA_6b2da6a1-436e-4bf0-b207-6cb3f8b1f414"
      unitRef="usd">7711151</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i9ad54f853b18472facb941b6fa20e521_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOC0xMS0xLTEtNjE0MzA_d156d39f-9b07-4bb3-9579-3c182ec42e83"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOC0xNy0xLTEtNjE0MzA_9eed1596-2575-4587-a4f3-f8be2536aad0"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib01b0d4a71e24d5180845b2744da7b80_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOS0xMy0xLTEtNjE0MzA_522e1c16-dbf3-4af9-9d79-7076efe79b3c"
      unitRef="usd">-169097</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfOS0xNy0xLTEtNjE0MzA_ab3d96df-b45f-42ea-acbf-c2d1b81c25d7"
      unitRef="usd">-169097</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib01b0d4a71e24d5180845b2744da7b80_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTAtMTMtMS0xLTYxNDMw_d37f3c52-cec0-4523-b7bd-5d1ad548f925"
      unitRef="usd">-6555</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTAtMTctMS0xLTYxNDMw_13661b0d-2576-49fe-849c-5b81d7e5f3bc"
      unitRef="usd">-6555</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ida57e8acbeb64025a8f23f21a9dd2033_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMS0xLTEtNjE0MzA_d8b4c4ad-edf1-4418-b648-1fddab35b2af"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ida57e8acbeb64025a8f23f21a9dd2033_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMy0xLTEtNjE0MzA_2a8f473b-4a42-472d-b111-e113463bbac8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i4c5328efdb974908ae8cfd3253ce76d8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtNS0xLTEtNjE0MzA_0b7b9b2a-71e5-4b46-8f72-3e2236df6d8b"
      unitRef="shares">226510720</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i4c5328efdb974908ae8cfd3253ce76d8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtNy0xLTEtNjE0MzA_fa8e207b-776f-4f91-85ae-70af9db9a19d"
      unitRef="usd">226509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42b8747dfa6a496aa4f8ff6db15082f4_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtOS0xLTEtNjE0MzA_b9f99f39-8c4d-4db4-b634-906493d242d1"
      unitRef="usd">1642419819</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0b90c0f76ed48918a32bab8f7514148_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMTEtMS0xLTYxNDMw_8ec67fe6-8bf0-4b90-b869-f59912844760"
      unitRef="usd">-1287103438</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i384f44b2bbbc4040b18237efb0444e8c_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMTMtMS0xLTYxNDMw_d855cb06-edce-4302-80b2-9db82c19e786"
      unitRef="usd">-457888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i158c20e44ccc4e16864d4c2cb9a584f3_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yNS9mcmFnOjkxMjAyM2RjNDkxNTQ4MmQ5Yjk1YzFhNmIwMjYwNTBkL3RhYmxlOjFkZTQwYzA5NjQxODQ2ODc5NzhjZGY5NTdiZjcwZjYzL3RhYmxlcmFuZ2U6MWRlNDBjMDk2NDE4NDY4Nzk3OGNkZjk1N2JmNzBmNjNfMTEtMTctMS0xLTYxNDMw_1bfc01d9-12b4-46ad-b8fb-39cc0caf0ae8"
      unitRef="usd">355085002</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMy0xLTEtMS02MTQzMA_1d94bb1c-6219-4dd5-994a-211b410f4749"
      unitRef="usd">-40649317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMy0zLTEtMS02MTQzMA_c8c6e0c3-e78b-4aff-b851-f149a311ffa4"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNS0xLTEtMS02MTQzMA_c00ab0cf-3841-404b-a076-6a3e515579f3"
      unitRef="usd">707378</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNS0zLTEtMS02MTQzMA_6df776ff-0fc4-4d0b-ac2a-2d881729b97c"
      unitRef="usd">929383</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNi0xLTEtMS02MTQzMA_345d34af-4709-4edf-a233-92acbcfe7814"
      unitRef="usd">82083</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNi0zLTEtMS02MTQzMA_7cd8673f-77b7-4465-8c02-b8c756efdf74"
      unitRef="usd">126770</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNy0xLTEtMS02MTQzMA_92f2ce37-911e-466f-9605-0168d290d4d3"
      unitRef="usd">362664</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNy0zLTEtMS02MTQzMA_92b79048-16d4-46a4-b01e-544a2863247b"
      unitRef="usd">319586</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfOS0xLTEtMS02MTQzMA_3889ef6b-71c7-4c8e-b719-5c87855bd74e"
      unitRef="usd">3809003</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfOS0zLTEtMS02MTQzMA_35d8d2ac-5ca6-4329-858f-3a88760e2289"
      unitRef="usd">7711151</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTItMS0xLTEtNjE0MzA_ede78b1b-5c0b-49cb-ac3c-306c1ce38b17"
      unitRef="usd">219999</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTItMy0xLTEtNjE0MzA_ff7ee72a-5139-452a-aa28-cf835716aac2"
      unitRef="usd">219999</ino:NonCashInterestIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTMtMS0xLTEtNjE0MzA_adf687ef-e366-4c9b-b194-80f5144f9efa"
      unitRef="usd">1159083</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTMtMy0xLTEtNjE0MzA_e846579a-91cd-4d07-89db-98a290402798"
      unitRef="usd">-125810</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTQtMS0xLTEtNjE0MzA_ab1429cc-c115-4c0a-ba5c-65051837a086"
      unitRef="usd">-2425676</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTQtMy0xLTEtNjE0MzA_bddb60be-3a77-4e1a-83ce-1283866fb191"
      unitRef="usd">-318684</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTUtMS0xLTEtNjE0MzA_1d25681c-642f-4a7f-82ef-35b449fd556d"
      unitRef="usd">-334297</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTUtMy0xLTEtNjE0MzA_f7d8e2d8-a939-49cc-a901-2f8d74ee2a40"
      unitRef="usd">-157666</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTYtMS0xLTEtNjE0MzA_12fd392c-2b37-4084-bd94-a9eb53f0f151"
      unitRef="usd">0</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTYtMy0xLTEtNjE0MzA_5d69dc35-b06d-457f-9dbf-a1166091a667"
      unitRef="usd">165215</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTgtMS0xLTEtNjE0MzA_47e97fc1-68b3-4da2-ba21-66ebea92d2ad"
      unitRef="usd">616639</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTgtMy0xLTEtNjE0MzA_52c6240b-e579-44d4-b287-193a90191240"
      unitRef="usd">-537728</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTktMS0xLTEtNjE0MzA_b3cbf27e-50a5-435e-8fbc-8ad466e81160"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMTktMy0xLTEtNjE0MzA_b1e3469e-ceed-4c19-a2be-1f87542590e0"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjItMS0xLTEtNjE0MzA_d650704f-7bea-4625-9443-0ea03382421c"
      unitRef="usd">3218215</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjItMy0xLTEtNjE0MzA_7aaf6a18-aacd-4a0d-af79-72416c724d04"
      unitRef="usd">-4840641</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjktMS0xLTEtNjE0MzA_c66f2125-32e8-4dc1-8433-d881018e8324"
      unitRef="usd">-6703110</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMjktMy0xLTEtNjE0MzA_8fcf762e-6e40-4cec-8850-b606291e3141"
      unitRef="usd">-541248</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzEtMS0xLTEtNjE0MzA_5d320343-8ddc-4b0d-84a6-afb10149d5d2"
      unitRef="usd">-39324542</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzEtMy0xLTEtNjE0MzA_5969f2e4-30cb-4caa-9cd1-7c99c82a97de"
      unitRef="usd">-7075934</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzQtMS0xLTEtNjE0MzA_48f9cf41-b5b9-4be4-950a-3ca8f7c732f0"
      unitRef="usd">-31527</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzQtMy0xLTEtNjE0MzA_fa15013f-5e75-4c85-9ffa-9538570c4e93"
      unitRef="usd">-151999</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzUtMS0xLTEtNjE0MzA_14065c51-94be-4bff-b4a8-9760efa2310a"
      unitRef="usd">-40737879</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzUtMy0xLTEtNjE0MzA_0ff07894-1111-49c3-8332-bd6f3dc18b28"
      unitRef="usd">-9000559</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzYtMS0xLTEtNjE0MzA_474cbd2e-c901-4202-8f60-d6c6ff043045"
      unitRef="usd">-4798227</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzYtMy0xLTEtNjE0MzA_5c70d4d3-559b-4daf-a627-608074546f0e"
      unitRef="usd">1501489</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzgtMS0xLTEtNjE0MzA_c25819ba-6638-44f3-a3a0-a6ec512f0ebb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfMzgtMy0xLTEtNjE0MzA_76e6b600-6682-40af-b703-f9c8ed0fe158"
      unitRef="usd">-9963</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDEtMS0xLTEtNjE0MzA_7b7854e3-6dde-4e25-86d8-cd63b61edd1e"
      unitRef="usd">-693691</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDEtMy0xLTEtNjE0MzA_b30fd2ac-9c9a-4767-833e-d8ee2297983f"
      unitRef="usd">-624673</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDItMS0xLTEtNjE0MzA_942da90c-0fed-42dd-9cdc-ab2acf03a2dd"
      unitRef="usd">1648292</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDItMy0xLTEtNjE0MzA_6cee1f32-7394-45e5-a6e4-921566d97466"
      unitRef="usd">723550</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDUtMS0xLTEtNjE0MzA_87aed83c-4366-4647-acdb-a0e711dcc1a0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDUtMy0xLTEtNjE0MzA_472a40a4-6f19-435b-b688-4e7ae1d5d0a3"
      unitRef="usd">-14826</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDYtMS0xLTEtNjE0MzA_e370ae86-ba6a-4beb-a0cb-d297f9edf280"
      unitRef="usd">-36664478</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDYtMy0xLTEtNjE0MzA_670a2490-e493-4027-acdf-ca79be7ab3aa"
      unitRef="usd">-61882102</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDgtMS0xLTEtNjE0MzA_d3f8f257-52c1-4a73-8680-3478d4110c1a"
      unitRef="usd">80431174</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDgtMy0xLTEtNjE0MzA_7d7db468-b2db-4738-bd9c-b2524c7a4be3"
      unitRef="usd">99722697</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDktMS0xLTEtNjE0MzA_b43d6674-d5de-408b-a385-ab8d7af784c0"
      unitRef="usd">93657050</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNDktMy0xLTEtNjE0MzA_673e3807-95a0-43e8-9933-a7eef88bd17f"
      unitRef="usd">123055048</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTAtMS0xLTEtNjE0MzA_e1f1f25b-cc99-48a3-9d6d-5cd3b4b39fb8"
      unitRef="usd">296983</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTAtMy0xLTEtNjE0MzA_b6c97274-fa90-480f-a6fa-d22054405153"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTEtMS0xLTEtNjE0MzA_eb321163-2e64-4f77-9baa-de08a8c76c43"
      unitRef="usd">6071000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTEtMy0xLTEtNjE0MzA_21912b38-f888-4cbe-bb23-10553cd4f3b4"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTItMS0xLTEtNjE0MzA_0fcc4e23-7ee1-439e-aa5b-0a54b47181d1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTItMy0xLTEtNjE0MzA_db5cbac7-8d6b-4d86-9c2a-a17d24695c9c"
      unitRef="usd">1999998</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTYtMS0xLTEtNjE0MzA_d586c875-a594-4df6-8eb0-f48f5de979a2"
      unitRef="usd">18999893</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNTYtMy0xLTEtNjE0MzA_cbf9180e-a9d7-4ce0-b78d-5b3749434fbf"
      unitRef="usd">21332353</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjAtMS0xLTEtNjE0MzA_c17eafa6-d0f5-4bec-8050-1b5fee6765ba"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjAtMy0xLTEtNjE0MzA_ffa1a80b-8d85-4994-aa57-df528b20aa07"
      unitRef="usd">29364538</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjEtMS0xLTEtNjE0MzA_a313ab63-c580-43d3-8205-540b4cfd75d9"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjEtMy0xLTEtNjE0MzA_3c1fe54d-76e1-4e4d-b7f5-8de1d1432334"
      unitRef="usd">83812</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjItMS0xLTEtNjE0MzA_d51cffef-9877-43fd-ac46-0cbed8672a4c"
      unitRef="usd">424704</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjItMy0xLTEtNjE0MzA_60808846-cff2-46a2-b59e-e31836d82228"
      unitRef="usd">1026333</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjUtMS0xLTEtNjE0MzA_b46999f0-2fe3-4996-a440-1bc2ba5155dc"
      unitRef="usd">-424704</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjUtMy0xLTEtNjE0MzA_8732d0c4-b1d5-4f9c-8009-2e2878c08cf0"
      unitRef="usd">28422017</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjYtMS0xLTEtNjE0MzA_7510c60b-66b6-4fc0-9be4-b534079ac8a3"
      unitRef="usd">-1918</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjYtMy0xLTEtNjE0MzA_b62cf9a6-7fa0-4279-a688-a2b9042719db"
      unitRef="usd">-6555</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjctMS0xLTEtNjE0MzA_0dd08681-6cb4-4b3b-ba21-f1da839bbd13"
      unitRef="usd">-18091207</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjctMy0xLTEtNjE0MzA_84ce376a-d26b-4b75-86f4-a08b5aec0645"
      unitRef="usd">-12134287</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjgtMS0xLTEtNjE0MzA_acf876fc-7da5-4794-9c34-134691e5ada3"
      unitRef="usd">46329359</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i037465b4f55945f6aec5c70683960daf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjgtMy0xLTEtNjE0MzA_e159084d-b4c4-4412-8102-7d2aecd116a2"
      unitRef="usd">71143778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjktMS0xLTEtNjE0MzA_e656c047-cea2-4828-a07e-e062e393e1ee"
      unitRef="usd">28238152</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i158c20e44ccc4e16864d4c2cb9a584f3_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNjktMy0xLTEtNjE0MzA_2cd68407-531f-465f-a10f-61dd7dae5920"
      unitRef="usd">59009491</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzItMS0xLTEtNjE0MzA_d0cb1353-3eee-4fd3-8971-f76214155235"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzItMy0xLTEtNjE0MzA_a28f62a4-e5aa-407f-8ab7-8355cb99c3ac"
      unitRef="usd">330779</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzMtMS0xLTEtNjE0MzA_d1b55ae4-18cf-41f6-8537-158249210b86"
      unitRef="usd">533487</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzMtMy0xLTEtNjE0MzA_fb31ccf4-7516-446f-ae7d-502984f15287"
      unitRef="usd">533487</us-gaap:InterestPaidNet>
    <ino:ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzUtMS0xLTEtNjE0MzA_d3acecc1-8fa4-4eab-aea4-b6ade4fd0319"
      unitRef="usd">14000000</ino:ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement>
    <ino:ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8yOC9mcmFnOmU1NTQ0Y2FiNzUwZTRkM2Y4NzVmMWI5ZjBlOTZhNDhkL3RhYmxlOjM0MmM4NTY3YzgwZDQyNTc4NWEwMDEyYjcxMzc2NTZjL3RhYmxlcmFuZ2U6MzQyYzg1NjdjODBkNDI1Nzg1YTAwMTJiNzEzNzY1NmNfNzUtMy0xLTEtNjE0MzA_263ffd50-a722-4ee4-87f1-d732ff4fdeb1"
      unitRef="usd">0</ino:ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement>
    <us-gaap:NatureOfOperations
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNC9mcmFnOjE5NGYyZGQzYTJiYzQ4Mjk4MzE3YWQ2ZGMxNDM0OWJjL3RleHRyZWdpb246MTk0ZjJkZDNhMmJjNDgyOTgzMTdhZDZkYzE0MzQ5YmNfMzQwOA_b09a65b4-83a0-451b-87f1-be2fcffa741c">Organization and Operations&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company&#x2019;s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In clinical trials, INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;INOVIO's lead candidates are focused on diseases associated with HPV. In October 2022 and February 2023, INOVIO announced data from the first and second cohorts, respectively, of its Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated Recurrent Respiratory Papillomatosis (RRP). In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp;amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, Indiana University, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for the Ebola virus; HPV-related precancers, including cervical, vulvar and anal dysplasia; HPV-related cancers, including head &amp;amp; neck; other HPV-related disorders, such as RRP; and glioblastoma (GBM).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfNTc2Nw_46e9089e-5e71-4b53-8ecd-9c7e71618e45">Basis of Presentation, Liquidity and Risks and Uncertainties&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2023 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2023. The balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2023 and December 31, 2022, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $40.6 million for the three months ended March 31, 2023. The Company had working capital of $178.7 million and an accumulated deficit of $1.5 billion as of March&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $223.8 million as of March&#160;31, 2023 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million under a Sales Agreement for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the three months ended March 31, 2023, no shares were sold under a Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfNTc2MQ_0f48d2ab-b845-447e-b5cd-14ac1c33200d">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2023 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2023. The balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2023 and December 31, 2022, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $40.6 million for the three months ended March 31, 2023. The Company had working capital of $178.7 million and an accumulated deficit of $1.5 billion as of March&#160;31, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $223.8 million as of March&#160;31, 2023 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million under a Sales Agreement for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the three months ended March 31, 2023, no shares were sold under a Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjMwOA_1411b0be-bd24-45b6-963c-e743849c4cf5"
      unitRef="usd">-40600000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjM3OQ_7ffedd1b-daf0-48f1-9b4e-628766b8c5aa"
      unitRef="usd">178700000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjQxMw_33ac9561-3c1b-48df-ab28-8796ba366d48"
      unitRef="usd">-1500000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMjc2MA_a2c022b7-14a5-4da2-9a7d-344ba26fe7ac"
      unitRef="usd">223800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id15b0217ea8c48b0ad7e9858e136caa6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfMzM4Nw_358f7bcf-2c43-43a2-9794-ddd0df9626eb"
      unitRef="usd">83000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i568f04797f3a472aa282f7114d801497_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF8zNy9mcmFnOjlhZDBiM2YxNjI4YzQ5NzI4YTY0MTA0ODI2Nzc2ZWI0L3RleHRyZWdpb246OWFkMGIzZjE2MjhjNDk3MjhhNjQxMDQ4MjY3NzZlYjRfNDk0NzgwMjMzMTg3Nw_fddbcf85-0618-41d8-8b2d-5b5a830e89f2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80MC9mcmFnOmE3NmNlMjAxYzU5NTQ3NGJhMmNhNTViYjAwN2M1Y2RlL3RleHRyZWdpb246YTc2Y2UyMDFjNTk1NDc0YmEyY2E1NWJiMDA3YzVjZGVfNTgxNg_b67367a5-85c7-4fec-bcbe-1dc484e8674e">Critical Accounting Policies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#x2019;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#x2019;s or the collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary smart device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80MC9mcmFnOmE3NmNlMjAxYzU5NTQ3NGJhMmNhNTViYjAwN2M1Y2RlL3RleHRyZWdpb246YTc2Y2UyMDFjNTk1NDc0YmEyY2E1NWJiMDA3YzVjZGVfNTgxOA_553695a5-6dc2-433a-a6a7-9b5eca1b792c">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#x2019;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#x2019;s or the collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80MC9mcmFnOmE3NmNlMjAxYzU5NTQ3NGJhMmNhNTViYjAwN2M1Y2RlL3RleHRyZWdpb246YTc2Y2UyMDFjNTk1NDc0YmEyY2E1NWJiMDA3YzVjZGVfNTgxOQ_306b72a5-8166-4883-805f-001a8e195d3a">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary smart device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfNDUw_55eea66f-cd86-432a-8aac-70b22b747cb0">Revenue Recognition  During the three months ended March 31, 2023 and 2022, the Company recognized revenue of $0 and $9,000, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $115,000 and $190,000, respectively, from various other contracts as a result of performance obligations being satisfied.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27c48d2543c3428ca9348a16927aa3ef_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfNzk_24703d69-a700-40c0-89e1-c71c5ce6b7e5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i424005e9738e406cbe32ab9e0559a2cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfODY_5a970dd4-5045-43b6-9816-c1722dffdb59"
      unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie808b6354eac4d61890c011e8296a807_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfMjE5OTAyMzI1NjMzNA_f580d70d-5acf-4f89-9e14-cbf18ddac52f"
      unitRef="usd">115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2794060b62c64f55ba10c6d991467be9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80Ni9mcmFnOjA2NThiZGZlOTBkMTRlZWRhZjViM2Q4YjY2ZGM1MzQxL3RleHRyZWdpb246MDY1OGJkZmU5MGQxNGVlZGFmNWIzZDhiNjZkYzUzNDFfMjE5OTAyMzI1NjMyNA_b635b3ed-997b-4ba0-9d45-1166cc8339e9"
      unitRef="usd">190000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYzMg_7b71e932-053b-4a93-b3a9-1b8ac62d53be">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,986,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,155,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,591,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,958,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,516,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,513,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended March 31, 2023 and 2022, the Company recorded gross realized gain on investments of $300 and $20,000, respectively, and gross realized loss on investments of $2.4 million and $339,000, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $3.2 million and $(4.8) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2023 and 2022. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2023, the Company had 24 available-for-sale securities in an unrealized loss position with an aggregate total unrealized loss of $6.5 million, all of which were in such position for longer than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2023&#160;were primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2023, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,513,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,480,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,032,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,136,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,104,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,032,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at March&#160;31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain or loss on investment in affiliated entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at March&#160;31, 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of March&#160;31, 2023 or December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYzMg_fc12dfb6-2eb2-448c-b042-5f73580e289a">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,986,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,155,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,591,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,958,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,516,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,513,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended March 31, 2023 and 2022, the Company recorded gross realized gain on investments of $300 and $20,000, respectively, and gross realized loss on investments of $2.4 million and $339,000, respectively. During the three months ended March 31, 2023 and 2022, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $3.2 million and $(4.8) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2023 and 2022. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2023, the Company had 24 available-for-sale securities in an unrealized loss position with an aggregate total unrealized loss of $6.5 million, all of which were in such position for longer than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2023&#160;were primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2023, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,513,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,480,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,032,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,136,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,104,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,032,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at March&#160;31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain or loss on investment in affiliated entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at March&#160;31, 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of March&#160;31, 2023 or December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYyNw_0b2b0a67-9459-4679-9487-5af633ee3b5f">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,986,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,155,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,591,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,958,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,516,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,513,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi0zLTEtMS02MTQzMA_8d5f0e33-c76c-41ea-aa0c-c4b7d8b47763"
      unitRef="usd">85986541</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi01LTEtMS02MTQzMA_a8023257-3efa-4764-a60b-13c7d26e0926"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi03LTEtMS02MTQzMA_1f3cc85e-2d0b-4cd7-9e0d-85a5605cc17f"
      unitRef="usd">6155299</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec1f816c2b0646358f12de50f5ec8fc4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMi05LTEtMS02MTQzMA_acdb1d5c-83ca-43e9-b27b-f6570c1dbe46"
      unitRef="usd">79831242</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="iea88717d3bae4c3282823b096cbc0010_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOmE4ZDY4NDg0NDI4NzQ2YThiOWVlMjkyNTNhZjBhZDAzXzE0_304db787-1ed4-43f5-a194-c481fd9d423f">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy0zLTEtMS02MTQzMA_24f0f9c1-0c90-4ee4-b2e0-d8174d4589fd"
      unitRef="usd">111591593</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy01LTEtMS02MTQzMA_a2bf81dc-bad3-41bc-bac8-6de7b9941fa3"
      unitRef="usd">57827</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy03LTEtMS02MTQzMA_66296d73-5b85-42d4-afc1-c53a48e3fea5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8ccee2a46994739b63689dc7b1cfbe3_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfMy05LTEtMS02MTQzMA_65fc74b6-b5b0-4b90-b839-2d191dd483d9"
      unitRef="usd">111649420</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="if7f21b141b3745859c0259a876d2e137_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOmU1NDAzYmY0MWVkMDQwZjg5YjczMjZkMjU3NDQwNDdlXzE0_6525f5c8-0921-42ff-b481-b4188a03199b">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0f9148075bf7401a924169db861cdb10_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS0zLTEtMS02MTQzMA_4978988c-0cc8-4bfa-974a-d100040b1fca"
      unitRef="usd">2977897</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0f9148075bf7401a924169db861cdb10_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS01LTEtMS02MTQzMA_6d95a20b-7165-4b33-9b91-fb6d64833e13"
      unitRef="usd">13182</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0f9148075bf7401a924169db861cdb10_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS03LTEtMS02MTQzMA_35dbef5d-b765-4e62-9a3e-5986fa7cf27d"
      unitRef="usd">314</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f9148075bf7401a924169db861cdb10_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNS05LTEtMS02MTQzMA_7344f6c0-0823-4866-ab88-1361ede9a83c"
      unitRef="usd">2990765</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi0zLTEtMS02MTQzMA_90947b0c-b374-4413-bbd6-66f531bbc057"
      unitRef="usd">1402093</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi01LTEtMS02MTQzMA_d31f864d-d248-49be-95f0-74a5abf60d36"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi03LTEtMS02MTQzMA_3b66ad6a-411e-4b04-821f-1b8d53d1cd47"
      unitRef="usd">360515</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieeb82e20dd9d4b969625c52a130ea384_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNi05LTEtMS02MTQzMA_e7c441f5-e0ec-48ef-95cc-a58399eccb72"
      unitRef="usd">1041578</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy0zLTEtMS02MTQzMA_6a0a5965-9029-4615-af3e-ea95f3133579"
      unitRef="usd">201958124</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy01LTEtMS02MTQzMA_abb80c0a-c0d9-44d9-94df-6356ed2a0c79"
      unitRef="usd">71009</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy03LTEtMS02MTQzMA_238e601c-88c8-45fa-9171-3a872dc1106b"
      unitRef="usd">6516128</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjg1NzFlNjc1YzJhNjRlMTdhM2Y5NjM0N2FkODgwMmI4L3RhYmxlcmFuZ2U6ODU3MWU2NzVjMmE2NGUxN2EzZjk2MzQ3YWQ4ODAyYjhfNy05LTEtMS02MTQzMA_6e03b933-2bbd-40be-851c-5f5cb1f7b570"
      unitRef="usd">195513005</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi0zLTEtMS02MTQzMA_28f6b457-cd0b-4b81-b43c-dfc5d757c0a7"
      unitRef="usd">117036232</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi01LTEtMS02MTQzMA_fd688fd2-385f-4d6c-bac5-3845dffa4671"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi03LTEtMS02MTQzMA_cfa69dce-88c2-47fd-92fd-d3be41b4cb8b"
      unitRef="usd">9373514</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9209877902d45a0a7da1b89265d7c5a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMi05LTEtMS02MTQzMA_196fe28d-4edc-4bb1-8c61-e91cd2a26fb1"
      unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="id19a9893ad2e465a8c17eb61b026acc4_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOmY5OTEzZDZkYTJkNzRmNGJhNzI4ZjY0MTc0ZWFkMDlkXzE0_1eb4bd84-1e3a-4542-b60d-9c6f7049e4f7">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy0zLTEtMS02MTQzMA_8d203c7b-cfd7-4c84-9508-921162e29968"
      unitRef="usd">95001209</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy01LTEtMS02MTQzMA_6f91b7cb-2e12-4a8f-82c9-d712f60568ce"
      unitRef="usd">7567</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy03LTEtMS02MTQzMA_0521d1ab-1882-49aa-bd14-deeab9d1bc6b"
      unitRef="usd">44266</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieeba06444a8843ee89be2729dfcafdd2_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfMy05LTEtMS02MTQzMA_76a49dbf-d291-4bd3-88fe-478d8244826f"
      unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i154f710696af44368c1b60a00236e33c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS0xLTEtMS02MTQzMC90ZXh0cmVnaW9uOjUzYzRmNzRkYWEyNjRiMzNiYzI3OGJmMGNkZWQyMDAxXzE0_2cb7239e-cf28-414c-bba6-9c26b367d3b9">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS0zLTEtMS02MTQzMA_859f1b80-47da-462f-b0b1-446633f68339"
      unitRef="usd">2977564</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS01LTEtMS02MTQzMA_73ca5645-d5bf-4f4b-a105-586840356363"
      unitRef="usd">13664</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS03LTEtMS02MTQzMA_e790144d-bd1d-4612-ac77-44bb4560921c"
      unitRef="usd">320</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b1662f455f64b0b86af2199c3c89353_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNS05LTEtMS02MTQzMA_b92b7e15-d534-4252-8174-67e3a3b7c3b1"
      unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi0zLTEtMS02MTQzMA_7e36e35a-137c-498e-b242-f3f8415ed0dd"
      unitRef="usd">1435592</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi01LTEtMS02MTQzMA_ca63571f-5514-4bf4-aea7-0e983502c6df"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi03LTEtMS02MTQzMA_ce577b53-e1d0-4db8-a1ae-577edde488a9"
      unitRef="usd">384331</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id737e22fc8c34147b1878efbc06b6fa0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNi05LTEtMS02MTQzMA_7ebe5d6d-04f9-421c-8644-e6a1576047d7"
      unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy0zLTEtMS02MTQzMA_b295131a-d6d6-4be7-8f45-fd6220b5f274"
      unitRef="usd">216450597</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy01LTEtMS02MTQzMA_5c362d94-3ca6-4ad7-9d51-5bdcdf069b75"
      unitRef="usd">21231</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy03LTEtMS02MTQzMA_a1a82ff7-0318-47b7-8128-5997c61643d1"
      unitRef="usd">9802431</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOmU2MTdjMTM0Y2RlZDQ0OWJhODNlMzlmNTBlZmZlYTM3L3RhYmxlcmFuZ2U6ZTYxN2MxMzRjZGVkNDQ5YmE4M2UzOWY1MGVmZmVhMzdfNy05LTEtMS02MTQzMA_e2a5ba81-b4bf-4f32-be80-df2f1404503a"
      unitRef="usd">206669397</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMjQw_349628a0-182a-4848-ac91-7cd86b49bc09"
      unitRef="usd">300</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMjQ3_03fdff45-a01f-4a36-b6d6-0665e9da3f61"
      unitRef="usd">20000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMzA3_a4d8a9b9-28a1-49ec-ac53-6a9051019e76"
      unitRef="usd">2400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMzE0_d79c1c28-17b8-4dda-82eb-acbffe1b04ff"
      unitRef="usd">339000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNTk3_811d6abf-f1fa-4553-b727-d5ed4225a759"
      unitRef="usd">3200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNjA0_503533a4-5c30-4f18-8bb5-e34082d69cdf"
      unitRef="usd">-4800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMTAzMw_5e4905d4-b031-4f63-b358-f739eab2841a"
      unitRef="position">24</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMTE1Mw_4b5da662-2670-4565-a4c9-3145af5465c7"
      unitRef="usd">-6500000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfNDYyOQ_f46cfa5d-704f-4c34-904f-7fc2273a081d">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,831,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,649,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,513,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,480,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,032,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,136,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,104,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,032,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49aeb1a300754d82b80cb3075a7d276d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC0xLTEtMS02MTQzMA_b0d44745-bc27-4c2c-83d1-84841fcf63d0"
      unitRef="usd">79831242</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9775574f1494394811d44684704ab67_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC0zLTEtMS02MTQzMA_9a2696eb-c2be-45df-ba0e-c5818f41417a"
      unitRef="usd">79831242</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i507494694b6d4d009b81bc247609f9e0_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC01LTEtMS02MTQzMA_0f087fef-c3e8-4c7f-b0e8-3c9e6101053c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa977781312f47e69160962e49c81570_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNC03LTEtMS02MTQzMA_73f4f462-ce97-4d20-b9fb-203f842bb5fe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07230fde15e54b399d452926ed0f53a3_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS0xLTEtMS02MTQzMA_1bed00a4-da95-4fbb-8591-c4f4f44bf2f6"
      unitRef="usd">111649420</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b64b5b5c9b64e5fa4434c4e168d2559_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS0zLTEtMS02MTQzMA_ff172641-73dd-4c8e-8155-4516d917a937"
      unitRef="usd">111649420</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b7e2166f3914844b66ea56e45631aad_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS01LTEtMS02MTQzMA_327108fa-38de-4514-b792-308b474db7e3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ef64995166349eab1facc6cf436dfb4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNS03LTEtMS02MTQzMA_3a9749f6-4bc5-4324-b4f8-7c374b0a6ac5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92d7cb8097694cbda0e2e5976080fed6_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy0xLTEtMS02MTQzMA_a2372a8f-0eb2-441d-a704-0432035c0788"
      unitRef="usd">2990765</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if837752dbae541949d9b5d2f3fc1d21a_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy0zLTEtMS02MTQzMA_177b434c-c45f-48f1-8457-e401b2a90957"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47d6af48af3740ed9e7512132b332b10_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy01LTEtMS02MTQzMA_20900158-e08c-4c6f-88d5-2ec18bb02b57"
      unitRef="usd">2990765</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i249d5e2b1d764f8f9849378142cdf683_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfNy03LTEtMS02MTQzMA_f0c582d5-1828-49fa-981c-54714f2c4875"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4538d285010f4df39235b50e6df231bb_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC0xLTEtMS02MTQzMA_e369dbf6-48db-44e6-95f9-247864a0d5b1"
      unitRef="usd">1041578</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i808771e2c7b748768ba48825de30ab59_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC0zLTEtMS02MTQzMA_939399eb-2a3a-4508-a65d-c9c4bc8c2ab7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i035ac45eddcd4ad0b877179ce402b012_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC01LTEtMS02MTQzMA_04db7cf8-3a19-42f6-a183-1f598c9000de"
      unitRef="usd">1041578</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i100ee50b23804321a39f1344ec331844_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOC03LTEtMS02MTQzMA_78f929df-258b-4915-bb23-f25a194cf62c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc54f897c91449868d75304b60ed52b5_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS0xLTEtMS02MTQzMA_fc210337-8b88-4636-882a-2571ab9beb73"
      unitRef="usd">195513005</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7764fa9747144127856f5f47e535b68b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS0zLTEtMS02MTQzMA_d3eec53f-bb98-4a48-84dc-23586b881345"
      unitRef="usd">191480662</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibeac876368b343568a773a83ca4cfa00_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS01LTEtMS02MTQzMA_90da2648-ad4f-40e5-80df-3b1658597cb1"
      unitRef="usd">4032343</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c9438d2a2b449a28a0426195cc69b58_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfOS03LTEtMS02MTQzMA_80bfe309-4c4e-4933-ab6c-e92f4a1f9d55"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icc54f897c91449868d75304b60ed52b5_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtMS0xLTEtNjE0MzA_af227dc0-b9c4-469a-88a7-d38d4f284982"
      unitRef="usd">2623781</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7764fa9747144127856f5f47e535b68b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtMy0xLTEtNjE0MzA_1d046af1-ecc1-45bb-acf6-b41e2fabb2a5"
      unitRef="usd">2623781</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibeac876368b343568a773a83ca4cfa00_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtNS0xLTEtNjE0MzA_2976bd22-bc45-470d-b580-95ca37748d64"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1c9438d2a2b449a28a0426195cc69b58_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTEtNy0xLTEtNjE0MzA_e4dc48b5-3430-4589-a831-73b8fa7929bd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icc54f897c91449868d75304b60ed52b5_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItMS0xLTEtNjE0MzA_20b0bbe1-4e9c-4073-90ab-57411984fc72"
      unitRef="usd">198136786</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7764fa9747144127856f5f47e535b68b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItMy0xLTEtNjE0MzA_d021dba8-ea04-4f29-93be-c375f0f48408"
      unitRef="usd">194104443</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibeac876368b343568a773a83ca4cfa00_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItNS0xLTEtNjE0MzA_14a35094-71fa-4078-8d52-be1727305aba"
      unitRef="usd">4032343</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c9438d2a2b449a28a0426195cc69b58_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjdjY2I4OGM2MmFhYzQ0N2U4ZTM4OTk1YmJkMTAxN2MwL3RhYmxlcmFuZ2U6N2NjYjg4YzYyYWFjNDQ3ZThlMzg5OTViYmQxMDE3YzBfMTItNy0xLTEtNjE0MzA_c472e83f-a6de-4d67-8ec4-3c0dc76d6fd4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i651421a71e44472594de779a6c90aa58_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC0xLTEtMS02MTQzMA_6b588531-6551-404b-b84d-e78bf17ed5cb"
      unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fe53fa638d94b9684c5bb12d5d28448_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC0zLTEtMS02MTQzMA_6db59d4d-4308-4829-ab0c-ffbbafb158a1"
      unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81d8611e12df41f6b46df72274195e75_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC01LTEtMS02MTQzMA_775e4482-41ef-47b0-baec-5184fca6f7e8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55f7ea859ca14010a0f5dc0c523bb83a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNC03LTEtMS02MTQzMA_9ebe70ec-91b4-4bc6-ae37-94ff8482bbe2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife8621666cb44531a664219b42fb568f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS0xLTEtMS02MTQzMA_c55ee8cd-4c82-42a1-90df-6864ed6e107d"
      unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76b95b05eddd474fa6a45fb6fbd8ae32_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS0zLTEtMS02MTQzMA_b0f8ec0e-ac4d-4eb5-bdf9-917833e61890"
      unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bc7276b422b4eb7b9f1e2ecd0d3c68f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS01LTEtMS02MTQzMA_25dc83d5-10bb-4339-8bcf-dc8e16897411"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb8759eb4716482494a75a4509d57041_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNS03LTEtMS02MTQzMA_cfcb9a1b-f98f-4ab7-9751-8238695ed830"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76596fa49ec24abb8271d264e6f19bab_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy0xLTEtMS02MTQzMA_71dd3647-1ea9-4176-8bf9-a827d3fc6c7f"
      unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34ea510fa47e424d943494f963231339_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy0zLTEtMS02MTQzMA_1153f4fe-ee1d-45ee-807b-0293e606469e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79060d2c3e3147b3b3d21d5d5bb394ab_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy01LTEtMS02MTQzMA_1a8d44fc-7a87-4182-a4f6-bf9971dfbddd"
      unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7398b2d88e70463d906bd72f9a1b2cf7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfNy03LTEtMS02MTQzMA_1828b431-c9e3-40cb-974e-c9986529ad7e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31e9b36e3881479fb2114bf17a00489a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC0xLTEtMS02MTQzMA_df393e52-1b25-4d08-8598-abc3e63a1984"
      unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2ec3a3107ab43409a0d2eeff38d951a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC0zLTEtMS02MTQzMA_b10cd081-3f73-49c1-9c55-ca9e2941df35"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f3d830b50b94da7b62468b24771824e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC01LTEtMS02MTQzMA_2a541832-3eea-42a0-9154-a17e42bca69b"
      unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee4653ccc0974003b1771f075fa5970c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOC03LTEtMS02MTQzMA_fb52c065-c405-453c-a128-7e8d8e1a86a0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a72e62f7c41430690c464a69f2537db_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS0xLTEtMS02MTQzMA_6b2aca1c-922b-4370-a33e-7637d9f53302"
      unitRef="usd">206669397</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS0zLTEtMS02MTQzMA_fe6908ac-ad84-4316-b8f1-1e1f349e298d"
      unitRef="usd">202627228</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS01LTEtMS02MTQzMA_d6322eb4-2634-48c9-a7e4-7e0083b77be5"
      unitRef="usd">4042169</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63d19f47994c4a2087e95232f349c61e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfOS03LTEtMS02MTQzMA_7d67e1cb-ff17-4750-b575-e9eee6dcfb4d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4a72e62f7c41430690c464a69f2537db_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtMS0xLTEtNjE0MzA_d30587ec-80d5-422f-b1cf-106741a198aa"
      unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtMy0xLTEtNjE0MzA_327c8188-cc2c-441c-bbf6-8368da504ae3"
      unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtNS0xLTEtNjE0MzA_f6cda8ac-2d29-4aef-9c7e-b0bbb1fd7edd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i63d19f47994c4a2087e95232f349c61e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTEtNy0xLTEtNjE0MzA_d201d136-2f2a-4cdf-8c26-adc5a1bdce99"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4a72e62f7c41430690c464a69f2537db_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItMS0xLTEtNjE0MzA_c850dd97-cfb7-45e2-b7a1-48d97e759dc2"
      unitRef="usd">208676539</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc011c3565f04ec7a8c74fa09188cbb0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItMy0xLTEtNjE0MzA_a28c6aea-40e2-4209-89f1-8a5e10230dcf"
      unitRef="usd">204634370</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9f82d964a8bc4b13bf3ae7272e55f5cc_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItNS0xLTEtNjE0MzA_09d5919d-d34f-4756-bafa-49f59451f34e"
      unitRef="usd">4042169</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63d19f47994c4a2087e95232f349c61e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RhYmxlOjRhMjcyNzAwMjQ1ODRmYmViNzNmNmQ0Y2E2ZTQ0YWIyL3RhYmxlcmFuZ2U6NGEyNzI3MDAyNDU4NGZiZWI3M2Y2ZDRjYTZlNDRhYjJfMTItNy0xLTEtNjE0MzA_529e7493-b491-4392-a654-50b76e4f655a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ib5590b7d3f8242afba7128120cfea182_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF80OS9mcmFnOjVlNTEyNGQ5MDA4NzRjN2Q5NzQ1NGJiYTYxOTZjNGE5L3RleHRyZWdpb246NWU1MTI0ZDkwMDg3NGM3ZDk3NDU0YmJhNjE5NmM0YTlfMjkxNw_60dc93e7-c0d6-4e0e-bb62-811ce8e3f218"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfODMw_becff48a-de3e-4d75-a3b3-cd855ea65c6b">Certain Balance Sheet Items&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance recovery (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,349,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,729,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,914,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,130,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,194,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,862,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,607,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,574,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,950,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,752,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,686,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(a)&#160;&#160;&#160;&#160;In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#x201c;Legal Proceedings.&#x201d; The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement.</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfODMx_b98c733d-25a3-487f-a7f3-c1decee1daf0">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance recovery (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,349,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,729,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,914,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,130,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMS0xLTEtMS02MTQzMA_d68d4863-27f4-4583-9710-55b0990ae9ef"
      unitRef="usd">0</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMS0zLTEtMS02MTQzMA_09c4f8a4-9db5-4c56-b1d5-a9d591524687"
      unitRef="usd">30000000</us-gaap:EstimatedInsuranceRecoveries>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMi0xLTEtMS02MTQzMA_304a32c5-526c-41db-97b6-773c673f0dd7"
      unitRef="usd">565072</ino:PrepaidManufacturingExpensesCurrent>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMi0zLTEtMS02MTQzMA_2c56f160-a495-4eb7-b615-2a67a4a61fb0"
      unitRef="usd">1401028</ino:PrepaidManufacturingExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMy0xLTEtMS02MTQzMA_e875ec11-650a-4007-978e-27550e95b863"
      unitRef="usd">4349241</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfMy0zLTEtMS02MTQzMA_92ab50e2-3ba0-472d-bcb8-d3e7e5359791"
      unitRef="usd">18729453</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfNC0xLTEtMS02MTQzMA_71869f19-780f-4804-a7a8-92b623b0a4e0"
      unitRef="usd">4914313</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOmM4MWFjMGRjNjI2ZjQyNGM4NWJlNmVmZjA3MWM5YWM0L3RhYmxlcmFuZ2U6YzgxYWMwZGM2MjZmNDI0Yzg1YmU2ZWZmMDcxYzlhYzRfNC0zLTEtMS02MTQzMA_2b08a06c-5221-48d5-9b75-a9a454ea7591"
      unitRef="usd">50130481</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfODMy_a32eb9b4-ed96-4204-8c43-14317e173c51">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,194,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,862,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,607,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,574,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,950,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,752,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,686,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(a)&#160;&#160;&#160;&#160;In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#x201c;Legal Proceedings.&#x201d; The final judicial order for the settlement was issued in January 2023. The settlement consisted of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement. During the three months ended March 31, 2023, the cash component of the settlement was released from escrow and the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement.</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMS0xLTEtMS02MTQzMA_4a515882-93ce-40ef-bf81-9527bee47489"
      unitRef="usd">11194396</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMS0zLTEtMS02MTQzMA_63a39825-bd49-42c3-8cbc-581e464b6b9c"
      unitRef="usd">19862487</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMi0xLTEtMS02MTQzMA_9b49e938-cb6e-45c0-bdbb-d65bf123b3cb"
      unitRef="usd">7607673</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMi0zLTEtMS02MTQzMA_9719073c-7c38-4c99-bfc5-536bd85d60b5"
      unitRef="usd">12574921</us-gaap:AccruedSalariesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMy0xLTEtMS02MTQzMA_a503314e-fbfa-438c-bcfc-35961430e66c"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfMy0zLTEtMS02MTQzMA_1241f662-a49d-4218-94d2-24c345a8622e"
      unitRef="usd">44000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNS0xLTEtMS02MTQzMA_d1544a6f-9a07-491d-acbe-cec66400e481"
      unitRef="usd">5950102</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNS0zLTEtMS02MTQzMA_dbc7e693-d7c7-409f-80ed-0a68d4639f56"
      unitRef="usd">3249477</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNi0xLTEtMS02MTQzMA_8a11ee10-ec2f-44ee-b433-8f037488931c"
      unitRef="usd">24752171</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RhYmxlOjI1NTg5Y2Y2MjcwOTRkYzJiZjQ4NGYzNGY5MDkzZjdmL3RhYmxlcmFuZ2U6MjU1ODljZjYyNzA5NGRjMmJmNDg0ZjM0ZjkwOTNmN2ZfNi0zLTEtMS02MTQzMA_34660b34-f7a0-4afb-9663-58366e5bcbf1"
      unitRef="usd">79686885</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ifd6835ef9291475398187809336a6e27_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfMzk4_7c71a5f2-e885-4708-8f07-3dc16fcd9a0c"
      unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares
      contextRef="ifd6835ef9291475398187809336a6e27_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfNDEz_375595a3-39cd-4628-b955-67cc2c41701b"
      unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i092045a4d4c24e66871ac745807bd523_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfNjg5_54f473a6-7f05-459f-bc51-523167f65284"
      unitRef="usd">252000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib97422d241744aecbec5cdc038a635ef_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81NS9mcmFnOjAxMTNkMjRmNTI1NjQ3NDJiZDQ5YjEyN2MyNGYyNzhjL3RleHRyZWdpb246MDExM2QyNGY1MjU2NDc0MmJkNDliMTI3YzI0ZjI3OGNfNTQ5NzU1ODE2MjE4_a15dbcd0-5549-48e5-aa2c-f69885ae1c37"
      unitRef="shares">9121000</us-gaap:CommonStockSharesIssued>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODU2_b060af59-adc6-4e5d-91e7-7f22352aa187">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,323,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,052,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,047,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,988,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,050,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,102,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,047,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,663,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,102,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,561,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,643,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense on intangible assets for the three months ended March 31, 2023 and 2022 was $82,000 and $127,000, respectively. Estimated aggregate amortization expense is $190,000 for the remainder of fiscal year 2023, $253,000 for 2024, $253,000 for 2025, $253,000 for 2026, $253,000 for 2027 and $845,000 for 2028 and subsequent years combined. There were no impairment or impairment indicators present and no losses were recorded during the three months ended March 31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODQ4_bb3d8f25-c1af-45cc-b5fd-cf57e90a4552">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,323,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,052,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,047,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,988,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,050,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,102,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,047,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,663,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,102,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,561,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,643,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;(b)Other intangible assets represent the estimated fair value of acquired intellectual property.</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy0zLTEtMS02MTQzMA_e13bdcea-f076-413a-81db-3dcd6283b82b"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy03LTEtMS02MTQzMA_ca37a7e0-d97a-420c-ade2-95948f12f0c9"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy05LTEtMS02MTQzMA_3b87eafe-54fd-4dc5-b7ed-5a22ddc69203"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMy0xMy0xLTEtNjE0MzA_b2eee07f-3ee5-4581-9899-3e9e88c3c527"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6ab95fd57f0f426ebe487aa41e25c7d4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0xLTEtMS02MTQzMA_e45560b7-21fd-4fda-b31e-d50228f9d2d4">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0zLTEtMS02MTQzMA_4da0ef77-8cc9-465c-8f14-112560d51421"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi01LTEtMS02MTQzMA_4eb81d03-b662-4df9-b027-b9c5f639b6ba"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic1a19d9746ce4d3b9b7eaa3e194e2533_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi03LTEtMS02MTQzMA_7bc1f10e-835d-4e53-ba99-a17b1b4052fd"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi05LTEtMS02MTQzMA_897d10dc-c997-46ab-88ab-03a69bfd6134"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0xMS0xLTEtNjE0MzA_757794fd-1dd7-44b8-88a8-38b845463773"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4476aa0e0eeb461daed73a3cb5dcc4b4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfNi0xMy0xLTEtNjE0MzA_c5578105-d3a6-4904-8d67-b41155cfaae8"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2fad80428c8a4c91a84c10d223b587df_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0xLTEtMS02MTQzMA_8bdd8eb3-8ece-4c2b-94b4-cb8654a8423e">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i768b12453cb44701902fe18cf70b486b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0zLTEtMS02MTQzMA_baab67b3-d09c-4910-9d13-4a9499d709ed"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i768b12453cb44701902fe18cf70b486b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS01LTEtMS02MTQzMA_10e58d6d-0a0c-43cf-b25f-df3b5c4823a7"
      unitRef="usd">3052222</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i768b12453cb44701902fe18cf70b486b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS03LTEtMS02MTQzMA_c8c35b23-61d7-4841-ad15-f047039a335b"
      unitRef="usd">2047778</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS05LTEtMS02MTQzMA_325ce742-85ad-41de-b661-05133c80f2af"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0xMS0xLTEtNjE0MzA_6d51a1a6-ca1c-4d99-b42e-f2d9a29b89c1"
      unitRef="usd">2988889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic0aa8b8d542b4a18832a3abd0f4eec61_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfOS0xMy0xLTEtNjE0MzA_7258bb9e-17ad-4c52-a5ae-86be0afdea87"
      unitRef="usd">2111111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6fb0a36935424e9b8c96652f09088bcd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMS0xLTEtNjE0MzA_04279b1a-7c7b-4ce8-b3c3-8ca2503e6365">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMy0xLTEtNjE0MzA_ed277668-a84b-4dc8-ba90-5a50bb513c4a"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtNS0xLTEtNjE0MzA_5c68d359-f06f-4705-9010-1d27710b6b6f"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ice8e2b00d3ec4eadb79ccdd9d20a9aa4_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtNy0xLTEtNjE0MzA_9f08f9fb-8b78-465b-ab09-d74a4cafc6ab"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5cc0c0bab6884b4380426817d471b00c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtOS0xLTEtNjE0MzA_ae345fb4-7b62-44bb-b2a4-5fd7e336e116"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5cc0c0bab6884b4380426817d471b00c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMTEtMS0xLTYxNDMw_85aef25a-ce2b-4218-8457-79da9e4784f5"
      unitRef="usd">4031250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5cc0c0bab6884b4380426817d471b00c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTAtMTMtMS0xLTYxNDMw_d3dac945-ead7-4bda-ae12-6f34b4b633d6"
      unitRef="usd">18750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9eedc0cc685c44ee9cb4b8772b34620b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMS0xLTEtNjE0MzA_302ef114-2c01-455b-bcc4-6c6363272d9d">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMy0xLTEtNjE0MzA_9ca6c4ac-9701-460f-bdaf-b6beaafc4e93"
      unitRef="usd">9150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtNS0xLTEtNjE0MzA_95363714-8fe4-4380-81a8-28b14b2d8d3d"
      unitRef="usd">7102222</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtNy0xLTEtNjE0MzA_e71d34e1-039e-4975-bb33-99ed65b2eb3e"
      unitRef="usd">2047778</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtOS0xLTEtNjE0MzA_963a8a9f-447f-42ef-8a6a-70a7ff1381c8"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMTEtMS0xLTYxNDMw_b10b6b8e-f3ee-48bf-9fc5-b7add15d3f32"
      unitRef="usd">8343900</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTEtMTMtMS0xLTYxNDMw_0536ea74-e2e6-43d0-a7d7-9c640ee61166"
      unitRef="usd">2129861</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItMy0xLTEtNjE0MzA_94c6b166-e074-4a25-9e3c-ffe330207845"
      unitRef="usd">19663371</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItNS0xLTEtNjE0MzA_f8358a70-25af-4d09-b571-90a859505ce3"
      unitRef="usd">7102222</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItNy0xLTEtNjE0MzA_d299b084-561e-4d25-832c-442a2bb64501"
      unitRef="usd">12561149</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItOS0xLTEtNjE0MzA_cdb8416c-c5df-4498-b488-5164cc855658"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItMTEtMS0xLTYxNDMw_5bb04c29-ffa2-446a-a61d-739de1961825"
      unitRef="usd">8343900</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RhYmxlOmExMjViOGQ3ZjNmNjRhODJhNzg5NmE3OGRlZmZjNWMxL3RhYmxlcmFuZ2U6YTEyNWI4ZDdmM2Y2NGE4MmE3ODk2YTc4ZGVmZmM1YzFfMTItMTMtMS0xLTYxNDMw_ba25f666-717c-49ec-b0fe-e7f557a622f9"
      unitRef="usd">12643232</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNDQ3_77996159-7075-4d6d-b47d-15e0635fef5c"
      unitRef="usd">82000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNTM5_488d52fc-3015-4cde-919c-c1a17dd483db"
      unitRef="usd">127000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjA5_397e6c36-004f-4f19-83cd-d337f8debf68"
      unitRef="usd">190000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjQ5_0a8f3bf1-c73c-42c5-9ab5-3ae2844819e9"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjYx_4a218ee2-f0d2-4411-be4e-6d9470a33985"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjcz_740bf366-318c-4c94-bf2a-6cf55b4d5170"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNjg1_4f431a79-171a-4f95-8b71-6b702eee73cf"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNzAw_fe52e923-ba97-4724-a90f-734b9cc77ba1"
      unitRef="usd">845000</ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNzUy_e9f8fa0f-2868-4108-a2b8-64e076d7cc0c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfNzUy_ed69688a-516b-4ca1-ac60-7fbcb3591706"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODAz_a3973b94-e34e-46c8-ad96-9f3e538c26b0"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF81OC9mcmFnOjgzYTZlMDBlZGEwZDQzZmU4OWQxZDRhOTE4Mzg4Njk3L3RleHRyZWdpb246ODNhNmUwMGVkYTBkNDNmZTg5ZDFkNGE5MTgzODg2OTdfODAz_dffcb68d-bd0e-4cae-883e-4dfecb1bf34a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTg1MA_ece3a0a1-8bec-4830-9f16-cfb753b80388">Convertible Debt&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at March&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,394,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For both the three months ended March 31, 2023 and 2022,&#160;the Company recognized $313,000 of interest expense related to the Notes, of which $267,000 related to the contractual interest coupon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,481,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i282e3fa937b948e186e4be58f112112e_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTM2_a94e8501-f6a1-4112-a28d-8f27d201541e"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i282e3fa937b948e186e4be58f112112e_I20190301"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTcz_87433d53-ad80-4076-ace1-e930e966bcad"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDA1_55a0397b-0092-4e9d-ae12-6ec1f6dd5941"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i282e3fa937b948e186e4be58f112112e_I20190301"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTgy_10b5df17-9965-417c-990f-fed57368a7d0"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i282e3fa937b948e186e4be58f112112e_I20190301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTM4MA_06bc82b2-45b8-4245-b014-959dc7920082"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTYwNg_a51a8bca-6cfc-4352-bcb8-ebc039d8b6d3"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTY1Nw_a1e40747-4d96-4ee1-bcc0-8c0c068f46ea"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTcxMw_7047755a-dbe1-4252-a39a-60d0a7918939"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="iae2deb332889417aa796180e6cd43280_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMTk4NA_c35cd689-4623-4c3c-a5a1-55000fb7e2c0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i282e3fa937b948e186e4be58f112112e_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjUwOA_125f8e0b-3704-4251-94dc-5a89c29458b8"
      unitRef="usd">16300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjYyNw_06aa3f0f-a96e-406a-82b3-05c191f42528"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjY2Ng_0045015b-167d-4a88-adab-307a8003c561"
      unitRef="usd">592000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ib5cef3158a4649a18541e2a3562c8711_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMjc1Nw_bc97abe5-4bc5-4b33-95df-75ab5a55b3cc"
      unitRef="usd">2200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMzc3Mw_a6b4f760-2729-486c-9321-4425972f0f08"
      unitRef="usd">1800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMzgyMQ_f6ef2c8a-5fa9-4685-aab9-0252f91c5d8c"
      unitRef="usd">-3300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ConvertibleDebt
      contextRef="ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfMzg3Mg_fdd16c04-e26a-4a9b-93ac-6e74c48ca495"
      unitRef="usd">1500000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTg1NQ_100abfb4-174f-43ef-ba4e-a2f01ba789e2">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at March&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,394,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfMC0xLTEtMS02MTQzMA_ff3748d2-d83f-4012-923e-26a71b3973a6"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfMS0xLTEtMS02MTQzMA_02eb8e7a-1782-4327-8dd3-f62003d4900b"
      unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfMy0xLTEtMS02MTQzMA_a8d6168b-9e79-46d9-ad4a-04d275603474"
      unitRef="usd">109074</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccruedInterest
      contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfNC0xLTEtMS02MTQzMA_c73ffcd6-3f4a-4d22-8ba0-a3e0d117b3ca"
      unitRef="usd">88915</ino:DebtInstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="i8e9a53ecc8b54b91ad4b62780f74c439_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmY1MGE3N2I1ZGRlYTRjNjA5N2RkOTNkYjYxMTQ1YmU4L3RhYmxlcmFuZ2U6ZjUwYTc3YjVkZGVhNGM2MDk3ZGQ5M2RiNjExNDViZThfNS0xLTEtMS02MTQzMA_2aea0ea4-efd1-474e-8625-8393bb301097"
      unitRef="usd">16394841</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="i0de4d1310e9b417ca7f60cde3199cf93_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDE3Mg_8455f797-d775-48db-9a55-ebbfbbe7e80f"
      unitRef="usd">313000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie617d1d3144a464890df59e30f71dfd0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDE3Mg_f2dac2c7-7af6-42cf-bd51-4a7536ac1f80"
      unitRef="usd">313000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ie617d1d3144a464890df59e30f71dfd0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDI0OA_2d85c0be-da6d-4076-bc05-edefc50114ad"
      unitRef="usd">267000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0de4d1310e9b417ca7f60cde3199cf93_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDI0OA_e0890f03-6a0e-44d8-91e4-941c3c2d0c8a"
      unitRef="usd">267000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNTg1Mg_f6a676e9-47d2-4e69-8a55-ec1aa9280d34">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,481,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RleHRyZWdpb246M2JlN2FkODQ4YjA0NGNkOTlhNzMzZGNiZjI1MzA0Y2VfNDYzNg_d842cba9-2197-46f9-bb5c-90290297f695"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmQ3MjAzZmE0Yjc2MzRkZmRiMGMxN2E0MzY0MWEyNmZhL3RhYmxlcmFuZ2U6ZDcyMDNmYTRiNzYzNGRmZGIwYzE3YTQzNjQxYTI2ZmFfMy0yLTEtMS02MTQzMA_bb24298c-4003-4cd0-83d4-90736abd83d3"
      unitRef="usd">533000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmQ3MjAzZmE0Yjc2MzRkZmRiMGMxN2E0MzY0MWEyNmZhL3RhYmxlcmFuZ2U6ZDcyMDNmYTRiNzYzNGRmZGIwYzE3YTQzNjQxYTI2ZmFfNC0yLTEtMS02MTQzMA_04adbeeb-55ba-4c1d-9ddb-b60aaaf39816"
      unitRef="usd">16948000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt
      contextRef="i7351252adfb6481e91a3344a5a0f071d_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82MS9mcmFnOjNiZTdhZDg0OGIwNDRjZDk5YTczM2RjYmYyNTMwNGNlL3RhYmxlOmQ3MjAzZmE0Yjc2MzRkZmRiMGMxN2E0MzY0MWEyNmZhL3RhYmxlcmFuZ2U6ZDcyMDNmYTRiNzYzNGRmZGIwYzE3YTQzNjQxYTI2ZmFfNi0yLTEtMS02MTQzMA_730c4594-303e-47e6-9200-703b515dbac7"
      unitRef="usd">17481000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDA5MQ_9b57014e-6af6-4fe9-9cc2-ae957d0f129b">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,739,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,739,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,091,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents (collectively, the &#x201c;Sales Agents&#x201d;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. No shares were sold under the 2021 Sales Agreement during the three months ended March 31, 2023. For the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company sold 8,480,483 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $3.52 per share, resulting in aggregate net proceeds of $29.4&#160;million. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; there was $167.4 million of remaining capacity under the 2021 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement, as described in Note 13.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan was 24,000,000 shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by 2,000,000. At March&#160;31, 2023, the Company had 2,761,477 shares of common stock available for future grant under the 2016 Incentive Plan, 1,994,799 shares underlying outstanding but unvested RSUs and options outstanding to purchase 13,239,324 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company's board of directors approved a new 2023 Omnibus Incentive Plan, subject to stockholder approval.  If approved, no further grants will be made under the 2016 Incentive Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2022 Inducement Plan will not exceed 2,000,000 shares. At March&#160;31, 2023, the Company had 1,573,125 shares of common stock available for future grant under the 2022 Inducement Plan, 155,000 shares underlying outstanding but unvested RSUs and options outstanding to purchase 271,875 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.&lt;/span&gt;&lt;/div&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2023, the Company had options outstanding to purchase 1,748,245 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDA4Nw_378d2ef2-b5eb-4b84-afd9-600d4bf06ff1">&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2023 and December&#160;31, 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,739,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,739,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,091,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjZjZDAxZDQyYThmMjRjOWM4ZDMxYTEwNTk4NWYyMjEzXzI4_4063d3ac-7e8a-48ce-afee-2b068a7c1b84"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjZjZDAxZDQyYThmMjRjOWM4ZDMxYTEwNTk4NWYyMjEzXzI4_9f68f3cc-56cf-4d05-9fcd-d5a2b6a9d3d8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0xLTEtMS02MTQzMA_ea5111e4-1e8e-47b0-b2bb-fe5914badeab"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi0zLTEtMS02MTQzMA_a66438e1-601c-4f02-ada9-2f1df19c6c1c"
      unitRef="shares">262739126</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi01LTEtMS02MTQzMA_4554b33f-b78c-41d0-9c30-8584323aeff5"
      unitRef="shares">262739126</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4a51b3e565934094b048701d97384fb1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfMi03LTEtMS02MTQzMA_628501d4-74e4-4b73-8207-e924ee4e9853"
      unitRef="shares">253091319</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic53065c277c54ed285075c2628977167_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjg1ZmI3MzY4NmZkMDRiNDY4YTNmYzUzNTEyMmE4YTg3XzQw_55ce9553-0a65-4b72-907e-101848a12e0a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifd58cfd5707b40a8ba848f715d75243e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0wLTEtMS02MTQzMC90ZXh0cmVnaW9uOjg1ZmI3MzY4NmZkMDRiNDY4YTNmYzUzNTEyMmE4YTg3XzQw_f4884089-c263-44db-ba56-c1b5da5f04f2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic53065c277c54ed285075c2628977167_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0xLTEtMS02MTQzMA_f52de025-3346-4067-8192-84d89a5787b9"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic53065c277c54ed285075c2628977167_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS0zLTEtMS02MTQzMA_ffa08e65-3689-4296-b3c1-a87d56f79c51"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic53065c277c54ed285075c2628977167_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS01LTEtMS02MTQzMA_91bc69da-e534-4472-95a7-49d01418aed1"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifd58cfd5707b40a8ba848f715d75243e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RhYmxlOmJlMmJjZGIzYjliNzQyYTZhOTdhYjcxNjEyYjBkMTg5L3RhYmxlcmFuZ2U6YmUyYmNkYjNiOWI3NDJhNmE5N2FiNzE2MTJiMGQxODlfNS03LTEtMS02MTQzMA_2f338b49-0225-4488-8b6d-eb5537ad2b3d"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="ib11d128f5b7d46c4afc00ddccd41927b_D20211109-20211109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDMx_7576e8eb-7a53-42f8-b74a-be1af62ec539"
      unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage
      contextRef="ib11d128f5b7d46c4afc00ddccd41927b_D20211109-20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNTUy_3fa58da9-86c9-47f6-acf3-a8a4255db82b"
      unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i3a8c9b4d47374eb8ac0b52b8d7f5d1ec_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNTQ5NzU1ODE5NTIz_4e5e2e57-752f-4b9e-a0e9-ce6e9d7830dc"
      unitRef="shares">0</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjE5OTAyMzI2MTg1NQ_a709d56e-c3a7-43b2-9dbd-40e0eb522e18"
      unitRef="shares">8480483</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjE5OTAyMzI2MTg2Ng_28c2a5e2-e860-4273-93bc-49eee02896f8"
      unitRef="usdPerShare">3.52</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="id3c01bfb6d72441aa89f5ebd1515b81e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjE5OTAyMzI2MTg3Mw_abe47116-f8b5-43f9-ba61-c32a37f32ab9"
      unitRef="usd">29400000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i1ea599a7a25b45f7b1f330755ed5da57_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfODYy_ae5555b4-d7f4-4ce0-9aa4-6192374deb33"
      unitRef="usd">167400000</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib97422d241744aecbec5cdc038a635ef_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNTQ5NzU1ODE4ODEy_a15dbcd0-5549-48e5-aa2c-f69885ae1c37"
      unitRef="shares">9121000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5dcce6012ae249d88a84eed499079c98_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMTk0OQ_9ac480be-66c6-4aa7-93d1-390306b61e99"
      unitRef="shares">24000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i5dcce6012ae249d88a84eed499079c98_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjA2MQ_7c62ccf6-adf9-411e-a88b-4e4806f1bf3b"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="i564a8962d6e44317a92f8b2819e51177_I20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjM2OA_e6a004ed-842f-4e1c-8e59-b8b400e3fe29"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjM5NQ_ac671580-41d2-4678-8278-c7f648611df5"
      unitRef="shares">2761477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjQ3OQ_23a912ca-cab0-4ce7-bdd3-26b915fc2660"
      unitRef="shares">1994799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i0eaaceda1bc748bbbc2b1a4e90554fe5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjU2Ng_71990a41-f1c5-45c2-be5a-b61171082d8c"
      unitRef="shares">13239324</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifbe75a7506d1456ba7caadb9076e0ed8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjcyMw_ec03712c-8de5-40b8-81f8-da1f75f42d53">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="ifbe75a7506d1456ba7caadb9076e0ed8_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMjc2NQ_354b4fcd-1ca3-4c6d-b766-505f97467264">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i40f17f0e740b43c29e5c8bb3c1255760_I20220624"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzM0MQ_e7daf2d2-bbb3-4885-b7ba-3a4189d017c1"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i27142f229fa048279b6b126bc5f26f7d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzM3NA_6da5a0c1-b2da-4b93-a700-dad7e1d39305"
      unitRef="shares">1573125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i27142f229fa048279b6b126bc5f26f7d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzQ1OQ_92df0589-ec8d-4a8d-9fcb-3edf2338ed4e"
      unitRef="shares">155000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i27142f229fa048279b6b126bc5f26f7d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzU0Ng_fd6ff9d8-6a7a-4704-af7f-86f2da408e27"
      unitRef="shares">271875</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i51eaae0fbbe940fca869c9447afe074b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfMzkwOQ_74ea4278-7911-4b19-a40e-bc964d5d5f14"
      unitRef="shares">1748245</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1d514f11ff234b3093019d9807fa2ffd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDAzNQ_178455ae-f31c-4595-aa46-b75ea583633f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i1d514f11ff234b3093019d9807fa2ffd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF82Ny9mcmFnOjM4OTk0ODU1ZTA0ZTRiZTNiOWE2Mjg2NjAwOTVmZjVjL3RleHRyZWdpb246Mzg5OTQ4NTVlMDRlNGJlM2I5YTYyODY2MDA5NWZmNWNfNDA3Nw_ff0ac801-9815-429b-b5cb-9bd2b81bde2d">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RleHRyZWdpb246OGExOWZlNTllMmVmNDgzZmE0YWI2ZTBkMTY2ODVjZmNfMTYxMA_b87c5c70-d47d-4951-a3a9-ea7ecccde1d1">Net Loss Per Share &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and RSUs and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 8) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2023 and 2022, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and RSUs and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.&lt;/span&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,259,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,097,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,491,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,462,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,305,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RleHRyZWdpb246OGExOWZlNTllMmVmNDgzZmE0YWI2ZTBkMTY2ODVjZmNfMTYxOA_4a87496b-c0e9-4e47-8e8e-632c4891b44c">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,259,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,097,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,491,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,462,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,305,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i921b1a2eed0045048faa0c08a241ab45_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMi0xLTEtMS02MTQzMA_c3d641e4-0b9c-4ede-81a4-477a52f36b76"
      unitRef="shares">15259444</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i60bda6ceb3ee454d9ac8642950c68c58_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMi0zLTEtMS02MTQzMA_e8df7a78-209f-42e3-90d7-1c58e882408b"
      unitRef="shares">14097063</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03ff7bbfafae4ca3999c42f1172d7aa0_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMy0xLTEtMS02MTQzMA_7f8a0e68-dcaf-46c1-ae8d-76aa32f9a857"
      unitRef="shares">2149799</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3c08ae29ea3f4f058c8448338f3ed45b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfMy0zLTEtMS02MTQzMA_f29e53fb-c8dd-41a4-b10c-ea5af93c360a"
      unitRef="shares">3491330</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib58a4b297f7b456087c6738a5502b9dd_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNC0xLTEtMS02MTQzMA_d8272ed6-f09f-44fd-a11b-497001118ab8"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibdc5a1af5a8d4d3e8d3c1e7c321d49f3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNC0zLTEtMS02MTQzMA_fd59b684-4424-42b9-9e1a-065216a5158f"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2779b2689b1147a59ccf83b443c35881_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNS0xLTEtMS02MTQzMA_4af28eb6-c2e1-4e4c-a36e-44cbcd2398ad"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2227a6874dff4a5eb1a92a35dc47787b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNS0zLTEtMS02MTQzMA_77fc7650-26dd-48db-9a2a-3684247da8f5"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf177595aa91424a9dda4724bee8580b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNi0xLTEtMS02MTQzMA_24c9ecd4-dcdf-4b90-a3ef-ea6a14830303"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i42874be0b5e343d3925a6e3e6d86611e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfNi0zLTEtMS02MTQzMA_dc884862-a2a6-440e-b024-45f9dff4e7bd"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfOS0xLTEtMS02MTQzMA_b4a06d63-17d5-464a-9e8c-402e1370e9dc"
      unitRef="shares">20462532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83MC9mcmFnOjhhMTlmZTU5ZTJlZjQ4M2ZhNGFiNmUwZDE2Njg1Y2ZjL3RhYmxlOjEyMzIzMjNmNjQyZjRjMzM5ZjliY2ZkZmI3Y2M1NTk4L3RhYmxlcmFuZ2U6MTIzMjMyM2Y2NDJmNGMzMzlmOWJjZmRmYjdjYzU1OThfOS0zLTEtMS02MTQzMA_c5f9a5d6-d49b-4e56-855e-968a4002da59"
      unitRef="shares">21305035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfNDIzMA_a59f5e60-3e50-4510-94cc-dba7bfa4651c">Stock-Based Compensation&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 was $3.6 million and $7.2 million, respectively, of which $1.5 million and $3.7 million, respectively, was included in research and development expenses, and $2.1 million and $3.5 million, respectively, was included in general and administrative expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, there was $10.5 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $0.97 and $2.48 for employee and director stock options granted during the three months ended March 31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, there was $6.1 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 1.7 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $1.20 and $3.33 for service-based RSUs granted during the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2023 and 2022 was $220,000 and $550,000, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfNDI0MA_c2c1f2e2-26e1-43a5-b662-eb22b8effeef">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.09%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMi0xLTEtMS02MTQzMA_fb7b3cc5-8035-457a-b7ab-36b999e54491"
      unitRef="number">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMi0zLTEtMS02MTQzMA_a9ddcaaa-9213-4afc-ae77-fea45cdafc2f"
      unitRef="number">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMy0xLTEtMS02MTQzMA_c6697570-4149-480b-97e3-e78ad0adba27"
      unitRef="number">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfMy0zLTEtMS02MTQzMA_7ea59fa5-ef8b-4178-a552-3ef6c8e51b5f"
      unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNC0xLTEtMS02MTQzMA_93bda79e-8f57-4402-bfb7-df127748be85">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNC0zLTEtMS02MTQzMA_f18ff0b0-c7c4-40a1-8c17-74c238b31f53">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id4156dde7c464886a817b59bf0c375b0_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNS0xLTEtMS02MTQzMA_f07eecb3-2d4d-4eb5-b954-76b1dacefd6c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2d1ffcee62674f349f88218d19394398_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RhYmxlOmNhYzAzYjZlZGM4ZTRhYTI5YjMwNDgxNzY1ZTljMWQyL3RhYmxlcmFuZ2U6Y2FjMDNiNmVkYzhlNGFhMjliMzA0ODE3NjVlOWMxZDJfNS0zLTEtMS02MTQzMA_ce4ec6fc-6df7-4852-bc04-32e03f9a0dfa"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="icffc34c375714623ba96b595bd73a117_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMTU1OA_ef60992e-bb54-4533-9b00-aebb82fbf02c"
      unitRef="usd">3600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i379a776732214db1b029bd03e5346c7a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI1OTgwNw_8b52be36-bdfc-40de-a4ff-7c70043a3950"
      unitRef="usd">7200000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if16f4b4774ea4c47a1523d104d021a00_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMTU5NA_fb57ac79-1dec-4f73-8f2e-6ff41331d61c"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5482985971d94cc99e0f3719ecaa6f37_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI1OTgxNA_563dfe82-f0de-4208-b1a4-18f168c63f5c"
      unitRef="usd">3700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie151e6230187439faf1df447c5fab34d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMTY3Ng_84c29113-fb8e-4c3a-8f4e-53cefabf7aab"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie341f3ddd4aa4162b175afe26aeb3606_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI1OTgyMQ_81887b1c-2571-448e-b3fa-b2947cd284b1"
      unitRef="usd">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjc5NQ_8eb3de79-9c5f-487e-85a5-ef0389c19223"
      unitRef="usd">10500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjk0NQ_3c0e5660-114b-48e6-8546-371868bbe5ad">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzA2NA_7659ace3-fb67-4863-be18-85b39a663861"
      unitRef="usdPerShare">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI2MDg0Mg_d38392bc-18b8-4af9-955e-b4e839cd344a"
      unitRef="usdPerShare">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i28a3ce5bb9c3471eb596c306b6ffd0d6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzIwOQ_053e04f2-3402-4604-a7b9-0d399f6f064e"
      unitRef="usd">6100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i41f4dedbddf9489aa3e6277504570a15_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzM2NA_bb283730-faf9-49b8-a293-d48f6f7c7702">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i41f4dedbddf9489aa3e6277504570a15_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzQzMw_0a6ad0df-3f58-4d69-ac31-93453a96ea24"
      unitRef="usdPerShare">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i06f13d07dc0c4ec3bd48386ff51e587a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI2MDg5NA_31fbf74c-e028-417d-9a51-0f5e09cfdc0d"
      unitRef="usdPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="i9e035331581449cda370e4641f850074_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMzc1OQ_d3c236e2-058a-4b50-bb51-e27f9b3b11ab"
      unitRef="usd">220000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i706026db14224393a7d5617daa1749ee_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83My9mcmFnOmY4NDJkY2M3YmEzMjRlZWE5MWI3ODU5MGI1OGQ1ZjE1L3RleHRyZWdpb246Zjg0MmRjYzdiYTMyNGVlYTkxYjc4NTkwYjU4ZDVmMTVfMjE5OTAyMzI2MDk0NQ_1201ed25-116f-4aaf-a539-8d83a3dd8e7c"
      unitRef="usd">550000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzczMw_4c97bb39-9332-4dad-970c-708604484098">Related Party Transactions&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owned 597,808 shares of common stock in PLS as of March&#160;31, 2023, representing an 18.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2023 and 2022, the Company recognized revenue from PLS of $0 and $9,000, respectively. At each of March&#160;31, 2023 and December&#160;31, 2022, the Company had an accounts receivable balance of $59,000 due from PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through June 2024, of which $3.3&#160;million had been exercised as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2023 and 2022, the Company recorded $211,000 and $1.5 million, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 14). Research and development expenses recorded from Wistar for the three months ended March 31, 2023 and 2022 were $422,000 and $181,000, respectively. At March&#160;31, 2023 and December&#160;31, 2022, the Company had an accounts receivable balance of $4.9 million and $9.9 million, respectively, and an accounts payable and accrued liability balance of $1.4 million and $1.2 million, respectively, related to Wistar. As of March&#160;31, 2023, the Company recorded $89,000 as deferred grant funding and $196,000 as prepaid expenses on the condensed consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ibc7ccae9f1db4ec7b179375d9ecbf470_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfODU_0a743407-5c2f-4120-8eec-6aeec40518f7"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ibc7ccae9f1db4ec7b179375d9ecbf470_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMTQz_4143926b-e260-4566-b0f1-3f289e981f05"
      unitRef="number">0.187</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0476acad69a0411cb71f91657c47d0de_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzgz_da5248c4-107d-4484-a14f-ec520dddd30b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic075c2d8dc3444418dcdc98130ee2157_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfNDEy_115dc1b1-1ff2-43dd-9106-51b45700d657"
      unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i2cf97ac8cf3a4bf6af4f7d01a5e00911_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfNTE5_03e733e1-8b63-4daf-80ed-71e9ce1f5d66"
      unitRef="usd">59000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i8b9a009f4c76409c87d174eac6f87a7f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfNTE5_e308313a-245a-4790-9a92-581f0545f9d6"
      unitRef="usd">59000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="icc24100fe12944b1b8aeebb2b2812137_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMTE3MQ_cd2da2ec-973b-4ac0-908f-3d66dfcde58a"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="icc24100fe12944b1b8aeebb2b2812137_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzcyNw_09d8bea9-04c8-481e-880d-16830339a709">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="ib159f7b94137458ebffea9382e581603_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjMxMw_319e358c-82ba-4bc3-98db-3ec38d2b9b1a"
      unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount
      contextRef="i16d63252834144b0aacf7c65dae0426e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjM3MQ_0ef96d04-ed63-4916-bd3c-369e0e246119"
      unitRef="usd">13600000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount
      contextRef="i32cb639fd4a343e690f4f52b559444f5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjU2Nw_077d88ef-5143-4688-8359-a9483dfe0e78"
      unitRef="usd">6000000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:CollaborativeAgreementAwardedExercisedAmount
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjYxMA_888ec9a2-a351-4562-a841-2c3f8032ea94"
      unitRef="usd">3300000</ino:CollaborativeAgreementAwardedExercisedAmount>
    <ino:GrantProceedsReceived
      contextRef="i5ab8e1cd29e04f13a5bc87f121c2aac5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjg2Mg_85d8a6ce-782f-465a-96c0-9212d552a13d"
      unitRef="usd">211000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i0bf7bb08585e4f10aed4274ac4f1ec00_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMjkyMw_a72b298d-7c8b-40db-bca4-b94e06a04989"
      unitRef="usd">1500000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i32cb639fd4a343e690f4f52b559444f5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzI1OA_46367bab-2318-475d-b2b9-7786aa280df3"
      unitRef="usd">422000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i0acd1375e3c24e7fa409126bcc9c1d51_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzM2Mg_88e711a6-ef03-46ed-b387-9560bb3439d8"
      unitRef="usd">181000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzQ1MQ_09334e58-8579-43df-8b03-37e67d2ad3a9"
      unitRef="usd">4900000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i7c90d97b8be2421a91f73fa2e1553a92_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzQ1OA_c7bb0ea1-81b8-49ab-94f4-ec99ff7121e0"
      unitRef="usd">9900000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzUzMw_f6b15116-62e8-4b02-9929-00fe53f06055"
      unitRef="usd">1400000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i7c90d97b8be2421a91f73fa2e1553a92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzU0MA_180f25f6-155b-40da-b6e4-0036e1299c5e"
      unitRef="usd">1200000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzYwOA_66e7a702-daae-4123-88cf-731409e19ea9"
      unitRef="usd">89000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="icbba60f01bb241bbabbb479069af98f1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF83OS9mcmFnOjUyZWRkODBmOTQ3NDRhOGQ5NGU3OTEyOTFmMGFlMjAzL3RleHRyZWdpb246NTJlZGQ4MGY5NDc0NGE4ZDk0ZTc5MTI5MWYwYWUyMDNfMzY0MQ_7c477856-6e7a-4991-bc5f-0e3a0fc6f584"
      unitRef="usd">196000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMTIxMjM_eebd81e6-8705-4216-8227-b8ef933c5bd7">Commitments and Contingencies                                                  &lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 0.7 to 6.8 ye&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of March&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,526,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,223,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,137,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,371,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,766,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,580,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,186,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2023 and 2022 were $840,000 and $830,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. The plaintiffs&#x2019; complaint was later amended to include certain of the Company&#x2019;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. During the three months ended March 31, 2023, the Company issued 9,121,000 shares of common stock pursuant to the securities class action settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accuses the Company&#x2019;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#x2019;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#x2019;s current directors as defendants. The Devarakonda complaint also names one of the Company&#x2019;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2023, the parties submitted a joint status report to the Court of Chancery reporting that the parties agreed to a settlement in principle, which also provided for the resolution of the consolidated derivative action and certain stockholder demands. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 19, 2023, the plaintiffs in the consolidated derivative action filed a motion for preliminary approval of settlement with the United States District Court for the Eastern District of Pennsylvania.  The proposed settlement provides for resolution of the consolidated derivative action, the derivative action pending in the Delaware Court of Chancery, and certain stockholder demands.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#x2019;s counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#x2019;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 18, 2021, GeneOne filed its answer to the Company&#x2019;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#x2019;s new matter. A trial date for this litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance &lt;/span&gt;&lt;/div&gt;carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i333fb2acbe2d4abebe17d055f53089d5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMTMw_4090a353-c80f-47b8-827d-e433ca31d99e"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="ic3eae36ce89f42ad9e65603a05d7c7aa_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjIx_fc60dccb-d7d7-41ad-863b-a33539ef0674"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i8608f45e71364d6db7f445deb5e26df9_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMzgy_1a941b0b-c7e4-4380-b21e-a0b396ddbef2">P0Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i4c3ac8cf648e4aa49f2a73b8fabfe262_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMzg4_a4672f8b-c2d2-4b78-b195-3077c5d9cd4c">P6Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMTIxMjU_7b7f29d2-e1db-457c-85b5-2bb7b6779d4c">As of March&#160;31, 2023, the maturities of the Company's operating lease liabilities were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,526,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,223,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,137,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,371,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,766,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,580,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,186,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMC0xLTEtMS02MTQzMA_0df65584-6128-4011-8a10-ab75791bce14"
      unitRef="usd">3136000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMS0xLTEtMS02MTQzMA_a0c43587-dcf2-4852-828d-906fa4cc1a55"
      unitRef="usd">3050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMi0xLTEtMS02MTQzMA_90832ea0-35cd-435e-b473-b0e3ca34fa41"
      unitRef="usd">3063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMy0xLTEtMS02MTQzMA_385ab8bf-b0f3-423d-8552-0955fd66b592"
      unitRef="usd">3139000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNC0xLTEtMS02MTQzMA_b22d7aa8-cb09-461e-a384-851395d6f4f7"
      unitRef="usd">2526000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNS0xLTEtMS02MTQzMA_b09cc1b3-cc75-428f-9d4b-40a46e77b130"
      unitRef="usd">4223000</ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNi0xLTEtMS02MTQzMA_7d0422d8-c7de-4a63-96e5-b6c406ca17ac"
      unitRef="usd">19137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfNy0xLTEtMS02MTQzMA_b0862323-c6f7-44de-a655-24b6ffccc722"
      unitRef="usd">4371000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfOC0xLTEtMS02MTQzMA_298db68e-19e3-4d60-9b17-32df0d7da917"
      unitRef="usd">14766000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfOS0xLTEtMS02MTQzMA_6d137f4c-a9dd-4b2f-b8ec-7c5edbbfcfcb"
      unitRef="usd">2580000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMTAtMS0xLTEtNjE0MzA_4f7bf0d1-5539-41ea-9328-228a2e1bad0b"
      unitRef="usd">12186000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMTItMS0xLTEtNjE0MzA_d3407d02-090b-4cc3-bb0e-250c999d7b8c">P5Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7e013b80260c4d9089f646bfa59fe02d_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RhYmxlOjE1YmFlMTdiZWVlZjRiMDFhZThhOGE2MTM4MDlkYjA1L3RhYmxlcmFuZ2U6MTViYWUxN2JlZWVmNGIwMWFlOGE4YTYxMzgwOWRiMDVfMTMtMS0xLTEtNjE0MzA_e1ae89d8-cab7-4a84-ac3c-c2829ff011c6"
      unitRef="number">0.086</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjA1Ng_7dd8d3f1-63ab-4d9c-a96b-7ccd4b11b359"
      unitRef="usd">840000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i80b602599e3341909f5278c9dec13c9e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjE5NQ_63d61c75-113c-459e-96f9-566e23868ec0"
      unitRef="usd">830000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseNumberOfAgreementsToSublease
      contextRef="i3a98975b0fc340d4b103c427cf0f43ea_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjQ4NA_63019596-c405-44a0-a69e-12be6e8746eb"
      unitRef="agreement">2</ino:LesseeOperatingLeaseNumberOfAgreementsToSublease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i9f906f0a3f6e4602a9e8cab308738534_D20191001-20191231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjUzNQ_5b739ff9-6f82-47be-ac27-76c894d0b8fa"
      unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i58c9cdabcabe4021909afd5c5a3081f2_I20210309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfNTA3MQ_ac1ece7e-9834-4f66-8444-adfdaf9102d0"
      unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares
      contextRef="i58c9cdabcabe4021909afd5c5a3081f2_I20210309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfNTA4Ng_84c6410a-b0db-4ca6-a804-b8842a4f12d9"
      unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i58c9cdabcabe4021909afd5c5a3081f2_I20210309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfNTIwMA_0452a3c6-7695-4d2a-802e-4faf0256b169"
      unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib97422d241744aecbec5cdc038a635ef_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84Mi9mcmFnOjFlMjA2NTYxNWVkNjQyZDRhZTllY2Y0ZmY2ZTI2ZTA0L3RleHRyZWdpb246MWUyMDY1NjE1ZWQ2NDJkNGFlOWVjZjRmZjZlMjZlMDRfMjE5OTAyMzI3Mjg0MA_a15dbcd0-5549-48e5-aa2c-f69885ae1c37"
      unitRef="shares">9121000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTUyNzk_4f14e26e-d9d2-4968-8da9-e7d05d20142c">Collaborative Agreements&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated on June 7, 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#x2019;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#x2019;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. In the fourth quarter of 2022, the Company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $200.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#x2019;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, the Company will supply Advaccine&#x2019;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#x2019;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#x2019; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#x2019; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus a $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. For each of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, no revenue was recognized from Advaccine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. During the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2022, the Company received funding of $1.2&#160;million from Advaccine that was recorded as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contra-research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of March&#160;31, 2023 there have been no significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously entered into agreements with CEPI, pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2023 and 2022, the Company received funding of $1.6 million and $2.0 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2023, the Company had $1.7&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to these CEPI grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three months ended March 31, 2023 and 2022, the Company received funding of $53,000 and $510,000, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2023, the Company had $2.3 million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2023 and 2022, the Company recorded $59,000 and $80,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2023, the Company had $96,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2023 and 2022, the Company recorded no contra-research and development expense related to this Gates grant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5 million. The Company determined that the OTA Agreement should be considered under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. The Company recorded contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses were incurred. During the three months ended March 31, 2022, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.2&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as contra-research and development expense related to the OTA Agreement. No amounts were recorded during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total purchase price under the Procurement Contract was $16.8&#160;million. The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD discontinued funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7&#160;million. All performance obligations under the Procurement Contract have been satisfied. During the three months ended March 31, 2023 and 2022, the Company recorded no revenue from the Procurement Contract.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTc4OA_71253738-fa95-4830-ac97-b5a615678bd3"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTkwMQ_c16acd84-f80e-4a5c-ae85-87e618812b22"
      unitRef="usd">200000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjYwNg_329f33c3-e25f-43ad-92b8-b70cb0c58493">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <us-gaap:CostMaintenance
      contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjk5OQ_b67e69c5-b87e-42ac-bb62-772e2c8697ba"
      unitRef="usd">1500000</us-gaap:CostMaintenance>
    <ino:AnnualMaintenancePeriod
      contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMzAxOA_83d26c02-2404-414a-bcdb-3cd58c5123a8">P5Y</ino:AnnualMaintenancePeriod>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i417613e580e94ab98741e8202729ade5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNDY2MA_38779e7b-b432-418a-8a95-4b01167081b7">P18M</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQxMQ_1a3d54f8-bd3e-47bb-932b-dd77290cc241"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ2Mg_120aec79-54f7-4ddb-95bd-9f3bfdd1996e"
      unitRef="usd">2000000</ino:CollaborationAgreementPaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12fc1c502f8942b7ad4bc3b5d8beb886_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNjMzNA_4d94e151-4f05-41b1-a61c-d1b1a6cb1ce0"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5a06a61d23a43f185271e37b7571874_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNjQyNw_15ec477c-1db2-4dd2-aa11-eb7cad892045"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5a06a61d23a43f185271e37b7571874_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNjQyNw_f0226d65-cf55-4910-b683-a097931ab70b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="id64c57b813344cb7a27bb83b05c69e89_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MzY0Mw_c6b8c953-c9ef-4253-8b0d-75686a10b1bb"
      unitRef="usd">1200000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNzQ4MA_65c9caf2-2f35-4410-9f00-16ec6509c0e8"
      unitRef="usd">20000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfODAyNg_d94aaada-2257-40e7-9f02-7a326bcee2f4">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfODY0OA_c194aa44-dc2d-4b99-ab84-8184cdba34cd">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i92384310f07943f08357ffcdc9a44938_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfODY5Ng_5f55bfd8-d64b-4daa-80d0-69807e054e3c">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i7a4a785614804e208d698da42727636c_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfOTQ4Mw_c31d7a96-b5d5-4f0d-a485-5e4f0f0d0f39"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="i7a4a785614804e208d698da42727636c_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTUyNzQ_58c573c7-625a-4d7f-b0c1-fde7fa340b38">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ia69f542558464145a2894966df1810dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfOTc2OQ_b7bcc2ab-2605-4b7a-a989-d07e4f18ce85"
      unitRef="usd">1600000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i125c5d9c06e64a2796725f967491bb88_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MDg2OQ_441e1417-40eb-4df9-a6a3-e6386d21aa29"
      unitRef="usd">2000000</ino:CollaborativeAgreementFundingReceived>
    <us-gaap:GrantsReceivable
      contextRef="if7941aaf07d1455db283f53a3ce532ff_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjc0ODc3OTA4NjI1NQ_dad61296-2bed-4f71-ad51-bb6864b2b08e"
      unitRef="usd">1700000</us-gaap:GrantsReceivable>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ia88027f914c346d898a03e87ce8843cc_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTAyNTU_bdea094c-6ee3-4114-89d6-4d2928cfe4a8"
      unitRef="usd">9000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i6685e6d0a07641c9a04cb5a2a1f626a0_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA0MjE_c3d11786-0734-4d17-8680-b7637527cdd7"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i6284362eaa524cb1ae66051b9a8416be_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA1OTk_e5de5e50-792c-4d1d-bee7-ea2904d72304"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ib99cbe6e413f48c58eac5aa5bc792556_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA3ODE_9e8a80c4-d683-49c1-8d7d-b4970232e337"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="iabc7dbe20d0344d694da0dff99be1e46_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTA4ODE_f3c7f890-fa60-43a2-a0b6-f75e7192fad8"
      unitRef="usd">53000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i226d2be71e7340ca94c685446a1e4897_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MTMwNQ_04995738-5790-44aa-b549-de1934aa1ff7"
      unitRef="usd">510000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="ib3ced90de62e425292ba059648c69c3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTEyMzg_337cfb36-5a2b-44f7-a22d-0f8f9f26742c"
      unitRef="usd">2300000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i3d44bceb01724751ae9ac3ef1c97f30c_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTE0NTk_ddf43136-e951-4096-a757-1f06bbf6a222"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ie31a2498c1414335a0ba4fe5e14b7127_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTE4MjI_7abb97d5-5539-46bc-a293-68702500bfce"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i7f1e77e31a004c85bce55c93571e12c7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTE4Nzg_8029a706-31f3-496b-a594-4d44f90fd559"
      unitRef="usd">59000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ica479a19e2b24b13b5c1515aad9cca2c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMjE5OTAyMzI3MTUxNg_3591b75c-7c54-40dd-9268-f9024bf3fd41"
      unitRef="usd">80000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="icc8c967179d64c8da0b633e32986c5b4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTIxNjk_93f88ae2-2f40-4282-83d0-14525e7de634"
      unitRef="usd">96000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="iffb01fd6e8e940fbbc1a27ee535e080e_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTIzMzY_1bf25633-ba02-4704-ba1a-30608906964e"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i4156146913df4fe29176b27642589675_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTI0Nzc_4d13870a-ff71-4645-91dc-3102c7158b25"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i3ad6c67aa76d4e239862ac53565b8b14_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTI0Nzc_a15533d8-5bfa-4ae0-a882-66e09f6f3c6e"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i34c3e1e467bd4c8cbd2f2d5dd0b6b83e_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTMwNTk_83e529c8-1792-4f4e-86f1-16c27f2a9564"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:GrantProceedsReceived
      contextRef="i4e1fd3bca48746d4a3e0157958b1362d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ5NzU1ODMxMDUy_f7ade52e-8605-4e55-86f2-6c4b8decf48a"
      unitRef="usd">3200000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i18a5a935641f47e3a61691a74380178e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTY0OTI2NzQ2MDAxNw_ebf1635a-bead-46f3-b1c8-7f9bf96e6e98"
      unitRef="usd">0</ino:GrantProceedsReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i63d4cb06945a44c5b005997ca2058e88_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTM3ODk_2b2bdb19-623f-48ec-818d-68fc8a6210c9"
      unitRef="usd">16800000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i1066c49f9fa944c18d0649a5a997b41d_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfMTQ1MzM_838fce7c-08ea-445d-9fc2-5d1fbc16d797"
      unitRef="usd">10700000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract
      contextRef="i168d6a6b6ac247679a22b560bd6e3455_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ5NzU1ODMxNjYz_1aabbeee-21aa-4d49-9452-8b2274d9bacf"
      unitRef="usd">0</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract
      contextRef="i1f4328f613794f8f851da2eea650c719_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84NS9mcmFnOmZiNmRlYzMyMTZjYjRjZWZiNTIxNmRmMTUzNGE3ZTQ2L3RleHRyZWdpb246ZmI2ZGVjMzIxNmNiNGNlZmI1MjE2ZGYxNTM0YTdlNDZfNTQ5NzU1ODMxNjYz_cd3ba51f-c0b3-4f67-ad1e-e411980527a3"
      unitRef="usd">0</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF84OC9mcmFnOmNjODVlYTMzNmVhYjRhYjA4MjEyMTZlNTcxMDJhZDk0L3RleHRyZWdpb246Y2M4NWVhMzM2ZWFiNGFiMDgyMTIxNmU1NzEwMmFkOTRfOTU3_a804e905-f417-4f3f-a5fd-b3cc0ed0fec5">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&#160;For the three months ended March 31, 2023 and 2022, the Company did not record any income tax provision/(benefit) due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfOTExMA_277d302b-6a44-405d-a1d5-c4759e6efcd3">Geneos Therapeutics, Inc. In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. The Company's &lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. Since the Company&#x2019;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continues to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company has concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-2 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remeasurement of  Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not made any further investment in Geneos subsequent to March 31, 2022. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, Geneos completed the closing of a Series A-3 preferred stock financing, in which the Company did not participate. Following this transaction, the Company held approximately 26% of the outstanding equity of Geneos on an as-converted to common stock basis. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ic8095048f54b4e7690bb30f2a7181f33_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMzYy_c52106a0-b297-41ae-b4a6-4a97dcdbe925"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i7b7d9f2ec0c742c5a03a7fa46f42aa3d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNDkx_19d9b6bb-ed39-42b4-a947-76c4ff8c6911"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i78a9b6e99d364eebaef954d914503da2_I20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNzg0_59721137-c45c-4d9e-a191-9c93fa08a5f0"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ide7c9f8aacf543c2ba69c1d46e1444ca_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODMz_8f1cadb7-5551-4545-a68b-0370f2f8396f"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i787f2661dbc54b07898d0c0364957c10_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTA4NA_b7a95716-b190-4830-9ff9-e788335f64e3"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0284cde70d5b460295a267e2aa3f9418_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTEzNQ_789e5037-c074-46f0-ba53-475cd8ed1ff4"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="iec22519de8e349f68787d4e3117cc5d1_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTgwNA_457e6132-447e-4a8a-aafe-a0f2a37beccd"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="iec22519de8e349f68787d4e3117cc5d1_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMTgxNw_df57cca4-c922-492c-98c6-3286cba7ff6f"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i0f6c4cef707f468e961ad855e0854c2d_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNDgyNQ_be278d0e-2b82-4da4-88a5-983ff8d5c773"
      unitRef="usd">1400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ia4c22ea43f794bf99527a5a0e7aedae4_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTQ1OA_f08b61a4-5666-4788-ae81-471c83a6ffcf"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="i0142d3c784c84195a77084a90fd44686_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTgyNQ_1d7cae29-eecd-4785-8463-56e4cf3a1004"
      unitRef="usd">-1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0142d3c784c84195a77084a90fd44686_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTg0Mw_dac26e57-9e39-4e39-b46f-a60b5e9d137c"
      unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ieeccae722fc04ed3b3e297f3f9746ac5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTkxMw_11acc0a4-676f-4767-925c-f4b104204a39"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifc519a3505b3405fb2c0d3cdd6a35310_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTkzOA_216340d4-2cb2-4366-9989-d707c9c76903"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8e7818a8a0894cb2bb8176800bac1b8f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjAyNQ_e1125cb2-42b2-4841-a369-4eb97cf4b125"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8fc6c62eb8cb4a31ad404dd9dea91a63_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjA2NA_2bccd27f-85c3-48e2-ab3e-a4ef17e5caab"
      unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="id0957b99b9e3448f9b409da3e4e79095_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjIzMA_a102a4bd-6f21-4d4d-865e-3c5d524eff54"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i86f4cd190cda49f78e14fc4d981780f7_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjYxNg_51f88dc8-5bcd-4d4e-9a45-7d911534f764"
      unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="idac4be03517e4f47adf6174fbe4aa9e1_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNjc5Ng_d3392517-c671-4b50-81ca-493e87f6998a"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i407a77b361714c38aa6bd43347213d19_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNzQzMQ_b082e989-8ff1-46f9-b19c-2141c6d9d3e7"
      unitRef="number">0.28</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODE4Nw_bee329fb-e928-4235-9f04-44c7a616bfbe"
      unitRef="usd">165000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfOTEwOQ_5a0ebda1-f593-4074-aab3-cef5476b0c02">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-2 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remeasurement of  Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODI3Mw_dc633547-496c-4ead-94e0-60d6db45fde7"
      unitRef="usd">-2200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if7582f4c63824263ac27d9d7d9dd30c2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfODQwMA_609f6526-2f9a-42ad-86b0-524ac1dca157"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9c8116a07c8d41bf95c7976eca960b36_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfMS0yLTEtMS02MTQzMA_9af11ed8-0844-4054-b92a-2055bd2acd61"
      unitRef="usd">1999998</us-gaap:EquityMethodInvestments>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfMi0yLTEtMS02MTQzMA_18119724-b97d-4e29-994a-03d3a8878841"
      unitRef="usd">165215</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1f6c1a078a8e43b9925402a2ae323e20_D20220301-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfMy0yLTEtMS02MTQzMA_9ebbb511-9a20-457a-908a-fb521c5bafb2"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if7582f4c63824263ac27d9d7d9dd30c2_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RhYmxlOjZiMDQxNjE3YzczZDQ3MDc4NWNkNGViNDc0YjlmMTA4L3RhYmxlcmFuZ2U6NmIwNDE2MTdjNzNkNDcwNzg1Y2Q0ZWI0NzRiOWYxMDhfNC0yLTEtMS02MTQzMA_63722e69-244f-41ab-ba1a-0e958806302f"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if7582f4c63824263ac27d9d7d9dd30c2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfMjE5OTAyMzI2NTAxNQ_936a7858-a41c-40f8-a20f-250026ac76ad"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i2b8a4fe327134fba97d18909d711eee6_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmZjZkNTkwZjBiMDQxN2VhMGYwNzcyYjM0ZWNjNWYwL3NlYzoxZmY2ZDU5MGYwYjA0MTdlYTBmMDc3MmIzNGVjYzVmMF85MS9mcmFnOjJjNmE4ZTRhY2ZmZDQ4YThhNGU1MjNlNjA4M2MzYzIzL3RleHRyZWdpb246MmM2YThlNGFjZmZkNDhhOGE0ZTUyM2U2MDgzYzNjMjNfNTQ5NzU1ODIzOTQz_eede03ac-6280-4cd4-993b-e48df896162c"
      unitRef="number">0.26</us-gaap:MinorityInterestOwnershipPercentageByParent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MO9HM6RT;?;M$'QE$U%CR=8S&P8MVN#(;564O@A$V1A$S^W3-M>QFRTD:0-_
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MKF0D*HD3];3+/N)!4*J/3=@(9QAQ+["^95\'$9]!+!D12^*(?59L?8:BJ=+
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M5]BYFT;[#Z9I^UA,YR63I((90GH7"89/-*VTF2B^,-UHRA7V-C,L\-\'"&V
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M.!Y$I9":IZ.PM[#IR-2HI(:%9:XN2V'?IJ#,;LR[_+CQ*#<%^HTH'55B TO
MIVIAR8M:E%R6H)TTFEE8C_FD.YSV?7P(^"EAYTYLYI6LC-EZYT<^YK$G! HR
M] B"EE>8@5(>B&B\'#!Y6](GGMI'].]!.VE9"0<SHW[)'(LQ_\I9#FM1*WPT
MNWLXZ+GQ>)E1+GS9KHF][7.6U0Y->4@F!J74S2KVASZ<)/0&%Q*20T(2>#>%
M LL[@2(=6;-CUD<3FC>"U)!-Y*3VA[)$2W\EY6$Z,SJG%D/.R')&R5P@.4ND
MA7J/CIDU>2;;%D;E8-T'-G^I);ZQCPMA*:  E)E0GT81$AT/&F6'TM.F='*A
M=#=A#X8 ')L3A_Q?@(ATM&*2HYAI<A7Q#K(.ZW4_LR1.NE?P>FUS>@&O=P&O
M[<+%)CQ/5@XM7:W?Y_0WZ/WSZ'[<AJX2&8PYS9,#^PH\??^N.XB_7>'>;[GW
MKZ&GDRPSM4:I-_XP=2YL[MA3Y8^7/<_WZ.=JI8!Z7Y=@A1^1LQK^OPH=0OPE
M'IS3$IU<6*J^"6/I6,!J[FZ[VT[^I+GP?\.;9^-!V(W4CBE84VK<N;WAS#:C
MV#AHJG#]5P9IF()9T.L%U@?0_[4Q>'1\@?8]3/\ 4$L#!!0    ( $F JE8(
M4NHV%@H  &PV   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULM9MK;]LX
M%H;_BN!=+%J@KL6+;MTD0&K-= IL9XIF9_<S(],Q=R31(\FYS*_?0TFV;))F
M','.A_AV2/&\.CQ\>-'5DZS^J%><-]YSD9?U]635-.M/LUF=K7C!ZH]RS4OX
M92FK@C7PL7J8U>N*LT5;J,AGV/?#6<%$.;FY:K_[7MU<R4V3BY)_K[QZ4Q2L
M>OG,<_ET/4&3[1<_Q,.J45_,;J[6[('?\>;W]?<*/LUVM2Q$P<M:R-*K^/)Z
M<HL^I316!5J+_PC^5.^]]Y0K]U+^H3Y\75Q/?-4BGO.L454P>'GD<Y[GJB9H
MQY]]I9/=-57!_??;VG]NG0=G[EG-YS+_KU@TJ^M)//$6?,DV>?-#/OW">X<"
M55\F\[K][SUUMA$89YNZD45?&%I0B+)[9<^]$'L%H!Y[ =P7P'H!>J0 Z0L0
MO4!XI #M"]!6F<Z55H>4->SFJI)/7J6LH3;UIA6S+0WNBU+=][NF@E\%E&MN
MYK)<P%WD"P_>U3(7"]; A[L&7N#V-K4GE]Z<U2OO9PB1VIMZO]^EWKN_O[^:
M-7!Y5<DLZR_UN;L4/G(IXGV39;.JO9_@D@M+^=1='F%'!3/P>^<\WCK_&3MK
M_,:JCQY!'SSL8V)IT/STXMCFC[MXRK-CQ0^\(;M;2=KZR+%;J>[2LKU+RTH6
M'N2&BC6B?.@ZEV@$KS_9;EM7+;57JQ+/IWK-,GX]@<Q2\^J13V[^\3<4^O^T
M27;.RM(S578@)]W)25VUW_P*23>7=6U3K"L9MB559GV\F5(_I E!T=7L<5\.
MBV64^!&)4')HF3I;,]+78.=KX R=V\7_(-5T_;V1D,\S668BYU[9BZ"^5>\S
M%6,;E2Y$>7J !><,L'-6EIZIL@/1PYWHH3/ 4@Z59H*I\<^F6E<ZV N=2 5.
MK$68:9;@A,1$"R]G6T9Z&NT\C9R>WA:R:L1?K:=J/!%EP\H'<0\!QNJ:-]8^
M%AE^Q=C7W9J;5@B'4>1KWCO;-]+[>.=]_";OAVZ3<R 6KU)H,I7+*?0KAQZQ
MX2D)<1A231"+&4J".-0$<39YI"#)3I#$G5EE.6T3"=!-]L=48=O"RV0!+%L?
M[0V)Z5?L)[ZO!X1I%T4(H0!I CB;.%( Y _4Y9\F 70%#A=H/(B-FI="5J!$
M^<@A8E3W*&7#K='0U[_OYQ2C!/XT/4XU3-TM'JO('H>B-_62=PM19W(#(])[
M#RY8B$U1*Y$$B-,/559=D.DNW/W$S!P62X2#&.FIP]WNL;K@01?LU.4'9[GX
M"SI(.PRK*%F!4%.(FN)5+;#A(:8X"*-0E\(T)"@.8ZI+X6SJ6"D&OD5.WKOY
M5Z\ 1,9:UBQ78;(4SZ#-\:S95WG@&J$XT3G-8H>"* SUO.ENXE@)!B9%;BC]
MPA1WJ1EW 6/'IFKG:-V0N@T%169?>,FE70]J^.GK4I@F4Q0&& 6Z%I= 5C0P
M*W+2V<T[)<;[7;_@?VY$\Z()P99+D8MV2@O?P.]630+3X1"%(3%RJ6D8D"C"
ML2[,); 2#5R)W&!YMV(55T&QHW=W2)@$:82$:8+;D- IT]VRL9X/G(G<H*GF
M;)NRVJ;,=P\'$<(>F<@9#*O3I:RFD$#X-FAJGFVJ=OYB%<B$S"G!*#9ZQ-QB
M26,U,]3IP^W'6)T&(D6Q>ZE@!?S-:VT2UR91CY4PU@AV#_WFZ(0.G0D?>]7.
M65MZKMH.I1W8%KGA]C;KJ$5-HKEX5.'V 73.\LU"B=RNS.A9Z5C<F2P;1CY!
M.J+,+88!19@:>>D2T(L'Z,5NZ/U>\343X/.S(GW>A9IL5AR8=U-5*F5W,3A6
M,&RR+DD(I@'%FF(62YA<!PG1D<?MTEC)!BK&;BK^K57G.-Y@$V()"K!.-Q8S
MF!&9<P!W:\9Z.[ N=K/NKN^LV0MK5P<@0%B651L^1,U^<"PV7*U,G1H>)N9.
M:;ND$NDCO<T4)IM^$!B278*)\<#$V,W$M[TZ&?P@,F#BIA+P?RN65083=:<T
M2F)LAHT-BGU$8T.$2U Q'J@8NZDXY4L.^6,!.?>1EYO7$ZX5 _'K:&PQF29)
MJ%.0N[ECY1C &+O!^+?7%YCT4?Z#8D6K*#8V3DB8(%T:FR&F862(<PDXQ@,<
M8S<<?ZD8C#/+3=E&QU:"EY$A8W(Q"FF,$V.\L2SF8A($^F*#N_%CQ1GX&;OY
MN1MN]N+"ZK0)N48_L1 SI VLSZ;=S1GK[H#!V+TR^^LI.QI6"<Q5UBD)PY!2
M8WG>9AJB&"8//M;5N 2YXH%<<?*F_<-N)GW"]@X^$U;V@IVSMO1<M1WNR [(
M2UY!WDV5K9ABW8,U&FM0$<M*;>Q3X/U(7^2WF29)A'&H+VRE[@:.%6  6.(&
MV.^5S#A?]"'5SKEEY16L4?/MEU-4,=$5AI\@\O7<.;=8(DP V7QC(N1N]%A1
M!LXE;LX]B(J,K44#R'8<\HD%1G$2)L:2ML50'V#<+1OK^=X1!3>NVL+A) E,
M$@W]" &1ZQ*8AH8$EX!5,L J<</JUQ-7:LGK.&HQF;9;.XD1\)<@4C(0*7$3
MZ6Z@75?R42Q@L+U_L8XO5B%,LD2Q\C$QXM^TQ(@0 "T=0MWM':O' *$D?--0
MNQ0E*[-3CNJ<B0][O<Y96WJNV@XU'=B5N-GU,+6(NMZ I%UZD46A-L[4;G,[
MT6F'G:U!)NLC.>=USK688!B=:$",#G@)TB4#Z1(WZ6IY5RD!L-ONM?)G7F7B
MR%H!,>G5T, TB4F,=+AU-W"L  /<$O>R[+_9,U?K2D(M$N3MM*X_TE2WNR4P
M\#3Y;C>MWQ9@3ZQ:V'4Q5URG%-/(-TC-8@CD'Q)BI*1+D"H=2)6^<B)AFZ+?
M]9.A]P?)VI:AK"?C+&1J%<9BB&.*L:\?H4O=#1\KS$"PU$VP/RV7/.NBXCEK
M]TT\F"-"WNCW4* +M;JI%97VC0J>1R";(T!+;2<4$J3/&VUF81#H>[#NQH\5
M9R!9ZB;9E&=5N\8DWJJ"A6E1["<(^\812ILIC.L4QT:H7()NZ4"WU$VW\V,*
M?/#N^8,H2]5_()#6O!+2=@+Z,S7QE88$QA1]W7ENL8P0HB325R#2WC)T61XZ
MO'=$ULVR#H>YVMMQNFK"*XXQC!R!OGAFL0P2WT^HO@B94O.XK2'?H:L#PE+W
M$=F[S7K=#1 P45%GDW*ISE_8,8V>]<3K66M+SU7;H8X#^E+W^NMMT6WQ;+=U
MEK+RUOOSX==.]-#7CRM83 CQ(WV7)W4W=:P4 [%2-[%^W9[]4UAB==7$RX 0
MJJ>]^8EVJ;L]8_T=()2Z(?3K$29O8Z!9<2_G#]"Y!A2S:A(;71Q1O_W353$M
M]:4 =X/?*LAL[S&<@E</[>-,M=?N:78/I>R^W3TR==L^**1]_QE]FG<//@W5
M=,]A?6,5C",U*+6$*OV/$=SSJGNTJ?O0R'7[L,^];!I9M&]7G"UXI0S@]Z64
MS?:#NL#N ;.;_P-02P,$%     @ 28"J5MX;7"?_!@  %@\  !@   !X;"]W
M;W)K<VAE971S+W-H965T."YX;6R=5VMOVS84_2N$!W0)YOJ5K"V:!^#8Z>*M
M30RG38$-^T!+UQ87BM1(RJ[[ZW<N)?G19<&V+[9(\;[./?=>\7QMW://B(+X
MDFOC+UI9",7;;M<G&>72=VQ!!F\6UN4R8.F675\XDFD4RG5WT.N]ZN92F=;E
M>=R;NLMS6P:M#$V=\&6>2[>Y(FW7%ZU^J]F8J646>*-[>5[()=U3^%1,'5;=
MK994Y62\LD8X6ERTAOVW5Z=\/AYX4+3V>\^"(YE;^\B+27K1ZK%#I"D)K$'B
M;T4CTIH5P8T_:YVMK4D6W']NM+^+L2.6N?0TLOJS2D-VT7K3$BDM9*G#S*YO
MJ([G1]:76.WCKUC79WLMD90^V+P6A@>Y,M6__%+C\&\$!K7 (/I=&8I>CF60
ME^?.KH7CT]#&#S'4* WGE.&DW >'MPIRX?+.+:517V4%D4G%74$NKOQY-\
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MJ6/HK(R>MF*OTIEN>(ISC^Z*1G6-WN+UJW <O#T2PZB/870,_05)^S]X\*5
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M-)A<!KY,N@]6+=U[MYFR5E7NL1"@#TT"V)\K3.3M![J@?Q%[^P=02P,$%
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MGNXA65"K<2-YTQ_XE'SM#GJ$ZASC$O2*N4"0?Q/Q83C6588@=KA*B*\2@8L
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M&&###A?$^.)-%2YE,^-QQ0N/"]RIR;( ON?&^/:%'72W](N_ 5!+ P04
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MHV@#OB\UN-Z\D('NWQ0G_P)02P,$%     @ 28"J5B4I5VCT$   #S,  !D
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MO_"[ QQ673XKJG?YJ@?"2(,AX9\.[K6JJ%]7(9QP_=6*")T.\9X?L?^3$'U
MFWH2_;/;EF'+2++;AY.W)-?&B?@\[0EC'P_E:]UQ#HI/ALRB[J*G,8X:LU@F
M'J_LO_>=:)@8H\RQXY9)CS@9#2)FF.!"V2J20Y2T6G[=;7XW) Q&W,,.2$)]
M*'SU]LTG[;DE7A@'Q6?%)V!,QII-"K=659JVWN$4/[3XK;G$\B&!?A7*"4V/
M-:VA)C%99ZC_).I;G>@]\MCDV,(\([&^&H:?__S?[S9F NXRCE,VBOP8?3UF
M7%!A7-E/+;>T+<HG'F@+EW2TMZ9[FFZ]<88NEQ #]B,UDDV</ZM&W314HDH%
MFM&JH6-_^CJC+BM\[<WKS%(Q"W),$T&YJ:KD3+-4M/W+.>#";=S!#PG#KJ"-
MLV1K96%IXR[4X<TJSP>5ZV34CJBJ-XG)=\&% @7Y]Q;$I[Y8AM.ET!KG\="4
MN]P D$$V#?Z?^H;-$81O568\Y^=\VL!O)X2&.MN^RY'Y9AT#6Y;LE_@"X@7Z
MDV9RP^QY.&A5I[=F7=25,#QN(&#VT'Z&\CL8H9$=%YN?/;U::*#]#KOR">W3
MH]'CIT&C(<$G<+OK>3_=>L!NZ6D8 \$\(C&'EAGE23T0*'BGAA**/(X)*]23
M .%$Y4UDI=80P":HVD11ELX]&#Z8P<"4PX9;9VG_#T.(C4>B?4.G:2@](*>5
MG_X]_E(]"8/;0/3KH"8Q<28N44,R'^>GG(L'M"WV_9245/#@S)O*+-?BC3;Q
MI8F8_7(X?]]XZ\?8)4+\3^^EK5Y7S5(NP[Z3I^7AE8RA1^#B:EP8U'A>6B@2
M/U3$Q3K-$&KASW>D2,00":;'QA$DC4U&<V;;=W$7B=&S<=80HF@EO1Y#O#L1
M5_+LSTK=H%&B\YZC79D[9A.?5Q*!])%W0GX]+X,N 4?*/RIA0[T<NQU^O84.
M)!9*\?;4],B>WY<I^"Q-+I$ SGFVAK=IR YG] . .S^EQ\WIQ[!AA/FB(.[U
MTEC3.SZ+IXZ1GE%5.;EY>SQF20%**^-PEC:$/-[W[ZN,_RJM7+U]__[MU<>?
M+FF0I5B_QW\-D'TY$DT(5W)EH;H'BM3FN4:P<QJ]\()#'%,',93Y$87?18[?
MWJF'T!)PO/9^Z]-G>+:U8F:@NU)J?O4JTGVVFP:G9?@;"BF2 R!:JGA8 ER6
MNGL.5SZ#)6^2G7/OIJ-MR9K65;/XY-])=N/193!N,DL>I^+\K@)MH-F^>J*5
M^99%[E3;^30X.GY:[0GU382D]31[7% G&-N>GV'KU6=!3,$)^D<L\E&1WT?:
M";;P+MECO#U92P>4C%$?3Y\B0$:&5G'/E,OHE*HOHA^G?**YW*9._(I;:--K
M\"TO\5_T#B"M,2SQ$*4#%HGTL/(@.96SA>2U^\^Q_+9N*SKJN62?K "YF\:F
M .>D_<"6._$#9ZVN_:L"^#F%>GC!(3WH]Y5\>@ Y>HK>K:G\.S#T*EJPR6K'
M+4S?;1R^ZR?>U$A/\1&>)NXSN,%(W%O1JY2<RQ.=^:T]UU7TYC4=X8\OY34%
M=^O59--4+.$KZX<A8K)[/I1 WNF.PXY>])>><#&>J WO!=;T?(%A7O&&SO#&
M0O+B3Q;>V(O/;GO+_2#Y(P44S"7_*48 AO][A>'J\-<>E_Z/',;;_9^*?) 6
M]9/>\"OQZ.'L_'3/OV@8/W2FY3]Y6!@D<,V_THLYRM(-^+XTIHL?:('A;V!>
M_R]02P,$%     @ 28"J5K-.I2R;$P  ;3X  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&ULM5MI<]NXEOTK*'>J)UTEV9(=)TYGJ7*<=,>OL[B2=&:J
MIN8#1$(27BB"CR#MJ'_]G'NQ$*0HQ^GEBRV)6.YZ[@+PZ8VIO]BU4HWXNBE*
M^^Q@W335ST='-ENKC;2'IE(EGBQ-O9$-OM:K(UO52N8\:5,<'<]F#X\V4I<'
MSY_R;U?U\Z>F;0I=JJM:V':SD?7VA2K,S;.#^4'XX8->K1OZX>CYTTJNU$?5
M_%Y=U?AV%%?)]4:55IM2U&KY[.!\_O.+!S2>!WS6ZL8FGP5QLC#F"WVYS)\=
MS(@@5:BLH14D_EVK"U44M!#(^(]?\R!N21/3SV'U7YAW\+*05EV8XK]UWJR?
M'9P=B%PM95LT'\S-:^7Y.:7U,E-8_BMN_-C9@<A:VYB-GPP*-KIT_^57+X>[
M3#CV$XZ9;K<14_E2-O+YT]K<B)I&8S7ZP*SR;!"G2U+*QZ;&4XUYS7-P4\B%
MJ24)1YRO:J4@\L8^/6JP.HTYROQ*+]Q*QWM6.A%O3=FLK7A5YBKOSS\"59&T
MXT#:B^-;%WPKZT-Q,I^(X]GQR2WKG4163WB]DSWKO:]7LM1_2+*&B;@PI36%
MSJ4SCC(75[6R8-W]8);B%UW*,M.R$!_QHQ.+^-_SA6UJV-+_C4G($?!@G #R
MKY]M)3/U[*"BO>IK=?#\QQ_F#V=/;F'O063OP6VK?Y<F_]Q*XCR_EEF&T>*%
M-M5:PBLRU38ZDX45']L_UJ:%7 \GXDV3'XKWI7BI,K59J#JH<381S5IAS*:2
MY59@456K7.BR,4**9%^ODC<Z@_\G-, [FO5WTG'_QQ_.CH]G3^(L_CY_\M-$
MW*QUMA8WT@J)U6&VO"MT0PK/!:CX5XM='C'Q<W%_ST#'U7";CNJPX:'X'7-K
M'@W.-Y;,C+Z,S.E+:E7+DBB"G+JQ-$!]S8K6DIYJPA\:D*MK8&TU 4R4[1*F
MVM:*R<W,9J-JLFC]ATJ7)_KFCYY8$5;.,)Q<0XG+=^^G#\YF,Q:\+@/IM6Y,
MK14S<('?Y41\DOI&PK%>FW(E?J,_M.=;F<E6W ?48I)C )#%F PJMP(2]7+[
M%3$%*[OE@L1XC9,3(?-<DU7 &3/3E@WO#7+.K9:'B4AR@]]+TXBUO'8L1K&P
M"!%\%H4S*CL1!@-(&[*D 7*YU(5FQ4/^V(Z&$-N(9:/24E_)C:VH:FUJ<0.9
M-*H$?27!"*C"$UDW0<=9:MV3A&88K4D5G.I=@IERVBG9T\YB5'6#H"M>OCN/
M>NLTKB'_JC89Z%/V4'S"FFS*;,=LP^Q.M2JDWU;V*10+U=PH5?;)@382^S/B
MWP:^"S6"Z;S-&BRR*LP"6KI:(U2*$V'5BC?R0AB*, /VD-L*:!1_,2H:'-32
ML&M6A2Q+E3LF2**D^QL 1]R=?\QT!<+!=K!27I$HYK$@5OVGE06&6R"&,PY/
MK/<8)C0S%DB';*=;9((EH8"<%A]CHB]UMP"VLVU58;? 4&JFDKR<I;Y08MD2
M4;"D"I:C%X7BW;U$PYZ.&[#6<Y.4,HU=W=[$,VR3C9P&M.1YA^+2R65IVAH8
M"EG4M Y$#ILX[L--KBWVQ^8MH7-#JV!LR=);MHQ_:@DJ':->?)WJ"";%Q?O/
MER^G\\=BK3#7%&9E6BN0GUG:UDLB%<J-+LB[W;:CZS+X$SGFAC)""TY@X**]
M,ZBF #R*N=V/&YD3:HJV6M:@"3:V9?L8."CVNG=R.$-J5A3D-=#0OV .R&_9
MU5CJ ;S"W,&2?=%KZ]"G</91(X*2X[<5^R@66X':%4$S;8W<.]F\K8S3L<S6
M&L(+GF<KE>FEQHH8B9AE2D@M<7V:DOC !,]6+9X:<"$KP,BU]Z0T@L0\*:AG
MZ"9[B2A1:U@)0C ,6ER;(G<>%Q4]M'/>G-=,X\ U)P])- (%2T]PP(L@5C8N
M1EIXW)B I:C-5A;-UL&$0\0U@H>P8*A0TURO-'0&]BE)7+'\ 4PTMF,(A"OP
M30(DZ21!TR-W1^]V0L'HWXB$C@SV=F=!'-BOO=P@\THUSH!@-QNQT,9J*%+6
MA/ TC?>5'@9;>N#W)['AD8MSG0(R76?M!KE+F5%PZ"5&C&@&07(E@\W"3KUP
M&'E3-YU0CB0[YCQ!T\5V.OR-BB=M?=Y$U-$@3R<_FCC41<C9*EECY++QKKK4
MM6T2XV-A[^/9R[QO/Z9FVR"+QR<D$+KPZ5.EZVC)K"=IFVECIOR$XDWCH@*,
MC0P; 0[64NYP[*AQSQPAA^(%_I=E$I(\'R"^S$$PL0F>"Q3&P6?&.4W#XEYS
M$DA3K,YY]"!(##"6]-F/ZL&0J8H'OV078JD<Q,P/3R/ D((D^8 V.3U<DN>P
MMD(N3;-X$[A9!J/6C:2()E=8&9S1=ITI@1!^NMCV2&S6' V]9SC'VL?<-Q&]
M&8* #\N[1A]SD1H( -V[FB>5/=DN<!*B![_@ 9GA:MV+&=M>TATGDMPX/H<M
M6NM2<II!:1JGZ 7'6" [DZA5G?HF!89ACD"\#9-\SU[/9!JKBJ7@"363+-F!
MJ8Q-Y]<^\8C&!RHA7PHJN]*"$BQPF$@A>2&J.%F'!(TX*]7*-)118T.K\(0^
M1AF VJ/^?IYVV87K3^-J'>0*FBT3-LM@-(XNWNF[Q9"@(KG&:#)Z\K^ _QWX
M,:[:-N+YH7BE&4J)R2VS2!F'9J7ML4!Q7__4QW3Z9))ED(Z"&2Y8-F38FM.L
M14V!Q*=?*4DT4[F4Q^D;Y/DV5+I4E[\YI^W0W[NO@]=0M:!F@EF[Q0W;RGT-
MPF-&L9#EE[JMFFQ+SS3U3L!,M@VPF3#4RWGZ#K@K,=EY*N_5KZ4<50S=G6A)
MH!FL#T9&W*;)>\^<0HK"C3\NYYPH&E%@=B-*=EGN6?5"<2BL4'6IBF4^B?+(
M2,"J7''NHI#%%AI\(I2KDBU0+E!"-BPC9-"53Q*BE%PTL1UZ+_I(W"OOV]N!
M;81BJAE8ZCW@N)N92@?.C=[$^@,*UHI" 6LF$9<'@1WCZ:7&K#6V3O]84Z5L
MKC55#PN%/=1?#7FLE_G9-Z@BDV9C?]+MS\7ET#(A$U6H.D@)%8YK4Y14Y!O/
M3)!DDL^KKYPC5/2D:9Q6"WG33T 5;*5U"?<="A6O_/./%^*3J71FQ</90_;W
ML]D9Z0JIMC-.'Y0<62EG$>&IAN:@*GU#V2,'"X;5@!2\+4@I) )JKWC4&!!!
M-#BFDC;$4$MI<XAVAK@!1 P\TCF-*0NN, %/&4N-CQ;(SI*TDY&<,M1<%BA7
M0O(89=;Q?UNUERH \J#J)!518(/HC 1QCET94BE9X[+ET-JO\=- VT%S?[\E
ME=D0WYANH)C22I?O _&R;S@[]Y1 G\H#M[V:<UBB^I(F'Q:CHBI:JLSO'2>3
M8T48IR=-45?!Y0X HD%9O:* Z=CU\ND$UBTH-V1+OE=#33D=-!!;- ,Q3+R-
M;-T<!^^=^))V"4D$TS4WA@:=-N]JB7&D,<(7(*&^32KBN.8@;1S3X+"X)6A(
MEM+6!^ 5.S.)#T.H&\?)BI-9O_EEAY2%RAOAAVM*;.-4P\F,Q_Q#\<NW%4#@
MMJ \+3/0W!_.%6O*1MIOAAD"#T6U<^BSN$B?]<X(Z#1#UB#-9\B=L&NH>.52
M:0X((#S5W >E-XNVMIQ'@MU5+3>^BQ6JB(1J#*A,S?5_0\UC1C6.JRF(.)4S
ML<66O)5.6BAGIVB1JP($UQR1\[I=Q9P3A%-7D%NM9*(, Z-&&DJ.B(G.6DCZ
M]9AK4Q%UFG@<>Q:*OBQMOP0H&H=#:!FT!RM@JM;0D ]\PIU(O&4-A ,SYLAU
M]CC+=<J^8<5'@3*34>V<N$$]I3\QC>(=Z1Q_VT,&C6#7P*1F!BRS:PC++J7G
MKF&V<P9$P)'4*[='LG[\VD/[3EQ#3.U,T==]?=$X/.H[D"-I&FT_M7O??A4^
M>Z;$S.4N63QVQ!<;SA5)&L@6:Y_B&](^%BW].5,X,?'))4O*VI:[NB]=1+J+
M30R:O#%,4$>7UG#5_G%7[?=%$!OR)(8Z'Q?"$ "\((#1%34Z7FB#_>LJ*#@]
M(SQ^3%3.']UV1HA*-#E_^Q .ZL(Y(?W8/T5,ZC!:]: C(SXY^&GBCQ5'2;S?
MS8DC04?,#D7NF[%.UG3&"2[.]I_U[5+0YY@*T_2\+XZ__;QOY(CO\Z__,SV9
M<V<6%DT'17JS:4M&<%EM8^^J.^[+%05W#TO49\$8-<T(CFHH6[:^:'E]]7F2
M=C?]@88K%[L,L)\1?6]KN\/,"4HV:T-CAHP!C"I' ;6/V7I#:&KD5^K/_)5F
M^%C_&U.#/+G9EY$3,$Y'G!Q1;3QV";4_1-HM8V.WFO%J(^LOBI*&D;;5GK9U
M:%KXY,WR%97<I<\H>6M7[]_2LO86S0E,,G*ADKYE86ZFM.E&Y]-&J=+>L76-
MY$<A!/9:V,.N;2SF$HCX_CXTBV\^^Y.=XZ2'^G?UB7L%:]JFIP>="2;<?QHW
MH'VM+M_.BA/NTL[Z=O]J9/\[]*YVVE8NTW(]*3]_D*)I3DO=M#NWMX(4[)_I
M:0W:4AVK=Q-#VA]9Q,8^9=G<QN],;A 8F%*.MM0O=:CT>(9G6WM[_X3+FAA6
M8EK'W+@6WT+Q7%>/+5%)<.VW-Z%.$OTQG+HP"!I-Z/*_JE"X;^"[5S4U;E7.
M39#+L@06.D6ER(X@<:U-:XMAO.[N#C'*7+RZNIR("O2UTIVENHJF=P!*)Q"Y
M0[D0VG;NI=AXHO &F9 42PQT!O/VU8>/SIE6QJ%V,[Q\L?=J Y''&0[?4G$W
M&O9F-M8X--?E-:*(MU]"F,9D7RH*+>(FM%7HNN36M=5"S0<SP?]LZQ/CAM:
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MLO06^.&!'E_4SH#V=TK9T\01C,_Y\F]02P,$%     @ 28"J5O7^(H^T P
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M J\+N*TMK]=B*1'FQJ U</'(23*7D\A2,.<2Y7O@10O,?@*<PIVJ;6G@M[K
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MO>$^W2Q,>VDX<F&)(AN%&>VVV+]X3W3HHW P.-S%<2A2L; _H'Q[(Q)83.=
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M-3/Z#: T#K2^%E1&[<!LT/U8XM]02P,$%     @ 28"J5I@=P# K P  T@8
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M\QKM]9T&]=IW5P,>V;>@879HX*=]WWI([[L_':HUEX;DK0@:CR;C '3?4?O
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MY6@M\X#0.7=35I>U$L1WKA V*-,\1)1Q#IW?=:7%J_UTF'+Q<K:-'D!3R*R
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M34+K#?A^:0RM-YZ@_\K-_@)02P,$%     @ 28"J5O/S8!C4 P  . \  !D
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M"T)WP.=KSM7KA1Z@+987_P)02P,$%     @ 28"J5J@SJ7P" P  2PL  !D
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M8!HV"*9AJ$R#I<WV&3 -ZX5I6!-56DI:#LDS-2T&6,/\6-,]!U!V*OQ6=0X
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MG6_J1QO.<JWS=?URI>*%*BH!\_TR-XBV?U,]+?'P=,S[_P-02P,$%     @
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MX<@[@'?W&IOYJ&"G6!5<D1*6**47EU@ V3;J=J)%;7O=0FCLG':XQF\;2!.
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MRZ'3<]@,YCQ+\%9MOD/IIVWYIBHQ^9-MRES/8=/,H$I+,"E(A2S>_*&LPQ;
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M!$Q-D.\7E(JWCJJURV\K_R]02P,$%     @ 28"J5B>+U(S'"   "5H  !D
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MY'GU<,GHG G]!O7Z(^?R]8EN8'OWY^GO4$L#!!0    ( $F JE:1G)!. 00
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MLLP<KC%*,-<3U/4E4T]4-= WJ%N7LW\!4$L#!!0    ( $F JE8\PZEOZ0(
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M,VLR;!?SD(?F(V$!"-9*\*A.\,B88-4OB>DBXS3OYA"ZYHRIWI-\3ZCZ4*V
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M[Z&84#_EA3R2V6_RD+<=#%LDW$K%XR)8CR!F2?Z7?B\NQ$& XYP(L(L ^RC
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M>]!J!UKLF[/*6F@X^32W.SB<,FDFP/N-$/IY8(X__7%W^2]02P,$%     @
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MG0^UV[G7[$/4QG153/+BWICEV5T^R^LGU6:OA4[=[$G,)C&'Q%P2\TC,)[&
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M965T-34N>&ULM=UK;]IH&L;QKV*QJ]6,U G8!D*R"5(G/MN=B=J=W1>K?>'
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M"&M$]?P0U?-WV6P\)U-+8@:)F21FD9A-8@Z)N23FD9A/8@&$-5([.:1V(EW
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M[-0-Q4MS_+_E"B\3YC'%"R((/0''-YRK^X9>H+UR1C\ 4$L#!!0    ( $F
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !)@*I68K$=S)D$  !X)0
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $F JE9 .\Z8^ 4  +P?   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !)@*I6+BEA^]P&  !V'0  &               @($[#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 28"J5IXM\^A0!0  Q10
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M965T-RYX;6Q02P$"% ,4    " !)@*I6WAM<)_\&   6#P  &
M    @($3-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M28"J5@3R$R O"0  QA@  !@              ("!2#L  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $F JE:*<K3!RPD  $D:   9
M          " @:U$  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#
M%     @ 28"J5ISB0X"I @  ZP4  !D              ("!KTX  'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !)@*I6TVT*C?(*  #=
M.0  &0              @(&/40  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+ 0(4 Q0    ( $F JE;<,%E8(0,  !4'   9              " @;A<
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 28"J5@RI
M9LUD!   LPH  !D              ("!$&   'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"% ,4    " !)@*I6;/2.AI@)  #)%P  &0
M    @(&K9   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M $F JE97HLQ6P@<  )05   9              " @7IN  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 28"J5GG[_W,5!0  ,0P  !D
M             ("!<W8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !)@*I6K#]^L;P%  "Q#P  &0              @(&_>P  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $F JE:R5.6%8P8
M +(0   9              " @;*!  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 28"J5B4I5VCT$   #S,  !D              ("!
M3(@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !)@*I6
MLTZE+)L3  !M/@  &0              @(%WF0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $F JE8#\"%6W@,  &@(   9
M      " @4FM  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 28"J5EQ;>?S$"P  ]RD  !D              ("!7K$  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !)@*I6$O'! T80  !)+P
M&0              @(%9O0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( $F JE;9"3I4<04  ),/   9              " @=;-  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 28"J5E=E@L-=
M P  V@<  !D              ("!?M,  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !)@*I6]?XBC[0#  !C"   &0
M@($2UP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $F
MJE;,GWXL/@,  $L'   9              " @?W:  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 28"J5KNV8J7% @  9 8  !D
M         ("!<MX  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !)@*I6F!W ,"L#  #2!@  &0              @(%NX0  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $F JE81DN/ZRP(  .@%
M   9              " @=#D  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ 28"J5N:V&)P8 P  X@8  !D              ("!TN<
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !)@*I6[NR>
M8A4#  #Q!@  &0              @($AZP  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( $F JE;S\V 8U ,  #@/   9
M  " @6WN  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M28"J5J@SJ7P" P  2PL  !D              ("!>/(  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !)@*I6M$7\<6 &   X*0  &0
M            @(&Q]0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( $F JE8<M<H:A@,  !4,   9              " @4C\  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 28"J5FS3DG^A"
M*5,  !D              ("!!0 ! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !)@*I6:5?QS+ "   Y!P  &0              @('=
M" $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $F JE;M
M()$CQ 0  +$;   9              " @<0+ 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 28"J5M]:T<]K!0  4B(  !D
M     ("!OQ ! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M" !)@*I6F:@/\#D#  ">#   &0              @(%A%@$ >&PO=V]R:W-H
M965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $F JE9>A%/86@<  +L^   9
M              " @=$9 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L!
M A0#%     @ 28"J5H$9Y^&J @  ;P8  !D              ("!8B$! 'AL
M+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !)@*I67LJH9<T"
M   7"@  &0              @(%#) $ >&PO=V]R:W-H965T<R]S:&5E=#0U
M+GAM;%!+ 0(4 Q0    ( $F JE;CTN3K.@,  &<-   9              "
M@4<G 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 28"J
M5B>+U(S'"   "5H  !D              ("!N"H! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !)@*I6D9R03@$$  #&%   &0
M        @(&V,P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( $F JE8\PZEOZ0(   X(   9              " @>XW 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 28"J5HV>+)!2!0  YQT
M !D              ("!#CL! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " !)@*I6=#@H_S$'  "]0   &0              @(&70 $
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $F JE8[S=;0
M%P8  - R   9              " @?]' 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ 28"J5MI986K3 P  ^@X  !D
M ("!34X! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !)
M@*I6_W7NF]$/  "4_   &0              @(%74@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( $F JE;5CK4XZ@D  -B#   9
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M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !)@*I6##^0_.4!  !_(0
M&@              @ %4>0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !)@*I6C^&W:=,!   V(0  $P              @ %Q>P$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0 !  '<1  !U?0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>231</ContextCount>
  <ElementCount>298</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognition</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails</Role>
      <ShortName>Convertible Debt - Balance of Convertible Bonds and Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsReceivableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ino-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ino-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsReceivableRelatedParties in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ino-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ino-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ino-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash, ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares, us-gaap:DebtInstrumentConvertibleConversionRatio1 -  ino-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ino-20230331.htm">ino-20230331.htm</File>
    <File>ino-20230331.xsd</File>
    <File>ino-20230331_cal.xml</File>
    <File>ino-20230331_def.xml</File>
    <File>ino-20230331_lab.xml</File>
    <File>ino-20230331_pre.xml</File>
    <File>ino-3312310qex312.htm</File>
    <File>ino-33123x10qex311.htm</File>
    <File>ino-33123x10qex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="592">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 592,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 231,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 489,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://www.inovio.com/20230331": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 57,
   "keyStandard": 241,
   "memberCustom": 33,
   "memberStandard": 31,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inovio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Critical Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "shortName": "Critical Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Revenue Recognition",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.inovio.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Short-term Investments and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Certain Balance Sheet Items",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItems",
     "shortName": "Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Convertible Debt",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.inovio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Collaborative Agreements",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Geneos Therapeutics, Inc.",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Certain Balance Sheet Items (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsTables",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Convertible Debt (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Revenue Recognition (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.inovio.com/role/RevenueRecognitionDetails",
     "shortName": "Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i27c48d2543c3428ca9348a16927aa3ef_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "icc54f897c91449868d75304b60ed52b5_I20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EstimatedInsuranceRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
     "shortName": "Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EstimatedInsuranceRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
     "shortName": "Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Convertible Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "ib8aaaf9aae3a42b0aa4f04a120058d05_I20220101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i8e9a53ecc8b54b91ad4b62780f74c439_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
     "shortName": "Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i8e9a53ecc8b54b91ad4b62780f74c439_I20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i8e9a53ecc8b54b91ad4b62780f74c439_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7351252adfb6481e91a3344a5a0f071d_I20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i5dcce6012ae249d88a84eed499079c98_I20160513",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "id4156dde7c464886a817b59bf0c375b0_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.inovio.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "id4156dde7c464886a817b59bf0c375b0_D20230101-20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i06a9a0ba408648df83848a10938d69f5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i06a9a0ba408648df83848a10938d69f5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i16d63252834144b0aacf7c65dae0426e_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementAmendedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i7e013b80260c4d9089f646bfa59fe02d_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Collaborative Agreements (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i4728bba8ed0e4a32bf8f4a33d626dd3f_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0284cde70d5b460295a267e2aa3f9418_I20200630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.inovio.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20230331.htm",
      "contextRef": "i0bd1d93be9f4496b858e5fe45c449087_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2022InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Inducement Plan",
        "label": "2022 Inducement Plan [Member]",
        "terseLabel": "2022 Inducement Plan"
       }
      }
     },
     "localname": "A2022InducementPlanMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccountsPayableAndAccruedExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Expenses [Line Items]",
        "terseLabel": "Accounts Payable and Accrued Expenses [Line Items]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesLineItems",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_AccountsPayableAndAccruedExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Expenses [Table]",
        "terseLabel": "Accounts Payable and Accrued Expenses [Table]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesTable",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AdvaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advaccine",
        "label": "Advaccine [Member]",
        "terseLabel": "Advaccine"
       }
      }
     },
     "localname": "AdvaccineMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AllOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Customers",
        "label": "All Other Customers [Member]",
        "terseLabel": "All Other Customers"
       }
      }
     },
     "localname": "AllOtherCustomersMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AnnualMaintenancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Maintenance Period",
        "label": "Annual Maintenance Period",
        "terseLabel": "Annual maintenance period"
       }
      }
     },
     "localname": "AnnualMaintenancePeriod",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation [Member]",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill and Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA2000DeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 2000 Device [Member]",
        "label": "CELLECTRA 2000 Device [Member]",
        "terseLabel": "CELLECTRA 2000 Device"
       }
      }
     },
     "localname": "CELLECTRA2000DeviceMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "label": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CertainBalanceSheetItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Balance Sheet Items",
        "label": "Certain Balance Sheet Items [Abstract]"
       }
      }
     },
     "localname": "CertainBalanceSheetItemsAbstract",
     "nsuri": "http://www.inovio.com/20230331",
     "xbrltype": "stringItemType"
    },
    "ino_ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Accrued Expenses Related To Issuance Of Common Stock For Legal Settlement",
        "label": "Change In Accrued Expenses Related To Issuance Of Common Stock For Legal Settlement",
        "terseLabel": "Issuance of common stock for the legal settlement"
       }
      }
     },
     "localname": "ChangeInAccruedExpensesRelatedToIssuanceOfCommonStockForLegalSettlement",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "(Gain) loss on equity investment in affiliated entity",
        "verboseLabel": "Gain (loss) on investment in affiliated entity"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementPaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Payment Earned",
        "label": "Collaboration Agreement, Payment Earned",
        "terseLabel": "Collaboration agreement, payment earned"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentEarned",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Amended Amount",
        "label": "Collaborative Agreement, Amended Amount",
        "terseLabel": "Collaborative agreement, amended amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAmendedAmount",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedExercisedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Exercised Amount",
        "label": "Collaborative Agreement, Awarded Exercised Amount",
        "terseLabel": "Collaborative agreement, awarded exercised amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedExercisedAmount",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Option Amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "terseLabel": "Awarded option amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received",
        "label": "Collaborative Agreement, Funding Received",
        "verboseLabel": "Funding received for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingReceived",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Agreement, number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementRevenueFromTheProcurementContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "label": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "terseLabel": "Collaborative arrangement , revenue from the procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueFromTheProcurementContract",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Accrued Interest",
        "label": "Debt Instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual Maturity\u00a0(in\u00a0years)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entity"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Of Defence [Member]",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Estimated aggregate amortization expense for 2028"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GainLossOnRemeasurementOfEquityMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Remeasurement Of Equity Method Investment",
        "label": "Gain (Loss) On Remeasurement Of Equity Method Investment",
        "negatedTerseLabel": "Gain on remeasurement of investment in Geneos"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfEquityMethodInvestment",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, Gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, Net Book Value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INO-4800 [Member]",
        "label": "INO-4800 [Member]",
        "terseLabel": "INO-4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "negatedLabel": "Loss from equity method investment, recorded and allocated to investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability, including from affiliated entity"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_JJosephKimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "J. Joseph Kim",
        "label": "J. Joseph Kim [Member]",
        "terseLabel": "J. Joseph Kim"
       }
      }
     },
     "localname": "JJosephKimMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever and MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Area leased (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_LesseeOperatingLeaseNumberOfAgreementsToSublease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "label": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfAgreementsToSublease",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_LicenseWithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License With Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements with affiliated entities"
       }
      }
     },
     "localname": "LicenseWithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LossContingencyEstimateOfPossibleLossValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Possible Loss, Value of Shares",
        "label": "Loss Contingency, Estimate of Possible Loss, Value of Shares",
        "terseLabel": "Estimate of shares settlement"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLossValueOfShares",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim",
        "label": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]",
        "terseLabel": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim"
       }
      }
     },
     "localname": "McDermidVInovioPharmaceuticalsIncAndJJosephKimMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Income (Expense)",
        "label": "Non-Cash Interest Income (Expense)",
        "negatedTerseLabel": "Non-cash interest on senior convertible notes"
       }
      }
     },
     "localname": "NonCashInterestIncomeExpense",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "terseLabel": "Number of potential shares authorized for issuance under share based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_PlumblineLifeSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences Inc",
        "label": "Plumbline Life Sciences Inc [Member]",
        "terseLabel": "Plumbline Life Sciences Inc"
       }
      }
     },
     "localname": "PlumblineLifeSciencesIncMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PrepaidManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Manufacturing Expenses, Current",
        "label": "Prepaid Manufacturing Expenses, Current",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpensesCurrent",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "terseLabel": "Sale of stock, sales proceeds of any common stock, percentage"
       }
      }
     },
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SalesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreements [Member]",
        "label": "Sales Agreements [Member]",
        "terseLabel": "Sales Agreements"
       }
      }
     },
     "localname": "SalesAgreementsMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego Office [Member]",
        "label": "San Diego Office [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoOfficeMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_SeriesA2OnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 One Preferred Stock",
        "label": "Series A-2 One Preferred Stock [Member]",
        "terseLabel": "Series A-2 One Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2OnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A One Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "verboseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "terseLabel": "Maximum contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Cash",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Cash",
        "terseLabel": "Settled in cash percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInCash",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percentage Settled In Shares",
        "terseLabel": "Settled in shares percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsPercentageSettledInShares",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Stock sale agreement weighted average price (in dollars per share)"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Maximum authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TheWistarInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Wistar Institute [Member]",
        "label": "The Wistar Institute [Member]",
        "terseLabel": "The Wistar Institute"
       }
      }
     },
     "localname": "TheWistarInstituteMember",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.inovio.com/20230331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r318",
      "r347",
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r160",
      "r207",
      "r214",
      "r220",
      "r272",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r453",
      "r456",
      "r458",
      "r459",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r160",
      "r207",
      "r214",
      "r220",
      "r272",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r453",
      "r456",
      "r458",
      "r459",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r160",
      "r207",
      "r214",
      "r220",
      "r272",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r453",
      "r456",
      "r458",
      "r459",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r255",
      "r626",
      "r692",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r382",
      "r542",
      "r571",
      "r602",
      "r603",
      "r623",
      "r634",
      "r640",
      "r689",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r382",
      "r542",
      "r571",
      "r602",
      "r603",
      "r623",
      "r634",
      "r640",
      "r689",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r255",
      "r626",
      "r692",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r253",
      "r544",
      "r624",
      "r639",
      "r684",
      "r685",
      "r692",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r253",
      "r544",
      "r624",
      "r639",
      "r684",
      "r685",
      "r692",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r374",
      "r382",
      "r409",
      "r410",
      "r411",
      "r518",
      "r542",
      "r571",
      "r602",
      "r603",
      "r623",
      "r634",
      "r640",
      "r682",
      "r689",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r374",
      "r382",
      "r409",
      "r410",
      "r411",
      "r518",
      "r542",
      "r571",
      "r602",
      "r603",
      "r623",
      "r634",
      "r640",
      "r682",
      "r689",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r601",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r601",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r318",
      "r347",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r673",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r602",
      "r603",
      "r730",
      "r732",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average Useful Life (Yrs)"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r208",
      "r209",
      "r210",
      "r258",
      "r259",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r436",
      "r437",
      "r438",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r134",
      "r151"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r122",
      "r124",
      "r148",
      "r175",
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r122",
      "r124",
      "r175",
      "r666"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r15",
      "r608"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r176",
      "r567",
      "r579",
      "r583"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r107",
      "r505",
      "r574",
      "r575",
      "r656",
      "r657",
      "r658",
      "r668",
      "r669",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r638"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "negatedLabel": "Additional paid-in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r668",
      "r669",
      "r670",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r208",
      "r209",
      "r210",
      "r211",
      "r220",
      "r258",
      "r259",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r418",
      "r419",
      "r420",
      "r427",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r438",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r101",
      "r102",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r45",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense on intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r144",
      "r170",
      "r199",
      "r243",
      "r247",
      "r251",
      "r268",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r444",
      "r446",
      "r469",
      "r638",
      "r687",
      "r688",
      "r728"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r164",
      "r178",
      "r199",
      "r268",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r444",
      "r446",
      "r469",
      "r638",
      "r687",
      "r688",
      "r728"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r261",
      "r280"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r260",
      "r280",
      "r563"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Debt securities, available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r52",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation, Liquidity and Risks and Uncertainties"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of fixed assets"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r47",
      "r166",
      "r606"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r42",
      "r47",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r42",
      "r116"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r199",
      "r223",
      "r224",
      "r226",
      "r228",
      "r235",
      "r236",
      "r268",
      "r304",
      "r307",
      "r308",
      "r309",
      "r313",
      "r314",
      "r345",
      "r346",
      "r349",
      "r353",
      "r360",
      "r469",
      "r604",
      "r647",
      "r663",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "verboseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements and Revenue Recognition"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r439",
      "r440",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Product"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r297",
      "r298",
      "r600",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r668",
      "r669",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common stock, other shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r638"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r106",
      "r111",
      "r182",
      "r184",
      "r189",
      "r564",
      "r568"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r3",
      "r128",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r1"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r80",
      "r315",
      "r316",
      "r327",
      "r328",
      "r329",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r345",
      "r346",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Cost, Maintenance",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r197",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r331",
      "r338",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r127",
      "r128",
      "r142",
      "r203",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r488",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r81",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r18",
      "r88",
      "r91",
      "r93",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r118",
      "r120",
      "r315",
      "r488",
      "r619",
      "r620"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Original principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r17",
      "r118",
      "r343",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r17",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r203",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r488",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r19",
      "r88",
      "r92",
      "r93",
      "r94",
      "r117",
      "r118",
      "r120",
      "r141",
      "r203",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r488",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r117",
      "r120",
      "r690"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "terseLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Realized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r264",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "verboseLabel": "Gain on deconsolidation of investment"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Remeasurement of Geneos Series A-1 preferred stock"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r119",
      "r690"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r45",
      "r75"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r371",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r386",
      "r414",
      "r415",
      "r417",
      "r421",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r12",
      "r306",
      "r307",
      "r308",
      "r312",
      "r313",
      "r314",
      "r509",
      "r666"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r133",
      "r152",
      "r306",
      "r307",
      "r308",
      "r312",
      "r313",
      "r314",
      "r509",
      "r666"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Accounts payable/accrued liabilities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r190",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r221",
      "r223",
      "r226",
      "r227",
      "r228",
      "r232",
      "r459",
      "r460",
      "r565",
      "r569",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r190",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r223",
      "r226",
      "r227",
      "r228",
      "r232",
      "r459",
      "r460",
      "r565",
      "r569",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r87",
      "r160",
      "r185",
      "r186",
      "r187",
      "r204",
      "r205",
      "r206",
      "r209",
      "r217",
      "r219",
      "r234",
      "r272",
      "r361",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r458",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r505",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r61",
      "r244",
      "r648"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Investment in equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r171",
      "r468",
      "r607"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r171",
      "r468"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "verboseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r570",
      "r677"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Net unrealized (gain) loss on available-for-sale equity securities",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.",
        "label": "Estimated Insurance Recoveries",
        "terseLabel": "Insurance recovery"
       }
      }
     },
     "localname": "EstimatedInsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r329",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r463",
      "r515",
      "r516",
      "r517",
      "r619",
      "r620",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r329",
      "r375",
      "r380",
      "r463",
      "r515",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r329",
      "r375",
      "r380",
      "r463",
      "r516",
      "r619",
      "r620",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r329",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r463",
      "r517",
      "r619",
      "r620",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r329",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r515",
      "r516",
      "r517",
      "r619",
      "r620",
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r262",
      "r263",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r284",
      "r340",
      "r358",
      "r448",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r616",
      "r674",
      "r675",
      "r676",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r168",
      "r293"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated aggregate amortization expense for remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Estimated aggregate amortization expense for 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "Estimated aggregate amortization expense for 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Estimated aggregate amortization expense for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r545",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r70",
      "r549"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r70",
      "r545"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, Net Book Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedTerseLabel": "Realized loss on short-term investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r167",
      "r285",
      "r562",
      "r617",
      "r638",
      "r680",
      "r681"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "totalLabel": "Goodwill, net book value",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r287",
      "r289",
      "r617"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r45",
      "r286",
      "r288",
      "r290",
      "r617"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r45",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r243",
      "r246",
      "r250",
      "r252",
      "r615"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r28",
      "r45",
      "r61",
      "r135",
      "r153",
      "r242"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Share of net loss in Geneos",
        "terseLabel": "Share in net loss of Geneos",
        "verboseLabel": "Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r424",
      "r425",
      "r426",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses, including due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, including from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r543",
      "r661"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue, including from affiliated entity"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets, including from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r65",
      "r68"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r119",
      "r137",
      "r188",
      "r241",
      "r487"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r34",
      "r335",
      "r344",
      "r621",
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, contractual interest"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r192",
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization of (discounts) premiums on investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r155",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r125",
      "r138",
      "r156",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r498",
      "r637"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r725"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r199",
      "r268",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r445",
      "r446",
      "r447",
      "r469",
      "r614",
      "r687",
      "r728",
      "r729"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r129",
      "r147",
      "r638",
      "r665",
      "r678",
      "r723"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r165",
      "r199",
      "r268",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r445",
      "r446",
      "r447",
      "r469",
      "r638",
      "r687",
      "r728",
      "r729"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements, including from affiliated entities"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r20",
      "r683"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Amount paid to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r128",
      "r145",
      "r328",
      "r342",
      "r619",
      "r620"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r78",
      "r203",
      "r333"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r19",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r299",
      "r300",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of cash settlement"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r22",
      "r32",
      "r105",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r42",
      "r43",
      "r46"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r46",
      "r136",
      "r154",
      "r163",
      "r181",
      "r183",
      "r187",
      "r199",
      "r208",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r225",
      "r243",
      "r246",
      "r250",
      "r252",
      "r268",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r460",
      "r469",
      "r615",
      "r687"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r53",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r220",
      "r232",
      "r258",
      "r259",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r418",
      "r419",
      "r420",
      "r427",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r438",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r243",
      "r246",
      "r250",
      "r252",
      "r615"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r662"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r497",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r496",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r134",
      "r151"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r179",
      "r180"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax",
        "verboseLabel": "Unrealized loss on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Certain Balance Sheet Items"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r653",
      "r679"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Investment in Geneos",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r638"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expense and other assets, current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r132",
      "r150",
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid balance"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r660"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of capital assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "verboseLabel": "Proceeds from sale or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r100"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r76",
      "r149",
      "r566",
      "r638"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r381",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r381",
      "r508",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r506",
      "r507",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r103",
      "r157",
      "r736"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses - Clinical Trial Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r95",
      "r146",
      "r578",
      "r583",
      "r638"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "netLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r160",
      "r204",
      "r205",
      "r206",
      "r209",
      "r217",
      "r219",
      "r272",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r458",
      "r574",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r239",
      "r240",
      "r245",
      "r248",
      "r249",
      "r253",
      "r254",
      "r255",
      "r370",
      "r371",
      "r544"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from related parties",
        "verboseLabel": "Revenue from collaborative arrangements and other contracts"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Summary of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Summary of Intangible Assets by Major Asset Class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r383",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r83",
      "r85",
      "r86",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r172",
      "r173",
      "r174",
      "r235",
      "r345",
      "r346",
      "r347",
      "r349",
      "r353",
      "r358",
      "r360",
      "r623",
      "r647",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r84",
      "r85",
      "r86",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r650",
      "r651",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r130",
      "r131",
      "r143",
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Critical Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r199",
      "r223",
      "r224",
      "r226",
      "r228",
      "r235",
      "r236",
      "r268",
      "r304",
      "r307",
      "r308",
      "r309",
      "r313",
      "r314",
      "r345",
      "r346",
      "r349",
      "r353",
      "r360",
      "r469",
      "r604",
      "r647",
      "r663",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r87",
      "r160",
      "r185",
      "r186",
      "r187",
      "r204",
      "r205",
      "r206",
      "r209",
      "r217",
      "r219",
      "r234",
      "r272",
      "r361",
      "r418",
      "r419",
      "r420",
      "r429",
      "r430",
      "r458",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r505",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r234",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r87",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for legal settlement and cash, net of financing costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r5",
      "r6",
      "r87",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r87",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for legal settlement and cash, net of financing costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r5",
      "r6",
      "r95",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r56",
      "r638",
      "r665",
      "r678",
      "r723"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r198",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r361",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r262",
      "r263",
      "r340",
      "r358",
      "r448",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r674",
      "r675",
      "r676",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r208",
      "r209",
      "r210",
      "r211",
      "r220",
      "r258",
      "r259",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r418",
      "r419",
      "r420",
      "r427",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r438",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r485",
      "r486",
      "r489",
      "r490",
      "r491",
      "r492",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r612",
      "r631",
      "r633",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r222",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r642": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r643": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r644": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r645": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r646": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001055726-23-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-23-000030-xbrl.zip
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M'ACXWA2^W#]+)-^\!-.SS&TKO,O+WG3)?M78TVW7WNKL 'GJ)VM7=;)[TM@
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MC%,%4B(4!N]88J#D/*Q\S0?)QKA8&4(JF^&$XHZ!$M5@^J3BR,12)@BROX/
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M@<0<R*HEK&9/6A%EJ O<6@U.C\0!/!WA*!)6Q.B1%[.?S_D5#_G9UN<F<WP
MCLP';[V/FBF=CGH01$J.&)<(;-\Y4"*S0I_IBVXD(J8>R50SE05'K6>**F P
M,!2XF@LW=":).16!"3X"Y335B\.,:><-E2@P 0RK.$)R'H[T^8X>;G0[(U6\
MB-PHD4!$>(L9(6"?4R,]3\6+C,&2Z3 /RTXS0\"I<"!5X$H)B9T$MF-(*AJM
MP9JQZ(FC=!Y"08F ZZG,7RC.8,JN[N]\6/#CZYQTS@0-;K%-1V6#(Z.IY%X'
M9R.3:'8MSD2UG0MP$<KC_.R67.];_;9MY9WP+H]AS^6AXR9\UOP8BP"F8ZJ<
M\4(;Q#!V5N*HL>#2,0GF?Y@37GI?='W?]7:*85+O+7'>50=2A4]Y[W@MQKR5
M VK]9AKY@F95N*I2FE<>_#GX@^&#=UIABD(@F,]#3'-V*3H=%]U%+8U3+E+#
M;!0FL@C,B0T/"&D\P^<7?5O-/;_<'%]Y-65!8"(=F9."(>V4]#@M33D1P:&3
M<;:5V"S19(SG?#G",$(Q8 +&H,56F1"L):DL"<&#U1PLTFD#M<&'V2/.K3_=
M2E+M?2)0LS"=TK@4K2S?7-V]<GMTR2A<.EGQE^K'T*>)OT'3\=B+F.N8SBL!
M$C*N@HTQ&$T5">"" Q4KA89&"@W-HAS\&;(F;FP>@YI+LYS*T>:]?F_2_AQZ
MNGY#]V7IK_ASQ%E!=?3,4$:#T @4'">6<V!C^#0'-NC<$'@ZR^S&JH"=)SH@
M%C$UW(+"C""4'3'&+2J!GT\P3RFL;=->9*2XX@'(BDSPC$AF''P);IB2,]N>
MQHR3=3I[S(WSH&IYH&!/!1D-V+=5O1VG72HXLJ!DG8HXGDZ"J[5&H(@PV,8,
M_C+66B8U$MI$K>(<''@SBW2=B$LCG49>2ZML((Q@HW&4-!H2,.?4:#*[KO^<
MD&I\$0%*:;3$.* 4&+(VV("EA_F,G"*E_3P8.=69F,&T-LN4)I.R8)SKM_L5
MF3;"&:B\O$J:V0BE*_*SP5ZF]T479NDN"?=,9R,/1]V=&'.W* ;MS9%TY;]C
M[XLSZ?J]XE6Z,+KYR8?2.1I,H,(%I2,CQNL@./BT!G$OG33F]T'-^]95N]OO
M'==#J([("IU.>=4Z-YW<+ B$[@<0!5*1\2 Q%<P+;V5DC/M@>2#"QQD^(.N1
MDW/K>2=O]R>P6CF9W"I'JVBZ8"JD9$H=B9'4JFALRJ<D\S7UYG*.IAYL%J73
M]LVTQ0IY9C&B#IQ&%U%D( H')\-B- C1ZN<P;'XT!JIK&#TQ!JI_)41VHW#,
MJ$[[HR>AWES]8=6C(YC\$1D:16 "$:.#<L:"M2*IXI1-@1:_F^IY-C#=#\<I
ME_+6+! [L'0*,P+'SW/'#= >QX'\ \:<O1.!$KW?Y;W\J*+JNBGOK%S5W48H
MVKG_N-WIGN?=]\>F:!L7^KW<F5:YW7$ CTDFUMR1E[A:)M'C4%62*'#05? (
M5!4E-H+18"CU HP$3^/@%*>1>0C_S!Z/CAS!E#2Z$]>*(NFO=._#X@:MEK'=
M0;[]G5;CV)7T]>7.-7]NG,L[D_92\---S*KI>.IK8"DP#5RAH,$CU4HR'!0\
M0A)M?)@'CW0)GFGY)YA$AQU')"K-B)7I %]'+??*!JN4F*-5U]\:/%-9T053
M @DCL"?4,!JQXD3B0*5--1747.3(SP!X'D^!NSDC=I &MQ@HG<[Q=((Y+JW"
ME#+F0,01::VB%G$GP!?2<[30]5N+N.EL R)4,8I11%*#B$.*<AEC2K4UC&DZ
M3\?\S"9XSN"QW3=Y=Q$ECS3,2,4%9@JQ0)#R0BMO&%CF4E!1':V*X=(@] (?
M*%J"YP? L]XUK3R%"&*WV#R#UVSG[GT1H&7PG5"6VYU.][R*(?SR_O+OY*J;
MLC1;X3P4:QU?W]S=^_@<$A&K&F)/#"M532D: ZB-T)$SPKE*NR$9-P0\!RV$
M!_L/(S]/YP4O03U[H)Z6&\P=]]HA$00# U$+27B$OYG&8"S.4R7!):AG$-33
MJ:4&)BLV!DS7=$0E]Y8H&CFM"H%0$F=X\\H2R[.%Y8DL$ANE$)%18^8H$UYI
M91 -2KJ@P.5R[D'H<;GH,:\XW6[L@ .$9BD".JZU%R$4#\(C@R08PR[MKG86
M3&*#HR!B>% 7&GIXZ</2PYL2AL< KR?Z6H.F8_&U! %)*$@PAA, %C9!I)/O
MK3:*86'#$EZ_)IG6-]^]VUQO[J[1]WOO4\)(D0<@[-5>.U$WG'\_KW6)[U_:
M\ZFULT$$AFEDZ;S+8!PW:=^8U(1SL<3WK,!K7DR Y\>P ;!Z&PCRB#+FA6;>
M(!^CUC;@P,0R'K;$\*R'OP@1GM@@<9"4(6<T<V#8,B8,(%CI>2@FL\3P[&!X
M.F>>4A>\1CZ O<P()YI8@[@68%<([6A81KN6T'V^X!;UC%D7+,*2,,G!<],&
M0!BQTS)2-%SZ'67=PX<E+'\(#1N-M<V.Z_K@Z]U.U[6ZG53/NY?;KK]J!G?<
MZ;:Z1U>398TW>2O5$*^'5M[QYBW(K7(+&GLS^6/IL7KZCH*JZ9AJTV-#F%8.
M,\PHY099PV+@ 3,K,1E47M)(#;>2(+5TUY:@_@%0ZQI23]XF TW'XK_)"%:O
M3-!&B#G%06IS[C3E8 UCXN;A'+ EJ&<7U%.J#FJ8U ;K0"QA%E/+'>:8&^.U
M<X:XI4.W!/7<>7C.*:>%Q%*GE&[EP?P0E 9*M!*.6[;T\)98GJ++%R-X>]&+
MH()F*%KKP%J6(7#* ]C$H\4Z.EK,6.)TSA;KIBEPT9-+L@Z:CFEG:<I=%QI3
M'\'/(QI+88D4C' %@GBYLW2)Z#FSBZGQP@EIC!2>!4+!<B#&@806W"J+V=(N
M7B)ZOHSB=(1YM<XLK0>CV%E/(O'<>S".K:(CJT.,K ZQC,G-%Z(WTEI++[WH
M3MP(,57JG[RM(9YN:XCQA.%8 -N96F>8DDRD&N$!82XU![%,!?%+R3QO,)J*
M.,3*<*-!GZ>3-66@1F"P7XUD5"$LU3P<=+2$T?3M1$%!F5HD-..&,<<M0EQK
MZ0Q!7(7A?K"E5GU&&(U+C0.QT)/4]EQJ48R$<$Q''8T&W&+ED6 ZB40M+<-?
M:-'EGIHE;G]);8]I'PT6R@LCK#".,"FD-H18+I#U(E#&^=+Z6^)V)LW-R"A1
M46 J-8LJ*HZ](2$8P9&36"_-S25N9]&^=0IICIB*G%D6I-#(6HI2@6RL<*1T
MF,F%9[PH\->!\S9T0K=L'H?"G%7%85-IV-7)YR\]D91C+/,KK?0ZDN! X#"2
M2O)1DT[S$>F@ 4-]6A6?70H^<L[R<Y'N=A'X(35^Y2079;0506M/!0O!FA U
M9UYCQA$%U5#E*,SD7O;9X*<[*_,/=FG_ E%\D$Y'98P#>4<=L4:D,ZZ8")B!
MEV1FFR@SP2)CI(94,A(AL+<.M ^22H.7ZA#PB^;2832DQ@R&5&:11>X&#G[E
M@'BBF ,^09[;=$J YH8(&9(&B9IA-=M$V8,G^GX+[-?-?_=A4/70.^[Z[<YY
M*"OC\<M?0U@@X@5'",?:!P7.LHY" 8MY%BC&TCGN\1?12C23@F[ZK/5+ 3PT
M#FL.1>&8"U$B&9E000MLO.(I@XPS-UP&0_BF'C>>38:<.5+B'ZB.C<>T,1SH
M14(JC"TULU%K3J0!\SQ($[P)@W35F:7@K%@=]ZCQ*PH.,^*IDZ#F%,.@WJ1$
MBAF-HF? :.+A$1LS&*F90<;ZL0,OQA2\",$Y$R0AT2$6/+4TD+2K,FK)1#IG
M>GM)P2?R%QY?]K,#"\10CKBE#/%HB4/ ;]X+^)%B- ?\-0IU[J53IM(]ZRU3
MECMQK]=UIW?.O81)">7:3B>\+T(,11%\U6*RD=#?A[U5D HKHPQ2FCE+K%58
M"H60-0Y;%6>7O9\ H-MP>KO=[2P0;B8B5%1TP@D2K'*6&0JF,$/,>_!TC,9&
MT#D0*A.@SCAQ^$,B;"[%B4>:2ZNUU> <,Q6U94A[0P,+4L.UV14GOSET)B-1
M1&3.8XV<3R?"2A4PBXYY#3I&H2B':"!$S2(:9L,I VJ0&E'C",P;QVQ E&,9
M6&32^"BP9-&F WMUP,.T#SK#:1^_.9,^3,%XZB:U\:5@,"3!E[<4@),J22MC
MA/6,4B8)IL#I%4?/+'1F@Z/)V.0KCL)A@R38[X%14+N$,T0,,8$2<-/1''#T
MC[F!Y$?]P+EDLBBY(J Y!56$$4&-(Q+,\/2_I\B1V66RV:/F1/A..X6Q ,9S
MRC-LH^9.:BF",UH@$(X# LUB%LB,$VA<B2'$JE0KBQ*)*1@X1DN/%?@?7F(<
M0A"S6[QB=M343]9J>)E?OBI"V>T7+I2#K\?!^&H\/C]__2?\-=)>47BN4406
M,;!)33KW3Q)+67".1_0Y$>?VGK)WU0(RM/-.[3CD1\>]5U2<]?YYD?O>\2N,
MT/^_4K5[_6=Y9CJO_[3%2[A[\'G0R9==F>((>NMUSUY1Z"F-OV9:^5'GE0O)
MQ%P9]#5J[KJM;O'J/U'UYY\17K@633MO7;WZ[R80L,P:X2+;[;9-Y[]?E*93
MUDJ8HCAH6.;7X15F\)3JZ\7@!23TT\H[8?1"F*2WV&]L-S<WLKWF6G-S[_XK
MW!G\K(QV;W-]?W>[N;VYEZTU-K+-_UW_:ZWQ=C-;WZG7M_?VMG<:TWL%_:0W
M^+2V]]=VXVUSI_$BVUA=7\T(XDS_T*A[QK;"J('M%@#WFDLYO&=E>#7Z\$^?
MEV<M<P6L5 VBNNF?0Q#:;J_7;;_B,.+S4 "#F];P(=7S!I>'8*=TE5*:\-X#
MKNKYT8.'K+!:L<++GO_RFE:K&GW],EK%-]=>5GT7HP8CECOKK53WP4NE^?G7
M"EUY\-[#-\%GO:SLMG*?C0AX9KS/.T>O4(:K7FX?\[*:BF]S*)XA#MW:V:UG
M?X)DZW0[C7X;.G'94 #NAIC6/ZW'7E,;=&1,"ZNX"CP&QAU\1>K1,G=9QR0U
MXT/^:J/K^DEDIRSQE:'S3C]>V8WN^3NR>WY ZWU_LGE^^%:?[)QLM0]/#D\;
MS=.+PY,W>7WCPV6#?#RNOSVX:%R[JX.3.CK\U#AI?#JX>$<;K8/K[N5A^X <
M;NSSU.;@9 W5F[YUT'S3KF\X6F]O7S?>?CPYN/[8KF^IRW?D\.K@DQ.-C=;Q
MP4GC=.?M[NEA<Y,TWFY?U=]NT\.335[?V&TW3@[S@^OZU0'Y<.[??F3^K[];
MAZ1U;D^Z:.?35EXG']CAV]U6O7F #DZVX;F^78<Q-]X>D$;[[Y/Z]=\GAUOJ
MJM[<1)\EXA9%JFLH.EUCA(6:XM'5G)(R@J?IM03=@%'M0Z5?;JGP.OLJV]Z!
M$A^ ^%EY%A34*AJPWH\R+5TE"#^)9W](%+!5KO6/B(*O\?V(K\G99?: 2ULA
M?CDWW;.GL^U:D9M6MM_)4\FLK+[W1$'/'K+M8.8GS[$?^N @AJ)UM1O.ND5O
M)8O=HFUZ\(#+WJN87P9?ZQ7]^63JK=R^W1<P)@+MC^L;1ZCQ:9,V-AR&^Q",
MZQJN\<;U =MYN]6&^X;W?(1G\<YALXMWF@<@!#8O=C8^X(.F@WOV01A\H(WK
M.EP[I8V3(W;PZ?"DCM7%N^9:K[Z'+M\U#RX;&_6+SP[;8*1D-<6DKS&!;4TA
M+6N2"<$&M7'=RNO_^L^4E_#/AW+A1BP,L?[,,!Z3N5*A^,/^VFYS<_?=0;:[
M^7YGMYF]W]_=VU]K-+/F3@;66!-,KO_Z3RS0/S'-=G8SS/_P_\AVMK+F7YO9
M'6OMQE);6V_"Y>$MFK)[<_6X?AZWVD5/4KM9]6<TO"E8BADH_FH:;VGP?G-W
M>P?,WL8&F.S/(&#>5V[7YB"X=%^\>/BEUH9G'J?;:MY<U:Z"*6JA,Y?BYE=L
MB&WT65L?1>"B)@6*-48)JAEI4 US\"^UU9I1M?*ZOK:[_E=&\8LL3?I7I<:,
M>BX[NPMI[E#*)V'N,/&T;I?FSM,=E *&5QU8\75[)YI6.<\&S^'&5KZSL0]&
M39TV/GV >[;RPT_;J+X!+9M_@S1JP=BWT9<&S]EI_=,V:S3!J+EV^' #I-:G
MOUM@\%PT3NJ7]?;^Y<ZGPW;]9/=Q@P>L?NE49#5"&*ZQ0'#-,"QK-N!(N"&:
M<#HT>-@B&SS-W;7&WG8R:Q;'XGFBO3'X,[(Z[DS$T.S8VMVI#U[C^?].DS^M
M9S]1[4T^8/0T.M[&0K.M[7>;66-G=?@>DQ/1FU64?RMO!>C=PIO/HP3^)1N0
M?%94!@2>8DT(S<$&E+JF%.<UI+G%$45A TH+.+B&F5+J9X-)C\+LF>TM)<#>
M&AAZC]M;MR'7+RXJ-KKW:V;5@WCMM,/"C\UWWC[*RL(!Q#O=&X;X?(173\Z.
M5C+3ZE57SO-47[U;7@Q^OO\6@IU=_LSD$P0WKKR<RB(-_9XI6 F@^U)SO",@
M3Q*!$Y=TN^$H+WM@C_924MAO)^TV^6=OG'8PA36%%'B\4K&:%9+6J$?*<4FU
M%WSE]79CY^/V3O;^K[7=^MKZYGYS>WWMW=Z+;+NQOOHU(W(:D/VZ\)TX4\DG
M(?J/S?]-=F1CK;Z9;,W=S;?;>\E":V9K>]G>^\WU[:WMS0V8UVR[N9>!Y9DB
M1O]80(>=LU4BQ=@]=K)*Q-.6*G^D5P8W"C;A.,  EC/C0$U<]FYW7+<XJ\I5
MI6TVIA>J)-WB:KWK[P<IX0U<RJ+KA;.B>Y[ZF=/HY' QI-TXWMDXP'72.&U
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MQKY> \: RVGC;.;A*K@7J>E9$5RHG U,!OU5M2C*[ _H%"1:5O;!)B^/NZE
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M^R)OM8#+$J7[-M6+[U6'L/B!1DC:P9P!S[7&0LD7V<5Q[HZ'>JU[GO1%!+$
M.J?JPG7+7JL"3=?V#&B&)>4G1/E&MU.M;C\D)9 ;C(&TB;0<R $;0B<S9Q6U
M!H?YE*857E3DN@AW9/0('""IVZ%(A@50<B@BP RX_Q3HSO>3 ;$D\.18.UF.
M>;=? AV2/J[*;]]5Q*!T1\)]H(>')&Q7<CR"E;J^\W%[HX9U=F[<?72L9O"
M@5EV ;?#(ZJ3F9)9>K<74/!5M6@[= H&YS_UCO/"IX,S4J[%BW1^ KB-Q_ \
MD!_M)#X2N(X#>#)):L ;P/5N2MH8C6-@%:8ETFI( %(8!_13]HNJF&!E/"=H
MWXQW(.<JH!;!A;1WJ@A'??!FN^EY%;Z3W"OOC&+TTH#YT?/S3G5X575"55&)
ML\%Q2/8JJ\Y]"QUW526.K/5[Q]TBOQZ\-?303>TN\G)INDP,\@]44K(B 18
MQ@%]P7%*FJ57!%.=+C;0695S5<$6:&/*H63KA*/!!CMP@H9&[>A<F) 4EG%
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M2ZB"2UY(N71EFGS\4#%!;+ASWQ@/<J'TIV=;>^>^.\@]I5:,6?,5+HSA6)G
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M0NXPBO\WCZ0HFQ#>OR$*CV85WB-&J)( $\D Y0XFU;> "2>XP@RBX%('8E)
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M# =G<S%$S\ZC4(?LN8.^':8V%WM^\N]!_U)T;Z\DEZV.ZJR.^=,VRWG "#-
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MWB[N$65GG/+B>'O8'=O>=7H]/ ES[]8=.8")A[ T1W_U;'^\T0\OX=/#@R9
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MOA7G7G><;P(5=!1;A]W#F%>TI"T.!V'B<]7[?BA*U*B\*L %<'&><EY+N.H
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M]8#GBG+Q9S?%UGO?A47+;/<N%F$'&[.DL[WK^GV8-/IW[!UDFOESL-?UH[+
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MKF\ZKZZF )P^G/BK'DMG<N#B<#M-_QX]7?&_LW&\]?VSB"#;1.#(80::8)(
ML4QHE!0ST3JJ.<E.KS,4P3.H<4[V=C/TS@OPPBE3DFA][X[W\P5V;V\8]X *
M6^/!&'AS\8:[%^'G@/<R4&_WWYQP:B/$SZ:QEP1HC#L1K)044:D U(4$@Y5[
M@QCAPB;!I?!J[;E<%^>*<;!.>[U,#-_WNX"G&;@SA8TF\,>,IC(,]P;]O3BL
MJM(16F/Q@@-PY=U].W,("YC<'83LN>UEY?A;-WX'YAIG5AJ.$R#YH,BJ95X,
M@([S##D>P$<@' [@=:TNW (//Q$UK2X\%=[8'0+GA4EFQY:'W[OCF@^'K4K\
M'0[&<'D6H]]LKW*@9A;T<9C%QJM:$BZ^_/M^WK'\38)7E%MC'G?^Y/0@>K.B
M@OD[.PVKA'> 4',YL')1 H%<'(W@KBPCQ_43BT#-C=OK,1S!<T$;*"3RS<**
M3D:M_YE8F A(P"S'$Q#<8#BJ92D8,>V6 S6@/X#Y=P^Z65B.!]6;^]FW?,;H
M86 >QKU7@5^]>%F@]O?@JYE@'F:P2[U)+EI8)%#^+DQ&X^$1[(GM'>5K8M[=
M4>63R6\9P>C+-."MU3;E-ZZW/IR&RS@ZQS9:W ^;D;42[&?(^.JOPF2'0P"P
M(9#XC"A.IGAJ2K/D^'F&.3<(_JXXJ=TZ:UAW]?:\>YF"ZJ4#VLK-H#(QU\31
M'7TMU#OPW:*/%:F8===<='1NO]9;OY?[!K4V5]T.!-RK::+PRB4P8!\XI%(9
M?R2=3^BNYK*2QJA^ Z5V-.X>3*NAIDEA!&]'^T#0@^\%8UQ6-GL]4+_AJ6DX
M.(#G#$;SJL%I_G6QUP7B'I4/)TODG >;EW .B_)R;/CL)<AG/=EQ.;Z,HCHJ
MSYFY%[+NT8-!9TN@P,*I-\!U1?$OVS8^4_->6-L%&?.#@J@_I:.<5D;>^_T8
M)KVXG5X!%/R=T70#ACT>;?3#GUWKNKTRIJW2>BR&[?Z[/,[LFRFAZ3MY)CLP
MH-][ __UB>DDG<W=H^VWGQ.7'DR.@!3F"7'/.#+Y-Y4\I8I9K$FM7';[DQ@V
MLF9'(L<\,BF(HEPX:35/PFB?J K)$;X&_.'M82[1.YS$M0>B:8 2 7Q0_':9
M+@#RXZB8A&<!@"UD5@%)$1 '-8UE+IR7[<!>F=DJJIL*[ID"$EJ3T=13>/+^
M;O]P,JZ%TUDL_6Q)CZM6[?E_N>&_GI_Q936AJ3"J3M$S.MG#47PV_>6W:8WK
M;K\L4+GIM].'WGG+%HO5Y!VLOO[M>S>,]Y\9LZX%R_$C=6I6_>+J6[)>0DL6
M@@*J[YA85T:>^S5>)^=^]Z/'$K8N^/FW_NBQ/_Y.,/K$!PL;QM1#&2Q;E]I<
MZK$7)!9>G!],EJZ]YX)'>@$'U9D17UF,MHH<;=5"L_**V=.UWB^Y//<:_;<X
MX;-#W,Z.5'KP^WC:W?HT]VXN1/8*<6.KO:\[V3EX4S.^3.;RHUFYMY-!MF/^
M C,$;/2L)X'MMU$.1[**]16TN?+I+W]F!TE%6F0I2+Q9ZDLL]7L80.D6TA^7
M)=TN#K,/_8&#YWW+6F7Y^$W1<I<6G3:+?A.+?MGE9K]>13K<5#N7^ZMP^7Y_
M,!RC;'[-NRROT\GFQFCQ-BM--(.\OT'>4/G8U>6I"DG.^W=KDML2M1),<(G/
MKEU$Z0%G$YTUQ<>3#V1L=,0RC)7@05.GL7<,_K J4"7/"6YH\H'.SP?Z$K[L
MTC=\^_46W3IXM;][_!9WZ ?^:6>+;^]\);L'?WS=VMG(>3_?%_.!.K3S9??+
M'M\]WCW:_?CJ2V?S+?NTL]_;.MX3VSM_=W</WOZSM?F2[1[_GCHO%EI?;7QV
M.'"NN$#.T]P$G7JD62!(<\U)\DFR@->>*]/68'!2_@A+NC8P]4AARAJEA% \
M$6XX,SP'6G(N-5>86R=5 U.K"U.+M9",I=+(Z)"G+B(N0D+.XHB\T$0G3CA1
MMH&I!J9696Y7@"F!%>"3--S)P /&QFD"PI@KB4TR$=\J3#VV6MEWAU"+Y8)P
MPEJEF)!G48,BI7);0O@MA]-+@@D6S#_B6MD-/#U2>+)9C5*:,$(35U$:(%0C
M:>3&:R)4 T^K"4^+)7442SQQ29&/!NR\0#%R)CE$<6[=09T3*:XB/#UZG_6/
M_6NE9]-X6([KCR[3I>G)=Y7#"M HA4A$%-PQ8P(7U% 9 TZ"6=98?:L*6HM]
MV3<^$P>[ABU'P1J!>'(.:6$(\CR#&7>))KGVG!#2EMRT^1F=(IO>KX^&L;63
MW DGO(%?HDB6<\8]CT3J0(4P#6.O+F,ONG-2(HI*3I!B(8"QI","91)87! 9
M#%'6,-4P]A-A;.Y4I$3*Q SA&F!=RFB%C%Q(1JR]W>.DQL+X69Y>=( PJ@C6
MR2*F0W;1$HZ<,A0QK!U7/, NLQNS,!I^7EU^IC$!:AN <LEXSJ\FR7HO?>),
MAN1XP\\KR<^+'@-FC>(FY<X3'B0SH\#//&FD/%/<82NM%ZO(SQ=X#*:),##8
M^&,(:*X\?>43#W5ZD8>9@S#KS- 02RKI3WEBGD0;.4.#\DYCHZ3AW@6+(XT"
M_L(:IQAD8["MJC X6O+$6,H4M3HA'!U%G). K,(<89 +F F/E=9KSVG;&-Q6
M<KG&Q8,_WVK8>LK623.E! W.1L&)X288)P)-+'D2*+&->K>2'+WH@B%*N>Q
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MPC>_GI6AI':$<@%V!1@<F!A,4R3:)X4=U](]2.B]<AC\%&?-Q]^=M4XJX*R
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M<[O9V=\]%/O;[[Z!!B(:NX?G.]N'=&<WI.;V1W:@E '+3!BDL!*(YW&#CJN
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M4.$^>:? 8TZ[\#Y##!:VOI''/'T;? V\[Z(P77&?N>ORK8;=T2<2D4ZRB]R
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MO9]JPG.TK3^G#6ZTWSL[((ZH+1#@3.'4S-6 B<^YX#:$=+KYV#1$*Z<D[02
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M/"FBBCJRLA+,X7'@-7;RGL]?IJ']UKE+6\JGYO;1IW'^BL4=_\><G?^SLX_
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MHLI("2T=JR(S6I:8,BFVY94NQ7P7RE5M$>9%9M8,.'69]$F]9?EZ,['CU)U
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M/H\O:)4CS+WR4L4\^GMQ9[VOHEKPJS[=JA#Q!8.B6C+7B;Z1,HJ8;QPJ@Z]
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MPP$6ZF=7]3+#C&]JNI"MU1Q8Y%*2^&KE-,Q\*%F+P?9.\B^P=01-C8MQPR=
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M>4?QH!ONLW=U3:^!A_5Y?E+=HM!6C\".Z=BU6N6K!/2+-2@%<:%7V,<9KL+
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MNW5293*]C2(D.=EQ\3WS6MR/&=Q@AD=1PE^FK2X8;'C'MYP8'"R:M5;/]/!
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M:G0 !5O [#@DEM>=]@>$V%$+X@,M4UXXIW_0O$%OAA^+<H$FQ)_BS>#O(C8
M[$69"^G#7&BF(.TIH?(1\M>+TY=_A['+N2Z8P'$87*@@86CII-/ZZT??IP<_
M,B&.$D/<7HNRA0UM^+8,-2^[2G0,ZX8]($WN')$..J<DG)>GY_QM?LA%/"H/
M_7C..X0!13"D"*>3!2 #LAM:\IQRH9-".N]<*C+,W<DYHMC1NGQ6Y'V6"IV:
M-'$/O(+[NPO)N]-QI:O%UMOE]323ZN6@3]\ I3/R3)(BJ8&=.&>P D5J4BQ
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MP=,V5 %G1.A7KHW//@AMW!^NMXZ9/'!T"](5A D*!FJ,[45"G&=(>!)M(0%
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M@;5X_@ I9.67)C*QZSN4<:<F5D8K+)#*;SFU&8_:#(G=2HE^][-*EU5T ]S
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MWN8!6,U;N6LW-67%Q1^@P9SS K_P U16U^)4NL3KNKSM)5]I"6,A1LS5ZD:
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MY3!79T9I[@I'LXS@&&C&6RZ&K< MT\0EXD];&C$F S)]MI>">]4G_-94/9&
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M=.3*[#^&ZHJ3LBF_ W,L^MY>4=+TTXPE)Z<%)'S'T/B&61*N4I4"5$)3MO-
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M9'=0KDX@=XFG(]!>HN)5?')]RA'BGUB)2N'0-$_'6&6FTP4DH7-IUJ'D'.F
M+%2<>GI\6T8LQV(42XGQP-XF^?C.YZ[26!J(N@F4L  QF3CL?CE*E>O(+OVW
MQ ;]Y02P09^T%M.'%%?J>J6N2J??%S=!0X=:=)0RQS!+7AV+]8G]I%9[(-Q%
MH-_AY82('[5T9M3R-GJUIEQC:18.C@;P@YH\1L0OOLC>&4%^MR&+D.@F\B*C
MY*.$1BDG N#&[5QPI[F)3&95%/GN>V+(B3T*B9H[M"$?*"SZ'&)I2V4)]W
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MBLNA"QL#&M8[@Z0= 4-YNB+N]2X-<RC?SG3>_+='N'R^B[L[@^)4I9<[CQ4
MFQ!?$^"C4ELH$A!!*9[HI)2IGSQUW3-,U0YAXL!\CSRV:*Z7,2C[ZP+_ZTCY
MY+!-4-&^,+PA@?/H^X#9FVS[>G^BG3%.7AC0R@,CEO%(?<3(20O7UN@AN"L"
MOBL=LKRIM7EN0Z(60;IN9FBVN+_F&MFN._:*TX4K1G@,;MB'_ZPT81F%*MO!
MIX^?/B;[$?_[5"F$749:UH5#Q7D6'L58Z3&C8"MZ_ZMHW HGXTF-(7'<S?@
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M+-]!#B/IPACE+-YI;B\I&S@ \NV:_F?H1#?(#!S1:EBW_2]86I_-+GR=#^M
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MGE]=6O>]#GQY<WM]T>E<]G*7;(CFYC9;J*:#F83<"4:O3#$>C)TP9,+2HZ?
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M9@)ZB"P4T)+^B*PH'G-K8W2S.3%(U;:K/+^FV'8:YF/HM-JQC,)*LE<A&!5
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MBU__X][O_ZZ6ORU""#\L__;J5^?C=;]('RM^^#^_O/F0/N$9L/%DOH!)NGX
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M/M8-2WK!LK3)12$AEM;-E^Y . Y][R/7-7K>.V9[::A<-/D>):- BLP95\L
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MSMX3:"^+<BY"6C]^70:X5A?'3O(DG5%,*EX/S^+I\%2))07:BUR[4;:.W#P
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M-$R5J)BV)C+@MM1\8I>%M4+%+K>!FS[_6U;B_@)K_R9*^7J2S]/2EKL!*AJ
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M4_]!E?)R5@3$I(OE3/ L&)%*,C#.5 ,Z&6)<\;[U".\'X#Q/"[.UGGK(U]L
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M>I8%)"^T]/<VB0[*O_V,H]7W'J)LW"-A/0^7L67,+\[J)C6*RB9R.ZO-+<@
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M+L!)562*A,85\@:T F20N&981"E&BE!BM_J^1QYTY(IO*^C6YTKM_+K<VNH
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M#H85AA?F XP<C#J, 8P%C .,.XP?3 1,$DP63 E,+4P[S"#,%,PJS ',%2P
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M.$DRCZ,/.@ZV8&NL-14^)1[5WU,D/I@.?:-E^$>X#%X'_'!\;<4IH>?!5=O
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MUHLNFO^]W*PMMU^@=*Y6!XZI*+\VGA)KBJMOYCV!QNS*J[-B.-*@UF',F%N
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M&#I\*-3<W (*=7GQ_=;2RXY);CDY9]V3W'%/M+)8\,H=PF-X8/Y0E+D-@NL
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M\V8-'1+-SR*B8,ABQYG_JEA$*#)B&ODB-//2QDUJ-_=04=A*HPD\#;*,=VE
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MV86V'(V:7$D5T]UM>W3FDTFO#FEO25.E\3&Z<J>_(N6F*T880DD#1=P KCL
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MC0BHU&9R>4WV(#1;^U7)0/EB7>.@9%#!G89(1BVGCKUS4]QDQBU)V<J!($T
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M6E\:8,E"-8]]T:K$IGE?,7.)^$^83?BV!NW3D7S*PVQ7V#YA-!D4<2N'T_'
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M01DWOXNA2;HFV$LMN?T&4&F[*T'2/;0L[K6PJY,Q/_W1DL\CT=*(?25)=,H
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M0QNU=__0]@=#W[S72N;Q"@OUZ*VSF/[Y/0P".4[M^F@0;W/76"+>QE,U2CO
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M3*B^FJXNDQZ^F$[%C1"4;H4I/KQ&)F>:6#3:?R]Y(\<"/3$RX0/JV'0(K[O
MW-'XJ;09*_VD$*R<QVQ8$.J:MV3<!UO^F1:CM+0AMP*/?Z9$WS*+&/T184F'
M<;L"JE)RO;S\#P;F _,4."/)<&=R+;.9#V5PLE0[6>V8<#BXWSN8(_!Q)W8O
M*_I$+4R@?U63KL<#19_YP1"R4IZ=T?[\75!U7C25RZP/ITQFD=5[X4 U_>WJ
M!?EG%)%QR,6(8.CYR;I-4,YB]?KHN$DF/EL&5C=<GNBDQPP7%6LOFD'QLZZ/
M1<TJ[WU>>.GKNAA>(9-J6YW%-EF"ASFXHXKST!'Z?,"\)2LMT<SK'=3)5QP%
MS$@-?@R2Q9F<?,/17HF?_S#IK_ X85<4]8)+8L]1Y%<>-&8SRX-WJ.'X2=-S
M!U_'X18:N^TN(3/D<A75_9@EA\?"O.<^ Y=TI@D_18B4Q(6_5Y8SM(.?!ZG5
MYET&>G[F)5R>TL==.0P89#[9\V$C&4/:[NM46*,'UBMT\H7F8?8>E#^K+#"X
MV+.-\>=L8CA[HOX.112REAZ2F.X[@=:F*]*=0.$1HPN9U.1EH/(4,W_DN]9R
M"A':<7=>48 %IDX7NP";F;M^I>:$= C7SV.70SD)2MOY1?QF2E=\G_K>4LA'
MV5(BX<N+;DV9N;9"[ K[%_PIW""+2.2D_0$^9LNL6_4-O@C$),D$^.;5T$1K
MO HC!F7SO4Z:.SV#H:D8?K>GS]E1@P!.J\_J(TGXZXLA=$Y*I:-D#']L\(69
M+T?P9RF4$\)K<],\23TQ\U!?JS_W5A][!"AFF^CD%I6I&ZCAM=OBO_Y3\9B_
M;T&W@4[_U8) !M)I>2^A<<D/XKDC99$UN'W6U,936*(2/[3%+Q_3-_&Y#2ZZ
MS1\'"A2/870MX4AM]\(D&A".Z:1I@5];R_3?1*>/I3[RO%F#)29FL)7 B'I6
M?3(/3A7)G>$Y0G?E3V@_GI[2-'[5Q,[(5\_?$@*FP%\F9_<V'#NV*-#G3>FA
M0U5U:GLFUNK0V=FM<5UFPA)X)Y\27>7.#;I;W[,1V;K^*II.4U^6\HZ[4^+:
M%4]V"PZU.=^F.-I$*RTY?;Q*,GJT85 QV>8O%1EPML"]\:,3P+??E+\_Y^;6
MWK*XU$-6'J\! Z?:; B,+EP=TGS>ZB]F/NVEGWNL%-X:VD&F5\FX2'_Q*OC<
MI< 8O'CU?EV"9ZR\%QGE_$O7O&Y5>Z*$-B$#6*T8@&@%PC^-^8($R^JE5Q%6
MKS^BX=!.0.8WP<8:BW*,4;ZRAOR=*LW\IQX+,-9W;S'MAXHW%D;K17^NF'N
M].RE3+Q-LMDT>(KZ>U<[UZD0_8O2X;6&0])N'"Z+_86"%3@BW/76,:8G&=UJ
M(@\C?GF<#DT36NR]K>:U.QN1>AT6#D6V*6?Z;2C=)%7MV;!%/\WP4*YS!;0Q
M>7'%P:U?E:C3I>XNV?7V.'OBU=YPYV*64M-"$4^E2-($/&5P>'U0:V:Z1)_
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M_\:RA3?TMU<+\/GG%6L.4OY?KD3_9QS'OK3!<Z\?_G_[U7/B02\WQDAM_V-
M3>^;$.LZ"%3[C\?=4%W6GXW_I?B_NW9]6F,M;B-A]SJ"\U-^O K.%_&-)Q#
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MA5Q]:SQ](#B-#1%^@?:">VNIBK*LSD!<OFFRQ?VW55U3Y@X/J\G(D0)3@.O
M&*8PSHS#CT'#&1^KKX[3J?K%:&$*A,\IXIJ;JYBSS0JOHGCF+I<#.(1:CR8$
M^T5$:W+EW)O(QJOQ4U7KZP46J[MC>-Y%3CD+OF\"<W".A>32K96:&!4X2RDC
MJDS(9TZDAP#*(ZI'@XY&YXW,I.U7^H5,T\[[8,P'HNN^ON,FU#;G%V'5/3*F
M$@KA+^AI\3.V'*J%K:['R+T^\*-8IO_Y]%QJ88M5D-OG]$ZO9-_[+EDO">S!
MT]_HKN< 0":N.4UJ9!O:EDF[1F].16^1LZ3L3#52N.W5,-+8#57%"3!UN*M*
MUB4;NB8;:D8G@14+A&#=8NB6('=R!4!L[+O,&V7LD6#X0(^(4EW&J&$0,T Y
MK5R5]^UT,6@S9?),ZJ>ZE5JK8)1KXBPMEZF= 07_B-J*,MW9?)E32YO67#;M
M'SP1]']<B*549$[OPNJ^'9W8H!@^26&-T,:?1?4+]=C0,0EP*5IR:Q(MNN-=
M 5D^::+#"MEO:18"$>=I6IWUDK"?;1);-R^!]K=D:3J>34N%.AZ\KEDKTF"'
MBZIS4D]!J8#NH,HH9-1.-"-;=X\I+HC=3CA^]5;!(=.B=5N'MN-MZO'^7*D?
M79/1*&]TP4D]J5UT[.B^16)_C+T"D EE6GB@IUC8)%V:<U:2-S# -SV.L(\S
M$*;>4WW6MJ6ISZ51<L6,TR>9JT?JA'U[&/K5<1*FO_B)<S:;XE-)Q-+@[]\9
M2TAG(18+&VL5G( !MQE][-)>\W63Q[O[L:MG]<4M1"C=RBJ\@6FIK=*75<<
M,-'BYV]YHI\R+] GW\GO233PQ+OAK'1T(#V*JC0(7TV--;(JX$%KT_-.B@67
MC:66<AMR9>W))0990Q>SK \66Z"L#=8 :O7N57Y]K5@:V9NN5C,-JSP5>Y;G
MX;QB(<6KPXJL'3]Y+;NAB XV:R(".GI>7@M"PG^ZDVQ(QDJV8LX_;6'A,2_T
MOB)=_\?Z?HR@ G\L/&)()^H8P*S92SG#2B)<J=U(("/.PG-"%#U@\G1T8F,#
M]-0RG82A!7V]JLJ1 L18HOE$'6<.*A_Y'G,.M@1;.E'.N4XF33=P=RE,$.>3
MQ [;K6"_?3#WLLQO]94>)33#:[+(D)11L\8D'PK3%1Z0Q<EH4]=HP[MREN7I
ME)?AQQXS?($)[0UZ4S'7L-?%:Z;:'UT*EHQ$E,)ELQZ:'%I ]JF]I*W@W'M6
M&I>:/2IK:_8 ?DJ?\7L>/HE=V;RN$>@//[?Y@AL-]]4J_1SEY,F69=VJJ2::
M)BV"K]R362.=*^G!=E-@,>^4J@]N,XU$=\JFMJA/CQ467E^/4".7X8PQT[?0
MKZ,N7_G2S[FM>Y'Y!/8-UKLC?2+8U6T=,A9EW<)GFV*"RG1E;J$5]T$BNG;D
MXHYEOTQ+K8Q9JOX9Y&[R*L9N$C(#G[C/$$0A$P1]7^02)6)@*@N+7,"I91'U
M3[NQKPUC?Q'$ZQ( [%J:Z9VJ'2S]9<[2R6-[R5G 2_$<M;-2+]L^0&2F68OM
M"%UZ6T<5+X[;LK2V0T<DEQPJX!Z+8HHGR"*99>Q>LT*W%D<G81_^SP/14#.%
M%K_R8[U9,<%!MP5).=C*W%O#IR#"3W1,LBH,G-NR:ET,G,LM1!U)[R%B_Z'!
M9C_;OTT'-<76L8D:L>=5D/AG;B7L%"?"5GP[CJ",5WZ;$)_MABJ<#L.'0>JK
MS0)W?<1] 6B6-@*.SU5ZY6Q#%*U/8A*$>SDB=KRO^F\3B!1IC#YW,R748F%I
M]PI&;KN(>;0II_6*J\<4?3')2V)&SE!OH$^F7 M>>>IU^.C?<T&5Q$8>ZAQJ
M?8];Y// 0)U)XP3E1/:KIL$@5F.A-1!@/TDC]B)U FS'"!L70Q0O2VR:=QKY
M-%W(*-J_C"#+58L>AKQES)U^0^[2NV54_=[BED:95AYK/N-$D<K_1-$N,XVW
MAJF)GJ+F5:5@4KP\061W3:\/UCP&@!0YD),!/^FJZ1X87@8DN?;C=OL 9@VH
M(4OV95?I"HKGY**M%G6U8P*0A7>J4T<2OH)1\L&]84["),ZOH5I4L2O2KX9'
MA;?DXB\\)0S_S(PY3XK/WFLMOB]IG-74"#$WT>D5:==.=(3O/<-Z<KWD6J C
M[OK;AT\F[=L,K? "^ !W30KWD9-78/'424OKXN^-@1^HX*_E"P@/C\A.JJ)S
MZL FIQ:'!$JMF*4\3,/A KIC+@GX:@[88K;%+B4W0V=\T7K+/_O'[\9!A4CS
M'OE =69PT8G$7;I9=^5Y0KRJA!=WQJ'S_.I.S8#VY+UIEN7IM#\YOT%XZ'98
MJ#L+.>="VH*]C[(%GX1A/YVBU>^\]/)N]EY'KM+%2F[P[XFI]-<_]*@_4(?_
M,;7GS[I2=UN.9K@PA+#RJ;(#LF"8[_M0T#9.6;NRQP@$?1N/3,%L&[COGOU5
M[%/'#!%EAX7,B]Y7S37%JLXO:4_>99>*9]D/WKIV>IWA:?.[<[A,U''NE)=Q
MI5I/!%DZ35;SW/EX&@7( I*KDD6NE%P_OG7I)I/!X0W1D,./4*#2 *.[]KT8
MID/!Z7K!.<PPS+G,8TW@&<NKR)2HR)5H0JA<KSS!L%D,E6U2+E >9V"XDY3^
M7RI:C9_P'?[QA7["*^J=8X>T*A9!-GJ6$>Y8[-C;%6#7X7 5N7H"-"D-'!*&
M:#6#D-=-CHQ^"W?WV1QMBF3I\?%U6/R16/SX\3"7395GM='1P\-GM;&NB@YO
M6FL?H5VM5&5*5/_!?3$2SBU,1IY7Q![@7DA(_-*OCS]ZV.O@3LR"DK^^%[W3
MRD3.0=."23CH^UH=N3\GV_;.V8?HM; =Z=(43.Y/;QYTPZ_!L9S) 0] [;\H
MM.(\U0^I4#G[M<\5$G(\C6_SU63V;@H1JG$3?6E0N @9C0E3#]/PILJFRN-=
M) !]["HG+S0<9E#-[7@,Z]Q_!U>W5[)[EX%"LEON_761,%62O#^A1;DGXOM*
MR%9&3U919*J!8.JSJ3WQ3=:;=>2+>4"=%RJKUXWWJ?^Q?- _"Q[S[LE^H,20
MS//66J2GN6L:_FFJ<6+_)IP"H&'\/-)RS]B^QL(QL5"RLZ^K6M-05Y"U1TA[
M^A>%8-UJOB+1U"YD<ZZX07$(UW\R>6T[)IA"1D=SU,+5I]*CT)(VO5]S2".;
M-CXWYW["J(I-*HV1B>\[_^FJ[*I*"U%K:.#VZ*1YV?5^ *YOMZ3-AR%\G5@#
MWY(\52NF3 >KA$A^ IFX;(<MDY BN_%^><#7PM1F*7=0JE=7 /8W:N;2*GY[
M+G7CSG\ ZUFMOHQ[U.CG=+-*+D/7Q%R>BL+=W#H7Q=6X4![I-H50?X!7(=6"
M\-P/D7-H?<IX&CQF "9BAJ6["6/EKF):A/-$N6Z4*&@V&>DAV95X']1.ZO>"
MK[(:1>=**^S8&VG@R*=*A(D=QCB%VY1B\25R[A8X_'+8)^>C\2I?9)'-7F(L
M6<AF7'XKL%UK0-;2%!;M:^6@$%,^WK<\I#)\R+GMA-S^S2G>(@:#N' >;S\"
M\G#@#AA\XIYF-.J%7H&Y-0#034M2&K?Z21  !+H W;0FM1\^#RE40/)&2#5T
M#Z;FQ9A$?:LBL@L1NW22KV_&)"+9S:.I/J;C  <O89_>Q,4S[U+E!E&ZOGFW
MEJCKM*:G\U;O4;S5\E:,T\_I,,_P '/'WC#VY%DKC2<KC%M<U.-63UO45V3D
M+THRI#+XQN-:CJM]JC1G3&]O5C25K;B5\'U;NH,9&K.*,,Q]BK]C)SNISD]7
M2?1X6?L5.[TIY5T0SZ^VBH>??]+OO9C)]&NW2R+8%* ">3YJCHYMNRQ(UGJC
M]DBN1,B]?(H:GJ!^@X+=?NQ@1R.[9'WVFNJN"(!=(G'E4M$AP1MDJHMZ?764
MI6?_'E>=3.?HP'B;3^''3RN6:7.0=_'H:F0+2X5V:V81L MPK+".Y>UJ*-QA
M8J9;^(IBN2VC?*\$SSWIF2#J82IID3=J?WM284E[AKV[8#@[\EQ'VZ?HH>E!
MGM?,U]U/GL#$FB4A5.*8NIW/UR)DR1PJ!U0U20\MF,XHIV?W'[;@DOZ+DO%N
M/BZ,ZEJ-GQ;W=VM=\J<J4KF,/9C.%FU)%AK:RPB:MHEOM9UTWE9HDRMOQ@^7
MWZB/0P!4 4"#IYBPGHNE$2#GF!]]8,\<]S*47AF(A&&<CXB?#QPK,"42)1!=
MG&PT X$FI0N(VMZGB[D4EH9KMC_&;.#]RFP3"Z]<--OR==ZP%8:Y>C3&QHR>
MN_Z)@_IU+6+]W3$_SH<O&TL5*]T+AFI">#AUD/J_*,IZGDU6:RE@6M%LO_)D
M$[?=OIB9Z8ILPA8]3&G-5C=/TNC"O)X[#STLX;NF\KT>,R#9DW$VLD/1(?DX
M=TF@N%[C<Q128CIG]=Q)UX)K8'8ZID$([]+M2]T%1, 7PJ]FP2?RCP\@3L/B
M7>B'8_$>R2U5QC]BV"[-U[3^KYR6?V6UC&P/K^X G=WY 2WM<J<>)2E]ZV?)
M[YM]!>N:LW5$;Q^=)+-E7AIZE,N^GZTRQ0>2;8;1X:,"SX'W[?;Q5= >/-'!
MN8O=%*_3$LIN(MJ +3FQ2[-7#M<[34&^)B0S?00QN>NC!/T3M16]^:Q<R350
MJV+'+,\@-@40Q=:-Y9J/B&+:R##PW=:^08=OC\">9K"][M%"O'F-8:/WD,%N
MKJ479D$4+V/\R+RLW,I*1EH'4S##]C^8:%16[7"8<P0!@]W]8P/W";*_8U"[
M OZC+<RQ>V!Y<075/TO.TI$X0#6K\$NKH./^[J3W_I3T(9_MD!:60!B?(@;P
M=W0T4@DS=V[WM_^;E!H;!5)J81WJTI3XV=/^TH#L/"=[YFN[*H%=[N/WT;NT
M2V#A4LI//;FZLJE[@CI^1QPV4-EV I-=KJ:HV\%>R;@3IJ._*'X!GF1[ ?P"
M,]<(W$"ISQCD]&G:5IN N(VE=0>FZ4VW+6QI_84-$O^0PVN;J'?>"6UN5ZI*
MM5 T= PGKC&<<_QOD(?G$(;KP$*B)SUC&>G-S:H@6GU??P/65T'<QAA"/F;+
M1[N'/G=W/(U5.U?9H1D2FZP;KQ"'/2MO'M0<U-9T<E)XGO>AXZ>>:V^$[5^_
M:VTP(36>V:6)U<RM2PG_KC/;.*N[=,_!WB*0Y&K'+N=6K>3W^18<Z$6;X0\_
M/&S=+Q=K:,LT:E<C<"YVS='NY%E4A0XO_3EH[#!Z7+WJ<9JYN>,>A^D=<-/[
M0CL&W<V(&.LT/:IDH&;A.\I_45QT<\Z@:2*@GV;K3P3QK-QI((S&I+Z/ATD^
M;[1.Q\;@;5G+U2SE"W^N]M3@ZBUWN907&-@JFW>!HAGG"SAP*/#..^@[.2*.
MY5H4OEG%TAIW.!$WV*6OZ_C8+N\)>_1QJRP,>J#N8&P,'-!_;,,M78(^5O!H
MPH)FD<-0RB#$G\>.PQ!9K0V;_V&LYS4\X &>^>2'6WJC0(T&SR; RYF6Q7TB
M(@KL-V58S@:(3PPB!$T[)O ^RZY%6%B;R\TN=3>1K=@7-V(D(OHFMQKQ6(ZY
MQQAZ- 1_?6*$D'(=ZI?Q]]LUQ'3*69 A7UFB>J&9='&#6BE!"9,426+%];\U
MMAN>-7?>+>&+![AII1?:_C;+RUZ("1Y&'Y5V4:7Z!D1G,?ZO$"GUQ,*<;_71
M;/.4X1Q-G]8ZGZMA*ME:,%3ZHVB+DNH1FE2UI4VC3GJT0@9EU;V($6I#6$5^
M3J\EOW<%JC-Y>O_4X-:1PIA<E-Y!OUWEUO2PRF0W&R469I)[)[:8F% +L2/W
MUO-DAT#KZ^?@ ?69U''(CW';-QF<MI49@\P*J*S[7GVFE-I%YDX17Y*H5DRT
M/"*(_/^;(OYH2!MW3]=D)ZL:%>(RR_UYF%M/;#<5L5V7^WSZX&,Z0Q0_'^@<
M2*J-=632?@WE=[E2:ZB7/4.>:_J3$W@"RC=L(R:[9_!YWGN?G7[0 J#.V2GN
MT!$E9QB,M4,;LFRY&G IY?O#,Y;)K?L'>!6G! S=P)W<3@H$7BQANV"]MP[/
MP^,K$%KTX0#!5_\.3[OE$!2<&\;Q1TW=>M.,Z@G&ET7W_QY6Z[?;[D8W"7@A
MRXM*&\E;FR;+8-./UO6BUZ0[)PN3;MJO+*%ZZP#/T$Q%!.+V6?JCI.^MC]BE
MHGFY93YW26!K!BJ=JW?,H6]K^)=K/VKH/4#MZZ'92RWUS?+QLWL*_A:@\,*Q
M63)99)C][)"]&Y@ ,WN4X8F!$^;S_TSB^.\N%?VJ9SHS-I:6UH\KN1&7RDFH
M&#QWK"^$^6ZZ@D#5PD?Q::(7GR )RM/MP]^16!CN_<HAZV&DV@&9OAVN;#[:
M)_;),N(3#96-_FT+)6_2G17?+KXA9%L2G4LW[>5^+F=BVIK14MPL"U?VE-#*
M^O?UQFJGV9Q6ZYQLF^*2O.X+K_"(&J3L8'C/.QUCS."!&/=_"ZR;4F7 _[PI
M#>LV&EBNB.N?S3UZF#4O4RK^.F1$4J4?;U%CBAF:791J\$F:U]E'S"]KQ2WP
M</3DM9_<#ZKGG\&41I'9OW 3<U9%-J>FMS?E.[>L2%QMR9<#B5O(DXSKR/H)
M[HL(/+?B/&Q ,K:B.B 9HZVEG5)F-.427@"'*W=FWWQD[SE_O_!5=_9 -SU*
MG*S;UB]RZ>T+HUK\L7?_;5S8?Y+LA ]6US)3L,$BFZF6?+NY@]NFAF,WX?FJ
M#;XXVD_JM"W(,LLB^H$I-WRH2:L/UE;PU_H)?(HS$-3:$V_5SC\W848@-]:,
ME ,G>'37=,:'LKKJGM]EQ")FH#FU;7@$X:E UR_@UD.M67VQRC4O1@VG,,M4
M-0V#=O8S+;IST6'C?K\7J?4A)^_)HPU8BD"Z@?J73ZM1LATML-\63"_:,(8.
MK/98[QGT(7E32POC\]T8_E59,F8K$ZN0Q88(S<;)*(%W[SW#"T(728K_U$9?
MF%_9&SW:*>\^P 58SIRG^S&^Q[J2\$M!+$!C6U](GT_!T7+\4'J8NAR9Y(D4
MJ'Y,#WR;%UR --"\\A#P8C2PW:/>VRZ@K]-5>)R*'I@+>OW,-W_*/<L^;X%7
MG8JUZ5TE,X-^1@ZJ+Y[S#'<\7PSX*IR]TAZ#6P$,*S'?30[#X9:[C0K[B6?6
M'2N\5I*KL59D&A)C-58>\@4D'?N1WH+0@A!(3^]%3\^"C,QIR\EI6U@:7%K^
M]CSQOQ-=]J]\,[6;_!O_;I@^QK2H4\/[8[R\;[D)=_*+X>24BDSI'++'] ?4
MSO]@C4]_481SHNJ2]!JLB84X9U*QK(.]BX.]F1.QUG/YHKQ90U9%?F8RF@N7
M1'UD0T;TJ(F@AX1&YJ0.I)@XW9H>;[:3@D"R&OQP=!F6IJZI")-CW;C4 '5=
M?&!\U6Q,#S_O#]H8-;:3"/24:L4OKX<93L<>,WS^RVRU4@\];[\_AS$F=;.@
MF,MJBR6%DGI=%5,)0&K]R5VPC^)\8;<UBRO9RO)6_[8UN:A%F=WT^$?#T\VQ
M[2.$5!)TQOG7MP6&J)=B^;">0#M;W<45>[\<17 Y[YYQ59F(Q$=P!>V;F#K>
M--;TOB[.\00_G]?TL\>Z]BI:ZH;_?ZRZ7 ;PCPV[I6PX_C9M@3YASP7KB&:G
M\L;BVCM(JNOK'</0T(6I(! +MM]SFC=FFK1?@TZ/S*IL5\J6R2Q!>=).S,;6
M+6W-/UY6;X"Q_'/@C_ZL1NCR0=($Z+%_41A") HO27^=ZN%K8%X84&$[5SFL
M&5H@6:<VS,36'-.J$>7C;1J=J>IX!SH?G0$E.Z*3QSN_LJ*>_J(\809'2]V8
M;EN>UZPS_D51?Y:ZK7$@=Z%HIAVKH3@3.@Z\Z9]^WG?L>Z5CVF?N23]H1.Y'
M;UK4\NZ)RP;_!K<<0_.5E,T%ZC")300<3+R9VG*GB'#+"6K(@->,J>9?,;T@
MU IY'?,KZX)%CVS;56=PDO7B=/=4M2BZW<?T-P*]<I>RQ74N+L'+R2C5"PD_
M&AM:TUA:'>K1]2I\N4AJXW'80D31,O_58WQ$%D>W3N01)."$GN-@PX7MKK<'
MU\^! ^M"(Y1$^JHB3OKK9[W,"/[X=J ;Y(%87J[=*Q:L+WCDBK8/]&-K?0[)
MX]),\N;[$381T[0FU-ZZD.HW+Q89I#(6<>MHW)X'UA%=33'>G=P7F64IBVW)
M'3>UNCS@6/K:A^!*GIU5LH-G&NGN7)KZT58(-$X6)_4/37;3/7R>_Y8#MXB9
M]]FK4UHV[@82;MQC]T049C,F<[$O\#?*$WEZS%N?'4[7-RQSV)PFDJ5$6Q]3
MMX:&1.[T+^VQUUVWM>G[Q)I'30O1155G0A1V+IW<Z8L\31B+$_,Y>NE@+1^!
MA&YV-W]&NG&C=#LS]5EH1$B]D62EL?J%-UX(]T:,)3N[3)CR,".0P-M1-P$Q
M?3Z_H,;.N<7SW@?N,T06&9-5#8_(AY".T=/8Q.&(RR,V*O?V6J.@?^KKNA9+
M,E/<P4BO+I[R)DI'*U&?!$4IW_>N?P!89SJM<N=:,7$D[DA$KVW9E(5_?1-^
M@$[\DFV_]8Z<6X?O>[OMZ#^M1)"TKU52+:U.[06_55:=9LZ]%W!SCRD9>+\C
MXEIQNCO!9(/HPURXO_!$-D!HYR=->MU$W)51%:T9?8M543E>'T_(^Y0]ILR>
MKQ:N.%>Y=4!SV&79#N4#95VN?GT: 9E!L[#2B<,),[5SR=[0DJ/%Y15JK5)<
MH&Z6SJ;=C[/H1G88B5O1!W$,R<'F1V;\!T'.O"K,1MO2*^_Z1G1RNVJ++DT/
M/]5N*2W7$^"-E!3/C)X:3)X2'_$RHC 7:TO8)O@+EGDF^\NN3\CHA:Y/VR]<
MWPNY\H((;6PV=+&AK%;88NJY5#NOR4O&,V L5S$M"0U/=ZHCI[/*L8;Y=6*;
M-I*^&VAE[+?CJ/-EDJ+>GP^2&^%\5#!)_]8O33J#[5 YGC,MYP/"9[7 ^QNF
M.[HX F%>2Z7AQZ_.8/NU=[^JDPU8H3DO][27;F97MU?_HEB8[IB";*Z7DJIS
MY^PYPG11,W&ITQHLGL4_+&/DM/ 2D<]'!^WX%%GZY!,5N DD:&&5<N5H@@6C
ML6M#RWL^LC5_8B405GS[\^DC$Y"[GQP5\A;(W8/.N7EX.%HILK*VY+?S0'O!
M7N[03P/M[CQ4<OI]GT2.B?G(3"F5M,T!A21_H[Z'@R? "@()G0W>E)M=H^44
M:@%9UM,MO)5U5TV\1CY$SC49Z.W5ZG>?_.#,Q&/II[LQ@.TIOMVVR:77=Q*/
M\\R3D=!G/JP +<>+_F4_)=[=9":S@0Z.>UW]C &#$[7#9+WRU#W;H;7S5(;:
M_HIWTN(IC[)4 @9?H@WNJRR^Y503^6EN&13QO&,<9@'WII2,=8L'TSYV]]^M
MM)N5#^T+<:#_=!U 8W+#4F "<OYCXPH+!M,H$Q/WYN91-P0FYE.>=3V]<*@V
M[^0X3/.&6=K?2[/69F_C9R-."[64X78?L_23\,A.C6HI.3:10!U85:& N\RJ
MBBG\<T"!OV2H\N4S1ZB1(B=\V9S84MT>ZLA5J9RZ%I((J1'/_D+[5AA(-N6;
MXE]7<,=FW5V@T6H&O)KAJERR%]HO2;Z_0#C7%<%FW9< #89QZ-XPT1\BX*\5
M?SC<!!24B4BD%6)=1PD&^!5CN\F)V[P5B,ML$K_6)=ZWBV/X-IK-B-:(5+C/
MU=\9@2"MX,_;-G#?Y14O9ZMZ #,[,&5>;CEZ."=8.,0RC)ZL(%;8$H5\>E;@
MJ]66,*;XI]+HPFQ,RI_?>GLZY]LC<W*65I#G 8'Y4[[8BE\-M9:C1/5_,;[B
M\#&Z "MO0)F.N!#HHRBKSAORFV^.OP22:SD!KL/OK2F\,N+$8^RY(RJ-57 ^
M#0V(E7(;WM0WCVP;<6WI:)0 U%,)JMS<F]8EF;;$3F*%& 9\=#;[A_I# +;N
MDN!,]KLD)+):S%VXBS=XJ?HV!?(4!\SJZJB0=$>#4'E_9::O=42(^3Y%Y+2A
M>NVF<PR<GQ[V<ZH/L(\=_IB/$VE.^D@CVN M01^74F&,N.4B]@YFL4F,98%A
MX\*6B;#!'K.5V[L6IDUDUMW5O:( #:_8N5>E E1Z9T9!/X32C(_]9] 9RTA'
M<SDQ4JM<C('3+1KQ457@1@>=OJE@_]!68*\\)<ATW)>4N,1E?AF#,/USKX6=
MG%*,_L!(03#!GE,+$V.JK>J=2&GZJ"WRGU,\&08?]V\2X-LX_:'>F;9/%P)M
MCOE),5T)21520[E3-9<IKDFI*926B';!>E]XRLEEQ'K_0 IL#>46D%*F1MXZ
M)T&68*>S4;7E^>2G/AO5ZLAS=F[4ZV/$3N7^5<@=-;\VQ87"*WZZ4-]@>.51
M6<]!&*+L=14.%",IY?DZ<HOBQ! L_!-S$V]"UH1Z2F#8G]/7E9>M@I*4IEE+
M7@(_QF-*QU:>>,Z8,)KQ;:(B4X+CF:M=0;.6JDMY>4&^B6>O-'Z([A!OE.*_
M4D%DY8XE_E_).LT\]#9X.[J7NAG:2)B4YB=\[Z[TIGQ["!:;[5!3L#FMFDXK
MT5=<^)UMRAZLSY3*>(1N*J&@5LA#<VA<;C_0-U@^Q%,P7S;C*=3;-708 M4,
M65^VRI//N-VVG/-T+Y^7'SJ,SK=B28K>8&XH9+H7F+(MR) H:GHCUB2:.9HS
M(K]#X[Y9_P5=D&]^DYNAT62EV?+-']V#\UW#[K?6 V\U%2-A/V*O'AVBT68$
M0?:\?G>!85[QE&$7;C&(8OBHRLCY>?7,HA@D-6=Y140H=QH__B[Y=CD;!S>(
MP"^_2RQYF\7KSM=!3RI[,3R]V/DGW:^_*%]'QT3S' 31FZD5]8KCRE6 F@2@
M?B [;W-HN=O=J3&_8%2BF$%Y8$_^Y-D@*XOW0U>,61<WS\3M7+A."X5:3H7E
M[L9"6W:=-38(JCC-^A9YZ5_.[,3D1JM\=I3C;G=TM]<?(?XR,#2)JM*3P^-.
MOU@GQZA ]63;]/G-X9SE@@%-W-J*Y(]#VT4_Q@;# ^J*7SU>^SA:6Q?ZG2GY
M#KDL4_P(D^&0'JLP[_46XP&33+M-<0A1DE6)O0&RL2^(M;*1.+4QB%>J:H0.
M=ON^JZM3,T<CB&U?NYJWTU3H!H67E$56G28S#V?&D53&?\?&Q^)^N:.!QMAU
M7/WPS@<<!U^8<S@ZWO>-%3)V'$2G#RW*;$ B)R@!QO'D/@^,W=GBT"&-ORBG
MO5Y$BX5AR$T%M*_&[IT0B!"8MQPQT%/LOA;X$I$Z*%J^DPRYM)^9O]/FMOT8
MP.Z4R\/9/J:9<SO=:R!B*>TV$"JQM3/TCELUL$';<*G!*'=01+$%?9XZ;O"X
M&E)8?';L8EG@TI([@"VE!L!]&SS+1 KT\O/RN3+D[<#QLB*49(C2I+3Z$T,<
M,Y4>[86-JRNJWZ:C7Z9903K>B\[X&P([WZ678N4L.G8;4J"'98C],CV&'YDL
MW) 7VVVX^MX0J1L"8[%;8W&56$N=#0?3FWMC\[D_<TQW:-$PN6C%T;HMD&I?
M#ULF3@=/?9>A?_DKV'=*Q@*+,GTG^$,JHW,YH;PL^II)Y()L.X6W0D)7,V^-
M%-ZAHS(+;Z[T0(GG:/--*(%[U(H"/#%VW\L9DFR)H:^.>_G.M<[_+PI?A5N]
MMK5'1;;-=G<;[Q38S^T&LF5I>YQ/XA<!_N84MK/1X/6*N8S_NBN5@UC_<"$=
M7LB=QW8P%PEO.3)(Z*.8V;(1*7D?;91XGL#5)-BGE5V(*<VME9T9;4E6A60'
M3# E.;9'$E(W]34/N2>;8\H-N25I1%L2PY*S_B0J>ZW)QM8=R2UJ836VZLX6
M(CKB1$C+S<\TTF,JVS4_LH85<3Y;DO&+SW&*">N6$RH9IWV@UKP2JADY"/B8
M.+-8L+0TN&U]!@0 ,3D^B#?:O=UT!E)X,NP%MZD."H,'V1$"B4/^)PT8C\ ;
M/SWU7^<%GKR-\^7K[Y^</EOP!JL<CNUL@JJ:8Z)#PYXC^1M<+^>",;O#S#VN
MU36LZS+U5+7%%HR+OY6IM06:R!O?)HVP4K^?K:&DNG;X=/067]XMJQ92SKJY
M&W%'\>PA  ?DZH_72?_J5!QZ8+H3GWL+=<M];.AVW")=RM24L]RBX<BM2B*;
M+KT4=4#V%K..)-C[E^_)P))OD.5<SIB(^NSM6!N(GUCV"JZ6EN+>QM?PL+KD
M@4_<5W5DO[91ZGR=4@,+MS/?I=P1-G[=BHQ ZTD4,SQ<'5N_9,GIW\N1T*FP
MK#L[0W1H7Q_F-0*O!OVC_%*W=PR0/'XPE/=]*(PS)HEBW)M-$.7>B/(-9Q[W
M;N@O=VH</JMZ"9YM&A.-B>)9%\MUT(ZP3Z("!Y$Z/9*OWI30VUKW>UBI@R67
M# /6FF3B><%UH"SSN9^85>Y4YI]E<Q(5<>S. [6R-5_-T7:.X0"*@O;]",D5
M43%KFJ1,16<RN="M9-!G\]6Q55/?%PTP1^B-W-6S&K[#K.8+U@#JR$:T="H,
M=,[%V%,J!7F VZUD46A\NJ',3Z*Q99YN$=]V1V%AEYVF.5C2BG3Y%E1BMB&/
MRT6]8J%I,5J[E*WW2'05&E>Z99"2)/CZP(S;%F&#P.0Q4'8"UQL--KY=[*^^
MR3UO\3>.'3D:N<!:R2V!33<4F_MNJAU)IO3.1[?V3434VE2]HL$A;!(BIW%O
MFZDXBBW$8*D@JHW.H4'X )1=D<AS'[^L6-*-[UW=,55;2B,S.T?3CRU$=RU$
M'=QJQX\PV+DZ M8!5YSS@H)F5OZ,-?V:(3Z<73(F'EBU"&0,,$JHX3'8>"?"
M2[EE[D(P:HB*X8VT(V:Y*JQC%KLJL5W4P_A3[Y89H]V?^["H]#B<P94ZL=)B
M8&G<,)VET^FPQNE06W1?7?SK++7Z5['RP(YKM%:@CH[<\4WJ$IN<9[VCLXA?
MF=.TKN11GHWX2@"UF==%M <ON=B%14,HNT60P0BF;I./^ %6<ZW%/FZ0UJ^3
M(RL6"-,I3+?RE4U)C1X(Q'K/"@(]@0+-[ORC_!\VKQR_UE,HR(]C5DQW;\!=
MRW[SAA!O0<5F2G$^_WC?-:[7ZX&)QH_#+RN.B7_UT7&Q_2\*\B]*YK-U0).X
M%BSJ46FV$=OP<U?I*_F>:A[OB9APXW/JU^J52)SEY3$A/SFE8Q"9O!ACKN3"
M_:B0%&GWA^[,'%$\XK<FDN \L7?-9HG+NOOO>#U^5=U$W1@Y<6ON/S0&/)LA
M[H)X$ERQ&^'/RI!CW9L[;F9?*,[Q7Y3!%)>>@4.]%=;/1W.WJ7[')$MS_8Y]
M9=.$<E,L!3.A.)H/9A+%(?DOOV:% VDL839,J_U<G?PB;A*,HO8OQ1JNCQI&
M!QRO%/ BW80_->(<(:0T]@DYVZR1QZ J)[R20,7('' P,DMT#OC(-/'\O5N4
MAM^X/C8GSA'<-+O=OR=4C7BTGEHK^8M"4WJINJ[[XQ[PH]F9H-J@7[&G=6;)
MOO[  ,2->'2\N%S;@JV$R&K2<_[/JAOJQC[ECA1&3:=SC?;/_:DHZWDO<A&3
M5PSQ7JS61Q#>N4R:]N@E0HC$KH3HTS,B>T=14Y[$+*X#:EHIW<L:/ IIJ\P*
MW#=VDDJC%EK-,NNTKM(N>:^:N]ACX#/(C+:%E=Q@Z"_],O$KKDYF(T]@:F/Y
MU!O9F<JY^(+<MI_/EIQ\WWOIGD-Z%U#W_U.4;03OY'GBW-'K_^#N+8/BZM9M
M80@)A$"0$"RX0X F0'!+($#P$(*[-=Z-NP0)3A/<(01W:5R#2R/!M;&FT<;=
M;]ZS]SFU][W[5MU;W]D_OEO]9ZY:7:NG]*PUGO',9XSM[3(IQEPR+XT0K$($
M2%@%.R%6^&1$\5Y9:^[.D)G2WGSG&PY!9&]EJSNSQ5^.JK<9;242_5_G*'!S
M:+']L?U#D\E$",CB>,.P!3@D%5%KJ/V1D1'8J6H8G&M>_0+'RD&]8NXLZGV.
M7,V(?O]B?N8S_Q&2TPR]N(1TM9EP*\J(GD:-R98("K2!^7\'XQTNXO7[1N$!
MC5<I;WB^2$0Z:S+ZA*N@6Z[E$S0V7*/573>$CM(5()(HHRS\:N*+_Q!>-VA%
M?:(EK:;@1 4>]3ZA2&0TH#-M.T-8$G4D%]4]*JC@2DKJRGJLC0TP"%?6'VGY
M+7(*?8J)R86[*$"C^E\L8XA#/3!_=-<V?VW=:+=W:Q I2S@M&M04QX[AKSQT
M/W!+'BX$3^ENXC![/0)X,1.U])PV0$Z1/O29]E]ZB_Y-$#DSYJ<(=# /KP A
M(5B !6CNO=_ID_YS?KAR0D<5830093%HC2V6V7@R)VNCC<5#LI):]-)]Y]YL
M]7.">]-PCJD]S]F_P-):Q$O^1UB-64:KM^S1VCN5[*T8:_A.XAU=EYK47W/H
M_Y-:7(;W2KQ(%(>?81TH"J<P/6_]QTO&_SU(#VQ=T:]XC=I8AH\$]@%^#L28
MO,U[8137!QO&3M--I7?=@  (V>L&YKJ;Z$JZ8-9T'%/]Z[1%C\_+%*@\I[(3
M>\*0_!!6VJ!G<L!XF/]31.3'H8RY(&WX)?"+S0'AGH?X(8CIMM8J>D/S^4SH
MN'I6(DW@3[JSR/2 ^QNAB'=N5-?2:P4[+E2A)?'5_D':Z5-#"3!MW&]%Y<NM
M0*\DD+9 8D^)JSE;J5:JY#I$.X^'E\5/P.5$]>\C4,N&/X&?"D\P8&[N7)LR
MQW7IQM1L"/]*"BGD_;)ASSX>6*_8D"X=.B2LOP@P6W./RGSERI#VN!G]G+?_
M0*8^D+#[K*:7ML2,SU4#\&375%[S\.@LE]^>,E-_-;46(&F()MF#"-8JIK1P
M'V;*/6J@-,<%4*>3W1H <E\ZG-I@R#[12<@ARP[F!MM_Q1$ ['^XC1&):VZ@
M]/?X=\JM_GW9'M\=^"P-EQS5"4C(JFZJKUJ=68NZ&+'$J1H71W."R-YGY Z9
M&.^*2Z?J7AZ^WO^LI!$O+8+3]_2Y'0J%&EFRO?^#UE?O8(.ID M(!\T;<L0B
M)Z=BFLR.U^9AAA9Z"Y50(<>9O$,H!F]7!"P9)B;KX%X,/RIRZ29"_'#7_'MJ
M, 3DG04_+K%S>WL^Q6F3-PHZ>UXOII)C_6ZV:)/?@_>5'IG-]"K\>KT^B Z2
M4%[^<4=!$LCV''6ISJQ?4=4\D+*PIQLP+4AN()KX[-05$=4?3)%PBVB&U'1*
MS6C2?4*6"-[,FAUAA#$\(N"G_+DC%KKDS;]J14E2_4M^',%;8UI+UGS"J3TW
M2%'#(?!\PH;&46A[EIH\54NI+\;!;:_[_V@6_TFRT2#AGU(V[XQ^_L?>8B/>
M3[@V.1^]\2V_QW=QA.3]3P::[_3W_K6,WQ>W?TK*E#O]LZ3CWX\=_*-H8V[U
M/Z9LOL8Z_T-7KY0(^I^0?TTF^TY&P8WN+R"'C0.MPN9M)FB/@S:+"-^IHG\"
MG>T?\"S8#NQF,"DN2V[N4RP6&+"XG^8;# BU6AB!DBOGL)]FO5+NHA*ZKAI9
M8_I@%ORM*DW/,ETCMVN]DGSPC5D5N:?3[W[5:C'[V1(C:B&TM('N!M_"=2QR
M^IA@K4A&=.9<+G!;=XI^XM2QZ665DQPR7%='DX_!Q;-'P]>\%_Y=.\BQ8889
MXKJ-68O1X<H-3$:$XA+]YZ3XZ%$[[O/L*2;R3YXZ"MZ\6<QQ+<U[GIJX^Y%G
MINKQ#Y0J##> ^?'(HHB/"DN3G^LHV-H+EG>GR6K_9<;3EW5M\N43!'I_YZ(L
MWH\^23' %&=SZ&+0.YUO%[%XU"T)3*EQ-K5ULIXNF$O6WAKEX^=W*MQA*2,L
MS/05UBU18S8TGG1T1UOPB.12J<D1%(+1C$CVY5?,KERMKCF&6O%,^!Z5K+I1
MKF6^P[/&%KDXL19F(_I'M9)= BF](P9,(AS#5$UY+]<ZE1UDX_K_?Y,.:G%L
M$O&XD=]2:BT^KX44]JSTY71#6L.6]+[YGR"FN!-DO*-^LE@86Y_E.KKZDE_Z
MB@DFNYEIORHLAI6ES1-/86N;976^"7 $'\JNQB6HOTFHUWY6$KZDH2W826A(
M+J\DS=63L1[^M![<3JK\[GCFMZ<:0_IWO6#11,_W79\ 5#UYD'2#VIA$@7-%
M&8<<-@$ZV@\&IM1-!RTW'F?<-*^"V]*+P; O$X*7EJ$"64U[U>WQ;JMS$6E#
M>'LP&6HDEZ4OA@.FB5I=JCV[E\L0--'.+[N8?X'TN)KOGO%]MZ_(UBO?HZAZ
M"ZVV?2KK3\OUQ]-_)O!JANT![:6N*WS6IO?S*,>G#[CKCDJTLF0X7OV1\"#M
M-DTW(+BX:D++M6\^'2<9Z8;_<49P.8PN6D@&'KH<[)O"/I[8O:(G(H(MTXVZ
MA=KOI*1%-'H,'0EM\FKK#7"["'2FX+@E*]U>?^489I4]?D"3(@2>K*8X8VKL
M"HC:#Y^E)#Z@R4++B#F/SQ28[TRCHU^-WW)4PX3:MQ"7A&69XVY+\]WC-N42
MKAY"/%7MO4W%1;*'&OV-F/D'H%E;TSB2:I%6B9^]QDX"WV[G&DG#HVL/-@=:
MAP[VS;^VUGI-GDLXU$WH;%F/6X>5;=J39G<M<@H?S11EE7.!,:PUH=;8 8(\
M4T5*W#*X=EBA0RAOJ(;)79O^ ]J1X>,!G^,6S-][Q8M>>6DNFNK"=I'[Y:_5
MYTBQ*QQ#:UMT#2UORX_2--M>!)9@ODDW)Y=6M4V+3!P6]UJ6R5PV&QJ\R[&'
M$[9,57.R?VTI)9BQMQ+6'O9?^MT<2-&NT,Q[U,>QA$356^GA>.V:BSV@39ZU
MG]E@#3V@)4T:Y 85UT@TVJQ*/* -VK2';)?4/: YJ^DM Y5)!^T6#-PTKF5Y
M5/5]2!O.%:XC+P)KZM)\A=/H:)*X9M3#4NYS+C\/;)X)(MM*JN/;?K7NB%C5
M7]Z>XZN;\]0>G0/>)_3"=+$3V[JL+65JMZB%IQ1S0.%GYKN('Q%EWZY3X+LF
M9JUJ3-7V*A>"ES@A+GH^%M*#:XJB0R[>#-C66G-DTS,^:ODNR^KSWJ7I_*GI
M7T"!:N6-0F)1(9U^%L,X@0T11&$UNBX?+=:DF/.4KES@(3[:SB,1UOTE6V-U
M]O/6_:R&NE&U,_S+@)%I>'FSY;GI$N5+VU<[HM2EO1JI=F+I_=MPJ2\F/,#O
M54*2MDZ$IOO]CYBYUN1D/I\-CJ7@5LX&^XBT7^L8>=:=O.T+H3/EHBB(80%5
M\7QK"FI8-X05ZD=$B[^T2;%O)9(XJ*@/N^\D=G@>00^AK<!A9K<PJW&SJ;=K
MI()6J.4)=0#4^33V1=B<(S_77(\2<$J>Q8$X7?00,+.J];5R.292,V!!R\^D
MU[$.28"Q.&MN9&KF:$9EGRW?AU<ARA:6BWGLD=JE#'#+8J##;?N7S_X-D:XK
M)AZ6.@Y'[$-PKBD#[;78L32WA2PK%V8&BJ22!F')[^L_(*I]2!=F4HJ$$K;V
M]Y.-DE-;*"D@FU:.PY9#S!SD12P#1'(F9#<6XYA9\0&-)4MB&^F[6E0NN\$#
M/3I^Z1#G"SWF&CU>G:[H$N]OH[._XS>UFF_'L2$;/E$WR &5Y0\V@NKCS:,#
MBUA/RJY*=#M@5FS2C2= =\-(GK?]<^JJFJH"(T5U2J]1/DB]G_7R?IZ<MLLM
M==Z+"W1I-0;+$LWZ6S-W=BI!?@]HF7JRAOO\4]:E %F533Z#\/XUQ]K<(L?2
MIKBGDD:^)D8&S5/$H8S&F35'#<,&W0ZCV$%5_OS-[FX4=*0-;%DT=#.N8#?8
MZ@#-54;23(3'@>Q!P;O6I95D"7 TV6U;_<!Q\TU2M-9A2,\EVXPACGV^-V,Z
MTZN&U/[>_@';">U4$/^1%6HR%@[^/;=_I,#C$"\A@]#&[NE53?S0:$Y29RVO
M;CNA LR2:2(R;+UQTP75ZI?R*=ZSJZYPN,QUFA_-R9/V>GO0/,=\7ZS"KM'_
MQ>V0XW'&<X&/\_Z9;%I2)0Q3%<$#B)-K/XY)Q\L%PL5LZYHRA&8513/T1OP#
M)D!5B=")\G=*#^UW\F<1[LV2"U%ID>:R?@FW5M)9NX>=M[[U7&="!J,G(P:8
MOMQ?[I8YPQHVSY)%']!T8><)"I-W$;=6B=Y0YWV"\3=N]9G$Y:P3G)'\WK!$
M/[E\W_6F3I7E2%>E1N9%L3AEYP(AT[7.0H_T,ZGM9\HA;=N2PZN</^^[?$\_
MZ]8S#>V[U5'M4_B))_<M3*G$].TX^/\<-#FZA G0IJ(8?KM::I.\0GS>K8_&
MU6"!R(\RS,1'=QZM[^Y9+0L$1)>^78J +7-EDY^X;:\A+(#7_!5RU>,?\>Y7
MV6SBH&<24O52$^6;-AQ; B.6)NB7%P-4 VEGEQ3?/1R0?1)U>^L-F*:UKE4Q
MZ2;-RCD^\@W7J >T&@V=@>@I9%C6\F;78=ZL%[^7O+5Z9W2NO0"^';6<V5P"
M1T2J LBCJ?*L&!ZK[U9>*.O6]GMK>A< 6+LIB;)OQB+O?0V8TC,W.Y<3DAL1
M(MCP68BDKT?%6(KU'\C#.0YA>/R] @H:,>F&*^&F?+U8R(S4<]GI3 '78RO:
M8&S_*]KO. 6A58M*6QVFY?H#._I2:JNZ)W+6MQ><M2VMNU@=E-/2X383,)8D
M+%Z1)%R.@RY>R:6B)2656!.*1E3Z#T64:E01;=@?_"EY-./^->0>!JV_UI19
MJNX:D'A^0,^RVM8<USYSXN9V<J5O[KR\KW*$10#7D U=8K'84>_T/E :<[!8
M[VF]<+_2^19!084ZOWBK7+0W!FC N:3X-+E)OG/=>H4M-N7@&$]_Y]W.7;SC
MF[DA?/\TS@=V@%& -F HOY9;R\!;N5[=TJ&?=6UIV7M@HG%]SE2\MW^8T<!T
M>\Z 4F^F*G?)48]C\BR/ZEHHU2E1GP_JPPDHXH[_!ND81P]/V'MOTB+#Q_9A
M_Y.+E!NWJ#T957K$?M>^\'3:@DEPZ8SJNK/,M,CEJFU'\8Z^-H6(8%=!L5;H
M4B(_6(+HDWY(%RV(VZ6","&\'C:G%#N^X)+OH",AO6JU\G:#I$$C&Y++V$G/
M 7>:3944(05H,7O8+=5S3.^-R/*%Y<6'9L+L-X.67ETJZ56Y4[SO@H9>46DZ
M8-KHY.=%SJ]7M: R_5YO V*[)E;#0O,.#!4<C@O>V!L&)PMZUW61RX*/ZL"B
M$1+8L#*'I(K$'[G-@'$]72@74)^B1EB ./LM,S6E.!81N7/HC>LQ*;-O<XI>
M7C68Y%[Y=N1$IY:W4:2AATC:@-4XNCV&Q#\AP?Q<VV4BHVY!2-L\46[0*3WS
M.#WWPC$^S:[NPC:9@?BO/%RLG*N<ZT=Z^EO\RO_C$)%4&1S<;971U:$],9]#
M1;6CYF6O.-3A1F65MNGF,)UL()\H!1%&^*:8.E4(*CR._>#3&]%3N-UP%:\;
MD:"D338S\[KBYY;,8%FYC95DOY+@(*>;$DVP!J?;C#"HG&3*3(^CW.%S$(()
M&OGS0HEO:]#F?!&%7<Q?Y\%4R9(ZSL]"U[.C\YOBN1/+58_M$&VOX$UYSRHW
MX759WX[G>%7<3#@WL/B=-&4D7'&?<;0KHOZ:*N+\"NPW"#,!@I^HL"B/2#!H
MM,X+T F?%\V'LI298,OF?\P/EJ']CJL_UYVR<#-4TK'@U]BI<58F5U-U^6O$
M:6ZLC@7\BL[-42+EQI4J52LD,[M7/R47?>>5AIG?L[0KL0SHL2CW2/_$$3(F
MXY=GIE1_(M:TF85]G4\9.^\;D\:]D7''%^'#W0&90)$@GB-$G$1NY_5>MP$I
MO$ 9=MHC&DE>S[;FDBG#?I8@AHQ1Z:4"0P;RW%H&JW:I<-6O45-X314P&"F5
M"M;@_O#F%/Y5U^+>.%PA9B_+TL<K)Y)QW'/BR_82))'L\&HQX=4^/0J%I4&!
MH:'5"#)@,Q:,AN!2M20Y(0^GC\Y1O]LU/#6+E9B\G/>Z&$EL5"@:!G /Y>DX
M/F- J]!#XWRD)U)+P&2+I8B00+>=V J.3I6-_4_M6PH/:(UW..UBHA)Q9Z_3
M(_5N/5&1A4,]_>7\:K;Z'F074X)%?];12=.,A23=@@3!6C-A.6$)B]=Q2,]A
MFG>(B[@[FJM8^3@]X[;@&MCISE=F<21<+5Z'CGN?]5,C*B-9DKLVF/)#D+Z>
M V.'R6??\FH65X<!3M1>4H5 ?AO><Q5=FN"<2!K*R@;)^AT21QX/;SJ'/07&
MN-D KO09+): $DHDVMDP7;R*J\M"X7Z_![F["(&6< ?&';$)(2CGNUQ*KYKI
MN?A[+&1685;^^[GL[JG5!BN]/SAR_'CI8,;O+HG:I[[%<&*Z /S,DNRER5R8
M!7-)@A(.M0>Y")L/"7&/##M)$(*=8WWIQN"WKY*UV_U<BW2&CU,O%'!E4M8R
M.R>D,N1@+0]0 ^D5Y<YOS"NY*#&U5Z0/=D04JX8]=8[FH6C''1J&'1\@NW@]
MFN]4!+039G'J_2S*ZHILV(IXYG*F&V4%.0ROD@;F"R)^C!^2+9J'Q\RQ8#?)
M#"] "#T[G*51?4_#WH]<@@8,,_7TA?17'JVM=SV@Z=@]H'UZO'QF=.M>/@0'
MBM%(]DQ!?J+V_MSB*L]=-L<WW2F>L%FC9H1(>\R-1<W[<E!:UU.\ZM^OKB9.
MF*N](K2:T'SM/%:3"T\\5ML8.XNP/V9(T/\R8J^D3K'*UHM]>L) -D)]#Z=?
M\&(^UZVMW3BZ._')V-S>U"?VS=FZG0H<>3^Q?PXK#H%2.&T8''B52^H?P-,7
MEAL;*HXX^FX:/PT.T6C[M#ZO=^6="7XZ&] "&@6Z@K>,#XSP/$P25>SKTW <
MS6'X3ZPNTSH-7HV_<:P5DU(=[N[H*M8T=$E$U)+U52ML+4Y4.UHWE00X50_(
M-$B/R F1M),X??$HT # FC_5^B(WVNXC#@%9[:W[J8]/RRHV---"ONSH]@#$
M,T*M%B&0ER,28#;;\NFO'%1 ;L]XA)6.EQBG""XZRQL%$O(*JM)R[S0VT.DF
M"!D9&E4$TDV43)0K\)A-'EJG9W$#866BIS0 UQ; ]5,.SJL$H<85!MS&F->1
MP\?M*>02*13-,2*-(LW-Y>1M(F-JZ.\V8JZC1UXGH%^*$#FW/UH>[Y60YHA>
M?[2TR4(($#OR(]]I,>Z>W+[EHI(D3#2,R9U0'Q$J2=65&5B032!;5^+BWZ5'
M&/!95?#"RF9/(;1KBAD:L[IQ9,>YJ]%1CZ](!>;C(M.6G&[&[?9>YHPQY(/,
M3JG$_!2H&H0#-M+&5"0JS#A,N5-PV^3UW*&#@HLNBBY>+V3Y&G4G ]8[^;8E
MQV<94K5R JRNNJ[?4Z6\E2&B**C)Q-(?".X<#X (4 6/GV[W/+&D=WC:M>H]
M\C82WM.BG2^0Z)'GD1\K)61F#=P5D_+B]?2&2&JF#AW VAL8,-VV@FDO'JM"
M#S&NUY4_K*L,UF'8^EKS@;AH:(74 C3ZUWUS)G*-Z23O#79Y+M4C(#@_U6A=
MZ<SG#;C&JBK=):-TH\YP(T.Z*,5.RW2&]+[AVI3_ZMP<Z@_(D%^H=M0'$:2C
ME&&,"?9ELVL/:+8&+-TK>Q2?)U%1+Q&K)NL6&_"!UDP-,<?&"35'U04XLO@9
MV\@ TU1#GE'Y1/,I14X)>%?^]%APA]R2E5J *L'Z:)U--3S*/3L ]7;?C$W*
MQG^GDIAS%*=_7XFM.48< "\[.-;/<JUH34E):5T4B!/8\Q"@*5MO2-@IN1*<
M=H<,JZB.3I;IU>V0-VK7O9<;D/30G//^D7ONJ.J$C/#BCUV\=Q&,B#ZNO;-0
MFSXQ;S,HR8C+\!V%1Q[;);3I29CD,>G;Y/^.U#0MV9^ZN/+C0MYFV'.^]TP4
M;[FH5GF#*.K5J&@%1D^_BG^^IGOF&A_,1?.+Z##U,]FM<F:U,7*AOGSZHI1A
MKZA('&_\Q43D(O.0;ME'=T312KA,O55;A6*,YJ$"#!(FU])HSG%)^FO:P9#D
M<!.O0Z[,4+.CN[7/U_HPS]D\RW.A?/;R37\KJAY9%GL1./_R;)]VS-D=-)U=
M:(*8JW<W'9SB*!%VF4^W7+!9&,>O,J<J/,T4$4T0%EQH4G%^FV'-9_,YK-S(
M^5XR]XU& *L)&05ZT7%B.-DO'6Z3 MPL$;_TR@:AS?R%BYUSG<DA<<QMA/V&
MMW-/4=5<E"AH?>C6;]#9"-UU<SBR)RWD&E*;4<'17D0Y:D%-DSH?9F'"&!MI
MTT94SN:LD+ACFR5=;:@5O<U HU?W[(UJ12R;#)MTV<_$ 8#&7P7<LPL]=5Y[
M/UUR\6UD=Y]S%=M$X.O-NXF%#\O2:/ZN^0:I-<YAN4]4CK4X=K6P,)\O48:\
M7IP$27W/?CO)0YQ57'O-*Z=\YHC,*FX=1%*%J@QDA+.]OTVY.OZL4B5V))9;
M=_ K JLI93'J]>T;!!^X9&=>!A>%I/R6#IE^GWQIS$;7_B28VEL(P64E>]T'
MY3Q2UO$M4J\8;VFRD%GFXD\QR+T'%7+!FP?4N[G]0$5<Z3I)A]82T\,_MHJR
MYPK&B^JHGX@M+[B;7Q-FB=4GXC&[GFOE^@@4 @;?CP^I3)!D)W73@S!)J*E[
M,^)%1NL$/$V#Q; J'%R/Q]^\3;7AF##B$WT15^DN_0W6]QF>E>E$IM47-:_Q
M%'M'IQ)C.AO$>#BA.QY?D.0/CB.=88ZOZ%,8&YQO3+"Z9E=W/'50R4[JF[2"
MFI.7/:"IWU3?C?YY@W .W7R0_DG]^U\3B44#RUQS5:<:VW)%K!J'ASKGC4 &
MUJY\5MY#HO?IQ7<<G4R\K7H_O%HD6XVDLW[Q>$45H@ZD4),W"36-@Y,_K%PP
MTQ%J1H*(4I3IA_ [0E\AM_ZU0:1E!SQP>K T^%9Z\-'WCRV\?Z+W8[\%<,Q,
M_-_0I7R(,XT55S+G7%Y$LT5GATVAZ83;U]'\I\<A@@,%^TFB A%4G4F4> =]
M(0EIB8Y&VTV/II&4^8]9R-/_LEGB,%ME=,2H>AR3W$Q 1L2-'E&%S2LB(L*^
M=4ZR1T6R8Y>8/@5FI58LN24O9,![LC**T*+KQY99_GUGU"+R.QICV,:>K/Y]
M  ;7OR&GHI;49EA3LJL_'J?X.ZN[P_*I(2'%XXQ/\R-SEBC@7F4]QE5ZJ^$+
M4>CW <DQ_Q:GB.=9S:;G_H&V_,M?;(C<ES8DJ!@%+9F0G=.NNV)Z'S YWDD3
MP6/9.-Y\C],(M\ R 7XA[3>SU:LR03;F0D&+?^(!$\V=Q)ZT%R^G66(N@1[,
M\2-2OA2Q+'[,J\GX2G_KU]^M[(!(^-W0\('SXX(+25=;.Y_FM]5))6\OQ1X3
MG_$]H!%09HO^&)$J>)T5%QVJN9+$0$8$)5LSOV9^\:CI1:3!MN]P='VS7#C4
ML[DC<SJ3N@B&&X!X^V8QR!<SCYT4\XDNZ8H<!^/0H2[4DJHI.3UW^U_-T+]5
MOU$/R_F"A3CG=,/FRR:+]6PZGO"(/&KTP-*F%[G:RPE+GZ!1?"/#@60<1\,1
MB>-Y]*H9)6+4ECP^=0[#-N\3*-U58O;\: 84=4W"((/40 "]/#O8Z3NA C&(
M$K-@4$PJ>FJA0J.7)-A5U^$L\\>T1QQ+?5J_DLGK.^4CQ-&:"K4 *1;@]GUT
M[IMITHO!=T[]R+?5Y,[C?Z^W2K)\CITX1=ZBD=ZA%GMORN=*Z2N<:WNGII5Q
M"2H ^N&1^4-LB$2<WQL( <4?\;BNO1Z_@U&%BJ-WMZ%VK/7)6]9?O,]E'QHZ
M-JVY/0H=3K1WW:!(*?!@"#Q57?N 4W+_*9'U5[Q!3VL\-X58=M6\0:"4*:,)
MJ0NU'KWE^A 0&?IJ*@DY^+X$I[[$=(57H$*9U;\_UP/W>,S=X-._*['XSTU[
MI>$%6_[*7^;.(S_RJ&[Y@>F38/68M/EPU54(_>H2.P$%[E0!'F. .R)1P!3=
MY8/O##SIA$*JW-%3ZO6Q5@ _Q:QHMLQ1L"FVV?HK-]E@RUMC]_423\&[9-!,
M.GFRL%![*@1RO-1+L'\?4$4M_O3>]G1E.&Y\VB>&_<6;"'BG(KAOP[:&^]*A
MN?DM:4Z1:18N,\2(#3=BMOZS]8F"0;?LD_#C@<>'\H 77:+,JL.X/_0(Y%X&
MJ/8_'EHS6=N#<>G_;2!$98L9"^BG2X59MKR)3?8ZU9]K"W)353(09Z)&'.I8
M9=>2E$BM?MV\*]LHG5_<<8N)'_><:UL_]6L5F>"XL"26-<5U69<5XN9DUJ8>
MXTZAI&B;7SJ]9WU<]1'0C?E($H6J<)CEJI6V6UJ(E,G?C8*J-W;M>%9%R.XT
M[G!_.-?/H3&C:\6=.E;7$@NNL&<X5Q9"0QN:_'_%7^Z_3BD\H,W;0'TSX/IT
ML>/"L9BOS_MZ<MP9,!I#!KH9IWCBGUYN938250421*6.JWS6/+2(R:(E1*_P
MJE&QV).N$X:RY/)QNH7O85.6Z*#3%27TD:=]&?Q-?RU<]TLOI7$WP#BQID4!
MNWK[B?O(X4B7X/#VN/1C#)U,:*>T26_"D/S(HPD*;%AH.X?MQF5+BBRE8W-0
MA;QK^"DW>;>#DIR2;NZQ%F6^+'9R@;@(>UBC&&X4!>VJF*Y+%"*1[<F]ANNZ
M7",V>N\[>HP7]H+'_UF+S'U#<-X]C.JMKLC,7M/M-&!EVTEGH(CT4-3JOQT@
M$JG$5*$>5S"E$/)X"W')\]. \HHA7+N<[%-AZ!&3UXZW0J( DT+=',='%D18
M;MCTWSUV@H>M N2G2P:Z:TM[.%Z$#I#CV)1\'H"[+.'S3UBT <\XBU3 O.<4
MTYYIW78"B?%?,02PMN8C.X=)3!H<1YX3;P695PC./T*&MC^K^YG)NA'\+I4\
M!]LDE8&<_L\H($(,WZE^_>J8_=JS^%$_77]NSG?KORM3&;9_71&JN#FWQW;I
M6)P?T.CGH]G-[(0ZC[\54E=[__?\M#MHQR_O!B3>AWQ (^=]'?WZ$#[Y@*9P
MON@3#;OG 7YZ\?)?_0@7WA9&J=$>UP(IN"[NE<!9OF\9!5$?&\*^DF!^U#R<
MV8*[SV2-2RL>?>1-XF0@\6LDAY+)D JC[:>[I2?+3I ))X.Q9G$7I]0 KG2#
MZ> W>A.S84W]3('X1#%]Z?T=O^]<&:,.I_H1VQPID6>KI9"\J;EAU<3ZS,D4
MW;FA$4G9Q T%)B/4?/IB:(.3P)K@M_X65GK+E2##GV0Y>$]*N4(R,<RM7[>T
MJL\%AG#F/7NAP'-9V^0E)XB8OJ.*28C5+XDTIWA:$"FJDO-$.5V:,O);DY-?
MO\8-WUB!;5(GYWO?9JON5.4)JG,O_U+E7I%W4W88@?3VD$L8U9X:"""X&[L0
M4F32= O/SGYYTG5 F1)7_T$5!CI7GJRO=@.M5\QRO>A!1363EL]^;QE4(-D;
MX R+S!J":#\=@,.7$WJ.!!_0W&)1BS(2<.1M>UR)4U<+2X$5GX>P+Y/6D16;
M/'OJ O]9W?:)KNER\4::PGYN$S%7I'L7KS#(0YM$;WJ?&VR]>@]I..ZD0?4(
MU.VU1I>$]GD()!W?52#O70;ME-_TC8]N]J7>9V,&BQ=<'"%O#+F.']!X5H72
ML]J'S1T//JG4K7^*KX">JXG+&#)LW-N4.6HVNIT8*K!Y97H_H(W^Y24-Z(:K
M#$[P.NK:44RG!?U,DII)5-8L!+;G,.V0/Z"=<>'2VR9,^S';3/ 89J>>X2;]
MY%[LU\2XI+_2+*+SR_ #*DQ^GZDF$#N3NI>HN6=DVNJW.?V#2'E.&6.\BOUC
MRK$V@*WD^ ]HYM<??<_^W%Q^NO> 1M-W]( 6[7^0#[W\GC3Z_0$MZ1[G+/X!
M[=@@,N2VK>+>9DX/-\'^KZ]<?;197ZA"=IYSC'2.PH[.KA[0>F;.<D]]P6K+
ME!JI7>:U))^5A;EG.>R&>C8M?(4SR\5QB&KLND[H9'[1CWQ0[-QOA:@&Z>5.
MFA*WY#'GD/5XUIW+<6F<RZB]RIB7 RV;-;4/N%G@-%HL-93!Q,_>IA$ORLZ3
MZL43&70@WI+P:#X2:8+1'NJ2X80XAN"'A[!\C_4-V8'@2$GR !A2A_UXL/=0
M[5N;J/NX,YN;0">&QBOW)L5=O2-[3^U\X D"1W)NOA&'B+>&7#1O_ICWNXJ!
M%NR'J3C#4?2[B2_Q4(8DQST9O#D>\ HJ,E&4WV=R/[*-$'B0;]^KW^RC5BY1
M!CHT;"QWNY(%1^C&;Z$F9ON<!=)>D[4VCPLIKM1T$0_!NL_>;C!E7 KQI.QR
M4@O7!W/([N2\G<.>??I:K8J+L.3KA;>GV#P6B+&@6$#&.BVNU/2P()!4[+T/
M44 Z]CJ-9N\<49R8/;;_TKF>3F$#5O%:21SER2R^K&4Z?T:?1K<1MQ:*^77R
M6Q>'AF+UJE.;7H[.KN<Z53V/;8<X%M$$XGC6=RH=VB%-^47DB#6NL0;')9XH
M7L>!.J[QH:B?")+FSN29)A!O0HQ96+X]_*T=VYU=1/FQ[GN)>,^#RX'V6-E#
MPM"(IW\^;T(C>)]&".!R_&7-_)>6S?!Z>XTT5AK9__V9JU6/#Y@$Y[4HG!\7
MKKFQYD6WQ$4,03DYQ4<.4M3*CX!7DV[^LZ:P\4?&.T5VU[T"W 7 ] +$<]V;
M+Q=^(+P))<8K6Z^-MXA^)<,OQJNIWFY2(I5X\OPOTO"%(IQ6%ZXZVAF>%"TJ
M1-1SZ< %;:49B7HH?\L_H:P<)AMX615G_YX1V(W)N @-XX76Q]4_DUZ1>.'D
MS(*<3KA4BR\ 4JXCGK"U6<U]B/55BHUSS!RSKQH8[)?W4A96(;0'4&</FQC*
M]OLA2A2L)*)J3]7N78^R[#;&9V?\U5%3E3,.=1M]!L!M&^)K_3R2S:]0]"HI
M:PD!H-6'4*&=T%\-S&OS!RY\V3V,FDQ!/[CMV6M*W,W6%-?V/XRHH(M(M/NO
MWOYJ/+'Q/X?L>RY$&;GRO#+M_NV1TBAP">#2_C7*V]RN-RO$%"X,U_L3F&SV
M==]Q@(GZ/Y-W!I]<J('QHCUR0[ PR_JP0O?<%!0U<UEEDS9L]9.+UP-D\<BR
M@UNS=W<@;!; 78_>%@CZFG<3[QD5EVR]>D&,)JC"/^RTP5%L]2E2%UMF5E*W
M:753(6G/PQYL0C(M2*':O9Q&M3[9=!4/-G,UJ XP,'/5O\J&;:71AN)?.1U<
M^8VT_I(XX(B9:M;&)<DO^IX-QH\-N\RL#3_Y5$]XI_#2[K$%N7<+Y3OO^JQ&
MEPQX92--AD=VI<1XTIN!N\V=J <T_2$_;94#*T8$5 F4BIK8@^J_6H"BK,Z9
MFE5R]%_9 %,/VL]S J4)^M]A*N)^H)>YMWVT/K3Q@*:EF^0G[F[.O*!2=\8Z
M^2W;^,P!3+@!BCT*6TA*6 <S,%S19#&OR 8#@1#LTUX9_*T$EM6V3Z0Q[8:;
M/H9W!LB;F2GM<,)+/D?M5PY7MQOL_+3X<?=EH=JM#V@, E-7ZMKG&8<TZHA2
M7$I."7T=)?=Z7;O+>L0(2F]@CDRF&;A332*Y:%E"K#=6]]Q0+ 'LH="'++<\
M 5?[64SXR3R@X:OTQ*HWI67(XLC+,<>;AM,Q0^CHK"S$Q9+7\#WZ08L>O(>+
M,<ZA[838#:F=^S_Z%3Q7);*@CW&5CS2^9<U!Q-V1R\N,Z=P?O>.NWE3>>0\W
MDT2MUXI.,YZ<;\8C 33+'1_7]T9A?7%7 !IK?+^]BJZYBCE#Q14RW031T)W4
MZ0_ZCJ,)U(K<A5Y"8V%ZI76JK@-@G^/4ZMG"3N[R9ZJ9:GAL<L.MZ]<LVV2W
MI.?M!IEIZ2\FJ<]8,H+YQXJ,*W;8NB+(4W1J->D0.30?AO0[+I&M)F/RQR*.
MS 2:OD*DJLM1$R=FH,F^&9!%,_#5]RM'N%,_-[:(=RE 7^4L9?+0\D[($#^B
M;ZTX6LG;1?B,'NS5T$$0HBW1$@E/'UI.XG6C/\^84KW?E8VB^2DHHK2*J^OA
M>%G"9YA&UNXIS!]CKDT45&?5M:T37_F%9JZZ1:]X66F0Z^[WZ(M-_\[9=)$H
M4XA,:VPI3-5'(ZU N3F=::YO=-B]I:)F5?HP26GB'JS^'R3D-2P47G)PK)]B
M0L*L]_D,[)=T?*5Y,A'F9PK1,7#298$["[?M&?K%!D,6=1J/A?,YOLCTZ&)]
M-*$C?4#;NZE S#E>"%3I6<EPW)Z**(S?RG4IMC6-3'4BN)#ER7V:-!HV:H0$
M$<Y=%&DX0O9BGT7>8 &&UA4'&X7V9)F=F$ HJ*S)O<QD7?[3YWDLJ=U!8,IW
M -G?E#6J& +5:/3+DLT,=P/XV)N%1_S07B%BN;7#\Q<3AQSQAARU^CH\41/E
M^NE5;^<KRK?NI@K'F-.LRDO\G-("#$#U10Y41]=1-,3&:R,*.:.3#*QSK.+#
M8X$XV2;+/X>*KLN:3KM"$'?L6R;VTQ5#?-LSB4,]^Q Z1U?P=MA]$'K;9P%"
ML%<<3W_&\[FU\X^=>M%\[.UXOT,RBLCO)7TIZ<!Q62 5B1]XY,NB;S&'QGI^
MT3VQ+/D@*D2*/\5P6\$8M.](.D/O=D7Q9V/=!\P8P/QVA(NZEQA6ML=BU33U
MYV2XX"J;3.=9J+YV@Z(<_',$%'OP:!86-VB@/+F*_ E.VAR_>AG]@&;"CPZB
MB>7WXQCI0>4_$QXF'@(*K6PC.F,SW*X$UW6[=EX@3DW6% ]&U20 S8]&-!(%
MJ7X:.P*O68#'""3P 6VX33K4*V<^/(,GMA7K4G)!))HPSK-4^@$-;@'RA&>=
M$E1)M(8&!F_N5>M?MZ]($4V=+=&URM(,%^=>"X)U I;;E7+PXW.OLH8S<.;5
M++E3/8=(*_.-HQOII)F$\+L]Z\@\K[["KY=:?G:C,-=5*42XOY.%FMRJ43K*
M<IBIP@AK8A3(7SKV,'A!V-"[$?Q^_&\<F/WX76!\P<V#%D"K:GYY#5*_9X2@
M\$/>VQB9);UFGY=!2#H!*MDN7@$\P\_]]O?4RN)4+Y%+Q^!R$?F-A?C$O1YY
M)18A:3Y2_OK$A=9E3;Z[B)L; 82E3+D 7<*]]2L=Z!L\+#TS@$IL.,DV,)"J
ME)(+:%6)(RAU&*1=/#4;9)I[)$-0$NWZXB![3O_<LZ$49+$AJZME 1P3KK:>
M='3->WHK)XMEEW<I(4XK)CL6G;)?\\YQ6(8 8WO:K-WS'(^-(94WEBT[5B@[
ME8$5&6P9!A$R^4ZI+&3*3P1YY_"&V834!.CRPB$K\!5_>9X9FQ9Y+/R.Y05W
MI 7+KJ^$?)GN6?S/DB:EUKT_6!M?LZXLSOMP>Q]6#EN_J5A+^K5H$NZ?L> ;
M0]VTP)*7Y^9R[!65;7KF6>NX<H:<OK:N; _>)RF5T^,3%W^Z^+S$#(6IPXKX
MSKYNAU\R!CFZ>3Z/);/OFI)=^I;Y1W;1VW/IL!_MT4E%.:GBHM9NM/PX+\$:
MCL90^<5/<]\6O3]^"]4K:J=T=RBRY-]+TH%2.R(+>#*0T6"E25TKX=(%GYTJ
M&14K0:<.I]9F_$_E9_MBN<T=I[%__E'>,YM5BZ&A-0SS_PML\6-<K,?_R\-/
M(DU$8J#S/@9=1OS8=UBE3J2BD#LAV[U2>RYW<MXM=)$^FB8ATPJ8C;]E(*J^
M 95A)O5EE]8M"60Q][=>%CO+2 W1M"OU'(S'U<YHB>W],*2[D*2L;XDA1"@B
MP$ALT"J:)N3XNT^Y*R(4QM[Z_OM_GL]?M)O7<KZO'=@;D7&-IBHS99^-)K@V
MC?YL4IPR0'"""ENO(I#'O8V  81+G\_0=3[#F>'X[;G D ]UCY(*3=E%ODEY
MY2%/Q'LT9AV_*JJOO/R#!1]/!NQM9GK\@Y^'?H<S$'[KVSZ6:J-M I_/S.Y6
MZZ^1[@O3\# %-LJ DNAL7@)P3PN,Z3%3,;9XJ;%O7/Y[63(#TH3IFX[&2SAQ
M'O0:RL4@_1]>0"* ]<X-OI^.D*=7%\- 0[P6M,7X. 5*H^X/0RL:?>VF-4F=
M37$8=5J[HA,3JMY"A0RA5^1.VF1DW D%0+>3/I,17=PG?;4)1'0;K'(_B)W*
M?B\J0LHG4_;4$K_G#5A3UJ):.UDV\W7K\(!!@D#"X!HSXI)>C@YB=Y-P;@)T
MX$KAWR)KCM_[]Z@UK^RF)@ME&+9<<)G%ZK <BPIW7U!WPVPJMKB,=T*6>@^&
MA"CQ,O$O1+B,ED%9WJ+7''0#_,YPII&,S+%I8X)?J%\_-U#15'^M: ,U,AK3
M[[DWONV&42QX<<P=\YW("9>.#-<A-,B('NW1$#T:1R<]_9(B_=#0T!^D[;!O
M6/PON02.?^2.2\_^J;CEG6K,?U9=@?<1-&$*-*#KP(M\*L78X*5_NOS?\!4E
MILL%\\VQ/7MXS*X.VP6%M4[=OIM63P^UPI(-0P"%]^15V'<X_/1 DUU2[-NE
MX86>+3&6K*FK6->^%>XZ1R(TP<@Z/%J_1^EX!J.E>I5'ZH$E<T?FI"S&%JXS
M-TTB"0G3PM%\Q= X]RO;<\E>^6T!<3(YH\7@%HY[4X-2 RKKM=N&KI>VROLC
M^U@8?W<EVD<X3 .T*Y1S>;3K0>[64Q4$9S"3X109,MI0W:'<5+6G")(3)V;@
MQ0]>6'-$U6)S3P-?U<6/M V%1]SF9_K?3<C6BWDJ)SLCA_NDTX=^.O#BU.3(
MX)STKGV**.D:SWMN:5)AP+H[4_'2ON,Q=]"G+MQW8STO53&>RKXT^LO8C_81
M!_W0<&>G[T'Y@,MY(*@JF4V285*;A+*MN)'""8%$!8I,1L*3,\M?X^-3Z?;K
MR 0H**,SI9!;O/CWRIC]<[/8ST?3Y $MI>P]]?;VCH^@F)IE]A2A9G3HT?SW
MNX9JYLY%7*&C(P,/T63'[Q\=A11B,#^)U]$>B(\;GRTECEA1WE*+LXM%9WY+
M!&]5Q@<.D;*3WNDW:;QB=S$'"Z*DR.]#0G[\V0IUNJ"S1#_IC;[[3[^67H_R
MHN.Z6?>C6]!\#RQ*2^8:2VW]@>@7E0U;+N<!8A3^;9O+;SK+6A\O#,/*_ >T
M+$_;F@7MY[!B-9]: LES+W%8Q@]6;URC5TH8]0%O#&WPO+\<KH?SW?71H6/[
M$Y 1?"<C"O./@(;YXU2A_X>ZM& S+Q1Z54G!H&J$Y9ID30H7*^E<K] Z.J-^
M*J5L;<)"0^*=*=Q"3\[VV#NY>NH9KO]IJ.PND=;37VADNA*__U\J9?G;#E^=
M9':K<7-K6S$U6Z2B4"C1-2Y^0!MLN%[A9"[JFHX()@1N>_ *SOJW2E\YU7^2
M#WE".VZ4]N&=#?BN %RZUP6]R<CX X&R!N86!F[_-(@#1%:\FM.P3#;V+,-Q
MR70=<5-A.#+M&!&MHJU,A2721/8ON11HO;G(9.CD9S3>14RAYCRG+OZK3R2<
M^^X'!-86LI9\M?OL2BR!V3SG>NV\_9+($V['KN:O'0S^U"^TM?18OA]%<]<T
MS#) 7TUOOBP@#XI)Z6,TXY%E!*H.4'Y%O6=TQ CK-5+LQGS<_7A($H4:*3N#
MRRZ1B"0%/R<J >#8#(O)\(?#PY[D3KFGKHW5?1!:1<+4"#%AO9Q3O 1F[SS-
MJ_E^I3#^][R?T(G@_UA/\L3Q_I]HW+\OVC_3M.K4ZO]4;_*#D>U_>3#I\8>A
MD7W4T!+H8!\(]FJ?!I_0BHDF*K>^/EFH%U6W5@_6Y;>=_4Y78=""]EE)].2C
M%.6G'K+XV(]FM&B #ZBA_:*YI:BE/3\'V_6Z"]L#)2DP@HT->7)V:SUS%@<5
MU: M5U[E5.+12W[K@VX*H%0P1N1+Z1CNME&TOK+SBVNM;?:)=?C= ,/2_0RL
M.C<LT%IG'^B.-\HDW4I34DT5)T=\7QV:(TU9W);2WPS4DQ&!(V_3'M#<-(DZ
MVK%,HU_5VNGD<:2PSH6$F:EI;9]%74A?M);EZ=OY2,Y_-G =3%:(OMS,/>*V
MJ"$Y:IIMJ_,47IFQOF-B.K_.V_=I+PGMXW6&XC\_YG7H\JWO'VJ6(H)<>' 9
M8A28QR0W"4NM\X 2_:8WM]KU4US5%3]^&!K=$W$XYA6X:%F^O??3'4B(K0<0
M;+<=K#0]H/4=L+>9 ?K!,;;M.BJ6]P85QQ%B+>J80)#NS?[R#<\F,4#C6VN1
MD.L5>OKR#0HNL<RL7ULM%GM!Y,!(,NZIR?(]?WU-V\/84U P72&WN_I"]/7G
MCX_OX9['HU8MR[^V7[@FE:7N"]2 B<M\2G.^BB6)BB<5K0W>;V['"<1L0\1I
MYF(%N7F.1Y!45;Y4EGK2:ZX)^2>R+(!DK?KK9"%#W_NP*96W/Y9[1S[>GHOI
M: 8)I2:.(]M<ZL_7<J1UO<N:7=ZV&SMYOZ#U8LBP$MJV %Z7HY;T?%3B;A_0
MMC:WK*@*)E.+52/0OXY8X"[GZA)&UCL+I]Q_6P\@9R"]H@J=N[H23>BI@S9[
M 9W3/K@X*_-R@@"48.MW5S^R2GV#WT4P(<:#WW/9F@64?L86$2%R#E&V01RY
M%,N\F:QXHO4^6>;UD>QC$_I%G#\ ))!7((Y7 '=),9L*/,\<-=\UL=?<-FTV
M]\KTV%==?H;I<@[KS@SZTTO<=#*N;7YUP46G>EOB')7@H')8_C&;_\C5<%KX
M688M!#K6%(TM.>%$O!MO2\Q_ MR" NLC=-+;[$XBJC4SKD ,JW/.+J]FBQ:2
M.P5\19.O6ZX>T X2NUL2 ;7S)U\:#7!<;&4<M,J K)L5HC(C+"]_#[)0QB0W
MAZ%'A.$TBXBP6NQ)+:;4Z[24(M]R(.NNMH77R;AK,:<3JGAO](F,7NDL_<#<
MZ].@'A9<=3P24^[""O"%$!PAE.NL6TWQMZK!YG&0/#ML@7N>LCQO?GTDEAOO
M3:7L<K@H^< WD([T&7_2L:;ZYZK:ZSB;P<0'-.S7YX8>">]@OUFE;RE=)(^/
MG7;X?27V&[RS/K7;6;2;/9>>2SWL"H&W "LFR,GUZ$3[UQ'M>79#/JHQ<H<R
MF&T63UY"UD9W65SSWFT+'7>0*?'L L:HHNH-+<WC-IJ59FL#'AD_5_N&7=UD
M/QO6*:'52,G #)"C*?C)4?HR7)+YJ?=G$^.>C4L)>M&(KX2\WJ6(S3-!Q ,:
MR76X;[O2Q%DIYR&4Y=7F=$NK")-,OP)8KMR=O^V4(ZC1T+WW XTRM,@R1:\I
M,4N_I<)*EH%<D.\D0#569?Q3XK#=5/GYQ6^?2:H4GLOK1EOFM(JL/EV(D(U9
MB35J7SZO"I$HB*Q(?ITW-<K,_30Z"X^S[QF75Y](DS->X)#Q@15<@ED"/377
M'M?!S#&$2K'V!9A25,ZN?V]7W3S /< $  U?Z!7C;L95M!VYV =,&5XJO-M)
MSR0.;4(A L ZO]8I2@K3Z(*@:PC;&%X1OF@TP"\6EA*=KY%A2!Q[D7G[FZSZ
MF9I\I%7U1%-US)=^HUI,<L@]WME.^Q@F7$ZZ8B6W^0M*@SJ,Q^7INA5CE89$
M>C'3GNS*0:C#:IG.$NG:<T\42C[3]WFJ<DY&5-&@>_1P(LO8=GL6G?EX:6_4
M%_DE+Q;LIB1Z"4-*%PYQEA4[((0JHPG_A8EIF:Q"O4)Z%:"_O\/7^]#8ERO!
M/$*$6F"MCQJ>S;Z7=S,1Y!JYF&61(7I[Z;B^<G)LN2>I)R!Z)7IFX2NN(N#'
M5;'10'P_.CNVF4/GT[HL,Q5Q=A],=G7\@":1U7BI37BX2/*3?%>%\K!_,:@R
M>8!<8)K.#<QR[">N?64!]-5V2*MK:UIC3MG[MC:=8;:5],KFL"VL::]$;"K!
M1>/]WNO]X)PH;X3@@.,("<!LXK/NOD.)S-%RM$/^#C341=K\\WHZSY2;-G;/
M'JNRT)<Y)L;I\<C$[?W44^XL]FJ"[L>J9N9N(/WD%3RJUEM''IR3/EC?GGV^
MKE5S4,ZTIRE&<95($9'IR66QMOP1+#\]+V3:"".QI9Q<@X:D9I3)@V*@&\%,
M]\($&+D8%>-'[_MD.<"O4+0>L%RZ6")WP04"=]ZHBV<ERK*=0OP8E+GIUX,A
M.I)#'>OW,Q_GZ]W1;[L_Z'"O!N9ZAJ&B]][WBJIT-ITUU4$Y]@P_3+_1.R[X
MEC_%9B5<SIDPIE?<VY6?>'12";!>9M-FBL\Q6\_&**;N\O:*ZW'92=:3=9KD
MY2XMGP?$V_2FYL_/,.DU?/_Y0C6!G,@Q7J]U*_^:,\>RE>*FX@'M0J-]J3OK
MP!PU?@IZOMAJXW))39$S=0H5<AK-T@Q+ B(@@@BD1J*T<?O]VR.6!S1+IDN3
MU0>TN\"?!"MB;*Z]=Q?Z?Q[R;-+$AT*)D7$T!LZI:B1T'@S!P?^0T638KSS4
MR&VQZ^OAOCRW[NGAFW_@0[-UB#(0G3W6UN^:-/".%Z)Z'Y&C?YN2+EWYR@_?
M4OIR<V2U?^2@.W*15^41%YYLA)ZLR;Q.G:+;69&ZU&V>DLN 1*I5YF"#K%(@
MW$3S?B)]9J. C>7JITC=09,7="29-HZF]MIW<DPPWI4WL['0%B?B>%$AK=8]
M*^F:V=>S@02@G6+AFC1V&4FEFO.M!U%YZG\=G F(TO-190&"9%H_9H=E!0.1
M@9E/TM;UHDC2"G<]4L#>+2WI2<O>$7N-#VCS\C*@2/EB775UEXIO]I$2^[GN
MYDA"4_QW_Q\AE,-SXQ]O= +PU4=6JSQ2%T7>"LD3@V7$#)17^$T2OF9=&VTS
MNUK\99H5XMG7S&[&"Y(VE?R4;PYK7"U;K^Q>/QC5)%M(",G4;I?JJH^#0IO%
M/7X.6EUO@%ANDWC9*>Z>G$\]H#FJB@KI /D>T&"(,;=KG6R+NZUJVI.,@9OW
MEHLE9GR]3!ESLZP6W-"G]8 [CBM;$F59,#_HXV)KXDHC<CE0;__-0LXCLMK@
MIA=NH"QJ?2%16[C2J)YQP8J3&YYLXG?RL-D&5PNLM"^Z8@8L-H>ZG&I,>]?[
M)!+#(R_ )\ 7(]CC>5,K$_>#\:3K.:QY5P0@JLX;(^.>#)52YKC1N,BWW9*W
M)WW5GIY.%JNWRSV^AL--/K#M\?WG<VB $@&^LGL]JLY>%70"+XD/PSO")KF1
MS$O*HPQQ E2/F09$YW]>985=W]8O?^G7O:](PKI!/)Y9I^L0_N)EK'[5V+Z;
MQFZWP-#<;'H>@OVMWRI*Q-+%!578%]EO,&3&F:%3:RS$PZ^3%4U,Y 31*JX:
M^"P3+(=@3142-K/%(M4^6M)N7,;;_S*[E>]4D%<U585.1-1B[.O(?B7TP6,U
M+ZZO0$>3YN>K3]##=ZC*Q_@[ $PO8_>2I!YOMV+#N!17<T]Y2$B(2%E".;&1
MMDU_)&6::F0M!=167H2%G/-ZWT]4'$XI9=#<E]K<&T3W+==QR]V^3.8-<@(>
M\=KWH F>^JTQ]O,.TC")Y&XI<ZN=H\VG:1':?GQO.)!4Q]1Y=JRY6J+CQ9LF
M^]P]-U4;IU]2\-O0P .:EC;\WC!&X_899]M.X<_&!9=IR=2B<H"&KEWLI_(&
M:9?X32'63O;2-#D75N)4E_:/WYP[-;3M8LJ)>X3D82R CY+<NHWRGZVYY4 +
MNH""J+(]Z?RZ$HVZ[*'54FO;8 %\5UN\1_B8KZ>=W)X))]B:@T8IQR;Z)HHO
M-NC#<4CQQM3<:6FQ%1T0-6ZV/F-+5M<N!OJ%VUM#ROG??]7,POF^F "*[SEE
M,ZT<^6G/]6S7"ZK?,[C,0 HK>ZEPXNN?PYR0^^T\BS$;3[-"6+-],5M4C@4^
M8) U"PPN:PZ[R@RBRIO@E)4K-7@9C8DQ8<'P603KFX8J/PE2SJ3O,@G,VT@$
M1#MS*L3B6>UF3!/IV3:J'K69<PGN2.4'V+F/33D<EL"FG0[2*>F*S?I&1XY+
MTSX%L=:!7T3$1D%[?R8/ZA6_T3\Y5)"<;/#[=CI".+XJ8/NR?(I%4?=:HR0.
MQC$G]-[)\)D%V=KOI=_7XF)<9E=I.UHY.9$TO],C1Q8]G$_Z*"62LJ[%#0NK
M#Z!<QG832S8$ P5'3"'C^Q_X^7R=E?.I^3&V6(\.VY46AR&>LZ9][YDL!P4H
MW*Q=9->4^\RHU^]H\@SJG)QL-6>:PC+9^@@^$5A1FN4,7*K(6[#QH8<=S8@K
MTN?QHD%-3($\B6!6Q$H)KGJ)%+'G(5H?+H$,01>NT5 7I:H, Z41QU G&@?'
MTH9Y B++LMAZL^_WKN8PF#3#VZPP8J_U99OV_(R+R!=V)3\66VIDV4H[6IK#
MX'1I?/YYTAB"<7/9IS1UB4#%O,5F(W%TK_-C.&?DONF<'>^WU.""7QV-Y.PK
M7;$#UK.F5?IS/;.[" =N9[5LE5@ 6>K4G-#:\':W*=EE,,(-W55]TA9T8W>(
M6[Y_!,NKQ?SQJ^;)^-HHE;P'<U\R5(+SY>E&8%%0)@N=A=7_X.XM@.+JGGU1
M$A((01(@6+#@/C 0&&"0!'>"N\/@#C,X$=S=)<&=P."#!8=!@C/ 0'!W"9[W
M??=\I^K\3YU;]]6[Y[YZ]7;MJMV[=M6:7:O7[C7]ZU]WITD;<)Y@&B:?#=YS
ME<CLM&VPGU:5!CPG&>7O8_/X$*6IOIV"QJ4-_K:RIO6:M:^H):_A0[3K_4'=
M8L&]%?/ZO9X6&GFN<=FR' V(6SSH^C'@8$7M<*YOKZX6=G=#'SEU\AIZU;DT
M@)A#0*&7T1OB;VQ:E_Y@2-_ZN;QGBB8I.3=N#7HM:6=M-Y,T3 GB?O5!-@'7
M*WU3C"*L8A/X,_*Z!L[;P?X@CVI='DS/1B\O#B]S7)]T<R$43\;"@1G. D)J
M!O[&6J_F"AO[7*)A 5SZF1?6(RT"(JES&X'D#;DGZ$!,38'KWX%'4%1=:-5E
MHZ[M[HG0V\98&@H'.1X0LVKFY-G&]]Z7H'0ELB'2T^NM3$[QB/= B\?$CYVD
M@N>"TN]'>_XR>:=@X7FR^>(V#1N!\<HUSHU073M6PZ^I2K:PRJ0:O'O  X'Z
MVI!@J[/B\:2T'7(^$AD1HH*A]>S MOH8/%BZH"Y=Y^O]=?U$Q<*?+^2S2(."
MGG!SKMK&K\KH4'';T *9D2Q-#=F5R$?/OG_1C\6_VM*=H2_.S!-1H(+%6')Z
M:HG.[.A$QK=+Y3--Z^%RAN;[RR$B!5,5)A*WAJ-39-M>SKL;P-2S JI>!.P:
M**Z0OA?(6(B:,6HI44O0_8-QU;?RA/M"F#$KWV+K#T;SA;_.+[\90ZC<022"
M.OWBH_5YUM;[ Q$3_)V*QG +I=TR8*K\^[AJ?5?,),P2M@U;);*3"<$F.9>K
M:<C(,"2Z6(YB8YLF!6(*<6:&G#J)=C_$5K38UQF2&\:D=QB;?F0J)30L-&T1
MT>7L7!I[W_%TG.<,KP9^/L!RN/N2.0E>M^M6"J=E+CO,FVM"*<=K!*T=)P2&
M[%35V"J Y9GS'%GZA)9+QI5UH]=0#O;0F8U-K>$IS:E&M0SEV_$/ROT>.?='
M7]"H);6O8)D=\V%;^Q>Q4X(ENR$5X[\CHQIR&TUI"U"+[]QT,YF)^/':WK//
M"!-09-3/.6B&2 GI1]^"H9$S8(WRXYLUB<W*%;XK7SI.-TG&:.U[)X,95Z$(
M<PM254(?,?-&B4DJF5$^Z17]$)Q5E"@Z<DFMT%?.1A>>=J33LX<GY;EG[TBW
M)U9C@1,?7_"R7G.8/F43E_4#4HS]#\9GP#M>S5J@4;DY7;XQEY<T))PE.ZC8
M*=5RPO=VQDR/90)AXJW!,E&>JSE?MNS?!=,WXM/4 <CO5Y@03)J0' =4!M@7
M[<BKT[.^'0[ZSVC/J7N30K,P"-CX-6:$,]C@E9-.DFY>C?8BR],P1C)K<QRS
MN#4@%.K*8GWJ^2YG.I/8VA'T0G.['),E-&20V*(P<=Y7T#<^>%$Z1=PCEEFL
M!Y\-]',.)T\LW2(.V]2\FCO@#P9DS+![YWZB7]NM)C2#"U0RRHI&_BJ?4 0P
M[Z]S;>"+I&?3R-_%<F."'O?L/S57^W=H3>N0^H!M]7W))9P)[*D=F.'/TV=L
M]:3GIW4)MO@=3D[R%88WO;W.X(W$H\U^>^,CR,%!1Z/PGI*]DF]F#BZ;?F_+
M+TM\7U+(SPW7S8,QN#LM4YCT@')^4E[VQQ@Z XSSJJ+"C#Z+,W)4UZ@XFT*#
M1'(8.HNYW.EE#@X%"MU6,FRTD,NRD3L21^O_W\J/UBGO\*W[.M%M"JT*^H.1
MX1Z+53BE%JLA:,ZZ .R:35[X"&U.+>4OBEUP]9.C" -VJ>L2<Z>6QY;:W:-6
MRU62O0\6X$ >2>-*FPC;K:3E ?J0-T*,+*>$9+!3JW<QT[?WUNZ_L=7W].9-
MOW!XA9+HF\.$O?0K=Z_*JL8V**+?X3!'^<?5<"X*N4^]LVCY=\IJBZ_P?O)]
M_\R\N[1%SKM,T?B(BDMZ,X;\&"SO4Q@J.DNH4 ),^B@ZZ_F[1\Q0 &EG-$<1
MZPHP;5^ ]U%Y3*]Z>4R^KMCGYTF_GE^LTO@MY[%V>@<8-L%88 %:,-]0!#^/
M; G,A &;":Q<Z#$N1R.)Y_9#S.><P%A%73>DZBTSUF[L]"E)GPI3#K_EJ__)
MK)GJ^&#WT&SZ?PD]KA*U+NNL.G\1)CI\B_UBQ=#G<538/X$!W$ 8^9V"[BUL
MBK:-9]<R2>#W?[R-^R\UXXK_8Y;\GN_S\"YG7;<)Q>?>)>1R6G9P?FEL)5,I
M<FSI@4JJ:\E):I]S]'#X8S59P);M5N#'AEPRJ_26;U/S%0QNN\RD=)T6A=!?
M?B"6FJ0,6L<AN9I$OX-/&7;HJKEE1_2 _8%5*7^*VM@L/X'VR&F,I+O/-'K^
M]2OIQ<BPFG/Z2AE"ZYUGY1]?U Z/3/U#O64;/%3>CYDOUD8M5HSH<#)'9M']
MJ.L<PS_0X'1R%.2#7S1@E0;G5#/CSK)FJ5@;JSXG]V .']PUG.%0-2LG::VR
MI].AB*WB5%W5;V3M)M.1B\<SW5A5<F!:Z<%R&NVJ1J$2S5PSK;_574;VUEG3
MT 2I+3:\C.).&%)8 JBRL+X \!JWN*M.R-+)4LB^"'.D%,9L5_MO6OW_]\17
MA+!%J*R_=.&N$Y2T.CQ]@IZ?[Z2':]5@8E*>SF<VT5,10+J?#U+LP(^M#Y )
M:&*(D4>;<(-"2N.+G6D#6K6WERI%P<G66 F4_ X]'^8^?PADB-&-6@,&LA!!
MW]E_D4XVJ@>_U9\WZAW=OO:3!Y[(H;C$[;0!Y1D!=PDI K*@TQ3] ZJF6_7(
M\^PA;=J/9QB]FO]D,2V[_\&PW?Q)66B"$P?_]0N$/55W,-I>',$YJ?IFIUQJ
M6*ES [H^UY_<VR/+,LT197HJZZY5.8%+),GH+F'UZN< 43>GTQJC>I^2Z\"3
M)?-W#CV )8?]T:&K^\^WLOTMOD9%]?)I[5KE*2P?>GJG7+9<5::=FL\V1SQ#
MJ++PCL;*ECXAYV$03.#_OW( _H=($Z-*87Q@_^K@!TE9RK>4MHS)/MX?YJV=
M)R-XXY2"\J]JXA]]X@O' 8/!XL_3C#;O/U;L/Q1<F6 _@3L^Y-4+K3(Y$YE\
M=")N+2ZN&G*2ZGRL<A5)3$'=$I^D+L]4!L]*532R;07+?IKU<>8JY.=ZTQ8Z
MK)50F189D@!BWN30LEH9:AM*.-<M-Q44M(["\U\4?'T8;Q7JD#,H=) UHWT^
MHVL%CTDM6\H>]3(B.?/*8S9-,_1^=CC-<N$0;:S[ZSO-F\CIG(K:59]_$H"2
M;1S=4R:%LB!?.Y<R*=.[%T,>A,]?],3I53F8'G(/*!(>GXP]R?LP]W']LZE@
M 3" /0QWZO+9067X4C8-A=P\NW FR8K&M* :R]V@9T\KN)X\+$;)6.I=42D#
M(DEJ4C-]R6Y=-FO/)!9",R$<:L<? M;=Z3:OT2EKEZ3E#"'A$RP=>+X).)(5
M%\[LQC%++5BJ;+)?B'JV8L;Q\])[^4"T.4.5K/Q\.I>6-CXVW!1$J]]O'!U<
MN<8M W@@:7$3E_IRS@P@EMK"JTE_A"[Y_W JP/,VZBNC5=[M"M 9XWCSX^IR
M3RY@IL8Z>]S5%3[0-NIUECH?8G;(NC<"R.Q,6L56H?+BU4RI"C'F_%E= X/-
MY6^UO8H.J2]A!8[17]6]I%-&YL@B"2.BKF!$",^U&/DGRBO5:[K; N&HB[/-
M,^$OKO5B]MJ['%;V'-D#8PG(=9S<;_LJ=_4^G98J/+/A^94J!'FO+\Q#0 %Q
M-*6WG1TO5DJL%#6'/WOI$AL;,C;&R.C/JRF+)50%K5E.[K -E3BR-N>)KCTP
MW3#1RI89&/F9\*E6L.]FFN H'Y%W2!7<B*;/MIBH*-OTL9\(@5W'4C$>+QEF
M=L1%>I^,34&=_)$,WU\#VF2(4L,W(5NISMFX?S!09&LYXD7BB8N<S45Q$T2*
M_$HRKZ,C85PC)'9)NQ)0@%$]QW=9*M>>7L9).4.^9Y$(OZBN)6VA?57T(^TT
MC:F%FI>+K6M4%V\-W1Z-%ZGLF^KM$1+RWSY&<U[MGO*S*E8X*/NFD%<L4UQ]
M"BY0V]PP&-CH2(PUGA@8L+^@F[1YJ%M?,_1A4TSO ^"-7\&X-1$)&;\C[',&
MS\L*[BUO+J[>L[ T2M<Z5-'8%O1K%?H<V'ON6!J;]AND5)QHMGL.=G5.U#.:
MZ0_J,.^DF24MT5L30P*93BV3 -*33T.C!UM1N5]S<^.C6Q>0>[%M#OA3"V;%
M?+KJD^D.!+0,'UDE.CIG@=,L?7C %TK ?@4YA59EC)/=HY>/WJURXWZ)!$L$
MVAJO5M*E<5 8U8SHCWOS>EM=$9P-)D^<#1QN$L[N0H?,*4L7C=;@ 5_[.@DM
M5J%\@MW!HE_?9NY[[@HVF#8REW=D[FBR-AY>9R5W#6TT#-9KU2Q["[WWT,L!
M'+MKGD[5[<_-K28F&\87N2480=V2DM;:;Z51)LHI$_9N3P5H&V@.#SAK&F*G
MM1?(*#Q)LX=K(![G79NG5 '?+.\4E.G<-@#LHV)CC"I\C6'^&ANH\@Y[R2V5
M=FZW&H$Z9G7U9YE<1H5(6UOE*QI(S4L!U5<]JN?:MJHR;\S!%.3!F6G$R^U#
MF<5UDXHTC1.-]+TR_D [3E\_CF+.2'C<@)!PA;)2=EKS%Q9J7,D)U5]>3D0T
M0G"+ZMC:U2=_,"KVCXY.KP,3.U+;Y.:W0EN%>I+NF7GR-&I 5/=B0VOVCK"L
M/?6J'6XM/\ZD@+&6WPS^W#UB]"L+8K'I1A-5+ZRUCK.^YN6@&;@JJL2Q-9/T
M]Z8='/C&6V9?E+A.G\YQ%HD#HQKPF7ROD"[H4IZF&E_B6;[HP;3,$I^6'\N?
M20.9ADC;T$6+!YX-S2S(;2[EI,G+9SW[TC+=*0*WF/#OEJX)7FFWG0<#C16S
M"7*]R!^"@S=)ZU#;H[T$EB]DB'F+;B@4>]I'A4\PR^M4)"8[:]0F/+O=6XSW
MX%-<Y%S?#,9EN3/IK>AND\C,SFE,H<0>\DG94,25-V]B- *0JV%9S#*MB2#%
M#A:QFZ@G(4=S?UN\-+YK+G5N/ UG(>C88"#OAV=RUD46-9C4"80M*MELU*D4
M]^P*&X+"KFXEM.T2X>+! 4$YU'=^!TA/G3;]UM4':4K ^L9["L$9#2&MOQM.
MB.G-6C(9KC"A%8@4U.Q_35AV*/^L!6:[1:TPM5KCL,G(7[HF&2C[38KZ>JS4
MO(I3?>7^GN>5NR0/7KPB1:-\_]_\?2S JH32JM+?Q9;S<.MIW0GF]MP:DR?,
MF)?L;)?T(D;)GSN*0W^<*L'JSA."=;V3;PH27S#SK+O';=D3-<4I\7)6?>EI
MOC%:"L#2FIOQV#S=.-1-M5DP6$)8W K(J"U7+:3=&TCUC%9.I\9J'?ON5T0X
M@<^7B&X_I!Z\[[T;XH-^V0<AP,)N^M.Z=(,[)<]E_#6*APRK"/-VQ D,AH^E
M?4G&\&>/HP7I,"\E>O+'Z5;FE&,'L<4&TJ_/CHA@9["MU$#0V8:#7@(0Z$)G
M3F1-]'>#/.:5GN"[\.QF:^M3:" _<5L9.$< X=+JE_(<<7!9)," %Y-5B6'.
MI7#7(60DVO.VF BVOO'5"QEC2(P"[L4H@G\LC1^G<@DOB:?<R.ZDU;A57\^L
M'6[1SF?SYMSG*ZES5)/>BKUO-LE?VJT!,4E'2S<>1Y?;(%?(4>0'>V:J9)W+
M?9DCT7"N@.)=YK"T/-#IF6!X!$. 2#,=; V98A*0LJ4X()E8_2L1@8L*':7Q
M6RCI1(\R_W;;/X6+UQTRG M9SW?48&TX^'U7+;6;0=I&-M*$@#56UD^V=6N/
M1RS9#8M9R&H:"=J\-Y_M2VFMQU 8X[J_<HOR"B=I#7AGD(K!>Y,EV,%U(=9Q
M4+W0ZVPM3N"GWEM[((F+S<&O75YM.+%E+%83SH*_&]VL6>4KTM3N9;:KM:P$
M6][>:1@*7!4/%M2;68CM$=9D297X<!,@HB4<336^U*PPQ\)AFC>U5W7ACR]F
MTVW=/%2U:.W,8FU^K7?_!\,HN[T1^0=CIJBQ:=EMJ*%MJL5-WNO+AQWH0!_C
M@W1"IR5'_TK?DI\\DU+EM?(UQ*5DV+#I"RM[#5DYAO14#R>@<_^N40X!=[V@
M""WL,,G1]H69V@=^@B6^U_,F?[RIOD2C#H.0QG*I;#"3[9Y>%B30.8E+K1YL
M]5-E7<K^VL\A7?N#0>A%"1A8W/Y9[^<I6$R^866CGT(JDYM0[GA:[FKM?Q)R
MFD12QJZZY"1\*1)T#A :G$1G_5ROC04"M.R+ 1DKUAS[Q=&>IQO.7NZ.'3+(
MVKQCY%!=J$W7?RN][$H_\X-.SUKU!E>JLJ$G&%1![(J4U";.41'.3A_LH0[.
M7DA=:=?ZK8W[.^KPQ?##M+44H\W^%J2PN.QLC/GW.AM7&,*[)D:@?D?Z#\9M
M+BU'I6*L5]YKYO!RNTM'9-'.M7>X0$+6=IY[57M[@VZ^H4Y%0<+NB'W4U6=A
M[?C27774/38V!SLP,,!C4FC69 1E'D5TN)A@I*=?*5_F"*GUIAI9W46DM#FS
MV**6B_O;A%!QDCE>,;S)73RGIE%23].#T]L]K!X\SRR8C>>('MRMD\'68,>L
MB@;4$)(S<4FCUG'(/=%_@PW$)JZ]M'5FT9?!E:+GV""D@F020EFV#+EGNF6M
MWUO]_3S2X>:-R>"LLM.PM]_P7!MET<FLN]"!M$4>'D2 N,;-Z\VO 1F>,]*X
MT(2X1;.85@'+I+48>J:%  9<(6+X,S@"\3^*)"$0M^F9.0'2.?<#MR[ZN?KV
M]U/UCWQ2Z%G?0C.3^N>\'7C00Z]4Q[@8/;Y0,K;&TIXVODL\IP2]$V]>6XGB
M-^9!1+B[K@6D=C:=[YY6]5[HO=Z4KJ8-/;&\+<9K6BASIEX&I+*V-?]6)ZL)
M_21^H]ROVTSQ\N'X9\-8BV'KX,;M'XQWH<81GBA</KH6^UPBGH3?8SJU.JZ%
MF=$FH#:R(5;Y#+ESE=RV-\AQI$=_UIB6B^! <%-"$9'35R*G*#CMAZ<1EV>.
MWU\KDAA@%[E<[9/2?STQH8TJ)U$8OW[6?"[%,,O&$QO^-EM]8'44HM)<"^@_
M<::Q\T&W0P*DBI^U[?6''/<53^[N*%=>[FPJCZ*XDHK&MD&A@HJ8"M7([CS^
MAH3L:ELCR'*UA4%]A[%6'?'!*T*R[BG]3,K08C%9KKC"R/[IQPDC^\$E;!K5
MY(V,[JA:U^Z7<#Y$?!J<3SQCRH*,.?_58B:*L=&Q/9RQI>'AV=QB@G)#@I&!
M/Y$)WR&W\73)UPCYS01!LQ"^%+U"8 QK7I3A>H(\_MQC'E(W/A8S0FLW*,03
MJZT$?':.E6DOB&XL9%[93(\1/*77L*C+MDV?$Y$8D']1N9&/O=Y;X[E4641(
M7JOV)%IP]JP.Y("/6F*SI#8KY90-9C/^,$D.2R0IIK>&NE+8]+*1RG;]\A/B
MG5R*>V;\CHZ7WKLX2 1GQE/,@)?N!O3:R&\XK4-,\6X)< (_A@F;S^HV0QD(
MV$Z<Y2<9F#8KRE,7BQ3CQ8,J]VBW.6CN7TLG(]1@8X[:G\&"E>"WM\&E]'NQ
MTV_OXN]PU,U.(0-V%$)%^[UCFKI?!^?(R"@L/H4I[RW,@UJ=O6$.^U,=65S
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M3GT+\'(AMN;@_8-Q([SJ %C:(0 % K1J?&L;@ U_,*P\5)AU]:E"%%^_3@0
MT+Q^#"7D;DQ4BXTZX=IU]3MQB1VRY><O'C\>4:_$_V;B 4-(;A.^H*7RSOA@
MF;<6EY =X':])> LCE^3K%)SLDG-F^@-YJ@]HOF#81/=W"NFH[<KHIW9+T4+
M]IW\/@;&]*C3M.F:6&KC3GSV7J'U-/$\[ L"SKV=BPKL*CTN#KX#%M_3..NM
MX3+UO4YVJ5(?\+":?OV6REBNV)KS[5251WV;M\ZZ:&)63)POJ9>S]J?N%.ME
M<JV KP^I_O!YD>\MP&2>I(U&3OO>:&+4P:#5K)_>XM[G0^;-G0.&R%S^,C[=
M82QFN-\M74KS4_:N.W"4!>,F/N>$!T+ZB9&[@O&P:SR8;U:R;CE0&6%<$X$:
M$9KHG7ZY>Z"GFS[GESD#S/!@>KP7R/=9J77U1R=)EF;,%L:/OLT]1XLF/9G1
M/;1LXI1.?_6/1!:+LC8@:'VM?QPK)OM9Y& 8FTYP>)#N]0X-0/69K^AN>FO*
M+I^^$WAWSU8OE6G9F8W_.>R@#;X5N;OCG[77VRY@J^^6Q)HZ<6A0.'!MJWI]
M;R7>U=2$O!@W4YGTO[MB9[$FK&L)<%3U\)-KMSW[!@"K]OD)XC7=>2&L>"NP
M#SSG'+3<S,B"#F19=#NKSIS[UITJ)SJ:7A?3902/%(222KUU>:MK$O=<T,<"
MGYQ&8"7CAS07RD>J E7#PBNN*>],'4/FNL-">D:_DM[D'/AP=+^1ZI]]BW-X
M>=#F?;Z9(P+)R;[V5RLQ/-'5#L].7R_IIU@>$N)#] CN0NE!.R<LGWE/] >W
M[\BZL[AE)PQ=MUT,%,$" PK7\H"?M2-)3-RG7B?5V85UC!,<#]_Z[F1[&EJ
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M+C K.H7LMC-TP8+>8>AP&Z48@,SY6RY1%\'#JXP0E"0 :KV&BML3>762=?J
ME[3_\3OAR-23=W"7Q<"C!]A9X,*__WC ]_>,1832%$C.(F#O*_,MQMH!)<)^
M<A! E@Z!@0MB5!E><JJ.GP/#LWR-ZF\LE.1?F:7XF"5-R5*"QMQ1/+A"C]Q_
M#Y'@A=+BQ8S,/I4+_RP0\*G\R$,5TCB[ (\91'_IG;RAPE9;-^Q/VQKHDZ;!
M2DUK0J1(1@5]WK_7.IGHN^=F)38BC*/YG]*Y_T\U#7_TL6W3Z&M'^NB8G5^A
M=RMGN_F;27) *B1QA6I2_DFB[-0H6M/U6R#=*;A>)1[*^U3FDQ-%YB[;ZM'B
M<G5P?0.F<YGRM([\6BA7\J- YA'K]S%US$NJLSHOJ'UI')3'DVA2S?>L,/]A
M'K/5';[?7SY3;@)=S$C :3@DM+&^NF&VNML9EBA2.^.@T^1.FE;J[9QPABBX
M+)#%X;HA1-D/\(X9" QV,SQR!/O-Y[N\N%@^"7.!0A\@"/DBGDM3<G=OX9$2
M3UQOH1@=GD>690/*8VH6=FT.[@A"S&P-P>4"U*-LF_]7RA[]J_B5H\, [MPU
M;X#3K+M-<63KBQ\VVFHV./)Y2&ZIU') #_V -^2!Z;;XE@),1,@G07^VVT2P
M<S *UMEI/4Q!]J]:N%^5SV5^1HM:X,]O82*)$XF?' M%_92?.*(:#XI:C'S#
M/Y.W99#;J$=-5W*680"@IN 23VJ.:.X6C$K03,NW7;,^LZF0^6$.\+L3DLRA
M37%Z_D\FALYOHLN/?GT18P?W.RV'.U1?+%V5I =),=\>2C]KS#R1Y")I=(-!
M;&I)S!^9A4\=E[V%61TA#RY/;46"SKQTL]"?)Z[;O;?MO-LS+BK(.@I+K0QH
M'<8*D=.K->0GJRVM+?^+J6'_CP@R^WE9I-'F,JUOYJ5;]2\1!<RG_[8VY:H]
MJB?)&@(7+F#'ON5)GO^IS-'CH_]:H_3Y[9&KV.K^Z1,F46D;2E;N.?^"+_^3
M9O(?$>1DIN1YW_QVNK<ZORV.1]:?)/[70/5?'U;;_;$HNCJ]VAWJ(8WEUR:8
MXV@;6HP]QEOW+3S]XJG-ZIE(\+-\R* ,,!Y=L%2WR:<A4*^S&>"W,-*V_P=#
MJ[T,12,Q.CHZO'_0_7=\[Q:%^LNI;<W6A+7E([JO<]8W%KEHE;](;CI^W  >
MX\7,6_ YR4)<G9Y9=&VP"+RN6J=3.(]^IY>7D_;]9=&_O]7Q_E]&_A"Z,IT/
M_HKH>:"I5+7C;Y<L!ZNP1,I:'2I),T."O7P>,.&<6:WI2GY .8\"(>&JGUA?
MBF?8/?7*\V[(L^K+2/>,\R$^,%O=B&FP9P%KA1;<L$^7\STK^)5;]QN\C^;[
MJQ*C'U$8$=R^M;[^VDO4O%<54]\(.B:U.+"@9.0K>"/&(N3U^.3=83<. P1"
MPL<?\7'[AH&RZM,L0A+_NWL"H>B_H,$ZW$=E5T&C_CD3N:'L93;_J*@:'ZUZ
MWN'8/W?7L<9LI;;QKV#Q8XGX?QE7:_]H;&F&_&W,XDS\306AW5V/@\K(KW=0
MUR;!=9H8/*L&"D7,L[%L10EBUFM6Y0K&W4ATW>_>1EQW?F@I3H:2!XJ"S9S1
M^47^+T.YFQBQ#UX]TFLYST1=Y!<JY_MYP:F HEA,P< =G_Z)0NK=R3V87^LM
MJ"KXJKJB@7M"BU[XA$_G1BQWO?< 8GC7D9M,76A_)]9#.S2FLODV1.9"Z TB
M2B#B@H/_8#KKZ^>!;O.*'^84S]M*BLK!>/&XK0)F&3@4+<P1<HO!&\N6MY<P
MXL?'FK,W!F05I2_D%!-Z%6Y\!3$6^8:/101.=-8)K:_[0R-LE5HB%B70'*_K
M4Z%8M^8N<VA5216M*?+A(@[:9#MRSM#8G#Y9:!)T*4>'.*!=#-)F4)%?0\.K
ME,7PQN/)N@K]U:.D(7F9\ZN*)>$9;C;--"Z+4RU(_SH'\35<M]B&+H>%^5=H
M3Y1/Z&<:Z85,:U&&4*^86,#R-SO>XFPA'3O86L-EPE:1:WMA2\Q./45=S@0'
M#:2Y)X- Z: L\^1D?WU=A6:C)F(91DF_5].VT;!T;GZY/>YV'WIDA>+RW+T(
MU?I1Z#9Y_G'5,S7T8U(1-_-GRDLK/]'T,'1^!"LO-N?F/D^?T_Z0;-E"A%>7
M#6.,30$IZT98G]PZV>^7Y.!PW+L8P/Z>D=+5:[*G=[RTMKDH,?'6A\O TJT'
MJT5?V7E*3X&ICW5B#:,K''VK:S$4^8-F8=(/'[^C;)Q7;ZBS,E$ES**6:FFT
M3\:QB7S?:G%M%6PI-*+5,IKW]K:KB]A=%2]+Z^\LY0S!!V2:&=7J?>NIUL+^
M@\X/$?U(Y@=@+<>ZR0&)\26X8Q8<>VQW" V+Y2#V5DX?KY55.5+%/QO[Q#L3
MDC3A#4X+,4\C3J7O[!Q/FG# ]AH=<U+4B52UI_+W*SB@],/,#OQX]OYM%J@\
M6O&(W"#),A WRV^6+@ZUA%-(D,B*'2X"G'U;96MEJK\3^W B<2--&5!7K,-7
M*:XJP-\1+[3MYUJX^UQ<!EFFD7I5V@$8>7C.MY!>;2S+=,;WB2Q&)_EKIJF4
M%':H+G+^1<W,PF&T,[;^CJ&3^@!FOPF \";'+<W[F-^=7X0J2 W>H?/Q+-E-
M#&^%GA Z6&?<RGE[4A$]]]M ^J=OU[PU^W[LBB _TQGJ0APOR^XPJ+RER<"P
M18%4AB\H=91767Q1*[\.Y HM[\R.RIFQ4\W0QYRQ*#KKQ0*+DH/!5/Q\&"?F
MM8:1<7T">ZMRLD4,*>YNV9($C3_L\#GB19CK)YO]P4EA$;S%F=_,@_K'U[=T
MMZ+,FPTS/T=,RW-J98 HS%+DHI0O7[NTC'E"+13LLPR;'$V*3_1#*5CCV@P+
MY2KJG)3[(_75G6D*/YVR[D^G4+Y,BXJ7(\)(5+UC." I-7>;+IVFEDBN/<M'
MJAB:MP/8M*#HRR0S(='KJET)/[U?*JG9(Q#F*QU/6X#MU,8I^CKYZ);75;$^
M(*0]TP<:O;+)@@T[VP8(W5?'7UV+-1(LTR-5QJA;&R-M1EEY7B>,FCPB?"%L
MH4$=U4=E0;:QFK\V.NOZYB&@#X#6I<HJ8"60W=4@G-=H<J<4CXV?IY;1Y1!I
M[B_RE(Y,/>X9/3S"-_PE"P-*9Z9L<\1!O,ULAK^4;L;@@A 6,%Q[QV#J'Q._
MC\>1#-TZ#&^"6[G6K*$[Q6EEZA,I$BL#;[SSOZ^.&N/B<E 6G(02N$J+RV[V
M#[@;N;C3/5LF:_2:MO";B-C;M!BR$TMA3G^R=5Q,[#+2[L_;X/'C#P:7T@:K
MV]&X4"]7XL&@AUD'I,'?P1N5W\'@Y"GY/G;V?&LA:O*[#-1QV%N42Z1#XE0V
M+:*5;ZUS,&V1-^E7")Q6<BF+GN,I5MN>YLGW(^WB0;.CR<%53RX1YL)O<?WS
ME=#D@5K!.8L4NQD[14YBB<MR%09&R*J#J-^M83LIB9+_R?5"&"&H^6KM#T9Z
M[G6@OTMK56@&\_7@RTCW"?J[+VXJJIW7D9Z$0N+XFX>J8X##LMRZ_AHN*J,"
M3G],X380;U039&TR=Q/]1:BKO,P#O*=M92%CMXF.H8@6+/C6Z$C;N\2$B#H7
M]HCJ5Q%P G@*S5V#)+1*%5K<6+.URZ;RDN/;.GA;[F>?'BK"&K$[[)>:'Q:)
MLSG#_7(X(@,0.F2P/QCB-P'2T\TMB3I.EC38.4).7AM_,$Q25Y:1P[DC]T>G
MT(;9:;Z>T9/(K!26K'>42S*=XQB-L_2_#/8>YO-H!@+P[0W9UO!?BS5'4CD<
M<"A-N7.M-Y".0P1D:.-EE,FTK[F*!JW>LTRH)61#NQ#V60S87FI=>J\#7W9E
MA?7JQ<;&6ZPG9#'A3*Q02+CNL [.M>.+KC$69!B\@JX]Q)H&=*W^P?#J;,ZX
MOLK 5*^T^S8YKM_*WUW@@UU$WB>P@P7;=L+^ZV]H<).37^I/;>;K4A4WHZR"
MV5\+UA:[,>,1 ?&*O[D^TW,/W/[GO/3_YR)VJ);X$=9P6^76+!.RJ=>94%/O
MKD6_*+M[EMG)>R5"KD"\9%U%:;AGN/+C?NGO!7/D'PS^^Q\;Z*LI;8/4LU.;
MKQ#G&<A*>KO,7]=OM.CG->W$$^Q&Q3TDNG\P7I\?2 #_8/C2XYZ<!M[ "5[L
M(\6XJF,! @H+#XC ^'%@;K-/<\64[HWVD=*=M$K=#.,9!&:3S[!#$RCE-(PQ
MMC&EA#RM!G$=&>'/FZC?Y.0^-S543*XCN6O-_O6IU7MY^1QP@"?=+SX>?)?N
M[HO:ZJ8XR:4\[L>55DS5G0$"W0Q!F]6J47?W"MMWVY,[@\V!?)/-TO4JSV*@
M$'X<?Z/?$KSV+>7^!X%1]AJ!\5/4V;_W=&PJ5=UU=O3*9J82QP?5(]D@27J8
MO>VFGRH7^Z6M8IX=^30AU2F*(LPBZC,?K9!I>-P;*0/<U=>M1G?O#G7$4[(7
M-P>V>$EK=7#"T7>"&XV<U20N-^3V[U=F0@3(OT8(=DJW+#@[U_N,2S[AU>L(
M6)#6;R4DB11@9"$WK39N-7<;$:F]>.LJ]90S2.G-Z.%PX2T\U /KX!!G9F 7
M&NG\=KV"**DY;*BO (XCKH'/B>=$4[%.(RU@C";^-(QGN^B:0/@P?G;V5I2@
MQ'*]581&GZ._M*E/X)XF[$";_V64T6152=LW9;6$F"/T[D*64_<LOV'XSKP5
MM!^7QJZIKSWY?4D?;^*R7?D>C19;_6$OT[A'9+K;N2W?$WH6!@2/-U\\\34N
M1B-@7;6;#P0X6A\9>_[.%_3;_(AT1X3,LC<G=-)=L*,[HZH^(W$,!SN,SX*'
M\>?ZD8S$K^,Q#K5"<=U6$)Z^!"[7I>GA\+QCQ7'5ZG>&S"E3*OG2"SH!'9:I
M.T]15BO:+S4,2)=EK,E*MA?X(F>)GJ6/UJX#N<_+;OMH)C12184!(/J#\^&F
M8NZ^"LM%G3[>%C=E_S*-;45#EOW;6(WH^<HQ^J7#C/7K0)S%B<3KOJ9N9\77
M1Z1&J8@\@7RG-@.ZA&]GWJ6FQU9^?275QKW"EZN7&7[:3^<- \2+3')TA-H"
M]@F XM7RC([L24UKIJ2$$$+2OT\(Y!3R=[F-ORMN6-WG5>K/OH3L@L!GM55#
M]4=UE9EV;/=SD@4<L5TD?4#CL._"D/C(8/UBTHCM2L?#61+JRXO$6XW4 _EF
M<6U"0K/A,"E# ]T]/X'L_K&4,2O@E8.5V6Y-((O3<WYZ)VI4A"\VE;]T]W=L
M4<A!)XXX7OO/H$(F\MXA=5L9H/)@X]_D]0ZIV(J"O$Q'QI2#QEIYGX8;1K?D
MM60<ZF_@<X%N97DQL+3:D!.I-LC%7O,), /"  GP.2,+Y#?\E45E0A;5K"^S
M1X3 ^S1Q'-U!O76[T<S"[YSQ(FWXU;#D,7-<],FA*R(5WUTP . V>([HLW@Z
M_W8#BXQ=U&'S] \&[A5UM9TA/!OW<;C#W2)Z+S-VWZ)7X?)RMWG%D%;5GZ69
MRI4V8EX@JZ PKI8S9@_9;V<?F!U=-G%U.J0<4&I_^%.T6:#< 2-4UYY3F?.+
MC+KTYW*P9?V35<X[$2\[&M%?F% 7BGWII];B5EOFIQ]L.]H>]#)[1?'+Q^-_
M?AG&5+?;$86@.G3P/#TNB.R.7R2^5(:QF4;)]RGY/>%4Q>39D;-(4 19>3LH
MTRF+3 RXZ^:HGPE!DA8+4C0">1,D&5C.6& F=2V?DW6>?8M2D,=C"--K*4B0
M#(B+X7$R'!Z<DWHB%XX.TEL.-K\R01W)=&W ^5&EABT=0M>Z@W<6L0;HZHB6
MA:^W3=5RV"8GMVI(MW*E_($OOFP_W,><L^$&W'U-,HH3LI:'2T>'@ T#W_DS
MG<VS-6229N6B(,\T>?9R40YIXZ>(LCLPCCR)3(X:ANUF<F^X9X]@JR?S999<
M<.; _\7=6T"UU75KH]1+H:4X*5:<XI#BUE*D>('B5BQX\ 2G+5H<@@=IT>(2
M($!P"TYQ @1W=X?>]SO?>^[]WG.^<\[]Q_GECILQ,L;:&<G*VFON/?><SWK6
M,W63FYK6;@,S4 !L6"-EZ"],U#V:J#;EA<36NA[Y Y63_M1TA<F00KT^599W
MD@%$(_FX\L-\F%+ >98 Y:,9IVH1G^^UQ3O+R'LLM&_CR'(RGN9UFBQ@T>21
M%0*<TNVS'\R=R;:ZN-Z)>^A'IM[6+N8]7=>\H4'95&@69P7G3ABF1OA,K-28
MC4Y8 G1QN=\C<'//;=NGMJ^W:S$R+IB>ON2!1HOS;H6-O0E+"ONC32U1<*56
MP3A4CO3'<:.EV@R#U:P8ETA'S8(?5+,W\ZE*@'(O[V2#:3TA M']$G%8Y(6%
M8<=J1)X-Y'7O4M6P.HFT*7;G';Y0>)7=HR^T3=$U;%Q.+BLB& K@U!2B2]BB
MU$W5,P$1QX(K?8-:-S;5S!R%4L'DU'@\'7*D"E5/8LH0/,=OM82RP(!D^)<S
M(-\*%1L6[2NVNCEJ&!@5IL5,W2T+5IZ+X0?DH^>F2"<JLP!<"C-+3'5EZ34,
M+<J2[^N*:O5!LH;*/<2W*C7=':VJB1XJ7IWJ1L<7>CZ?W)@[P"1Z60JF",+W
MP\E5,VZM6P>/G9/$ NMIC "JV<+IC1K4SO4[PUB@S$NG[9(9-6*L6]V"K1HD
M<AH9;5#]&\>'WZ[2]/1M5H?-!ERRG0>O*9B@C6^5B>4W3A%";.7P0K$BN,9?
MY9+98G1[%!I8M3?7W54"(!$\<IU^V!U&,V E<_OJEA?,=_LJ0%K'[/3?$%?7
M]]YOCUT/0Q+Y'X@,2O@I\=JD/@HD[@7I4TP=B6][XTN*"7:;J8PY?::XMN74
MG (F"*6:&[I#WMB"[YJ"($>6( CD3%34>:#W4G=N5@:#O$@"#WQO&RN=_W2X
M*Y*HXHH<T">/3[",+3)^62W*0#K%2>RTT(9_OYE7D5SHY=]'0F":TUW82QIZ
MF$K&WDNUKPP0ZL;?A\N3E,,\OJ%??OLFF!2-J&B,,FD<4@-'3F[X:"W3XBK*
MEU^<2Z>F-WH!+F",@X.5=""=J1L(B_.)OJ.;I+'Z#[ZTQB6NX4#_<5V?FBZ5
MG8BQDPRF("*G#7\UTT5H^LN5#DR%>V[,8"3RH#P^P,SAA2X%GMY_A _]#S;Q
MK7?\IAY63]H/Y(V[Q#E("(1UA'Z>T=T%E5*,=&@10K@:43!I9\0=GHE(:]60
M);X7N"M\$ <]!&1Y6+<6TG?&I?M'8FZG7_5J$-1>05Q+!5.FZZ6#U0)@,:(H
M5/[IWM0.*X;SW=>I;>\!S<IC-1MJJ>;;%A#?<WD:MF1![=0X)V=YQXMG"515
MD'LN@#?LIW\.<'\/#;]*]M!-G"1&>.VF;UCW U^K<M'@-E*-VN^X7M\+30!P
M-JM(F JNQE8#"V,6=A'?>(\/'_RXRO%ZW3AK+R#2OR[&^;9HF5HU82LJTXH=
M$\#09A:689M;\MHL-?!\ PE90E8H95_X.K6_I,?AP+G;^O)O10;Z6NDY_GCW
M]?7-  5AW$/_<2SYOT9MQIA%'%X8G@5E\K3:4D>/EGNN?%/,9&4;#5@K?QUP
M^XY*319D?JM$O]M8$<YUEK9Y$851NG%GWB_=O/@^S ](FQS@2%+DT@R.BMD_
M<?AR.## ,K2\S-7\D=(7"1I C:=DZ$QO6;N1@5;?,TAF?LVN</U5]!M'8^QG
MH+L0R,2!X(L)#: N_L\! 7JQ'64/:J:;LO>/I X7>:L;K8$#BWN49CR1 D'U
MD;,&YGQ/Y:C1'$IDD6]7,KFX/_:W.?:W"<* 7LF-,CC8-E'B?5_8Z%4@F(SR
M!8QEG^9E=T/IE_U4\5KTI5I58GH'E/RT:;E:X)215/+]_TXX_!^0U#R?2^H,
M_4>ECI>GX>(D;NGB^<LS#!OA+N<?*.I-F4\]]Q85LER/PVJ75N-G>M2=_/FA
MM\<-@?8^")'T*G=O@^JTQR=& ,RW_J(%G97:QSS 6O$^L60V4\9!2D4Q]42"
MYTE#UX9IR=,SM_:7 Y\/_^6/)6M6>.AB&5BSPX/>+S_:$%J^:XJ+ ^]3PDT*
MG.[_VW=+1R8+O>2<!! R-A6\[(G[5=]['\/(@U,ZCR)[_9%<4DR^18>MZ)9X
M#[J8:7]+3]Q"_K.'>RZ3'5O*]57LM8O;FF-"(=WH@?2W-^^X",.\#/E+VJ3,
M6%92*Z3Z=MHJ[K;_%U(=F1,>2/3LZDUJX3D!4:G"7TC7WWG4_DZ4^:L&C)QZ
MC-&&<2ZWW6\<Y.;>_)GV2Z[3?S[?;*)_855K"^]EGG\9S0"Y)BXQ"VL _MQ_
M TE?WPM1)KV9O 9ZJ.O^(^?ZC;S(?V10O,C-'9:(03/N!1>2[UVF%?',.=$Y
MYB+S55K-8B[O7MY($?E2IX48?[U+1 99?O\YR])=SJ0OH==FN)A8MS;+Q5FG
M/*?B$$%Y3F^HOE#:<Y=N/_VUTOVP7 &4[A+R.5[]P;O/BI_6K&8'/;U<CA,T
MWMLH[#"Q'XB.5^(0.)!&ARN.'L;A-_V8SF<_B:IACE@N!9(0*SR0N1VA3JUZ
M-K:%GQLUZMA4I"80FR EE!V98 L0K-)X%<7@ ,9MBXZC""_0C^QXE=%98O7,
M_U]] <1H8'?7Z^VF@4KQB."32+.GYAS:L/Z%= GW<MEEI<61(12!II>C*$*>
M$/7MOC_5%P_?SINB,M&.K%<VWF\?> T=J'XP";E !/9V<AQIQ63T;0[,Z**G
MP%+]\O<2*0DQ7U\\*ZK>-ILZ$D7H=39F=U1.\";<M][DP%,Y>)O<*5PNA" ^
MIXOY>=T?46W61U0?'1-AJQ7TAKLRK*0ZP\U1;UK5]$0VI8%&[FEB$9F-3E17
M<@8F%G?QDI53*SX23W,9%(N[)-1?2SKY\_]SBC#XRCM#=8%9 HD&:Z:)+54T
M1!U/^)RW=_PX%L)^SN^TA4?PE[/V+@N0:^)L6U3:EPC*O=LPC1@HGNG3F 4M
M!76:TL&YHTVAI[J1:;BF(&X&X;O,R^$RV_?FDDN>1&(V^DC4A<C\=+1$<=JW
MAW^U+?$)9-\%'3)3A=?DZR="B,(- WN#J>AV^::C&TKY5?)B!>B:K=</3B+0
M"7BZ*-/#YZB;^Q':M"_=?,B#7W^>[287\&JKO0V=O]'6,-I!HJ[S+_,HT,24
M!\M=J2OG@LA\O -SB;32^86SDAQM,5]EU.YM/&_HM9I5S1(AX=]R.!,RT$*2
M;@W(X6??K%)O@:"ER3$(E;?YHDW)Q(T41$0Q_4H6CV_"%/)'(,)(@_B8ADGK
MJ2P717G4[61K9M R]^11LJ5N57"[8PQR<#NNS5BK&&^M84Q54DZ.J69"\G9+
MK/DRI?YAROR'5E\,#W9?_+K@2S^=W308CZRQVZ4H^B;P?01KO]I//+@ VN05
M;=(E4S^FYZ![\%XW(\EWMF2'\V1Z.,7ZN'RS_K6AQ7YG3#R"\/QMMYMN^P$9
MN+#2?MS\?*,@.*D* 3E"Z;T*#JJ'3E3>ZDR[\C_15E'JJM5%;B^_;5WC3JNH
M\C;M0H?44P_Q/V ^:(PPNSJ_DG$X*E#0W#D,^'3[],5&&% G)[9X\U"KBM!5
M^?Z0O%$[RYYC"JZT><AT]XPY(1=U?4/O<$/V*P/R=??^C(Q/27X-;1<BC>GG
M$,EI<70$6M>JG@R$?A?@\2Z7U,5M.M&7'91_V:B.L^F;&<)9R2<J&$85L?RC
MT-O+?UWA<&9:W-Z2@(6/8KY*T[E[J1][$<EVD:+Z3"KD$9P0DY,,!%/7"UIN
M9M0X3+'(]:X$N4&MQQLCU549:/V4BPLD3+&7 R&R$A48@;>>:XC;O) 54&)<
MQ4ND3:,#5W]3LMGRQI5 ]0W#A"EYM5QU^I&]>YNQHBU'S&+AA<S7 <FVF@\$
MM_BDW&*Q&L%S(S02';R/Z'E,!+<T<,O%?^/$=V?FU[U@-O"N+^M-'1JF[GFT
MLD8W?ZC1L)DUF!C\3(-9I7^\$VOXE/AJ>M+?XW0L)U'=JBAB6TG",G5D*/U'
M^WUOT?,$BQ]4U4X'93<DM4^J3(B8'\8,=IN*Z8JY#4BWOYGNJEG"^,6'&/>G
M-1HG;G$VJ<V#*1;9TJ6MVQL&2T=X[ (A1Y*ZF,C3U,N3B .$Y>RK+*.VI0&6
M7\SY/4%RC"(>VE(:P6PW.OI[LI(BJ;ZJ2UX-P3LY5=.)SQ/"QY/LJH)-MCI2
M\R+[I>26VP3(6:C%LKT3Z1^>> M39[0"R3:],RU*C Q?$KS4S6-'B\E,X/\"
MR(C)'5*IW\&/@?DIW6^?TP0-H,]@>R4S[A\^CB6X2=!S/2B;:C<?:,49D.CW
MCCM\9E/X.$I:[:%T03M5F>9:L)7J-Y\4KN#7QT7KTS0'Z'Z#!/M]75*95N=S
M%XV/OGPG3+N4IP$M77]8D2OYU"6O"'I>5V3CI#AA/7F+M^!^K'DS:?0;AYHN
MCM4*S 7KM:8,7/!?<5S5"WM$)QG3^YJ!U*!1S+.^DZXP+E)H,E*Q:*FM;V 0
M$OHKY;9P>B@%\2"?_HYI$F_RDZ/I@G85C@G6DZHI%97!88'"UI4],@@$^KDF
M^,N)_:NJ-'\?7N,E#\TXR:")T37%N87!_O5A'UR$W*(W_GG>MWC-XN(+DEH[
MXPB7E91K#\A%VG 8FKUG#'_=F$7T<U9<GAEM;(X&G=2,S-,"[<(.<$Z2XGIF
MN9ZC$"CB'"SUALY7O'>+_B(\Q3IW1/GU"":W+C=E>R)+XH6RW?C&L?6I[;R4
MG[7O,F?-F(S9JQ\[T],S"R?=FZ.!I=:V?-$H9%1P<J>G6(8J,A2EA4,>,Q#O
M[_2RE-P&W*/_K?QL8W1\=$,^O$=13,?NE&];FS=9O823\0"?4<W<&A-$C\L4
M=,+Z=C)CS+*2CB[B2-.Z@6'#TW5UTL=[%WK2M#JU=YM@4;=VI6Q;SY*]O#;
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M7+2<WX(4T[$V)<K>.>+?F[P-PH;/["#B0]-^2!%V;E5EL\(M_.K$#N,!R]4
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M:V&"C+N?T21_KT8\QN$#=VE13WT$6JG-+%2O5!KDA&LQ4MAJ?TO#I,OG\H0
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M?,%_Z- &HK<*FO@F0+\\P^/_WC(L\AT+R^,[-1IKS\X/OMO@:L.$K4^[G7L
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M.6!?[@0YZ9Y,W08"&ZOJ5CT;(&QG]'0;BXCEO<"^M:)C 2ULJPP<BGK7H_&
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MCLNL6-:TG4@+9:0P\@4/Q8LK\PJ7H&>P]9Z!,Y=US25-9_*H,%;83LENW@7
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M0?7 /3,S35Y'0+'G3/7<07M%N9_6-P>BC6LF]A.&8BJ>DA5R2LZ)0H* W*S
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MK+E"475QUU/DJW\1;3ACJF+@M)ML,->A[L$Z)#OY*@^3_MU;Q1^;/<.KJSS
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M@8;67?1[5^M2"_V=33M<I&.>,3Q=R>Q#I"3.6T0*BI0D"ULEPIG9>GD\4K2
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MJCJ1D:G&*=\\ _3YDL9G8TE]L;)@&F?'%.T1(319R>"^>VL2:<9 [RH9#VD
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M5&E6I$JL839N=)$CF6HPTUM>S:*D"(/-;8,Y;DG$2/B:;WZ:A*9]MVY%GK6
MA"LK]<[CDLQ#P+/DTJ[]$LV."UGN>Y7N4CCC9>,(*8]-5M1\^C[GW0QWATG>
M'-QK?(<L/]@V19J)Y:.E-)-K-[@E<^8V-Q=JWY.-F-_MC,BZO\1\U+_&Y_Z+
MZC#4^$=F1[5D!5CGMOH 4?;[X/5^7I\=0VL%OXG>\>RK15@T;-[)FC\QR2^O
M)G&+*'W]N1#C\U9!;-9"7"M:/5G!LQVW)UG%G/8:;)_6$OW0^?-[QX30EB]W
MNVK[\R$-%=#N'.6$_ 3J=IS)-,-Z>Z]<3W.'BHH#'$:H :+-0<N%&)AK.N7G
M8'#1QN>^NH%?ZQ&3[!Y<:G*^0QEDB70N2DU1G4+LQ,)'E-\&SN6)YM_>FZ^;
M:&*V&GW%3/^>U[7N05$YS-7CZS[S1O YSH<JF?^+NZ\.:JO=^J4&;8%2H+@[
M+0Y%@[0XQ8H[% LN@1(<*KB[2W&'H@&"%)?@;@E%@DL)&O3V/7+GO-]\][OG
MW)DS9^;N)#/[^6?GL;V>]5OR6T9JP_?P:AB?+4NN_E3N)XT!A-^Z^YG,&HJ<
MI[?O OR6V<Q=P2P48A<#+H.\"KWOC"@-C8]L*B-?3QJ1)4P<V959&3(8&+Q>
MC;.I+"EL+FQ3'6O8=)_-IPL?;,5E:JL@IF WU"YK?%TF1XQYA.;V&1^KFKA0
M5$<-G1?KQ#\'=FO(A$47A'5[YRR0R%C#N2]A:CM*RK@"IVOU.JQG*VDX":Y=
M:].4JI]<DM3M8D%,\L6O-S]013$[KZ?K9K$X%4&.849:W_S%A9RH92^_,(T&
M29Q%-EU^VH-^8TQZ)71MH%O/#" 0D"-[YZW-4A9%$5=WKA] T _2.&WJMJJ;
M_L)<S8<35YW.5TP3*OIT E6S F::[*C46&8A+V9[9==^#DU('E]?EJ,J+V%I
MH2.B5I#7\L@$BJD4D2(-D\9JU&W>GEW.Q!\+'![4LS1,9!VZ\;6NB*'2\ES3
M$,EC_H^MX4_H%'!3F]>^JMO:WG!2D9'M9K0_,B] CO[<(1:UZ<KG6HRC3TI_
MNQ*.S??[\N3C<_XCC&L(L0$$ BU/"M#^-C[;_LGG<,5KX:Y&+Z HZ'MQ)#]G
MS6+Y7M*5\*+Y>7GZC8U@S0*/6IB:VH%C16RZ>V:\>8U3PPW#H_;Y2C9X@)^:
MD8E.2[K3)@SESS76C([S"=^&7=(@+TE,A'L&NJ7E0T(#WCSJ[P^=^ZWU9H2$
M9 ;(I"Z%SJ=F+@?63=YAT#3>O+Q=WA-7_D2_C4_ P/L! ]^5CP_\'..>%0,?
MB^D]8A=Z,+&5NX[(@>%!U2W08\M=SN0]\1(EG(22DQF\RT$1V$@O/7D/^[$M
M>X(2Q\?@\J,Z^-'1(*]J#,$V8M-Q:X [.!)>,=ES M3+A>:>9&[]R'[.V,5(
M'LQWK_JC96B&1<^8.&,O]N7P-[M#2LT]Q&#QQ>SJ0K^V]8(1="*;&:SELNUJ
M1,W!:[2CBK8IJJ_P!/FI9Z>_=K;";IYR09G7G2'2\MLZ3VKL3K.7PHUW=F[V
MFY1@@_1EW7'_DV!S2SK>-Q8TM%&ZC8-])9:0B*B/RKST"B/)$K2V[UV"C-J.
MC.N%HJD90TR2UA+GBS_-RC0N8#$5N&':*6W0_^)-P<E<4KY83*;1+1#N5)<^
MZ-Q\N,<@YBD$3'IB'IO^Q;+KQ;G[]ID]NVQIIZ.QR#.>RUS,KDU#LI0/(VMF
M5GD?+O5::G0;/)K\/)*)5:21'QY]D_D;6'!L6Z^<8"IM6.T-[Y_S=+E\"M.J
M6"7AA16B'C%>%/F+*Q0KS1SE7O,]LCWI6^#,]0IC1QYL[E-?F39?N@N:]7T.
M&$BU@<M-CP;^4M&7_SK#"/2C^'DU/M&^VC[VR%,&GALG2\NE'?XC_J]1;@"
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MQ\'6-SWW]5.7UQU3?GX1]V*;KB"-X"^3Z7XO>1]C: A:ZWGN+599JT>E6GQ
M-)0D*R=X7N^5&+@\O:4>#G_T*A8J]U!JXW:J)B%^@#TXW'/9^_:WYHQ^=^K,
M%71B36J7G@27O&!)C&DNF$>_@-1&<ONU4M486YPM/*\, (V&-E%*99UM%*GD
M.IB9BT>>J]*?0-3;NB\YJPOQ8$'[\P"1ACN,@<O?#ZSZ\@=N;3N]PXC_@S+2
MY.$=!NJW1 <6G!5<9-D;]Y^,_@:A6TI*[-(JG;2<LM)[]/3BCM*J7=B"OX_;
M5/>D_CW9_"4Q*45E&Q][-'OFJCNIJ2.YT+V>(HB9F=/3"I$]J37X][?&)-PD
M]$GRN7&35W9+=O5TD)FZML8*YF]3PKHK2;<%.8X(<1_E_M3^!ZHQ,1]GOLCY
M0=H?#L<X/AVV7ONU*U5^)$BY?2D1?S(P/#)+K6\38>6>A)AHZE7_$@G:K4U(
M!JAPJX.2)N0>_Q('EK24A56&. V[I1<+PB6I*!*6595SLU"^ZA]=IQ<+]Y"8
M@@7S320-RJ,ZLY6/4*ZC!!2>5]T^:",\\,J@)6.0NKSJ0&I\+.&-CKO[YJZO
MK'HK@A]NFC$WU"0.T-R^L2K<UV,M(?+)$JFL['M">*%UW&Q1X349(SBRS!1.
M\:( =,023(["-8VT]=9)K>T;,?^<C4Q3H6HSX8G,YT*>ODCON@QB!O)["FGH
M:-@B!)@8EWO>\:EE,+::L_94!8VZ@G5?V%1,6S'Q12^X)G@B(957IZJ52VV'
MN7(ZPZ_0?+!;M_A&Q"AA_]Z90_P=QOP7SNQ9H#!EYFWMR=.](3G@M35DE$W!
M=!F9IN<_'9%'L["R> TS#73ZZ<$KM*C<IYIVZ]M*VWY;1!ATIK:?5RY0]5YS
MR&;O=(^_T2C7KGXH2ICMJ&L<IBY>.F]HVDXY6_\"<>_[*)Y2=0^C>\C!Y6'4
M1'H^Z3Z@?# H86;F_F-;);Z3[6&U#_,!JOA ':[W31\RLT25!]89>']M&S0:
M=ZGS&9S)O[0=,,=4Q2WN&2C1Y1-B_XAN 0TYJDOQ12?X.H)B^>Z)VCO1FC,O
M.=:W"MILP\GRO_$UJNJA[5XP/Z&TB,-TMR*,F+_6]0K,^-POPHA<?KM6A7-R
MXU)T$G9=7MQG6_M*P0BW;<ARWDC?J4)CN];/L"Q]@Z^%HY<(40Y5:-4OB_,4
MXO-F&5YX)^;3-, "LZ!A7%@P:&Q,=VR2T;C=IT;K_?IE5I>UL;XQ;*/P@ZYS
M5T.P/J:S5Z4+UWZ^?10E5)PZR-RL*J!(W<GS3J LFI_#*FI !V*,[<82-&SP
MOL>L/@T5,+VGDT$N;_7%>BDO[64>79PP _V#^P0$(+";C,?H%[XZT6P&3HI.
MGY&($,?M-GQ?0X-=LCZW#2V.(LR9[9Y>]=0Z9:^(RZ4=!Q4QCD)?]E*3)W(K
MS=X*'[WYQPN3FT/"5?G>_OMTGD>HVM0%W4&P"QF;6_'[ IPD1Z.FUVZETU7/
MFQ1>'P^]?:$FR[X.M*#GV#AH(VY?PN%,ZD*,[E!&&JK04&"/NIP.D N98JX$
MMJD+6PB2K@0)" ,3O@A]&@HPSKA9]462[2\W<>+AG/TR\-8V9ELUO :D;IN)
M2S%DL<*^8(&?O%Q-"7N:/<[B3=RL@CO[Y8*&3:^I=+**O(G)3RGI5W 5(XDJ
M[PSTK5C<@@8H:GB;TJ9/MYG_Y=SU4IG&I?AKX\DLN/#&;TDU38)P<$0<?4F
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MY>Q7])A9.'PJ9CX/ASMIZLT1WKK?%!EI9)TG[[;?821 ]9U&#B]'FHM$K]T
M:#Y .]<!\%ACIF#Q5OQQN8@$*AJ]/!=5WG9[^%OY?7>:4SH$=\&&@O9ZEZ55
MD7VS:[N>OCI@)Z83L50+( JXN15Z0?R'L<*G\E9YHXFF\Z*YG ')'K4WM*X\
M\!L'O^/8O.Q<NE&5\.JS:>82S=C?IKJ46]N=_:UN!_M_9C9R&EMY9FOE=FS0
M&5(9:QS?=*)8NHUY[M1NU2!OG^V(.[ X)!8A_CE8Q<:]Q7#==>SGZH"M3W)[
M5]B,*@?'0O5,.=>X>J4$F>2KGQP,=0V#WJ[.P[X+#\#UV1JV#IW3:"$+*[)7
M;4"X"./#@QLL.6JW5PH4;A+W&)F'#]"B+=8.)4NXFJ;4"8LW1NF$*)NC9B<.
MLQBT\ZB U#1Y(,A/R+P:2.M^YM6<F7J<[73U[>J-+0T.BK2%.>X3+'\9D%$E
MEA*,Z#UUCDPPHZ:)$@7%9C:"K)!)$N_[5R)%MM>1>@5JB2S#  </%"S>B'C$
M$$V@IFA=?)";8$XTS@ (M2*QY>_-L/<I'DMF-Z<1>"TC(9L'4W<J\ZY#[!\@
MUC75%L,2?\,/'$-T,L[]Z_;6Y8(6--KS_&IVV0?(">41QH;@C$X@C"2'>C8.
M#_U$VHKPUH</[)XZ'.9=RA[!RL]EIW*O/>I>5V*26SQ<0JTD#QGVXT08*W?]
M7 6M+!<WI^>)@7>;RLRXQ<GT)Y-/V7\.SW+F#2&:* N'^_0T*IA$E.XPSC"A
M<L@32D\.*>VS+RM+OM,"%AL#_M=MHFM4=QB9<5L&/JOYK6I9/WX)AK@T>'H2
MK<F<JS=PW+[+!IP+TBR/%4E?%I$991?DG1DDNS*OM.]+C-6ZGIK KF%5?/!O
MWQ-TTQ1/&<#G 183V=.HQU[#=Q@V;45-QGF^5Y5G@B9;5R("MPB;<@Z%AR-!
M&DJFU8WL&]1'<BM14C1Q>>K"-Z:-)!D<8F&S ?J ,5W,%36:EMIF"><K$0OJ
M_6_I6OM(&!,QFZ%Y,8R26]C[_?C4*3W;O2_],5?XBNR'4?T#9*TO>^5>Q5H(
M4?3Z\ADTK<FE8[\<*+7N!UU>7-O4B*]5^^X83YX&IQ*Q4/W&AD>H#(NB^%B@
M$O@\@WBI:G,$.;G"J=SV4BPJ9XJJBJ=C:OK+/@1-E6?- +[#:.7!B;P<)92@
MT5CZSJ"[PP>SY%J/X@FHTD\:D!:WQZ-S[6K'G5(]C+EP;*(,G6]N-'EF(RZS
M7>+J"EZY?=XQ*5P0KL.X2?1$&09>3?/^N" VX4NPYQXT='#2[#+YUB+*4.SK
M]3@A7ZQV3&8[_P\.&(I]63S$8+-C8PCU^-A>9=?XV.;LH >7KHPK\08R^ Y/
MCEZ5*?5U_DQ+Y[39L]KD!Q_ZGR*Y";U4D.!OM5[=?),<0"O+_2F/0BI!/V/3
MS/YJ=7EC->4-*\7D\X=+PK/4/@5F(3[(>PXF81?FA%I=OR%6F]<&!&Y?9#CA
M ]'BR&:J/VQ.&A8Z))-5<XEH=U IJR[7#Z) ME4V]!W 31";88OI10M&2SJ\
MMFI*"QV2UP(Y0<,V>=7&W6JC#W^EP'#&AG 9-61H 1&Q V1/^FBAGT-YL*$
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MB*DMK34[=Q='\7\RHFA;?#Q].7S1%[^$O^U#._?VM7W2-?-:)7P Y]6:M<P
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MTL*C-C>V^S='L&,S2*D2[5->$FYW^ +>\%^LJ Z+-TZU4/H""O'V'1M3)U)
MO_,3MUK#6=E7@K*Y3(DZTJZY7CM&YN:8KX.S,_;)&'[0IV2JOEJ_*M HVA;M
MX"I38W;R7"X3__;]\VEJX]39V;(;$NG)W!B$*:9(G=O)$Q'X77&\YL*&,&V
M=;6IFS\-=NL&4W!K;D6X_%(;>[6U@8 -=OO=WHKDYAY7R#C5N#0BIDYV9NYR
M/^]GA'[;JM+PO?,CI^+G^ #6B'5,^N;S(EF/>3*BB1VH-BS_.'WU>N$0CPL%
M=SH"E_$HC_ [3=Z84*/\HI1338]7DL$KO73!GD'N=9,-<;8/!#&S=,0^$*/,
M$->]H/-4&&_0K=?IZO@"SZK-J Z-G<VN9'K':?3V7V?Y OU/?] :F>R:2,6;
M?4>Z1$E_\*I^>=5*LB..Z;7VD^]\#PP0X=QP2*/8J?5D#U3]_,UIS.WQUI[R
MI?+THK/L;$((:%TD.4-XXIOX,S:YM^\C%$V=Q5\KG<@:'Y.W;!N<"80\^T@<
M\E%76B9=6MH@["W!>KI>1D9&6P8XS"0_BC?7CLWX<#,<%!E.N*BQ,]@0U,#!
M7K,J1=M.NG MT[^H,X0LNSN:^104%<>;>U5Q<C/#7Y_F$E;3>W@D1=>T>'DI
MNV[1W$SD&$;008D-+GGG)IH%Y']4;[>.-<S-5R0 KM8J=O9\W@VNJ8I9_#(T
MZ[NKW3"<CIRI;!0[9 %,#I@C^_F89T@]"AD=)Z$R76TG>C6<[S3GZG%X-+#D
M:+@ $*==K9SCJ2.'N"^GUTWNCJ<;I&D1^?VYG=JNL:(>D87/5%VDIM91,^/?
MR\J49@B[W_]RG57>!5&X[K:QG\Y1^ZCA&K?KO0(3)H 9M33R%QQ3=)CSC.PC
M81 ;YC/+AZM]IYDVM:_U*%TF,[,I@^#]%I^MR4M-2([_\.UR@-!U?F#<=)TY
M]SRR4%7U2[64:48N7+Y/+3><XP]:;^A6=.[J(;2LOW?KU<OV(?<L:PR<5L\\
M!O3HWC[[*RJ^JZ^=\W012R,*(6#$#WW=UP"!K:?1FX H^2T\]-B/#%@T\5CI
M7S>Y/G#2F^,1XEE[KBOKV(Q*G13'=\TS["<R;ROJ! 5%RDI5HA[DJ*)5P'<:
MA.<V-MII&C7>?0; )KN[XLP]V' !C2I__S5C^Q?7Y/(DHZO$G?!U2'0C2N^G
M5.W*77_SO5,1K\4@\0HT.JS#UL+L;;AHG+/&2!]7=&*;>LJ-=6:;M3.-5BIF
M0OKR0IV5MG-S2;W$['3KJCTW >DO6&Q1#4^]M<KT5#?+.J^3_&V@,=_;*9\7
M^3'-Q(Z6Q0GS14#'@9;!#<S7CZ"9<RZ\Q2(;<%R3,_5%51E'7&K1MM)5'MUO
M%01_60 ')LG5=?)^%.2!5G18W#]_\98S J0,^/9?_=Q8^>@*.%/3#"UPP(S]
MJ6&7_82M#>/U]_W@%5/+:-[GTD0FA>&S!V%\6*+% JZ/(M*G\Q2.W2M8B[R-
M378>UN5?>]Q&E5U)_$U6Z;VXG62_@?PB[+SK+(LI9(8:F-(I:XIR(@0R8C5]
MZ+@3]7"V$O7(![;BATM'!F_=:+C=J(/X&;RTXQ;Z0U)2MP[XI3QD;]+!=P:,
M3):Z[9JAFJ'J#@4ZNM#^0JS-H#<"%C,E.FQMRS4#2[/-@^6FCQIUW&"CJ6I<
MB+ [QEE0T%6SD44SM&^+ =0]^.LVM/(K(:5N?JG*F=\\$KM)['?S9M4-'W1N
M!ZG;^GQ#S,SM%^RUB7:;],K.'[2-]-LDU&%N45R&PU'44:?HU$!O=4.5@OE2
M&V^M?7+,$/HLL6+_M);$4J08>M&'[Y:[F+A&\1VX52P71@*L8^]<Z=F3PCV!
MEK?,96R)"_!A$O\4+8(YWE2Q!(/"UB%5SNC"//97)T=Z+;P&'O[G23O%&0\1
MO:*H^SMQ3^%CHOHYI^DBQIY894(KHVXR F'=L1^\H=ELB=%5&B-:ORRK+9 ?
M\8A\IZ<^UPA^+K8B%M$&OGIC0$C,,DSK]B031TL^.R^5:)/*VAF[*)\**&!]
M<D.1"A38+(EC%VDV(&*:BFKCTJEYYR+QS+7[V9NO_>\X>UC?]KXS'7G;3_3B
M*QKD!8@3!.#>4YE ]C=E+@+BM'ZW\^?XD"-V!LSMANT&47>+JR%\(0L/>5P9
MT4J+A.;G6L/*5YG;6:G:R6U-?)LB_G&!O$>WG_.<_%3MA9EXK5R3EDM[19-'
M>QXQI,137:<=H]?)\[ ZRZ<;#>'L+27O&?X*W8V#C?E1+]^_,BH^<WT=6 %H
MRITSAJ,3)W2K'61Z 1*Z]<T/2 7\8]J,4OFN"4&*MG3FSNR4%3D"Y^OZ<U^@
M(#YG[K/1$OKI.^;!EC=A_!ST!B3TSL-)DV.-LMW8XN-2!E3Z;PA=7LS[$EDD
M?8%&\ />;Z@5\ 9F3I^@M^"P-B.F6@B?.W^(^@1BB<VQ"1+/58F-S%A-LK'>
M3[ZH(?-V$/7QM%1Z/U90(Q3^ I9<&0Z.33NODH]R;R/>4,8<BW1HEX,4KWA-
MK1/[> 7^;C0GF/<"7X5.Y)"I'^@UB!+=Z94=O/QDH] _",HJP_'?"I/:GA'3
M<,4#-KXVG-\2=VS_X!_J%D7NU>C,XS0Y9?DES% ?2!K&\(K/FC$O/K*%0^30
ME1"80PXJI0:Y^9$? R/LL-6=9@M>GKK/N1-_!EQX.^=SZ'4.Q\?E@4<BLD/D
M1IJ!WKV_/0($E==S..TLJ&-U5^=3F3#NE&DQU[LD G5#%B),4CVW+;G]Q=95
M[%\OGKJPJU7 U.IX+X-\QEZ[1!?>WZ.6[DJFSS3[LPP*%73BZTA,W&X$^=(Z
M+27J&Q_T.-+,M^ZU5K%_+N9MQ*KH^IHOG(SI:'^J#?_-__#$V#67",4/'N"/
M8A>\W65%%FK*.2 )\DLHI-1V:@47\?Z@2;:'#VH.3B<TV]PN9VJJ8=T*B]<Y
M;R'_H#'/97ZN]=2[62-?1:"$@S@633IR>TVZ#&Z45*UJUFONR8RZM]@LV)+0
MH1%9%]O!F@1>0=D);X3? D"UPB(.E?< ,S4?4WOB=V+[Q._GDG!WRJ0&LG1&
M;^.<Y?;:[,0FCMCDQ#$XY!@%_SI_D1=6@5#\4;<%YC#6K'(9IUV?,5LGLO&&
M +MS*0T^LTL<H^@*<+ <[@^+YB=RW+\Z?UUTID<.+[H'^O-CO5\<D\=#J)#I
M7P/)!YN)W4B4Z :2 J,D>K?O#,6T;<%,##,^!HA\(X>%/V@17%XIO)N[$LY_
MT.A;9/TX8GQ>IJX.O;:L*K@9SMM&=B2P^H@K%4S=:4'Q4%9#(,[\:)6BX^_S
M*KJG77?-%[V;>SMA-?WZ76_>PIY2OFB>[QP"&H_)^-?WCI$U/6,_XRBZ3*41
MU*M>=TM'-G!O@G27&FIT @U2G0GJ$\-% D,'<P\82[3642ABMYWUK8WV*^,
M@L^YYU8"I8/^9 9J$XGLKRM *12.CE'.)B25(5>HSP9VJ)R17Q07U<<H-=N
MRJ$]/<D&)ST0UCD)+K^(N0QH^M,OX_<^EF?Q7!E?"?JL0K"'ZD<M)17LNUAT
M@3\GB57$4P?7(%]L^G9<6K"]*ZO%QD4\F2QM53V<9M--8E\3;W)NMR=96Q"Z
MTGLAZ(8*^0N7YKG)14M_WI^6V+9Y/YC8=V3/21D*AI$K&2?%XO(+@%QQNXD6
M&4 0<0B64?^XQ<:.5'GOMRO?S4'UQ OE#!@-T] (_:IB7>).MD+'^$ PD*6N
ME4E6>)G>P@/QGO%VPLBB+A<NFH0R_ROU7XO*8^U$8BQZ'L&/*5:/</04A=(#
MI&1Q)/!)OQI,MBA\)R]S&-SIDA8 $SA-VU%VO8K1UY2'<PF+4=* \ 6@_Z*Y
M?MH-^<M:Q6GN<P]8_,"AQBK\%LOOA6K*AYQ A\R'H)"Y76+>,UYYE3Y%I0*0
MBGBF7X&KM3 51NN)?A6CFOX(EVZ-B'3_NW%E=%J-/J<M"5I+^F<KTNSP880Z
M$\)G4<AI!#G5E"%\3G9;):A_%#XZR.0Q2#?*Y'@Z73G(D$360O9F@]M=&,"I
M]&5C<WY;27_["EHXAL[/\7)UFXN;O3_I(JEX4"K#WX+=V+9CE&=.4KYX1D#6
MH3Z_$,;;+"T3)?[I/T:?RIL"TZR+N_9'9'<LUEP**KI8^5Q^47:3RX!*>HFW
MQ+F(W03T.][$T<S.V]&:4?M$?NR"B3NIPG\"4Y?LC3Y($!LWJ!^9;B?,BQJ(
MQNW F;63L_2IA-%F;/CI"2O,7<0L '@_'C(A$JP_=:/D6258XW6#/S%N!WLK
M%Z026]";8YG'*PJB942\DE?(6 K!7/O[%;LPM.E>46P>V)$SK)>>WVEM':=B
M+^[4]:'/JB3L0SM_KE)_5-N,&YX' *H3W(WNT5SYUI@\GI3V6<9"=ML":F%I
M-+M#SKGR8"C6^$!ULJ9%6"$T$WG(_F-*9"_ZFN-PD$\ HW8NLF7[\4WO>\%M
M]F<!KE5].%/X3"3_Z53)U-F'TBYHQZA!$-%K@/O<BV.J^&+I.T1QP;\0\&@7
M-YJ=2RZ)W4(!&V]7M]X:>/:U(M>7PXX/4;4TLE!BMOMK[UL 2_#OI/*V!(M*
M53W24X _,NI150GWX"G\?+I&VA?.:+8AK'-.]#=6T2O6KM%+8G"8\Z+5PS^V
MK@2]^1IBL2_J%S]W^X+H5(B^HC/F@$+6227I^0M:3$]7^CX+4:"F,S4I(:,\
M[CG$ZH6KM!N1'-&[1'DI,M?O;F[REEUH.&<)23]!_H7(H>OEKW[\L;.'UIE3
M %F:]$3T$7LF@< R=Q^;RPKU-!$W'AI&+I=[ZL<:609ZGY>2'P""_^FL\G]'
MA4%YX)43WPU\W"!XA)QS-4UM^\,?M'I^GD;\65S$Z&Z@<#3"#0$ P#3Q>5>T
M9/VNOH"GEA%B6M\+ 4( "G;DBH9*],#66OSMK4)>3KUS_^^/(BW7WUZ6_LNZ
M%A*V-JGS 8*N-MRHW]0&<<7P ;W%0WEF[4,^*,,1(+W:9UGB2418+D>L0V)I
M09X:,T[?$8<=PX*<#>06)8740>Y86P==JBC_;&Z8. /9^=;7>>KAH?\6DO'_
MVRP_#EHILVM8^=;%Y;/Y)065A\DVS.?,Z?$L2Z\%6#*UT[5U-#:I_ K>/UJ:
MPN.W[R'7)7R<5#,S+: "*#Y9WX%WC;UO&T0[/;). S"P/CH"@QA>O,C^^T;
M^;J?^:BH%9^Z0MHRV*1"^K]S7@IG([+UNT9$FC1;%$>ZA]V.N]8.V.^?V(F'
M73<YV+K.3%76"LI1EI,$2D[C 9IP!VZ\ZPYL@&0^-F=>'TTDB<(XB3I;/S[[
MB-$^0CW2-7HW@N"8^0_,[/\V$O+?/,9J"53;0>AS\66>I>8]ZS)FZE4Z7$39
M;>,LD#0NG K@71+=,?+&T@'+]<,KS8CVJ(8! .\;DKUK!J=S7RGAI"G]V)#F
MD5GJB>EV5>MS+,Q@+&HQ(NLJ<VZL_?G7%CEM"4.XD\K-0BV8OB9>;<)5WP+4
MB^VE24-+]ET-?NCS3S>GRQ<E85DNA;&X7 [SD=@1M;*^G:2.Q0YG?;?3H*]+
MEXI5(& 3K$>52?SQK_"=SQVK:Q6=$25('2]/^]3Z Y<KO8V-Y3]B^%\6F!AX
M6+WBY>GPN<$P*W%^7#]LQ*QT#]<P-#;[EUGXI\T-"A^(5ACC<5?W*,);@)^/
M9=JE-0==5(E%-D>-U!Y['A6JRSX!U?Z4V=":FD]<L5## UQG!4B;T;IA-\?C
M"XN_;N@JVSP*/WX;P.1;/7N@=+1HPV1)/>DC+$M#D3NXF+!PJFT3'UZ FY#5
MNY\!4Q4[C6_!,3#)^-I@_]\CV_^4^/[F<GC]7LQR[UNRF[V1>C'GAXTC^ 8_
M+5PW;G ARZHDI):XU@W^7*5?1%@#]OSQ.&GY,3=I$':MW7$15P<7=FK2?30H
M#NB]O*8HWC_(*^+%4:>G$,I.=ZL#)(FC3U,CCRQZ5>P63\P$Q=2=;1[/3[I6
M5X..6=:1MU'EZP,J7C  \UX@ETM>H,$GF.C0\496=@:<'&%7WERSZ\R+<GPL
M^+W+;<S3_096BPFYS%&;@$T'Y@B1[KN@_);GK/9BGIYKQ?:&F9WJ%3Y)"K/&
M'2?$?0#XJ9R='&X/"]TNYS8*:P!5R_OL<)ADZ@3;\I0_==).S(9056#I-9B/
MEAD5U#QS?>*A&&BDBL8J]P$RS^!P'W:-3K,^6'D)SYE*60"?OWY:M2SATYD1
MFB],L(2CF =R0ZJ_5A4CDEL!GA[?_4$CLR-13IQVM\_OQQ#X?(ML57<JHE-1
MS\ZJZNU52I'[<G?A9RN(8*K8T=3F2Y+.\LELO1XFDDNAWQP3E!29=-M-7 U(
M7!"]^O#(^EP(RF_X]6B5!A!TB((9!9EE_.".?I_G1X"[$$O44Y0J=Y?02]06
MAN)OUINIYQMK/K<Z>7R7,3'M._1+G/[6<30Z0($\HWF_+/B&:SF]#?&Z\QO_
M4W.IZ5X:J,5"@?,70PN"Y E]"[2NKC%V?AS9]@PR__F=1LZ[Z;/S'8TQGL0$
M/VG@HSW#K&@13WF3KJZ/CYM1D4T:2/.&E_ZP:?=8D_ A9QFPL"2V4U1JSQD<
M8.C@WFC",ZDE=:W'@=K3:\Q.],K5_^(_XE1=G%F?8Q;X\';J9@XWN9LF1\1)
M+]U@M*L-HG+W-B*R1U'"<[6Y^\LYQ;O,&FV[*A:LYK:?D]B9L2A3E4$7M)M6
MJP\^M9C5%QX!KT+$)AO.& OTKF+F.);-YR*_4\J]7)$9/LT^TA)MY\NG!>??
M8.69(P]C%C3V8!F\AD+^%8I!';.2VK/7^$ZR#/E.*JDSOD-3 (_0BO'UV@"G
M_H;WK"*<2Z9!8A8-R<T<8[#!Y(1#-8O1J@E<XCTGC&(N/G-/%Q@!?>4"E^?F
M<E(]_A;I:,9RYIB:3D,_Q] @K;HLI.^N(P\VQ4L&+6"_A!:1!#$[;)4%OGR1
M5 \GG/J9J-NL>]&PJ%[./G:GP*3[!TV0<A@;X#+:S=\"1JPR)/FEY1 FZ]?F
MO(@<0@/UL^QNUUTR:N=L'VCM:581*UDOMQ14Z;=)(I(A:ES/U&79+F0MJ5=9
MZFZCG J3G-H3C0R<ZY0V_/F;="9H?N>#1*^/(^<?WF[JA'_2G?61;Z'\_D7+
MNPXQL)HG4GG%9+I!$)A3XI^4*^$A0U;-SDQY70.+<X7$L!G!)F]B2 T7>KCU
MS)WDTI\'?4F0=-7JD6 1]N <U:%Y<RD0KS#9=Z:&ZRU3LV]85_'TBQ9;!PQP
MO]B>NZ)>ZS,5!R\O[G@.KO+^7FC*Y+/@,>1Z;,0QFO,'#6?S2 95(I"-L_?:
M2UDN.O78%J>Y3V :ZJCF[L*33_#RJA**YB#TOKOHCFW>)5Q=)^)%N[7MN:B(
M0E)"GG#MLF&H(X%DT2)D]LG@W8RS[M/H:-;9$-H]]+6>9P>0ID]Q'%0"9V-#
MHSC#RP%]".(5>..L?KAZ$C3M>_R O,#-\JV7_4UYE0'A9T$OS]@& 0M"K[WG
MVW/XW6OYA3T?-K:,1)7%&=1F'IJ"W*#^5#_V23P3M"D*THRMFN]EH6;$U?J:
M4:$:6:N\'2:Z7?TO5],&,2F],N;@-*=*F)KMYN::C!56(]M\6<D_LJZWPZ&O
M+3,#+^[;H;D.#M=W3F4K 2ESIT/JZOW[N[_LV9-<B.L;RWR]VPZ4N_NCI\O>
M;CM(6O[2*=5R<[VCG[=YUV5._XS^^<A'2:3D1V4X+2VB%@L B02<(%&0*O/V
MGVL'ORPP1UN&3X>%:_EYV/FI#[M!3>W9[7#$_8))26M3/1<PSN:A=N9\<,/2
M>NHP9!3_I.=VE TXFSDLOWZA'@INSJC6L;B*K8J@VPKI&7IZ%37.7Z(R0T,)
M8>%D3UVM&DN(SCT:VK^[,FI4M#Z! ?S%Z3K@[E&W[@T<FXR)KR*B*A*__A>S
M/3!T CY4W;,(A<LX%2GHK?59;,\L_$"WV6])3/4'DK1%BW_T*)\:6&#<VA[@
MF$J6UDN/;?UK;U/D15Y0@@"0>^5'E_[^UTYGEVE@S.ESCH268=63P]W;^I7E
M@6D*)A75QKRFD!^JR,-]$J<E;&Q9E2UU)38FZ]"E@6"SH+24;REYF8<YU6F"
M-O'2$NTHZ,\0B[N_'!*Z/(RJ;E59AX?5+^.J]&YOYT[D.0W/C0W<W?MTL -J
M._W?:1CA,:?A"^SN9^CQU?\N[RN 7EN1>(6(&;;5GM/MS=4LV@@L/$"@%0U\
M69/>*S4A'GS.Y"'EDA14TC[87)UT)3&K2R0)Q(M<NXM$V2U [2'REG&B=I9O
MW7N5=+I[YBZZB]YM ;:A(=15JD^"Q;RM]^/GA7;B6P2M *F2--P,<P\+Z"ZF
MBP&C4Z3?DG\-ESGL#;*/S$=48^ +$[@VEG;;D^))F)(H<B]<#OS:M$[5E>1.
MY HL;B+HN1YPC*T_<5@:79H05!#".%T<JO?^C=(XVV!MUSLVLXHK _V(17%?
M ,C&/V[]RJ.T=:+4&8%@_Y[7XU^ST!)FK8L0UAAH]*\[9ZD:ZJDH;^85E) 4
M<TQ,/9(.72]Y:P?D%R_^5,>694$$5\29PVC=3FX$[207'94!;S4=\NG4"0<Z
M;7Y;,4L$$7L6R\;$G[(8Y5F3>K!BLB^[+%2[23&ZP9<_6B(@32P'Y0F,]8MV
MQ3FCO! 5+Q6Q47P-NZJYS_>\\]34-V)J9.S1R\8C?C[5&$LZME6\N0G]>566
MKN]VVIYT\RL+/H]P_H@ \,,=,5LZ"M@O9'[W#3=&5C U#CD:E7S>-IQ;9^29
MVQH;VJ>R-&0-L2%< 40EFVP49@8UAS[,'G$N('8C^7)KR^JUZO8_W##0"[[R
M,KC/5 ZT)X6/0X)FIIOD<\."WK97EVXBJM</AWI:A@L]4K.G3^+8WUA6+$VE
M18)'P4/*#?S<=P0V$*(6U^FUUT=\;3*TOU< KA0$0T(A9Q\Z=BS-DF"#"^;G
MD[>RT[9W36'Z]-9'(R1Y#->E*ZE-E]O?M9IN.I.%$8\#X*F\UB4-)WAA6!8[
M:HMK!O.3!9GW=I'PC2 W[_J!]7;8Q%P*>,$[M+>W-K*!38H[K(>-[-<#MZSY
MJ1(IK#V6VYHSJ%)R[#*U[WW<?<V"IE/#B!I!U?B=@Q#J30RH.;.C'5?S;-N
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M/IW1O8+K<!?'6M&9P\OA7#T:)!LV!OF4>;Y+N5B=49-1Y&!,;4>$=;N0 G=
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M!^P&K=/1@U0]?T2@@1?QZ*G.K?67UL0Z%-K[1)7_H-'4 J!! =FY?]"LOCR
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M8[RB(%*58H*6U+:6-USZ09A7P+0@ J(X;,H=SK7.,OKZ.G":*ZZ':\=N)(M
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M',LZF"MQK1](,I^F+B<)!CZ1G-@V<H"D&:>WBZ\XG<_BNO0=2_PRPY"XDPA
MP.^5:RV#BN9=@32US2I?X^9CI77*NW/E GV5?"6AA86=#/C3I!G<'_O,-82
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M1;05-5>#&W"J/Y(6I/5G1OVK&)^V8XNS1(!05K?=@<<=CGQ[>+LIHS$J([N
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M:JE.4O+:TMT\%4!EGU48/Q>@$-"[E&&8]2.0DI5E'_X\X_H=RQR@/PYYTAJ
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M:4(TB=BXBD@^0Y,%CN3NMU^:%.?A%>W#[./RHB\[M!#K5+A3%9O7JOOMGUA
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M*WEWQ'Q<D?#!VL-?8B=B,*@4S^XM>'=O;>_$+-<G*-7&?>OL;/%W9^.M2:>
MWY*QVEQ-TB:#*X/P+?HZ7>W6Z;>_&,%U9T<'5PT\RX\7U9XS>[VSUC$?[W5X
MN9VSLS"CDI51E%'T%+ [\A'+)@II'EGQLOEMA*J6/W,9E40?B@[^ZIC/,*$8
MG+7*?\(]&S36P7W)5!I(!27*UJV2W]G=QZHR5,&5FL><]O@O&YLU-,>"LD&'
M]Y&[U&Q^@,7;N!YEAD;T^@V&9<;,HF%.Z'+'@D.)!IB%8HBRP>RZ EW9@BK&
M:GL:.B+14Q445CWR8\7UK@W',C))E#%R.97RCU??7ZG_:N$3M!D2^=S"(%G#
MP3+.^S>1X?%C>HD?8Q!3"N\FQ-6LT:NM'+$^42%>GT&Q8O0G!$]6XV;O@42I
MD)P-*%/9*[1E'5Y.,F!V<Z,78G1:> >0V:63F'T*:8G3)A!7&_)0BZ\E$PCP
M_ K_; QL_S,AQ YVGP4%/F5H]\8$NL*#]R@NW.\ &T[ _5NZG(T8LWZ:R68,
M9?J>:GHL4_N,Y>O?%*ZU<GQ7%7-!VAF(/Y5S2[W-<+T6D+<>NB'B9/WCR5V%
M"-.:J F$LH<^@B,]&K/599 /&%?BU+815(,CDD,QE18K6)B8U-/.\[8/9R51
M5?JF/FL\WY;I1=F.O([8S$E F(&($+F,N9RL= .SXGVCG.+MQFSGG*W7S<8I
MS\T1,@#D&NK]H-A]?.3:L5(V=384A%GL22[N'A@DD'=)FM&9IF!OW$^R_=ZA
M+O8\KB+?<D69D'I\99JM77.@B4*I8RBM=QF]6'#FVY&U:V0#R0L(:^J2\#4*
MC@LW6)%;B5/-8=^V\"#7%("1%Q'#"=F8.!] 8FP(18J]IXL:^FWX:[UL B<R
MB=P_22!?9G]=_15N,JR69I=1&92%=[DF+'/PF2HGM%)NY0._YSZ6@:MQT+'&
M;EA8<Z4LG>A+37*#@RL)O:2MC[D+#>&P3L[BG/ W:>C&P< W7XB&@ATVC>RE
MAD PPK#?JBQ+0X4EKM;9("2G+8YZR3,P^-GO\/2H]VP/2.][>O/&^!.CW<A+
MHHE^034\<_AN3^JNV>(R8YZ5"!&V-\]W.^6GHUM6M-&@<F1,_:L[P)O;YO23
MBLZ:C',U5.#<3V%R@9I7S29)L*U*-/OKJTZS"5N/AYK;JA)DG#J,+B3;J*6R
MAG#7U\*NR2]#JR<>,U$FDW'V"$T[".6?C-!H+7^R<;_5"K,G2*ZAJPS4IK;C
M3 'K)4)Q/];=HP7Q[GI:K.)F$X3T39?'D^^;YA?.8D _5ZB%RSMH4/0[K3<F
M62S(9CWC%(>H;7;F7P(;F;<\^7I9L3;"BV"H0V75-1O!PB)K<TP'-F/P%XG=
M=ZO_%Z!KB282*D+ $MF8,S;M'TA$I.I;N<JO:UEE*.FS20^E:\5(TA6&"8M:
M\8)>LQV:%>NH(^2)8TI$&ZED2%Q3BA8&^:+4FA9ED^8[X*-#3%10I=)^#JBR
M&GL?3U73)7.Z[J*L&UB/<L)P':_DDTHJRMKEW,%!4FL!,?<U5I,GB97H>5<_
MT<L(,C@Q#,%&^(/Y5KEMOA1VW#LXPO2)CXE3+%NMHI%.2492/+32PIE47""Y
M,Z.'QZ9[P_-9'@63J/Q/GQ:_FO*3!8VE +,\Q!9^.,\!,J%6"VX0'<:^J4/Y
MO,'"D\0FKI(XTCU>6ZSYE?_O.X -4D-(?D?>7C4?.^X:GY'!<E3AW9]S%>!P
M/=!Q7/]L>8]&\)K0;O_WT:Z9C\I0?_0?0--0#)Z_K:9-,JF2*SX+ZE"QWV=A
M,0$^-C(RQ7&Q[.\5P0J0B4'J,*X2_%EBSK_=728_MV9D!\\L2PG!_0-7,;2S
MCZ+0,W:PD]H,:6'01KCDT'G3R/-<]N;VA<3@SKQW[(Z]*S<+9D,7SAT+,C][
MZ9A.Q.\ 9G%!Z>.Z#Q3VM<.=&;-K%QRCVS,@7D[G8U"^T_, #41SG?YY%ISP
M)3*K.AN5/\D+#7VD$G5A?'%(MC,S/EFODI]\>=6\L&\=$36Q;"<"Q;3R)4]V
MP=%=0(WPD)HX''K<Z:G0N19P"1O((Z(U+\ C=)2QN4)(*!RSF &9?N<5*+(^
MLIB7SGVYH!(&XI>\93CY\VM.AWITR*^+7U>(@G."93"%1*01U5&"*V@M)?_\
M)U6=I9.U1Y":&0-J:#KB9*V3]:IH$3DM"KR 8!?FN%8ZK\^^778>%=\!;F0N
MOK3X?N7?CI?*CIE-LXSG2[P/\EPZ?U'/NS:"O=UC\PPT0K@8$*5[; [8TQXL
ML4T0;U_Q!4TYI*C;[Z%*=E3N  +-?";YC;<2/TJW8\W>!Y?D;V^I]@;0/>RG
M=7$;*FIA#?*3RMQ19?"F/%N>;]?P$*IYT/-D#JF1'&/0LI3)56@2F9&1-;VQ
MLC R)W84$6:J,L9OIB+HH/+&(#K6YE+Y5>;U1<'P@G!AJMD48B#\B*>)X<PJ
M\M&8R1;-2B;Z(H>WM-$C0"X$9<ECP:_#W^JF%CDD<^):)6YI\RRZWQ#W.3]C
M7,^P=DC-Q*A8Q''?216#\6V8TKMM@>C]Q28IMC'CWFB,:=FSSJT:<'KQBGE9
MI:JO2Z$HA[J@SE-+T>)F@5B7&..FS8[9#-&M:<\66+T3M,N1VL1A)\6RXXI#
M?_7T9#8@KA;6O(N]I>N0K.M#G<VIM=P!,!Z]53O(22_S3"AP?$LX:!8<S[O7
MNO= :%/1WKS\XEK[6NL6V<PO,E-\<(6XY8L_9;;)<X>#AW*RW6;J5?N%UPI'
M9RJH5=EZEW?TOB(=3OG1$OA%UGX]U:_3)$>4<WZ14K-YP=.9A:@^=-O%*VZQ
MQF01-;(M^[@K)8__$CG"H'3LO!6">,LGVA?\@5"=M7>W9IJ^_ QW "UT8QZ!
MH(D*CP_TF]U<-(6=JYZ5'K6/\_MHY_(IN:&D5V*-XW)@1V]_IS(=K>\5*2^:
MIU]M)QLCFR'95E?MOWCFR_T6W+)JXL7!;HY-Z/%L5<[I]N@!$/_Y;9/+P4%&
MD E\#FYH'OC<KHA@S^(^CHMW!;>N(XITN.>&"RS#M<CDDRRE(N \ER@U^ <7
MM?B'M5,3W0$\&C>R12._:/S:W_8^WNM,Q>-R61RO]E':O?'=O5&5+!1=UT .
MI>?8@&WE<7?VSS["?!E IWZ]7IXX7D$I0TE_8A6I[3<KE(ZB?N=6"9,#C5($
MW5-E/54>&!-)B: :MY/^GA#/&:G.FI/<8N@TU%@7$Q^4><9C<'9Q!^#%7.>X
MJ*0%W 8-7?C=-N_4V!EY;CA0C9UNW@$8#NX =$3J\_%!.W> ?!>QB8R,^?F,
M]H5 XP"-ZZSMRE5LZOP)S&C=W7SVAE>B\CURR63<X-TYK_)*2^)R0LF0ZJ-M
MUVX+"_<Z8JMZNK>.6S%=+Q\-BK5?19P.V;"6E)V(/E[>OKPADTX9U &@SVGP
M[X_HXU.?)UX.I.NI:[.Q#/W@62@=TR^FM@P4/M!6_KG";F(W,*QTN&0YR _+
M0H^DZZ_ FW91 ? JC^FF_O6B3WIFD!@?SCL !_.8YTW>9%"XVB60M%-BJKW[
M.<1#A:;*2U<\+'JVS+!]1O\K-<<6TL1XONAQ%"[ ^H<Y5G9X+Z&>*1&"7Y?V
MIE;>T5<,L2,_NIF#5W+0JJ>PQ'?II6'QXOD45IVG9;+,\.51X$,?#I:$G-7<
MWCZ6:-)$-?%Z92NG*7_>5TDNJ(C6N,X@R0\7?$NL&SUEC7*<]7Z234;-2D82
MJY>EI>\^<7 ^4*NA%Y-V8CO]?HN^ R#\2:_/ F08N?$'_LD]70IWL7,QH;;C
MAK7-%7L(XFT'J%'@\Y6<%N)\BA/>X_/(R+19QI6-,<BLJ+N;.*OB6779(G<1
MW![)4'H<J-/)9T>K-NR0).#J49S+=F)4>X19^=7P<RZX+-O_TX-219]G#TQ?
M\9BUO"%C*3Z"QHI^"_\Q^+%>]\!K^6BI$OUMB9_0VRO*-"V-S=.&/89N.N?<
M6/KO#:.FGN8,Q.ZD+6\ZVMX;^&E1?Y]:T3((Y:WRXT/]N&+ J(=VII(YJ<7'
M9@*?ODQ%2\_.N&=\1B_5BR_='D5Y54B[%D<@XD2W#2)8O^H/F/1^U8]1Q<WY
M%PF+M!869WI,X*ACQ2GB.':6GM7&R2J8\H?3$1K=-&/Y8W#NAEPG#$^_=NG6
MBXY*-D2VP.V^Y7_,O?1M!O<94E=JO'CWR+LHT];*DVHYZH5;TCNV0V( *:/7
MH;F-UP?&G:J9YP&_YMHU*Y3?<;F?8?)+EH'7>R5U_1XN:J,C6%+#SX'$]?CR
M3.#595):"\+*.\ BS8S2L>2889<E]EQTQT?@]RN19V32$>#(QD?YH-.LZO#K
M;Z1 E3X>1=8'!XPDK^SK_X%^HG=M8P42D*MUYPYJEK"4(9.J6/B'^ VL">RU
M7A6>V 4>[2@@L;/^ 2*Y-AIVS_QV:039PY49[\%/,3WS(%G9%I)B@BCRWIX9
M6?B2%V:^D?9=6+0O<BZ+R23B#0M9??FFY(@1QSMP@WS6KV^[2<$/8L(J(1&U
ME_.C:PZAH^!'E]6F:7WI6^#O!R)L7C9>N[W_/+F \I'77_[2NS93(D%/5R9\
M*Y_NO3T/GD/5.M]2P/]B'_A7C-=\YA+?6QS?'"!]A2;\KO3.Z=^]_D<5>WMH
MF5Y+CJ"^GQ'15=OJ?>S;+@<#K6+HODHHA,>Q.S04PQ5SKFU'Z_"@'L,>3ITJ
M@A)RCHU?VU<"LNX F9[H+55N?4/C-6&<L><N[6$"0\N6HMW?,IR[]G.<]/M/
M1)]\,<0EF+-T<6:OCQZ"0&!DQ,EB=;AXD7B0_669:Y%DJ>3H"\@A:M?T7S9,
MPL'^Z2EOC>'0.T##U?9-=548PN"@D3XTX370%Y%KKY]&V$8I/9O.N)8E^48[
MB!\2GR:S])W0.D S'!;<2+,CO[',?XH]?^XF= >8NBTC]=I7H/9\N\^;Y3;*
M$MDAM.M=/;+R =P[\N CHD:(O,""]2'K8ZZW%E@9&;6!!)CK"//(GX+%7M<_
M./[O)H<_!IZV[#S0L#\]TMI6"<#AX8E\S%-&#%E &K.617[G,I,=G4]CS.E5
M6RZG9'-QCAA_U/C8=TWW!OM=Q@T2Q.8Z(7.2'*C>-P3)R1+(NH"E0 9 MX&'
MVE\6O\Q4K(7KKIQ.DEG'DQ1.U]B8 @.Y[/Q<DA]I_\%?O98Q4G< IY=6N-_*
MH]O(_Q$D0,1@9Q 8.'![,Q9H\;@NXJLKRH[XI6ODOK=EF)&FQ@^8(+ 2H4%E
M8HQ+L1\[8#P]BZ]3<Q4K!KQ^D%]O%!D(@R=.3#RMYBHBV280C:CC(AE@* 0,
M6'7/(<='T9-5RBX6$?G ^^X/#=HR_J5DA8&<W/@/_ZL YNF_RWRWORJ8]&F&
M+ZS=9%><$Y%^[I+]EX[\]\1P#)WRO]=E^0R;^8^W.4OW"LZ_C.6!W--76$6U
MJ8W7_UUB_!\G.2C^3>H;HV3MF;NQ%Z%&<3-U+>!SCWGC_R-IGGPQY5-W-*RD
MR-7PG=9;N.YO[Y3=S_>,>JU6'MCY&#YTQ!J6RYL:UVK@(G7!'W.E7_&<QF&/
M2IM@NJL-@<7!!3NDMJ_FXCB82M+[!]?&^5L.$SM\M(;N14-(VOU(]$LXO$\P
ME%-O:G':F&IW!7P%(\<C[-$3(A_31M*&AP;PW=(?"?-<?$ZD%V!\\6M@A%F'
M2U#O);AT->XC^TQTXC8!4S+ZPB$-3T#=P=.(Q+-?BD7^1XN:[KRE-R9B=FYG
MB _^XHCV%[F;K +Y9VOX/^:V0?!45A.A$\@CQ^3=NWY86"-:0_NCH44<?M/K
MG.D!HQ&10\$GN2/"0]$MRFRFZO8&M8_"!SY/Y37Z%09/9/J1E0MB-NI%')"*
MU5H0FF8)4F#SPX.C<=-YVS?;LQ6<^.,.<"ZR)PAJ/,^GWVT\UKUIKU1*C=2W
MQ+15FF>BYEXZ*UU+HPU$8_/Q3SYZV3P%];[,"I,L>?-+ 4PUTN?TM&^P;"ZL
MET^_AME-6EQ:D$S6DEFKA[T.S@7B6789>-C_F&=9!HO='1D@LOY?5ZWL68!>
M+ZL;]C3E6E1'6]JXLZ-BF4STU$\YD+:\[*]_#&H;T$-J]*:9P?+P#A"3D:J0
MZ@W>"BJ^ DO",7< :@%VW*?_J6MP_WYXZO;S*EBM;)M.('+D,RZ!'^56L!7'
MB?/JL:NFMU<95"3>K&(JQLK</#5&(G7^4SL5U/.7E>/W(8XF(F^##QCCY5N^
M%,.DZXP+$UFNZ-"$V(1T)1D7K6@S$83@'4!0;]'_*OI@@M >YE&.Z8>=$/]N
MY'KD6Y*7I: GH+,"-<:)H^+10E GNNI:D&QZ>R_28[G'1HM?8@19-5Y^"+AP
MY""QJ1 #=BA9]H5,OK@'?H)IEZ>:G3N4>M2W,AE'WISOO52YS-[#J&,ST>J8
M2&C49(97CG%-WS&BL;I1P]'91ZD/+.AP+"-/+LN<3.\ &^NM*ABCJN>3)_0H
MXPH.669I]D.4[C&;U@^8%"%//W*HF5;JO4+/A7-K'E^1JX>/3YGZC[GK?28?
MBY6MMD2/B*.>&[+F;>[4RW70<5I)3.&8H<V#K =@W/IOY7HFLUNB^B&(642'
M66)'(9?@^/P8[%FZ0&J#K46)9*!?*'+=Y5>XU/4;OE45*EH?9Z1"?#*R+27O
M^Y7TYN'LIKZHN\KD0*H!W^)!=EU1^A*U5.)WJW.==)P3:I'3FM#R0>MS'OUY
MAN7TW_9[A4KKC::=1(C!^]B=M1X4"V9O*31G<=L5=MZ5-732:9LU5\FT8#^/
M;/+3*>"T,Q'C<8;HN1W7I?Q&&)> [X7I.^K#7B2L_*[?)?[Q*[AMY'H(<7)1
M?@>8K>EI36ZH9H6/'RQE1*Y=T!Y5^=0>8I!TT%8GEOIY;O06VC1$H'_*RWP-
M3GHK9^W>[Y3D?V!JF3;O:6)LD8MT@DC2!M]:;RKB;5'5)*;4_I3FJKD$>#E5
MF\D07%DM+S:OU8_[(>6\'%F.%NMJ5O;8J*H/;5F._)@[!>B:C3B7473F@3+T
M)9[KN1H;9E<CNU(WVP'6HYZ!.N[J7?,#6<#JIL)W]K%=_79<:07C(OI'3995
M9?7?*OTT!V9R%U[^51.;5/D9;1X7.:PA2H+@JK^'P[BR<;J#-9@Z@^QFX^;/
M#'@\;D7*O_O^FEK-IL:U3H59_:U!3)_]3+T^ISE'NE[,STE2A#YQ(3YX3RBJ
M%2/)NUDCL2G2TIIF:LP+H9"/XKN&&GS(YLK+ )F A=BHU765<>5I!HV8];--
M*2!DCZF?&<6KBW/$UJ>L2UH54_!"GN<>.6(+<G<UK#ME<M\P2",SZL7K'BD.
M^!N(>!XPY&WP=:9G-?]*=ON)NA&(2J@B*7Q1 I!Z*X<O,\S(V#V,W#5WX@VZ
MN+EU&OJ>]*NV'R4F;5HIBQ'H,23YVL #6G7I CCSR?;N+?6+/\&Y+ZDV.+B+
ME,@\$3[<FA(,3*&L,B2F$9U;_46]LB\RTA'<;-T3EC:VVT?Y)EY?R;-'I$[A
MH;"#-*\U2#,\'J2KD_ ]\R.V"=%>^*1ZYWC^MEQ)5%E-G@-1M+U(O WU7; 2
MG)?D3TJY( T/[*A!9U3#.A+B=MH3OXI-MIV\]C#67_$94'SUX>"ALA:8>J!]
MEP^'ZU!QY^01E)&"\C)9$YG8+#'D^=Q@G:? 2_BW41Y(9'K^DNGQ[[<TB*QM
M&&SG]:SZ;FP&VIL6A.]YI@*2)*HD1J2@/AY C9MD JG7H;X[@T=JS!,L6PFA
M$>:1D?DUM.]#7.*!DCU9_*I8(YWFZC]@"E7DK#XR,B<FM<:0VKX%,]L1^%J9
M&9:1:D5>E _T>.\:%8B%BK(,#;>V'$G P%=IVE_;7H4EQU*531RR)K?V45Z>
M.4?[27ZXZHAS6@B,M .[V@2QV=Q87^E6NWZ3HR)/4I0! .;E01H_(B ^,!A,
M0,#O9LA.W@C&"4EMF7)R *-1Y.J' @8_,^T4NWK]49%\NTRCXH>FQL#!<ND%
M/#T+L+WW/@U34ZN8VO+Q>)90O2_D4:P=VN;PHPW^SQ53T0!=<6[& R8\%^GE
MU>+?2SEU!S(3P+C'!X$Y?APK%IO0VM5XB4GDZ,9W"1]_1%F9FP'+T!-Y_I3<
M/;#^B.;9@<F)+54]8J"I>5[/<%X=<4UJCX6W8:9Y8[*UHQS#IT%P66&N8'J9
M'\U1QJX_'\#(]&)O"YUY.8!TH#F?B.@.BX7FQZQE?F]9NW=E=[M_B/L<:O0(
M"+BN[F*15^J=I87!9#K#EX;JN?[GIT;Q!8&!$+=U#)RGV.NC7ZR 6%_S>JG0
M]ZKAG>.,T:C^W/Z54FTHV%_@\\ S@4130%*ME=JU<L/6$.V>4D&=!>BDH(+R
M#M [9_"E8 7.]+Y=$X^U(AS&,>(:F%#]5#LIZJQH.3-&=P_MV_C=MC7\V9:C
MG,K&SW2AY("75'+'%^PW4PH>(Y=.]0ZEN0<V+M/<[Q*@,3$R;?7^^UW?+.O,
M<V;\^*)]W(=-)_5N;#V4;UW%.E_/\/S,B.4R-QXXU(^K)F(0'^D#P&")FM^^
M+4!==S7((#^L]P",/H8]8HT;Y;O%]T3=)3$;$JK#ZN^TM31'-B[Z6<'^KR%Q
MP?IZ$/.;KN5W<2&1L]6*X:4IIGMZKC:V[?BDJ(19_#1P-M>JEZ!'JV\!3Y@3
MT_.I"S-V$].EQ_#SM@MRB]VYI>,]DI8@479T^9+:4$%HT\WS_MNG;:EJ69?N
M\7JG1MR"+;:3\?A&[#FI>L:<QG< _=.0#Y8\WLT-22;+:#.6GWL$CVH.?.,2
M%OL,J L/J0LQ8;[U^[W[T^'I[$4@3T^;4U63F">ATQ,R6#.[@.%IKH;69(>]
M]E9=9ML3^GF,@WZR\I;S,\8DI&$!6(1.5F9WD<!B.<YO42R>C6+_:YNYV8Y$
MA< EF12S',$PCT4&8+4VPRZ-[W2!S<NK*JEO/@KO?9T &=X0OIOL=;8LZUQ9
M\.R.#7T0A38;+>DX)_&7(2VPN#YSD#<L>O^MF0+)A6BOC.R+ ,TX%;U?91T9
M.HDZ/B+-?1QZ#A^61#HJ/*Z*\5Z,%9RFL% S#Z#%B)@4!\+DA6+E$*7"D\!^
M'0/Z;$2-2=,Y=G1A,V=Q?H/&?H:,=+T$?(U;R=XSF?M3-(L87EJG3GA/*.K
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MU(?3&U3#MQS)*>A]7?:?'W7A3LT^+6VX2NI_:I1RRC/%5RFV129O1=0KQJH
MI]/62;]7F: O&6RE:_W%),+-0L\#>O6(E@EH>=!2AO#<!NV^)0H"\K7-D*>A
MY[94[NLFS1LV[4@5]>]T.0=^//DJ%4C[]-[AW5OIU6,+W.C\("_=>ROU_.<Q
MGL-^LX"&X[PPATT YV91HNYN-EP:HYC>K!YBTLIFQ\.V.]@0+(A F"\G8QXO
M@"Y\914![K2WK;NMQ)MGJ-K<;S5LHI[%]A0^/L4*LD>]-;L1#@H^/!?92K2'
M5#P83TVR)4.9NZ;+%=^>(*H>M0IE9>LY"5[6.9P'P"0'EC8O6R13)).&VM'=
M8W!IO''O<P0OLMH;X></4)&;9E$98HWB&I;87A)86AML/9!G97F19GW3Y-(3
M2.W6XBXO]?/X[,Z6RWE7O2C5M==]2:VUHE:!PXZ)?4/8'E:PL#-.Y!0F],7)
M$6B99<DP?+NW/O4)7;X2[IA/M$/4XLLX6N?LZDGKZ1DHZ'GJ^6<-\#^\/T^]
M#[FEL!*$FJS5@=D+RZ.C^QZ*1ZJAO4&=[TTE:_9=F4 (KO'>V1W.UWOCB15$
M-/5B0AOF'Q;$@DEO^-F,&D$]_-:3Y7ACMLAR?"P=U&PP:4&Z]P97!&EG9M2P
M;$:\I7_[?G:/>X.,T]N5#3"9!]!A96@7*TSH@^8&#A[I<>RP6(WY48WH5 FM
M&M[0KAX@S5'9,M<+TM_QO9HZ>7)L<*L<'Q?X?<($^#X!(#112*4]J5FK'JDJ
M=FO?2I#/KGLUY'EF.&7?H%3,XWNBG9-?4]R.S"6SG]Q8YF@(M7*_^/9G1D]=
M5'-L?B2DR/VS6!T &>6B8DB?"A[5A0 $A0\,T@8! @S)!A_"D-,RHA.BKQ2@
MAG,>Q%FE*PZ;5?7T3>.1*3%J6]@%-9YH*A,CE 9/Z5M" HKO!F=8G"6^,_'_
M3%$"?9N+>KZQ@S43.94T[P>T+>_9I.449W5Y-:+$H+P\RIK(_E37;H!C:<K_
MV3#0[)RW.^?5"9^*UDZRZI U/(4C]P43"P!#!8Z<OIV=9E$<$+A,/@V*UU6(
M_XU&[FSYNB&'31Y=VJ/?S\ ^OE)1E-G=F#5=D4?!O@UAOXC/S.*RP:DS:+Z5
M#+GAG8493KL=[>DTZDIEUY?04PMM?'7&,.,^Q7@4N6[I>K WNJASF?+^B<5F
MB+A'D3160$4!UOA-9PNIUIA.9+:_&CN%&OU7MC7=*T#I4+"+ H-,8Q#P_/FT
MG=%H\-3QL1N9:+VO_5-^UZO2#SG4*<73AQ"?Y^8[&TMM7[)+6X:,9AG^C%X=
M"&3.K!#$MYALSZ=1Q[Z!LY?YX^C'O43+0**/H7$D"5U@G_C4#]-.L^5VW9PO
M"BIQPXT(8GINE-E[D]S@E1T%.]=X=LF]0BPBF3E7%6$GD 6C9&:5LZC$LIQ0
M(YU +-3DCQ$M,'N"!X",J97"LC;>M$K)J=C$6EC6PZ;\"EK%"A'P!1V)'*J8
M\3NF-Y,<P9KC%HN%COK8C*+J*^1&U9X-)F E06:94"$]FG(F9BWL;J@;)NTM
MX]A$MDK-X!6^-695]CZ-1%,=YKI)M3([H#%J/VJ-K$M1/5XS*F\R*I^AV:8R
MFG^:'TE5/QBG'Z'/%"'\*YTWY,\<(YXE+]:(/D)_)(P>_(Z)X(D5/HD+(\C3
M4GGI%/P#) #0!!=/$A6PUT]Y8I1QX2F<<J:D@C4[];?BL?R&>QGQ7>F<L!AR
M6;"2?K'JB1H'-OM^"IKQ\64O/&= =_521@HSK[,,CTS2RW<^C4NA5$=4,?>;
M%89=)=>GYF7CD]$]=CCM!DL,_.1=B\.QXW;8" &*^+.72B1$^!--.VYH9R,W
MGD\QT6FL!>#TSU07Q]@JSI6*L-MY&LWOW?O!]A)GX0H<UOFF'-+E)A&B'E%Y
M4(RG*VR,&B.$XP0*6$<#.$P4-1^>O"%-("4-CZSA%07(-.>T*GLJ89^2E^_W
MD<<4EYVRQ;OWW)3COGC_*:U28B!;KH..RK9.>?'#2@ 7*5NBQV[X D&M8Z!9
M?<^\+\V:\23L<?I2_%@L@6Q2'S<N?X6HX#O+FO8W>@.S)+]RNAK)O8C-=[8S
M<0J'=EK[6/5L !-KO*D C:5^9*41!4&04"RY(#:#+QYATEXG$S<"PO93D1Z?
M0'Q\C8KXQ^H^;0MS;:.P[N'DR<0M0?PNQMF6SDBOGK^*F[2&2O\PA+; .08/
M> 2&B"F7C&U#:W0\- ,RSER<BOFTMHI\]YG;&M>3-[OK]-GG2!HV27SYW+WU
MQ5Z*Y./S[Z#V)?"%J01I75)DRW[X*7I%%0?Q72&&RD,P=N T\\7F4=M61O?3
M=151%!DU/&5)PH0JLW^Z7$&;UCXSG)]9D;W/V241$*G<TD0V;3%I(DL0G00@
M$E+ES%>[2?>GS]&'\TW8Y%.+JH*L)FYK"EQ?R^AH']L"2.*3MO7EZ4+@<F.H
M-".+=8850(7CZ.J>NN&W]5)'%I0:'Y,">,(_W0,$1R'<*\M">R$?BU/4MMX\
MOA+5,/LJ]ZI>9VB47 ,K3CZ^/Z/US#Y%GE<OOKZ<!.41+5XNRK)CO#P!JFLH
MKMSKZ1=@XC0ROU)[%K_M$DH7D]B+B#*>L]>3L$,&E6&BO=M;8[K26LV:QY$N
MVF)U']IJF^:HS7.R/(L@V:5/R<"9Z768L.4Q?!&V1+FVFSJ&C.)E#=)&C+,4
M3NN87SEUT+=TJ074.(A06M;4HBFX4?/5%Z>WE84XI\DSE1E7\8M.PQ<>*J?P
MATP^!HCDL=#1N A:X@)*ZV?<D>VAJ.3@@H?R3PLC38';!**\O(IL2VIG/+BI
MUS7H8TS6V%^G 8(5'-9(P).X%[QF)\?=;%XC4I&"JQ1@$9E=$I+3B&DGPLU<
M:PN(* R=;*WRU_9K@PBM1ST$LYF4491IBZ9+HZ-+9F8/'QVZ(QNU1-JOR-PM
M=4QT^78;RG>C5AQ\^2U$FO@NEBU;VV9GV.%\V=OE%-P]:9FB&>R2$@+>% <X
MO(<D[0N0&Y9"1!7(1<%C>XJI^0$;1N)4-KJ\;#DOFM6@>[;1!9:B*V1)*3-8
M&\C8;B7S.B'K;,UJZQN9D3!6%O_8)IO>.UAYL^+!JU5IH\@3>=!14SDB40K)
MT;;/.F!:I!VUUY4@PZU4UE7]$'X'^P1?<X'E.CY;U/<>(%%30K^=,T# O#-T
M*LZ</%@4\CRH:(:V/(X #O%AWIY6\4ODK(J34-_4;S5)3V$@IHV,F$]7M>E;
M)!%7K-1A]8H3""5:P<#KB/*V/W\:ZI6YQ2:) W]1\@NBNM]H/XTM6:^D J3P
M"+WL<_]WT&N28WHSLW=F??2C]/3#J](JG1B\)_]&N/6@NJ2VWE'W3H.W50;J
MO1^P:ZM,R-7JI1Q\6,*'N#Z3H'XKSZMK%>ABSN&SQ(] PM?*L0ZZ>#\WX+$Z
M7RY>V%Z7+@SZK%&^T#670K X"J'!$)/"5*FUW F-SP]C&OAJ\5I@3YV?OS,4
M%)[KR_]G'/MC3WQ0_)6@NM5%-XWE?&7NXRD1'SK03@QW3.7XQF[/P=Z]7HWS
M;/U*HY9@I^L &H=;FMZ^VWWI8A08/#6'K1?.@P7.'M(<TMEAPGVU,XJ?90ZZ
M87;HFM"N(7/%GTW7+R"(&C#"CF!N/K3QY"6OJ!M]H;.R05:3'D2BQJ(>G)HI
M/45'(\64(#1B*"]R04=#1IO-0A>+UA/L^_>6,Y)T]A@55?YX<A/)R:O7]XE[
MYL2S*$ \8FI%>&,M!>A&@Q-+!2A9E,_A>^;:<B6J*'99=S!C;K7Y]J-(AA87
M29QA&AB+Z,G-D=2N-\:W.UA-#$V M)0MBF-RZ7X!;C=B6E(/UL^9]<#1G7F_
MBG)]&:M$5R_"!?.^(F2)(ES9"O7ZA<]I U\N_R>5D\N<*;3F +QM$\WLG-A4
M6WMM+*T\-D[\A&32[%91>>RG(.:/OB?7;N+;,B5&S1EXTY6^T:+\[2]D+05)
MZ #= [NLN&JO3I[PQ>VT&A62*^,\S#U78Q2PW/EE:#C-HD_"%2_XD4FNWFL%
M+)3W",S\V1S,1?P*_8?^.S1 "!X>$(\8^*>8UOXW!47^[R47_:F^!'K"0.\=
M&A85>)O2QXB39N.10^/6_1%7=\MAO,!CE8EAKB]*'UWY<D]P]>K9^!%K!9\(
M-5B/+R;V>F5 %[>"!?97ZNOTP94[=\'?>X\< PI<B46&.BA5'@T<ZFX'U< 5
M>S^3F+F <C<K)F 4Q%ITWX:FDL%:!* ^21K53R[Q]8/QB;P]RGN+9ZD="H*U
M'U?-!Q)$GL3\NW<@?G3/9('' :<)W*[KZH!79OD5G!^]F,E]09YZ?'WUI36U
M9,"!Z( \C;M6V60JZ1?1:^O/"#S-1:U>PJ,/!#)\G]AXWTN[*!%^[:>(2VT)
M_Q)4\RBR*;9%5!1ZTO;-%&>3:@D[.9?X)ZHE#\$F"[P.;P-:N0VL?L0_=K\F
MS+X5\@I6>\UF<6HN4BZ'!^83LWOQ_?]-TM';-L]IT"_[WLMY;'Z[<K*([#:(
ME2W)!8?E=^X:I>>,8Z<#W!8_%]OZJPUP];X\>$OKVN@>\N_#GX]MST(BTNEF
M1=)9"<_V'7/I^J6[QYW4$3%?@2&A^M%<2:D.ZR^9$6!2AU;MHD9'._PALYZ)
MN1JQ6C7Q\'7AXFSOZ/5TFXVX005@LC0+0RQ\>#@L?#$+^6CW'ZX:T=]H!Y_A
MC@-9&:ZB-575/CQ!<"SB#=^T\G&N<W,NPD%!^)*5P!L;?7HP1+7F#>M,V1<,
MC!;QB[JBI/Y?QZEW HP5VBZIS1['9V^E1\=G2S5I0M"#4CQ!Z#\ )9E1R_$\
M?V9T$:/;COVXC:_QZB4<,SK+SWOX#P%@ZZN:B,X8[=1,K=-]6;;Q 03K\>W3
M&::(NJZM]\:%(_^E45S#KG5A[= M8%3G[D6X7N'?M-O529G_/>WP[XQ[^:5_
M=X[%DOC^AZ=_1$3Y-VUVULS+<;]W*#6HB-)Q D5IU#]>;8N:NV</8\3#7@!9
M:RG;ORJWOZ'/^C_J9#4+M ^ ZV.OCL^<C7Z4:YMKWM^Y&^CK-\=,(1V@J:,0
M2DPJW.KLT*J0F[:B6;<D+8ADPWM4N>4E$"/^_9P#H&!K&U"8WH4X]W7AC>M^
M$XM5OS^5^%4P.VEPBS(]X0PW\NEG55KC=^*VE1E+=G,X[4<[-8,K="'8@<5V
M'ZX 3U=> 5EX,R=V;B=2L+B'K>B;=H93;8T%=T%5P*&RCQ;'R=8(J.*^=YE1
ML9EM TH_*J_&<,3[)=GN&!Z4T$V&F=#U$:]0:HNH]QMQPG\\S]//ESX7&_"]
M=@C9EB@)']#VPZ]I4J]ER!Q9,\WP>/1#* -XJ[2'PA^4$ZFIJC9=\'4_75[/
MW&VN-< .%X0%9F71Q+RZG8XN^#JMQ!U5/4+6N/T! V8%I EX/Z?\ 6 4GT&U
M$W!T^9-,'W2JO[0F:\6!]NF$^,, 7SMPL>UQ/U.&;#!\[ UVK8 U=X.14V:L
M-FO?#X _R<GSOS3D]_;^XMT<'=O\8X%=@$ZMG#A(SOY?YS>5.OFW26HOM;I7
MB-,%.M7=9W?8%:S'");99+BJ3<[@38>6R" ^,L,7RJ0]H]@D9)";O]&8IAY,
M:=/:?Z.U<1S9BC=,/988:97PQ1;+=-G7:)$[YT*MC24/F#!:@79V/($!>:LO
MCR[OEP(UW,V[V.H#L7>T3%(/4D[< 9;8?AT)2+]T9OG(>=&0^E+']ND'6U]/
M/3U,O?O[#H+&6CR^&L+H,V6.PXVM(=[?:!GP#J=OY[XYE$%U13.B"4]\#BI(
M/$'$GN+MTS]H#X=XSS/"JA_"%@W2D B7"O]-9GC.XB^5!\MM3R#P!67'@I9%
M3F&DKHP"#!@H!F&=BW.D^-8Z>(HI*DE[T$/[?A@W?4U1N"[+$+,MW207=U0_
MA>'>:K;S_>YP>HJUY4XMX(YH1G*EIIJ!(&EZ8:PUW<WI;$9/S[8URJN5BJIE
MS'$X:M/BO0P%D9TTUHDAS-$5W*98':XD=O+THUA'"E])'FB42 ?#P#(^BK42
MSS5SBS&?M(_5DT6A+EX)M#30/K- *J>5F?@)'::H:2/''8$<5#E38&AQRI,W
MO:C8EREJ")5;KP<7I6:_SCM:<TD:%1BPXIF0LU0CB,'X@%9A\,:3!2OD]4^L
M!GO2;HSF_)FKPX#2)6S+V)GYANZL#,L5\^U'*9U7;-KO'THC^OKVV"F]GL2G
MF\2E[^=G[\>+$J1Q>,__1JL'YRUGV?O$L)-I=*ZI3HO3?39WC<$-3__D&=]]
M_DHI92"8J&A(/Z:()YYYMXO=L$[U7N;K9)I1GQ)EX5F[0)^Y>'(MX?'<O!FN
M^)#<Z!HIX3=";CG:'M>Y&C;^W1XF\7"S8*R^:R^EE6B1YW0C(W^^SP\ K:0+
ME5X9G"Q8%EZ&7[E%8BT[4A;N6K3[-;&T(Z*=#EENT:\TZ8T40W&KJPPB#H<V
M%5G<//WJ]98K]UD42DZB*^9;'WZA_'2#Q^M?SYBRTX7%>40;ZN0YEGLK1_U@
M0EW=:+C1GS2U)#1)H</-O/)$JT"">]'% G;RTY/Z0GV^DUZ@<V+GM1U8]E"K
M/:]1SG"V$*WCQUQET^YB[7=D$9KI!C[%+9/5(":+,U@W37?"C'=G2%_):*3'
M(T4T"6(Z8ED*5]F0[\9JZ*EU#15P_B$*PKAN$VDB[^.87@,[O58VX4$1$[$;
M_E83RYK (15WVY*+HH:.T3$;1>XR^Z/B;I$S94N/8ZTI3O"%PAZ2.T7/R'+6
MN^,XP919MJD7%H<GU=,NK-Z_M+_T]-:\&""S(]I&_JV<I>/]D1!%L]4COE"3
MOH^]UT>'QM856MW<F$VJO$LK?1E/82L+K/4A+X!G DIZFP.,F<8EOUS8' 5X
MTQ!KL3OF'S^9T9 <%=2X@DA>UGVO^7AE?;<]7>Z1[&F$LF^OG=;+H4L?,?1M
MW#]K=0X70N\WK*"71YV5]M!H9H%XCKZ'<*%XK'BR[UX=39Y5:D[QLBZK]=2X
M2FM<NIZ8UR7YZTX45<;#Q*<6H@$*HL)FN,2M4B%QH6]MTPT\.PNA1E,S-VY^
MVELS_'<B0^Y3@FNOW?#Y:5AY6^(D&=<M-ET_/(SCQ;F^?Z\V9:%Z<'#WETAB
M&M6.:I<:C.QX<02@;CG^VG4'C/\M#+DZY0-.S#^=P'<,=R$5?M\*O.B;T7Y<
MWO*,-4XAV#BVA14HV&(T/=$TFUZ4TR_NV]S(2R!XE_3-^X.)D *B\R1-/L2V
MZ0<CC8VA'?"%24'79?#/UY@$A=6I;:)?"G%$<4,*GTM2*C[Z!'XYW?GY!2HN
M)6V(QM5UT(H-+&>AQG6ULVHVZ;*4$ 1$P/A_H_FIXB[U]J7O-]\*FC3+'.KI
M7KB[E;V7_]48.CDVX+.4CXT*ONRKM"M,ECWS]^TJGC&)AUH?3#$1I-+2%EBV
MO&R\O_(OKJY%3BQH*:)S ED-KXM&D)YF?F\H#5!F);(3O]%R>,S%(XG?(])?
MNN@$8%5B=O/Y5_NJF@F$OK/B;S#HTLQ_I=MCCESN'=IR[ B*[.NBW;.8U \D
M'@]J+%</0<+0::IHHO'W46P-I6.;'J"\.D]>X<7HS#Y-1,LM"*)X$MO'.19J
M0KQ=I?DH(.QM+Q9>6#]II'X,FA>.-RQ^NE(3+("9R'R0A' -0<XL=(6IJ-I!
M,\LCE\2VO]U9K-G6[7'F%16"%"/3MQ>9M4QR(!8I; $8"I <5I$,?Y>]XY]U
MPTO#\3-,O]%:V=D<SB51Z[_1D.9!_>?)GQPA CF8+((YW]B(7VQ<$O2IW3Q0
M%!_\1I-G)5AB<*YQF&?Q(W]O\ 5T7A5R+V%S;CKC)_,EZR]Q/"?)>X2)7E-C
MO47S;S1KLTEA.TLK#8>1+S_4Z O&^"&2K(0WKN,MMT =%%^J6VQSQ/\@[RVC
MX@J6?]&)$@($$CP0$MPAZ. D$-R".P1WA\$A(;CK#$Z X*Z#$V30 8*[,Q!D
MD,%EAI=S_^?<=<Y:3^ZZ]]WWY?7>^T-_V7NO[NJN^E7UKTH&%HV251OU4SW?
M0%NPHH>S\N*<H&-/M&"A8=B5/R R%L'+Z9Q4\WR9>$6(.3W;Z_!WI:\(.Y7L
M8WZ]=$W)RJ\B\W*P3:>2C_8<Z%$!OD$>.2GJ-V)75L%SYXFI)FJT%E:85KS$
M=;SF&]Q$RYI+[?7/+A<^0VYY$+X=X]N+S?Z/C<B]#6[8"/YA9'EY?O"6NIJK
MH53-K$WM)S*5H4LD"';YRI.0EM;Z[&N4X$OA.AZ>UE8>IO-5QW.EF,5=RZ+D
MF0;7>6O#WN,;/>QSXM\);2N"V_T1FTP#\ ,DE22M8D16)EF:>7T[!2?_&"L^
MR5V9J(F4>D/!"83.F$V[O*#6J!R%L)S\Y'W8V))_,Z/\7F6K.7WY#J+VZ:66
MI[LHS?-N%"P/M.%+)<UE-'7M7(R+\7_5(4Z*5T*/[Y;,&5 CGL%;<:0C5>I[
M[KE))[5GE7<,.$0_BIQT&_TB3OMRAWO^&\^E(*$460*0G2RN^B=:^%<E=3NS
M"E6TQJT_(PTVQJ5H-#,06TH\H=3"ZUOAS(66KIWA76D!]"B')C#2@51<2AH'
MC6S_4?&2W&XW=X\J-KW)C]C%T7"U6(=K"1NHG0#,P65'<> XM7D&L&/C9A24
MIBJE9>6F)U/M[,PS,3^(F]UE0+3E#*=43Q_LEHE#TXIDCK,5.]^BYP,MMSD"
M&-<YIBS$+VR-,5,=0^R!VKZV1V_J3NB71=W[NKO@WK>J0 7A5M^79_W3PYT-
MD\-0W*,>'F#!W17%X!'>S*Q1(/7.8>?E\D^G,^Z+_OE.8<<6\*N 3FU?XT[(
M[<NMG,BFX48&R7N ;<$](.I6*4BVF"\2>=Y)9.#W9G*ZLOLAWH91T.\SG#A<
M2<OZML[:I0QH.')8\/@3;.6U>GM</0DPEJ^_"@JA3>XVX:@!<MP)BA(D-%\*
M?XMP00QS=M\#+)&&['NCD_;7@EL]]P!PNG$;2J'/7PC?SJ7.[AY@"KGM:&''
M;!P6EP9"EV_T*Q2_\MS82=D^WQP?GJX _UI-: [H:)5,')JPXM_]<GSR;KQ3
M/7Y@M)L;KV'Y:@&+?KV_U'TE;U*-D$?.M+@G.^_QT5_++JW=Z!X0VG/DDD^7
M><WK- ;.+?.B[?6*&/XC+A=T.P>>=0L,T>^[O-:\(C? )^6E6(@:T4$%>C(0
MEG#VC62QGM855?8NT_QQ^($4ARY<4$-D]^#2YEEI*^7J[?;1?E 1E<@6XEK-
MX3BQB+T^ ^^3[J-8#9.T$)!H8AE-AG6C*+WA]&@9[=T?)6F%TT_?(S*4I5P:
MH^Q:2OPSF#/M*XU',BFB[M(0+TF3SX+_&W2*6:X4EM[DSW?RX&@>K).?\Z$_
M]N#()1RTM.\L,W491TE>[YTEX/8M71&G^]*-$B3.%C11?$N>NF[K*QQ=8&V.
MWI:>4:<W7U[Z"V>UXV^\=PK?(_*"^ -2?\0*?$M]D*:,%>AIVS_ELTK<*%#&
MIA-#2&C.\^TMVPR?LCR)UUK*35:T"UEB5(^EB65-4F/_S''WR2_F6^/RU5T/
M3S^"=;+=%K711F&+/5O^BMEV(Y;5@3"C%=.;:X=EY::.ZD_8&U3M.^8MM)RE
M?2O8/O([=S\[YS%*3O-]^NX)NSD,RE+;1[>!Y2/G$'OD8> OEY"[M)SE<]W5
ML=N[XWO SC6I;K3Q\+4WAVK^V8H">TJ?J?/43B=XR+@DIN]WN2B(8[7=5&B:
M14),$34F\HW =8,-,1@?)5P_J&QO!Q%94)T_E:M/UO9D6/T$7O9_=2AYTTCD
MNIOR2O\4G7)K"!YN=?+O% M5MS;T=9/<6^:K>C]M9]!:B)IV/=_3?RIT8?00
ME%X?NQ9 ./)@F CT^+G\!(%NM)$L+.6L4=S[?<;WG\=Z_2K*IQMN4S2MQE4%
MA946![H%UA^BS9JE!X;5ENP_49N2D\F&_5PU;GS5E3H6UTP9KQ,D9S?R^-?)
MR)-PI0TP^8?Y2$':A'"ZAY8N7"Z!_.KX2[.+Y&<OJB%V#7@Y^(IV=D?\+[P'
MLMF4*Q+?A;_;0_0]3P\2H"E%3HS'J@F%P9T<>T->>9W^,OYY=K6G4[,]/+F?
M7$!V[KG>&3!7T3H$:9]&KHC9JSFJ+O*MQ9$/J\#KI.$0=D\EE@(@E+W3$K\4
M:3G4['@C]_%,'SPOM9F"4$U<2]!<*9H3$UT91Z;^FHZ[_K'[_,+!YAIK+HE'
M9LAWP=;,D:S=8^/$10I(K<W0#7?^"%I/$7WOZ6\JR*S_*-3+/)&<.O6YX(^:
MET2N/;R6W2Z#E-&JP^119&1-21X\%='/R]^<&8;@*"%^KCC0RV*>P1=B13VD
MFZ A44-#[,3^TB]Q>/K5F4SY:BO?2%(I_FB46&FW5:T7 W@E;>F^P><?*VE4
MVKU0.JO<Y4=$S1:QCS2KSQ:,?I9K-1LV]G,X1EJ9M2N0")O_3FK_Z)%,T[X(
M7D;H+?!<S=8M,XG>>+9H-^XB094.G5.-BKQBM0/XI?/ITK8W=NK*>+BD.!6+
MW?V6\DQ,AM;+?10ARKOAL/U)OE_D,RT*#1O#:@&ZX7-"!H9I<R%HC(&P>-+Q
M/YS:QIIZ&<VK4&^[=M&[D7/#?G:[_#_=9/M:YC0YZC:E!]-K]:B!3UK<J=_(
M;!&4PWUU1"F<=U>C)Y()%]^.5QW.#UCN 5I",<[&P29@R)E=I]-<0Q7"W,P/
M]P1O&?_W=2VBHV*&)VEO8I_%!^-6YH\Y ^X^2[(/CRP$?X9A9@V3ZU=.K!<7
M%%0E?LF,E',8"<P=KKEQ]9FH,RO=?%ON*<]KT(6;MBK+E8X<R$WQ^BZ-5$SY
MVI1QMU#H:-K.VZM69X3I3PVH0TIV$5P3 ^_4-P_[.#P0NZ2OR-\E2_022E-@
M$]EXIH >%[3K:1;U11.=7V1%ZM;W*=X)]*T)7R7MWB7WPH\D_@*J/93@U]\#
M(EK77E1+/*-&>%[Y[*3T)I9*F.C!].7&A9X6?7H_;>-2B)2?=N%,?SFE%:%7
MR?JTSPQ=>2FVY23)VH3<\I/98:?SS95"M&?4+MVF>N78[6D)?YC.[UDA+3/J
M2M5^"*S914$T5'#3-S4#?KA!Q>NOHK:(+2?]I\>2GX$P5J'K H1\4.0I+FO*
MEPVIV]SDKB'EDIO@/[DTX7Q^R'U'@U@S+!)(5OM^3>BN0IA)*$7].V8!(:Q=
MCW&-3ETJY%B.!DG'I+[&<7>:BB^;K_HB8&5#D_Q,8:1WON5K.*7<*6FUBH-!
M=H\=;8W%@>%OGR#9+],ZQ:%RHP](2;Y_WGP7,Y?#'!>321?^>)$Z3K"42,K<
M>D0OX"2JA\PNM4S\*9=/K*AO3Y)E'=?$-LH (J?$.!(G5G*X%W"PR;)V#\ 6
MD:R3&P(GE,BK]B=?FPD#C10O%W.L%L1!?\YL"OBF^5A[:#9OM#7-W%(7R*.E
M%JXIC=1^DM9<E@Y,:$/5X&9LA-T.9Q_IS'M7=IRX&$RM++>>AX^^8.^3ZU-U
MD&?GG52Q3/=75\E7*;48B$Z2*TRW<Y_5F#R8/%>$B<VBX^LK4;O"K^U49ZW+
M8;-6CS)#^?UB'S'_7B=>"!U]X9S#_F;OJ8/1>8!92NC'4&L;P79A]M)&B-;R
MN-!H<8]/'>^TP\=9!F&^*+"<:1D8-O).6FVR]GA(A.SQ]$ZD;2-M;"\WCCV^
M1L%9=MW%V0K2@0I41A@J*;'C<I'/OQLZ)1 C^20T6JG),QT_-#SD&A2RC;6[
MFSIW8%4W1KJM62(CX[;3,QART==\>)=14JHMJ'9YJ9GP74O249?W9R,8V=O!
M<A484V8J/TV,VY+XN<:^;0!:&Q*WD6&0&&A5=VDL.[CDWU*4EL\D1S!BY'+Z
MUN6;7_#C%9-WXJD4WJ?GS59A#IK?1(SD+X1DMDKF$[$X/3]'H1XC48*/HEI]
MTY;GVY)K'0Y19NRFF)>)<)-/-*[5ZN(J7]=616)5 _GC_>;3FO<#1#@*N?8B
M#7V+,SA3A[9^R4J?+Q+V/EY9_&2)!"0!(?J??O7"[[A<1[8J\_>G?6X(CH(;
M;(D,LT*2R*_)]BAKTVU8+1B:A="'LH/#3LK2MWE(JE@1& ZBU/F &SD:FSG7
M;$I.S7!AX)>QZBI]D5$L8&)U2F_KH2VV1AE8:LNNI'X#D?BR[^^4:1#$67H/
MF/#7UHHVN#KI=$+3PGT]JXCO <?G57NRU9BWNB.%W4:Q=X6=6 EFF-_AD73
M+_^+#OBK=(CR!-RL:L-5<Q,:.SC9$->I9N3'REOYRZ-".RG,ZD\Z^0ON]?DK
MQK^/1]5E?4??\J*#9TF]TFS\\)/$Q.=@.BNSYJA,Z1F6=5_ J);+J398AH#
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MVF^VK^2*'&88[]*K\!K2+4P>'I 0@ VNKB)Z>#IQ2SZN""XV;I_9-KY^(NJ
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MKYR'Z3$#:\T/<&H>_W[P[4%X$FCH'=_(_@AQ_*0N?#1K6$(3Y<56<"=U%6U
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MUB>]'X1Q^<J8D"JAPS5B])"!E3^7?-AXX!'.^ZCWX77OHX"X\)$>'A[O?]S
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M_8Y9\[NIA<\E%ZB\GXD@%>^X;L>GL5&%/?#8>6\6?G/^]C\,T!#].[-.WGO
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M*]OI:]![B8*"F/4Z&4B,%:Z/M=LZUC')#8!ZR1I,IR6).B 3S9QL>,VA7)'
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MS;6\CQ9I&NTY\+ JX<P1D=XB7GL/SZZLH3OA2 9&Y'%N*7=]EQ=2F8C4,4S
M#FT1G[3NIP2@JW0Y$$8[S-29E#@T7J)]:"6! 7 ]YA;@Z9E[L/O,3'JMN0.4
M>4[AT?EFCH*<)..!7N"*C1BIEX-X>C>[5OUZXXF""_6E9YJ7PK#&<3L]>L]
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ML71Q08%EZM; N/4R PO0[W6S2O<HOJ0IM_O7+FSI?8M#)B5R1T_"C>>D(4G
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MO:^&;61FH9!0-]<4$WZL?65TN,/J]WY(FFH)GZY'9Y;ULGNI#W.Z_BS^2UT
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M YAROF[P]5VX)"N^ 93.W@"\2TM@E^2XG6#@ MY#(?!*5Z$%OON/!P.E^C<
M:Z#B[$FITB#H-)9Y$QX$Q>/7-O?[4F\ )M2!.U.G$3,+]3**6YKE177(4R&]
M&P#P!H"MY$N%Q5TVOKZVO0$$W9$B(S-8GB4=7J@)/XJ)DK625XV=.'?H"J)F
M'4.EQ%/#L%V/JB0E-C"YGAZEWD)37R G^S> Q+*8D_XE>2ALM5Z"J>I5ZJVO
M)_2'=;3;OM(!3#MT0$D%I<SY>:PNO\H1AMT]A!C9=W(#.+@&"JP<NW=D*K4S
MHOW#E2^?E/0F:!VX7=O+'W\I2]7OA(&.]"\F)OM"T+6"%6C]M*,1Y(6K]0W
MN NI>MET4! /!VYVR'F+@N=$]U>&=PR>_ AHUN(^EE7<Z!_(CDUQ,3:4V-@
MW7]EG2.8*[GI?KO;,C65:WS.8ZZUNC2N+\G/?+X*F.\CM])!DH]JW!/@(K):
M=<H(O %8$%%>G[\)C%&*B&)3WE$(69<L-2N23%64J2?\Q94J@*QUQR*\=K!M
M6U:Q.3T#,?TK^Z)Q+Z:W3O83[W3\UM(<G^"X?])8[4EZ/378("+S7<A5@.5
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MKN/(ZI5*J35A-=PGH\-<-X&XO9BG)BV!W &2)!^T8=)\BZ3I6P58,M@LMVQ
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ML'50IWR@Y[M/P8#][-#$%._4MJZ#C"B+;3C?&\Z^L=!F/F$[E\[]/LWN!'L
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MQ:3MV!EMU3//3=JMYU7;IWK[,N?N\R%1=DFIFHM?0@5K2ACKX77]#X"/-0^
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MYHJ>Z\,1AC&,YL&W[PZ34+55F^URS&WVUR?))]-8XQV8%]Y,UD&57.?P8]5
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M_E4X#&$%<7,0M)]RMHU/@"-H>M>7^W_MNM@)6FT6F^[A\&?A3O>K S>A\+0
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M&7NL.+A&*\<CT=/E,*B$(\@M'H?W59 _+?@F^3FAE#C^S5?G;$'WWN5M5]W
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MK%86;*2_M1_K;<C /V3/83_VZ[]QG1U]X!_S-*R/^6_4:N&N?/V?K_UWX='
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M'Y*Z\I<;*_KKFE9A>&0:_%<).7\QBPY3));K/YLWZ*^&D4^B8X;_Q;XE__2
M9HB4__>*F%G]V#],)'\7[R#IM('.PNE]EA5RA-<][#%0]%0,=:FU>(,(C4:^
M.WPI)T?O+*;9J8N1\D>]09=(&P<%P'69X1X4JMC!FC8PQ<BF+?\DN?[G9.NA
M7[BO$O.GA7N=Q[]!Z&:MC7Z=J*?6^$4UN3@][03O.:[AA0(DLV0Q6_N"<DIY
MJ$_BV:62=<E<L3R7/0]\ODWY2 9':D*A2(B%K\Q,@)LV=,9H-<9O-7^S(<^3
M3G@3)'+V+H#+_=69AZ]Y;UZ!D+#,OF%% ?A)WB2YLTAY0YCOG7<CN]*SM 8]
M@@X2T:S8+A@[ICXY='JBCR[](W8UE@!!0K-H0K-G-_>RYN@BX$\JEQIYS4C\
M&_K0@U:[(9'F;7FP:^G#DNFCP;-W\%G8IT4W%I>1BH'Y'>K/C?";TH6Y[%C9
M)!'VVKB"+.8A*VX$*F^9XO3EV4&B"A.1]6KR#/<$FLL-)^T!QO*S^L#\,^;
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M4!%W_PWZ62A[YT)UOL*G0?S]4>G,=0D<DQ]Y$(F@3%L@;A)?P(H[B<AZYBR
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M6K0C &!=&W91,O;,/Y".)>U_\P3FO79Z0(@EKHLYJ'/II;NA,2(C^EF+\9*
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M<IQCQ*[:>QI;D0^,2D5@HK/!^S68A_ ]-VJ6&BR5/ ]J3.N#-!>A9<R<6W>
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M#,=:0#&9Q;UHZ@ V4/&$Z<QG[Z.-PP<3SM[TZ93Y$>/PCO*I:G()D6IC\>_
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MQ!HC[.H+7_]+WA,.-N^0'U_S67#Q"^=OL@/K4?MP&!7L.0D=\W;TD>M#VZB
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M@%RM8E.\><53Z7FW<+EW5[.O234<DQJF23_EG(>DS#9WO*-@0(O!]>C<]2B
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MZ[KSO3N$X7%FM#3V7Z]P2;W9/G)WC^&)*Z ,P?]4D]BW39/O[I@%4]P[7L]
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MJ9>Z.?J]4,49!CM;.]%,"449?+D=F9L0?$[##7J;?T,FU3LJYI+ BX== X!
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M]W[!Q4FIT%L&^$C&>34=T!#2W'(K4(V+&]-7O21]*/-ZL0V4/0V.7KI%&O4
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MYP)&KX5S#\X>F[,%L,D9EO0VMXR>\@^K.K5FF.Z%.B[57-H7G+,#S-6:FL#
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MX[M46QCM711;2OO/LQ=YHP79/KP_O##4;EY9\$R7?EO^<15 ]A;,/^AW(QS
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MPNI"K*UG@56R$;"7$=Z5T05E27[I'_^)0P_Q7U%\UG]R;;W*7Z)H7*Z[TQJ
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M<!@^(PDG#+Y\>]HLTOB#- /V9TC3N1_Y1)M,'SB[ 77X$8"FY6!V\P\[/#X
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M,71'B?,9 @BI7,%N6GK @5OEOA;M\R98MM8'VI[]3&U7'0QI%?S6C%XI'%*
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MR4OCDEAA0GI?VUK!,<G#D[&1;LU(/L<.%)]N]LW*5#*K48$SSQ%M"CWA^,3
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M4C1B<_SF/9BP4IN "RTTIO_[FJ^ @:0LMEX"]\FYV?#?O,#_,Y3;H V8RH^
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MJ?\.,ME1\$&LSLJ\F"77H_:V,1I706'1A0X*,&27B9;1?7%1M2$Z&D'ZC5B
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MP^J9-=U=,P[Q ;3JY86%L!A%H(B#/NUR 'U$1*T1\_[!YCRMYB%SW>3"I\^
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M8L]7=_9"B?(I#0O3^SZY3#:.,R!--4MO+';D"K6:-7/+@//G2PO\1_DU6QY
M_ 5!T^NJ0 WG@OP (?8%6%IDVI[EU2(SR/@HXE?\QH)0WI+Y%W4E'PH>P(HC
M=NB%"TL:A1<C88-S'9;#3''!+/Y#ZN]Y+?0"0WCI\E[]3+\O93CE:D&O@I9X
MM\OH&F3E&UDL2$92NRPX9_(6(CQ#TE"*S\M%90G>.$+X 8@"[\Z2=Q?%;=?8
MI_6!U\VG3CC%<;#U,C5^Q!1^B["+V\N-^7?J-MXV,DK3$.TKI>?\ZAL6=(L]
M)]#U\K[]Z['DC<3>U!%G.2=$NYZ,KS1IA+9V 9 K8V1[;9WFECOO_<CAYHS
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MQ)9U;S<NC1;D^_^9Y/"_L Y$+?.(A/$F4/?,^7+L))_'=(BW?D\Z"2+.)XB
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M84N,KZW(G,\B^@$<G/9C*^.]'],.&G6+ @V[*IZ&;(DM&YB.;#7*^=O)_$2
MF.JJ+_#:?PT?GQW9.RFI2W/6'BE(>_Q&@A3[FI"LY9N 8Y83O3?#:-8;*93I
M+4I1R]@YW0 ?36!-4_UK?6TAS8QAR\A8SM.QF&E^)OZ(9A&D(8^1!4+#_$8
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M$_ZZ&RR+$2CZ-#0S-7,<)_8[UC*B>(UMEQ5FNR!;<'Z-7NVL7QY5[^0&I X
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M&1W0D*)2?Y7\KQ_97\"$C=-)C>(Z-ZFQ-/O7M^B)\AR2:/QA>*4=$-<FBM8
M6ZCZCI:05(\0=Q/?-YJW54LEO$\KU/@BC=+9"P?MGELOIU112=AO? K;^*)A
MG),(ALSNQ*MP_(#J-J6EB^^2:I1--.Z7)T]?"V):X69VZL6!Y0(/-HY>G8A
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M7_C[( X)N5Q^ZN@@@\EG^*PSY4H9-@3V\,K'<A\*VUF+D^QUOAH5*V5H/=H
MVT]LDKXJ%D?G/B:4(L2-Q_BT()0$X+%N7H$+T=6\I<XJM_8Q38@A$7TBNSOA
M;PK09H%L4O ?UMF:X5>YKSOC$D\J>$%[-=;L.YMC3Z8ZD1H1LZ6,9%I#="&E
MTC:;+QUGA\W#/MH.?^O%]!U8'%I; W\!=]9UNUS@.F&JA'6$9M?",^?3N8/F
M/M75[7#N6T#R1N>,MZNO\.05#F;*<PIA]-NV&874X7N%M9IAFPVO*K_(6V2^
MQN"U;?HW,]C_?VQ8_G"J-3\IO\Y&F 5>;H'N4?#'9KI_1H<<K%J)'>\2-DA@
M\ONXMN/<'!Q,BAZFADN<M3S%M.NACR$ R(HG-#L  G._9KN0?"DV.!.AT>@B
M.2F%XDW6R\$9#"9UW[SK(IU$B%%U<JL^??0E!94KHI%5U^?7C.J!&0P1%TTM
M688'NYA +/1HH((&+#6\UUP?:1-.\HP'2N_0,RWSA3B2F(CYPM\=\'8#(%8C
M"0_JGRWZ1H_D/'[^LP5@<E[+,FKW\=CC+86N8:JJ70O$PM<7=:C?E[(GFV6
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M?UZYG-2"V@0Q-SN)=LO0LOJSB]RT>F%TV32&@F.N;U\XI4=:=#(_-D#;G8!
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ME:ZU_9&XA? 6-C\ETR.(>?;7[_)T<A;;J9GB)02O^W]QM;'IBA=2-(Y[<!P
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M^1M/=VJW(%;<A(Z(FE'EOK5X2+'!@+']SX(SBR<;_,759S2>.4_,*6,*0KA
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M. ,B$:C_*,Z :<!C2"(4Q5Q$Q&/2SD [T=/R#*^=H.!120JS#6"-K):77DY
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M2J<VCST/6!**",-4ACH-KI20)AZ&U(M][.,@0M0J1^+Y+I?&RZW$@)+U8(+
ML0B;V8IN<9N8BSO(6FG=F8+F*#BR_PPZG-7H,P?@I:5G\>9H,I%"-<1[^^/&
M![=*DP3YL4ZTRN-(D8C:L]:U 3"F21JDQ M(:A<$<KJSY05[;&5M_/9777'L
MK'$M_Y!UY;)_M.:64X ;<XH#$*?GDA:]?1]8(ZA3:CD#ACM*.=71W%1R1N$C
M%'+N#7M?^IO6C/VB7EV%,4)A&B#HIXQ!A%@ TT1@&#*"O53& DECKWF_X:79
M%)UL0 MG[@7?P^J\OWLL A//:#/EK?S7QS0=Y:G>:V@VG_0Q\?O>YZ-_'^EG
MSC99)3[H;.KOU=YQ<Y?1M;@N2U&5OY+_R(O7:U*6']7H=9YFWT]EP"0,6.UI
M5JLV"1%2VP$6JSD9)I1:E?6Q[']I$[<1'];R@YT"H-% 9Q+_#UW^6RL!M!9C
MO<V6HV3H;YX.^ZD]SLYAM_="CP//E1_:LO=Y/='CH#GP18]LQDGJE%_)U^SA
MZ>$@N023DJ01UW5_!((HBM6N)0P#Z"4)"WU))!5&(4AVW2Z-]EHQ'2=-.87Y
M>=?T-$A.3&(GTG=TV+I-EW(*VXN2I3C ^/NF2K''^M)$*6<@LTN3<JJQ[YDD
MY8R"9U*DG'M[G)'[1M!*AZRN<WVFJ8O_U;7_5A'W$:=A!#EB*434#V&*TA R
M&> X\!*.4M_&F#W1S]+8^W6^>=892;7%I$6VLT5/@6EF<SJ :.KMJ)(0[$0$
MOT]2+/(,#H[,Q%.]S&H.GE'UI=EW[G$["BB+:G5;Y/R)5>7UAK?7(LMVGX10
M&$@_2: @00@1]E.8XB2%7DHH"0(D,3>*FQKL96G3OQ6TCBUH);7<E@Z#.DP$
MSJ":W,\\ B5C&C!"88@$5 ,] E#_VDW^X;9GF?I&ZG43W^SAL5'9G^_%>JUS
M6I#-MU5(4QQX<0PC0I'V7L608#^&7I@&E*4XQ-PH@?[QYI<VT=N0X5I$T,IH
M&V*]!]]Y%_-EH$P\I:WP&!$O?4SM"^*C]YJ;.1[ZF"J'\<]'GQJ93%J4I1 G
M2M>W^6;*-_JZQM?JRY]B_2Q^S3?5?;D*9"I$P F,_=C3-GP,<8Q2*!FF24(3
M/PB1C0T_5I"E37[U02'+S-1CA\#,\I\#V(D)I%'A"ARD,MSJ<06J'% !;DG&
MK\"_"U* FXW#@)=+072537NL&/.FWKX0K(,\W9>V-XX:VY+W95/U6!>]^R36
M^M[]+2ETVH(V=F<E91)0+A!,HDB'YOD1Q-K,2<,P\M,H47L9J] \PWZ71GR=
MV&UA>BUWDU2%2*E&2BL A%Z^K%/WFPZ$&1]. ._$]+=%=B>RSC9="PU:J:]
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MX9%7)^$08>1!Q6DQ)#%'4(H@\8D7)!Y1/)979&VX/ZN;M2*O;>/3?7]?=!^
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MQ&S'!:;*],\-C-\9Z3W\SR>=#G/+XN^>/V8K1:N^%V,$<:+-:R_U(>%)#*5
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M@@=!RB?MD"#57HOJ?7V.\%043;+_,G-5:6W4, UD(+)K;[:<1*/4[&<I&M>
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M<AONMB\>L_/G=7.-Q,14.FH0P.^U/L D),#MN%BD5IYI?.9*LNQTLM@E5W:
MY%":Y4N:GR_AL@,0]E(ONVAOW%[@DRC5BLCN54]OQ+-8YX]U#&[3_RJ1(>=^
MBJ#GQ1(B0CDD:1!"XJL]0!P(F1+?SN0?[&]YEGTG;AT]QG<"VQGPPR";V>G.
M@)MX#=E#K"=I1U#N[&TC1!R9U<-]S6H]&ZG]TD@V>VD<A;3ER,LO^37[SZ>L
M$'4 YA=1//3"+U<LB@-":  Q%SJ+7YI"K*M"RB2E'HNP2 3K+O6:48E1OT8S
M8_]V[\24<JL:NB=ZI<XER':2VE&*&>AFU.(.R)GJ1K;R@BH'K<2@"?K]\B+H
MUQW96&'DB'3,^IR5?*Q@>$E"=B_;WW/\DE7:AGJ_X=ESQI_(NKX[$HM8,0Q1
MQ!,&/D0")Y FC-<FC1_A@/FA47:<DSTL;2M="ZG)92>F]>7$XU .TXD3@":F
MCA'86-TH'-3_@JN"Q]N=[0[@H%K]RWW##X[>HE1%IGVX=8JMWS9957[Z_%L;
M(Y%P-<%CGD+"(QV%X@>0IBB&42)Y2$,94&%UU66PMZ5-]5M1R+QXT(D7(%4V
M!0?%5OSFE!<\:06LMRL#@ =)K"RY"$,_# (%N"<A(8& V/.8$#3@-+ ,^W$&
M^6Q[P@[B6E[PFVN(C7>$;F";?D=X!"_P@Y*U_'&"N!\C7-SM"P?ZFGM?>%[M
M(_M"@Y=&E+"-?XJ\7CC19[')\N*C#I%[\R04C*C]U&F<)!&F"*:828@881!'
M)($R8JF' T3],#&N;6O8Z=)8O!\65]8RVP036L%]_BAC"A G)A@M\?_9+S4!
M&J%!+3508NM#=S2FIJXIKA;%=B? =Z9C!V<XVQ7KM01LJ(JO:5/SE?>U5&ZO
M[J_MN_8T_D&4I1#;&N<?A+(Q/V2$9NNL^O8E?R5N2<:OI2+);=0)(V',>1!#
M&6H_'Q(1) 'Q().2"D;59AP9$[I]]TNC]B_WHA!$2VA..B- /T_KTT(Y,<$W
MPE^!K?B@EO\*;#6X E]R\$H K<45J/4P"/%Q ;TY\T\[!#.M 5,-A=62,![)
M@<5A1*.S+1/C%>XO&!>T,LYSTW/KOM_H&P77&_XK*?X0E3[";A(][2X9Z!QX
M:BDCV::]6M@<=^\2'/0B/Q!E,HT)3$-=T,Z7/J24QS#V,9=2$.0'EN?24XFZ
M//?%U.E1)AMT,Z_($@9RXN6P/VS9IKE)I8=OIR9H].S?K_JA3AW:Z JZ&\^-
MMC_N)1&=)+7+U*/BR)TSF9BS>H*F!ONE$VGR_L:N/JS02]P;T?S_^TV;CZN\
M)=^T9$H2]9OB2?!N%53BK5"(4!K[' I) HA83"$-?+7*Q#A,HY!Y-!6V:\L8
M09:W<G12@\=&[)IT2"-X=\6AO%*4Q-9/-;UPM9!4^:X*AWI*7U'.;._)CAQ)
MTP5CZM&9?#EH! <_="K\J)>%[6C=]D:K503T-'%)\I<@Z8S"1PDQ,T%? M0A
M_5[4VFARS1_$%_+UF*5&.$&41"&,L*^OZC($,0T"*"56S(H"$49&.:--.EN:
MQZ>1%2AA1[#<:4B-N<P)4-,S5HO1');G>4C<4<_IKN8FF+-*'Z&1\^^,O/G_
M)+[DG\1:FP"WI-#TTT6T;_A'I5+SCY6'/2E2S&' ]!7_, TAEOI$T/.0Q,03
M*+#*N&S8[](HY*6=]7-G8ZT-5NV+!L",92: =6+">=,8HJW,H!7:X>UZ.T1<
M7:,W['7>^_)V4!Q<C+=\W?Y,ZW5.UG7!:)D7;Q\S+AXR5E^[*03?B%)M83?Y
M<^U%[]+P1)0D(2(42A0)B*2^!8-E!*, 4X:$Q*''3(^TK'M?&CEM%:@OLW<J
M@+X.H*>$^=F+_;B</_6:%.V).<L2Z!'1#?:(FQ]V38K\3&==SD? ZI!K-((#
M9USV;<YVQ#5:W?X)U_A&1A84Z248T%'/^^D'5K&GHY,]'X8(>1!%"88I#3!$
M5(@@#KPH\BR/J88[7*#+L)\%I;[OM,W/02RN\!OB':8^1R*F.OA;%X[T(ICZ
ML5JMXT@DF&(1Q58IPMRA/<NV83CWC/IQ6O3--@_N,)UX_7WYZ;Y,+>-P^V"&
MB:LJ+,.=S5MVQ4CQ@SHK9F^-=6RJN2K*2L="Z!JI/@II(#T"L8B1XG".(66)
MA#&52*1^@IE=G=\7[2^-1#KQ@$Y#8.N_W$?.U&4Y&H_)O90M%$TDT]NOW;'6
M:_*85<K0^*\FX53]4#\BZII5V;/SLY6C,#GS7.ZW/K.S\JAJA_[)XX^-F^9O
M2;%18U7>BN+SO3(/7Y$R8ZO0BX3:V?O0\[U0G_URB'6Y$^[[U)=12"@QNBLZ
MV,O2IGPM%/@AVP">K]>D*('ZDD&IY?W1C@&.@VK& Q=#-3$;=/(!)2"H);P"
MM8SNYO@@!(YF^O$^9IWO@VJ^G/7##SM);-[Z%U?(8R35&84][JG=0QQQ7>G6
MATDLD$\C3H1GM7LXWLW29O]EEX_.0&HV]2\':G)7W'[>\JLNM=9DR<I?3W)@
M<**3[YF:_/7P<<"9I^V]_UVY^E\*LJG>/6VT0?=."7G=Q2AUGRZA0<@\S&!"
M$P\BS *($9.01-@G 2<)9=S4Z6_:Z=*XH987R$;@[>GC-Z!']2"JZYNYX]EX
M$,Y[^*> =NK#R"X->P-O*_05T&*#K=SG.68\K.9N_"G@G<E[[PIF*Z>]+5X#
MOGKCIF9ST=LJU_?,6[\[SK0;O.+2Y1]Z\U2G ?ZBP!>K$",?*]L.>A[!.E8M
MA33! 8P$$5%*$QKX1CP_6H*ED;[Z$&,[X\\>=#.[<%(H)R9YDWMR50YH=T^N
MOB%7*^'.IAR-GR-ST[[_62W1T?"\-%+'-S2.Y 8JB]\4K^_59[B+ :Z?R#8L
M>UR+.G'LB@1^DC(OUMM<!)% *<329]JZ19S'"&-B%61WD31+([^=G.!S13:<
M%+P$OSWR^E1-7Z"J]>F%U^LGMRJUJ; -0S#<#*<9E<XV2%,?RDT[/M84ZP17
M1W1[F2RS4J\3V%[2L)M&[=-.?A*/;4K7ZSM%[KK#U[H/43R2HOKV47W.;_('
MDFU6E.&$"F5A8A91B&(_@"E#"'+L)P*G4H1F-=2M>ET:Q?:E!%I,\'LCJ$5Z
M2G/(A^EQ,B G=TA:8VB5QM(:DPM26YKW-5NZ2VOU^RDP[5\>X\6DE2Y[7M2.
ME/9R5W= NDH\7R?%]& B?4_13( A25(*F9\$01)S+_$L7)<#/2V-6KK;C5DK
MGXWK; A0$S>D(Y@F]SW2"NP$O=I>"'WO&#(;%Z,CZ&;S*XZ%T-*3: #+H/MP
MZ/T9?88&:NP["DU>&+=QKG-<WN=K]4;9I"5884JP'S(*O83H3#)A"'$@)/0B
M[*5",$)3;U7E%5F;[88/N[ BR6U'TWV_7W0?ZF/-G[,<W-Z3XD$]]U1EC*S+
M*_5[]E.3.;A5XN__#@=^\H] U,K8[6R/X)U2YC/!!8P)(A!A&4(J90*))\.$
MD)1A$:T>19'E7&WPBFH.U%]V-V&HC;C+-CJ> 5"RUEF;+\93!K'/=.;K,*%J
MK4=I  F-4BAY&'(6I8B$:8OGVXUA80T7:':=31B0TYQ*N@+2S(]R&303+^Y]
MX?ZA2P%T755%1I^:M$!5KN\^.@U<.(V(([?&D0YF]56<5O"E V+@27NOPINL
M$$Q!W]Z\BI&RW&D20$P94[SI11"'C*C%BDO))(VQ;^PZV&]Z:49\)YVY-^ %
M5.>W_.,!F-H\;P5S>)7LM+X7[-E?-#C;QORX(OW=]XDG[.??S9\;];'?9X^M
M(RD5)"(>26$8Z+RV'J&0BD1"ENH-=D(01Y'I!'S1]M)FX%:\$9ZYE["=GXP7
M@#'Q;+3 P6HZGM#X@OGXLL79)N0)5?HS\M0C=E.2BVSUM@XSJ_>"1%^Q$&](
M1;J8)LHICN) PE#]H!;(T(>I%U*8B$19R(P+QHSJP)SK:&F3M9$5](0%6EJ[
MZ+&SZ Y/8Y>833RGQ\)E/,%-L3@RVTO!?KK+GW]633237?VPF^=G&YYETINJ
MUS& \?/C/#J_9IN\Z!H79?4AVXCWE7@H5RGRL!01UXF!*402,4BX'T,1X! C
MXF'*K:[RG.QI:82@DZ3DFTKUM];[X^TMMM^UQ* 6V3) X33(9IMF)]!-S L7
MH6:]:3Z+B*.]\^E^9MU"GU7WY4[Z_ MC\OZLU8^YCM%ZWAW-7?])U/O\^D$?
MT:U\DDB.? :3VLCGVH@@@L&(B"!DF,E(&I&&87]+HXY6.)T_X,DF\-P$VF&J
MF "PB0EC3UJP%?<*="!>3P"B3?X=IV#.EG'G,E M$^P80S284N=\*S,FT3%6
M:3]MCOEK]L2KEM:W#X_K_)L074*UA*.8(P(9\B)%LRB&)/132$D8$<H%82PT
MI=F#UI=&JDI T$EHS@:'H)TGT(N@F-Z^VJ(P(E79(1SF5'@1+#,1GX9'M$+^
MY(;>3JH]0&:'[\Q&72?%[1/5Z8?&;1_?99NL$A\4Z_&7:62NF1KXISH/93_?
MS"JB,HD2$4)?,L5= 9>0HLB#?HR2B'EA@#E9;>H\3(;'K?9"&'W :?,!]T69
M[OM]_S*S5!T6T\D.^L+;[3U'C)#9IG0BU.=ATT9X6$M_F)AJ!/;6.]CQ\#G:
MVHX08-8][WB 7FZ&+VAI)"N2K*BK0+WZ]JJ)KOA\+T3U2Y$_/6:;N^;>240(
M5[MB[6"/*41(GT6G4JJ=<RB0X%Z( ]_&OV;2Z=),NUV]K"M OX%6;E +#CK)
MQUT*,AH#0Z9SC.S4W.8$5'M"LT#)%869=#DO:5F <$!3-N^ZJNBTO739YF2[
MIF6E#QE61!$01DQ ?6X/%2$A2"D1.HN?"%&2<!G*2ZLXG>K<9C+-DX:UN?U4
M5XO+MQ>2&T.MOC;7*RSPUTM+,YT<$C.VF@;FB3GK1 FFW>7O5G3P>R>\VPHG
MEHA-5FKI9,??N;S2.4#.EU0ZVX+[#6C/H'O;Y/#=)5! B8AHP ,82Y9")&,,
M2>1C*.-8!$'(%<$1.WH;*<GRN.YM664/]<Z'#"=$UDG=[9-=C!VQRW>ECD;A
M>VY-=1;51\%>;DNG27]Q(98S[%.'I%C,9M4 *IL=JTESXRY$]DJ,/I-LK>U-
M-<4_D[5XK4_V%5D_D?6OI-(/?5O)-$Q(A#T8AYYBT"0*(4U)"B,O]3%*) Z$
M\1F$=>]+V\CV1 2=C'__=W[L_>,/V:;YX9L:I=(P'^RX$3E_P#$ISA/S8GUM
M<"?\%=B*#Y7\4"L C@W#E(C;7=*<#/DY+VZ>'H%2CP#KC<!#JXJC\YC1$)ZY
MY&G7YJP7/T>I^_(RZ+A&QIGCGX2N2RUXEW6X/6M,:(RB2%^MXS*$*$ (XBB@
MD. TI326'L9&:\5P-TM;%/J'"%S(C&6&T2QGT#2SA"_':&)"[P0$V\S@[B[M
MF('@R$(]T<FL!NBPHB_MRS-/CYO[MT7.A."ESDJIV>7F_Z/N6YL;Q[$L_PHC
M)F*V*L+H)0D0)&8^.5^UCLU*YV:Z9J*C/BCPM#DM2VY)SDK/KU^ #XG6@P(H
M@.;,=&=GVB)P[X%X<'%Q'^K[@[95[^3JL=/@?I:0..9I1D J8J6Y@&J[,<L5
M2"AAN6*,,N3H6+2;>'H'[5;NNAQPM7WJ$W6[:];=GK;BNS&'Y5K8,8E_? ,S
MRVM@*\M0@UD)#8S4T8T%KLY<XP:3)^ZQG'14+G(#8I^;')\>6N:6KK7YL][,
ML":@V-2K+:1I,0>3&- 44J 2%%.!4)82)]-D._+4K)%*,&V?VY:H.83*CBT&
M 1"8$)K2L>_[E!]0'79/46]57]MQ1Z[FNJ?.8976_0\,[1[R^+A<5+G^C4$;
MJQ1G2E& J$D]3%@&:!YSD*)"X8(FA2JD6^.0O1FF]B[6 M9E8ES[A.R#9_=6
M7@1)X+>S0:,2+L 9X*3JWIJ"[(\_<C^0$^H=M@(Y]<$+BD'=K-?/4GS0%NOB
M_FM5N*8*86A;#4FA9S5.ZMI#!O6;S!*1@(3HTS^2*0)%SB5(BD2;_PJE66Q5
MA&.X"%-C@H\_Y8J7Z\I K>@@6C[5S9#-[1JGZX<JOL#8/>8:7'_JV_<_UE?1
M0F[,/S;T9_34%,@>4,'';?7LF";LF@2FHDK =52+?]5&454_!97<45../+I>
MK4Q(2)U=0Y7^KD2?EBLE2WUZ\W@'-QQ-G]6#W 08O[K0((".5A\:-M)  CTZ
M:.>+]>YE]Y'F>U?E%'UY-O1M#D;FV[KUZNKO7]4=9,82A!+,$T#C7&A[2A!
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M\;.8 JJPN<3)- %(PB&3MM7A7P\]M5>[D<[M3' $L?Y7^#(< K^W+03O+X3
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M% E/0(P2GA8JSU5LE33O.O'4-H*3?9)I+7XD6_DC6BEP:4/?$^MQ_AP2"N7
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M2C_^-*7:I?BD533V^'.]P=ZJCW2UT(2[UL9T98[O@K@E)KA0B01Y@@E E!2
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M_$*;.:]_T/GDK$"XX"E7($_-@1,K"5@B3"5'3"&,$_WK8O94Q19\W]#5QM(
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MPA#)+$]C:%4T^@(9IO8B?VVN)NKV6U>!4E[/+<QY"VT$N$/?79S*J;R**B5
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MCD?9N$UG:0PI@RD!,2X00)@S4 B5@22/DP2F.<NI54DXN^FF9M+5H?"R%FY
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M6SQ.KEQ'@6A9A5;P5T;M7$OOMB6[+HK=AAT0Z,!TT46X#EXY>FSXQ8C_:U4
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MWE7/\-I6P6BG8?C\OU +X"MAQK=XXR;4! +W(.$FU#S#]H3?]3'6;#$W"TV
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M@TK=Z!*7QP;:74UU]%MUS?_Y7*ZD.)WK_^[E=U,J_;VID7Y7Q38@+'+$\P+
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M#. 4Q0!I"PDP"3G@N8!<II@7V#*+SGK.Z9T1&P&UU51+6$4EG3*A+O4T[Z_
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MT><^D-Q#EWHQ\!6K='R2<8.3>A4]B$;J__2EN>>["!GC.IEQG$&:Q!(42!*
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MIB(2A NHOY811)ARF"*]+DH#G,8TIBDAJD?]:2]G>B3QC%%\:L;R9_!4'2R
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M2E)(8F(.W5(,,]-V1H0!$Y2(,(F=E..]>38U:MP-;*_H!UFK/&!QT =DI_J
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M_+]_>_TA?<:S -/Y:AWFJ2ZPFO[3:O/#UXL4UAN9/TO7#X_^1OT.+G\-ZH^
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MB/YQ<(P\.X'$.UQ.%_GG>?Z)3MZ)T2IQQAAXI0G3B601BPJ SHGD>,J,B2:
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MLYK@LTA_^_"9Y+9Z>[ZN)3TULIXHE[@+@H LZTU*$G0(\B@A"B%L9E)@\0U
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MH<MC@]QI'ADW'JPJ&NI\ (C*1&!T3OB"(:F[]K+1Z([G*!LY^;L[K Z@SW[
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M/D'EN,[FJ:]]6JFKCWCGAI]2F_$39^2KO%R<G2VVS?\GUFDO2FV'$',"%4R
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M2V-M=A34%=/<"QVV7=45[+=M-;Z]G(75C3)],K2^5GA!4K*VG^49O(T<N"*
MBQA3:9[.^@Q)7;>FV@<?CUN@XU71:VGQG=Y/!]N;AS^G?7.J 2W-HZV)Z !)
M&%P&CJ)Z-XI.,18SJ;W.63:UI.E[:5%UXY)LOI[FZ>R\)C9=OV#]_$>:G9,H
MM[-QSKZ<7V87/]YBR?-D=(R&=ICTH'A!B%I:L"+:*'D.!N-@!JD5%YTVQ=H'
M>4_<AXZAZEX-WL/-JH[SLQ[[N,%Z:PUYCW!<!R.F?,'B:[_J>H-?,RVBS0HD
M&M3"%^%EZP35<3MLW7 2[C97>O%[6.:- M]NIK"NZF/^UJBL5N=GVY_=O9,K
M5C.,'JPMO'9AJB\@+ *W15JGN'2I]4US6PZ^Z_Y;^Z#W"6_QU$#HU=8^T0KF
MB*O:YSYSV!XV YK>_;J-:&L8SSF U[8V4-((+ML$DMF2950B-?=*3]K)YC6N
M5HAOOV!-OI]_>HVTH2X?<+]=7 E]NWL/R5W@09$D"B)%>W6:4^W PJ3VF%,0
MPK9.<#N S.^II\T^*+MK$8?68)^7> \6/A_^!/_$IPU5I3V@B7NF4K80ZS(&
M#SS4IG#(/ 2M-4CCA2DQ8G*M7ZN&K=7>WDC]ANO/BWPC?_3&Y)5@**+SM;&!
MH&->%T=X1PFU<TGB-N;8? 3[<S1U74N]#T+NM8ENJ8P^C<\AQ<(_(7TU.U5I
M].5J(U5&/\CL\(71UH;(;!U;*24%%L5ZB,8$*)%O9A<D8UJW#QVN,/H-_G[C
MPY>+.7V9MK5-;Y<O/]<:R5?SF[\Q)>^"T+0Y5R8UX]SFJ(#EFFJG*<3QRBJP
MS"&*R"BV:=U<]BB"NRVCW@=3=TWAZ538PW/_94.,S?O-Q6O.BS^FJPGR$!V3
MH3;#J"(T!IS)&3 5K9D-T@TP[.818D8^=D\'B'L#8%IHIP.8W:3_I\49'3B3
MD@OMQ%P;6*5ZB2,TQ,PU6,ZTLQ;K_.'6,?H]*L9^GVVBWKOI2,?)N@>T4!B^
MF&\8^ W/(B[)M0VBU"YD)I$45"(_U#%'SFC06(S%[&SKYBGWB!CY:N)(K3[0
M4_=P$7> D0_G<47>;%A^JQ6N-_>.RL9[R1AXXR(H%\D+X ;!!^Y2D4$:UOR9
MX#%BQLT\&_'@:J*='F!V3?Z;<$9?WFSBO]V&R0HN8E*0K&>@E-?@D+[E2>J@
M4Q16M;Z8>9ZJD0^V-NJ_"ZJVNA@179L20N)F==TW^\(*<RED*42VH/.^5D='
MDI1VM;%)B2I%Z\6=9.V'RS4?^O"1,=%8>XN6HNS TAQJK%]/Y[BI%)P8.K2Y
MT9I.<$GBXSZ3^(J&DH5*+HI0>.M:RZ.)'K=ET7@'Y&FUW06\U]NVPS5C<1*D
MK3V9'#!ND8X!$\$E1Z+S0JB0%.W1UFU5;Q'P?5XH'*C\>] [5!/[P\AO833'
M3S7%Y.@S\Z^+Y=](("_#E^DZS"99&^9"C,!U=2:\H0T8"H-L%9TBDFO)G[NF
MO_^IWZ?+?APTCI1M!^;E?7V[F&.^3- D$9V?G6\2FW[",DW3]01C$-(D ];:
M6D?*'7BN#.@2L#AAK,?6U0'/4_5]GG]M#%%CG1UKG3ZVN[\*J\_U?_51]2OY
MIMMTDDT?O(^W^^!->"[*<$1P&A7Y$(:#\SX =Z)8KS"7T+PX<V?J=@*G^OL$
MYT Z[,!4DB@38E[5Y/97J]5Y[3>RR0B]O!"<N*!RY"Q#M?2@)$H(27O H)3S
MW''=O*7#LT3MA$7]]XG%MAKK-2/V/7[%^3G6%H6?YM/-M<#!V1>/?U:3(;4[
M$=IL2NUFM6TIRGSSO/W7Z?KSR_/5FGSXY?5<J6(C^N AZD31:*H.F_<&N-2*
MJ:Q#$.T'T^Y$6H-!W>'3IV4]I3=%.!?+;H/P$'14JEB07-4BQD >0OV69RG1
MRB"C:AU)/D7/V--FVV/E@5G:;;0QXE&X6JXGOX5_7RPO);/:OKI*E5.NSVB*
MUX/<&@@^!"#[K(V.P2#?J5R//OX&CNB[:PP]O/+HA2&--+IH)MZ1P;&]H;[%
MP\4=-7>N%DE'T"AU;=ZGR.W+]$>0+'%32K8[O?8\@Y%'"1@'*BTTNF@MWI$?
M<-[-SL\B_04Y>04_I"F25U93Q"^>'YR( 64NP*P@V12NB1,> )-.S"6'7,9G
MO)CG5QD/#8U4N!A$GB,CX\5L=M$$]&*S7+# "DM$: $Z?^NP*Y4@>LE!>H[,
MAI("VAT@\<C'CW-Q.0P66DBP@U#[D9/U.BJD\S0)U'5"=6W!$2T'1PQ!<2P4
MGZW5[D3>ZWXO<L,U2VKMBPRBB@Z@]8RKO^U@,)U_JHT.Z?_RQ_ 'L:A1:TG;
MST7:/4X7B#4_NF@L+$97QQ*?-D1\B,PNG>$#<7+OQGM8I?5ZM;//")@/YV=G
M8?EM<3W%HBR6JUM3+ Z_%QJ(D!-/R3E41*>?I!.9"1E3K."UH*21$!UGH),7
M1<I2 F]=PG>Z23KUXV]\ZIVA*]LC2_E<8DX.C QD+7R)X#,&*#*B=\B2$*T%
ML -9W\T\G'WP<^_$;ZR>#@[]JSFVK^8DH/--_XP:A_L@$]<V D^1@4(IP''R
MM247(?L2G%*M'VP>(67\YJY-5;YH+_\.8+3)O"SU$F>>/^#RZS21SW%C2O(U
M=ZN/])&KA__J(L1CA6-";B"0+$&%D,%7STA[EHK%&)5KC;V6](\+V": 6G2B
MW9%O77X[7Y^'V2_G\WQY6Z"UPY2#@!)+H*UN2RV(ER!<"9$;QHORSSB,#W[P
MN)@93[^+5L)N&*<<;@7_\N'C<N-4?_MQ.IM='QL7_(1D(A>2HCLKB1]%)T;(
MB>*NPF2V4G&=6K^G/DW1N!<SHZ-N +5U<!37L3_3,J5?JR+[";\L5M/U!2LJ
M:AX$=W5'.9(2.;].ZPPQ6E>K^P2&YA6RCY,S;J9B-_!KI; .L/?;8KG^%#[A
MCR']#?/U3JHI1IA__/:7#[\NR.#.J^@^?%G,5PNB\>?:=>;+<KJZWG&E>&NR
M!"N+!B62K9G"@KQJ'4Q16BH=&L.T#>7CIC=V@^@18- !^'>9EGM]Z8LR>_)M
M+(A(VULI5\#5CL-1<3ILM+!6MT[3W8O \2=<#!EV#Z>KD4.61P17MLQ=/A&0
MHWW9$7 BM1&TT1BP4+WL&&H;+D/[S2#/11I,:9>2E[T7'KEV=#@ +$ZEC0YL
MWN/"NYXRF;*P7@I )@PHS A>>@Z*+#C65!_K6_>H?IZJ<:W;\. ;2#]=1-EW
M>;JSR<[(^9C^Y[;[]*9GW40J"N"45O65T]36709<80[0<Y:UD<PUGQB[+XTC
MMSUKC))G0-A488<;P<4ZS$X!R.L:M%^7B]7J+_,EAEEE^-<ZG;<>!EA?Y:TT
M)A5&;G:=^: BHQV>"M)7B-Y[G5GS"9]-"!_7E(X+W0%4^SV8V$?9KO7?UVQ3
M>,9S3!Z<K"%D[68=O8\@2U 40[(@L/5+=1/"Q[V7ZA31AZMVU!K_YZ5Z6P 3
MEE@(11G@SM8J]:P@N/KHP$I4]:[7G-!=O4W;N+=+)\9E$P7UV39ZG\2L-V%9
M^_E_Q=-DJ-U;[L1Y:$^S>_ILLZR4CF@#,&M++4>)$&26@#QJPWUP4;4.'?K*
M-G/*T0[3 ;CQ%'Q*:<&98 $C4]87KVWS5MI_3]EF^^#GD&RS?=33P771U9[_
M\=O5E_]]BDLBZO.WU_@59]LBL,2M,[57+:/03VGO(10DUDKD+L4<;6@];&<W
MROK/1=L+$'=ST=IKIR?,W3QG[O-W\>QE%>U*S0Q$0]ZMLCF!YY:!"T2;35XF
MWWJ^YEX$CIQ<-@!"'@-A<W7UA,57\R_GZ]5&8OSBM3,;+;7,#IC7=:!Z$.!R
M'7=<?&'.IZ!-Z\#C"7(ZP5E[$#P&MR,UT@&XKMV2^KJ_V8B96XJ21 9O(DDF
M%DF2H8#):V5\02Z2:CVA[3X5_;\D'W-H'BGU[G#S,JSQTV(Y_<^-ABX;WT8K
M"K( 114RZ%(;""9HBKZ#1.ETCJ6U0_8\5;T$ 8?I_4D8':V$#F!U?QZ X$()
MC0SH_"<&'//TE0B@52"C'9VA;=@Z^["OD0NMM?SL"(9]1-X!9O9[&-><(?<Z
M@RY6@N**0\Q"@@XZ1B=)CK'Y/*'F*52#O2,,?? -IZL.@/BT\-[?>.6;D*1*
M]H)!SLK4^V@+44D#DC:7L4%C+*W?;7>G[GM*LMH+(GO=E1VLK^\&B9O&V\I)
MY#8:BE<\UN<7!RX9!LAXD;%8%GWKE-+=J?N>,JZ&1^+>^NH B7<ON7_Y^F9Z
M.^-ARY5%"INM!7*"TS9KVT5)?H=+/#$KF#7#S-A]CK)QC^/3(7  /76 OJ?W
MU>T\A7>U@H;T^N:\.L%OR^7WJXG))$4I$C CR.')]=)(8 (TG'OIO!+FM(?U
MCH2/^_3?B_4<0LL=0/O^YGP[O]4-7.J4Z']@L'8#S]*1QZ(="31K[96*$5N#
M]AF2QFV=?3HXMM1,/\,$KCEX^_L<\X]A5MM_?_A,PJ\L!43+-!0F25PB,PB1
M99!<6F,))Y*UGHOY%#T[(<U\_TAKII/O/^6IMBK;_.WK:8C3V44I]N;O<UA?
M_9/%/+RO2EA.YY\V:>.GR9 ZEKH3)U0U%>8(^5>E#D'C&H+1G@QLYO15[=18
MF"Y9YAQEZY#V=/E7-U[3K_8[XOK7Y>+\"^GAZHHN.DL'BY.^/FZ:#,$E"4)%
M.F[0FXBM:Z%WH:N7>_2F"'HB(::-@CIP-F_P=,-._++$_SC'>?JV><B2*L60
MC07O:Y5"X9Y8<A&$$'5L5Y"R^;26'<CJ)"6A&18>!UL3Q?2$M8<8NDC>D((+
M(TN$& .QQ$V Z*T'7XL;R7V*,@V6Z_<X6=U@K0T4=LBQ.D8OG4)M=>727#:4
MBDP4)0M@\+63CR<_FK8EH-#<>V70YM97D[O0U0G86H%AEX2^8S33 ]H>:;(7
MDQ;." .AN-I<-$;PCC$@X3$9>$BR^;SD8[IF#O;<,OQAV4 !751:-NW9(P6Q
M+[@"C;PF(#E%IX,ID)0I,3CE*>9M#+^__\:9>T%JR,:9^VAW5&P_W,TQ95JD
M\%1?.SDH)#L?K!(@2@CH2\SF[C2Y_W*M,_?2\).M,_<1=A=V\+H'X[W^B\R)
M; N)H3C#R-.M?2$2,51<M$%GST1LG3;X.#5_1RTS#T%;8W5UX,H]U7U12,<9
M5Q:LB;2+-'T59"R0G?6N&,NQ-$]8_2_1+O,8Z+526 ?8:]0G$86ULO83054'
M >MB:Y/0 EPPJR-J9GGK]^'_OUUF0T2/ (,.P+]C+:$(/CEN!1BK%*CZO.I4
M%A"%5LZ'4/)P97''UP(/9HY/>1W=2CT]@6ZGPD*4+F>F(QC4NA86<MI11D'P
MK"CKK/.\=2[$WU\Q\%X(.:H8>!]U]83%!TI/.;(B7-:0O'*@.!TL028'W"A'
M@1UMY3 8\K[O8N"]0+!',? ^&NDBHGZ(&7'!C"S"ZF02V$U[IMI>.V03P486
MG!#.QN9-KIX@IY.[ZE'@=8A&NH67O&#&DDC0\PQ).E_+RA "ZMKZQN?L,7J6
M!LL?N$].)X[:*/ Z1"-]P>LA[_8J#OM >MQ(]&7XLDG]?GV5C)EYBE*Q!!3Z
MB&JO+<3B"V@I"EIC#;/#Y; <1O.XX? )(XH3J+0'_^Z!VX*KGVWS,A^2Q(W4
MM1"M$;* "2J"REZ"URX!*T4I9-&9YO7-Q]+<B:=X$H0]_R0]G+J[L-$[M^PT
MKF3!=/68%3DW2M0<S.I*IY))QMYA,8V!W+2GZBG?G ?$S*$=5_=17Q? ?*@"
M<N(TP^PY Q%LG7HN"AUBC$$JQ(6RBHZNUB!\B(Z1@YTQ 7>T6CHXU+<RNCIH
M?IJNTFQ1_?H)2S8:3\=&D)9<=VD+1)$X>!G1>LN2EJT[!SY*S,@ASZA6K8F"
MFDV5:%I%59\^ZV"!&\+;^"WOEO@E3'.8Y[?KS[A\>;ZL:MI*XO"JJ&-6:U#E
MU(S9(ZN6:H+-8[1<(58;:;P-#KACLE[?*'#);7J@&R9"%M:89\2]RSI''XRK
M]?2L%I/2SCQ?UC7>8ZIOB_685R)P:Z0'1KL!E(\*8D +W)?ZLHC<V];- I^B
M9QS/K+FV[QV"K50P\J"YBVWX6YB?ESK#K"9S__S'%YRO<'6Q)R>F),\S24>P
M'$!9GH ^1!%W4FL9!#K+=M@5.RPUCE<U&%B&$' 'SM/&8%_P=<'*)2>,%570
M1, D/*B@2NWF&B S&U!+:<W=P>I'&Y_'J1G'?1K<]#02?P= NLW$BPM78.L#
M7+*4M2H!)0=BBYQ(Q1VX$B08;HM0B)JEUEE1.Y USAWOX-!JK9#OR_]^D=+B
MG(*<=^%;O4\AUY1^LCS'2WD,X(3OO.2 GOAA;)_"'<_&>J%3A.B8 &58@2"X
M!NU%3L5%EJ0<T1VOGWU'>"_N"6_[X"(%TQJY ,\I -Z<\(Y[#:G8*'1V,I2T
M R>[K=:QR[V/1F]Z40.(><3S;[5<3UY/U]-/&Z6\#*MMXVD7DD 5"_AHZZM<
ML<2'T2")!^*K8/ [.4_T\3>..?KN^HA[>.7Q #.$7A?-A-P51&KR\D5Z@4\\
M&8X)A!-TQ%O!P".C^#(&I8K7M3BC.5"NUQ\'+BWT^2@T#A3NR,'[;^DG7)Y-
M\_]ZM3GJWWT.R[.0\'P]36&V>C5/M)_^Q_]8K/#+Y_\Y/;O,(6$Z!?((P1=>
MB#]'_IOP%BA"2 QCIBT5=SB*#EF[%^ <JNW%"44_,K2>-<ROKU[;@XV)2PHU
MC3*\=A7()$)BC>*,HD(V6=QM[G28;_-ZKP2;06Z)!CRN!A1Z!Y'^'<X^+D.^
MO+0@+M\LYNDBN@PQ."NXAQP#.8A2*0@A.Y#".9]R"J;Y<(E=:>O82SH0%W??
MW(904A_@J\+Z0%%)O9Z_O,AP7MJL10!?DR*44W5J@A(0C$<LEMED6K=9>)B2
MCNU9,V =JX .8'3M0[PG#2V_7MVZ$IDJ6LN)#U/OV8J'*+F"XK21U@HC9.LT
M_,=H&>_*^T10:J*$#L"TO5C=2NA&3\\'S6W,.2CK!3A7(J@4/'@3Z"OCD$EE
M3-*MVQ'M0=YX5^$G@MQ0JNH A8]*\#Z?DQQ52'HS YD\6Q6#AJAC!N6E\BYX
MI>_&C:T]LZ?(&Z>5^7C.63-5-7NB.>)@7:Q6+Q?S]73^J3:KNTRMV(P"6$V)
MV>V@"R%-O="!A($!!>>,O 57;WN8#R;EJ'EN?<KN0M@XK<U/>>0V5\_(=QL[
M,;1).WQ;+EJWZ^*"9=R S!3'JYAKQ*,8%"]RE#$)E>^ [\$[COU7W@E=]CM$
MUPD4T<$!>^VN?L#U>K:I5WEQ5N7ZXO= RLL?%]MTCK!<?YNDJ)/AV0./K/;G
M= B^N%JW4O,Z.-IT%V4- XD="-P)C.X[!./PZNH BS?&BFXWT[8Q#6TIZ;$V
MN5$ND8_@<@0?,$*T/%F5N JL=7W:(Z3LA"__'>.KA0KZG SRZV*1?Y_.9F&>
M7]&'S3]5\[U-'+J<OO+$KQR>6--FW0;9-0,(H-&<CLME7SRP[%59Q56&!L\V
M2VXEU+ERV[<+0J$'*X,1Z*VTKO49M!>!#6<3I_\XG]+F^64ZGZ[Q]?0KWEW^
MQV^_A7]?+%_.PNKB92<+95 9!CG4_F"ECF36J0#J+# SA9:WONH[BN!QZR*'
M0]X34XP'UNK(.2'OB9-MXH-0,G&2"S@M:H\)3]Y'#?>M)7)M#,R:G6;J/),$
M<K5@-S.(AU;PXEAI]P"1RXP#6U,8)(7A6$<H>G)6HS&AUJ3DFB:<V&[5C+N
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M7]9H@BRMA43O&]@'IC-N'-(1%[<M7B\53.!HW,1/F]S0MH3M@BZ>Q;(HE:*
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MHO]&\]56)4N<?]ELD=^^7__)AXMN%R_^A<OR8QGT#=H%).%4)M.R4%I_>FT
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M\G"\O:1M[;YTW@=E$&QES\5X'2$*"F!%)I/X3)>B"R76T F-1V]PN,X7QU;
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MM,9^K?SCQ6OVT0N5WQ?S13Y=S/'TQ7P]2XOR_3/EK_/%Z>++]\OF>T$:(JM
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M",%8E*'U>=4#RY<.F\?87+@30..3JG(ZL+WA&6QCH=>XG+/GZ;0WN.&U<=*
MD;'==0L'&AE]F:@@/<;/,G"HL>EOIP6^+@J9@*NVC6;>L, ;CU)C\/CG;/WU
M,M_L]5_Y]+S,YE]>K%:->+5\QK]. A*6%!1$':B5_ 2(*;6.9R$YDRA[[$U0
MM<<TQR;$G8C+=VP%CT;^=_]I<.&@M!6_KI5R^]TK7-.;Q?+F06!T3**0AU@"
MFW_9HO?L+-B*VA87919V[S-]T!3&)L^=ED4]J@(G8&G_QH)K/<S:%>;F+E\7
MFV.1 J2PDCV1G(']:0072_0I698:=3:CM^<P.K_N1(SD0;J9CI=X8PN].9\W
MJ]YN*:]NS:-A4;AJ(9'08 P21"%X49A,6VQ4V>QM\>X8<'0ZW<D:N$.U,TG(
M75CM]6*[HNT:.?[ZR(K'5I\^+Z_8&SE=?&M_?A)Y6I9=8MB\Y' D5AM17(#L
M?*(0HY.WWY9W/H '3V9TMMW)0O686ITDC+<KO-J73FLK^3P &1HI4V;!1F4B
M^\9HA10J:K7C8\C]@XW.JSM9&!ZBE;UA]B<MTZ(+)\G%H!LW8[N22VI_P1Y%
MLCF 0"^VG4EJ9JDA)E^M+/9V?YE[6$GN'6(8J'[=QX^>&IB4Q;H6UIO97U0^
M+&>9+F/\B[XW+_Z%K-YRXDL4+5J"1B_7C#)"4L&!UUAM)!^U]SO;L,'##P/@
MK_V*\A2:&QF<F[WU8;EHEYRK:[>VW1EYF4$;X\%4Q0MP'$G)%+U.UJ*]?5EX
M)_3N_/!AP/JU'T0.E_I$;=J-B\O/7ZFM\'RYI;:ZV"@G*>88 U8@%!5,D8X-
MM]&@2C3)6X-:#>%_VWL"P^#W;_,D<D3M3;-3PM]H3HL5+V^)W^A\/<NKM_/\
M1R.,V=Q8[MTP8=CG=NB;L,<".K5/V."3@<#H84_L;:.JH]7ZBD.>I)#)4&1L
M.-=ZZ7HV7[Z ,J@<>V2ABD&DYSM<C3X\HT,O?W]GT2]GZ^^7GWN1S9V4]I;#
M%E )2SO< R#Q6<\KK,Z(DDL.G9=YYT3&S3_NB(7;][J'BWV2+0&<3SG5!$DH
MEH@W&4*0MK6<$38*BS+V8,"97DN #NI\E-5_!]D^&U;_F+42R3?&^J+Y']^\
M05U!6.FLUUG;-*B*YU=E]=]%YWNQ^N^B@+&CN+M\@O^U+86C5@BGBX 8JFZW
M;@%"E0A:$T8JWCH[Y,K^H3&> ]__3NI<'$&V(UN>]_^:\^=\G7W;;)^@!*94
M'*B !,;65O<056/NR"*$QES8@^KOAT''K5/I>P[M+\VIP."R]):*H)Q#8Y]+
M8*1*$(N.(/C+F+.J0??P2VX-.Y[!.$!Q=ZE_#RE.^:RHV1@5'#5OG>-[K 21
MA *OJE#6U.KCD.+S:9X5!REMZ(FPBP0GD.!TU0ONY2FN5N_KI_4B_^=F:S@5
M^7#+%I"7!(8T?Q6KA" 19; D(O:FRKIW,N-6G/4[.?I*?0+PN3G_RUT52K'(
MWI!KK4J,9Y\<<Y;L(27> 1I=INYU8S_-8N0N>'W4>[L.[#!9CWSL?*+EC%8O
MWL_IP^7HFY5<DII&<H6/7 A86H\+TA -&^0:;"W:FF 'L9X\/,K()?L'ZF]Q
M%&%.P8@LSLX6\Q\6@*%&JQ,$*BVX+Q$P90]2EY1\INQ+?P:36Y,8N:J^#UCZ
MB'@"&+D3Y]E0TF@]^" #^UHN0N(H'U)5-E.516;7&29[FY7CY7_U1<K!@I[&
M.:/NLXV>XSUA0[O\*2R;X#7O@.:N:Y1".EE#&-)0ZI%A1BY=[W[2=!'GR#<?
MU\Q.K__KG-WYWVG]=5'>SO]DEWY3"_C33XFNKIL#1=(2#0AOL36151"KRZT"
M-6'(7GL_J'SND6N20^8X+N;Z7J\]F:Y&QN1]Z[C<M8G05%3@<XJMMRQ!1*U!
MN!I0.A6*&51M] CJ'I[%>!<V3X>"Q5%4,N6;OJ L+\1P9)!:R;.0[87>5FB/
M:DHKE20.R9"?YDU?3QT.O?C;1: 3<*AOV^MW5UEESJFHK4"H' 6T[=)Z6%D!
M-:80JQ"D1._@Z][)C$OETO_BKX_4)P"?+7_"ZO/B1>;-MJ1KKK7+M;V=?SI/
MJUF987,A3V2@9(10X*K@!:IB.."L!1(J5XN.0MUN]'-XL+;K)*>5*;,G.&X'
M=$?5U 2@>%ML5\\\'VB9F_Z^T&_?/VPT<%*TE*FR:2XN63#.V58V(L%:J0)Z
M7WP:U'OH -OVP/2F]4#>!W['TL[8UPPM!O[P<^K)V=ELVW'YYC:[=%A/7(Z&
M7/'0+OO9*54)4O$1JJZUI&P3#BJLV&_T:;VB'0:O)]+!!,S;W:'/'=OH)$DR
MUGH)6K6G9Q,L1!4E1(M!!%Z7,KT=M\&3F];E1!_3=AS-3 !RKR@OYJO%Z:QL
M-/0WCIG>+]\M5JN+,K<3XW2C7).0BV$/&'4"CGP<:.-,*"J8F'IS23TRI6G%
M"7W@U5,+HU93W[.@C_0GGIYOOGQ?/[:ZE3G=V$<_K5<$AY%(0+;5@=$*(9KF
M'2BT06PBKT&=_?9'W8XS'I?Y\4E >4P=CMW,:9X79]3FON&TNM/6KSX2GL[^
MF\J+>7EQNOD\*I\7-YR-F))2L5@6KL^M(;B%D!'!9A6=J,+H.(3JL<MDQB6#
M[.__/;V&#N#-^](&[F)&!RW[I+((G4;;&BWP3C,LWL#!.U#RE7))YD;3D4[6
M<M#$QF5X/(Y1[*^10X'V^<CAQ^HD.%MMS86]C[::4AJ-2TA0HC=:EN*-'51
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MBN3ER@(E4R0VMU8IW1EI3_!&,T+*S2& ?$(=3L#H#;M\%>B"E5F#)@I@M-.
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M#LIXL]V@YV+!9YE4%O(()%[<)ADO1I*]3SS[5&GI0F2B/F]%!WMRG_%"L.A
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ML(FRT!+ M *6@R8"4F"2J21CKL*?Q?J)M+(6@@;DRFGH'; -F2B?@8&N!%+
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M*5JTJPN;*DCUVXTFLM?NFO5_F@S6+8,L1>^;V%T075]1[!F6AE[22YGV_4R
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M              "  9@A P!I;F\M,C R,S S,S%?9S$N:G!G4$L! A0#%
M  @ 28"J5M@+_=&'Z0  T'H) !0              ( !YTH) &EN;RTR,#(S
M,#,S,5]L86(N>&UL4$L! A0#%     @ 28"J5I5["/29C   2B(& !0
M         ( !H#0* &EN;RTR,#(S,#,S,5]P<F4N>&UL4$L! A0#%     @
M28"J5C8+1V%="   D"<  !4              ( !:\$* &EN;RTS,S$R,S$P
M<65X,S$R+FAT;5!+ 0(4 Q0    ( $F JE8%DX 33@@  *PE   6
M      "  ?O)"@!I;F\M,S,Q,C-X,3!Q97@S,3$N:'1M4$L! A0#%     @
M28"J5I>W9TIK!@  W2   !8              ( !?=(* &EN;RTS,S$R,W@Q
A,'%E>#,R,2YH=&U02P4&      H "@"0 @  '-D*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
